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Preface 
The term “Autoimmune disorders” refers to a heterogeneous and multifaceted group
of diseases which can affect virtually any organ system of the human body. They all 
arise from a misdirected attack of the organism’s immune defenses against ”self
molecules” initially designed to protect them, resulting in chronic inflammation, 
autoantibody formation and tissue damage. They can be divided into systemic
(response against ubiquitous self antigens) and organ-specific (against specific organs).
Despite the unprecedented progress in the field of autoimmunity, the initial triggers
for the aberrant immune reaction against “self” still remain to be defined. The
interplay of environmental triggers, and an appropriate genetic makeup seem to be the 
prevailing belief for the pathogenesis of autoimmunity with many questions still 
unanswered. Furthermore, the contribution of autoimmune mechanisms in the 
generation of co-morbid conditions mainly manifested as cardiovascular burden or
malignant transformation is currently a focus of intensive research.
The present edition entitled “Autoimmune disorders - Pathogenetic aspects” aims to
present the current available evidence of etiopathogenetic insights of both systemic
and organ specific autoimmune disorders, the crossover interactions among 
autoimmunity, cardiovascular morbidity and malignancy, as well as novel findings in 
the exciting fields of osteoimmunology and immunology of pregnancy.
We hope that this edition will provide a comprehensive overview of the recent
advances in the field of autoimmunity, and at the same time foster further research 
efforts which will ultimately translate into better patient outcomes.
Clio P. Mavragani, MD
Department of Experimental Physiology,
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Autoimmune Diseases: 
The Role of Environment and Gene Interactions 
Wellington K. Ayensu1,3, Emmanuel O. Keku2, Raphael D. Isokpehi1,3, 
Ibrahim O. Farah1, Chris A. Arthur4 and Sophia S. Leggett4  
1College of Science, Engineering & Technology, Jackson State University, Jackson, 
2Department of Public Health and Preventive Medicine, School of Medicine, 
St. George’s University, St. George, Grenada,  
3Bioinformatics Section; Jackson State University, Jackson, 




Data from epidemiological studies indicate global increase in the incidence and prevalence of 
numerous autoimmune diseases (AD) as seen in the United States (Jacobson et al.1997). 
According to estimate from the US National Institute of Health (NIH) the prevalence of AD is 
in the range of 23.5 billion. From 1996 to date at least 237,203 cases per year of AD are 
diagnosed in the US; and of this, 42,137 are new cases of primary glomerulonephritis, multiple 
sclerosis, polymyositis/dermatomyositis and systemic lupus erythematosus (SLE). Early in 
1996 alone 6,722,573 women and 1,789,273 men suffered from varieties of diseases that had 
components of autoimmunity. Currently up to 150 autoimmune based diseases have been 
identified and approximately 40 more are awaiting confirmation. Similarly the incidence of 
several autoallergic diseases, type 1 insulin dependent diabetes mellitus (IDDM), rheumatoid 
arthritis, and Graves’ disease, hyperthyroidism included are on the increase. Of the 1.2 million 
new cases of AD diagnosed every 5 years, at least one or more cases will include these 
autoimmune disease components. (Jacobson et al.1997) 
The global incidence and prevalence for each AD is currently lacking and that calls for 
improvement on data collection and reporting. Nearly 10% of developed world’s population 
suffer from AD and contribute significantly to chronic diseases and mortality. Women are 
three times more likely to be at risk than men in acquiring these diseases with non-Caucasians 
at higher risk. We are also seeing global prevalence of allergic respiratory diseases on the 
increase for the past 20-30 years. Over 15 million people in US suffer from asthma alone; 
approximately 50 million are diagnosed with some form of allergic diseases (Smith et al, 1997). 
Presently the direct annual health care cost for AD in US is in excess of $100 billion US dollars 
as compared to $57 billion for cancer. Hospitalization alone takes over half the cost of the 
direct expenditures. Almost 20% of the population classified as ‘high-cost patients’ consume 
more than 80% of the resources. Consequently the cost to public health from clinical 
management of these conditions is on the increase. All indications point to future better 
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management of asthmatics through research and interventional efforts directed at 
communities, hospitalizations and high-cost patients in order to decrease health care resource 
use and provide cost savings. This calls for rigorous investigations into the role of 
environmental xenobiotics/substances and/or pollutants that are risk factors in the 
development of autoimmune diseases. In this chapter we intend to survey the public health 
concerns imposed by pollutants of the air, water and the food chain with concentration on 
typical examples of the effects of mercury on health to demonstrate the likelihood of dangers 
imposed through environmental and genetic disturbances in health. 
2. Environmental chemicals and autoimmune diseases 
Many scientists concur that several species within mammals to amphibians, birds, reptiles, and 
fish so far under monitoring systems are close to total extinction; well over 30,000 plant and 
animal species are estimated to be lost each year, a morbidity rate generally agreed to be much 
faster than at any time. Loss of species seems to be explained in most cases through the global 
weather changes as well as pollutional activities of man. But industrial activities seem to play 
major role in this problem; the latest data emanating from the industrial front estimate that at 
least 85,000 possible pollutants are currently being released into the environment through 
industrial activities alone http://www.epa.gov/glnpo/lmmb/substs.html (FDA/EPA).  
2.1 Chemicals and substances of public health concern 
These pollutants cover the heavy metals like thallium, aluminium, cadmium, lead, gold and 
mercury as well as pesticides, herbicides, preservatives, dyes, plastics, bisphenol A and rubber 
products. The Environmental Working Group indicated from studies in 2005 that a cocktail of 
287 pollutants are measured in new born US fetal cord blood (http://www.ewg.org/ 
reports/bodyburden2/execsumm.php). Perfluorooctanoic acid (PFOA or C8), and 
perfluorooctanoate, a synthetic but stable perfluorinated carboxylic acid and fluorosurfactant 
PFOA’s were included in the findings as well as pesticides, dioxins, flame retardants. Recently 
another concern has been brought to the limelight by the internal Florida Department of 
Environmental Protection (DEP) Workgroup. It is stated that the current update of the 
American Chemical Society’s Abstract Service reveals that as of August 2007 over 98% of the 
commercially available compounds are not under regulatory practices as they should be. This 
amounts to about 15 million out of over 32 million substances commonly referred to as 
Emerging Substances of Concern, or ESOC that have been registered for regulation (Chemical 
Abstract Service [CAS] website): http://www.cas.org/cgi-bin/cas/regreport.pl. 
Much uncertainty surrounds the outcome from releases of these substances into the 
environment. No information about the pharmacokinetics or pharmacodynamics 
interactions among life forms on these substances are available. No available information on 
transport and toxicological effects are on record. Within two years between 2005 and 2007 
over 5 million new chemicals have been reported to be registered and 5 million more 
chemicals became commercially available. Currently CAS informs that within each week 
more than 50 new substances or additions to existing substances to the database is the norm; 
http://www.cas.org/index.html. Apparently the ratio of unregulated to regulated 
chemicals keeps growing exponentially. The ESOC chemicals fall under various categories 
of organic groups encompassing from flame retardants (PBDEs), pharmaceuticals to 
endocrine-modulating chemicals (EMCs), nanoparticles to biological metabolites as well as 
newly discovered Industrial chemicals and toxins. They are constantly being discharged into 
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the environment where they find their way into our water bodies posing an unknown level 
of risk to life forms including humans, animals, and plants.  
Regulatory Agencies are therefore challenged to find answers to solve what may be an 
unknown outcome of these ESOC substances being continually released into the biosphere. 
In the absence of detail knowledge on the environmental outcome and without effective 
regulation no useful assessment can be made on the environmental risk posed. Thus vast 
majority of ESOC substances have to be non-traditionally managed by other means such as 
prevention and effects-based environmental assessment methods. That effort is even more 
tasking and presents difficulties in monitoring the trends of the etiology of diseases now 
becoming prevalent in the environment under such practices. ESOC substances are now 
recognized to be of global concern; among these are included polybromina -teddiphenyl 
ethers (PBDEs), perfluorooctanoic acid (PFOA), siloxanes, perfluorooctanesulfonate (PFOS) 
and hexa- bromocyclododecanes (HBCDs). PBDEs and HBCDs come under flame-retardant 
chemicals that are moderately long-lived and volatile; readily released to the atmosphere 
because they do not strongly bind to substrates. Once in the atmosphere they are globally 
transported and readily bioaccumulate in biological tissues.  
2.1.1 Nanoparticles  
Human activities now have added sources of environmental contaminants. Human-
originated nanomaterials are naturally man-made structures that differ in size range from 1 
to 100 nanometers (nm). They are commonly used in drug delivery nanotherapeutic 
pharmaceuticals, cosmetics, personal care products, energy storage products, fabrics, 
lubricants and equipments like golf balls. The use of nanomaterials has been on the increase 
and now it is ubiquitous. Their minuscule sizes allow traversing not only biological 
membranes but also the blood/brain barrier (BBB) and display physical and chemical 
properties different from parental compounds. Examples are gold or silver metals known to 
be inducers of autoimmunity but also possess magnetic properties. 
The intrinsic stereospecificity of these substances allow these molecules to play significant 
toxicological role in the environment (Donaldson et al 2004) and are therefore of public 
health concern. Carbon black displays enhanced severe effect than titanium dioxide 
(Renwick et al 2004), while the nanoparticle sizes of both chemicals are inducers of increased 
lung inflammation and destruction of the epithelial linings than their larger size. 
Adsorptions onto the surface of nanoparticles may play synergistic role in the reactivity; in 
vitro studies with fractions of diesel exhaust particles showed effects on cells (Xia et al 2004). 
Atmospheric nanoparticles may be complex enough to form interactions with organics and 
metals capable of higher levels of toxicity; metallic iron potentiates the effect of carbon black 
nanoparticles resulting in enhanced reactivity displayed as oxidative stress (Wilson et al 
2002). Conversely other combinations with pullulan (polysaccharide polymer of maltotriose 
units, also known as α-1,4- ;α-1,6-glucan) and dextran tend to reduce toxicity of the 
respective nanoparticles (Gupta and Gupta 2005, Berry et al 2003). 
Some nanoscale materials may be catalytic or behave as semiconductors, properties that can 
only increase the likelihood that nanomaterial could produce unanticipated toxicological 
effects. Nonbiodegradable ceramics, metals and metal oxides within nanomaterials are quite 
environmentally stable and persistent (EPA, 2007) and therefore undergo bioaccumulation 
in the food chain (Biswas and Wu, 2005). They are currently implicated in the induction of 
acute and chronic biological toxicity (Oberdörster, 2004a and 2004b; Lovern and Klaper, 
2005; Lam et al., 2004; Shvedovaet al., 2005; Fortner et al., 2005) of unknown physiological 
mechanisms and hence consequences.  
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the environment where they find their way into our water bodies posing an unknown level 
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2.1.2 Particulate matter  
Nanoparticles compare with particle pollution or particulate matter (PM), a group of 
complex mixture of extremely small air-borne particles and liquid droplets in air 
suspensions. There are a number of components covering acids (nitrates and sulfates, 
organic chemicals, metals, soil or dust and sulfates, organic chemicals, metals, soil or dust or 
mold spores). Particles less than 10 micrometers in diameter (PM10) pose an even worse 
health concern because of their inhalation properties that allow for accumulation in the 
respiratory system; they are found in all types of combustion (motor vehicles, power plants, 
wood burning, etc.) and some industrial processes. Severe health risks are posed among fine 
particles less than 2.5 micrometers in diameter (PM2.5). Fine particles easily lodge and 
penetrate deeply into the bronchial tree and into the deepest alveolar areas of the lung upon 
inhalation. Coarse particles measuring between 2.5 and 10 micrometers are derived from 
crushing or grinding operations, and dust from paved or unpaved roads.   
Properties of PM link them to a variety of significant health problems starting from 
offensive asthma to early mortality of exposed patients who suffer from cardiac and 
bronchial diseases. Exposures to PM result in high rate of respiratory symptoms involving 
irritation of the airways, coughing, or difficulty breathing, decline in lung functions, 
aggravated asthma, and development of chronic bronchitis, irregular heartbeat and nonfatal 
heart attacks. Individuals with a variety of health issues particularly those with prior heart 
or lung diseases tend to suffer premature deaths on exposure to PM. Children and older 
adults are the most likely to be affected by particle pollution exposure but healthy 
individuals are found to experience temporary symptoms from exposure to elevated levels 
www.epa.gov/asthma; and plays esthetic role by significantly effecting visibility 
impairment in the nation’s cities and national parks. To protect public health and welfare, 
EPA has continually issued National Ambient Air Quality Standards (NAAQS) since 1971 
for six criteria pollutants among which are particulate matter and Sulfur Dioxide (SO2), 
Ozone (O3), Nitrogen Dioxide (NO2), Lead (Pb), and Carbon Monoxide (CO). The NAAQS 
from EPA has undergone revisions in 1987 and 1997 and again in September 2006 and it is 
helpful to familiarize oneself; there is an urgent need for studies to unravel the 
pharmacokinetics and pharmacodynamics of these particles to help disclose the role played 
in disease pathogenesis especially concerning the autoimmune state- asthma being one of 
the priorities.  
3. Autoimmune diseases: etiologies and mechanisms 
All indications show that tissue burdens of PBDE in life forms including humans are 
doubling in every two to five years. Human breast milk has been found to contain as much 
as 419 ng/g lipid weight of PBDE (Schecter et al., 2003). The question then arises whether 
these molecules contribute to what we measure in the increases in the incidence of ADs. 
These substances are known to interfere with the reproductive and developmental stages of 
mammals as well as in birds and invertebrates (McKernan et al., 2006, Wollenberger 2005); 
they are carcinogenic, endocrine-modulating, and have neurotoxicological effects 
(Birnbaum, 2005). Autoimmune diseases present a major affront to the health of Americans 
as well as of global concern. Vast arrays of diseases come under auto-allergic/–immunity; 
these cover maladies that may present as localized to be organ specific or systemically 
distributed to the extremities to involve all organ systems typically noted in systemic lupus 
erythematosus (SLE). In health the Immune System guards us against invasion of foreign 
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substances including harmful bacteria, viruses, and parasites quite well without any 
perturbation. At times, however this machinery loses control and begins to attack even the 
self itself. Hypersensitivity responses resulting from direct attack of body components by 
antibodies or immune cells instead of attacking foreign substances alone generally come 
under autoimmunity or autoallergic responses. Autoimmune state becomes apparent with 
rise of demonstrable presence of autoantibodies or complexes of these with body substances 
or the presence of cells, T lymphocytes that attack self-constituents. Minor and harmless 
autoimmune states exist in normal persons in general; it is part component of the defense 
system as envisaged by Jerne‘s hypothesis (<http://www.enotes.com/microbiology 
encyclopedia/). In the disease state, however, autoimmunity becomes defined when the 
benign state results rather in pathology; it sets in motion homeostatic deterioration. The 
process is dependent on both genetic influences and environmental triggers. 
For the past decades it has been conclusively demonstrated that alleles of the major 
histocompatibility complex (MHC) contribute to the susceptibility to autoimmunity but 
relatively recently there is an unparalleled discovery of novel genes in molecular pathways 
implicated in autoimmunity. Some of the variants identified clearly participate in the 
modulation of T-lymphocyte (T-cell) activation and do contribute to many different forms of 
human autoimmunity. Other genes tend to have restricted roles, with susceptibility 
apparently confined to one autoimmune condition or to a specific ethnic group. To gain 
insight into the initiation mechanisms of autoimmune diseases requires identification of the 
genetic determinants underlying disease pathogenesis and this implicates new biochemical 
pathways. The Autoimmune state may be either the direct originator of disease itself or arise 
as a secondary disease from perturbations from other chronic diseases. Direct autoimmune 
states are phenotypically demonstrated in patients that have antibodies in the active disease 
phase: examples are represented by idiopathic thrombocytopenia (ITP), Grave’s disease and 
myasthenia gravis, pemphigus vulgaris and bullous pemphigoid, diseases that can be 
transferred among species through antibody transfers. 
Disease transfer through T lymphocytes exchanges have not conclusively been demonstrated to 
lead to pathology but with the aid of cytokines may rather alleviate or exacerbate disease state. 
Indirect cause of autoimmunity has been defined by Rose and Bona, 1993 as when disease can 
be induced in an animal model. SLE is well represented by several genetically determined 
mouse models which, while not exactly clinical replica of the human disease do very closely 
replicate pathological and serological characteristics clinically seen to occur. Hashimoto's 
thyroiditis and multiple sclerosis can be reproduced by immunizing animals with an antigen 
analogous to the putative autoantigen of the human disease. Absence of direct and indirect 
evidence with markers describing the state of autoimmunity become circumstantial: positive 
family histories for disease, presence of certain MHC class II alleles are examples.  
Currently it takes a great effort to assess accurately the initiation levels of these diseases in 
humans; the very initiating factors are difficult to focus on and in which stage/s or area of the 
metabolic processes gets initially disturbed becomes challenging to screen and allow for 
therapeutic management. Majority of ADs such as multiple sclerosis (MS), insulin-dependent 
diabetes mellitus (IDDM), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and 
thyroiditis one finds representative spectrum of autoimmune diseases that appear to have 
etiological background in dysregulated immune system. Enough supporting evidence exist to 
confirm the autoimmune nature of many of these disorders but still it is gravely challenging to 
decipher their precise etiology and/or the initiating factors. Of late a small fraction of the T 
cells, the regulatory T cells are among the focal area of studies and have become recognized as 
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particularly crucial for control of autoreactive immune responses. Normally the processing of 
a self antigen by the antigen presenting cells (APC) allow binding of processed antigenic 
fragments to the MHC molecules within the APC followed by display of these MHC-peptide 
complexes on APC’s membrane surface for presentation to the appropriate T cells; this 
eventually terminates in activation of antigen-specific T cells. These T cells are then capable of 
attacking the self tissues expressing that particular self antigen. The process is believed to be 
the critical steps in the initiation of anti-self T cell responses. 
Genome wide studies indicate that costimulatory signals examplified by CTLA4 or PD1 and 
the modulators of T-cell receptor signaling (LYP, encoded by PTPN22), somehow must be 
confirmatory key checkpoint for human autoimmunity as happens in the T-cell during the 
period of T-cell receptor training to eliminate self-antigen carrying T cells in the thymus. 
This notion of the crypticity of self antigenic determinants (Sercarz et al., 1993; Moudgil and 
Sercarz, 2005) takes strength from the premise that rely on potentially immunogenic regions 
(determinants/epitopes) within a self antigen that are processed and presented by the MHC 
molecule to T cells at different levels of immunogenecity. This means that certain ‘dominant 
self’ epitopes are well processed and presented, whereas others, the (cryptic or recessive 
self) (Sercarz et al., 1993) ones are poorly or never processed and presented. Thus this type 
of staging of determinants (dominance/crypticity) in turn plays a critical role in thymus 
gradation of the T cell repertoire: the T cells specific for dominant self epitopes are tolerized 
with ease while those purportly aimed at cryptic self epitopes evade tolerance induction and 
become part of the mature T cell repertoire (Gammon and Sercarz, 1989; Cibotti et al., 1992; 
Sinha et al., 2004). 
T cells that evade tolerance induction are capable of being activated in the periphery under 
certain stressful inflammatory circumstances such as occur during infection; this has the 
consequence of enhanced processing and presentation of once latent (cryptic) determinants 
(Lehmann et al., 1992; Lanzavecchia, 1995). These activated T cells at times are capable of 
escaping appropriate constraint from regulatory T cells and permitted to execute their 
effector function of initiating autoimmune damage. The unveiling of previously cryptic 
determinants leading to activation of self-reactive T cells that escaped tolerance induction 
during thymic selection, owing to the crypticity of self determinants is considered a primary 
cornerstone of a theory of autoimmunity (Moudgil and Sercarz, 2005). The idea of 
determinant hierarchy provides a vital link between the thymic selection of potentially 
autoreactive T cells and the subsequent activation of these T cells in the periphery under 
conditions that facilitate the revelation of previously cryptic determinants. Peripheral 
ongoing immune tolerance of the mature immune system also attracts attention as another 
source of autoimmune initiation. This idea is supported by variations seen in the 
expressions of “self-antigen” in the thymus (e.g., insulin in T1D); in this instance T-cells are 
selected for survival according to the affinity of their cell surface receptors for self-antigen. 
This may represent a major key step in the genesis of autoimmune disease. 
Other means of autoimmune genesis stem from APCs. These cells play crucial role in 
antigen processing and presentation to the T-helper (Th) cells. Dendritic cells for example 
are key cells in the initiation and perpetuation of immune responses. Highly polymorphic 
genes within the MHC, with links to autoimmune inductions, encode proteins to which 
antigens bind and presented directly to T-cells by APCs. Another source of autoimmune 
initiation focus on the cell surface marker CD4-positive Th cells; they are the conductors of 
the adaptive immune response and many genes with an established role in autoimmune 
disease have their expression in this cell type.  
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Autoimmune diseases present specific issues that need attention. Drugs used to manage 
known chronic and acute diseases are implicated in triggering and are therefore thought to 
be indirect causes of various autoimmune diseases following administration. Many of the 
prescription drugs commonly used for highly prevalent diseases come under this category: 
these inexhaustively include drugs like Alferon N, Allopurinol, Atenolol, Atorvastatin, 
captopril, Penicillin, Carbamazepine, chlorpromazine, Chlorthalidone, cimetidine, 
Ethosuximide, gold salts, griseofulvin, Hydralazine, Interleukins, Infergen, Interferons, 
Interferon Alfa, Hydrochlorothiazide, Intron A, Isoniazid, Levodopa, Lithium, Lovastatin, 
Mesantoin, Methimazole, Methyldopa, Methylsergide, Metoprolol, Minocycline, Minoxidil, 
Ophthalmic timolol, Nitrofurantoin, Oral contraceptives, Quinidine, Phenytoin, PegIntron, 
P-aminobenzoic, Penicillamine, Perphenazine, Trimethadione, Pravostatin, Phenylbutazone, 
Procainamide, Valproic acid, Propylthiouracil, Simvastatin, sulfasalazine, sulfonamides, 
streptomycin, Sulfonamide antimicrobials, Tetracyclines, Tiotropium Bromide inhaler and 
Tumor Necrosis factor. 
The concern here can well be summarized with the incidence and/or prevalence of asthma, 
one of the most common chronic diseases of childhood estimated to affect 6 million children. 
More than 22 million Americans are diagnosed with asthma, and approximately 50 million 
of individuals are diagnosed with some form of allergic diseases. Presently in US the annual 
direct health care cost for AD in general is in excess of $100 billion US dollars as compared 
to $57 billion for cancer. Hospitalization alone takes over half the cost of the direct 
expenditures. “High- cost patients” that form about 20% of the population spend more than 
80% of the resources. As a result, the cost to public health from clinical management of these 
conditions is on the increase.  
4. Global problems associated with asthma and COPD 
Epidemiological data following the natural history of asthma reveal that in 1999 mortality 
rates from the disease declined in comparison to previous years. This was followed by a surge 
in recent decades in asthma prevalence also in the United States and other Western countries; 
data suggest this trend may also be reaching a plateau. The general trend of global asthma 
incidence is rising worldwide but looking at US data we see increased morbidity and mortality 
from asthma from 1980s -1990s with plateau in the 1990s. This finding is the reverse of what 
was seen in the 1978-1980 where an increase in mortality due to asthma was measured: from 
1990-1999 mortality declined. Commencing from 1995 the rate of outpatient visits for asthma 
increased; whereas the rates of hospital admissions declined from 19.5 per 10,000 of the 
population in 1995 to 15.7 in 1998 attributed to enhanced rates of dispensed steroid 
prescriptions for inhaled medications. This finding has been interpreted as due to the 
improved treatment of asthma responsible for these favorable developments. 
The implication, if it holds supports explanations of certain changes in environmental 
chemicals releases. Recent increases in asthmatic conditions in the population may be linked 
to many causes the cardinal one being the amount and types of substances that are being 
released increasingly into the biosphere. Releases of substances most of which have an 
unknown effect and still others closely linked to inductions of asthmatic features in the ever 
increasing population with genetic predispositions present ominous threat to the very 
survival of several species including man himself.  
Exposures to environmental factors early on in childhood play significant role in the risk in 
developing asthma. Clinicians have known for quite a while that asthma is not a single 
disease. Risk to asthma stems from early environmental factors as well as the presence of 
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susceptibility genes; subsequent disease induction and progression from inflammation as 
well as response to therapeutic agents plays big roles in disease etiology. It is a typical 
consequence of environmentally induced autoallergic disease known to be heterogeneous 
(Asosingh et al 2007, Dompeling et al, 2000, Dweik et al, 2001, Kharitonov and Barnes, 2001, 
Weiss, 2002, Pascual and Peters 2005, Salvato, 2001, Wu et al, 2000) existing in many forms. 
The immunologic profile of the asthmatic airways presents as proliferation and activation of 
helper T lymphocytes (CD4+) of the subtype TH2 responsible for the allergic inflammation 
in atopic asthmatics. Upon stimulation these cells release a number of cytokines covering IL-
4, agent for IgE synthesis, IL-5, essential for eosinophils’ maturation, and IL-3 and 
granulocyte-macrophage colony-stimulating factor, GMCSF (Bolland and Ravetch 2000, 
Candore et al, 2002, Lang et al, 2010, Pollard et al 1997). 
In allergic as well as nonallergic individuals we observe populations of eosinophils in the 
airways with increased levels in asthmatics with allergies http://www. clevelandclinicmeded 
.com/ medical pubs/disease management/allergy/ bronchial-asthma/that have higher rates of 
asthmatic attacks. These cells serve as the source of mediators that exert damaging effects on the 
airways. Ultimately, mediators lead to degranulation of effector/proinflammatory cells in the 
airways that release other mediators and oxidants, a common final pathway that culminates in 
chronic injury and inflammation commonly seen in asthma. Chronicity of the asthmatic 
condition has been confirmed by several parameters. Low pH and high output of reactive 
oxygen and nitrogen species (ROS) during asthmatic exacerbations are specific biomarkers in 
expired air reflecting altered airway redox problems (Clynes et al, 1988, Comhair et al, 2000, De 
Raeve et al, 1997, Dweik et al 2001). Superoxide, hydrogen peroxide, and hydroxyl radicals are 
among ROS agents that are responsible for the inflammatory changes in the asthmatic airway 
(Candore et al 2002, Bolland and Ravetch 2000, Pollard et al, 1997). These ROS originate from 
the lungs of asthmatic patients induced by activated inflammatory cells (ie, eosinophils, alveolar 
macrophages, and neutrophils) (Holgate et al, 2000). 
Pathogenicity in asthma in particular is portrayed by overall interactions between neural 
mechanisms, inflammatory cell mediators such as leukotrienes and prostaglandins, and 
intrinsic abnormalities of the arachidonic acid pathway and smooth muscle; all these cells 
play significant roles in the initial as well as disease progression. Inflammation is the most 
likely etiological basis of airway hyperreactivity and variable airflow obstruction.  
Asthma usually persists into later childhood and adulthood from early childhood in the 
presence of the appropriate genetic background. Tolerance to allergens is a normal security 
that prevents such responses, but the specific immunological events that mediate tolerance 
in this setting are still under scrutiny. Despite the explosion of information about asthma, 
the nature of the basic pathogenesis has not been established. However, asthma clearly does 
not result from a single genetic abnormality, but is rather a complex multigenic disease with 
a strong environmental contribution. For example, asthmatic children and adults sensitive to 
inhalant allergens such as dust mites, mold spores, cat dander, etc portray such reactions 
right from childhood compared with adult-onset asthmatics. Local epithelial environment 
within the connective tissue is believed to be actively involved in regulation of events and 
the relation between the airway epithelium and the subepithelial mesenchyme is proposed 
to be a key determinant in the concept of airway remodeling (Davies et al, 2003; Weiss, 2002; 
Li and Wilson 1997, Pascual and Peters, 2005, Salvato 2001). Difficulties and/or problems 
underlying diagnosis and classification of these diseases are simply due to the fact that most 
of the ADs become apparent only at variable phases of several chronic stages of organic 
ailments. Some ADs present as auto allergies covering several fields of diseases: the 
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incidence of several of these diseases is also on the increase and covers type 1 insulin 
dependent diabetes mellitus (IDDM), rheumatoid arthritis, and Graves’ disease, 
hyperthyroidism included. There is scarcity of information on the global incidence and 
prevalence for each AD. Some autoimmune/allergic diseases (AD) can be seen in cases of 
chronic obstructive pulmonary diseases (COPD). As such the incidence of these disorders 
has not been well defined. However, sharp global increases in the prevalence have been 
observed in the United States. 
Etiological initiators of and pathogenesis of most ADs are obscure; they are presumed to be 
numerous with cigarette smoking a typical COPD-associated. Cigarette smoking is clearly 
the major risk factor for COPD but exposures to other noxious substances including dusts 
and chemicals found under occupational settings are known to contribute to the 
development of the disease (Pauwels et al, 2001).The attributable fraction contributing to 
COPD cases caused by occupational exposures is estimated to be in the range of less than 
15% to as high as 31% among those who never smoked (Hnizdo et al, 2004). We find that 
minority groups have been historically overexposed to hazardous industrial substances and 
are candidates with increased risk for work-related airflow obstruction putting them highly 
in the AD group as well; making it necessary to improve on data collection and reporting. 
Estimation shows, however that nearly 10% of developed world’s population suffer from 
AD and contribute significantly to chronic diseases and mortality. Women are three times 
more likely at risk than men in acquiring these diseases with non-Caucasians in the higher 
risk groups. The global prevalence of allergic respiratory diseases including COPD has been 
also on the increase for the past 20-30 years.  
5. Mercury as environmental inducer of autoimmunity  
Psychoneuroimmunological studies demonstrate in various ways that homeostatic 
regulation of the internal milieu links the soma with the neural pathways; stressors effects 
relate the two in bidirectional pathways. Current Naturopathic Medical view of diseases 
also links the involvement of the genes to autoimmune proneness. In this wise the authors 
concentrate on the metal mercury as a representative highly reactive toxic agent within the 
body as a means of gaining an insight into the problem of etiologies of autoimmune 
diseases. Mercury has a high affinity binding to sulfhydryl as well as to hydroxyl, carboxyl, 
and phosphoryl functional groups very commonly displayed on macromolecules, proteins 
and the genetic materials. It is widely distributed as an environmental and industrial 
pollutant. No known beneficial metabolomic effect is assigned to mercury in the physiology 
of humans, yet a 70 kg man is loaded with an equivalent of 13mg mercury (Pier, 1975) 
distributed in the skin, nails, hair, and kidneys. The net outcome of exposure to mercury is 
dose-dependent and at low concentrations mercury is the agent for the induction of several 
diseases that affect most systems of the body. 
The central nervous system (CNS), the brain and the kidneys suffer most where Mercury 
Induced Autoimmunity (MeIA) can be particularly threatening in onset and severe among 
especially non-Caucasians that manifest defined major histocompatibility complex (MHC) 
haplotypes. Several data confirm that mercury is also associated with polyclonal cell 
stimulation. Mercury Induced Autoimmunity (MeIA) engages helper T lymphocytes in the 
induction of disease process in responder animals (Jiang YG, Möller G 1995, Horwitz and 
Stohl, 1993; Puck JM, Sneller MC. 1997) and in humans (Liossis et al 1996). It is suggested there 
is a genetic basis for airway hyperresponsiveness with linkage to chromosomes 5q, 11q (Li and 
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Wilson1997) and 12q24 in Hispanic subgroups (Salvato 2001). While MeIA is well characterized 
into different arrays of disease susceptibility in animal studies (De Raeve et al 1997) and in 
humans (Holgate et al, 2000, Li and Wilson 1997,) the role of mercury in the pathogenesis of 
autoallergic/immune syndromes like asthma and SLE is not well characterized.  
Our Microarray data resulting from low doses (1-3 μg/mL) exposures of human cell lines to 
mercury indicate differential expressions of several genes located on many human 
chromosomes. Most genes affected were expressed more than twice the control level; several 
genes were also down-regulated with mercury treatment. We found close to a total of two 
hundred highly up-regulated genes with greater than a two-fold change difference (p ≤ 
0.002) in the lowest mercury concentration (1µg/mL); 12 genes were moderately over-
expressed with an increase of more than one fold (p ≤ 0.005); and a total of more than two 
thousand genes were down-regulated albeit most repressions were not statistically 
significant (p0.05) according to the Wilcoxon’s Signed Rank test. Only forty of these genes 
were down regulated to statistically significant levels at p≤0.05 according to the Welch’s 
ANOVA/- Welch’s test. Clear distinctions were seen in the gene expression profiles of the 
experimental versus controls. Affected genes distributed among almost all of human 
chromosomes with higher than normal effects on genes associated with chromosomes 1-10, 
12, 14-18, 20 (sex-determining region Y), 21 (splicing factor and ATP-binding), X (including 
BCL-co-repressor). Genes affected include potassium voltage-gated channel–subfamily H 
member 2 (KCNH2), stress responses, G-protein signal transduction, putative MAPK 
activating protein (PM20, PM21), ras homolog gene family, cytokine receptor activity and 
polymerase (DNA directed), regulatory subunit (50kDa), leptin receptor involved in 
hematopoietin/interferon-class (D200-domain), and thymidine kinase 2, mitochondrial TK2 
(HGNC) and related genes. Closely associated genes on a chromosome tend to be influenced 
for expression perhaps due to the availability of close and adjacent phosphorylation receptors 
found by bioinformatics tools.  
Identified genes of interest that were over- or under-expressed operate in several pathways 
including principally the immune and cell cycle (cyclin-dependent kinases) pathways, 
apoptosis, and cytokine expressions (Figs 1-3) as well as the TGF-beta and the GABA, 
NMDA receptor subtypes. We have since confirmed that mercury has significant effect on 
GABA receptors in microarray experimentations in murine cell lines (unpublished data). 
Our lab results reinforce the capability of mercury exerting significant influence in most 
metabolic processes probably generating ROS (Kavuru et al 1998; Lang 2000, 2006, 
Montuschi and Barnes 2002, Wu et al 2000) that participate in the degree of disease outcome 
of the autoallergic/asthmatic syndromes.  The auto allergic phase is the body’s adverse 
response to the onslaught resulting in signs and symptoms invariably difficult to 
definitively differentially diagnose early on in disease. Estimates from the National Institute 
of Health (NIH) data indicate that in US alone the prevalence of AD to be about 23.5 billion 
(Jacobson et al, 1997); in 1996 approximately 1 in 31(3.13%) or 8.5 million people were 
afflicted with one form or other of AD. Since then at least 237,203 cases of AD are diagnosed 
annually; of this 42,137 are new cases of primary glomerulonephritis, multiple sclerosis, 
polymyositis/ dermatomyositis and systemic lupus erythematosus (SLE). Of the total 
6,722,573 are women and 1,789,273 men suffering from varieties of diseases that had 
autoimmune components (Jacobson et al, 1997, Smith et al, 1997). Currently almost 100 types 
of AD have been identified and approximately 40 more autoimmune-based diseases are 
awaiting clarification and confirmation.  
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Fig. 1. Results: HepG2 Genes affected by Mercury exposure 
5.1 Mercury toxicity: evidence for autoimmunity and neural problems  
Mercury (Hg) has long been recognized as a neurotoxicant; however, many experiments 
with murine models have conclusively implicated this heavy metal as inducer of 
autoallergies as well as immunotoxicant. In particular Hg has consistently been shown to 
induce autoimmune disease in susceptible animals with phenotypic consequence of 
autoantibodies overproduction and pathophysiological signs of lupus-like diseases. This 
finding has been endorsed by epidemiological studies demonstrating links between 
occupational Hg exposure and lupus. Mercury rather may interact with triggering events, 
such as genetic predisposition, exposure to antigens, or infection, to exacerbate disease. Non 
mercury-susceptible mice that are exposed to mercury do succumb to mercury-induced 
autoimmune disease (MeIA) with very low doses and short term exposures of inorganic Hg 
(20-200 µg/kg) exacerbates disease and accelerates mortality in the graft versus host disease 
model of chronic lupus in C57Bl/6 x DBA/2 mice. 
Furthermore, low dose Hg exposure increases the severity and prevalence of experimental 
autoimmune myocarditis (induced by immunization with cardiac myosin peptide in 
adjuvant) in A/J mice. Immunosuppression as well as immuno-stimulatory signals results 
from exposure to the metal in many species humans and rodents included (Pollard et al., 
1999). MeIA is prominent among some genetically predisposed individuals that carry 
syntenic genes as haplotypes in linkage disequilibrium.  Some of these individuals are 
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Fig. 2. Results: HepG2 Genes affected by Mercury exposure 
genetically prone to develop spontaneous autoimmune diseases. The etiology and 
pathogenicity of these, mostly systenic, autoimmune states have been difficult to trace. 
Immunological findings support the notion that the origins of majority of these idiopathic 
autoimmune diseases can be traced to environmental contaminants of the biosphere with 
xenobiotic compounds like silver, gold and mercury strongly implicated. Exposure to low 
levels of mercury (<40μg/kg body weight) in susceptible persons may be unsafe; predisposed 
individuals develop all types of AD typically systemic lupus erythematosus (SLE). Evidence is 
derived not only from experiments of nature as happened in Miamata in Japan but also from 
many strains of inbred mice described below. These strains of animals do develop lupus-like 
disease that imitate closely a simplified version of human systemic lupus erythematous (SLE), 
with the production of autoantibodies and the subsequent development of immune-complex 
mediated glomerulonephritis (Theofilopoulos et al., 1985). 
The general consensus is that the dose of mercury, duration of exposure as well as the genetic 
background of the exposed animal (Hanley et al., 2002; Hultman et al., 1992, 1993; Jiang and 
Möller, 1995; Kono et al., 1998; Pollard et al., 2002) contributes to disease outcome. The H-2 
haplotype plays important role in the specificity of resulting autoantibody as well as 
susceptibility to immune complex generation; but there is a role for involvement of non-MHC 
genes in MeIA susceptibility also. Acute renal tubular lesions and immunosuppression follow 
exposure to large doses, whereas chronic administration of smaller doses of mercury  
leads to the development of SLE (Bariety et al., 1971; Kasturi et al., 1995; Roman-Franco 
et al., 1978). Mercury-induced autoimmunity shares the same pathogenicity and clinical 
 




Fig. 3. Key for Both Figs 1 and 2 
manifestations seen in patients suffering from clinically diagnosed systemic lupus 
erythematosus (SLE) (Dubey et al., 1991; Hirsch et al., 1982; Mathieson et al., 1992); the 
symptomatology is also the same (Biancone et al., 1996; Jiang and Möller, 1995; Kono et al., 
1998) with very minor differences.  
In humans most of the genes participating in immunity are located on the major 
histocompatibility complex (MHC) on chromosome 6 with its equivalent on the H-2 region on 
chromosome 17 in mice. The complexity of the interactions leading to disease state are reflected 
in the arrays of disease manifestations. Various susceptibility modes are demonstrated by 
different combinations of gene haplotypes in different strains of animals.  BALB/c mice of H-2d 
haplotype are highly susceptible to MeIA phenotypically demonstrated as lymphoproliferation 
without accompanying immune-complex glomerulonephritis (ICGN) (Jiang and Möller, 1995). 
Mice with B10.D2 haplotype specificity are capable of lymphoproliferation but with less severe 
ICGN than BALB/c mice on exposure to mercury. The H-2d haplotype DBA/2 strain of mice is 
however, resistant to both lymphoproliferation and ICGN (Hultman et al., 1992; Jiang and 
Möller, 1995; Kono et al., 1998; Takeuchi et al., 1995). RT-1n rats are susceptible, whereas RT-11 
haplotypes are resistant (Eneström and Hultman, 1995; Sapin et al., 1984). An H-2s haplotype 
carrying A.SW mice and others show high susceptibility to Hg-induced autoantibodies, 
whereas C57BL/6 strains (H-2b) are less susceptible. DBA/2 mice strains bearing H-2d 
haplotypes are not responsive while H-2k–bearing mice show intermediate susceptibility 
(Dubey et al., 1991; Hultman et al., 1993; Jiang and Möller, 1995; Kono et al., 1998).  
Most SLE susceptibility loci have been mapped in New Zealand hybrid models; at least 12 of 
them are located outside the H-1, the murine major histocompatibility complex, H-2. Three 
regions commonly noted by linkage studies in New Zealand models are found on murine 
chromosomes 1, 4, and 7 (Drake 1995, Kono et al., 1994, Morel et al., 1994); these have 
equivalent syntenies in human loci (Duits et al., 1995; Moser et al., 1998; Salmon et al., 1996) 
that seem to be ethnically distinct (Duits et al., 1995: Salmon et al., 1996). Another region 
along both H-2 class II and TNF-_ gene polymorphisms have been described to act as H-2-
linked predisposing genetic elements for the development of SLE; a very strong evidence 
suggests the contribution of TNF- polymorphism that may be the modulator of the initial 
steps of disease development (The Wbw2 locus (telomeric to H-2)) which was not linked 
with autoantibody production might play a role in determining lupus susceptibility; this 
reaffirms the clustering of functionally related H-2 and non-H-2 genes in the H-2 region on 
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chromosome 17 to be active players in the induction of SLE, a typical example of AD usually 
quoted. Genetic variants do exist in autoimmune susceptibility that may be a basis for health 
disparity among races and forewarns that in dealing with xenobiotics like mercury, 
susceptibility among different racial groups may exhibit differences enough to be taken into 
account in therapeutic managements.  
It has been determined that mercury is immunologically processed uniquely in disease 
pathogenesis. The process involves the antinuclear autoantibody, (AnoA Abs) response 
directed against fibrillarin. The AnoA Abs response directed against fibrillarin is one of the 
most representative manifestations of MeIA that is linked to H-2s (Hanley et al., 2002; 
Hultman et al., 1992; Hultman et al., 1993; Pollard et al., 2002) and, more specifically, to the 
class II I-As molecule, by analysis of H-2 congenic mice (Pollard et al., 2002) and is described 
below. The discovery of potential SLE inducibility on mercury exposure in humans offers 
the opportunity for comparison with data from murine models of SLE. This means that 
identification of potential SLE susceptibility loci in humans offers the chance to compare 
data from murine models of SLE induced by xenobiotics such as mercury. 
Mercury-induced cell death (MeICD) is processed through proteolytic breakdown of fibrillarin, 
a 34kDa MWt macrophage degradable protein component of small nucleolarribonucleoprotein 
particles (snRNPs); the generation of a unique (19kDa) proteolytic fragment required no pre-
interaction between mercury and fibrillarin (Pollard et al, 1997, 2002). 
MeICD was associated with a novel protease transiently synthesized and that stimulate self-
reactivity quite differently from that elicited by full-length protein. Above all xenobiotic-
induced autoimmunity characterized by autoantibody responses against native self-Ag did not 
require pre-interaction between xenobiotic and Ag. The genetically restricted anti-fibrillarin 
autoantibody response of MeIA was not found directed against a fibrillarin-Hg complex as 
expected of MHC-dependent antigen processing although a metal-protein interaction 
occurred (Pollard et al., 1997, 2002). This finding endorses a longstanding belief that SLE-
prone patients could generate self-autoantibodies spontaneously even without any physical 
presence of observable inducers of auto-antigens. Cell demise through MeICD was found to 
be mediated through both nonapoptotic and apoptotic protease activities but the processing 
pathway of fibrillarin was different enough to suggest the action of different proteases 
(Casiano et al., 1996; Pollard et al., 1997, 2002). It was surmised that the cleavage patterns for 
a number of auto-antigens must differ between non-apoptosis (HgCl2, heat, ethanol) and 
apoptosis (anti-Fas) induced cell death (Casiola-Rosen et al., 1995; Pollard et al., 1997). 
Apparently an MHC-restricted autoantibody response and interaction with HgCl2 are 
characteristics that differentiate fibrillarin as an autoantigen in HgCl2-induced 
autoimmunity. The observation that specific cleavage fragments of fibrillarin result from 
HgCl2 induced death and not other forms of cell death means that novel cleavage fragments 
probably act as autoimmunogens. Besides other effects of mercury on the immune system 
including specific cytokine requirements (Gillespie et al., 1995; Ochel et al., 1991; Van Vliet 
et al., 1993), inhibition of Fas-mediated cell death are possible means of terminating self-
tolerance leading to the equivalent of the SLE state (Whitekus et al., 1999).   
As detected in Asthmatic states MeIA is one of the autoimmune models in which TH1/TH2 
imbalance play critical roles (Biancone et al., 1996; Dubey et al., 1991; Hirsch et al., 1982; 
Jiang and Möller, 1995; Mirtcheva et al., 1989; Sapin et al., 1984). Although the mechanism 
by which mercury modifies the immune system is obscure, cationic mercury has a high 
affinity for sulfhydryl groups as the principal site for binding and also has a substantial 
affinity for amines, phosphoryl, carboxyl, and hydroxyl groups (ATSDR, 1999). Mercury is 
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capable of linking with macromolecules including the genetic materials and proteins to form 
complexes that can activate the immune system. Some of the modified proteins may have 
epitopes closely resembling self-immunogens (cryptic antigens) easily leading to 
autoimmune disorders in predisposed individuals (Pollard et al., 1997, 2002; Takeuchi et al., 
1995). The activation of CD4+ and CD8+ T cells requires a prior induction of antigen 
presenting cells (APC) (Jiang and Möller, 1995). Mercury binds to molecules on accessory 
APC cells and transforms molecules on these cells to superantigens capable of activating T 
cells with a particular set of Vβ Ag-binding receptors (Jiang and Möller, 1995). The 
mechanism of MeIA can therefore be differentiated from mechanisms induced by polyclonal 
cell-activators (PCA) such as pokeweed mitogen, PWM. These PCA do not require helper T 
cells assistance in antibody/cellular inductions. 
The presence or absence of IFN-γ on the responder or the non-responder TH1/TH2 cell types 
respectively is thought to be prerequisite in the response to or failure of response respectively 
(Kono et al., 1998). The balance between the TH1/TH2-type responses does not contribute 
directly to autoimmune susceptibility. Rather IFN-γ has been found to be necessary for the 
activation of the immune system to respond to poor epitopes, including both self and non-self 
Ags leading to humoral and cellular auto responses. Dose differentials of IFN-γ appear to 
directly contribute to disease proneness. High dose immunization with Ag and a strong 
adjuvant tend to override the IFN-γ requirement (Ferber et al., 1996; Jones et al., 1997). 
Similarly, a strong genetic predisposition may decrease the threshold for susceptibility enough 
to overcome the IFN-γ requirement (Abbas et al., 1996). Susceptibility to autoimmune diseases 
therefore is generally considered a multi-process with many stages or focal barriers evidenced 
by clinical observations in SLE patients (Andre et al., 1996; Hultgren et al., 1996; Manoury-
Schwartz et al., 1997; Vermeire et al., 1997). Lupus is therefore not inherited as a simple 
Mendelian trait but inherited as a multifactorial and complex trait. 
Latest information confirms that the steps to disease state are characterized by unknown, 
but a large number of susceptibility alleles that give rise to quantitative phenotypic effects. 
Dose effect allows each of the susceptibility alleles to have partial contribution to probability 
of increased disease severity. Still nongenetic factors do contribute to disease susceptibility. 
Recent linkage analyses have revealed over 100 large genomic regions, each represented as a 
quantitative trait locus (QTL)http://www.discoverymedicine.com/tag/quantitative-trait-
locus/ that are associated with increased susceptibility to lupus in mice (Kono et al., 2006) 
and at least 8 validated QTLs in families of lupus patients (Tsao, 2003) that partially overlap 
with the mouse QTLs. Some of the genes contribute to the murine lupus QTLs and 
participate in human SLE. Analysis of these genes is providing insight into pathogenesis of 
human SLE. Use has been made of linkage analyses on some model murine species that 
spontaneously get the lupus; these have involved analyses using 129, MRL-Faslpr, BXSB.Yaa, 
and the F1 hybrid between NZB and NZW (BWF1) and their recombinant inbred 
derivatives, NZM2410 and NZM2328.  
Statistically significant associations between over 100 genomic regions and a lupus-related 
phenotype covering most commonly lupus nephritis or anti-nuclear autoantibody (ANA) 
synthesis have been analyzed. Through substitution techniques whereby for example a QTL 
located in a lupus susceptible strain was replaced with the corresponding genomic interval 
from a resistant strain only 35 of the 100 genomic regions have been so far confirmed (Morel, 
2010). Substitution of the Adnz1 region (in NZM.C57Lc4 congenic strain) in lupus-prone 
NZM2328 mice with the appropriate genomic interval from a non-autoimmune genome led to 
the predicted and expected milder form of glomerulonephritis (Waters et al., 2004). Conversely 
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when the susceptible QTL was bred into a non-autoimmune genome such as B6.NZM2410.Sle1 
mice, which carry the NZM2410-derivedSle1 QTL that showed the strongest association with 
lupus nephritis, produced the expected high levels of ANA (Mohan et al., 1998). The 
implication was that none of the susceptibility loci was sufficient for the induction of full-
blown lupus pathology; each of these loci directed the expression of typical phenotypes such 
as ANA or increased lymphocyte activation (Morel et al., 1997). Therefore each of these 
component phenotypes itself has an independent genetic basis, at least in the mouse. 
In human SLE, risk haplotypes of some of the susceptibility genes such as STAT4 
(Sigurdsson et al., 2008) or IRF7/PHRF1 (Salloum et al., 2010) correspond to production of 
specific autoantibody profiles, suggesting that, as in mice, component phenotypes have 
unique genetic basis also. Confounders make the human analyses harder and difficult to 
explore due to the unavoidable co-expressivity of all other susceptibility alleles. Intersections 
of gene-function properties have been identified among the 35 validated murine susceptibility 
loci. High overlaps have been detected on chromosomes 1, 4, 7, and 13; longer areas are seen 
on chromosome 1; where 16 independent loci have been identified in 6 strains. The overlap is 
very conspicuous in the telomeric portion of chromosome 1 with its equivalent region 
localized in the human 1q23-42 site, a region identified to have many known linkages to 
human SLE (Tsao, 2003). These results tend to imply that at least some lupus-prone genes are 
shared among lupus-prone mouse strains and humans as well in that region. 
Characterization of the original QTLs lupus congenic strains corresponded to a cluster of 
susceptibility loci best demonstrated for Sle1: this corresponds to at least 7 independent loci. 
Phenotypic expressions of Sle1, ANA synthesis have been linked with 3 independent sub-
loci, Sle1a, Sle1b, and Sle1c (Morel et al., 2001). Further studies demonstrated that ANA 
production was feasible by the way of various distinct paths in each of these 3 sub loci. Sle1a 
regulates inducement of activated, nucleosome-reactive CD4+ T cells and inhibits the 
number of CD4+ Foxp3+ http://www.discoverymedicine.com/tag/foxp3/regulatory T cells 
(Chen et al., 2005a; Cuda et al., 2007) with contribution from two independent sub-loci 
within Sle1a, Sle1a1 and Sle1a2 (Cuda et al., 2010). Findings indicate Sle1b function to 
regulate tolerance in immature B cells (Kumar et al., 2006; Wandstrat et al., 2004). Sle1c, with 
its two subloci, Sle1c1 affects germinal center B-cell responses, and Sle1c2, that induces 
appearance of autoreactive CD4+ T cells respectively (Boackle et al., 2001; Chen et al., 2005b). 
Sle1d, sandwiched betweenSle1b and Sle1c2, enhances the severity of glomerulonephritis 
when mice carrying this allele are crossed with NZW mice (Morel et al., 2001). Also 
interlocked between Sle1a and Sle1b is the Fcgr2b the presence of which reduces expression 
on germinal-center B cells and plasma cells (Rahman et al., 2007): a phenotype known to 
have links with lupus patients (Mackay et al., 2006). The obvious deduction is that other 
lupus-prone strains may express identical state of genetic complexity in that region and at 
other loci and therefore is an avenue of either common or strain-specific genes, possible 
determinant of individual gene level and hence probable disparity among races. 
Synergistic interactions between specific loci were also found to be linked with co-expressivity 
found in Sle1 and Yaa on a B6 background that led to severe lupus nephritis (Croker et al., 
2003); the co-expression of either Sle2 or Sle3 with Yaa achieved only the phenotypes of either 
parent strains. In humans genetic interactions have been harder to identify for SLE (Harley et 
al., 2009) partly due to the extreme genetic diversity co-segregating with any gene or locus of 
interest. Additive effects have, however, been identified between risk variants ofSTAT4 and 
IRF5 (Abelson et al., 2009; Sigurdsson et al., 2008), suggestive of specific genetic interactions in 
human SLE. The co-expression of Sle1, Sle2, and Sle3 on a B6 background has been seen to give 
rise to fully penetrant lupus nephritis (Morel et al., 2000).  
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A clear demonstration of mercury’s possible influence on several metabolic pathways is 
seen in the number of possible pathways affected Figures 1-3: red coloration indicates 
upregulated genes and blue coloration indicates inhibition of gene expression on exposure 
to mercury. Mercury exposure leads to effects on several of biochemical pathways involving 
products of genes in cell cycle signaling: G2/M checkpoint regulation, TGF-β, IGF-1, insulin 
receptor activity, chemokine, Wint/ β-catenin, integrin, PPAR, SAPK/JNK, JAK/Stat, B and 
T cell receptor, G-protein-coupled receptor, IL-2, ERK/MAPK, death receptor signaling such 
as apoptosis, NF-κB, cell cycle and above all immune responses regulated by most of these 
genes. Pathways indicated are examples of mercury’s potential to affect susceptible 
individuals that carry MHC haplotype combinations and who are prone to develop not only 
autoimmune and/or cancerous diseases but risk factors for obesity and other chronic 
associated diseases yet to be evaluated through mercury toxicity. 
Our studies confirm that several genes in haplotype combinations are subjected to pronounced 
changes on exposure to environmental mercury. Among these genes we mention the 
transforming factor beta (TGF-β) superfamily of cytokines. This group of family genes is 
associated with regulating the cell cycle essentially for maintenance of normal immunological 
homeostasis and lymphocyte proliferation. Proteins synthesized from these genes play 
important roles in regulating essential cellular functions such as differentiation and apoptosis. 
TGF-β superfamily of cytokines is over expressed on mercury exposure. Some cells, 
lymphocytes among them are known to respond to TGF-β by undergoing apoptosis. 
Apoptosis may lead up to accumulation of self-antigens within a localized part of the body 
and break the body’s immunological tolerance to give rise to the autoimmune state. The 
mechanisms regulating this process are yet to be clarified. Over expression of TGF-β cytokines 
induced by mercury may lead to transcription of Smad6 and Smad7; these molecules act as 
inhibitors of TG  apoptosis is necessary for maintenance of tolerance. Failure to eliminate 
immature B cells has the consequence of autoimmune diseases and cancer development. 
Several aberrant functions associated with many pathways involving the cell cycle and the 
immune responses are therefore possible through intoxication with mercury. Such wide effects 
of mercury translate to risk associations when disease susceptibility is our prime concern. This 
means that it is only at the right genetic combinations and the appropriate line-up of 
associated genes that disease susceptibility ensues. That goes to argue for severity of disease as 
well. Mercury-exposed individuals carrying the appropriate allelic-combinations located on 
specific haplotypes are prone to develop autoimmune diseases.  
Not only do some metals induce autoimmunity but can also affect the nervous system when 
present during fetal development. Mercury readily crosses the human placenta and 
accumulates in fetal tissue during gestation (David et al., 1972). Mercury can concentrate in 
umbilical cord blood significantly more than in the maternal blood (Sakamoto et al., 2004). 
This could affect various developmental processes (Clarkson, 1997; Hassett-Sipple et al., 
1997; Pendergrass et al., 1997) leading to behavioral dysfunctions associated with autism 
(Bernard et al., 2001) and others. Arrhythmias and cardiomyopathies have also been 
associated with mercury toxicity. Mercury intoxication can result in mental retardation, 
cerebral palsy, seizures and ultimately death (WHO, 1990). For the early protection of 
children, it becomes necessary to come up with reliable and relevant tools that identify 
chemicals with developmental neurotoxicity potential. Once identified, these neurotoxicants 
need to come under regulatory practices in order to restrict their use and to control exposure 
as, for example in the case of lead (Silbergeld, 1997).  
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A clear demonstration of mercury’s possible influence on several metabolic pathways is 
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5.2 Spontaneous lupus: who are at risk 
To date genetic mappings endorse genetic susceptibility to autoimmunity and confirms it to be 
highly associated with individuals with certain combinations of genes in MHC-haplotype 
linkages: Fasl (CD95/L), Sap (serum amyloid P-component), Fcγr2b (FcγRIIB), Cr2 
(CD21/CD35) and Ptprc (CD45) amongst them. Deficiency in individuals of Fcer1g (FcRγ-
chain) results in resistance to autoimmunity. These genes are not by any means exhaustive. As 
mentioned above gene type and dosage seem to determine severity of autoimmune diseases. 
This indicates that susceptibility and/or initiation factors operate via multiple pathways 
subjected to regulatory or focal checkpoints that finally give rise to the pathological state. The 
situation is exemplified by SLE, type 1 diabetes, IDDM and RA patients. In genetically 
predisposed patients the synthesis of autoantibodies and/or the generation of cellular attack of 
self-antigens may follow different pathways. Such mechanisms are known to be influenced by 
gene dosage and contributions from ethnic and environmental background. Clinical 
management or treatment schedules need to vary accordingly.  
Thus lupus susceptibility genes are now of deep interest to immunologists/allergists and 
are being identified in the mouse and their contribution to the disease state is being actively 
sought through analysis of rare or common variants. Discoveries of the roles of the 
susceptible lupus genes mainly in the mouse have given insights and critical lead to links 
with human SLE disease patterns. However the molecular mechanisms by which they 
contribute to autoimmune pathogenesis are yet to be clearly defined. The multifactorial 
complex nature of lupus disease susceptibility is currently thought to operate via a 
combination of common genetic variants that result in small phenotypic effects; rare 
variants end in large phenotypic effects (Cirulli et al., 2010). So far identified common 
variants in lupus susceptibility genes include the PTPN22 or IRF5 among others. Genome 
wide Association studies (GWAS) and analysis also reveals scarce variants such as C4 and 
TREX (Graham et al., 2009). Rare SIAE variants responsible for the loss-of-function have 
been linked with autoreactive B cells (Surolia et al., 2010); the lpr and gld in humans 
represented in lupus-prone murine strains lead to a functional decline in CD95 or C95L, 
respectively (Cohen et al., 1992); the Yaa mutation, an equivalent of a Tlr7 gene duplication 
(Pisitkun et al., 2006), and a mutation in the Coronin A1 gene in the B6.Faslpr/Scr strain that 
regulates CD4+ T cell activation (Haraldsson et al., 2008) have all been located. 
The murine equivalent of humans common variant genes have now been identified for SLE. 
NZB and NZW allele of Fcgr2b encode a negative regulator of B-cell signaling and 
predicates an autoimmune phenotype (Rahman et al., 2007; Xiu et al., 2002). Studies 
currently endorse links between FCGR2B variants and human SLE (Lee et al., 2009). Cr2 
polymorphism that function to encode the complement receptor type 2, a B-cell co-receptor 
known to contribute to the Sle1c1 phenotypes (Boackle et al., 2001; Chen et al., 2005b). SLE 
patients do carry a common CR2 haplotype more frequently than in healthy controls; and 
follicular dendritic cells (FDC) express a novel CR2 splice variants of SLE patients (Douglas 
et al., 2009; Wu et al., 2007). Sle1b corresponds to polymorphisms in four signaling 
lymphocytic activation molecule (SLAM) family member genes (Wandstrat et al., 2004), 
including Ly108 directly implicated in the regulation of B-cell tolerance (Kumar et al., 2006). 
Variants of SLAMF3 (LY9) and SLAMF4 (CD244) have also been linked with human SLE 
(Graham et al., 2008; Suzuki et al., 2008). For the Sle1 sub-loci, Sle1a.1 corresponds to the 
expression of a novel splice isoform of the Pbx1 gene that is associated with increased CD4+ 
T cell activation in both mice and humans (Cuda et al.,2007, 2010). Searches are still going on 
to reveal the mechanisms linking Pbx1 expression and T cell phenotypes. Complex 
 
Autoimmune Diseases: The Role of Environment and Gene Interactions 
 
21 
phenotypic expressions are associated with Sle3 locus that includes myeloid cell-induced 
CD4+ T-cell activation (Zhu et al., 2005) and mild glomerulonephritis (Mohan et al., 1999). 
Kallikrein (Klk) polymorphic genes, serine esterases that regulate a wide spectrum of 
biological functions in the kidney including inflammation, apoptosis, redox balance, fibrosis, 
and local blood pressure located in the Sle3 interval have been linked with increased 
susceptibility to nephritis in SLE mice and SLE patients (Liu et al., 2009).  
To date close to 22 identified and validated loci with confirmed associations with SLE 
susceptibility (Graham et al., 2009) have been mentioned in the literature. These loci are 
placed in one of four groups on the basis of mouse characteristics (Morel, 2010). Group one 
genes are thought to be directly implicated in lupus pathogenesis through their capacity to 
either induce or modulate disease in the mouse. A representative one is STAT4, a 
transcription factor linked with signal transduction of the IL-12 and IL-23 receptors that has 
a critical role in regulating the effector functions of helper T cells (Korman et al., 2008). In 
addition, Stat4 deficiency modifies disease severity in the NZM lupus models (Jacob et al., 
2003; Xu et al., 2006). The IRF5 whose risk alleles are associated with an increased 
production of interferon alpha (IFNα) in SLE patients (Niewold et al., 2008) is a puzzling 
piece. In two different murine models (Richez et al., 2010; Savitsky et al., 2010) IRF5 
however, failed to establish a link between IRF5 and IFNα, pointing instead to a 
transcriptional control of the IgG2a locus. It is still not clarified if these discrepancies reflect 
species-specific functions of IRF5 or whether the association between IRF5 polymorphisms 
and IFNα production does not involve a direct mechanistic link between the two genes. The 
second group covers GWAS-identified SLE susceptibility genes with known functions in the 
murine immune system but without current established link with lupus pathogenesis in 
man. For example, tumor necrosis factor alpha-induced protein 3 (TNFAIP3) and its binding 
partner TNFAIP3-interacting protein 1 (TNIP1) are negative regulators of nuclear factor κB 
signaling and tumor necrosis factor (TNF)-mediated apoptosis (Vereecke et al., 2009). 
These findings imply that overexpression of TNFAIP3 would inhibit pathogenesis in lupus-
prone mice; its deficiency would exacerbate disease. Newly discovered genes without a 
known function are placed in the third category of genes associated with SLE in GWAS. The 
JAZF1 in this group has now been associated with multiple human phenotypes (Gateva et 
al., 2009) still awaiting detailed basic functions workout. FCGR2A belongs to the fourth 
group of genes and is associated with SLE risk in GWAS but has no equivalent ancestral 
gene in the mouse, and therefore cannot yield information for human SLE analysis.  
6. Conclusions  
The Biosphere is gradually being overwhelmed with several substances from industrial and 
other activities that has direct role in changes in the incidence and prevalent measures in 
various diseases. Among these diseases the autoimmune state seems to be a major avenue 
that impacts and disrupts the homeostatic mechanisms. Autoimmune diseases like asthma 
are excellent representation of environmental problems acting as indicators of atmospheric 
as well as the air, the soil and water bodies that are affected by pollutional activities. Thus 
rises in the incidence and the prevalence of AD within the communities count as direct role 
of the environmental pollution affecting the gene pool and becomes public health concern. It 
is important to follow the effects of these substances and the pathways of disease 
pathogenesis. Currently GWAS is becoming a powerful tool or vehicle that is helping in the 
understanding the functional roles of the polymorphic alleles particularly those alleles 
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prevailing across ethnic groups. Analyses of population differences in autoimmune state is a 
first and important step in unraveling the complexity of these genes affected by 
environmental pollutants represented by mercury. It is common knowledge now that 
environmental contaminants through the food chains occur; pesticides are found in fruits, 
vegetables and cereals of European origin estimated to contain about 300 biocides in food 
products (Commission of the European Communities, 2007, Suñol, 2009), also seen in the 
urine in majority of US population (Mage et al., 2004); and human adipose tissue, serum, and 
placenta in agricultural areas (López-Espinosa et al., 2007). 
Studies in the laboratory reveal increasing concern as to whether pesticides currently used can 
cause neurodevelopmental toxicity (Bjorling-Poulsen et al., 2008). Similar concerns go for 
several substances released into the environment. Regulatory checks help to determine the role 
they play in diseases seen in the population. We are at a time that full-genome association 
analyses can produce equivocal array of data, some of which are likely to provide vital new 
biological insights into autoimmunity that may hold the key to novel therapies. The state of the 
matter is that susceptibility alleles of autoimmune diseases are now believed to fall into two 
general groups: (1) those genes that confer susceptibility to multiple autoimmune phenotypes 
(CTLA4, TPN22, PDCD1, FCRL3); and (2) those that confer tissue specificity to autoimmunity 
(INS in T1D, PADI4 in RA). Of note also is that allelic diversity within the MHC is also a major 
determinant of tissue specificity. Having a clear understanding of the genetic basis of 
autoimmunity and the application of this knowledge to appropriate clinical therapies may 
provide clinical social medicine benefits in several ways. It may be possible to have early 
diagnostic tools to detect high risk individuals at the highest genetic risk in prospective 
longitudinal studies aimed at defining the role of manageable/preventable environmental 
influences on disease. Also the identification of genetically susceptible individuals will enable 
targeting of preventive therapy once it becomes available at or evasion of detrimental 
environmental influences. It may also be helpful to align genetic profiles with prognosis as 
seen in degrees of disease severity in SLE, RA, IDDM etc or response to specific therapies so 
that more appropriate or aggressive treatments can be selectively targeted. This will 
particularly be of unimaginable use in health disparity studies.  
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that more appropriate or aggressive treatments can be selectively targeted. This will 
particularly be of unimaginable use in health disparity studies.  
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1. Introduction 
Transcription factors of the interferon regulatory factor (IRF) family have a critical role in 
the activation of interferon (IFN) genes. All cellular IRFs share a region of homology in the 
amino terminus encompassing a highly conserved DNA binding motif characterized by five 
tryptophan repeats, but show variability in the carboxy (C-) terminal part of the IRF 
polypeptides. While some of these IRFs like IRF-3 and IRF-7 have a critical role in the 
antiviral response, the others like IRF-1, IRF-4 and IRF-8 have basic roles in the development 
and function of lymphoid cells. Recently, the importance of IRF-5 in the antiviral and 
inflammatory response in vivo has been clearly established, but it was also shown that this 
IRF has a basic function in apoptosis and B cells and macrophage differentiation. More 
interestingly, the role of IRF-5 pathogenicity in autoimmune diseases has been also 
established, as IRF-5 has been identified as one of the primary risk factors associated with 
Systemic Lupus Erythematosus (SLE) and other autoimmune diseases. This chapter will 
review the current knowledge of the mechanisms of IRF-5 activation by the TLR7 pathway 
and the genetic modifications of IRF-5 that may contribute to the dysregulation of the innate 
and adaptive immune response associated with the autoimmune disease. Furthermore we 
will summarize the contribution of the SLE mouse models to our understanding of the role 
of IRF-5 and TLR7 in the induction of the autoimmune diseases. 
2. Type I IFN and SLE 
Autoimmune diseases are characterized by a dysregulated expression of Type I IFN, hyper-
reactivity of B cells and the production of auto-antibodies. Leukocytes from patients with 
different autoimmune disorders such as SLE, psoriasis, dermatomyositis and rheumatic 
arthritis all show overexpression of interferon-induced genes. Furthermore, clinical use of 
IFNα leads to development of autoimmune syndromes like type I diabetes, psoriasis and 
inflammatory arthritis (Gota and Calabrese 2003). Till date, it has not been determined 
whether the uncontrolled production of Type I IFN is a consequence of dysregulated 
function of the immune system or due to genetic variations of the factors involved in IFN 
induction or IFN signalling pathway. Type I IFNs are produced by all leucocytes in response 
to TLR7 or TLR9 activation and the plasmacytoid dendritic cells (pDC) are the most active 
producer of IFNα. pDCs represent only about 1% of the PBMCs, but they can secrete up to 
109 IFNα molecules per cell within 12 hours (Fitzgerald-Bocarsly et al., 2008). 
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SLE is a classical systemic autoimmune disease. The link between SLE and Type I IFN is 
indisputable, reviewed in (Crow 2009). The elevation of type I IFNs is the hallmark of 
autoimmune diseases. In SLE, there is a correlation between IFN levels and the presence of 
anti-ds (double-stranded) DNA antibodies and disease progression. Interferon-stimulated 
genes (ISG) signature is a marker for severity of the disease (Baechler et al., 2003). Also the 
high levels of IFNα are a heritable risk for SLE (Niewold et al., 2007). 
Clinical findings show that elevated pDC populations along with higher IFN mRNA levels 
present in dermal lesions of SLE patients contribute to elevated IFN levels. (Blomberg et al., 
2001). pDCs also accumulate in active lupus nephritis and migrate to the glomeruli 
(Silvestris et al., 2003). Immune complexes containing nucleic acid found in the serum from 
lupus patients are known to trigger a type I IFN response in pDCs (Bengtsson et al., 2000). 
The IgG RNA/DNA complexes are internalized via receptors [fragment crystallizable 
gamma receptor IIa (FcγRIIa)] expressed on pDCs, and stimulate endosomic TLR7 or TLR9 
followed by activation of IRF-5 and IRF-7 and IFNα production. Both TLR7 and TLR9 are 
expressed in pDCs. RNA-containing immune complexes signalling through TLR7 are 
especially efficient in inducing IFNα and there is a direct correlation between serum levels 
of IFNα and the presence of autoantibodies to RNA-protein complexes (Vollmer et al., 2005). 
Autoantibodies reactive against RNA-containing autoantigens are detected in the 
cerebrospinal fluid of patients with cerebral lupus (Santer et al., 2009). An indirect evidence 
for the role of IFNα in autoimmune disease is the observation showing that patients 
receiving anti-IFN therapy for other diseases (such as HCV-related hepatitis treated with 
IFNα) develop autoantibodies and SLE-like syndrome (Ho et al., 2008). Another indirect 
observation is the induction of anti-dsDNA antibodies and full-blown SLE during a clinical 
anti-TNFα therapy in patients with rheumatoid arthritis (RA) (De Rycke et al., 2005). In vitro, 
TNFα suppresses IFNα expression and thus suppression of TNFα in patients with arthritis, 
with the antibody treatment, may result in enhancement of IFNα production.  
3. Induction of innate antiviral response 
Almost all nucleated cells respond to viral infections by producing Type I IFNs. Type I IFNs 
(IFNα and IFNβ) are an essential part of the antiviral response; however, their unregulated 
production is associated with pathology. Virus mediated Type I IFN induction is a classical 
example of transcriptional regulation. Virus infection induces activation of two families of 
transcriptional factors, NFκB and IRF family. The IRF proteins possess a common DNA 
binding domain at the N terminus characterized by a helix-turn-helix motif. The motif is 
rich in tryptophan residues and binds the GAAA and AANNGAAA domains in the virus 
responsive element (VRE) of Type I IFN promoters. The C-terminal regions of IRFs are 
distinct and contain IRF-associated domains (IADs) which are required for protein-protein 
interactions: either with other IRFs or other transcriptional factors. Two members of the IRF 
family, IRF-3 and IRF-7 are the major players in the induction of Type I IFN (Au et al., 1998; 
Au et al., 1995; Marie et al., 1998; Ronco et al., 1998). In the uninfected cell, they are localized 
to the cytoplasm, but in response to a viral infection, they are phosphorylated and 
translocate to the nucleus where they associate with the co-activator CREB-binding protein 
and stimulate transcription of IfnA and IfnB genes. While IRF-3 alone is sufficient for 
induction of IfnB gene, IRF-7 expression is essential for expression of the entire battery of 
IfnA genes, reviewed in (Pitha and Kunzi 2007). Both IRFs can be activated by a signalling 
pathway that initiates upon binding of viral dsRNA to membrane Toll-like Receptors, TLR3 
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and TL4, or cytoplasmic receptors, Retinoic acid-Inducible Gene (RIG)-I or Melanoma 
Differentiation-Associated gene (MDA)-5. Recent data, however, shows that IRF-3 can be 
also activated by binding of the viral DNA to the cytoplasmic receptor, Absent In Melanoma 
(AIM)-2 (Ishikawa and Barber 2011).  
4. Role of IRF-5 in the induction of an antiviral response 
Another IRF, IRF-5 also stimulates Type I IFN production in infected cells. IRF-5 differs 
from IRF-3 and IRF-7 in activation and function. While IRF-3 and IRF-7 are induced by 
TLR3, TLR4 or RIG-I/MDA5 pathways, IRF-5 is activated only by TLR7 and TLR9 in a 
Myeloid Differentiation factor 88 (MyD88)-dependent pathway and consequently, only 
certain viral infections (Newcastle disease virus, NDV; VSV; and HSV) can activate IRF-5 
(Barnes et al., 2001). The activation of IRF-5 results in the transcription of nine differently 
alternatively spliced IRF-5 mRNAs, these isoforms are cell-type specific and have distinct 
functions (Mancl et al., 2005). 
Ectopic expression of IRF-5 induces several IFNα subtypes; however, the subtypes induced 
by IRF-5 and IRF-7 are distinct, e.g. IRF-7 induces mostly IfnA1 while the major subtype 
induced by IRF-5 is IfnA8 (Barnes et al., 2001).  
5. Downstream effectors of IFNs 
The Type I IFN system is well characterized and well-studied. Type I IFNs mediate their 
action by engaging the ubiquitously expressed IFNα receptor (IFNAR) complex which has 
two units, IFNAR1 and IFNAR2, reviewed in (Uze et al., 2007). On binding to their 
respective receptors, IFNs exert their multiple effects through receptor-mediated signalling 
pathways, resulting in the induction of IFN-stimulated genes (ISGs). The major signalling 
pathway is the JAK-STAT pathway; beginning from the Janus kinases (JAK1 and Tyk2) and 
followed by tyrosine phosphorylation of pre-existing signal transducer and activator of 
transcription (STAT). On phosphorylation, STAT1 and STAT2 assemble together, associate 
with interferon regulatory factor 9 (IRF-9) and form a multimeric complex (ISGF3) that 
translocates to the nucleus, where it interacts with interferon-responsive elements (ISRE) 
present in the 5’ flanking region of ISG (Improta et al., 1994; Levy and Darnell 2002). While 
ISGF3 seems to be the main transcription factor regulating transcription of ISGs, Type I IFN 
also stimulates formation of STAT1 homodimers that bind to a slightly different DNA 
domain, the IFNγ activated site (GAS), present in the promoters of ISG that can be induced 
both by Type I IFN and IFNγ. The signalling by Type I IFN is not limited to the JAK–STAT 
pathway as this receptor can also activate both the Mitogen-Activated Protein kinase 
(MAPK) and Phosphoinositide 3-kinase (PI3K) pathways (Platanias 2005). Activation of 
IFNs through the IFNARs followed by amplification of the signal via downstream pathways 
results in activation of more than 300 ISGs. The function of the majority of ISGs has yet to be 
determined; however, the antiviral function of several of the ISG have been recently 
characterized, and the proteins described (Samuel 2001; Schoggins et al., 2011). 
Among these, ISG15 is one of the very early induced ISGs that influence a panoply of 
cellular functions; ISG15 is a ubiquitin homologue which is covalently attached to lysine 
residues (ISGylation) of the targeted proteins. Recent evidence indicates the existence of 
cross-talk between ubiquitinylation and ISGylation. Since ubiquitinylation is a component of 
many cellular and stress induced signalling pathway, ISGylation can effectively interfere 
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and TL4, or cytoplasmic receptors, Retinoic acid-Inducible Gene (RIG)-I or Melanoma 
Differentiation-Associated gene (MDA)-5. Recent data, however, shows that IRF-3 can be 
also activated by binding of the viral DNA to the cytoplasmic receptor, Absent In Melanoma 
(AIM)-2 (Ishikawa and Barber 2011).  
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alternatively spliced IRF-5 mRNAs, these isoforms are cell-type specific and have distinct 
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by IRF-5 and IRF-7 are distinct, e.g. IRF-7 induces mostly IfnA1 while the major subtype 
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action by engaging the ubiquitously expressed IFNα receptor (IFNAR) complex which has 
two units, IFNAR1 and IFNAR2, reviewed in (Uze et al., 2007). On binding to their 
respective receptors, IFNs exert their multiple effects through receptor-mediated signalling 
pathways, resulting in the induction of IFN-stimulated genes (ISGs). The major signalling 
pathway is the JAK-STAT pathway; beginning from the Janus kinases (JAK1 and Tyk2) and 
followed by tyrosine phosphorylation of pre-existing signal transducer and activator of 
transcription (STAT). On phosphorylation, STAT1 and STAT2 assemble together, associate 
with interferon regulatory factor 9 (IRF-9) and form a multimeric complex (ISGF3) that 
translocates to the nucleus, where it interacts with interferon-responsive elements (ISRE) 
present in the 5’ flanking region of ISG (Improta et al., 1994; Levy and Darnell 2002). While 
ISGF3 seems to be the main transcription factor regulating transcription of ISGs, Type I IFN 
also stimulates formation of STAT1 homodimers that bind to a slightly different DNA 
domain, the IFNγ activated site (GAS), present in the promoters of ISG that can be induced 
both by Type I IFN and IFNγ. The signalling by Type I IFN is not limited to the JAK–STAT 
pathway as this receptor can also activate both the Mitogen-Activated Protein kinase 
(MAPK) and Phosphoinositide 3-kinase (PI3K) pathways (Platanias 2005). Activation of 
IFNs through the IFNARs followed by amplification of the signal via downstream pathways 
results in activation of more than 300 ISGs. The function of the majority of ISGs has yet to be 
determined; however, the antiviral function of several of the ISG have been recently 
characterized, and the proteins described (Samuel 2001; Schoggins et al., 2011). 
Among these, ISG15 is one of the very early induced ISGs that influence a panoply of 
cellular functions; ISG15 is a ubiquitin homologue which is covalently attached to lysine 
residues (ISGylation) of the targeted proteins. Recent evidence indicates the existence of 
cross-talk between ubiquitinylation and ISGylation. Since ubiquitinylation is a component of 
many cellular and stress induced signalling pathway, ISGylation can effectively interfere 
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with these pathways. Activation of ISGylation proceeds by similar enzymatic pathways as 
used for ubiquitinylation, and interestingly, all enzymes required for ISGylation are induced 
by IFN. Similar to ubiquitinylation, the ISGylation process is reversible and de-ISGYlating 
enzymes provide an additional level of control over the entire process. More than a hundred 
ISG15 targets have been identified, and some of these genes such as RIG-I, JAK1, Protein 
Kinase R (PKR) and STAT-1 are part of the IFN response system while others have different 
cellular functions. However, unlike the degradation-driven ubiquitinylation, ISGylation in 
many cases inhibits ubiquitinylation, reviewed in (Skaug and Chen 2010).  
Another IFN induced gene with multiple functions is a constitutively expressed dsRNA 
dependent PKR whose expression is enhanced by Type I IFN. The inactive monomers of 
PKR are activated by viral RNA, PKR is phosphorylated and forms active dimers. Activated 
PKR catalyzes phosphorylation of several substrates including the α subunit of the initiation 
factor eIF-2 (eIF-2α) (Samuel 1993), as well as the transcription factor inhibitor IκB (Kumar et 
al., 1994). Thus PKR affects both viral replication and many cellular functions, reviewed in 
(Pindel and Sadler 2011). 
Other ISGs such as cytidine deaminases of the APOBEC family and adenosine deaminase 
ADAR1 have been recently characterized but their cellular functions are yet to be 
determined (Chiu and Greene 2008; George et al., 2011; Schoggins et al., 2011). Also 
interesting is a recent finding from the Rice group (Schoggins et al., 2011) which shows that 
IRF-1, induced by both IFNγ and Type I IFN has antiviral activity against a large group of 
distinct viruses and that this antiviral activity is not IFN-mediated. This group also 
identified large number of novel antiviral ISGs and showed that a number of these proteins 
function at the translational level. 
In addition, there are reports of host-produced antiviral micro-RNAs (miRNAs) in response 
to IFNs (Hansen et al., 2010; Lagos et al., 2010; O'Connell et al., 2007; Pedersen et al., 2007). 
Even though first identified in fishes and invertebrates, it was assumed that miRNAs were 
not elicited as a first line of defence in mammals. However, microarray analysis of general 
IFNα/β response identified a few candidate miRNAs which are increased or attenuated in 
response to IFNα/β. Some of these target IFNB mRNA and thus serve as negative regulators 
of the IFN system, while others are induced during the innate antiviral response. Therefore 
it seems that IFN-induced cellular miRNAs may represent fine-tuning of the IFN system. 
6. Role of IRF-5 in the innate immune response 
The transcription factor IRF-5 plays a key role in the innate antiviral and inflammatory 
response. In vitro studies had initially indicated that IRF-5 may be involved in the antiviral 
response (Barnes et al., 2001), and when genetically modified Irf-5-/- mice became available, 
the importance of IRF-5 in the antiviral and inflammatory response in vivo was also 
demonstrated (Paun et al., 2008; Takaoka et al., 2005). Irf-5-/- mice exhibit high susceptibility 
to viral infection and show reductions in serum levels of Type I IFN as well as inflammatory 
cytokines such as IL-6 and TNFα. IRF-5 shows a cell type specific expression in B cells, DC, 
monocytes and macrophages. In contrast to IRF-3 and IRF-7, IRF-5 is activated only by TLR7 
and TLR9 MyD88 dependent pathway and unlike IRF-3 and IRF-7, not by TLR3 or RIG I 
pathways (Schoenemeyer et al., 2005). The MyD88 mediated activation of IRF-5 involves the 
formation of a tertiary complex consisting of MyD88 and tetramers of IRAK1, IRAK4, 
TRAF6 and IRF-5 and IRF-7. It was shown that both K63 ubiquitinylation by TRAF6 and 
phosphorylation are necessary for activation and translocation of IRF-5 to the nucleus, but 
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the kinase that activates IRF-5 has not yet been identified (Balkhi et al., 2008). Activated IRF-
5 forms homodimers and heterodimers with IRF-3 and IRF-7, but while the IRF-5 synergizes 
with IRF-3 activation, it inhibits the transcriptional activity of IRF-7 (Barnes et al., 2004). In 
addition to its role in the early inflammatory response, IRF-5 also has pro-apoptotic 
functions. 
The observations discussed above show an important role for IRF-5 in the regulation of 
early inflammatory cytokines and chemokines’ expression, as well as Type I IFN genes. The 
function of IRF-5 was also examined in vivo using the genetically modified Irf-5-/- mouse 
model. These mice exhibit an increased susceptibility to viral infection and reductions in 
serum levels of type I IFNs as well as inflammatory cytokines such as interleukin-6 and 
tumor necrosis factor alpha (TNFα) (Paun et al., 2008; Takaoka et al., 2005). Examination of 
the cells type in which expression of inflammatory cytokines and IFN depends on IRF-5 
show that IRF-5 is required for the TLR9 mediated induction of IFN β in DC, but not in 
peritoneal macrophages, while the stimulation of inflammatory cytokines expression was 
dependent on IRF-5 in both cell types. These data indicate that the function of IRF-5 may be 
cell type specific. 
Unexpectedly, approximately 80% of Irf-5-/- mice, (94% C57BL/6) developed an age-related 
splenomegaly, associated with a dramatic accumulation of CD19+B220− B cells (Lien et al., 
2010). The age-related splenomegaly was dependent on genotype, and developed in mice 
with the mixture of 129 and C57BL/6 genotype, but did not occur in mice that were 98% of 
C57BL/6 background (unpublished data). Interestingly, the Irf-5-/- C57BL6 mice have 
attenuated responses to T-cell dependent (TD) and T-cell independent (TI) antigens 
(unpublished data), with a marked down-regulation of serum levels of antigen specific 
IgG2a and IgG2c. The Taniguchi group (Savitsky et al., 2010) has shown that the down-
regulation of IgG2a production occurred also in in vitro cultured IRF-5 knockout DC cells 
stimulated with CpG oligodeoxynucleotides. The synthesis of IL-6 and TNFα was also 
down-regulated in IRF-5 knockout B cell stimulated with TLR 9 ligand, indicating that the 
function of these cells is impaired (Lien et al., 2010). 
7. Role of IRF-5 in autoimmune diseases 
The demonstration that IRF-5 is important not only for the induction of Type I IFN genes, 
but also for the inflammatory cytokines gave new insights into the regulation of the innate 
inflammatory response. However, there is also accumulating evidence that IRF-5 may play 
an important role in the dysregulation of the immune system leading to autoimmune 
diseases. Several distinctly spliced human IRF-5 isoforms (designated variants 1-10), which 
show cell type-specific expression and distinct cellular localization, were identified (Mancl et 
al., 2005). The most common variations are insertions or deletions in exon 6. The majority of 
IRF-5 isotypes do not differ in their DNA binding sites, but differ in the interaction domain. 
The transcription of IRF-5 is started at one of the three different promoters. Transcript 
initiated at exon 1A and 1B are expressed constitutively in B cells and pDC, while transcript 
1c is induced by IFN. It should be however noted that spliced variants of IRF-5 were 
identified only in human cells, while in inbred strains of mice, IRF-5 encodes for a dominant 
unspliced transcript. 
It has been known for a long time that the autoimmune disease SLE exhibits genetic 
predisposition, which was later mapped to a specific region on human chromosome 6. 
When the sequence of the human genome became available, it was found that the genomic 
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with these pathways. Activation of ISGylation proceeds by similar enzymatic pathways as 
used for ubiquitinylation, and interestingly, all enzymes required for ISGylation are induced 
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the kinase that activates IRF-5 has not yet been identified (Balkhi et al., 2008). Activated IRF-
5 forms homodimers and heterodimers with IRF-3 and IRF-7, but while the IRF-5 synergizes 
with IRF-3 activation, it inhibits the transcriptional activity of IRF-7 (Barnes et al., 2004). In 
addition to its role in the early inflammatory response, IRF-5 also has pro-apoptotic 
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the cells type in which expression of inflammatory cytokines and IFN depends on IRF-5 
show that IRF-5 is required for the TLR9 mediated induction of IFN β in DC, but not in 
peritoneal macrophages, while the stimulation of inflammatory cytokines expression was 
dependent on IRF-5 in both cell types. These data indicate that the function of IRF-5 may be 
cell type specific. 
Unexpectedly, approximately 80% of Irf-5-/- mice, (94% C57BL/6) developed an age-related 
splenomegaly, associated with a dramatic accumulation of CD19+B220− B cells (Lien et al., 
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show cell type-specific expression and distinct cellular localization, were identified (Mancl et 
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IRF-5 isotypes do not differ in their DNA binding sites, but differ in the interaction domain. 
The transcription of IRF-5 is started at one of the three different promoters. Transcript 
initiated at exon 1A and 1B are expressed constitutively in B cells and pDC, while transcript 
1c is induced by IFN. It should be however noted that spliced variants of IRF-5 were 
identified only in human cells, while in inbred strains of mice, IRF-5 encodes for a dominant 
unspliced transcript. 
It has been known for a long time that the autoimmune disease SLE exhibits genetic 
predisposition, which was later mapped to a specific region on human chromosome 6. 
When the sequence of the human genome became available, it was found that the genomic 
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region associated with predisposition to SLE showed the presence of several genes 
associated with the Type I IFN induction and signalling pathway. One of these genes is IRF-
5 and a common SNP haplotype in IRF-5 (rs 2004640T) was identified in Scandinavian 
cohorts as a risk factor for SLE. Interestingly, the same SNP haplotype of IRF-5 has been 
shown later to be associated with numerous other autoimmune disorders, such as 
rheumatoid arthritis (RA) (Sigurdsson et al., 2007) and others (Kozyrev and Alarcon-
Riquelme 2007). Three specific functional alleles of IRF-5 were identified that define risk 
factors for SLE (Graham et al., 2006). The rs 2004640 G allele expresses isotypes initiated 
from exon 1A and 1C, while the rs 2004640T allele expresses transcripts from exon 1B, which 
provides a stronger promoter and increases the expression of IRF-5. The second SNP is the 
in-frame insertion- of 30 bp in exon 6 that alters the proline, glutamic acid and serine rich 
regions and encodes a protein that is similar to unspliced isotype IRF-5v5. The third SNP 
introduces a variation in the poly A termination site that makes the 3’UTR shorter which 
leads to an increased stability of IRF-5 mRNA (Graham et al., 2006). All together, these 
modifications in the IRF-5 gene result in elevated levels of IRF-5 protein which is larger than 
the proteins encoded by the spliced IRF- transcripts. Many additional SNPs in IRF-5 have 
been later identified and are reviewed in (Kozyrev and Alarcon-Riquelme 2007). The high 
levels of lupus associated IRF-5 expression have been detected in PBMCs of Lupus patients 
(Feng et al., 2010). Dysregulated expression of Type I IFN is associated with SLE 
pathogenesis (Niewold et al., 2007) and gene array analysis of PMBCs from SLE patients has 
revealed elevated expression of IFN-stimulated genes (Crow et al., 2003). Thus, the 
connection between expression of specific IRF-5 haplotypes and dysregulated production of 
Type I IFN has been emerging. Interestingly neither IRF-3 or IRF-7 or other members of IRF 
family were found to be associated with predisposition to autoimmune disease. Thus IRF-5 
is possibly the most important factor in the predisposition to the inflammatory diseases. 
8. IRF-5 functions in uninfected cells 
Another unique feature of IRF-5 is that it is also induced upon DNA damage by p53 (Mori et 
al., 2002). This establishes the connection between IRF-5 and p53-apoptotic pathways and 
identifies its possible role in tumor suppression. However, IRF-5 induces apoptosis in p53 
independent manner (Barnes et al., 2003). Irf-5-/- Mouse Embyronic Fibroblasts (MEFs) 
expressing c-Ras do not undergo apoptosis even under DNA damage and can efficiently 
form tumors in mice. These MEFs are also resistant to viral induced apoptosis even though 
their IFN and cytokine profiles are normal (Yanai et al., 2007). However, there are several 
indications that IRF-5 and p53 pro-apoptotic function are independent. Several p53 targets 
are activated in Irf-5-/- cells and overexpression of IRF-5 can stop the growth of B cell tumor 
lymphoma in the absence of p53 (Barnes et al., 2003). Ectopic expression of IRF-5 induces 
DNA damage-induced apoptosis in p53-deficient colon cancer cells (Hu et al., 2005). IRF-5 is 
also involved in Fas/CD95-induced apoptosis, a p53 independent phenomenon (Couzinet et 
al., 2008). IRF-5 stimulates the cyclin-dependent kinase inhibitor p21, but it also stimulates 
the expression of the pro-apoptotic genes Bak1, Bax, caspase 8, and DAP kinase 2, thus 
indicating its ability to promote cell cycle arrest and apoptosis independently of p53 (Barnes 
et al., 2003). 
Udalova and colleagues have also identified IRF-5 as a lineage-defining factor for 
macrophages (Krausgruber et al., 2011). Their work shows, for the first time, that IRF-5 can 
be both a transcription activator and repressor. Macrophages differentiate into two 
 
IRF-5 - A New Link to Autoimmune Diseases 
 
41 
functionally opposite types depending on the differentiation stimulus. When bone marrow 
macrophages are grown with granulocyte–macrophage colony stimulating factor (GM-CSF), 
they differentiate into M1 type, classical pro-inflammatory macrophages which secrete 
cytokines like IL-12. However, when they are differentiated with M-CSF, they differentiate 
to the M2 type, which secretes anti-inflammatory cytokines like IL-10. The authors show 
that differentiation to M1 macrophages is accompanied by an increase in IRF-5 levels. 
Overexpression of IRF-5 in M2 macrophages forces them to express a pro-inflammatory 
profile of cytokines and lowers IL-10 levels, basically making the M2 macrophages 
functionally similar to M1. Conversely, knockdown of IRF-5 levels in M1 macrophages 
converts M1 macrophages to the M2 expression profile, producing high levels of IL-10 and 
low levels of proinflammatory cytokines. Thus IRF-5 is a determinant of macrophage 
plasticity. The authors also demonstrate that in macrophages, IRF-5 functions as a negative 
regulator of IL-10. These results open the field to many other questions such as possible cell 
type specificity of the suppression of IL-10 transcription, or how many other genes are 
negatively regulated by IRF-5. The analysis of the IRF-5 signature profile in human B cell 
line BJAB identifies large number of both up-regulated and down regulated genes (Barnes et 
al., 2004). 
9. Activation of IRF-5 by the TLR7 pathway 
TLR7 and TLR9 recognize viral ss (single stranded)-RNA or a B form of dsDNA 
respectively. The recognition is dependent on endosomal internalization and acidification. 
The TLR7/9 signalling pathway is mediated by an adaptor molecule MyD88 (Kawai et al., 
1999; Muzio et al., 1997). MyD88 has two domains: a C-terminal Toll/IL-1 Receptor (TIR) 
domain that is required for the interaction with the TLRs and an amino terminal death 
domain (DD) that interacts with members of the IL-1 receptor associated kinase (IRAK) 
family (Martin and Wesche 2002). This association between IRAK1 and MyD88 results in 
self-phosphorylation of IRAK-1, as well as phosphorylation by the related kinase, IRAK-4 
(Cao et al., 1996; Li et al., 2002). After phosphorylation, IRAK1 dissociates from MyD88 and 
now binds to TRAF6 (TNF receptor-associated factor 6) (Burns et al., 2000). TRAF6-mediated 
K63-linked ubiquitinylation is required for IRF-5 nuclear translocation in TLR7/9-MyD88-
dependent signalling (Balkhi et al., 2008). IRF-5 homo-dimerizes upon phosphorylation of 
serine/ threonine residues at the C-terminal end by a still undefined kinase and translocates 
to the nucleus (Chen et al., 2008). Thus, both ubiquitinylation and phosphorylation of IRF-5 
are required for nuclear translocation. IRF-5 also associates with Ikkα kinase, but that results 
in degradation of IRF-5-rather than activation (Balkhi et al., 2010). It should be noted that 
TLR 7 and TL9 are the only know pathways that lead to the activation of IRF-5. Unlike IRF-3 
or IRF-7, IRF-5 is not activated by TLR3 or TLR 4 via TIR-domain-containing adapter-
inducing IFNβ (Trif) pathways or by the RIG-I/MAV IPS-1 pathways. 
Several ligands can activate TLR7. TLR7 recognizes viral ssRNA , but IFN production can be 
also induced  in response to imiquimod and resiquimod (Hemmi et al., 2002). In addition, 
several other guanine nucleoside analogs are recognized exclusively via TLR7 (Lee and Kim 
2007). Of physiological ligands, guanosine and uridine-rich ssRNA oligonucleotides derived 
from HIV-1, stimulate DCs and macrophages to secrete IFNα and other pro-inflammatory 
cytokines via murine TLR7 (Heil et al., 2004). TLR7 also responds to ssRNA (polyU) or 
ssRNA derived from wild-type influenza virus (Diebold et al., 2004). Since these sequences 
can originate from viral as well as endogenous RNA, TLR7 may be unable to discriminate 
between self and non-self RNA and see the self RNA as sensors of endogenous danger 
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region associated with predisposition to SLE showed the presence of several genes 
associated with the Type I IFN induction and signalling pathway. One of these genes is IRF-
5 and a common SNP haplotype in IRF-5 (rs 2004640T) was identified in Scandinavian 
cohorts as a risk factor for SLE. Interestingly, the same SNP haplotype of IRF-5 has been 
shown later to be associated with numerous other autoimmune disorders, such as 
rheumatoid arthritis (RA) (Sigurdsson et al., 2007) and others (Kozyrev and Alarcon-
Riquelme 2007). Three specific functional alleles of IRF-5 were identified that define risk 
factors for SLE (Graham et al., 2006). The rs 2004640 G allele expresses isotypes initiated 
from exon 1A and 1C, while the rs 2004640T allele expresses transcripts from exon 1B, which 
provides a stronger promoter and increases the expression of IRF-5. The second SNP is the 
in-frame insertion- of 30 bp in exon 6 that alters the proline, glutamic acid and serine rich 
regions and encodes a protein that is similar to unspliced isotype IRF-5v5. The third SNP 
introduces a variation in the poly A termination site that makes the 3’UTR shorter which 
leads to an increased stability of IRF-5 mRNA (Graham et al., 2006). All together, these 
modifications in the IRF-5 gene result in elevated levels of IRF-5 protein which is larger than 
the proteins encoded by the spliced IRF- transcripts. Many additional SNPs in IRF-5 have 
been later identified and are reviewed in (Kozyrev and Alarcon-Riquelme 2007). The high 
levels of lupus associated IRF-5 expression have been detected in PBMCs of Lupus patients 
(Feng et al., 2010). Dysregulated expression of Type I IFN is associated with SLE 
pathogenesis (Niewold et al., 2007) and gene array analysis of PMBCs from SLE patients has 
revealed elevated expression of IFN-stimulated genes (Crow et al., 2003). Thus, the 
connection between expression of specific IRF-5 haplotypes and dysregulated production of 
Type I IFN has been emerging. Interestingly neither IRF-3 or IRF-7 or other members of IRF 
family were found to be associated with predisposition to autoimmune disease. Thus IRF-5 
is possibly the most important factor in the predisposition to the inflammatory diseases. 
8. IRF-5 functions in uninfected cells 
Another unique feature of IRF-5 is that it is also induced upon DNA damage by p53 (Mori et 
al., 2002). This establishes the connection between IRF-5 and p53-apoptotic pathways and 
identifies its possible role in tumor suppression. However, IRF-5 induces apoptosis in p53 
independent manner (Barnes et al., 2003). Irf-5-/- Mouse Embyronic Fibroblasts (MEFs) 
expressing c-Ras do not undergo apoptosis even under DNA damage and can efficiently 
form tumors in mice. These MEFs are also resistant to viral induced apoptosis even though 
their IFN and cytokine profiles are normal (Yanai et al., 2007). However, there are several 
indications that IRF-5 and p53 pro-apoptotic function are independent. Several p53 targets 
are activated in Irf-5-/- cells and overexpression of IRF-5 can stop the growth of B cell tumor 
lymphoma in the absence of p53 (Barnes et al., 2003). Ectopic expression of IRF-5 induces 
DNA damage-induced apoptosis in p53-deficient colon cancer cells (Hu et al., 2005). IRF-5 is 
also involved in Fas/CD95-induced apoptosis, a p53 independent phenomenon (Couzinet et 
al., 2008). IRF-5 stimulates the cyclin-dependent kinase inhibitor p21, but it also stimulates 
the expression of the pro-apoptotic genes Bak1, Bax, caspase 8, and DAP kinase 2, thus 
indicating its ability to promote cell cycle arrest and apoptosis independently of p53 (Barnes 
et al., 2003). 
Udalova and colleagues have also identified IRF-5 as a lineage-defining factor for 
macrophages (Krausgruber et al., 2011). Their work shows, for the first time, that IRF-5 can 
be both a transcription activator and repressor. Macrophages differentiate into two 
 
IRF-5 - A New Link to Autoimmune Diseases 
 
41 
functionally opposite types depending on the differentiation stimulus. When bone marrow 
macrophages are grown with granulocyte–macrophage colony stimulating factor (GM-CSF), 
they differentiate into M1 type, classical pro-inflammatory macrophages which secrete 
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Several ligands can activate TLR7. TLR7 recognizes viral ssRNA , but IFN production can be 
also induced  in response to imiquimod and resiquimod (Hemmi et al., 2002). In addition, 
several other guanine nucleoside analogs are recognized exclusively via TLR7 (Lee and Kim 
2007). Of physiological ligands, guanosine and uridine-rich ssRNA oligonucleotides derived 
from HIV-1, stimulate DCs and macrophages to secrete IFNα and other pro-inflammatory 
cytokines via murine TLR7 (Heil et al., 2004). TLR7 also responds to ssRNA (polyU) or 
ssRNA derived from wild-type influenza virus (Diebold et al., 2004). Since these sequences 
can originate from viral as well as endogenous RNA, TLR7 may be unable to discriminate 
between self and non-self RNA and see the self RNA as sensors of endogenous danger 
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signals. Accordingly, small nuclear ribonucleoproteins (snRNPs), a major component of the 
immune complexes associated with SLE can activate human pDCs by TLR7 induced 
signaling pathway and stimulate production of Type I IFNs and other proinflammatory 
cytokines. Interestingly, the TLR7 pathway can also be activated by nuclear 
ribonucleoprotein complexes (Savarese et al., 2006). 
10. Mouse models of SLE 
The mouse model of SLE provides additional information on the mechanism of SLE 
pathogenicity. NZB mice develop spontaneous lupus, produce autoantibodies and develop 
glomerulonephritis. Duplication of TLR7 and transposition of the TLR7 gene as seen in the 
Yaa mutation promotes the SLE like symptoms. The B cells of murine lupus model also 
show an accelerated class switching, which is controlled by the genotype (Vyse et al., 1996). 
Our results showed that in addition to a decreased production of Type I IFN and 
inflammatory cytokines, Irf-5-/- mice exhibit an alteration of the B cells phenotype, associated 
with age related expansion of CD19+B220- group of B cells, decrease in plasma cells and 
splenomegaly (Lien et al., 2010). However, the mechanism by which IRF-5 controls B cells 
differentiation to plasma cells is not known. Irf-5-/- mice have also decreased levels of natural 
antibodies and T cells dependent antigenic stimulation leads to profound decrease in serum 
IgG2a (Savitsky et al., 2010). Finally the requirement of IRF-5 for the development of lupus 
like disease was demonstrated in FcγRIIB-/- mice, where IRF-5 deficiency profoundly 
decreased the manifestation of the disease (Richez et al., 2010). Two other IRFs, IRF-4 and 
IRF-8 have critical functions in the B cell differentiation program. B cells development is 
blocked at the pre-B cells stage in IRF-4 and IRF-8 compound null mice (Lu et al., 2003). IRF-
4 also functions in late B cells development regulating IgG class switching and plasma cell 
development (Sciammas et al., 2006). IRF-8 has a role in germinal centre transcription 
program (Lee et al., 2006). Altogether, these data indicate that several members of the IRF 
family can affect B-cell development, however the strong genetic association between IRF-5 
and autoimmune disease point out to a unique functions of IRF-5 in the immune system. 
11. Induction of autoimmunity by IFNs 
How the IFNs contribute to SLE and its progress remains to be fully explained. The presence 
of immunogenic complexes leads to dendritic cell activation and thus there is a greater 
antigen presentation and more IFNs are secreted. IFNα increases the expression of 
autoantigens such as Ro52 and also induces apoptosis via translocation of Ro52 to the 
nucleus (Baechler et al., 2004; Bennett et al., 2003). Type I IFNs also induce the maturation 
and activation of dendritic cells, along with upregulation of MHC Class I and II molecules 
(Baccala et al., 2007). This promotes the development of helper T cells (Th1). In addition, 
Type I IFNs also enhance antibody production and class switching, decrease the selectivity 
of B cells for CpG-rich DNA, and permit stimulation by even non-CpG DNA and thereby 
promote an autoimmune response (Jego et al., 2003; Le Bon et al., 2006). How does IRF-5 
contribute to this picture? 
12. Genetic association studies and SLE 
Genetic and population association studies provide a more comprehensive picture of the 
role of IFNs in SLE, reviewed in (Delgado-Vega et al., 2010). Of the entire battery of genes 
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identified by genome wide association studies, most of the genes are involved in innate 
and adaptive immune responses. These can be divided into the following groups: (1) 
genes implicated in processing and presentation of immune complexes, (2) genes involved 
in the IFN-inducing pathways, and (3) genes involved in the Type I IFN signalling 
pathway. Of the first group, the MHC region shows up as a prime candidate in correlation 
studies, but is challenging to study since the region has hundreds of potential candidate 
genes (Deng and Tsao 2010; Sestak et al., 2011). In the IFN-inducing pathways, 
transcription factor IRF-5 was the first identified gene directly to be associated with 
increased risk of lupus (Graham et al., 2006; Sigurdsson et al., 2005). IRF-5 allele variants 
with the highest probability of being causal were identified and shown to affect IRF-5 
expression. Patients with a risk haplotype of IRF-5 show higher serum IFN activity, when 
compared to patients lacking this risk genotype. Finally, in the IFN signalling pathway, 
STAT4, a downstream interacting protein of IFNAR, is also strongly associated with lupus 
(Kariuki et al., 2009). STAT4 is associated with increased sensitivity to IFNα and the 
presence of anti-dsDNA autoantibodies. In addition, polymorphisms in the Janus kinase 
tyrosine kinase 2 (TYK2), which binds to IFNAR, and is part of the initiation of the JAK-
STAT pathway, was also found to be associated with lupus and strengthen the link 
between IFNα expression and SLE. Several other gene products that are part of the IFN 
signalling pathway, such as TNFAIP3, TYK2, and TREX1, have been also associated with 
susceptibility to SLE (Adrianto et al., 2011; Fan et al., 2011; Hellquist et al., 2009). Recently 
identified SNPs in IRF7 also seem to be associated with SLE. (Fu et al., 2011). It is unlikely 
that the alteration of the function of a single master gene will be responsible for the 
pathogenesis of SLE; rather it may be combination of malfunction of several genes. 
Without doubt there is still the potential of finding new genes that contribute to the 
development of SLE. 
13. IRF-5 polymorphisms and association with SLE 
IRF-5 was identified as a risk factor for SLE in two very important association studies. 
Sigurdsson et al. looked at sets of lupus patients from Sweden, Finland and Iceland and 
analyzed 4 SNPs of IRF-5 (Sigurdsson et al., 2005). Graham et al. (Graham et al., 2007) 
describe two functional SNPs within the IRF-5 gene which are a risk haplotype for SLE. One 
SNP, rs2004640, creates a donor splice site in intron 1 of IRF-5 and the isoform expresses an 
alternative of untranslated exon 1B. A second SNP is located about 5 kb downstream of IRF-
5 and could not be tied to functional importance but is used as a haplotype tag (Graham et 
al., 2007). Later, several groups identified a second polymorphism that has more easily 
identifiable functional roles. rs10954213 alters the polyadenylation site of IRF-5 and the 
resultant mRNA cal be correlated to higher levels of IRF-5 seen in SLE (Sigurdsson et al., 
2008). The A allele of this SNP leads to a shorter and more stable mRNA. Finally, an 
insertion- deletion is found in the 6th exon of IRF-5 that can potentially change the protein 
isoforms expressed IRF-5 by 10 amino acids (Kozyrev et al., 2007). The deletion results in 
expression of the isoforms V1 and V4, while the insertion give rise to isoforms V5 and V6. 
The lupus risk haplotype, TCA, includes the insertion TCA and thus individuals with lupus 
are expected to express the corresponding isoforms (V5 and V6). The sequence added by the 
insertion/deletion gives rise to a proline-rich region which can be potentially recruited for 
additional protein –protein interactions and/or protein stability by altering the degradation 
rate of the resulting protein. 
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Even though the genetic association of lupus and IRF-5 has been consistent, the initial 
studies dealt with an overwhelmingly European population and there are some suggestions 
that the association factors might be population specific. Studies in Asian populations have 
identified new susceptibility genes for lupus, while some of the previously known ones 
have been discounted (Kawasaki et al., 2008; Li et al., 2011; Shimane et al., 2009; Shin et al., 
2008; Siu et al., 2008), reviewed in (Kim et al., 2009). Given that the majority of lupus patients 
are women, genetic imprinting remains yet an unexplored topic. However very interesting 
is a recent finding showing that IRF-5 is expressed at higher levels in female than in male 
mice and that the IRF-5 promoter is under hormonal regulation (Shen et al., 2010).  
14. Conclusions and future perspectives 
Identification of the IRF-5 gene as a genetic risk factor for SLE helps to dissect its role in the 
IFNα pathway in pathogenesis of SLE. The SNP, rs10954213, that affects the levels of IRF-5 
expression through increasing the stability of its mRNA, has a great impact on function and 
expression of protein, but has not found to be strongly associated as a risk haplotype. Thus 
many questions remain. Higher levels of IRF-5 might result not only in continued 
production of type I IFN but also of the proinflammatory cytokines. Are these cytokines 
responsible for the activation of the immune cells such as B cells? Hyper activation of B cells 
is one of the markers of SLE and the results in mice indicate that IRF-5 has an important role 
in cell differentiation and induction of IgG2a subtype, which is an important subtype for the 
induction of autoimmunity. In humans, the IgG2a isotype corresponds to IgG1, which is the 
dominant subclass of serum autoantibodies in SLE (Manolova et al., 2002). The biological 
role of IRF-5 isoforms remains to be determined. Presently we do not know whether TCA 
haplotype IRF-5 has a distinct function from the other IRF-5 variants or whether it induces 
different group of the inflammatory genes or IFN A variants. It would be of great interest to 
learn about the roles of the IRF-5 induced genes and their variation in SLE patients. Now 
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that IRF-5 has been identified as an important factor in induction of type IFN in lupus, it 
will be important to determine which of the other IRF-5 regulated genes contribute to the 
pathogenicity of the disease. A recent observation that EBV might also be implicated in the 
activation of Type I IFN in SLE patients (Yadav et al., 2011) might be an important link in 
dissecting the cross-talk between genetic predisposition or risk factors and environmental 
stimuli. Is there any cross talk between IRF-5 and some of the other gene products that were 
also identified to be associated with Lupus disease? Many of these questions remain yet to 
be explored to understand the impact of IRF-5 in SLE biology (Figure 1). 
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1. Introduction 
The immune system is responsible for the defense against a wide array of pathogens but 
without responding to each individual’s (self) antigens. Autoimmune diseases are 
characterized by a loss of tolerance to self antigens that leads to the appearance of auto-
reactive lymphocytes. The main factors that contribute to the development of autoimmunity 
are genetic susceptibility and infection. Disease susceptibility is the result of the combined 
action of multiple genes. It has been shown that certain gene polymorphisms can influence 
the establishment of self-tolerance. The human immune system is a complex machinery 
involving numerous proteins. Cell-surface proteins expressed by leukocytes are of particular 
relevance due not only to their participation in the network of interactions that regulate the 
innate and adaptive immune responses, but also to their potential as excellent targets for 
diagnostic and therapeutic interventions (Diaz-Ramos et al., 2011). These molecules deliver 
signals that modulate leukocyte development, activation, survival, clonal expansion, and 
important effector functions. Some of these cell-surface signaling molecules have the 
capacity to activate lymphocytes and other leukocytes, while others function as down-
modulators of immune responses, playing a key role in the establishment of tolerance to self 
antigens. Thus, it is not surprising that many of the allelic variants associated with 
autoimmunity identified, to date, correspond to leukocyte cell-surface molecules (Maier & 
Hafler, 2009). In this review we will discuss recent observations that point to a key role of 
signaling lymphocyte activation molecule family (SLAMF) receptors in the development of 
autoimmunity.  
2. Signaling lymphocyte activation molecule family of cell-surface molecules 
In recent years, the SLAMF of leukocyte cell-surface molecules has been identified as a 
group of receptors that modulates the activation and differentiation of a wide array of cell 
types involved in both innate and adaptive immune responses (Calpe et al., 2008; Detre et 
al., 2010; Schwartzberg et al., 2009; Vinuesa et al., 2010). The SLAMF, also known as the 
CD150 family, consists of nine structurally related leukocyte cell-surface glycoproteins that 
belong to the immunoglobulin (Ig) superfamily, namely: SLAMF1 (CD150 or SLAM), 
SLAMF2 (CD48), SLAMF3 (CD229 or LY9), SLAMF4 (CD244 or 2B4), SLAMF5 (CD84), 
SLAMF6 (CD352, NTB-A or Ly108), SLAMF7 (CD319 or CRACC), SLAMF8 (CD353 or 
BLAME) and SLAMF9 (CD84-H1) (Table 1).  
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1. Introduction 
The immune system is responsible for the defense against a wide array of pathogens but 
without responding to each individual’s (self) antigens. Autoimmune diseases are 
characterized by a loss of tolerance to self antigens that leads to the appearance of auto-
reactive lymphocytes. The main factors that contribute to the development of autoimmunity 
are genetic susceptibility and infection. Disease susceptibility is the result of the combined 
action of multiple genes. It has been shown that certain gene polymorphisms can influence 
the establishment of self-tolerance. The human immune system is a complex machinery 
involving numerous proteins. Cell-surface proteins expressed by leukocytes are of particular 
relevance due not only to their participation in the network of interactions that regulate the 
innate and adaptive immune responses, but also to their potential as excellent targets for 
diagnostic and therapeutic interventions (Diaz-Ramos et al., 2011). These molecules deliver 
signals that modulate leukocyte development, activation, survival, clonal expansion, and 
important effector functions. Some of these cell-surface signaling molecules have the 
capacity to activate lymphocytes and other leukocytes, while others function as down-
modulators of immune responses, playing a key role in the establishment of tolerance to self 
antigens. Thus, it is not surprising that many of the allelic variants associated with 
autoimmunity identified, to date, correspond to leukocyte cell-surface molecules (Maier & 
Hafler, 2009). In this review we will discuss recent observations that point to a key role of 
signaling lymphocyte activation molecule family (SLAMF) receptors in the development of 
autoimmunity.  
2. Signaling lymphocyte activation molecule family of cell-surface molecules 
In recent years, the SLAMF of leukocyte cell-surface molecules has been identified as a 
group of receptors that modulates the activation and differentiation of a wide array of cell 
types involved in both innate and adaptive immune responses (Calpe et al., 2008; Detre et 
al., 2010; Schwartzberg et al., 2009; Vinuesa et al., 2010). The SLAMF, also known as the 
CD150 family, consists of nine structurally related leukocyte cell-surface glycoproteins that 
belong to the immunoglobulin (Ig) superfamily, namely: SLAMF1 (CD150 or SLAM), 
SLAMF2 (CD48), SLAMF3 (CD229 or LY9), SLAMF4 (CD244 or 2B4), SLAMF5 (CD84), 
SLAMF6 (CD352, NTB-A or Ly108), SLAMF7 (CD319 or CRACC), SLAMF8 (CD353 or 
BLAME) and SLAMF9 (CD84-H1) (Table 1).  
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Receptor Aliases Expression 
SLAMF1 CD150, SLAM B, T, DC, platelet, Mф 
SLAMF2 CD48 B, T, monocyte, NK, DC, pDC, granulocytes, HSC, MPP 
SLAMF3 CD229, LY9 B, T, pDC 
SLAMF4 CD244, 2B4 NK, CD8 and γδ T,  monocyte, basophil, eosinophil, mast cell, HSC, MPP 
SLAMF5 CD84 B, T, mast cell, platelet, monocyte, granulocytes, Mф,  DC, pDC, HSC, MPP 
SLAMF6 CD352, NTB-A (Ly108 in mice) B, T, NK, neutrophil, pDC 
SLAMF7 CD319, CRACC, CS1 B, T, NK, DC, pDC 
SLAMF8 CD353, BLAME B, DC, monocyte, Mф 
SLAMF9 CD84-H1, SF2001 B, T, monocyte, DC 
 
Table 1. Members of the SLAM (CD150) family. The expression data apply largely to human 
cells. Receptor gene name is shown in bold. B=B cells, DC=dendritic cell, 
pDC=plasmacytoid DC, HSC= hematopoietic stem cells, Mф=macrophages, 
MPP=multipotent hematopoietic progenitors, NK=natural killer cells, SLAMF=SLAM 
family, T=T cells. 
2.1 Genomic organization of the SLAM locus 
Seven of the genes encoding SLAMF members are clustered within a 400-500 kilobase (kb) 
genomic segment on human chromosome 1q23 and on mouse chromosome 1H3 (Calpe et 
al., 2008; Engel et al., 2003). However, genes coding CD353 and SLAMF9 (CD84-H1) are 
located outside of, but in close proximity to, the SLAM locus (Calpe et al., 2008; Veillette et 
al., 2006). This characteristic implies that those genes encoding the SLAMF members were 
created by successive gene duplications of a single ancestor gene, raising the possibility that 
numerous polymorphisms and splice variants of most of the family members have 
subsequently been formed in this way. The majority of such variations mainly affect their 
corresponding ectodomains or the length of their respective cytoplasmic tails (Calpe et al., 
2008; Veillette, 2010). Human EAT-2 and mouse Eat-2a and Eat-2b genes are also located 
close to the SLAM locus. Although the SLAMF genes are equally arranged in mouse and 
human genomes, they differ in its orientation; the genes that in humans are closer to the 
centromere are situated in mice closer to the telomere.  
2.2 Structural characteristics of the SLAMF glycoproteins 
2.2.1 Immunoglobulin domains and ligand interaction 
SLAMF receptors are composed of an extracellular ectodomain formed by two Ig-like 
domains; one variable (V)-like lacking disulfide bonds followed by a truncated Ig constant 2 
(C2)-like domain with two intradomain disulfide bonds, with the exception of CD229 
(SLAMF3), which possesses four Ig-like domains (two tandem repeats of V-Ig/C2-Ig sets). 
SLAMF molecules are type I transmembrane glycoproteins containing a cytoplasmic tail, 
with the exception of CD48, which has a glycosylphosphatidylinositol (GPI) membrane 
anchor (Figure 1) (Calpe et al., 2008; Engel et al., 2003; Ma et al., 2007).  
 




























































ITSM (T-I/V-Y-x-x-V/I)  
Fig. 1. Structural representation of the human SLAM family members. This structurally-
related family of cell-surface receptors is composed by nine members. Their extracellular 
regions have two, or four in the case of CD229, Ig-like domains. 
Excluding CD244, which recognizes CD48 as its ligand, SLAMF members are also 
characterized by acting as self-ligands through their N-terminal Ig domain (Table 2) (Engel 
et al., 2003). No interactions with other hematopoietic cell-surface molecules have been 
described, although CD150 (SLAM) has been reported to be one the major receptors for the 
measles virus, which accounts for its cell tropism (Tatsuo et al., 2000). Strikingly, mouse 
CD150 has recently been described as a microbial sensor that positively regulates bacterial 
killing by macrophages (Berger et al., 2010; Sintes & Engel, 2011). CD150 is able to efficiently 
recognize the porins OmpC and OmpF of E. coli’s outer membrane. Afterwards, the 
CD150/E.coli complex becomes internalized within the macrophage phagosome to govern 
key processes of bacterial removal machinery such as phagosome maturation and free 
radical species production by the NOX2 complex (Berger et al., 2010). Moreover, CD48 is 
known to interact with the Gram-negative lectin FimH in macrophages as well as in mast 
cells, although counter to CD150 functionality, FimH+ bacteria undergo encapsulation in 
caveolae rather than becoming internalized within mast cell phagosomes (Baorto et al., 1997; 
Shin et al., 2000). Whether other SLAMF members might function as bacterial receptors 
remains to be elucidated. 
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Receptor Aliases Expression 
SLAMF1 CD150, SLAM B, T, DC, platelet, Mф 
SLAMF2 CD48 B, T, monocyte, NK, DC, pDC, granulocytes, HSC, MPP 
SLAMF3 CD229, LY9 B, T, pDC 
SLAMF4 CD244, 2B4 NK, CD8 and γδ T,  monocyte, basophil, eosinophil, mast cell, HSC, MPP 
SLAMF5 CD84 B, T, mast cell, platelet, monocyte, granulocytes, Mф,  DC, pDC, HSC, MPP 
SLAMF6 CD352, NTB-A (Ly108 in mice) B, T, NK, neutrophil, pDC 
SLAMF7 CD319, CRACC, CS1 B, T, NK, DC, pDC 
SLAMF8 CD353, BLAME B, DC, monocyte, Mф 
SLAMF9 CD84-H1, SF2001 B, T, monocyte, DC 
 
Table 1. Members of the SLAM (CD150) family. The expression data apply largely to human 
cells. Receptor gene name is shown in bold. B=B cells, DC=dendritic cell, 
pDC=plasmacytoid DC, HSC= hematopoietic stem cells, Mф=macrophages, 
MPP=multipotent hematopoietic progenitors, NK=natural killer cells, SLAMF=SLAM 
family, T=T cells. 
2.1 Genomic organization of the SLAM locus 
Seven of the genes encoding SLAMF members are clustered within a 400-500 kilobase (kb) 
genomic segment on human chromosome 1q23 and on mouse chromosome 1H3 (Calpe et 
al., 2008; Engel et al., 2003). However, genes coding CD353 and SLAMF9 (CD84-H1) are 
located outside of, but in close proximity to, the SLAM locus (Calpe et al., 2008; Veillette et 
al., 2006). This characteristic implies that those genes encoding the SLAMF members were 
created by successive gene duplications of a single ancestor gene, raising the possibility that 
numerous polymorphisms and splice variants of most of the family members have 
subsequently been formed in this way. The majority of such variations mainly affect their 
corresponding ectodomains or the length of their respective cytoplasmic tails (Calpe et al., 
2008; Veillette, 2010). Human EAT-2 and mouse Eat-2a and Eat-2b genes are also located 
close to the SLAM locus. Although the SLAMF genes are equally arranged in mouse and 
human genomes, they differ in its orientation; the genes that in humans are closer to the 
centromere are situated in mice closer to the telomere.  
2.2 Structural characteristics of the SLAMF glycoproteins 
2.2.1 Immunoglobulin domains and ligand interaction 
SLAMF receptors are composed of an extracellular ectodomain formed by two Ig-like 
domains; one variable (V)-like lacking disulfide bonds followed by a truncated Ig constant 2 
(C2)-like domain with two intradomain disulfide bonds, with the exception of CD229 
(SLAMF3), which possesses four Ig-like domains (two tandem repeats of V-Ig/C2-Ig sets). 
SLAMF molecules are type I transmembrane glycoproteins containing a cytoplasmic tail, 
with the exception of CD48, which has a glycosylphosphatidylinositol (GPI) membrane 
anchor (Figure 1) (Calpe et al., 2008; Engel et al., 2003; Ma et al., 2007).  
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Fig. 1. Structural representation of the human SLAM family members. This structurally-
related family of cell-surface receptors is composed by nine members. Their extracellular 
regions have two, or four in the case of CD229, Ig-like domains. 
Excluding CD244, which recognizes CD48 as its ligand, SLAMF members are also 
characterized by acting as self-ligands through their N-terminal Ig domain (Table 2) (Engel 
et al., 2003). No interactions with other hematopoietic cell-surface molecules have been 
described, although CD150 (SLAM) has been reported to be one the major receptors for the 
measles virus, which accounts for its cell tropism (Tatsuo et al., 2000). Strikingly, mouse 
CD150 has recently been described as a microbial sensor that positively regulates bacterial 
killing by macrophages (Berger et al., 2010; Sintes & Engel, 2011). CD150 is able to efficiently 
recognize the porins OmpC and OmpF of E. coli’s outer membrane. Afterwards, the 
CD150/E.coli complex becomes internalized within the macrophage phagosome to govern 
key processes of bacterial removal machinery such as phagosome maturation and free 
radical species production by the NOX2 complex (Berger et al., 2010). Moreover, CD48 is 
known to interact with the Gram-negative lectin FimH in macrophages as well as in mast 
cells, although counter to CD150 functionality, FimH+ bacteria undergo encapsulation in 
caveolae rather than becoming internalized within mast cell phagosomes (Baorto et al., 1997; 
Shin et al., 2000). Whether other SLAMF members might function as bacterial receptors 
remains to be elucidated. 
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Receptor Ligands ITSMs SAP/EAT-2 recruitment 
SLAMF1 SLAMF1, measles virus, Gram-negative bacteria 2 + 
SLAMF2 SLAMF4, CD2, FimH None - 
SLAMF3 SLAMF3 H: 2 M: 1 + 
SLAMF4 SLAMF2 4 + 
SLAMF5 SLAMF5 2 + 
SLAMF6 SLAMF6 2 + 
SLAMF7 SLAMF7 H: 1 M: 0 EAT-2 (H) 
SLAMF8 ND None - 
SLAMF9 ND None -  
Table 2. SLAM family ligands and ITSMs. H=human, ITSMs=immunoreceptor tyrosine-
based binding motifs, M=mouse, ND=not determined, SLAMF=SLAM family. 
2.2.2 The immunoreceptor tyrosine-based switch motif and cell signaling 
Unlike other cosignaling molecules, the cytoplasmic tails of six of the SLAMF receptors 
(SLAMF1,3-7) do not contain any ITAMs or ITIMs motifs, but rather possess one or more 
copies of a unique immunoreceptor tyrosine-based switch motif (ITSM) T-I/V-Y-x-x-V/I 
(where T is threonine, I is isoleucine, V is valine, Y is tyrosine and x denotes any amino 
acid), in addition to various tyrosine Y residues (Detre et al., 2010; Engel et al., 2003) (Figure 
1 and Table 2). In the same way ITAM or ITIM becomes phosphorylated after receptor 
ligation, the homophilic engagement of SLAMF members triggers the phosphorylation of Y 
residues within the ITSM. Subsequently, ITSM serves as a docking site for intracellular 
adapter molecules and enzymes bearing SH2 domains such as SHP-2, SHP-1, Csk, and 
SHIP-1 (Mikhalap et al., 1999; Parolini et al., 2000; Tangye et al., 1999). The adapter 
molecules SLAM-associated protein (SAP), EWS/FLI activated transcript-2 (EAT-2) and 
EAT-2-related transducer (ERT), have high affinity for this unique motif (Calpe et al., 2008; 
Veillette et al., 2009). Importantly, the SAP-encoding gene (SH2D1A) is mutated in patients 
with X-linked lymphoproliferative disease.  
SH2D1A is located on the X chromosome in humans and mice (Xq25 and XA5, respectively), 
which differs from SLAMF receptors and EAT-2 (Calpe et al., 2008).  SAP is a small protein 
(15 kDa) composed of a SH2 domain followed by a 28-amino-acid tail (Figure 2). Human 
and mouse SAP molecules share 87% of their amino acid sequence, being highly similar in 
the SH2 domain. SAP is known to be expressed by NK, T cells, NKT cells, eosinophils, 
platelets and a subset of B cells (Engel et al., 2003). The SAP/SLAMF-receptor interaction 
occurs between the arginine 32 (R32), located in the SH2-domain of SAP, and the pY-
containing ITSMs of SLAMF molecules. Apart from engaging these pY residues, SAP is able 
to specifically bind to the nonphosphorylated Y281 from one of the CD150 ITSMs. The high 
avidity shown by SAP to bind to these pY residues explain its ability to block the interaction 
of other SH2-containing molecules of lesser affinity to the same motif (Finerty et al., 2002; 
Howie et al., 2002; Lewis et al., 2001; Poy et al., 1999; Sayos et al., 1998).  
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              1 
Human SAP:    MDAVAVYHGKISRETGEKLLLATGLDGSYLLRDSESVPGVYCLCVLYHGYIYTYRVSQTETGSWSAETAPGVHKRYFRKI  80 
Mouse Sap:    MDAVTVYHGKISRETGEKLLLATGLDGSYLLRDSESVPGVYCLCVLYQGYIYTYRVSQTETGSWSAETAPGVHKRFFRKV  80 
Human EAT-2:  MD-LPYYHGRLTKQDCETLLLKEGVDGNFLLRDSESIPGVLCLCVSFKNIVYTYRIFREKHGYYRIQTAEGSPKQVFPSL  79 
Mouse Eat-2a: MD-LPYYHGCLTKRECEALLLKGGVDGNFLIRDSESVPGALCLCVSFKKLVYSYRIFREKHGYYRIETDAHTPRTIFPNL  79 
Mouse Eat-2b: MD-LPYYHGCLTKRECEALLLKGGVDGNFLIRDSESVPGALCLCVSFKKLVYNYRIFREKNGYYRIETEPSTPKTIFPNL  79 
               
     
Human SAP:    81  KNLISAFQKPDQGIVIPLQYPVEKKSSARSTQG-----TTGIREDPDVCLKAP  128 
Mouse Sap:    81  KNLISAFQKPDQGIVTPLQYPVEK-SSGRGPQA-----PTG-RRDSDICLNAP  126 
Human EAT-2:  80  KELISKFEKPNQGMVVHLLKPIKRTSPSLRWRGLKLELETFVNSNSDYVDVLP  132 
Mouse Eat-2a: 80  QELVSKYGKPGQGLVVHLSNPIMRNNLCQRGRRMELELNVYENTDEEYVDVLP  132 
Mouse Eat-2b: 80  EELISKFKTPGQGMVVHLSNPIMRSGFCPGARRLNLEANVYENTDEEYVDVLP  132  
Fig. 2. Alignment of SAP and EAT-2 amino acidic sequences. The SH2 domains of SAP and 
EAT-2 are boxed. Conserved residues among both adaptors are highlighted in yellow, and 
those specifically conserved for each molecule are shown in bold. In green are the tyrosine 
residues present in the tail of EAT-2. 
One of the particular features of SAP is that its arginine 78 (R78) interacts with the aspartic 
acid residue 100 (D100) of Fyn, a Src-related protein tyrosine kinase. Such association 
sequentially mediates Fyn recruitment to the cytoplasmic tail of the CD150 receptor and, 
following tyrosine phosphorylation, leads to the recruitment of SHIP, docking protein (Dok) 
1, and Dok2 (Chan et al., 2003; Chen et al., 2006; Latour et al., 2001; Latour et al., 2003). 
Therefore, SAP has the ability to simultaneously associate with SLAMF molecules and Fyn, 
thus forming a trimolecular complex that also reportedly regulates the activation of Vav-1, 
Casitas B-lineage lymphoma (Cbl), Bcl-10, and protein kinase C-theta (PKC-θ)-mediated 
activation of NF-κB1 in T cells (Cannons et al., 2004; Cannons et al., 2010b; Claus et al., 2008; 
Zhong & Veillette, 2008). Furthermore, SAP can additionally engage Lck, which 
phosphorylates CD84, CD150, CD229 and CD244 (Howie et al., 2002; Martin et al., 2005; 
Nakajima et al., 2000; Tangye et al., 2003). The SAP-SH2 domain has also been described as 
interacting with the SH3 domain of PAK-interacting protein (β-PIX), a guanine nucleotide 
exchange factor (GEF) specific for Rac/Cdc42 GTPases (Gu et al., 2006). 
Both human and murine EAT-2 genes are located at chromosome 1 (1q23 in humans and 
1H3 in mice), in close proximity to SLAMF loci (Calpe et al., 2006). In contrast to human 
EAT-2, mouse and rat EAT-2 genes are duplicated with an identical genomic organization 
and encode two similar proteins, namely EAT-2A or EAT-2 and EAT-2B or ERT (Engel et al., 
2003). The EAT-2B-encoding gene is a non-functional pseudo-gene in humans. In a manner 
similar to SAP, human and mouse EAT-2 genes encode small proteins composed of an SH2 
domain followed by a short C-terminal tail, but also containing one and two tyrosines, 
respectively (Y120 and Y127) (Figure 2) (Calpe et al., 2006; Roncagalli et al., 2005). EAT-2 is 
preferentially found not only in NK cells, but also in DC and macrophages, whereas EAT-2B 
is detected only in NK cells. Human EAT-2 is expressed by NK cells, activated CD4+ and 
CD8+ T cells, and γδ T lymphocytes (Calpe et al., 2006; Morra et al., 2001; Tassi & Colonna, 
2005). 
EAT-2 and EAT-2B can bind to the Src-like kinases Hck, Lyn, Lck, and Fgr kinases through 
their catalytic domains, although neither can directly bind to the SH3 domain of Fyn since 
both lack the R78 responsible for the association of SAP with Fyn (Calpe et al., 2006; Latour 
et al., 2003). Nevertheless, EAT-2 and mouse EAT-2A can couple to the SH2 domain of Fyn 
in NK cells when their C-terminal tyrosines undergo phosphorylation (Clarkson et al., 2007). 
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Receptor Ligands ITSMs SAP/EAT-2 recruitment 
SLAMF1 SLAMF1, measles virus, Gram-negative bacteria 2 + 
SLAMF2 SLAMF4, CD2, FimH None - 
SLAMF3 SLAMF3 H: 2 M: 1 + 
SLAMF4 SLAMF2 4 + 
SLAMF5 SLAMF5 2 + 
SLAMF6 SLAMF6 2 + 
SLAMF7 SLAMF7 H: 1 M: 0 EAT-2 (H) 
SLAMF8 ND None - 
SLAMF9 ND None -  
Table 2. SLAM family ligands and ITSMs. H=human, ITSMs=immunoreceptor tyrosine-
based binding motifs, M=mouse, ND=not determined, SLAMF=SLAM family. 
2.2.2 The immunoreceptor tyrosine-based switch motif and cell signaling 
Unlike other cosignaling molecules, the cytoplasmic tails of six of the SLAMF receptors 
(SLAMF1,3-7) do not contain any ITAMs or ITIMs motifs, but rather possess one or more 
copies of a unique immunoreceptor tyrosine-based switch motif (ITSM) T-I/V-Y-x-x-V/I 
(where T is threonine, I is isoleucine, V is valine, Y is tyrosine and x denotes any amino 
acid), in addition to various tyrosine Y residues (Detre et al., 2010; Engel et al., 2003) (Figure 
1 and Table 2). In the same way ITAM or ITIM becomes phosphorylated after receptor 
ligation, the homophilic engagement of SLAMF members triggers the phosphorylation of Y 
residues within the ITSM. Subsequently, ITSM serves as a docking site for intracellular 
adapter molecules and enzymes bearing SH2 domains such as SHP-2, SHP-1, Csk, and 
SHIP-1 (Mikhalap et al., 1999; Parolini et al., 2000; Tangye et al., 1999). The adapter 
molecules SLAM-associated protein (SAP), EWS/FLI activated transcript-2 (EAT-2) and 
EAT-2-related transducer (ERT), have high affinity for this unique motif (Calpe et al., 2008; 
Veillette et al., 2009). Importantly, the SAP-encoding gene (SH2D1A) is mutated in patients 
with X-linked lymphoproliferative disease.  
SH2D1A is located on the X chromosome in humans and mice (Xq25 and XA5, respectively), 
which differs from SLAMF receptors and EAT-2 (Calpe et al., 2008).  SAP is a small protein 
(15 kDa) composed of a SH2 domain followed by a 28-amino-acid tail (Figure 2). Human 
and mouse SAP molecules share 87% of their amino acid sequence, being highly similar in 
the SH2 domain. SAP is known to be expressed by NK, T cells, NKT cells, eosinophils, 
platelets and a subset of B cells (Engel et al., 2003). The SAP/SLAMF-receptor interaction 
occurs between the arginine 32 (R32), located in the SH2-domain of SAP, and the pY-
containing ITSMs of SLAMF molecules. Apart from engaging these pY residues, SAP is able 
to specifically bind to the nonphosphorylated Y281 from one of the CD150 ITSMs. The high 
avidity shown by SAP to bind to these pY residues explain its ability to block the interaction 
of other SH2-containing molecules of lesser affinity to the same motif (Finerty et al., 2002; 
Howie et al., 2002; Lewis et al., 2001; Poy et al., 1999; Sayos et al., 1998).  
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              1 
Human SAP:    MDAVAVYHGKISRETGEKLLLATGLDGSYLLRDSESVPGVYCLCVLYHGYIYTYRVSQTETGSWSAETAPGVHKRYFRKI  80 
Mouse Sap:    MDAVTVYHGKISRETGEKLLLATGLDGSYLLRDSESVPGVYCLCVLYQGYIYTYRVSQTETGSWSAETAPGVHKRFFRKV  80 
Human EAT-2:  MD-LPYYHGRLTKQDCETLLLKEGVDGNFLLRDSESIPGVLCLCVSFKNIVYTYRIFREKHGYYRIQTAEGSPKQVFPSL  79 
Mouse Eat-2a: MD-LPYYHGCLTKRECEALLLKGGVDGNFLIRDSESVPGALCLCVSFKKLVYSYRIFREKHGYYRIETDAHTPRTIFPNL  79 
Mouse Eat-2b: MD-LPYYHGCLTKRECEALLLKGGVDGNFLIRDSESVPGALCLCVSFKKLVYNYRIFREKNGYYRIETEPSTPKTIFPNL  79 
               
     
Human SAP:    81  KNLISAFQKPDQGIVIPLQYPVEKKSSARSTQG-----TTGIREDPDVCLKAP  128 
Mouse Sap:    81  KNLISAFQKPDQGIVTPLQYPVEK-SSGRGPQA-----PTG-RRDSDICLNAP  126 
Human EAT-2:  80  KELISKFEKPNQGMVVHLLKPIKRTSPSLRWRGLKLELETFVNSNSDYVDVLP  132 
Mouse Eat-2a: 80  QELVSKYGKPGQGLVVHLSNPIMRNNLCQRGRRMELELNVYENTDEEYVDVLP  132 
Mouse Eat-2b: 80  EELISKFKTPGQGMVVHLSNPIMRSGFCPGARRLNLEANVYENTDEEYVDVLP  132  
Fig. 2. Alignment of SAP and EAT-2 amino acidic sequences. The SH2 domains of SAP and 
EAT-2 are boxed. Conserved residues among both adaptors are highlighted in yellow, and 
those specifically conserved for each molecule are shown in bold. In green are the tyrosine 
residues present in the tail of EAT-2. 
One of the particular features of SAP is that its arginine 78 (R78) interacts with the aspartic 
acid residue 100 (D100) of Fyn, a Src-related protein tyrosine kinase. Such association 
sequentially mediates Fyn recruitment to the cytoplasmic tail of the CD150 receptor and, 
following tyrosine phosphorylation, leads to the recruitment of SHIP, docking protein (Dok) 
1, and Dok2 (Chan et al., 2003; Chen et al., 2006; Latour et al., 2001; Latour et al., 2003). 
Therefore, SAP has the ability to simultaneously associate with SLAMF molecules and Fyn, 
thus forming a trimolecular complex that also reportedly regulates the activation of Vav-1, 
Casitas B-lineage lymphoma (Cbl), Bcl-10, and protein kinase C-theta (PKC-θ)-mediated 
activation of NF-κB1 in T cells (Cannons et al., 2004; Cannons et al., 2010b; Claus et al., 2008; 
Zhong & Veillette, 2008). Furthermore, SAP can additionally engage Lck, which 
phosphorylates CD84, CD150, CD229 and CD244 (Howie et al., 2002; Martin et al., 2005; 
Nakajima et al., 2000; Tangye et al., 2003). The SAP-SH2 domain has also been described as 
interacting with the SH3 domain of PAK-interacting protein (β-PIX), a guanine nucleotide 
exchange factor (GEF) specific for Rac/Cdc42 GTPases (Gu et al., 2006). 
Both human and murine EAT-2 genes are located at chromosome 1 (1q23 in humans and 
1H3 in mice), in close proximity to SLAMF loci (Calpe et al., 2006). In contrast to human 
EAT-2, mouse and rat EAT-2 genes are duplicated with an identical genomic organization 
and encode two similar proteins, namely EAT-2A or EAT-2 and EAT-2B or ERT (Engel et al., 
2003). The EAT-2B-encoding gene is a non-functional pseudo-gene in humans. In a manner 
similar to SAP, human and mouse EAT-2 genes encode small proteins composed of an SH2 
domain followed by a short C-terminal tail, but also containing one and two tyrosines, 
respectively (Y120 and Y127) (Figure 2) (Calpe et al., 2006; Roncagalli et al., 2005). EAT-2 is 
preferentially found not only in NK cells, but also in DC and macrophages, whereas EAT-2B 
is detected only in NK cells. Human EAT-2 is expressed by NK cells, activated CD4+ and 
CD8+ T cells, and γδ T lymphocytes (Calpe et al., 2006; Morra et al., 2001; Tassi & Colonna, 
2005). 
EAT-2 and EAT-2B can bind to the Src-like kinases Hck, Lyn, Lck, and Fgr kinases through 
their catalytic domains, although neither can directly bind to the SH3 domain of Fyn since 
both lack the R78 responsible for the association of SAP with Fyn (Calpe et al., 2006; Latour 
et al., 2003). Nevertheless, EAT-2 and mouse EAT-2A can couple to the SH2 domain of Fyn 
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Another significant difference between EAT-2 and SAP is that EAT-2-mediated function has 
not been properly characterized. It was initially believed that these two adapter molecules 
played opposing roles in leukocyte activation (Ma et al., 2007). Multiple and more accurate 
studies have clearly confirmed that SAP is a positive regulator of lymphocyte activation, 
although data concerning EAT-2 activity remains controversial (Clarkson et al., 2007; Cruz-
Munoz et al., 2009; Roncagalli et al., 2005; Tassi & Colonna, 2005; Wang et al., 2010b). 
Roncagalli et al. first described that, unlike SAP, EAT-2 and ERT were inhibitors of NK cell 
function when they became associated with CD244 (2B4) in 129Sv mice (Roncagalli et al., 
2005). On the other hand, this same group demonstrated that mouse CD319 (SLAMF7) acts 
as a positive regulator of NK cell in a EAT-2A-dependent manner (Cruz-Munoz et al., 2009). 
Interestingly, a recent paper has shed light on the role played by EAT-2 in C57BL/6 NK 
cells. Wang and colleagues have shown that both, EAT-2A and ERT positively regulate 
mouse CD244- and CD84-specific NK cell functions (Wang et al., 2010b). The authors 
attribute this disparity in mouse EAT-2 functionality to the genetic background used to 
generate mice lacking or overexpressing EAT-2. Although there is convincing evidence, 
using mice with a pure genetic background, that EAT-2 acts as a positive modulator of NK 
cell functions, further experiments are needed to determine the mechanisms underlying 
EAT-2 downstream signaling.  
It is important to keep in mind that SAP and EAT-2 specifically participate in the recruitment 
of Src-like kinases at the right time and in a precise cell compartment. In addition, since SAP 
and EAT-2 can bind to the same ITSM, it has been suggested that both adapter molecules may 
be able to compete for the same docking site. The outcome of this competition can result in the 
differential recruitment of intracellular kinases or phosphatases, and thus, in variations in the 
nature and intensity of activation and differentiation processes. 
2.3 SLAMF receptors are expressed on hematopoietic cells 
SLAMF receptors display a wide-ranging and differential distribution pattern among 
hematopoietic cells. They can be found on many immune cell types including different 
subsets of T and B lymphocytes, NK and NKT cells, monocytes, macrophages, DCs, pDCs, 
platelets, granulocytes, and hematopoietic stem and progenitor cells (Table 1) (Calpe et al., 
2008; Engel et al., 2003; Ma et al., 2007). It should be noted that the analyses of SLAMF 
expression in mouse have thus far not been as exhaustive as in humans, and therefore some 
species-specific discrepancies may exist. As summarized in Table 1, their heterogeneous, but 
sometimes overlapping, expression patterns indicate that SLAMF members may play either 
redundant or specific functions in the regulation of a broad range of both innate and 
adaptive immune responses. 
Kiel and colleagues first discovered that SLAMF receptors are selectively expressed among 
primitive mouse progenitors in the adult bone marrow in such a way that it is possible to 
highly purify HSCs using a simple combination of monoclonal antibodies (mAbs) against 
three of these receptors (CD150, CD244, and CD48) (Kiel et al., 2005). However, the direct 
combination of mAbs against SLAMF receptors is not suitable for purification of human 
HSCs (Sintes et al., 2008). 
2.4 SLAMF receptors function as regulators of innate and adaptive immune 
responses 
These receptors have been shown to modulate lymphocyte activation processes that are key 
elements in the initiation and progression of autoimmune diseases, such as the development 
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of NKT cells, cytokine production in the thymus and periphery, NK- and CD8+ T- cell 
cytotoxicity, or germinal center (GC)-dependent antibody production (Figure 3 and Table 3) 
(Ma et al., 2007; Schwartzberg et al., 2009). 
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Fig. 3. SLAM family-mediated functions. 
The differentiation of NKT cells and other innate-like lymphocytes appears to be triggered by 
SAP/Fyn signaling, which occurs when CD150 (SLAMF1) and Ly108 (SLAMF6) both present 
on the surface of double positive (DP) thymocytes, though not on thymic epithelial cells, 
homotypically engage (Griewank et al., 2007; Veillette et al., 2007). Additionally, non-obese 
diabetic (NOD) mice display diminished NKT cell numbers, which has been linked to a 
deficiency in CD150 expression during the DP thymocyte stage (Jordan et al., 2007). 
Supporting this concept, a recent paper has shown that impaired CD150 signaling affects the 
production of IL-4 and IL-10 by NOD mice NKT cells (Baev et al., 2008). Yet another recent 
report found that CD1d, CD150, Ly108, and SAP expression in DP thymocytes can be 
controlled by the transcription factor c-Myb. This regulation seems to be highly selective as 
other SLAMF members located in the same locus, such as SLAMF2, SLAMF3, and SLAMF5, 
are not affected (Hu et al., 2010). Despite this data, the generation of double or triple knock-out 
mice for specific SLAMF molecules would not only aid in comprehensively mapping those 
cell-surface molecules essential to the development of innate-like lymphocytes such as NKT 
cells, but would also help to precisely identify the overlapping functions of SLAMF receptors.  
Although EBV is unable to infect mouse cells, several studies of SAP-deficient mice (SAP-/-) 
have unraveled the various molecular and cellular mechanisms involved in the 
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Receptor Functions (self-ligation, Ab stimulation or mutant mice) 
SLAMF1 
T: ↑ IL-4, IFN-γ secretion 
Mф: ↑ bacterial killing, IL-6, IL-12, TNF-α secretion 
DC: ↑ IL-8, IL-12 secretion 
Platelet: ↑ aggregates stability 
SLAMF2 T: ↑ proliferation, IL-2 secretion B, NK, DC: regulates proliferation and activation 
SLAMF3 T: ↓  IFN-γ secretion, ERK activation      ↑ IL-2, IL-4 secretion and T-cell proliferation 
SLAMF4 NK, CD8 T: ↑ cytotocicity, IFN-γ secretion Eosinophil: ↑ killing, cytokines, peroxidase release 
SLAMF5 
T:  ↑ proliferation, IFN-γ secretion, TFH function, T-B cell adhesion 
Mast cell: ↓ FcεRI-mediated signalling 
Platelet: ↑ aggregates stability 
SLAMF6 
NK: ↑ cytotoxicity, IL-8,  IFN-γ, TNF-α secretion 
CD8 T: ↑ cytotoxicity,  IFN-γ secretion 
CD4 T: Th1 polarized response 
Neutrophil: ↑ bacterial killing, ROS and cytokine production 




Table 3. Functions of SLAMF members. Ab= antibody, B=B cells, DC=dendritic cell, 
IFN=interferon, IL=interleukin, Mф=macrophages, ND=not determined, NK=natural killer 
cells, SLAMF=SLAM family, T=T cells, Th1=T helper 1 cell. 
pathogenesis of XLP. In contrast to XLP patients, mice lacking SAP exhibit increased levels 
of CD8+ T cell cytotoxicity compared with their wild-type (wt) counterparts (Chen et al., 
2005; Crotty et al., 2006; Czar et al., 2001; Wu et al., 2001). After acute infection with 
lymphocytic choriomeningitis virus (LCMV) mice presented elevated levels of Ag-specific 
and IFN-γ secreting CD8+ T cells. However, these mice died since were unable to resolve 
chronic infections (Crotty et al., 2006; Czar et al., 2001; Wu et al., 2001). Concomitantly, SAP-
/- mice can also present compromised antibody responses to viruses such as murine γ-
herpesvirus-68 (MHV-68) and influenza, as well as to parasites like Toxoplasma gondii and 
Leishmania major (Chen et al., 2005; Czar et al., 2001; Kamperschroer et al., 2006; Wu et al., 
2001; Yin et al., 2003). 
Multiple studies have clearly demonstrated the existence of a specific defect in CD4+ T cell 
immunity. As in humans, SAP-/- mouse CD4+ T cells are afflicted with such a defect; 
namely, they fail to properly differentiate into Th2 cells, subsequently presenting reduced 
levels of IL-4 (derived from diminished GATA-3 transcription factor levels), IL-10, and IL-
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13. It has also been reported that SAP-mediated IL-4 release is dependent upon Fyn. On the 
other hand, Th1 cytokines such as IFN-γ typically become elevated (Cannons et al., 2004; 
Czar et al., 2001; Davidson et al., 2004; Wu et al., 2001). In addition, Wu et al. demonstrated 
that following infection with the parasite L. major, which is dependent upon Th2 cytokines 
to induce disease, SAP-/- mice became more resistant to the parasitic infections (Wu et al., 
2001). XLP patients exhibit an extreme deficiency in IL-10 secretion by CD4+ T cells, but not 
in either IL-4 or IFN-γ production (Ma et al., 2005). In this same study Ma et al. reported that 
upon Ag-stimulation of CD4+ T cells, ICOS (CD278) levels are reduced in XLP patients in the 
same way that occurs in SAP-/- T cells (Cannons et al., 2006; Ma et al., 2005). 
Another group of defects noted in both SAP-/- mice and XLP patients concern B cell-
mediated responses, including the absence of GC formation and deficient humoral 
responses to T cell-dependent antigen following viral infection or immunization (Cannons 
et al., 2006; Crotty et al., 2003; Hron et al., 2004). In this regard, diminished numbers of 
memory B cells in the peripheral blood, as well as long-lived plasma cells, are usually 
observed in SAP-/- mice. As a consequence, low titers of serum antibodies are detected 
(Crotty et al., 2003; Czar et al., 2001; Ma et al., 2005; Qi et al., 2008; Yin et al., 2003). It was 
initially postulated that these alterations might largely stem from defects inherent to B-cell 
responses, even though it remains unclear whether or not B cells express SAP. However, 
compelling and abundant evidence indicates that the defective help provided to B cells by 
SAP-/- CD4+ TFH cells is responsible for this impaired GC formation (Cannons et al., 2006; 
Crotty et al., 2003; Ma et al., 2005). The help that T cells, namely TFH, provide to GC B cells is 
widely known to be essential to the effective production of memory B cells and long lived 
plasma cells, as well as for successful Ig class switching and antibody affinity maturation 
(Vinuesa et al., 2005; Vinuesa et al., 2010). This direct role played by T cells was confirmed 
by adoptive transfer of wt CD4+ T cells to SAP-/- mice, since they were able to abrogate this 
GC defect (Cannons et al., 2006; Crotty et al., 2003; Morra et al., 2005). Concomitantly, an 
excellent study from Qi and colleagues revealed that SAP deficiency selectively impairs the 
capacity of CD4+ T cells to firmly interact with cognate B cells, but not with DCs (Qi et al., 
2008). SAP-/- mice exhibit impaired recruitment and retention of T cells within the emerging 
GC, a defect which abrogates the GC reaction’s sustainability. Along this same line of 
investigation, this group has recently reported that mouse CD84 and Ly108 are required for 
long-lasting T-cell:B-cell contact, optimal TFH function, and GC formation, although to a 
lesser extent compared with SAP-/- mice (Cannons et al., 2010a). Nevertheless, how cognate 
T:B interactions are influenced by SLAMF/SAP-mediated signals has not been fully 
elucidated. 
3. Role of SLAMF receptors in autoimmune disease susceptibility 
Multiple cellular and molecular mechanisms are required to maintain self-tolerance, and 
failure at any of these checkpoints can precipitate tolerance breakdown and lead to 
autoimmunity. Autoimmune diseases are characterized by variable etiologies and courses of 
pathogenesis, principally due to the different ways tolerance breakdown occurs. A wide 
array of genomic association studies suggests that the heterogeneous and alternative 
contribution of various genetic factors determines to some extent autoimmune disease 
susceptibility (Vyse & Todd, 1996; Wandstrat & Wakeland, 2001). Interestingly, the 
functional pathways that are defective in several human and murine autoimmune 
conditions frequently overlap (Krishnan et al., 2006; Morel, 2010). Chromosome 1 comprises 
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a large amount of polymorphic genes related to an assortment of autoimmune disorders 
such as systemic lupus erythematosus (SLE), inflammatory bowel diseases (IBD), 
rheumatoid arthritis (RA) or multiple sclerosis (Morel, 2010; Tsao et al., 1997; Vyse & Todd, 
1996; Wandstrat et al., 2004). 
3.1 SLAM locus haplotypes and polymorphisms in mice and humans systemic 
autoimmunity 
A wide array of clinical manifestations are associated with human and mouse SLE, an 
autoimmune condition in which both environmental factors and a predisposing genetic 
background contribute to its development. This pathology is clearly marked by a humoral 
autoimmune component derived from the loss of tolerance to nuclear Ag due to the 
production of antinuclear antibodies (ANA) such as anti-chromatin and anti-ss or dsDNA. 
These functional abnormality result in the accumulation of immune complex deposits in the 
kidney that can ultimately lead to fatal nephritis (Crispin et al., 2010; Fairhurst et al., 2006; 
Krishnan et al., 2006). Given the important immunoregulatory functions of the SLAMF 
receptors described above, it is not surprising that there is increasing evidence of their 
contribution to autoimmune disease susceptibility, particularly for SLE, but also diabetes. In 
fact, two major susceptibility loci for these two diseases, Sle1b and Nkt1, correspond to the 
locus on chromosome 1 where the genes encoding for the SLAM receptors are located 
(Wang et al., 2010a). Genetic and genomic analysis of this locus has revealed a high degree 
of polymorphism both in mice and humans. Studies in mice have allowed the identification 
and characterization of two major haplotypes of this locus: the haplotype 1, represented by 
C57BL/6 and related strains and the haplotype 2 by BALB/c and strains of mice that 
develop auto-antibodies spontaneously, e.g. NZB/NZW and NZM2410 (Furukawa et al., 
2010; Morel et al., 2001; Wandstrat et al., 2004; Wang et al., 2010a). The differences between 
these two haplotypes are mainly based on: a) genomic structural variations (for example, an 
increase from one to four in the number of copies of CD244); (b) nonsynonymous mutations 
in the ligand binding domains of CD229, CD84 and CD48; (c) changes in the levels of 
transcription of some SLAMF genes; (d) and changes in the expression of isoforms 
generated by alternative splicing of some members of the family (Wang et al., 2010a). In the 
complex task of studying SLE pathogenesis, the contribution of mouse models has been 
extremely helpful due to their ability to closely mimic human SLE (Morel, 2010). In 
particular, mapping analysis of the autoimmune-prone NZM2410 (NZB x NZW, F1) mouse 
strain, which bears all the susceptibility Sle loci (Sle1, Sle2, and Sle3), revealed that these 
animals can fully develop SLE. These loci can independently cause a loss of tolerance to 
chromatin, the extent of which can differ over various serological and cellular phenotypes 
(Morel et al., 2001). Congenic mice (B6.Sle1b), derived from the mouse strains NZM2410 
(NZB x NZW/F1) and C57BL/6, that contain the Sle1b locus (haplotype 2) in a haplotype 1 
background produce high titers of anti-nuclear antibodies and develop lupus (Figure 4) 
(Morel et al., 2001; Wandstrat et al., 2004). Thus, if a gene in this region of chromosome 1 is 
knockout through homologous recombination in 129-derived embryonic stem cells (ES cells) 
and the resultant mouse is backcrossed with B6, the interpretation of the phenotype of the 
mutant mouse may be affected by epistatic interactions between the 129 and B6 genomes. 
This has been recently observed by analysing the phenotype of knockout mice of two 
SLAMF genes (SLAMF1 and SLAMF2), which were generated with a 129-derived ES cell 
line. While Slamf1-/- and Slamf2-/- mice develop features of lupus if backcrossed on to the B6 
genetic background [B6.129], Slamf1-/- and Slamf2-/- mice, backcrossed on the BALB/c 
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background [BALB/c.129], do not manifest any sign of autoimmune disease (Keszei et al., 
2011a). 
Genetic linkage and association studies of families containing SLE patients as well as case-
control studies of populations have identified several linkage regions, including one at 1q23, 
which contains multiple susceptibility genes, such as those present in the SLAM locus (Tsao 
et al., 2002). Indeed, the 1q23 locus has been identified in several genome-wide scans in 
humans and it has been replicated in subsequent linkage studies that have targeted this 
region (Moser et al., 1998; Shai et al., 1999). 
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Fig. 4. SLAM haplotype 2 in the context of the B6 genome results in spontaneous 
autoimmunity. 
Furthermore, as already mentioned, the syntenic region in mice has also been related to 
different mouse models of spontaneous lupus (Morel et al., 2001). Interestingly, SAP-/- mice 
(129SvJ background) are resistant to experimentally pristane-induced lupus. A deficiency in 
Sh2d1a abrogates the development of hypergammaglobulinemia, autoantibodies including 
anti-dsDNA, and renal disease (Hron et al., 2004). However, the mechanisms by which this 
SAP deficiency protects mice against lupus remain to be elucidated. 
A family-based association study of UK and Canadian families with SLE has revealed 
multiple polymorphisms (SNPs) in the promoter and coding region of two members of the 
SLAMF, SLAMF3 (CD229) and SLAMF7 (CD319) (Cunninghame Graham et al., 2008). The 
authors of this study found that the strongest association was with a nonsynonymous SNP 
(rs509749) in exon 8 of SLAMF3 (CD229). This Val602Met change in the cytoplasmic tail lies 
within the consensus binding site for SAP and may therefore affect downstream signaling 
events of SLAMF3. The risk allele of this variant was found associated with decreased 
numbers of CD4+ naïve T cells and activated T cells and with increased numbers of CD8+ 
memory T cells. According to the authors, the skewing in the T-cell populations may 
indicate a state of chronic T-cell activation (Cunninghame Graham et al., 2008). Despite of 
these data, the association of this polymorphism with SLE has not been replicated in 
independent cohorts of SLE patients both of Japanese and European origin (Suarez-Gestal et 
al., 2009; Suzuki et al., 2008). Polymorphisms in another member of the SLAMF, namely 
SLAMF4 (CD244), have also been found associated with rheumatoid arthritis (RA) and SLE 
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a large amount of polymorphic genes related to an assortment of autoimmune disorders 
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background [BALB/c.129], do not manifest any sign of autoimmune disease (Keszei et al., 
2011a). 
Genetic linkage and association studies of families containing SLE patients as well as case-
control studies of populations have identified several linkage regions, including one at 1q23, 
which contains multiple susceptibility genes, such as those present in the SLAM locus (Tsao 
et al., 2002). Indeed, the 1q23 locus has been identified in several genome-wide scans in 
humans and it has been replicated in subsequent linkage studies that have targeted this 
region (Moser et al., 1998; Shai et al., 1999). 
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Fig. 4. SLAM haplotype 2 in the context of the B6 genome results in spontaneous 
autoimmunity. 
Furthermore, as already mentioned, the syntenic region in mice has also been related to 
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Sh2d1a abrogates the development of hypergammaglobulinemia, autoantibodies including 
anti-dsDNA, and renal disease (Hron et al., 2004). However, the mechanisms by which this 
SAP deficiency protects mice against lupus remain to be elucidated. 
A family-based association study of UK and Canadian families with SLE has revealed 
multiple polymorphisms (SNPs) in the promoter and coding region of two members of the 
SLAMF, SLAMF3 (CD229) and SLAMF7 (CD319) (Cunninghame Graham et al., 2008). The 
authors of this study found that the strongest association was with a nonsynonymous SNP 
(rs509749) in exon 8 of SLAMF3 (CD229). This Val602Met change in the cytoplasmic tail lies 
within the consensus binding site for SAP and may therefore affect downstream signaling 
events of SLAMF3. The risk allele of this variant was found associated with decreased 
numbers of CD4+ naïve T cells and activated T cells and with increased numbers of CD8+ 
memory T cells. According to the authors, the skewing in the T-cell populations may 
indicate a state of chronic T-cell activation (Cunninghame Graham et al., 2008). Despite of 
these data, the association of this polymorphism with SLE has not been replicated in 
independent cohorts of SLE patients both of Japanese and European origin (Suarez-Gestal et 
al., 2009; Suzuki et al., 2008). Polymorphisms in another member of the SLAMF, namely 
SLAMF4 (CD244), have also been found associated with rheumatoid arthritis (RA) and SLE 
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(Suzuki et al., 2008). In one large-scale, case-control association study, two SNPs (rs3766379 
and rs6682654) were found associated with increased susceptibility to RA in two 
independent cohorts from Japan. Interestingly, the genotype distribution of these SLAMF4 
(CD244) SNPs in a SLE cohort was similar to that in the RA cohorts, suggesting that these 
polymorphisms in SLAMF4 (CD244) increase the risk for developing RA as well as SLE 
(Suzuki et al., 2008). In a recently published report, the SNP (rs3766379) in the SLAMF4 
(CD244) gene was also found significantly associated with the susceptibility to SLE in 
another cohort of individuals of Japanese origin. This association was preferentially 
observed in subsets of SLE patients with nephritis and neuropsychiatric lupus (Ota et al., 
2010). Taken together, and despite some conflicting results, these studies clearly indicate a 
high degree of polymorphism among the SLAMF genes and suggest the contribution of 
some of them in conferring susceptibility to autoimmunity. Further investigations are 
needed to determine the precise role and mechanism of these cell-receptors and their 
variants in increasing the risk to develop autoimmune diseases. 
3.2 SLAMF spliced variants and their role in autoimmunity  
As mentioned above, polymorphisms of the SLAMF genes also result in the differential 
expression of isoforms generated by alternative splicing.  These variations in splice isoform 
expression are likely to have functional consequences and have also been implicated as 
candidates for other autoimmune susceptibility loci (Evsyukova et al., 2010; Gillett et al., 
2009; Muschen et al., 1999; Ueda et al., 2003). 
One of the strongest candidates of the SLAMF linked to lupus susceptibly in mice is Ly108 
(CD352, SLAMF6). The polymorphism in Ly108 results in the expression of two 
alternatively spliced isoforms which differ exclusively in their cytoplasmic region 
(Wandstrat et al., 2004). These two isoforms, Ly108-1 and Ly108-2, are differentially 
expressed between normal mice and mice susceptible to lupus: whereas the expression of 
Ly108-1, with two domains ITSM, is increased in the B and T cells of lupus-prone mice, 
Ly108-2, with three motifs ITSM, is increased in these cells in normal animals (Kumar et al., 
2006). The higher expression of the isoform Ly108-1 in lymphocytes of lupus–prone mice is 
associated with increased survival rates and ill-suited elimination of autoreactive B cells, 
resulting in increased autoantibody production (Kumar et al., 2006). Regardless of the fact 
that it bears an ITSM less than Ly108-2, Ly108-1 is more apt than Ly108-2 to trigger SAP-
mediated tyrosine-phosphorylation signals, which involve Vav-1 and c-Cbl in T cells (Zhong 
& Veillette, 2008). Recently, Ly108 has been reported to promote long-lived stable T:B cell 
contacts (Cannons et al., 2010a). Since functional defects in both T and B lymphocytes are 
required for ANA production, it is possible that dysregulation of Ly108 isoform 
downstream signaling (derived from T:B engagement) might lead to disruption of 
peripheral tolerance and triggering of the autoimmune process in SLE. A third protein 
isoform, Ly108-H1, which is absent in two lupus-prone congenic animals has been recently 
identified (Keszei et al., 2011b). Ly108-H1 is encoded by a splice variant of Ly108 that lacks 
both exons 7 and 8. Transgenic mice expressing Ly108-H1 isoform present a dramatic 
reduction of CD4+ T cell–dependent autoimmunity in congenic B6.Sle1b mice, 
demonstrating that an immune response–suppressing isoform of Ly108 can regulate the 
pathogenesis of lupus. Nonetheless, how Ly108 isoform-mediated signals are able to breach 
this tolerance remains to be clarified. Interestingly, SLAMF6-driven co-stimulation of 
human peripheral T cells is defective in SLE T cells (Chatterjee et al., 2011). 
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Spliced variants of SLAMF receptors have been also studied in humans. Human activated T 
cells express, in addition to membrane-form of SLAMF1, mRNA encoding a soluble secreted 
form of SLAMF1 (sSLAMF1) lacking 30 amino acids (aa) encompassing the entire 22-aa 
transmembrane region (Cocks et al., 1995). This soluble isoform may play a role in 
immunomodulation since sSLAM induces proliferation of purified B cells, but also Ig 
synthesis by these cells (Punnonen et al., 1997).  
Most importantly, an altered expression of two SLAMF receptors in humans, SLAMF4 
(CD244) and SLAMF7 (CD319), as well as a differential expression of isoforms of these 
molecules has been described in PBMCs from patients with SLE (Kim et al., 2010). Two 
different splice variants of human SLAMF4 (CD244), h2B4-A and h2B4-B, with different 
functional roles in human NK cells, had been previously identified by the same authors 
(Kumaresan & Mathew, 2000; Mathew et al., 2009). While both isoforms share the same 
intracellular domain, h2B4-B has five additional amino acids between the V and the C2 
regions and is differentially regulated in SLE patients. In contrast, the two SLAMF7 (CD319) 
isoforms described, CS1-L and CS1-S, have identical extracellular domains but differ in their 
cytoplasmic tail. CS1-S lacks the two ITSM required for intracellular signaling and while 
CS1-L functions as an activating receptor, CS1-S does not show any signaling function in 
NK cells (Lee et al., 2004). Whereas healthy individuals express three-to sevenfold higher 
levels of CS1-L over CS1-S, this expression ratio is altered in SLE patients. This differential 
expression of both isoforms in PBMCs of SLE patients is reminiscent of Ly108 expression in 
lupus-prone mice (Kim et al., 2010). 
Thus, an emerging concept derived from these and other studies, is that the differential 
expression of SLAMF receptor isoforms may contribute to susceptibility to break self-
tolerance. In addition to the findings described above, cDNAs enoding SLAMF receptors 
that lack an extracellular domain, part of the cytoplasmic tail or the transmembrane 
segment, have been found in different databases (Ensemble, NCBI, EC gene). All these 
cDNAs, generated by alternative splicing, are mainly based on ESTs (Expressed Sequence 
Tags) and require experimental validation. Although it is not yet known if they are 
expressed as proteins, their expression would clearly have functional consequences, as it has 
been demonstrated in the case of Ly108 in mice. Indeed, the lack of an extracellular Ig 
domain can directly affect the recognition and the binding to the ligand, and changes that 
affect the length of the cytoplasmic tail can dramatically affect signal transduction. 
Preliminary data from our laboratory confirm the existence at the protein level of some of 
the isoforms predicted for CD84 (SLAMF5) and CD229 (SLAMF3) molecules (unpublished 
results). Altogether, these data suggest a critical role of aberrant expression of SLAMF 
spliced variants in conferring susceptibility to autoimmune diseases, in particular to SLE. 
4. Conclusion 
Lessons from genetic studies in mice have been key to support the hypothesis that SLAMF 
receptors function as disease modifiers and/or susceptibility factors of systemic 
autoimmunity. These studies are especially relevant since the phenotype of genetically 
manipulated mice is very similar to that in SLE patients, with the production of 
autoantibodies as well as multiorgan involvement, including severe nephritis. Although the 
interpretation of the phenotypes of knockout mice of the SLAMF receptors has been 
complicated by issues related to genetic background, all the data clearly underscore that 
these receptors play a critical role in the development of autoimmune diseases. An emerging 
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resulting in increased autoantibody production (Kumar et al., 2006). Regardless of the fact 
that it bears an ITSM less than Ly108-2, Ly108-1 is more apt than Ly108-2 to trigger SAP-
mediated tyrosine-phosphorylation signals, which involve Vav-1 and c-Cbl in T cells (Zhong 
& Veillette, 2008). Recently, Ly108 has been reported to promote long-lived stable T:B cell 
contacts (Cannons et al., 2010a). Since functional defects in both T and B lymphocytes are 
required for ANA production, it is possible that dysregulation of Ly108 isoform 
downstream signaling (derived from T:B engagement) might lead to disruption of 
peripheral tolerance and triggering of the autoimmune process in SLE. A third protein 
isoform, Ly108-H1, which is absent in two lupus-prone congenic animals has been recently 
identified (Keszei et al., 2011b). Ly108-H1 is encoded by a splice variant of Ly108 that lacks 
both exons 7 and 8. Transgenic mice expressing Ly108-H1 isoform present a dramatic 
reduction of CD4+ T cell–dependent autoimmunity in congenic B6.Sle1b mice, 
demonstrating that an immune response–suppressing isoform of Ly108 can regulate the 
pathogenesis of lupus. Nonetheless, how Ly108 isoform-mediated signals are able to breach 
this tolerance remains to be clarified. Interestingly, SLAMF6-driven co-stimulation of 
human peripheral T cells is defective in SLE T cells (Chatterjee et al., 2011). 
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complicated by issues related to genetic background, all the data clearly underscore that 
these receptors play a critical role in the development of autoimmune diseases. An emerging 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
66
concept is that aberrant alternative splicing plays an important role in the pathogenesis of 
autoimmune diseases. Studies reviewed in this chapter show that SLAMF isoforms 
expression appears to be altered in lupus patients. We believe that the study of the interplay 
between SLAMF isoforms in SLE patients will help identify pathways regulated during 
autoimmune processes, giving further insight into mechanisms underlying disease 
susceptibility and possible therapeutic approaches.  
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1. Introduction 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that mostly attacks 
synovial joints, although other tissues and organs can be affected. The final effect is usually 
the destruction of articular cartilage and ankylosis of the joints, with a prevalence of the 
wrist and small joints of the hand. Diagnostic criteria have recently been revised (Aletaha et 
al., 2010; Neogi et al., 2010). The prevalence of RA is about 1% in the total population, being 
women more affected than men in a ratio of approximately 2-3:1 (Alamanos & Drosos, 
2005). 
RA is considered an autoimmune disorder, although the etiology and pathogenesis of the 
disease remain unclear. A complex set of factors are involved in the onset of the disease, 
including genetic and environmental. The strongest genetic association is with the genes 
encoding major histocompatibility complex (MHC, HLA in human) class II molecules 
(Gregersen et al., 1987; Stastny, 1978), although other genes have been associated with RA, 
including PTPN22, STAT4, TRAF1/C5, and others. 
Antibodies against the Fc fraction of IgG are found in the serum of about 80% of patients 
with RA. These autoantibodies are called rheumatoid factor (RF), and the consideration of 
RA as an autoimmune disease has largely been based on the presence of RF in the serum of 
patients. Nevertheless, the presence of RF is not exclusive of RA and that, together with the 
absence of definitive data demonstrating an arthritogenic effect of RF, suggest that these 
antibodies are produced as a consequence of the immune response rather than being the 
cause of it (Nemazee, 1985; Tarkowski et al., 1985). However, the adaptive immune response 
seems to play an important role in the disease as suggested by the strong association of RA 
with the presence of some HLA class II alleles. Autoantibodies against citrullinated proteins 
(ACPAs) have been described in the serum of about 50-70% of RA patients in comparison 
with about 2% of the healthy population (Avouac et al., 2006; Kroot et al., 2000; Nishimura 
et al., 2007; Schellekens et al., 2000; van Gaalen et al., 2004; Vincent et al., 2002). The presence 
of ACPAs is very stable during the course of the disease and is quite specific for RA. These 
antibodies can be detected several years before of symptomatic disease, making the presence 
of ACPAs a good clinical marker for RA. Patients containing ACPAs in the serum usually 
have a more severe disease. The presence of these antibodies correlates very well with the 
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presence of some of the HLA-DR alleles containing the “shared epitope” (see below). All of 
these data have led to the postulation that there actually are two different disorders 
(Klareskog et al., 2008). However, the cause of the specificity of the generation of ACPAs in 
RA and whether the antibodies are pathogenic or secondary to the joint inflammation 
remain unanswered. 
Many reports have been published in the last years describing some of the features of the 
antibodies that recognize citrullinated proteins and showing some of the proteins that are 
target of these autoantibodies. The generation of an effective B cell response requires the 
recognition by specific CD4+ T cells of peptides derived of the antigen in the context of MHC 
class II molecules. In this chapter some of the data indicating the importance of anti-
citrulline responses will be reviewed and concretely emphasize on reviewing the last reports 
dealing with MHC presentation and T cell responses to citrullinated peptides will be done. 
2. HLA and rheumatoid arthritis 
The strongest genetic association of RA susceptibility is with some specific HLA class II 
alleles. In Northern Europe, the strongest association is with the serotype HLA-DR4 
(Jaraquemada et al., 1986; Stastny, 1978). The association is with some allelic variants of 
HLA-DR4, including DRB1*0401, *0404, *0405 and *0408. However, other HLA-DR4 
subtypes do not confer predisposition to RA. In Southern Europe and other populations the 
susceptibility to RA is associated to alleles other than DR4. Thus, DRB1*0101, *0102, *1402 
and *1001 have been reported with predisposition to RA (Cutbush et al., 1993; de Juan et al., 
1994; Gonzalez-Escribano et al., 1999; Hameed et al., 1997; Lacki et al., 2000; Mody & 
Hammond, 1994; Poor et al., 2007; Salvarani et al., 1999; Sanchez et al., 1990; Yelamos et al., 
1993). A major feature shared by the alleles that confer susceptibility to RA is the presence of 
some residues at position 67 and 70-74 of the third hypervariable region of DRB1 (Table 1). 
Thus, the presence of specific residues in these positions (L…(Q/R)(K/R)RAA) led to the 
proposal of the “shared epitope” hypothesis (Gregersen et al., 1987), in which the molecular 
basis for the association of some alleles with RA was restricted to this critical region in the  
chain of HLA-DR molecules. The P4 residue of the peptide core directly interacts with some 
of the residues that are part of the shared epitope (SE). Other residues are exposed to 
outside the binding groove. Thus, the side chains of these amino acids could be involved in 
the pathogenesis of the disease by defining the peptide preference or directly interacting 
with the T cell receptor (TCR), influencing the T cell repertoire selection, and specific T cell 
activation. Alternatively, molecular mimicry of this HLA-DR region and proteins from 
pathogenic agents might contribute to the disease process. Other mechanisms have been 
proposed to explain the role that the SE plays in the disease, including direct triggering by 
the five-amino acid SE sequence leading to NO production (Ling et al., 2007), ability to bind 
to heat shock proteins (Auger et al., 1996), and the ability to present citrullinated peptides 
(Hill et al., 2003). A putative “protective epitope” has also been defined for the same region, 
with the sequence DERAA, corresponding to DRB1*0402, *1102, *1301, *1302, and *1304, and 
is associated with a less severe disease (van der Helm-van Mil et al., 2005).  
HLA genes show strong linkage disequilibrium, so they segregate as haplotypes with a low 
recombination rate, specially between HLA-DR and HLA-DQ. Different data indicate that 
some HLA-DQ alleles that segregate with given HLA-DR alleles play an important role in 
RA, although these data are not totally understood. The combination of the presence of the 
SE-containing HLA-DR alleles and specific HLA-DQ alleles opened the possibility that 
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peptides containing the SE can be presented to T cells in the context of specific HLA-DQ, 
shaping the T-cell repertoire (Salvat et al., 1994). 
 
 
Table 1. Residues in the shared epitope positions in HLA-DR molecules differentially 
associated to RA 
3. Citrullination 
Citrullination is a post-translational protein modification that consists in the deimination of 
the positive charged amino acid arginine, generating the neutral amino acid citrulline 
(Figure 1). The process requires high concentrations of Ca2+ and is produced in 
inflammatory environments (Baeten et al., 2001; Chavanas et al., 2004; Vossenaar et al., 
2003). Other mechanism that triggers arginine deimination is apoptosis (Baeten et al., 2001). 
Environmental insults such as smoking increases the expression of PAD2 and induces 
citrullination in the mouse (Makrygiannakis et al., 2008). 
The conversion of arginine to citrulline is carried out by a family of enzymes known as 
peptidyl arginine deiminases (PADs) (Vossenaar et al., 2003). Five members of this family of 
enzymes have been described in human (PAD1, PAD2, PAD3, PAD4 and PAD6). The 
members or this family are differentially expressed in many cell types (including neutrophils, 
monocytes, and macrophages) and tissues (Migliorini et al., 2005; Nijenhuis et al., 2004; van 
Venrooij & Pruijn, 2000; Vossenaar et al., 2003; Wysocka et al., 2006). Thus, PAD2 and PAD4 
are expressed in the synovium of patients with RA, but PAD1, PAD3 and PAD6 are not 
(Foulquier et al., 2007). At least some functional haplotypes of PAD4 are associated with RA 
(Suzuki et al., 2003). Interestingly, PAD4 is capable of self-citrullination, which can regulate its 
activity and control the citrullination of other proteins (Andrade et al., 2010). 
Citrullinated proteins have been detected in several inflamed tissues: arthritic joins 
(Vossenaar et al., 2004a), brain (Nicholas & Whitaker, 2002), muscle and lymphoid organs 
(Makrygiannakis et al., 2006) and lungs (Bongartz et al., 2007; Klareskog et al., 2006). In 
addition, some proteins from the epidermis and central nervous system are constitutively 
citrullinated (Kubilus et al., 1979; Nicholas et al., 2003). 
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The function of citrullination is not totally understood, although it is important in some 
physiological processes such as apoptosis (Asaga et al., 1998) and cell differentiation 
(Senshu et al., 1996). The loss of a positive charge can produce changes in some relevant 
protein features. Thus, electrostatic interactions are usually important in generating and 
maintaining protein structures. A citrullinated protein modifies some of the interactions that 
stabilize the native conformation, and decreases its isoelectric point, affecting the secondary 
and tertiary structure, which can result in a different protein folding that may modify the 
function of the protein (Gyorgy et al., 2006). Regarding the specific protein functions 
affected by citrullination it has been reported that arginine deimination influences protein–
protein interaction (Tarcsa et al., 1996), and can modulate signalling potency (Proost et al., 
2008). In addition, citrullinated proteins often change their sensitivity to degradation by 
proteolytic enzymes (Pritzker et al., 2000). 
 
 
Fig. 1. Conversion of arginine to citrulline. The protein posttranslational modification 
known as citrullination consists in a deimination of arginine to citrulline. The reaction is 
carried out by an enzyme of the family of peptidyl arginine deiminases (PAD), and requires 
high concentration of Ca2+. This reaction results in the loss of a positive charge in the 
protein. 
4. Citrulline and rheumatoid arthritis 
As mentioned above, the presence of citrullinated proteins is detected in the joints of 
patients with RA (Baeten et al., 2001), although it is not exclusive for rheumatoid synovial 
tissue (Vossenaar et al., 2004a). The specificity of citrullination has not been solved and 
several proteins have been found to be citrullinated in the synovium, including vimentin 
(Bang et al., 2007; Vossenaar et al., 2004b), fibrinogen (Masson-Bessiere et al., 2001), and 
collagen type II (Klareskog et al., 2008). The role of these modified proteins in the joints 
remains unknown, although some of these proteins are known targets of the autoimmune 
response. Thus, specific antibodies have been detected in RA patients that recognize 
citrullinated filaggrin (Nijenhuis et al., 2004; Schellekens et al., 1998; Sebbag et al., 1995; 
Simon et al., 1993), fibrinogen (Bang et al., 2007), vimentin (Burkhardt et al., 2005; Despres et 
al., 1994; Hayem et al., 1999; Hueber et al., 1999) and collagen type II (Burkhardt et al., 2005). 
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A relevant feature of ACPAs is that their presence is RA specific. Thus, in contrast with RF, 
patients with inflammatory diseases other than RA rarely carry ACPAs in serum. It still 
remains unclear why ACPAs are present in the serum of most RA patients but absent in the 
serum of other systemic autoinflammatory diseases. 
As with RF, the generation of ACPAs in the serum of RA patients can occur several years 
before the onset of the disease (Aho et al., 2000; Kurki et al., 1992; Nielen et al., 2004; 
Rantapaa-Dahlqvist et al., 2003). The detection of these ACPAs can be used as clinical tests 
to predict the clinical course of the disease (Kastbom et al., 2004; Ronnelid et al., 2005). There 
are some clinical and genetic differences between ACPA+ and ACPA- RA patients. 
Clinically, ACPA+ RA patients have a more severe disease course than patients without 
detectable ACPAs (Forslind et al., 2004; Kastbom et al., 2004; Kroot et al., 2000; Ronnelid et 
al., 2005). Genetically, the detection of ACPAs in the serum of RA patients correlates very 
well with the presence of HLA-DR alleles containing the SE, which does not happen with 
RF. Some reports have shown that the presence of HLA-DRB1 alleles containing the SE is 
directly related and restricted to the ACPA+ subset of RA (Huizinga et al., 2005; van der 
Helm-van Mil et al., 2006) and SE alleles influence both the magnitude and the specificity of 
this RA-specific antibody response (Verpoort et al., 2007). Other HLA-DRB1-independent 
genetic associations in the HLA region to ACPA positivity have been reported (Okada et al., 
2009). In contrast, ACPA- RA is not related with the SE-carrying HLA-DRB1 alleles and it 
has been associated with HLA-DRB1*03 (Irigoyen et al., 2005), an DRB1 allele that does not 
contain the SE. Taking together, it seems clear that ACPA+ and ACPA- RA do not present 
the same genetic background or clinical course and evidence strongly suggest that these are 
two different RA subsets, so they should be considered as different entities when treated.  
Since ACPAs are developed before the onset of the disease and their presence predicts a 
more severe clinical course, this seems to indicate that the immune response against 
citrullinated proteins contribute to the pathogenesis of this form of RA.  
5. Citrullinated peptides and HLA 
The SE contains residues 70-74 of the DR chain, and is located in one -helix of the binding 
groove. These residues are located in a position such that some of them can interact with the 
peptide bound to the HLA-DR molecule. Concretely, the crystal structures of HLA-DR1 and 
HLA-DR4 with different peptides have shown that the residues Lys71 in DRB1*0401 and 
Arg71 in DRB1*0101 directly interact with the amino acid located in position 4 (P4) of the 
peptide core bound to the binding groove of HLA-DR molecules (Dessen et al., 1997; 
Rosloniec et al., 2006). The binding motifs of the peptides associated to HLA-DR1 and HLA-
DR4 were described years ago. More recently, our group reported an exhaustive analysis of 
the peptide pool associated to HLA-DR10 by mass spectrometry and identified the anchor 
motif of the peptide repertoire bound to this RA-associated allele (Alvarez et al., 2008). This 
motif was consistent with a more recent report by Kwok´s group using an approach based 
on binding assays (James et al., 2010). An important structural information extracted from 
these data is that HLA-DR molecules containing the SE do not bind peptides with basic 
residues in P4 position. This is due to the presence of basic residues at position 71 of the 
HLA-DR  chain (table 1). 
Conversion of the basic amino acid arginine to the neutral citrulline produces the loss of a 
net positive charge on the protein or peptide that suffer this post-translational modification. 
Thus, citrulline is a neutral, polar, large amino acid with structural features similar to 
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The function of citrullination is not totally understood, although it is important in some 
physiological processes such as apoptosis (Asaga et al., 1998) and cell differentiation 
(Senshu et al., 1996). The loss of a positive charge can produce changes in some relevant 
protein features. Thus, electrostatic interactions are usually important in generating and 
maintaining protein structures. A citrullinated protein modifies some of the interactions that 
stabilize the native conformation, and decreases its isoelectric point, affecting the secondary 
and tertiary structure, which can result in a different protein folding that may modify the 
function of the protein (Gyorgy et al., 2006). Regarding the specific protein functions 
affected by citrullination it has been reported that arginine deimination influences protein–
protein interaction (Tarcsa et al., 1996), and can modulate signalling potency (Proost et al., 
2008). In addition, citrullinated proteins often change their sensitivity to degradation by 
proteolytic enzymes (Pritzker et al., 2000). 
 
 
Fig. 1. Conversion of arginine to citrulline. The protein posttranslational modification 
known as citrullination consists in a deimination of arginine to citrulline. The reaction is 
carried out by an enzyme of the family of peptidyl arginine deiminases (PAD), and requires 
high concentration of Ca2+. This reaction results in the loss of a positive charge in the 
protein. 
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patients with RA (Baeten et al., 2001), although it is not exclusive for rheumatoid synovial 
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collagen type II (Klareskog et al., 2008). The role of these modified proteins in the joints 
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Simon et al., 1993), fibrinogen (Bang et al., 2007), vimentin (Burkhardt et al., 2005; Despres et 
al., 1994; Hayem et al., 1999; Hueber et al., 1999) and collagen type II (Burkhardt et al., 2005). 
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A relevant feature of ACPAs is that their presence is RA specific. Thus, in contrast with RF, 
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genetic associations in the HLA region to ACPA positivity have been reported (Okada et al., 
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has been associated with HLA-DRB1*03 (Irigoyen et al., 2005), an DRB1 allele that does not 
contain the SE. Taking together, it seems clear that ACPA+ and ACPA- RA do not present 
the same genetic background or clinical course and evidence strongly suggest that these are 
two different RA subsets, so they should be considered as different entities when treated.  
Since ACPAs are developed before the onset of the disease and their presence predicts a 
more severe clinical course, this seems to indicate that the immune response against 
citrullinated proteins contribute to the pathogenesis of this form of RA.  
5. Citrullinated peptides and HLA 
The SE contains residues 70-74 of the DR chain, and is located in one -helix of the binding 
groove. These residues are located in a position such that some of them can interact with the 
peptide bound to the HLA-DR molecule. Concretely, the crystal structures of HLA-DR1 and 
HLA-DR4 with different peptides have shown that the residues Lys71 in DRB1*0401 and 
Arg71 in DRB1*0101 directly interact with the amino acid located in position 4 (P4) of the 
peptide core bound to the binding groove of HLA-DR molecules (Dessen et al., 1997; 
Rosloniec et al., 2006). The binding motifs of the peptides associated to HLA-DR1 and HLA-
DR4 were described years ago. More recently, our group reported an exhaustive analysis of 
the peptide pool associated to HLA-DR10 by mass spectrometry and identified the anchor 
motif of the peptide repertoire bound to this RA-associated allele (Alvarez et al., 2008). This 
motif was consistent with a more recent report by Kwok´s group using an approach based 
on binding assays (James et al., 2010). An important structural information extracted from 
these data is that HLA-DR molecules containing the SE do not bind peptides with basic 
residues in P4 position. This is due to the presence of basic residues at position 71 of the 
HLA-DR  chain (table 1). 
Conversion of the basic amino acid arginine to the neutral citrulline produces the loss of a 
net positive charge on the protein or peptide that suffer this post-translational modification. 
Thus, citrulline is a neutral, polar, large amino acid with structural features similar to 
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glutamine. Interestingly, peptides with arginine in P4 are poorly tolerated for the HLA-DR 
molecules that comprise the SE alleles (Fremont et al., 1996; Friede et al., 1996), while 
peptides with glutamine in P4 of the binding core have been described for DRB1*0101, 
DRB1*0401 and DRB1*1001 (Alvarez et al., 2008; Dengjel et al., 2005; Muntasell et al., 2004; 
Stern et al., 1994; Verreck et al., 1996). Basic residues, such as arginine or lysine, in P4 
position of the peptide core produce electrostatic repulsion with the basic residues in 
position 71 of the  chain in the HLA-DR molecules that contain the SE. However, glutamine 
can accommodate well in the pocket and can be stabilized by hydrogen bonds with Arg71 or 
Lys71 in the HLA-DR  chain. Thus, positively charged amino acids (e.g., arginine) in P4 
inhibit peptide binding to RA-related HLA-DR molecules containing the SE, whereas 
peptides with uncharged polarity (e.g., glutamine) are bound to these molecules with high 
affinity (Hammer et al., 1994; Hammer et al., 1995). Peptides with citrullin in P4 would 
interact favourably at the P4 anchoring pocket of SE-containing HLA-DR molecules. This 
was confirmed both for DRB1*0101, DRB1*0401 (Hill et al., 2003) and DRB1*1001 (James et 
al., 2010). Concretely, modified peptides derived from joint associated proteins were able to 
bind to RA-associated MHC molecules: the peptide spanning residues 65-77 from vimentin, 
vimentin (65-77) to DRB1*0101 and DRB1*0401 (Hill et al., 2003), and peptides vimentin (58-
72), Fib A (737-751), Fib B (68-82) and cartilage intermediate layer protein CILP (982-996) to 
DRB1*1001 (James et al., 2010). These data open the possibility that in the inflamed joint, 
some arginines may be deiminated by activated PAD2 or PAD4 and, after protein 
catabolism, citrulline-containing peptides would be bound to SE HLA-DR molecules. 
The peptide repertoires associated to many MHC molecules have been described, both for 
MHC class I and for MHC class II. However, up to now, no peptide with citrulline in P4 has 
been reported to be a natural ligand of any HLA-DR molecule. Some reasons make the 
identification of citrullinated peptides from the peptide repertoire bound to HLA-DR 
molecules very difficult. First, the conditions to obtain high level of protein citrullination are 
not totally controlled, although some protocols have been reported, as increasing intracellular 
calcium by the addition of ionomicine to the cell culture (Vossenaar et al., 2004c). Second and 
more important, after deimination induction, most of the peptides will remain containing 
arginine instead of citrulline, and probably, the amount of citrullinated peptides in the peptide 
pool will be low. Mass spectrometry analysis give information of the most abundant peptides 
in the MHC-associated peptide pools making complicated to find a low-abundance 
citrullinated peptide. An approach that could be used to solve these problems would be to 
enrich citrullinated peptides in the sample. Antibodies specific for citrullinated peptides can 
not be used because they can recognize some peptides but not others. A technique for the 
specific enrichment of citrulline-containing peptides has been described, based on the 
immobilization of a glyoxal derivative that reacts exclusively with the ureido group of the 
citrulline residue al low pH (Tutturen et al., 2010). The ureido group can be chemically 
modified by diacetyl monoxime and antipyrine (Senshu et al., 1992). The chemically modified 
citrulline can be detected, using a specific antibody, by Western blotting and 
immunohistochemistry (Makrygiannakis et al., 2008). Peptides or proteins containing the 
modified citrulline can also be detected by mass spectrometry (Stensland et al., 2009). 
6. T cell responses to HLA-restricted citrullinated peptides 
The induction of a typical humoral response that results in a production of classes of 
antibodies others than IgM requires the help of CD4 T cells. T cells recognize complexes 
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formed by MHC molecules and peptides derived from antigenic proteins. In the case of 
ACPAs, the targets of the immune response are modified self proteins, as vimentin, fillagrin, 
fibrinogen and collagen type II. CD4 T cells that help in the generation of an anti-
citrullinated proteins B cell response do not necessarily recognize citrullinated peptides. 
However, a role of T cell responses in RA is well known, which makes the identification of T 
cell responses against citrullinated peptides presented in the context of RA-related HLA-DR 
of great interest. These peptides could be citrullinated outside the binding core, in the core 
positions other than P4, or in P4, as discussed above. 
In the last years, T cell responses to citrulline-containing peptides have been studied. First, 
using DR4-IE transgenic mice (expressing the chimeric molecule DR4-IE, that contains the 
DR4 binding groove and part of the murine class II molecule), Hill and collaborators 
demonstrated that deimination of arginine to citrulline significantly increased the peptide-
MHC affinity when arginine was in P4 position. In addition, activated CD4+ T cells were 
detected in these transgenic mice against a peptide spanning residues 65 to 77 of vimentin, 
vimentin (65-77), which had a citrulline in position 70 instead of the arginine of the 
unmodified protein. These results revealed that HLA-DRB1 alleles with the SE could initiate 
an specific autoimmune response to citrullinated self-antigens in DR4-transgenic mice (Hill 
et al., 2003). In this animal model, citrullinated fibrinogen induced arthritis. The disease 
induced in these mice was characterized by synovial hyperplasia followed by ankylosis, but 
lacked a large leukocyte infiltrate. Specific humoral and cellular responses to citrullinated 
components were observed, which were absent in wild-type mice immunized with 
citrullinated or unmodified fibrinogen and in transgenic mice immunized with unmodified 
fibrinogen (Hill et al., 2008). HLA-DRB1*0401–restricted T cell reactivity to fibrinogen (371-
383) was clearly seen in transgenic mice after immunization with either citrullinated 
fibrinogen or unmodified fibrinogen, whereas no specific response to this peptide was 
detected in wild-type mice. Ten peptides derived from ,  or  chains of human fibrinogen 
containing an aliphatic or aromatic residue in P1 position of the binding core and arginine 
or citrulline at P4 were tested to generate T cell responses. Only one citrullinated peptide, 
FibαR84Cit, induced a consistent T cell response, whereas no response was seen against the 
corresponding arginine-containing peptide Fibα79-91. Therefore, these data confirm that a 
citrullinated protein can be arthritogenic when RA-associated alleles are expressed, and 
specific T cell responses to citrullinated peptides are part of the immune response. 
Citrullinated peptides-specific T cell activation plays an important role in the development 
and progression of arthritis in this animal model. Thus, when given prior to disease onset, 
treatment with CTLA-4Ig, an agent that blocks T cell costimulation, prevented T cell 
activation induced by citrullinated human fibrinogen. This effect was not seen with non-
specific IgG1 (Yue et al.). 
Other approach using the mouse model detected that a response against citrullinated 
peptides could be generated even when the antigen was administrated in unmodified form. 
Concretely, HEL was used as a model antigen, and T cells specifically reactive to 
citrullinated epitopes were detected among the responding repertoire to immunization with 
an unmodified HEL protein. In addition, antigen presenting cells (APCs), including 
dendritic cells and peritoneal macrophages, were able to present citrullinated peptides when 
provided an intact, unmodified HEL ex vivo (Ireland et al., 2006). Therefore, APCs were 
capable to capture and process the antigen, to deiminate some specific arginine residues and 
to present some citrullin-containing peptides to T cells in a correct way to induce an specific 
response against citrullinated peptides. 
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modified by diacetyl monoxime and antipyrine (Senshu et al., 1992). The chemically modified 
citrulline can be detected, using a specific antibody, by Western blotting and 
immunohistochemistry (Makrygiannakis et al., 2008). Peptides or proteins containing the 
modified citrulline can also be detected by mass spectrometry (Stensland et al., 2009). 
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citrullinated protein can be arthritogenic when RA-associated alleles are expressed, and 
specific T cell responses to citrullinated peptides are part of the immune response. 
Citrullinated peptides-specific T cell activation plays an important role in the development 
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treatment with CTLA-4Ig, an agent that blocks T cell costimulation, prevented T cell 
activation induced by citrullinated human fibrinogen. This effect was not seen with non-
specific IgG1 (Yue et al.). 
Other approach using the mouse model detected that a response against citrullinated 
peptides could be generated even when the antigen was administrated in unmodified form. 
Concretely, HEL was used as a model antigen, and T cells specifically reactive to 
citrullinated epitopes were detected among the responding repertoire to immunization with 
an unmodified HEL protein. In addition, antigen presenting cells (APCs), including 
dendritic cells and peritoneal macrophages, were able to present citrullinated peptides when 
provided an intact, unmodified HEL ex vivo (Ireland et al., 2006). Therefore, APCs were 
capable to capture and process the antigen, to deiminate some specific arginine residues and 
to present some citrullin-containing peptides to T cells in a correct way to induce an specific 
response against citrullinated peptides. 
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More than 90% of patients positive for citrullinated vimentin-specific ACPAs carry SE-
containing HLA-DRB1 alleles. In a DR4-transgenic mouse model, animals were immunized 
with 33 citrulline-containing peptides (all possible citrullinated peptides of human 
vimentin) and tested for T cell reactivity. T cell responses were generated against some of 
these peptides restricted by HLA-DRB1*0401 (vimentin (26-44) and vimentin (415-433). 
Antigen presenting cells were able to generate these peptides from entire vimentin. In 
addition, T cell reactivity against these citrullinated peptides derived from vimentin were 
observed when PBMCs from ACPAs-positive, HLA-DR4-positive patients with RA were 
used (Feitsma et al.). These data strongly suggest the presence of HLA-DRB1*0401-restricted 
T cell responses against citrullinated vimentin-derived peptides in RA patients. The data do 
not exclude T cell responses against non-citrullinated peptides restricted by this or other 
HLA-DRB1 alleles, that also could facilitate a humoral response against citrullinated 
epitopes. 
The generation of T cell responses against citrullinated peptides has also been confirmed for 
other autoantigens. Thus, a proliferative response was observed in more than 60% RA 
patients after stimulation with citrullinated aggrecan-derived peptide, aggrecan (84-103) 
(von Delwig et al., 2010). This response was absent in PBMCs from healthy controls, and 
there was no response to the unmodified aggrecan analog peptide, indicating that citrulline 
residue is required for T cell recognition. In addition, cytokine production was analyzed by 
ELISA and intracellular cytokine analysis. High levels of the proinflammatory cytokine 
interleukin-17 (IL-17) was produced by PBMCs from RA patients in response to stimulation 
with citrullinated aggrecan. This IL-17 production was absent when PBMCs from RA 
patients and healthy controls were stimulated with the unmodified aggrecan-derived 
peptide. Therefore, citrullinated aggrecan-specific T cells may play a role in the 
pathogenesis of RA and in the inflammatory process.  
Most of the T cell responses to citrullinated peptides have been generated in models that 
express HLA-DRB1*0401. In addition, responses against citrullinated peptides restricted by 
the RA-associated, SE-containing HLA-DRB1*1001 molecule have been obtained (James et 
al., 2010). Authors demonstrated that HLA-DRB1*1001 can accommodate citrulline in three 
anchor positions, and three of the modified peptides that were evaluated developed specific 
CD4+ T cell responses. These peptides derived from fibrinogen , fibrinogen  and cartilage 
intermediate-layer protein, and these data suggest a role for these three proteins as relevant 
antigens in RA in HLA-DRB1*1001+ patients. In addition, T cell clones specific for these 
sequences proliferated only in response to citrullinated peptides. One more time, these data 
suggest that deimination of arginine can have as a consequence the generation of new HLA-
DR ligands that can be recognized by T cells as neoepitopes, and may play an important role 
in the initiation or progression of RA. As described recently, T cell responses to other post-
translational modifications may play a similar role in generating inflammatory responses. 
One of this could be carbamylation of lysine to homocitrulline. Thus, mice were immunized 
with carbamylated peptides, which induced chemotaxis, and T and B cell responses. Mice 
immunized with carbamylated peptides developed erosive arthritis when citrullinated 
peptides were injected intra-articularly. In addition, T and B cells induced arthritis after 
adoptive transfer into normal recipients (Mydel et al., 2010). Therefore, the T cell response to 
homocitrulline-derived peptides, as well as the subsequent production of anti-
homocitrulline Abs, was critical for the induction of autoimmune responses against 
citrulline-derived peptides which may provide a novel mechanism for the pathogenesis of 
arthritis. 
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Constitutive protein citrullination occurs in some tissues in absence of inflammation, which 
imply the existence of tolerance against these modified proteins. The thymus is the organ 
where the immunocompetent T cell repertoire is generated. During selection processes to 
generate central T cell tolerance, about 95-97% of the thymocytes die by apoptosis, which is 
an inductor of citrullination. Thus, PAD activity and arginine deimination may be active in 
this organ. Citrullinated peptides that bind to HLA-DR molecules in the thymus should not 
be able to induce an immune response in periphery. Differences in the machinery of antigen 
processing have been reported between thymic cells and other presenting cells. Thus, the 
identification and analysis of HLA-DR-associated citrullinated peptides in the thymus could 
reveal which peptides can generate central tolerance. 
7. Conclusions 
The finding that the sera of most RA patients contain antibodies specifc for citrullinated 
proteins opened the possibility of a new mechanism in the etiology of the disease. These 
antibodies are specific for RA, can be detected years before the development of the disease, 
and correlate with the presence of SE-containing alleles. In the last years, relevant advances 
on the identification of the citrullination process in the inflamed joints by PADs´activity, the 
presentation by RA-associated HLA-DR molecules that contain the SE, and T cell responses 
against citrullinated proteins have been made. Nevertheless, it remains to be defined which 
citrullinated peptides are really involved in the development of the disease in humans and if 
any of them can efficiently be presented in the context of various SE-containing HLA-DR 
molecules. 
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More than 90% of patients positive for citrullinated vimentin-specific ACPAs carry SE-
containing HLA-DRB1 alleles. In a DR4-transgenic mouse model, animals were immunized 
with 33 citrulline-containing peptides (all possible citrullinated peptides of human 
vimentin) and tested for T cell reactivity. T cell responses were generated against some of 
these peptides restricted by HLA-DRB1*0401 (vimentin (26-44) and vimentin (415-433). 
Antigen presenting cells were able to generate these peptides from entire vimentin. In 
addition, T cell reactivity against these citrullinated peptides derived from vimentin were 
observed when PBMCs from ACPAs-positive, HLA-DR4-positive patients with RA were 
used (Feitsma et al.). These data strongly suggest the presence of HLA-DRB1*0401-restricted 
T cell responses against citrullinated vimentin-derived peptides in RA patients. The data do 
not exclude T cell responses against non-citrullinated peptides restricted by this or other 
HLA-DRB1 alleles, that also could facilitate a humoral response against citrullinated 
epitopes. 
The generation of T cell responses against citrullinated peptides has also been confirmed for 
other autoantigens. Thus, a proliferative response was observed in more than 60% RA 
patients after stimulation with citrullinated aggrecan-derived peptide, aggrecan (84-103) 
(von Delwig et al., 2010). This response was absent in PBMCs from healthy controls, and 
there was no response to the unmodified aggrecan analog peptide, indicating that citrulline 
residue is required for T cell recognition. In addition, cytokine production was analyzed by 
ELISA and intracellular cytokine analysis. High levels of the proinflammatory cytokine 
interleukin-17 (IL-17) was produced by PBMCs from RA patients in response to stimulation 
with citrullinated aggrecan. This IL-17 production was absent when PBMCs from RA 
patients and healthy controls were stimulated with the unmodified aggrecan-derived 
peptide. Therefore, citrullinated aggrecan-specific T cells may play a role in the 
pathogenesis of RA and in the inflammatory process.  
Most of the T cell responses to citrullinated peptides have been generated in models that 
express HLA-DRB1*0401. In addition, responses against citrullinated peptides restricted by 
the RA-associated, SE-containing HLA-DRB1*1001 molecule have been obtained (James et 
al., 2010). Authors demonstrated that HLA-DRB1*1001 can accommodate citrulline in three 
anchor positions, and three of the modified peptides that were evaluated developed specific 
CD4+ T cell responses. These peptides derived from fibrinogen , fibrinogen  and cartilage 
intermediate-layer protein, and these data suggest a role for these three proteins as relevant 
antigens in RA in HLA-DRB1*1001+ patients. In addition, T cell clones specific for these 
sequences proliferated only in response to citrullinated peptides. One more time, these data 
suggest that deimination of arginine can have as a consequence the generation of new HLA-
DR ligands that can be recognized by T cells as neoepitopes, and may play an important role 
in the initiation or progression of RA. As described recently, T cell responses to other post-
translational modifications may play a similar role in generating inflammatory responses. 
One of this could be carbamylation of lysine to homocitrulline. Thus, mice were immunized 
with carbamylated peptides, which induced chemotaxis, and T and B cell responses. Mice 
immunized with carbamylated peptides developed erosive arthritis when citrullinated 
peptides were injected intra-articularly. In addition, T and B cells induced arthritis after 
adoptive transfer into normal recipients (Mydel et al., 2010). Therefore, the T cell response to 
homocitrulline-derived peptides, as well as the subsequent production of anti-
homocitrulline Abs, was critical for the induction of autoimmune responses against 
citrulline-derived peptides which may provide a novel mechanism for the pathogenesis of 
arthritis. 
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Constitutive protein citrullination occurs in some tissues in absence of inflammation, which 
imply the existence of tolerance against these modified proteins. The thymus is the organ 
where the immunocompetent T cell repertoire is generated. During selection processes to 
generate central T cell tolerance, about 95-97% of the thymocytes die by apoptosis, which is 
an inductor of citrullination. Thus, PAD activity and arginine deimination may be active in 
this organ. Citrullinated peptides that bind to HLA-DR molecules in the thymus should not 
be able to induce an immune response in periphery. Differences in the machinery of antigen 
processing have been reported between thymic cells and other presenting cells. Thus, the 
identification and analysis of HLA-DR-associated citrullinated peptides in the thymus could 
reveal which peptides can generate central tolerance. 
7. Conclusions 
The finding that the sera of most RA patients contain antibodies specifc for citrullinated 
proteins opened the possibility of a new mechanism in the etiology of the disease. These 
antibodies are specific for RA, can be detected years before the development of the disease, 
and correlate with the presence of SE-containing alleles. In the last years, relevant advances 
on the identification of the citrullination process in the inflamed joints by PADs´activity, the 
presentation by RA-associated HLA-DR molecules that contain the SE, and T cell responses 
against citrullinated proteins have been made. Nevertheless, it remains to be defined which 
citrullinated peptides are really involved in the development of the disease in humans and if 
any of them can efficiently be presented in the context of various SE-containing HLA-DR 
molecules. 
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1. Introduction 
Autoimmune diseases develop when the immune system starts producing antibodies and T 
cells that are targeting components of the body. Such state occurs when the ability to 
recognition of self is disturbed and the immune cells attack healthy cells. The autoimmune 
diseases are frequently accompanied by self-destruction which is realized via apoptosis. 
There are two signaling pathways how the immune cells induce apoptosis in the target cells: 
1) receptor-mediated; 2) receptor-independent. In the first mechanism, so called “death 
receptors” that are located on plasma membrane of the target cell are involved, while their 
“death ligands” are either located on the surface of the immune cell, or released by these 
cells and acting in free form. The corresponding ligand-receptor interactions cause 
activation of “death receptors” which use special “death domains” for contacting with 
specific intracellular signaling proteins and formation of death-inducing signaling complex 
(DISC). It is considered that this complex is capable of interacting with procaspase 8 and 
activating this initiator caspase. It is also probable that from this moment (activation of 
caspase 8), cascade of the apoptotic events gains irreversible character (Ashkenazi & Dixit, 
1998). The receptor-independent mechanisms of apoptosis induction in which the immune 
cells take part, differ significantly (Vermijlen et al., 2001). These mechanisms are based on 
the ability of cytotoxic T cells to induce formation of special pores in plasma membrane of 
the target cells. Through these pores, calcium cations and protein granzyme B penetrates the 
target cells where they directly activate apoptotic enzymes – the caspases.  
Fas-receptor that belongs to a family of tumor necrosis factor (TNF) receptors (Orlinick & 
Chao, 1998) is a typical “death receptor”. It is known that TNF is produced by activated 
macrophages and T cells as a host response to infection (Tartaglia & Goeddel, 1992). Its 
interaction with specific plasma membrane receptors induces production of transcription 
factors NF-kB and AP-1 which take part in the activation of specific genes whose products 
are involved in the inflammation and immunomodulation (Tartaglia & Goeddel, 1992). 
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After association with the adaptor protein TRADD, TNF receptor can interact with the 
procaspase 8, and this occurs during the TNF-induced apoptosis.  
Apo2L or TRAIL is another TNF-like ligand that can induce apoptosis in various cell lines 
including tumor ones (Pradhan, Krahling, Williamson, & Schlegel, 1997). Since the 
population of mature T cells gains sensitivity to the TRAIL-induced apoptosis after their 
stimulation with the interleukin 2, it is considered that TRAIL takes part in elimination of 
the peripheral T lymphocytes.  
The receptor-independent apoptosis is the main mechanism by which the cytotoxic 
lymphocytes destroy virus-infected cells, as well as tumor cells (Ploegh, 1998). This 
mechanism is based on exocytosis of special dense granules which interact with plasma 
membrane of the target cells. These granules contain cytolytic substances which can 
polymerize in the presence of calcium cations and form macromolecular channels in the 
plasma membrane of the target cells. These channels are used for penetration of the 
granzyme B – serine protease that is capable of activating various caspases, for example the 
procaspase 3 (Goping et al., 2003). An elevated expression of the antiapoptotic 
mitochondrial protein Bcl-2 blocks such activation of the caspase 3, while the granzyme B 
blocks functioning of the Bcl-2. Thus, granzyme B is critical agent in the induction of 
apoptosis caused by the cytotoxic T cells.  
1.1 SLE 
Systemic Lupus Erythematosus (SLE) is a chronic, usually life-long, potentially fatal 
autoimmune disease characterized by unpredictable exacerbations and remissions with 
variable clinical manifestations. In SLE patients, there is a high probability for clinical 
involvement of the joints, skin, kidney, brain, lung, heart, serosa and gastrointestinal tract. 
Women and minorities are disproportionately affected, and Lupus SLE is most common in 
women of child-bearing age. A recent study identified a prevalence in the Unites States of 
500 per 100,000 (1:200) in women (Belmont, 2010). SLE is a multifactorial disease involving 
genetic, environmental and hormonal factors. Its precise pathogenesis is unclear. There is 
growing evidence in favor of clearance deficiency of apoptotic cells as a core mechanism in 
SLE pathogenesis.  
1.2 Clearance and SLE 
Defective clearance of apoptotic cells causes secondary necrosis with a release of 
intracellular content and inflammatory mediators. This occurrence is considered as an 
intrinsic defect that can cause permanent presence of cellular debris responsible for the 
initiation of systemic autoimmunity in such diseases as SLE (for details see the review 
(Munoz, Lauber, Schiller, Manfredi, & Herrmann, 2010)). Macrophages respond and present 
self-antigens to T and B cells. Pathogenic autoantibodies are the primary cause of tissue 
damage in patients with lupus. The production of these antibodies arises by means of 
complex mechanisms involving every key facet of the immune system. Thus, restoring 
organism’s ability to remove dying cells and impaired macromolecules (improving 
clearance efficiency) can serve as a perspective approach to treatment of autoimmune 
disorders and achieving clinical remission. 
1.3 Ways to improve clearance 
The apoptotic markers located in plasma membrane of the cell are very important, since 
they allow detecting apoptosis without violation of cell integrity. At present, phosphatidyl 
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serine externalization is the most widely used apoptotic marker on PM (Fadok et al., 1992). 
It is detected by the annexin V binding test (Reutelingsperger & Christiaan Peter, 1998). 
Recently, we found that apoptosis is accompanied by not only the loss of plasma membrane 
asymmetry caused by phosphatidyl serine externalization, but also by changes in cell 
surface glycoconjugates described by us (R. Bilyy & Stoika, 2007; R. O. Bilyy, Antonyuk, & 
Stoika, 2004; R. O. Bilyy & Stoika, 2003). Similar results were obtained by the group headed 
by Prof. Martin Herrmann (Heyder et al., 2003). Further findings of our (R. Bilyy et al., 2005; 
R. O. Bilyy et al., 2004) and other groups (Batisse et al., 2004; Franz et al., 2006; Franz et al., 
2007) allowed us to consider that an increase in the exposure levels of α-D-mannose- and β-
D-galactose-rich GPs of the PM is a characteristic feature of the apoptotic cells. Their 
expression is substantially increased after apoptosis induction.  Two independent 
mechanisms can lead to the appearance of altered surface glycoepitopes. One mechanism is 
the activation of surface sialidases resulting in exposure of desialylated (galactose-rich) 
surface glycoepitopes. 
These glyconeoepitopes have been proposed for both the detection of apoptotic cells  (R. O. 
Bilyy et al., 2004) and their isolation from the mixed populations (Stoika, Bilyy, & Antoniuk, 
2006). Moreover, these glycoepitops can be directly involved in clearance of the apoptotic 
cells by the macrophages, serving as an “eat-me” signals of the apoptotic cells, as we have 
shown in (Meesmann et al., 2010). Our finding explains the previously known fact of surface 
glycopattern contribution to the clearance of dying and aged cells (Savill, Fadok, Henson, & 
Haslett, 1993). We effectively used changed apoptotic cell glycopattern for detection of 
dying cells in blood samples at the autoimmune disorders (R. Bilyy et al., 2009). We have 
proved that artificial desialylation of apoptotic and viable cells enhances their clearance by 
macrophages. This was confirmed in both cell lines and isolated human PMN and 
monocytes differentiated to macrophages (Meesmann et al., 2010).  
Detection of both annexin V (van den Eijnde et al., 1997) and fluorescent conjugates of 
lectins (Heyder et al., 2003) usually requires using complex equipment like flow cytometer 
and/or fluorescent microscope. Evaluation of phosphatidyl serine externalization should be 
conducted as soon as possible after blood isolation, and cannot be done after the majority of 
available fixation procedure, since it would result in false-positive results; while the GPs are 
not affected by cell fixation or staining procedure. We have focused at the development of a 
test aimed to detect cell surface glycoconjugate changes during apoptotic cell death. We 
utilized the multivalency of lectin molecules for inducing agglutination of apoptotic cells, 
resulting from their altered surface GP content, and developed a specific test for apoptosis 
measurement (R. Bilyy & Stoika, 2007; Stoika et al., 2006).  
2. Lymphocyte desialylation at SLE 
Previously, we (R. Bilyy et al., 2009) demonstrated a significant increase in apoptosis incidence 
in the perypheral blood lymphocytes of RA patients comparing with lymphocytes of clinically 
healthy donors. That increase was detected by both flow cytometry and lectin-induced 
agglutination testing of apoptosis. We concluded that apoptosis-related changes in 
glycoconjugates of plasma membrane of the peripheral blood lymphocytes in RA patients can 
be used as a reliable and simple tool for apoptosis measurement during this and, probably, 
other autoimmune disorders. Detection of glycoconjugates via specific lectin binding is 
compatible with other available fixation/staining procedures, and can be recommended as an 
additional indicator in the multi-parameter automated detection systems. 
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Here we estimated changes in cell surface GP expression, namely changes in ß-D-containing 
glycans, in the peripheral blood lymphocytes of SLE patients and clinically healthy donors, 
and compared these changes with the level of apoptotic cells detected by the alternative 
methods. Detection of ß-D-containing glycans was performed by using VAA lectin staining, 
since this lectin binds to the surface of both early and late apoptotic cells, as can be seen at 
the confocal image on Fig. 1. 
 
 
Fig. 1. Confocal microscopy of Jurkat T-cells at early (e) and late (l) stages of apoptosis 
progression, staining with VAA lectin. Lectin binds with cell surface, both cells are PI-
negative. 
Study of the peripheral blood lymphocytes of healthy donors revealed that their 
populations contained 0.707±0.121 % of cells with noticeable pre-G1 peak in cell cycle, with 
a range of 1.95% (minimal value - 0.14% and maximal value – 2.09), while the SLE patients 
were characterized by a markedly increased number of apoptotic cells (if judged by the 
appearance of G1 peak) – 4.47±0.50 %, with a wide range of 10.72% (minimal value – 0.86% 
and maximal value 11.62 %) (significance of the difference between two groups was 
P<0.001). 
The lectin-induced agglutination test is based on the evaluation of minimal concentration of 
ß-D-galactose specific Viscum album lectin (VAA) used for cell agglutination. The principle 
of lectin-induced agglutination test is described in Fig. 2. Previously, it was proved that the 
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level of these GPs was increased at apoptosis, and the concentration of lectin used for 
agglutination is in a reverse dependence upon the amount of cell surface GPs – the higher 
amount of the apoptotic like GPs is present on the cell surface - the less amount of lectin is 
needed for agglutination of these cells. Agglutination of lymphocytes of clinically healthy 
donors (0.32% and 0.12% of apoptotic cells), and of SLE patients (4.91% and 2.37% of 




0 1 2 3 4 5 6 7 8 72 -3 -4 Agglutination level 
20001 1000 500 250 125 62,5 31,3 15,6 7,8 15,6 - - Lectin concentration 
Fig. 2. Principle of lectin-stimulated agglutination test. Agglutination level corresponds to 
minimal lectin concentration, needed for cell agglutination. Notes: 1 – our data indicate that 
lectin concentration, 2000 µg/ml agglutinates almost all intact cells. 2,3,4 – this conditions 
indicates possible errors in sample preparation and needs to be re-tested.  
In the group of healthy donors, the mean lectin concentration needed to agglutinate 
lymphocytes was 1,500±121.27 µg/ml, while in the group of SLE patients, this indicator 
equaled 306.19±128.17 (significance of the difference between two groups was P<0.001) 
(Table 1). Thus, the ratio between the lectin concentrations in two studied groups 
constituted almost 4 times. This could be caused by two reasons: 1. increased basal (overall) 
lectin binding by cells in population; 2. increased number of cells that specifically bind the 
lectin. To clarify these mechanisms, smears of peripheral blood lymphocytes were subjected 
to lectin-cytochemical analysis based on using VAA lectin with subsequent 
microphotography and densitometric study. It revealed that basal staining in control group 
was 0.153±0.013 a.u., while in the SLE patients it was 0.144±0.01 a.u. There was no 
significant differences between two cell populations, while the number of cells that were 
intensively stained in both populations was significantly different (see Table 1). Thus, we 
suggested that difference in agglutination between lymphocytes of two groups is due to an 
increased percentage of cells exposing galactose-rich glycoconjugates on their surface. 
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 Healthy donors, n=18 SLE patients, n=23 p 
% of apoptotic cells1 0.707 ± 0.121% 4.471 ±0.502 % p<0.001 
Agglutination2 1,500 ± 121.27 µg/ml 306.19±128.17 µg/ml p<0.001 
Basal VAA staining3 0.153 ± 0.013 a.u. 0.144 ± 0.010 a.u. 0.061 
% of VAA stained cells 4.783 ± 0.936 % 8.27 ± 1.30 % p<0.05 
1 – judged by content of pre-G1 cells, measured by flow cytometry;  
2 – measured by lectin-induced agglutination;  
3 – measured by lectin-cytochemical analysis. 
Table 1. Number of apoptotic cells and changes in plasma membrane glycoconjugates of 
lymphocytes in clinically healthy donors and SLE patients. 
Correlation analysis of the amount of apoptotic cells detected by flow cytometry, and of 
minimal lectin concentration, needed for cell agglutination detected by lectin-stimulated 
agglutination, revealed a strong negative correlation between these two parameters (R=-
0,764, P<0.001, see Fig.4). As previously established, the agglutinating lectin concentration is 
reversely proportional to the amount of apoptotic cells. Thus, the amount of apoptotic cells 
established by both methods – pre-G1 cell detection by flow cytometry and the lectin-
induced agglutination – is well correlated. It should be noted that lectin-induced 
agglutination is much easier and cheaper in performing.  
The correlation study between the amount of apoptotic cells detected by the Annexin V-
FITC labeling and by testing based on using mannose-specific lectin from Narcissus 
pseudonarcissus (both detected by flow cytometry) was performed, and strong correlation 
between both parameters (R=0.725) was demonstrated (Heyder et al., 2003). Thus, specific 
changes in cell surface glycoconjugate pattern can be effectively used for detection of 
apoptotic cells at SLE and, probably, other at other autoimmune disorders. 
The study of peripheral blood lymphocytes of 23 SLE patients and that of 18 clinically 
healthy donors revealed a significantly increased incidence of apoptosis in the SLE patients. 
That was detected by both flow cytometry and lectin-induced agglutination testing. High 
correlation between these results obtained by using two different methods suggests that 
apoptosis-related changes in plasma membrane glycoconjugates of the peripheral blood 
lymphocytes at SLE can be used as a reliable and easy tool for apoptosis measurement 
during autoimmune disorders. Detection of glycoconjugates via specific lectin binding is 
compatible with other available fixation/staining procedures. It can be recommended as an 
additional indicator in the multi-parameter automated detection systems.  
Thus, the obtained data demonstrated that SLE was accompanied by an appearance of 
apoptotic cells possessing desialylated glycoepitopes (rich in terminal ß-D-containing 
glycans). Taking into account the above described clauses that desialylated glycans are 
important for cell clearance and that SLE potentially results from insufficient cell clearance, 
an intriguing question appears– are there any desialylating agents in blood of SLE patients.  
3. Desialylating abzymes at SLE 
Mammalian sialidases (related enzymes including bacterial and viral are also referred as 
neuraminidases) are glycosidases responsible for the removal of sialic acids from the 
glycoproteins and glycolipids. They have been implicated to participate in many biological 
processes, particularly in lysosomal catabolism (Miyagi, Wada, Yamaguchi, Hata, & 
 
Cell Surface Glycans at SLE – Changes During Cells Death, 




Fig. 3. Detection of apoptotic cells by measuring amount of pre-G1 cells using PI staining by 
flow cytometry (A) and minimal concentration needed for lectin-induced agglutination (B) 
of peripheral blood lymphocytes of two normal healthy donors and two SLE patients.  
Shiozaki, 2008; Monti, Preti, Venerando, & Borsani, 2002). Altered sialylation of 
glycoproteins and glycolipids is observed as a ubiquitous phenotype in cancer. It leads to an 
appearance of tumor-associated antigens, aberrant adhesion and disturbance of 
transmembrane signalling (Miyagi, Wada, & Yamaguchi, 2008; Miyagi, Wada, Yamaguchi, 
& Hata, 2004). Aberrant sialylation is closely associated with the malignant phenotype of 
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cancer cells, including metastatic potential and invasiveness (Miyagi, Wada, & Yamaguchi, 
2008; Miyagi et al., 2004; Miyagi, Wada, Yamaguchi, Shiozaki, et al., 2008). However, its 
biological significance and molecular mechanisms have not been fully elucidated.  
 
 
Fig. 4. Correlation analysis between specific lectin concentrations needed for lymphocyte 
agglutination and a percentage of the apoptotic cells. Lectin concentration needed for 
agglutination is reversely proportional to the amount of apoptotic cells.  
Neuraminidases are abundant in prokaryotes and viruses, while only 4 sialidases are known 
in human (Miyagi, Wada, Yamaguchi, Shiozaki, et al., 2008). The last described one, Neu4, 
was reported only in 2003 (Comelli, Amado, Lustig, & Paulson, 2003). Neu 1 is a lysosomal 
sialidase, and Neu2 is localized in lysosomes and involved in digestion of N–glycans, and 
Neu3, known as ganglioside sialidase, is localized in plasma membrane and involved in 
ganglioside metabolism (Monti et al., 2000). Neu4 is localized in lysosomes (Seyrantepe et 
al., 2004) and can be translocated to mitochondria (Yamaguchi et al., 2005) and endoplasmic 
reticulum (Bigi et al.). However, none of known sialidases is active in the body fluids (blood 
or lymph). There is no evidence that plasma membrane sialidase Neu3 (or any other 
sialidase) can be shed from cell surface into the blood flow (Miyagi, Wada, Yamaguchi, 
Shiozaki, et al., 2008). While detecting increased neuraminidase activity on the surface of 
apoptotic cells (R. Bilyy, Tomin, & Stoika, 2010), we failed to detect any sialidase activity in 
culture media that could result from enzyme secretion/release during cell death. 
We have focused our attention at the catalytic antibodies. These antibodies, now named as 
"abzymes", were first obtained in 1986 (Pollack, Jacobs, & Schultz, 1986; Tramontano, Janda, 
& Lerner, 1986), the first example of natural abzymes was IgG found in bronchial asthma 
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patients, cleaving intestinal vasoactive peptide (Paul et al., 1989). Abzyme’s properties were 
discussed in more detail in recent reviews (Belogurov, Kozyr, Ponomarenko, & Gabibov, 
2009; Georgy A. Nevinsky & Buneva, 2005; Planque et al., 2008; Taguchi et al., 2008). 
Abzymes were detected in human organism at a variety of autoimmune and non-
autoimmune pathologies (Gabibov, Ponomarenko, Tretyak, Paltsev, & Suchkov, 2006; G. A. 
Nevinsky & Buneva, 2003), and various peptides, proteins, nucleic acids and 
oligosaccharides can serve as substrates for the catalytically active antibodies in human and 
other mammalians (Hanson, Nishiyama, & Paul, 2005; Lacroix-Desmazes et al., 2006). The 
involvement of abzymes in pathogenesis of autoimmune disorders has been documented 
(Gabibov et al., 2006; Hanson et al., 2005; Lacroix-Desmazes et al., 2006; G. A. Nevinsky & 
Buneva, 2003). Catalytically active antibodies are typically found in patients with 
autoimmune disorders, however, they have also been detected in cancer patients. DNA-
hydrolyzing activity of IgG auto-Ab from blood serum of patients with various types of 
lymphoproliferative diseases was described (Kozyr et al., 1998; Kozyr et al., 1996). Testing of 
the abzymes in patients with hematological tumors and SLE revealed a linkage of anti-DNA  
 
 
Fig. 5. Comparative analysis of sialidase activity of IgGs obtained by chromatography on 
Protein G – Sepharose from blood serum of SLE patients (A) and SDS-PAG electrophoresis 
of IgG-preparations (B), n = 14. The position on the gel of heavy (H) and light (L) chains of 
IgGs molecules is indicated. 
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Ab catalysis with mature B-cell tumors, and an increased probability of DNA-abzymes 
formation at the autoimmune conditions (Gabibov et al., 2006). These data suggest a 
similarity between the mechanisms of abzyme formation at SLE and B-cell lymphomas. 
Peptide-hydrolyzing and DNA-hydrolyzing activities of Bence Jones proteins isolated from 
blood serum of myeloma patients are well studied (Paul et al., 1995; Sun, Gao, Kirnarskiy, 
Rees, & Paul, 1997). There are numerous data demonstrating that the catalytic activity of 
anti-DNA IgGs and Bence Jones proteins are associated with their cytotoxic activity and 
correlate with the disease pathogenesis (Gabibov, Kozyr, & Kolesnikov, 2000; Kozyr et al., 
2002; Matsuura, Ohara, Munakata, Hifumi, & Uda, 2006; Sashchenko et al., 2001; Sinohara & 
Matsuura, 2000). Recently, we demonstrated that anti-histone H1 IgGs isolated from blood 
serum of multiple sclerosis patients, were capable of hydrolyzing histone H1 (Kit, 
Starykovych, Richter, & Stoika, 2008). IgGs with similar proteolytic activity were also found 
in blood serum of patients with SLE (Magorivska et al., 2010) and multiple myeloma 
(Magorivska et al., 2009). Recently, we have shown that in the blood serum of some multiple 
myeloma patients there are immunoglobulins IgG possessing sialidase activity (R. Bilyy, 
Tomin, Mahorivska, et al., 2010). These data suggest an important role of abzymes at the 
autoimmune and oncological diseases. However, further studies are needed for better 
understanding of humoral immunity functions under normal and pathological conditions. 
Here we demonstrated for the first time that blood serum of SLE patients contains 
catalytically active IgGs possessing sialidase activity. Biological consequences of such 
phenomenon are discussed. 
The reason for studying neuraminidase activity of Ab in SLE patients is based on data 
showing that Ig preparations obtained by precipitation with 50% saturated ammonium 
sulphate from blood serum of 14 SLE patients possessed a significant capability of 
hydrolyzing neuramidase substrate 4-MUNA (Fig. 5), while Ig preparations of 12 healthy  
 
 
Fig. 6. Purification of IgG-abzymes from blood serum of SLE patients. Step 1 - Three-fold Ab 
precipitation with ammonium sulfate. Step 2 - IgG isolation by affinity chromatography on 
protein G-Sepharose column. Step 3 - HPLC size exclusion chromatography at pH 2.6, 
favoring dissociation of the immune complexes on Bio-Sec 250 column. 
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donors, obtained in the similar manner, were devoid of significant level of sialidase activity. 
Thus, we suggested that at least a part of this catalytic activity could be linked to abzymes 
present in the Ig preparations. To verify this suggestion, the catalytically active Ig 
preparations obtained with ammonium sulphate precipitation were further purified by the 
chromatography on protein G-sepharose column (Fig. 6) and additionally purified by HPLC 




































Fig. 7. Typical HPLC size exclusion chromatography on Bio-Sec 250 column (PBS, pH 6.8) 
elution profile of IgG preparation after purification by affinity chromatography on protein 
G-Sepharose (top) and additional size exclusion chromatography of this IgG sample at pH 
2.6 (glycine*HCl), favoring dissociation of the immune complexes on Bio-Sec 250 column 
(bottom). Peaks indicated by shading were collected and used for further analysis. 
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IgG, and studied their sialidase activity. It was found that both IgG preparation and its 
(Fab)2 fragments possessed sialidase activity towards 4-MUNA, but not galactosidase 
activity towards 4-MU-Gal (Fig. 8). Sialidase activity towards 4-MUNA was not inhibited in 
the presence of 10 mM 4-MU (p<0.05). 
 
 
A – Homogeneity determination of IgGs and their (Fab)2 by SDS electrophoresis in gradient PAGE (5–
16%) in the absence (-) or presence (+) of beta-mercaptoethanol (in non-reducing and reducing 
conditions, respectively). M: protein molecular mass markers (kDa).  
B – Sialidase activity of IgGs and their (Fab)2 in the absence (-) or presence (+) of specific sialidase 
inhibitor DANA.  
Fig. 8. Evidences that sialidase activity of IgG preparations puried by the affinity 
chromatography on protein G-sepharose from blood serum of SLE patient is an intrinsic 
properties of antibodies.  
To prove that sialidase activity of IgG fractions isolated from the SLE patients is an intrinsic 
property of the abzymes and is not caused by the co-puried enzymes/impurities, we 
applied the same criteria to the purity of catalytic Ab which have been proposed earlier (G. 
A. Nevinsky & Buneva, 2003; Paul et al., 1989). To rule out possible enzymatic 
contamination tightly bound to IgG molecule, we performed HPLC-SEC chromatography at 
the acidic conditions (pH 2.6), that are known to guarantee dissociation of antibody-antigen 
complexes (Hanson et al., 2005; G. A. Nevinsky & Buneva, 2003) (Fig. 7). It was confirmed 
by the SDS-PAGE electrophoresis and Western-blot analysis using anti(human)-IgG Ab that 
Cell Surface Glycans at SLE – Changes During Cells Death, 
Utilization for Disease Detection and Molecular Mechanism Underlying Their Modification 
 
101 
the main chromatographic peak is an electrophoretically homogeneous IgG. Its sialidase 
activity was tested and shown to be attributable to IgG fraction. HPLC purification resulted 
in the retention of ~50% of original sialidase activity of protein-G purified IgG sample. 
Sialidase activity was significantly decreased when the reaction was performed in the 
presence of pan-neuraminidase inhibitor DANA that excludes a possibility of non-specific 
hydrolysis reaction. The mechanism of DANA action is connected with its resemblance of 
the unhydrolyzable transition-state analogue formed during sialic acid cleavage which is 
irreversibly bound by active centers of most neuraminidases (Chavas et al., 2005). 
It is known, that the pH optimum of different sialidases is in range of pH 4–6.5. We have 
shown that isolated IgG is active under the physiological pH of blood serum. By using 
buffer systems in the pH range 3-9, we found that studied IgG samples revealed maximum 
speed reaction at pH range of 4.5÷6.0, nevertheless at pH 7.4 all samples retained from 27 to 
52% of their maximal activity, measured at NaCl concentration equal to that of blood serum. 
This suggests its potential enzymatic effectiveness in blood serum.  
In order to determine the speed of catalytic reaction of both IgG and corresponding (Fab)2-
fragments, we have calculated kinetic parameters (Km, Vmax, kcat) for sialidase reaction at 
0.1–100 µM concentrations of the substrate. Computer analysis demonstrated that the 
observed reaction belongs to a single substrate type, described by classical Michaelis-
Menten equation. The calculated data for different studies sialyl abzymes were: 
Km=44.4÷1600 µM and kcat=0.045÷23.1 min-1 (Fig. 9). The catalysis mediated by an articial 
abzymes is usually characterized by relatively low reaction rates: kcat values are 102–106-fold 
lower than for the canonical enzymes (Georgy A. Nevinsky & Buneva, 2005). The known 
kcat values for natural abzymes vary in the range of 0.001–40 min-1. The kcat values detected 
for MUNA hydrolysis (0.045÷23.1 depending on sample) are comparable with the typical 
kcat values established for others abzymes. To validate the kinetics assay, we have used C. 
perfringens neuraminidase as standard for kinetic parameters measurement. According to 
the obtained results, C. perfringens Km equals to 89.2 µM for 4-MUNA, which is in a good 
accordance with the literature data of 120 µM (Li et al., 1994)(Inoue & Kitajima, 2006), while 
Vmax was detected to be 2856 µmol/min/mg. The obtained Km value of IgG were of similar 
range, while Vmax of IgG was significantly lower (kcat significantly higher) than that of C. 
perfringens neuraminidase. 
Principal question concerning a role of the discovered abzymes possessing sialidase activity 
is whether they can use as potential desialylation substrates also glycoproteins and 
glycolipids that are present in human’s blood plasma and cells. Earlier, we have shown that 
sialyl-abzymes from multiple myeloma patients act towards human RBC by desialylating 
them and promoting agglutination with PNA lectins (R. Bilyy, Tomin, Mahorivska, et al., 
2010). It is known that the peanut agglutinin (PNA) agglutinates human RBC after their 
sialidase treatment resulting in the exposure of sub-terminal Gal-residues (Nakano, Fontes 
Piazza, & Avila-Campos, 2006). Here, by incubating IgG preparation form SLE sera with 
RBC of NHD (blood group A(0)) and using subsequent agglutination test with different 
PNA lectin concentrations, we demonstrated an ability of IgG-abzyme obtained from blood 
serum of SLEs patient desialylate human RBCs directly. Agglutination was observed at 
PNA concentration 7 µg/ml, while when the IgG preparation from NHD was used, 
agglutination was achieved at 250 µg/ml; PBS served here as a negative control (no 
agglutination at 1,000 µg/ml, and Clostridium perfringens neuraminidase (10 mU) served as a 
positive control, agglutination at 7µg/ml of PNA. Thus treatment with sialyl abzymes from 
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properties of antibodies.  
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the main chromatographic peak is an electrophoretically homogeneous IgG. Its sialidase 
activity was tested and shown to be attributable to IgG fraction. HPLC purification resulted 
in the retention of ~50% of original sialidase activity of protein-G purified IgG sample. 
Sialidase activity was significantly decreased when the reaction was performed in the 
presence of pan-neuraminidase inhibitor DANA that excludes a possibility of non-specific 
hydrolysis reaction. The mechanism of DANA action is connected with its resemblance of 
the unhydrolyzable transition-state analogue formed during sialic acid cleavage which is 
irreversibly bound by active centers of most neuraminidases (Chavas et al., 2005). 
It is known, that the pH optimum of different sialidases is in range of pH 4–6.5. We have 
shown that isolated IgG is active under the physiological pH of blood serum. By using 
buffer systems in the pH range 3-9, we found that studied IgG samples revealed maximum 
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agglutination was achieved at 250 µg/ml; PBS served here as a negative control (no 
agglutination at 1,000 µg/ml, and Clostridium perfringens neuraminidase (10 mU) served as a 
positive control, agglutination at 7µg/ml of PNA. Thus treatment with sialyl abzymes from 
 
 




Fig. 9. Kinetic parameters (Michaelis-Menten and Lineweaver-Burk plots) of sialidase 
reaction catalyzed by the IgG (A) or its (Fab)2-fragments (B). The incubation time for all 
samples was 180 min.  
SLE patient have increased the amount of desialylated glycoepitopes for 250 µg /7 µg =35 
times. We also used as substrates for sialyl abzymes: a) gangliodes of mouse brain and b) 
total surface glycans on eukaryotic (human T-leukemia Jurkat) cells. Ganglioside fraction 
was isolated from mouse brain and was incubated with sialil-abzyme and neuraminidase. 
Both sialil-abzyme and neuraminidase caused desialylation of GM3 and increase in the 
content of free sialic (neuraminic) acid (Fig.10). Treatment of human leukemia Jurkat cells 
with sialil-abzyme and neuraminidase caused a decrease in the level of a2,6-sialil-reach 
surface glycoconjugates (if judged by binding of FITC-labeled SNA lectin analyzed by flow 
cytometry) (Fig 11). Moreover, treatment of Jurkat cells with sialil-abzyme and 
neuraminidase also caused an increase in the level of desialylated glycoepitopes, if judged 
by binding of PNA lectin (biotynilated, treated with streptavidin-FITC and analyzed by flow 
cytometry) (Fig. 11). 
Thus, isolated sialyl abzymes were desialylating both human RBC, gangliosides and total 
surface glycoepitopes of the eukaryotic cells and were active under pH and ion content 
values of human blood serum. 
We have demonstrated previously unknown catalytic activity in the IgG antibodies of SLE 
patients – an intrinsic sialidase activity. Such activity was present in the IgG of blood serum 
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Fig. 10. Desialation of gangliosids by sialidase active IgGs obtained from blood serum of 
SLE patients possessing highest sialidase activity. Gangl+Neu – gangliosides incubated with 
neuramidase from C. perphringers; Gangl+IgG – gangliosides incubated with sialidase active 
IgGs; Gangl – gangliosides without incubation (control). The positions of free neuraninic 
acid (Neu5Ac), gangliosides GM3 and GD3 are shown by arrows on the right hand. 
of SLE patients and absent in the IgG of NHD. Sialidase activity was detected under 
different conditions which exclude a possibility of contamination or artefacts. It was blocked 
by typical sialidase inhibitor (DANA), expressed under physiological pH, and corresponded 
to classical Michaelis-Menten kinetics. Since DANA is an unhydrolyzable transitional state 
analogue of hydrolysis reaction, one can assume that the mechanism of action of IgG with 
sialidase activity is similar to that of sialidase enzyme. Moreover, the described IgGs 
possessing sialidase activity were capable of direct desialylation of human RBCs, 
ganglyosides and T-lymphocytes. The reason for appearance of discovered sialidase activity 
is not fully understood. One of the possible suggestions is their anti-idiotypic antibody as 
the "internal image" of an active site of endo- or exogenic sialidases, as known for other 
abzymes (Friboulet, Izadyar, Avalle, Roseto, & Thomas, 1994). 
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Jurkat cells were stained with FITC-labeled SNA (left), or biotinilated PNA lectin (right), stained with 
streptavidin-FITC. Cells were either treated with Neuraminidase, 10mU or sialil-abzyme, 10 uM for 3h 
at 37°C. Data represent normalized MFI of lectin binding. SNA lectin binds terminal a2,6-sialic acid 
residues, while PNA lectin binds desialylated glycoepitopes (Antonyuk, 2005). 
Fig. 11. Analysis of lectin binding to human Jurkat T-cells. 
The level of IgG molecule’s sialylation was reported to be critical in defining their pro- or anti-
inflamatory properties (Kaneko, Nimmerjahn, & Ravetch, 2006). Anti-inflamatory activity of 
immunoglobulins was tightly connected with the presence of α2,6-sialylated Asn297 in the IgG 
molecule (Anthony, Nimmerjahn, et al., 2008). Macrophages receptors responsible for binding 
sialylated IgG and modulating its anti-inflamatory action were also described (Anthony, 
Wermeling, Karlsson, & Ravetch, 2008). Agalactosylated and desialylated IgG antibodies’ 
action in vivo depends on binding of cellular Fc receptors (Nimmerjahn, Anthony, & Ravetch, 
2007). Specific glycoforms, if present in populations of immunoglobulin molecules, are 
connected with disease-associated alterations and can serve as diagnostic biomarkers at 
rheumatoid arthritis and other diseases (Arnold, Wormald, Sim, Rudd, & Dwek, 2007). Blood 
serum level of desialylylated form of IgG (IgG-G0) isolated from patients with rheumatoid 
arthritis, are more that 2 standard deviations above those levels in the age-matched healthy 
control (R. B. Parekh et al., 1985). They correlate with the disease activity and fall during 
remission periods (Rook et al., 1991). High levels of desialylylated IgG-G0 are also 
characteristic for other disorders: Crohn’s disease, SLE complicated by Sjogren’s syndrome, 
and tuberculosis (Bond et al., 1997; R. Parekh et al., 1989; R. B. Parekh et al., 1985). The enzyme 
EndoS from Streptococcus pyogenes that cleaves IgG glycan between two GlcNAc residues, was 
used for “making autoantibodies safe” (Scanlan, Burton, & Dwek, 2008). The action of EndoS 
truncated IgG glycans and IgG molecules lost the ability to initiate activating signals through 
C1q, FcRs and MBL, while the ability to interact with inhibitory FcRIIB was preserved 
(Collin, Shannon, & Bjorck, 2008). 
4. Summary 
In previous studies, we have shown that cell surface glycopattern is changed during 
apoptosis. This, in part, results from activation of surface sialidases, with desialylated 
glycoproteins being characteristic markers of apoptosis (R. Bilyy & Stoika, 2007). Such 
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feature was successfully utilized for lymphocyte screening in the autoimmune patients (R. 
Bilyy et al., 2009). It is widely accepted that altered glycoepitopes (desialylaed) are 
important surface markers for clearance of apoptotic cells (R. Bilyy & Stoika, 2007). We have 
shown (Meesmann et al., 2010) that desialylation of cell surface epitopes in viable cells, 
caused by sialidase, acts as an “eat-me” signal for macrophages and is needed for 
elimination of late apoptotic cells along with phosphatydilserine exposure, needed for 
elimination of early apoptotic cells. Apoptotic cells possess an elevated neuraminidase 
activity on their surface, however, we failed to detect any sialidase activity in culture media 
that could result from enzyme secretion/release during cell death. As we have shown, SLE – 
a disease resulting from insufficient cell clearance (Munoz et al., 2010) - is accompanied by 
the appearance of desialylated lymphocytes in blood stream. At the same time, some of SLE 
patients possessed abzymes with sialydase activity in their blood. The exact role of sialyl 
abzymes at SLE is currently unclear, as well as their relation to apoptotic cell desialylation 
and clearance. The abzymes possessing sialidase activity can change surface sialylation level 
and, thus, alter the glycocalyx of SLE patients’ cells and promote their clearance. They can 
also influence the immune response by acting towards blood serum IgG molecules. 
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diseases, lupus is very intriguing both clinically and immunologically for its systemic nature 
and complexity in pathogenesis. The disease is characterized by multi-organ involvement 
and presence of autoantibodies to a variety of self antigens, particularly of the nuclear 
components [3]. Deposition of the immune complexes may trigger complement activation 
causing tissue damages. The broad auto-reactivities and hyperactivity of B cells are known 
to be predominately T cell-dependent [4], but the cellular and molecular mechanisms 
underlying such a systemic loss of B and T cell tolerance are yet to be fully understood. In 
contrast to B cell hyperactivity [5], reduced Interleukin 2 (IL-2) production and aberrant 
responsiveness of T cells are characteristic of SLE [6, 7]. Moreover, impaired cellular 
immunity, complement deficiency, defects in the clearance of dying cells by macrophages 
[8-10], roles of DC and the disrupted mechanisms of tolerance induction [11-14] are among 
many immunological characteristics of, or potential mechanisms proposed for, the disease.  
2. Regulatory T cells 
Regulatory T cells (Treg) belong to a specialized group or subsets of CD4+ T cells with 
immunoregulatory capacity, which have been shown to play many important roles in 
maintaining peripheral tolerance [15, 16]. Treg can actively suppress self–reactive 
lymphocytes that escape central tolerance. The so-called naturally occurring Treg cells 
(nTreg), which constitutively express high levels of surface IL-2 receptor  chain (IL-2R, 
CD25) [17, 18], are originated from the thymus. Mice deficient in the CD4+CD25hi Treg cells 
developed a multi-systemic autoimmune disease, including gastritis, oophoritis, arthritis, 
and thyroiditis. Co-transfer of Treg cells with self-reactive cells could prevent the 
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development of experimentally-induced autoimmune diseases [17, 19]. Another relatively 
more specific marker of Treg cells is the intracellular molecule Foxp3 (forkhead box P3). The 
Foxp3 gene is crucial in the development and function of Treg cells in both humans [20, 21] 
and mice [22-24], and defective Foxp3 expression generates strong activation of the immune 
system resulting in multi-organ autoimmune diseases [25, 26]. Foxp3 transduction has been 
shown to convert naive CD4+CD25- T cells into CD25+ regulatory cells with suppressive 
activity [22]. Expression of Foxp3 can also be induced in CD4+CD25–  T cells upon activation 
[27] or in the presence of TGF-ß [28, 29]. These findings suggest that the microenvironment 
could influence the expression of Foxp3 during an immune response, inducing and 
promoting the expansion of peripheral Treg, also known as the inducible or adaptive Treg 
cells [27].  
Treg may exert their immunosuppressive effects through cell-cell contacts and by the release 
of immunosuppressive cytokines such as IL-10 and TGF-[30]. More recently, IL-35 has 
been identified to be the very cytokine not only directly associated with Treg functions but 
also their peripheral expansion [31, 32] [33, 34], including the induction of a unique human 
Treg subset (iTR35) which could exert its immunosuppressive functions in an IL-35-
dependent, but IL-10, TGF- and Foxp3-independent, mechanism. Thus, although the 
induction and activation of Treg may be individually and cumulatively antigen-driven [35], 
these cells can suppress T effector cell (Teff) activation in an antigen non-specific manner 
[36, 37], e.g. by the release of immunosuppressive cytokines and via their inhibitory effects 
on antigen presenting cells (APC), DC in particular [38]. Indeed, the lack of Treg has been 
associated with many organ-specific autoimmune diseases [15, 17, 39] and, more recently, 
systemic autoimmune disorders including SLE [40-90]. 
3. Aberrant Treg frequencies and functions associated with lupus disorders 
In recent years, Treg aberrations have been widely demonstrated in both SLE patients [40, 
41, 43-48, 51-67, 71-80, 82-86, 88] and lupus mouse models [42, 49, 50, 68-70, 81, 87, 89-98]. 
These studies provided thus a plausible explanation for the systemic nature of the disease. A 
lack of Treg-mediated immune regulation in lupus is now a general consensus, although 
there have been differences in the findings as to whether a reduced Treg frequency [40-46, 
49-53, 58-61, 68, 71-75, 82-84, 88, 90], defective Treg functions [44, 48, 53, 57, 59, 60, 66, 70, 76, 
80, 89, 90] or both, or alternatively an insensitivity of the Treg target cells [66, 67, 70, 89, 99], 
are truly accountable.  
By using CD25 as the marker, an early study by Crispin and colleagues first showed that, in 
lupus patients with active disease, the frequencies of Treg (CD4+CD25+/bright) were 
significantly decreased, while T cells with an activated T helper (Th) effector phenotype 
(CD4+CD69+) increased [40]. An imbalance of Treg versus Teff was therefore proposed as a 
potential mechanism of disease development, and similar findings from many subsequent 
clinical studies mentioned above also confirmed this notion. Since IL-2 receptor (IL-2R) can 
be up-regulated on activated effector T and B lymphocytes too, the use of CD25 (alpha chain 
of IL-2R) as a Treg marker has understandably its limitation. Nevertheless, the identification 
of Foxp3, a relatively more specific if not exclusive marker of Treg, later allowed further 
verifications for the proposed link between Treg aberrations and systemic autoimmunity 
[49-51, 53, 57, 61, 68, 71, 73, 74, 76, 83, 88, 100].  
However, there have also been controversial findings from other studies showing that the 
frequency of Treg cells, either defined as CD4+CD25bright or CD4+Foxp3+, could be normal 
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[48, 66, 67, 70, 85, 86] or even increased [47, 54-56, 58, 62-65, 69, 74, 76-79, 81] in lupus 
disease. Instead, some of these studies suggested that Treg were functionally defective and 
less capable of suppressing those potentially auto-reactive lymphocytes in lupus patients 
[44, 48, 53, 57, 59, 60, 66, 76, 80], and the mouse models [70, 89, 90]. Again, alternative 
findings demonstrating lupus Treg being functionally normal [49, 50, 62, 67, 85], or at least 
normal in majority of patients tested [48, 64], or even enhanced in some way [68, 80, 87] 
added further confusion as well as interest to the matter.  
Upon a closer examination, these seemingly discrepant findings can in fact be logically 
explained. Two most critical issues to be addressed are about the true causal relationship 
between the Treg changes and disease kinetics, and the complex underlying immunological 
mechanisms involved as discussed below.  
4. Treg deficiency in systemic autoimmunity – the mutually causative 
relationship  
In terms of disease kinetics, for example, low Treg frequencies are often found to be 
associated with SLE patients having active, but less so inactive, disease [40, 45, 83], or in 
patients on certain anti-inflammatory drugs undergoing clinical remission [47, 55, 56, 86]. 
Considering the multi-factorial nature, variability in disease onset and genetic heterogeneity 
of human lupus, however, it is also not surprising to note that such clinical association has 
not been always an obvious case [43, 48, 54, 62, 64].  
Nevertheless, findings from studies using animal models especially inbred strains of mice 
which develop spontaneously a lupus like disease have offered some useful insights in this 
regard. The MRL/MpJ-lpr/lpr (MRL/lpr) mice develop spontaneously an age-dependent 
lupus-like disease and have been widely used as an animal model of human lupus. We have 
previously shown how the characteristic age-dependent biphasic changes of Treg frequency 
in the mice could reflect vividly a desperate, though eventually failed, attempt of the 
immune system trying to control auto-aggression [68]. After an early increase, Treg 
frequency (ratio) within the total CD4 T cell population in the peripheral lymphoid organs 
rapidly declined with age (Fig. 1A-1B), followed immediately by the onset and exacerbation 
of clinical disease [68], yet the total Treg number were in general higher compared to those 
in the control MRL/+ mouse strain (Fig. 1C). 
Interestingly, in a similar study, it was demonstrated that peripheral Treg frequency in the 
NZB/W F1 strain of mice, another spontaneous lupus mouse model, was rather reduced at 
young age. In contrast, in the aged and diseased mice, a higher Treg frequency was detected 
in the renal draining lymph nodes, though also decreased in the spleen, as compared to 
normal BALB/c mice [50]. This may again reflect the differences in severity and kinetics of 
disease progression, in relation to the age-dependent Treg cell changes, between the 
MRL/lpr and NZB/W F1 strains. As shown in Fig. 1C, the total Treg numbers were 
constantly higher in the MRL/lpr strain too. This suggests that it is the Treg:Teff balance, 
rather than absolute Treg number, which is more relevant and critical to the disease kinetics. 
Such balance appears to have been maintained in the young MRL/lpr mice at least until 2-3 
months of age, a stage prior to the development of overt clinical disease [2]. Compared to 
the MRL/lpr strain, NZB/W F1 mice develop a relatively milder clinical disease and at a 
much later stage [2]. The increased Treg frequency in the NZB/W F1 diseased mice could 
also reflect similarly the ongoing feedback regulatory mechanism yet relatively more 
sustainable in this mouse strain.  
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(Data from EJI 2008. 38:1664-76 with permission) 
Fig. 1. Age-dependent bi-phasic changes of splenic Treg frequency in MRL/lpr mice. 
Freshly isolated splenocytes were stained for CD4, CD25, CD45RB and Foxp3 in different 
combinations, and analyzed by multicolor flow cytometry. Treg cells were identified by 
means of (A) CD4+CD25hiCD45RBlow/Int and (B, and C) CD4+Foxp3+, and shown as the 
percentage of total CD4+ cell population (A, and B) and absolute Treg number per spleen 
(C) for each mouse. Data shown are Treg frequencies calculated from individual mice of 
different age (female), of the MRL/+ (open circles, n=58) and MRL/lpr (filled triangles, 
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In other words, although the original defect(s) leading to the initiation of lupus may differ in 
SLE patients and these different lupus mouse models, changes in Treg versus Teff can be a 
true reflection of the capacity, or limitation, of the immune system trying to control the 
pathogenic autoimmune responses. 
5. Defective Treg-mediated suppression in systemic autoimmunity –  
the underlying immunological mechanisms 
The next important question concerns the complex immunological mechanisms underlying 
Treg deficiency in lupus disorders. Defects in the Teff cells and DC in particular have been 
found to contribute either directly or indirectly to the aberrant Treg-mediated suppression. 
These include abnormal Teff and DC functional status, and their expression of, or 
responsiveness to, certain cytokines critically involved in Treg and/or Teff functions.  
5.1 Teff resistance 
It was demonstrated that Teff cells isolated from lupus patients were less susceptible to 
Treg-mediated suppression [66, 67], and the level of resistance inversely correlated with 
patients’ clinical disease activities [67]. Similar findings have also been shown in several 
lupus-prone mouse strains [70, 89, 99]. Based on their findings, the authors concluded that it 
was the enhanced resistance of responder cells (i.e. Teff), rather than defects in Treg 
themselves, that was to be blamed for the defective Treg-mediated suppression. A lack of 
Fas-mediated Teff activation induced cell death (AICD) and low surface expression of T cell 
inhibitory molecules (e.g. CTLA-4), or their ligands (CD80, CD86) on APC, are among the 
possible mechanisms proposed.  
Moreover, it was also shown that the aberrant resistance of Teff could be associated with the 
activation state or lineage-commitment of Teff cells. While Treg isolated from the 
autoimmune BALB/c-lpr/lpr and gld/gld Fas/FasL-deficient mice could block naïve T cell 
activation and differentiation into the Th1 phenotype, they were unable to suppress those 
pre-existing lineage-committed IFN--producing effector Th1 cells [99]. 
5.2 Lack of Teff-derived soluble factors essential for Treg functions & expansion 
However, soluble factors produced by Teff cells are also known to be crucial for normal Treg 
functions. IL-2 produced by activated Teff, for example, is an essential growth factor for Treg 
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responsible for an early and progressive defect in T cell proliferation, which could be restored 
by exogenous IL-2 [7]. The cytokine was indeed later found to be able to restore Treg 
expansion and functions, both in vitro and in vivo, in the lupus mice [68, 87]. In other words, 
under normal physiological conditions, the Treg-mediated suppressive action has to be 
‘endorsed’ by their ‘target cells’ too. When such a ‘mutual agreement’ is no longer in order, i.e. 
the lack of ‘informed consent’ from their target cells, Treg cells are left functionally powerless 
allowing subsequently the rapid expansion of autoreactive T and B cells. 
5.3 Imbalanced peripheral Treg versus Teff expansion 
The imbalance between Treg and Teff, including Th1 [99], expansion has provided a good 
basis and some mechanistic explanations for the systemic nature of lupus disorders [14, 68]. 
 




(Data from EJI 2008. 38:1664-76 with permission) 
Fig. 1. Age-dependent bi-phasic changes of splenic Treg frequency in MRL/lpr mice. 
Freshly isolated splenocytes were stained for CD4, CD25, CD45RB and Foxp3 in different 
combinations, and analyzed by multicolor flow cytometry. Treg cells were identified by 
means of (A) CD4+CD25hiCD45RBlow/Int and (B, and C) CD4+Foxp3+, and shown as the 
percentage of total CD4+ cell population (A, and B) and absolute Treg number per spleen 
(C) for each mouse. Data shown are Treg frequencies calculated from individual mice of 
different age (female), of the MRL/+ (open circles, n=58) and MRL/lpr (filled triangles, 
















































0 4 8 12 16 20 24 28 32 36 40























Regulatory T Cell Deficiency in Systemic Autoimmune Disorders 
 – Causal Relationship and Underlying Immunological Mechanisms 
 
115 
In other words, although the original defect(s) leading to the initiation of lupus may differ in 
SLE patients and these different lupus mouse models, changes in Treg versus Teff can be a 
true reflection of the capacity, or limitation, of the immune system trying to control the 
pathogenic autoimmune responses. 
5. Defective Treg-mediated suppression in systemic autoimmunity –  
the underlying immunological mechanisms 
The next important question concerns the complex immunological mechanisms underlying 
Treg deficiency in lupus disorders. Defects in the Teff cells and DC in particular have been 
found to contribute either directly or indirectly to the aberrant Treg-mediated suppression. 
These include abnormal Teff and DC functional status, and their expression of, or 
responsiveness to, certain cytokines critically involved in Treg and/or Teff functions.  
5.1 Teff resistance 
It was demonstrated that Teff cells isolated from lupus patients were less susceptible to 
Treg-mediated suppression [66, 67], and the level of resistance inversely correlated with 
patients’ clinical disease activities [67]. Similar findings have also been shown in several 
lupus-prone mouse strains [70, 89, 99]. Based on their findings, the authors concluded that it 
was the enhanced resistance of responder cells (i.e. Teff), rather than defects in Treg 
themselves, that was to be blamed for the defective Treg-mediated suppression. A lack of 
Fas-mediated Teff activation induced cell death (AICD) and low surface expression of T cell 
inhibitory molecules (e.g. CTLA-4), or their ligands (CD80, CD86) on APC, are among the 
possible mechanisms proposed.  
Moreover, it was also shown that the aberrant resistance of Teff could be associated with the 
activation state or lineage-commitment of Teff cells. While Treg isolated from the 
autoimmune BALB/c-lpr/lpr and gld/gld Fas/FasL-deficient mice could block naïve T cell 
activation and differentiation into the Th1 phenotype, they were unable to suppress those 
pre-existing lineage-committed IFN--producing effector Th1 cells [99]. 
5.2 Lack of Teff-derived soluble factors essential for Treg functions & expansion 
However, soluble factors produced by Teff cells are also known to be crucial for normal Treg 
functions. IL-2 produced by activated Teff, for example, is an essential growth factor for Treg 
cell differentiation and proliferation, and a potent inducer of Treg IL-10 expression [101]. We 
have previously demonstrated that, in two unrelated lupus mouse models, IL-2 deficiency is 
responsible for an early and progressive defect in T cell proliferation, which could be restored 
by exogenous IL-2 [7]. The cytokine was indeed later found to be able to restore Treg 
expansion and functions, both in vitro and in vivo, in the lupus mice [68, 87]. In other words, 
under normal physiological conditions, the Treg-mediated suppressive action has to be 
‘endorsed’ by their ‘target cells’ too. When such a ‘mutual agreement’ is no longer in order, i.e. 
the lack of ‘informed consent’ from their target cells, Treg cells are left functionally powerless 
allowing subsequently the rapid expansion of autoreactive T and B cells. 
5.3 Imbalanced peripheral Treg versus Teff expansion 
The imbalance between Treg and Teff, including Th1 [99], expansion has provided a good 
basis and some mechanistic explanations for the systemic nature of lupus disorders [14, 68]. 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
116 
Th17 is another subset of specialized T helper cells, which produce the signature cytokine 
IL-17, or IL-17A. IL-17 mediates various inflammatory responses such as recruitment of 
monocytes and neutrophils [102], T cell infiltration and activation [103], induction of further 
proinflammatory cytokine expression [104] and, Th17 as a new pathogenic cell type, has 
been implicated in many autoimmune inflammatory diseases (reviewed in [105]). IL-17 
producing Th17 cells also contribute to the pathogenesis and development of SLE. Several 
groups have shown that the numbers of Th17 cells and notably the ratio between Th17 and 
Treg were altered in SLE patients [75, 82, 106-108]. The number of Th17 cells in the blood of 
SLE patients was elevated [82] and accordingly serum IL-17 levels were increased [82, 109, 
110]. However, the changes in the number of Th17 cells itself did not seem to correlate with 
lupus disease development, whereas the ratio between Treg and Th17 cells had a very clear 
inverse correlation with disease activity, especially in those patients with acute nephritis 
[107]. Moreover, the low Treg:Th17 ratios were also found to be restorable following clinical 
treatment that controlled disease activity [108]. 
5.4 Cytokines differentially involved in driving Treg & Teff differentiation 
Naive CD4+ T helper cells can be induced to differentiate into Th1, Th2, Th17 and Treg 
phenotypes depending to the local cytokine milieu. The presence of IL-12 signalling through 
STAT-4 (signal transduction and activator of transcription-4) drives towards Th1, whereas 
IL-4 (signalling through STAT-6) skews towards Th2 [111]. Interestingly, the differentiation 
of pro-inflammatory Th17 and anti-inflammatory Treg cells, two seemingly mutually 
exclusive cell types, follows a very similar pattern. Differentiation into both of these T cell 
subsets requires TGF-, a cytokine capable of inducing expression of Foxp3 and RORt, 
which are essential transcription factors for the development of Treg and Th17 cells, 
respectively [28, 112]. Under homeostatic non-inflammatory conditions, TGF- induces only 
Treg, as Treg expressed Foxp3 itself is capable of suppressing Th17 development by binding 
to RORt and thereby inhibiting its activity as a transcriptional activator [113]. Only in the 
presence of certain potent pro-inflammatory cytokines including IL-6, IL-21 and IL-23, the 
Foxp3 mediated inhibition of RORt can be abrogated and differentiation into Th17 cells 
initiated [113, 114]. 
5.5 Roles of DC 
Aberrant DC functions play evidently crucial roles in lupus disease induction, e.g. by 
driving the pathogenic Th1 type of responses [14] or skewing Teff versus Treg expansion 
[68]. Fig. 2A shows clearly that the DC generated from MRL/lpr mice are functionally 
defective in driving Treg, but not Teff, cell expansion. The importance of Treg:Th17 ratio for 
lupus disease activity has also been highlighted by work performed by Kang et al on the 
role of tolerogenic DC. The authors showed that injection of lupus-prone mice with a 
nucleosomal histone peptide epitope (H471-94) induced TGF- producing Treg while 
suppressing inflammatory Th17 cells, with a general increase in survival. This was 
attributed to the induction of tolerogenic DC which produced enhanced levels of TGF-, but 
decreased IL-6 expression [115]. Another study by Wan et al also pointed to the role of IL-6 
produced by DC in blocking Treg function, and its genetic linkage (sle1) in mice originated 
from the NZM2410 lupus mouse strain [90]. In addition, aberrant expression of Type 1 
interferon (IFN-) by APC has also been shown to block Treg functions contributing to the 
Treg versus Teff imbalance in lupus disease [65, 81, 116].  
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(Data from EJI 2008. 38:1664-76 with permission) 
Fig. 2. Defects in DCs and Treg cells of MRL/lpr mice.  A. MRL/lpr DCs are defective in 
promoting Treg but not Teff cell proliferation. Treg and Teff cells were purified from spleens of 
MRL/+ mice (3-month, female), and DCs were generated from bone marrow precursor cells 
of age-sex-matched MRL/+ or MRL/lpr mice (3-month, female). After labeling with CFSE, 
the Treg or Teff cells were stimulated with anti-CD3 mAb for 5 days, in the presence or 
absence of live MRL/lpr or MRL/+ DCs (as indicated in the graphs). B. Restoration of Treg 
promoting capacity of MRL/lpr DCs by exogenous IL-2 and IL-15. The CSFE-labeled splenic Treg 
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5 days, in the presence or absence of live MRL/lpr or MRL/+ DCs, and with or without 
addition of recombinant mouse IL-2 (10 ng/ml) or IL-15 (40 ng/ml), as indicated in the 
respective graphs. C. Restoration of a defect in MRL/lpr Treg proliferation by IL-2, but not IL-15. 
CSFE-labeled splenic Treg cells purified from MRL/lpr mice were stimulated with anti-CD3 
mAb for 5 days, in the presence or absence of live MRL/lpr or MRL/+ DCs, and with or 
without addition of recombinant mouse IL-2 (10 ng/ml) or IL-15 (40 ng/ml). Cell division 
(CFSE dilution) was determined by flow cytometry. Controls were cells stimulated in the 
same way but in the absence of DCs. CM: culture medium control. Data shown were 
representative FACS profiles of more than 3 repeated experiments.  
5.6 Possible Treg intrinsic defects 
Furthermore, certain intrinsic defects associated with Treg themselves might also be 
involved [68]. IL-15 is a pleiotropic cytokine akin to IL-2 [117, 118], which is produced by 
monocytic cells including DC [119, 120] rather than T cells. IL-15 mediates its functions 
through the - and -chains of the IL-2 receptor together with an unique IL-15 -chain, and 
is known to be involved in the regulation of normal differentiation and expansion of T cells 
including Treg [121]. While the defect of MRL/lpr DC in driving expansion of the wild type 
(MRL/+) control Treg mentioned above (Fig. 2A) could be restored by adding exogenous 
IL-2 or IL-15 (Fig. 2B), the MRL/lpr Treg though also restorable by IL-2 failed completely to 
respond to IL-15 (Fig. 2C). These findings suggest that the MRL/lpr Treg possibly have an 
intrinsic defect as well in their responsiveness to the IL-2-like non-T cell-derived cytokine. It 
would also be very interesting to know how these cells may respond to other factors, such as 
IL-35 known to be closely associated with Treg functions [32]. 
6. Therapeutic implications of Treg in systemic autoimmune disorders 
As discussed above, though also a result of overt autoimmune response itself, the lack of 
Treg mediated immune regulation contributes evidently to the early onset and kinetics of 
lupus disease development. Normalization of Treg frequencies and functions by restoring 
the Treg:Teff balance, may therefore prove to be clinically beneficial, hence a reasonable 
treatment strategy for the human disease. This concept has recently been tested in animal 
models by direct adoptive transfer of ex vivo derived, or in vitro expanded, Treg with 
encouraging results [68, 96, 122]. The treated mice had significantly delayed clinical disease 
as evident by delayed onset of glomerulonephritis, reduced proteinuria and skin lesions, 
and prolonged mouse survival [68, 96, 122]. 
Besides reconstitution of the Treg population by adoptive transfer, potential treatment 
methods to achieve an in vivo expansion of endogenous Treg and a normalization of the 
ratio between Treg and Teff, might be as diverse as the initial reasons for the deficiency in 
the Treg population. Accordingly, it has been shown that administration of rIL-2 promotes 
the proliferation of endogenous Treg and delays the progression of established disease, most 
likely by re-establishing the homeostatic balance of Treg and effector T cells [87].  
Supporting evidence from earlier studies also indicates that tolerance induction by injecting 
various tolerogenic peptides [91, 115, 123], anti-thymocyte globulin agents [95], or oral 
administration of anti-CD3 antibodies [97], are all associated with in vivo Treg expansion. 
It needs to be clearly pointed out that, while transfer of Treg may be beneficial against 
autoimmune syndromes [68], severe side effects such as infections following excessive (high 
dose) Treg treatment especially in non-adult mice can also occur (Yang et al, unpublished 
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observations). Therefore, similar to the use of any immunosuppressive drug, caution should 
be taken about potential side effects of the treatment, for patients of young ages in 
particular.   
7. Concluding remarks 
In summary, immune regulation by Treg is an important mechanism against systemic 
autoimmunity, and a general lack of Treg-mediated suppression is evident in lupus 
disorder. Different findings from studies of lupus patients and various animal disease 
models about the aberrant changes in Treg frequency and functionality reflect vividly the 
disease kinetics, severity, and often the on-going desperate attempts of the immune system 
to control auto-aggression. Clarification of their true causal relationship is undoubtedly very 
important not only for our understanding of the complex disease mechanisms, but also for 
rational design of therapeutic strategies for our patients. 
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1. Introduction 
Disturbances in immune tolerance provoke autoimmune aggression, i.e., a specific immune 
response to auto-Ags with subsequent development of an autoimmune syndrome or an 
autoimmune disease (Suchkov et al., 2007). 
A crucial role in formation of autoimmune syndromes and progression of autoimmune 
diseases is played by inborn (in the first place, HLA-associated) predisposition coupled with 
impaired immune responsiveness of the invaded organism. Noteworthy, initiation and 
progression of autoaggressive reactions cannot be triggered without preliminary activation 
of signaling reaction cascades, which include:  
i. polyclonal activation of autoreactive cytotoxic T lymphocytes (CTL) by super-Ag 
(multimolecular protein complexes composed of microbial Ags, Ags and/or haptens of 
the carrier or intermediary drug-related metabolites) demonstrating broad spectrum of 
epitopes; 
ii. release of sequestered or intramolecular (cryptic) autoepitopes after the tissue damage 
or organ injures during the inflammatory process; 
iii. anti-idiotypic Ab formation that can damage own tissue and promote autoagression; 
iv. effect of mimicking epitopes (microbial Ags cross-reacting with autoepitopes of human 
tissues and organs). 
Of particular interest in this respect is so-called molecular mimicry. Its biological mechanism 
is based on cross-reactivity, i.e., ability of the infected organism to cross-react, by virtue of 
structural homology between its auto-Ags and microbial Ags, with the microbial antigen 
thereby triggering miscellaneous immune reactions. Under these conditions, the role of 
autoaggressors is played simultaneously by two different groups of Ags, namely, mimicking 
Ags of the microbial pathogen and patient’s own autoAgs. Their interactions form the 
clinical picture of the postinfectious autoimmune syndrome (PIFA), one of main clinical 
variants of syndromeal immune pathology (Paltsev et al., 2009a).  
Today, the key role of the immune system in the pathogenesis of chronically relapsing 
infectious diseases (CRID) leaves no doubt. Their clinical course is controlled by an immense 
variety of factors and their combinations among which the immunologic syndrome (IS) 
reflecting the origin and severity of disturbances in immune homeostasis occupies a special 
niche. The concept of IS is not new in principle and is widely met in the current literature. 
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However, the term ”clinico-immunological syndrome” (CIS) is far less explicit and needs to be 
supplemented with a pathogenetically rationalized, clinically significant formulaic 
definition encompassing the tremendous body of evidence accumulated thus far in the 
modern literature (Paltsev et al., 2009b) (Fig. 1).  
 
 
Fig. 1. Clinical and immunological criteria of PIFSI 
PIFSI – postinfectious secondary immunodeficiency syndrome. 
In this section, we shall consider one of the most important clinical aspects of CIS, viz., 
postinfectious CIS (PICIS) whose role for practitioners in clinical medicine can hardly be 
overestimated. PICIS being a form of secondary (syndromal) immune pathology associated 
with the underlying (infectious) disease is provoked by a variety of factors including 
infectious pathogens of various etiology, clinical progression and complication of the 
disease proper, or inadequately applied antimicrobial therapy. The most common forms of 
this syndrome are as follows:  
i. postinfectious secondary immunodeficiency syndrome (PIFSI); 
ii. (ii) postinfectious autoimmune syndrome (PIFA); 
iii. autoimmune syndrome coupled with postinfectious secondary immunodeficiency 
(PIFASID) (Suchkov et al., 2004). 
Predisposition to one or another form of syndromeal immune pathology depends on a great 
number of genetically determined factors, which play a key role in the formation of patient’s 
own immune resources. Its functional activity is controlled by coordinated functioning of 
innate and adaptive immune mechanisms; however, their role in the development and 
chronization of infectious processes is still open to question, which strongly impedes the 
construction of state-of-art immunopathogenetic models (Fig. 2). 
 




Fig. 2. The innate and adaptive branches of immunity. 
In this context, analysis of major immunopathologic manifestations in patients with PICIS-
related chronically relapsing infectious diseases and construction of basic algorithms for 
state-of-art immunogenetic diagnostic protocols becomes a prime target for clinical 
medicine. 
Human immune system is a complex physiological mechanism whereby the human 
organism protects itself from exogenous etiopathogenic attacks. Its functional activity is 
provided by two types of protective immune mechanisms, one of which is specific and the 
other one is nonspecific. The main outcome of the immune response to etiopathogenic attacks 
is formation of two populations of regulatory Т helper cells (Th cells). The Th population is 
further subdivided into Th1 cells responsible for activation of effector links of cell-mediated 
immunity (macrophages and cytotoxic T lymphocytes/CTL) and Th2 cells exerting control 
over antibody (AB) production (McGuirk & Mills, 2002) (Fig. 3). 
However, the key factor in determining a particular type of the immune response and, 
correspondingly, a particular form of CIS, is localization (extracellular or intracellular) of the 
etiopathogen (Fig. 4). 
The latter circumstance is of particular importance from both pathogenetic and  clinical 
points of view, since the majority of currently known pathogenic microorganisms can 
escape from immune control and, in doing so, change the scenario of genetically 
programmed immune  responsiveness thereby provoking unpredictable complications for 
the patient and hindering physician’s attempts to implement adequate treatment strategies 
(Azikury, 1985; Aitpaev & Seisembekov, 1987). 
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As targets for our investigation, we chose three classical models of CRID, namely, 
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myocardites (М). All these pathologies have one common feature (i.e., association with a 
concrete organ or a tissue), but differ from one another both topically and pathogenetically. 
Although the panel of immunologic disturbances varies substantially depending on the 
clinical form of PICIS, immune statuses of patients and clinical manifestations of the 
diseases are very similar (Antonov & Tsinzerling, 2001; Borisov, 2000; Kukhtevich et al., 
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2.1 Immunopathological factors as biomarkers and biopredictors of chronization of 
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Emergence and accumulation, in patient’s blood, of inflammation markers whose 
concentration reaches the highest level in patients with PIFA and degresses in the direction 
from PIFASID to PIFSI are the most common markers of chronization of infectious diseases 
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Zhmurov et al., 2000; Rumyantsev & Goncharova, 2000). 
2.1.2 Abnormalities in the innate branch of immunity as a PICIS-related factor 
Miscellaneous shifts in the innate branch of immunity play a no less important role in 
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mechanisms is a salient feature of PIFSI, while PIFA and PIFASID are distinguished for 
disproportions in individual links of innate immunity and/or disbalance in the functional 
activity of its specific mechanisms (Bauer et al., 2001; Bingen-Bidois et al., 2002; Blackwell et 
al., 1987; Carballido et al., 2003; Dantzer & Wollman, 2003). 
Complement deficiency. In patients with PIFA and PIFASID, outbursts of activity in the С5 
and С5а components of the complement are usually observed against the background of 
stable operation of the majority of other links of the immune system (PIFA)  or pronounced 
disproportions between them (PIFASID). 
Deficiency of phagocytosis and cytotoxicity mechanisms. To factors responsible for 
chronization of infectious diseases, one may relate oppositely directed changes in 
phagocytosis and cytotoxicity parameters.  In PIFSI, both mechanisms are strongly 
suppressed, while in PIFA and PIFASID relative stability of certain components of both 
systems is concomitant with disproportions in other components. 
Deficiency of dendritic cells. Dendritic cells (DCs) are among the most essential regulatory 
factors in the innate branch of immunity. In patients with PIFSI, the specific contribution of 
these cells is rather small, while in case of PIFASID and PIFA DCs play a prominent role and 
show a tendency for activation (Sanaev et al., 2008; Cherepakhina et al., 2009). 
2.1.3 Abnormalities in the adaptive branch of immunity as a PICIS-related factor 
Deficiency of Т cell-mediated immunity. Among other disturbances in the adaptive branch 
of immunity, special attention should be given to differently directed changes in Т cell-
mediated immunity. PIFSI, for example, is characterized by enhanced suppression of Т cell 
functions resulting from disproportions in immunoregulatory components and massive 
apoptosis of Т cells. In contrast, activation of Т cell-mediated immunity is critical for PIFA 
and PIFASID, being more pronounced for the former and less pronounced for the latter. 
Deficiency of humoral immunity. Suppression of humoral immunity is a characteristic 
feature of PIFSI, while PIFA and PIFASID are associated with its activation. The activating 
effect of quantitative and qualitative (functional) mechanisms of humoral immunity is 
especially apparent in PIFA, while in patients with PIFASID this effect is far less expressed. 
Disproportions in the cytokin spectrum of the blood. PIFSI is associated with significant 
reduction of the population of antiinflammatory cytokins, while in PIFA this population is 
predominant. PIFASID is characterized by general disproportions in the cytokin spectrum at 
large (Cherepakhina et al., 2010a). 
3. PICIS and its main clinical forms 
3.1 PIFSI 
The main clinical manifestations of PIFSI are related to disturbances in antimicrobial 
protective mechanisms due to deficiency of the innate branch of immunity and development 
of secondary immune pathologies in the adaptive branch of immunity. The latter manifest 
themselves as chronically relapsing infectious diseases of bacterial or mixed origin 
(Shogenov et al., 2006). 
3.2 PIFA 
During induction and progression of CRID, some autoreactive CTL cross-reacting with 
microbial antigens (Ags) in the paradigm of the infectious process undergo activation by 
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hazardous factors including molecular mimicry (Khitrov et al., 2007a; Fujinami et al., 2006; 
Rose & Mackay, 2000; Benoist & Mathis, 2001). Its consequences are especially apparent 
during recognition of determinant autoAgs by Т cells and subsequent formation of the PIFA 
syndrome (Fig. 5). The latter attack any target organ or tissue of the infected organism by a 
rocket mechanism.  The risk of PIFA development increases dramatically with increasing 
incidence of infectious diseases and the panel of infecting pathogens (mixed infections). 
 
 
Note: The primary infectious (microbial) pathogen triggers a  postinfectious autoimmune syndrome 
(PIFA) through activation of two different mechanisms: (i) depletion of intrinsic (antigenic) molecular 
mimicry pools of cross-reacting (mimicking) antigenic determinants of the infecting pathogen (red 
arrows); (b) generation, by the infectious pathogen, of antigen-nonspecific signals (blue arrows) able to 
induce inflammation and thus enhance  immune  responsiveness (so-called adjuvant effect). 
Fig. 5. A schematic representation of the postinfectious autoimmune syndrome (PIFA). 
There exist at least three different interpretations for the relatedness of the infectious process 
to the risk of PIFA in response to activation of autoreactive clones of Т and В lymphocytes, 
namely: (i) stimulation by microbial superAgs; (ii) secretion of cryptic (intramolecular) 
autoAg determinants in response to cell damage induced by persisting infections and  (iii) 
molecular mimicry. These pathogenetic mechanisms are not mutually exclusive and play a 
crucial role in definite (as a rule, early) steps of PIFA-related CRID. The main triggering 
factors in the PIFA initiation step are: (i) antigenic activity of the microbial pathogen and (ii) 
tropism of the microbial pathogen towards definite cell populations, organs and tissues as 
targets for its cytopathic effect (Vturin et al., 1994; Manges et al., 2004). 
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Contrary to PIFSI, all classes of antimicrobial ABs (antibacterial, antiviral, antiparasitic, etc.) 
are morbid in PIFA. Although in the majority of patients the incidence and titers of 
antibacterial and antiviral ABs are more or less identical, in certain forms of CRID (e.g., CPN 
or М) antiparasitic ABs are detected in highest titers, while in patients with other 
pathologies (e.g., ICIIP) they are absent. These findings can be attributed to clinical 
manifestations of the underlying diseases rather than to inadequate functioning of 
triggering mechanisms of PIFA) (Cherepakhina et al., 2010b). 
Indeed, autoaggression provoked by insufficient coordination between two branches of 
immunity and hyperfunction of its adaptive branch is a dominant feature of PIFA. Its 
unique feature is a vast repertoire of antiorganic and antitissue autoABs responsible for 
multiseropositivity and specific autoimmune inflammation markers, e.g., anti-B7-HI autoABs) 
(Khitrov et al., 2007). 
By illustration, antimyelin and antineuronal autoABs are usually associated with ICIIP.  
Patients with CPN contain predominantly anti-THG autoABs as highly specific markers of 
autoimmune inflammation in renal tissue, while the presence of anti-КМ autoABs indicates 
AIM (Miller et al., 1970). 
To the most informative models of PIFA one may relate autoimmune myocarditis (AIM), 
autoimmune encephalomyelitis (AEM), ICIIP, rheumatoid arthritis (РА), autoimmune 
hepatitis (AIHe), autoimmune colienteritis (AICE), autoimmune pancreatitis (AIPCT), 
autoimmune gastritis (AIGa), autoimmune (streptococcal) glomerulonephritis (AGN), 
CPN, etc. 
Autoimmune myocarditis (AIM) usually develops in genetically predisposed individuals 
infected with the Coxsackievirus-3 virus (CVB3) and is one of the most typical 
manifestations of molecular mimicry. The presence, in circulating blood, of cardiomyosin-
autoreactive cytotoxic Т lymphocytes (КМ-autoreactive CTL) and anti-КМ autoABs is 
prerequisite to AIM development. Their interactions in patients with PIFA or PIFASID 
initiate myocardial lesions in response to enhanced secretion of sequestered autoAgs 
(Shogenov et al., 2010) (Fig. 6).  
In type I diabetes mellitus (DM I), insulitis develops in genetically predisposed individuals 
at the earliest (preclinical) stages of the disease (as a rule, against the background of 
infection with the Coxsackie-4 virus (CVB4)), and is further transformed into PIFA. This 
pathological process is mediated by autoreactive CTL and autoABs against islet autoAgs.  
Their coordinated functioning initiates the destruction (direct or indirect) of beta cells, e.g., 
through secretion of cytokins, generation of free radicals or apoptosis of beta cells, 
eventually resulting in PIFA or PIFASID. 
The main causal factors in initiation of chronically relapsing autoimmune colienteritis 
(AICE) are mimicking AGs of microbial or dietary origin. These AGs are localized in the 
intestinal lumen where they activate immune cells of intestinal mucosa.  Having penetrated 
into these cells, AGs begin to interact with tissue immunocytes (most frequently, with 
lymphocytes and DCs) thereby triggering adaptive immune responses. Innate immune 
resources also become activated under the stimulating effect of microbial products due to 
activation of specific surface receptors of intestinal epithelium. This reaction cascade 
stimulates the secretion of numerous cytokins and chemokins able to activate immunocytes  
of intestinal mucosa. Activation of antigen-presenting cells (APC) (e.g., DCs) initiate 
enhanced production of Th1 cells (Crohn’s disease) or atypical Th2 cells (ulcerative colitis). 
In addition to major cytokins  stimulating the activity of Th1 cells (IL-12, IL-18, etc.), 
activated macrophages give rise to a great diversity of antiinflammatory cytokins (IL-1, IL-6, 
 
 




Note: AB – antibody; CTL – cytotoxic Т lymphocyte; IFN - interferon; IL – interleukin; NK – natural 
killer cell; DCМП – dilated cardiomyopathy. 
Fig. 6. Initiation and progression of myocarditis 
TNF alpha, etc.) endowed with an ability to stimulate the activity of different cell 
populations (including endothelial cells) in inflammation foci by promoting enhanced 
migration of lymphocytes, fibroblasts and epithelial cells from the vascular network to 
inflammation niduses, which significantly deteriorates the clinical picture of autoimmune 
nidal inflammation (Khaitov & Pinegin, 2000; Bach, 2005). 
3.3 PIFASID 
A salient feature of this syndrome is equal contribution of associated abnormalities to both 
branches of immunity. Its clinical picture is distinguished for mixed-type 
immunopathology, viz., autoimmune syndrome coupled with immunodeficiency and 
concurrent deterioration of antiinfectious protection.  
4. Associative correlation between clinical manifestations of PICIS and CRID 
The associativity between microbial infection and various immunopathological states with 
PICIS can be correlative or causal. In patients with CRID, syndromal forms of immune 
pathologies depend critically on the stage of the inflammatory process occurring in target 
organs or tissues and general chronization of the disease (Sanaev et al., 2007). 
For example, early stages of CRID are concomitant with PIFSI (› 50%), whereas the 
contribution of PIFA and PIFASID does not exceed 20%. At the subsequent stages, the 
clinical picture is different, viz., the contribution of the autoimmune syndrome increases 
dramatically (to 50% at the intermediate stages (PIFA) and to 60% at the final stage 
(PIFASID). 
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The correlation between the stage of CRID and the form of PICIS is also characterized by the 
involvement of an additional (third) component, viz., clinical form or variant of CRID. Here 
are several analytical examples related to:  
1. clinical form of CRID. In patients with primary pyelonephritis (PPNP) and infectious 
myocarditis (IM), PIFSI is detected in 75% of cases, whereas in patients with secondary 
pyelonephrites (SPNP) and AIM the contribution of PIFSI is notably decreased (to 25%) 
giving way to autoaggression (the contribution of PIFA and PIFASID increases to 60% 
and 85%, respectively); 
2. stage of CRID. At early stages (< 3 months for CPN and < 1 month for myocarditis (М)), 
PIFSI is detected in 40% of cases; however, at later stages of CRID its share decreases 
appreciably, while that of autoimmune syndromes increases in contrast; 
3. rate of progression and chronization of CRID. In patients with relapsing or rapidly 
progressing CRID (e.g., ICIIP or AIM), the contribution of PIFSI does not exceed 32-
36%, while the share of autoimmune syndromes reaches 80-100%. In such patients, 
persistent forms of meningoencephalitis (e.g., ICIIP) or AIM associated with myocardial 
dystrophies are predominant. 
These findings suggest that PIFSI is not only the outcome of the infectious process, but also 
represents a factor responsible for its lingering and chronically relapsing course. Further 
progression and chronization of CRID are controlled by postinfectious autoaggression 
factors, such as PIFA and PIFASID. 
5. Clinico-immunological criteria of PICIS and state-of-art immunogenetic 
diagnostic algorithms 
So far, there is no unique set of criteria for adequate assessment of immune statuses of 
patients with different forms of PICIS, most probably, due to immense diversity of clinical 
manifestations of syndromal immunopathologies and factors responsible for their 
emergence. Moreover, existing laboratory protocols for assessing immune statuses are 
nonspecific and do not include specific analyses of microbial pathogens (Vinnitskij, 2002; 
Kolesnikov et al., 2001; Cherepakhina et al., 2010c). 
With this in mind and in order to procure adequate evaluation of many syndromal immune 
pathologies, we developed a series of clinical and immunologic tests and criteria for more 
precise diagnosis of PICIS. The criteria for constructing immunogram charts include: 
i. screening of abnormalities in the innate branch of immunity (selective markers of 
phagocytosis,  natural cytotoxicity (NCT), basic functional parameters of DC- and Ag-
presenting cells (APC)   and complement components (if necessary); 
ii. screening of abnormalities in the adaptive branch of immunity (selective markers of effector 
or regulatory links of the immune system, serotyping of  blood elements for anti-
organic and anti-tissue autoABs concurrently with identification  of Abs against 
mimicking Ag determinants of  infecting pathogens). 
The main criteria in the etiotropic diagnosis step (design of microbial landscape  maps) 
include: 
i. identification and localization of  microbial gene pools; 
ii. serological profiles of antimicrobial ABs. 
The novel diagnostic ideology is based on a combination of two categories of investigations: 
i. pathogenetically oriented diagnosis of PICIS and (ii) etiotropic diagnosis of microbial 
pathogens as the main causal factors of PICIS. 
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The most efficient technological strategies will be based on: 
i. at the immunodiagnostics stage (cytofluorimetric analysis of  processing and presentation 
of AGs on the surface of APC, monitoring of antiorganic and antitissue autoAB pools, 
analysis of metabolic profiles of individual cells, etc.); 
ii. etiotropic diagnostics (combination of conventional techniques for culturing microbial 
cells with advanced molecular diagnostics strategies based on sequencing of microbial 
genomes, screening of biological fluids and tissues for antimicrobial ABs, etc.). 
6. Conclusion 
Morbidity from infectious pathologies (e.g., CRID), in the first place, those provoked by 
viruses, conditionally pathogenic (“opportunistic”) microflora  and/or pathogens endowed 
with atypical properties including muiltiple resistance to antibacterial drugs, is steadily 
increasing. Among other things, CRID-affected individuals are characterized by lowering 
general immune responsiveness concurrent with unusual forms of immune responses to the 
clinical course of the infectious pathology. Studies in this field including our own 
investigations established that PICIS is one of the most important clinical manifestations of 
CRID, since it determines, in many features, the progression and chronization of underlying 
pathologies and their possible complications. The monosyndromal dominant form of PICIS in 
patients with CRID is PIFSI. However, more than 30% of CRID patients suffer from more 
specific forms of PICIS concomitant with autoimmune aggression (PIFA) or from combined 
immunopathological forms (e.g., PIFASID). 
Clinical forms of PICIS and, correspondingly, immunologic disturbances in patients with 
CRID correlate associatively with the clinical picture of the disease. It is not excluded that 
chronization of infectious inflammatory processes involves a general sequence of 
pathogenetically important factors, which differ in inner architechtonics of each of PICIS 
variants and thus demonstrate their high criterial significance. 
Future progress in clinical immunology and immune biotechnology may open up fresh 
opportunities for introduction into routine clinical practice of advanced protocols for 
immunogenetic diagnostics of PICIS-related infectious diseases and design of state-of-art 
treatment-and-rehabilitation protocols based on the use of the most advanced 
immunogenetic tools and strategies. 
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genomes, screening of biological fluids and tissues for antimicrobial ABs, etc.). 
6. Conclusion 
Morbidity from infectious pathologies (e.g., CRID), in the first place, those provoked by 
viruses, conditionally pathogenic (“opportunistic”) microflora  and/or pathogens endowed 
with atypical properties including muiltiple resistance to antibacterial drugs, is steadily 
increasing. Among other things, CRID-affected individuals are characterized by lowering 
general immune responsiveness concurrent with unusual forms of immune responses to the 
clinical course of the infectious pathology. Studies in this field including our own 
investigations established that PICIS is one of the most important clinical manifestations of 
CRID, since it determines, in many features, the progression and chronization of underlying 
pathologies and their possible complications. The monosyndromal dominant form of PICIS in 
patients with CRID is PIFSI. However, more than 30% of CRID patients suffer from more 
specific forms of PICIS concomitant with autoimmune aggression (PIFA) or from combined 
immunopathological forms (e.g., PIFASID). 
Clinical forms of PICIS and, correspondingly, immunologic disturbances in patients with 
CRID correlate associatively with the clinical picture of the disease. It is not excluded that 
chronization of infectious inflammatory processes involves a general sequence of 
pathogenetically important factors, which differ in inner architechtonics of each of PICIS 
variants and thus demonstrate their high criterial significance. 
Future progress in clinical immunology and immune biotechnology may open up fresh 
opportunities for introduction into routine clinical practice of advanced protocols for 
immunogenetic diagnostics of PICIS-related infectious diseases and design of state-of-art 
treatment-and-rehabilitation protocols based on the use of the most advanced 
immunogenetic tools and strategies. 
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1. Introduction 
Peroxynitrite is a member of reactive nitrogen species that also includes nitric oxide (·NO) 
and nitrogen dioxide radical (NO2·). Peroxynitrite is a reactive nitrogen species and an anion 
with the formula (ONOO−). It is an unstable ‘valence isomer’ of nitrate (NO3−), making it an 
oxidant and nitrating agent. Because of its oxidizing properties, peroxynitrite can damage a 
wide range of molecules in cells, including DNA and proteins (1). It is produced by the body 
in response to a variety of environmental toxins, stress, ultraviolet light and many other 
stimuli. It is also produced in the body due to ischemia/ reperfusion injury and 
inflammation (2, 3). In vivo, peroxynitrite is formed in the macrophages, endothelial cells, 
platelets, leukocytes, neurons, etc by the reaction between O2· – and ·NO (4, 5). Tissue 
inflammation and chronic infection lead to the overproduction of ·NO and O2·–, which 
rapidly combine to yield peroxynitrite: O2· – + ·NO → ONO2−. Endothelial ·NO synthase 
(eNOS) is responsible for most of the vascular ·NO produced. The eNOS oxidizes its 
substrate L-arginine to L-citrulline and ·NO. A functional eNOS requires dimerization of the 
enzyme, the substrate L-arginine, and an essential cofactor, BH4 (5,6,7,8-tetrahydro-L-
biopterin). The O2· – produced can react with vascular ·NO to form peroxynitrite. 
Diminished levels of BH4 promote O2· – production by eNOS. The transformation of eNOS 
from a vasoprotective enzyme to a contributor to oxidative stress has been observed in 
several in vitro systems, animal models of cardiovascular diseases and in patients with 
cardiovascular risk factors (6). In inflammation or septic shock, ·NO is also synthesized by 
the inducible ·NO synthase (iNOS), an isoform that is expressed in many cell types 
including vascular endothelial cells, vascular smooth muscle and inflammatory cells in 
response to pro-inflammatory cytokines. Peroxynitrite, can be formed intravascularly in 
various disease conditions when there is overproduction of either ·NO or O2· – (7). The 
intravascular formation of peroxynitrite can result in oxidative modifications of plasma and 
vessel wall proteins including the formation of protein-3-nitrotyrosine. Protein tyrosine 
nitration in plasma or vessel wall proteins may be indicative of peroxynitrite formation, and 
constitutes a good biomarker of ·NO-derived oxidant production in the vascular space. 
Detection of 3-nitrotyrosine in vivo has attracted considerable interest not only as a 
biomarker of peroxynitrite formation but also as a predictor of vascular risk (8). 
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Peroxynitrite is a potent oxidant and nitrating species formed by rapid reaction of two free 
radicals – nitric oxide  and superoxide anion (9). It can modify variety of biomolecules but 
possesses high affinity for tyrosine residues in proteins, and 3-nitrotyrosine is a relatively 
specific marker of peroxynitrite mediated damage to proteins (10). Other markers of 
peroxynitrite-induced protein modifications are; cysteine oxidation, oxidation/nitration of 
tryptophan and tyrosine, protein carbonyls, dityrosine and fragmentation. In view of 
numerous reports on detection of significant amount of 3-nitrotyrosine in various 
pathological conditions, the significance of non-enzymatic tyrosine nitration in health and 
disease has become a subject of great interest. Protein nitration has been observed in 
atherosclerosis, hypertension, Parkinson’s, Huntington’s and Alzheimer’s disease (11-13), 
multiple sclerosis (14), autoimmune myocarditis (15), systemic lupus erythematosus (SLE) 
(16) and rheumatoid arthritis (17). Furthermore, self proteins become immunologically 
active if their structure is altered. Accumulations of a variety of chemically modified 
proteins have been reported in inflamed tissues or apoptotic cells (18). 
Histones are highly conserved proteins but poorly immunogenic. These positively charged 
proteins were found to be immunogenic after acetylation or complexation with RNA. 
Autoantibodies against histones are present as often as anti-DNA antibodies in SLE. It has 
been demonstrated that anti-native DNA autoantibodies are commonly co-present with 
anti-histone autoantibodies and may react with each of the five chromatin-associated 
histones and also with H3–H4 and H2A–H2B complex (19). However, importance of anti-
histone antibodies in SLE is confounded by discrepancies in their reported prevalence, 
isotype, specificity and correlation with symptoms. Over expression of inducible nitric oxide 
synthase enzyme has been seen in numerous tissues of active SLE patients, vis-à-vis higher 
level of serum nitrotyrosine. Nitrotyrosine serves as a long-term indicator of peroxynitrite-
mediated protein modification and it is not affected by endogenous source of NOx or serum 
thiol (20). The in vivo nitration of histones (as shown in cultured cells exposed to nitric oxide 
donors and mutatect tumour tissues) appears to be a potentially useful marker for 
demonstrating extended exposure of cells/tissues to NO derived reactive nitrogen species. 
The generation of peroxynitrite by activated macrophages, neutrophils and endothelial cells 
and presence of nitrotyrosine in human tissues, fluids and in animal models of various 
diseases needs further investigation on protein-peroxynitrite interactions (21).  
2. Cellular biochemistry and pathology  
Peroxynitrite is a relatively long-lived oxidant that may serve as an important cytotoxic agent. 
Its biological effects are due to its reactivity toward a large number of molecules including 
lipids, amino acids, and nucleic acids. It is involved in tissue damage in a number of 
pathophysiological conditions such as neurodegenerative diseases, cardiovascular disorders, 
etc. (1-3). Evidence suggests that most of the cytotoxicity attributed to nitric oxide is due to 
peroxynitrite, produced from the reaction between the free radical species, ·NO and O2· – . 
Peroxynitrite interacts with lipids, DNA and proteins causing oxidative damage and other free 
radical induced chain reactions. These reactions trigger cellular responses such as cell 
signaling, oxidative injury, committing cells to necrosis or apoptosis. In vivo, peroxynitrite 
generation represents a crucial pathological mechanism in conditions such as stroke, myocardial 
infarction, chronic heart failure, diabetes, inflammation, neurodegenerative disorders and 
cancer. Even though nucleic acid antigens are by themselves poorly immunogenic, their 
antigenicity can be enhanced by modification through different free radicals (8). 
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Peroxynitrite exhibits unique chemical reactivities such as protein nitration, DNA strand 
breakage, base modification, etc., which may have cytotoxic effects and also lead to 
mutagenesis. It is thought to be involved in both cell death and an increased cancer risk (8-
22,23). The reaction of peroxynitrite with lipids leads to peroxidation (malondialdehyde and 
conjugated diene formation) and formation of nitrito-, nitro-, nitrosoperoxo-, and nitrated 
lipid oxidation derivatives (24-26). Peroxynitrite is a particularly effective oxidant of 
aromatic molecules, thioethers and organosulfur compounds that include free amino acids 
and polypeptide residues. 
The reaction of various amino acids with peroxynitrite leads to the following products: 1) 
cysteine and glutathione are converted to disulfides; 2) methionine is converted to sulfoxide 
or is fragmented to ethylene and dimethyl disulfides. Dimethyl sulfoxide is oxidized to 
formaldehyde; and 3) tyrosine and tryptophan undergo one electron oxidation to radical 
cations, which are hydroxylated, nitrated and dimerized (27-29). Exposure of amino acids, 
peptides and proteins to ionizing radiation such as gamma radiation and peroxynitrite in 
the presence of O2, give rise to hydroperoxides. These hydroperoxides decompose to oxygen 
and carbon centered radicals on exposure to copper (Cu+) and other transition metal ions. 
Hydroperoxide formation on nuclear proteins results in oxidative damage to associated 
DNA. These hydroperoxide-derived radicals react readily with pyrimidine DNA bases and 
nucleosides to form adduct species, for example 8-oxo-dG. This adduct is highly mutagenic 
and induces G:C to T:A transversions in human DNA after replication (30). 
A change in the structure of DNA could either be due to radiation or due to interaction with 
different free radicals (31). Since there are many polybasic compounds in the vicinity of 
DNA, there exists a possibility of their interaction with DNA on exposure to radiation or 
free radicals. Lysine and arginine-rich histones in nucleosomes on modification by 
environmental agents form histone-DNA adducts, making it immunogenic. It appears that 
the pathogenic anti-DNA autoantibodies are generated through some modified epitopes on 
nucleic acids (32-34). Prominent DNA modifications induced by exposure to peroxynitrite 
include the formation of 8-nitro-guanine and 8-oxyguanine, as well as the induction of 
single-strand breaks (35). Peroxynitrite reacts significantly only with guanine, which upon 
oxidation and nitration leads to mutagenicity and strand breaks, respectively. Peroxynitrite 
also damages DNA by covalent bond formation and removal of DNA bases (36). 
Purine nucleotides are vulnerable to oxidation and to adduct formation (37,38). 
Peroxynitrite is a mutagenic agent with a potential to produce nitration, nitrosation and 
deamination of DNA bases. Methylation of cytosine in DNA is important for the regulation 
of gene expression and normal methylation patterns are altered by the carcinogenic effect of 
peroxynitrite (39). Prominent DNA modifications induced by peroxynitrite include the 
formation of 8-nitro-guanine and 8-oxyguanine, as well as the induction of single strand 
breaks (40). DNA single strand breaks generated by peroxynitrite leads to activation of the 
nuclear enzyme, poly (ADP-ribose) synthetase (PARS), which can trigger cellular suicidal 
pathway. Single strand breaks generated by peroxynitrite can arise from two processes: 1) 
sugar damage, which involves abstraction of hydrogen leading to the formation of sugar 
radical or 2) base damage, which rapidly depurinates to generate abasic sites, finally 
resulting in single strand breaks (41). Peroxynitrite is mutagenic in the supF gene inducing G 
to T transversions and deletions clustered at the 5’ end of the gene. The mutagenicity of 
peroxynitrite is believed to result from chemical modifications at guanine leading to 
miscoding (42). Carcinogenesis is induced by altered DNA or tissue damage, mutations and 
chromosomal aberrations (43,44). Peroxynitrite is a mutagenic agent with the potential to 
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produce nitration, nitrosation and deamination reactions on DNA bases. It reacts 
significantly only with guanine, which upon oxidation and nitration leads to mutagenicity 
and strand breaks, respectively (45,46). Peroxynitrite levels are elevated in inflammation and 
infection and play an important role in autoimmunity and carcinogenesis (Figure 1). It 
damages tumor suppressor genes and leads to the expression of proto-oncogenes. 
Peroxynitrite induced DNA damage leading to mutations has been strongly implicated in 
carcinogenesis (47) (Figure 1). 
 
 
Fig. 1. The role of peroxynitrite, a reactive nitrogen species, in the etiopathogenesis of 
autoimmune disorders, such as systemic lupus erythematosus (SLE) and progressive 
systemic sclerosis (PSS). 
Proteins are targets of reactive nitrogen species such as peroxynitrite and NO2. Among the 
various amino acids in proteins, tryptophan residues are especially susceptible to attack by 
reactive nitrogen species (48). Peroxynitrite is capable of oxidizing protein and non-protein 
sulfhydryl (-SH) groups including lipid peroxidation and reactivity with aromatic amino 
acid side chain in proteins to form nitroadducts (49). Peroxynitrite induced tyrosine 
nitration may lead to dysfunction of nitrated proteins, SOD, cytoskeletal proteins, neuronal 
tyrosine hydroxylase, cytochrome P450 and prostacyclin synthase (50-53). Oxidation of 
critical -SH groups is responsible for the inhibition of mitochondrial and cytosolic aconitase 
and other critical enzymes in the mitochondrial respiratory chain (54). Peroxynitrite 
mediated nitration of myofibrillar creatine kinase activity may lead to contractile 
dysfunction of the heart (55). Peroxynitrite-modified cellular proteins are subject to 
accelerated degradation via the proteosome (56). 
Adducts arise from the chemical modification of bases in DNA or amino acids in proteins by 
toxic chemicals and high energy UV radiation. Many chemicals known to be carcinogenic in 
(neoepitopes)
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humans have been shown to form adducts. Ultraviolet radiation is regarded as one of the 
major environmental factors responsible for the photoconjugation of DNA with amino acid 
residues. Lysine is an amino acid of particular interest as a potential participant in DNA-
protein photo-cross-linking. Nearly 60% of thymine and cytosine bases in DNA are modified 
due to lysine photoaddition and approximately every helical turn of DNA contains one lysine 
molecule in the photobound state (57). It appears to enhance the antigenicity of the DNA-
lysine adduct, suggesting possible roles of peroxynitrite-induced neoepitopes in damaged 
DNA in the production of autoantibodies in cancer patients (58). 
Ahmad et al have characterised the peroxynitrite treated human-DNA lysine photoadduct 
(59). We have investigated the photochemical addition of lysine to native DNA in view of its 
potential importance in the photo-cross-linking of histones to DNA in chromatin. The C-2 
carbon atom of thymine in DNA undergoes a covalent photoaddition reaction with the ε-
amino group of lysine on UV irradiation to form a DNA-lysine photoconjugate or photoadduct 
(57). The UV spectroscopic analysis of the DNA-lysine photoadduct showed 
hyperchromism, indicating either the formation of single-stranded breaks in DNA or 
“breathing” of a double-stranded polymer at the site of lysine conjugation. Peroxynitrite 
caused substantial damage to the DNA-lysine adduct as evident from the hyperchromicity 
of the spectral curve, which could be attributed to the generation of strand breaks (Figure 
2A). On peroxynitrite modification, the hypochromicity increased, which may be due to the 
shielding effect of lysine, limiting the sites for peroxynitrite action. Hypochromicity may 
also be attributed to the extensive cross-linking between peroxynitrite and the DNA-lysine 
adduct (31). 
As shown in Figure 2B, the fluorescence emission intensity (FI) was highest for native DNA 
(curve 1) and least for the DNA-lysine photoadduct (curve 3). However, on peroxynitrite 
modification there was a change in the emission intensity, as seen in the figure (curve 2). A 
decrease in FI of 45.2% for the DNA-lysine photoadduct in comparison to the peroxynitrite-
modified DNA-lysine adduct was observed from fluorescence spectroscopy measurements. 
Loss of FI of 21.3% in the peroxynitrite-modified adduct with respect to native DNA is 
indicative of the loss of structural integrity in DNA and generation of single-strand regions 
(59). The UV absorption and fluorescence characteristics of native and modified lysine 
photoadduct have been summarized in Table 1. 
 
Properties Native DNA Native adduct Modified adduct 
 




75 70 85 
 
Hyperchromicity (%) — 52 84 
 
Loss of FI (%) — 76.1 21.3 
 
Table 1. Absorption and fluorescence characteristics of native DNA, DNA-lysine 
photoadduct (native adduct) and peroxynitrite-modified photoadduct (modified adduct) 
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Properties Native DNA Native adduct Modified adduct 
 




75 70 85 
 
Hyperchromicity (%) — 52 84 
 
Loss of FI (%) — 76.1 21.3 
 
Table 1. Absorption and fluorescence characteristics of native DNA, DNA-lysine 
photoadduct (native adduct) and peroxynitrite-modified photoadduct (modified adduct) 
 






Fig. 2. UV absorption spectra of native DNA (curve 3), DNA-lysine photoadduct (curve 2) 
and peroxynitrite-modified adduct (curve 1). 2B: Fluorescence spectra of native DNA (curve 
1), DNA-lysine photoadduct (curve 3), and peroxynitrite-modified adduct (curve 2). 
The melting profile of the DNA-lysine photoadduct reveals that the ultraviolet radiation 
induced covalent incorporation of lysine into the native DNA. The photoaddition of lysine 
to DNA might have obliterated the favorable A = T and G = C pairing interaction of double 
helical native DNA (57), thus decreasing the duplex melting temperature (Tm) by 5ºC 
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relative to the fully paired parent native DNA. In the study, on peroxynitrite treatment, the 
Tm of the DNA-lysine adduct increased by 15◦C with respect to the native DNA-lysine 
photoadduct (Figure 3). This may be due to shielding of the available sites for peroxynitrite 
action by lysine. Hence, more energy would be needed to break the covalent bonding 
between lysine and the DNA bases in order to denature the double helix (59). 
 
 
Fig. 3. Thermal melting profile of native DNA (curve 2), DNA-lysine photoadduct (curve 1), 
and peroxynitrite-modified photoadduct (curve 3). 
Biological significance of tyrosine nitration has generated much interest among biomedical 
scientists because abnormal generation of 3-nitrotyrosine in vivo in diverse pathological 
conditions have been proved without doubt. Peroxynitrite is a strong oxidant that can 
oxidize a variety of biomolecules including proteins and non-protein thiol, protein 
sulphides, lipids and deoxyribose. The markers of oxidative damage to proteins include 
mainly carbonyls of lysine, arginine, threonine and proline, oxidized tryptophan, tyrosine 
and cysteine residues and fragmented protein. One persistent footprint left by peroxynitrite 
is nitration of phenolic ring of tyrosine residues in protein. The resultant 3-nitrotyrosine is a 
relatively specific marker of nitrosative stress. A recent study on repair of protein nitration 
in rat tissues by 3-nitrotyrosine denitrase activity suggests that a tyrosine nitration–
denitration pathway participates in nitric oxide/peroxynitrite dependent signal 
transduction, a phenomenon similar to phosphorylation–dephosphorylation system. The 
reports suggest that 3-nitrotyrosine has importance not only as biomarker of nitrogen 
mediated tissue injury but also as a means to gain insight into molecular mechanisms of 
nitric oxide related physiological and pathophysiological phenomena. Furthermore, 
hypernitrotyrosinemia has also been reported in various inflammatory diseases including 
SLE, Sjogren’s syndrome, vasculitis and rheumatoid arthritis (60). 
Alteration of DNA or proteins resulting from photomodification or peroxynitrite could lead 
to the development of antibodies or mutations to modified DNA. Therefore, the DNA-lysine 
photoadduct and modified photoadduct could have important implications in various 
pathophysiological conditions such as toxicology, carcinogenesis, and autoimmune 
phenomena (57). 
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3. Autoimmune phenomenon 
Manifestations of autoimmunity are often complex and heterogenous. It has been postulated 
that the immune response against host antigens could be due to genetic predisposition, 
exaggerated B cell activity, cross-reactivity between foreign and host antigens, etc. The 
foreign antigens arise as a consequence of infection, inflammation, drug administration, 
environmental factors, free radicals, etc (57,61). It has been established that not only oxygen 
but nitrogen free radicals play an important role in the pathogenesis of several human 
diseases. Reactive nitrogen species is produced by the reaction of nitric oxide with 
superoxide. Nitric oxide radical participate in some pathological conditions such as arthritis, 
vasculitis, asthma, hypertension, etc. It is also an unstable molecule like oxygen free radical 
but less reactive and can react with proteins (31).  
Two diseases that are considered as a prototype for systemic autoimmunity are systemic 
lupus erythematosus (SLE) and rheumatoid arthritis (RA). SLE is a multi-systemic disorder 
characterized by a variety of autoantibodies and abnormal lymphocyte function that are 
responsible for many of the clinical manifestations important in diagnosis. A hallmark of 
SLE is the presence of antinuclear antibodies (ANA). ANA are prototype autoantibodies 
that mark the course of rheumatic diseases (62). Because of the close association between 
ANA and clinical diagnosis, these antibodies have become a key component in the 
evaluation of patients. These antibodies target a diverse range of macromolecules including 
DNA, RNA, proteins and protein-nucleic acid (PNA) complexes. Antibodies to DNA have 
been particularly associated with SLE which is considered to be a prototype autoimmune 
disease. Native DNA is no longer regarded as the antigen initiating the disease mainly 
immunization with nDNA does not produce SLE like symptoms. A few of the possible 
candidates could be polynucleotides, denatured DNA, RNA or modified DNA.  While 
antibodies to single stranded DNA are formed in several inflammatory complexes including 
RA; antibodies to double stranded DNA serve as an immunochemical marker in the 
diagnosis of SLE (63). Serum obtained form SLE individuals have been shown to possess 
anti-DNA antibodies of diverse antigenic specificity. These anti-DNA autoantibodies have 
been used to evaluate therapeutic effect and clinical features of SLE patients (64,65).  
The origin of autoantibody remains an enigma and the production of anti-DNA antibodies 
is even more complicated. Even though nucleic acid antigens are themselves poorly 
immunogenic, their antigenicity can be enhanced by modification with agents such as free 
radicals. Autoantibodies produced against such modified macromolecule are the hallmark 
of systemic human disease, SLE. B cell hyperactivity and the production of pathogenic 
autoantibodies is the main immunonological event in the pathogenesis of this disease. One 
approach to study the pathogenesis of SLE and determine how the autoantibody response is 
initiated and sustained is to analyse variable genes expressed by antibodies. Quantification 
of this repertoire has revealed the presence of a specific expansion of IgG clonotypes that 
impart reactivity with disease related autoantigens. The amino acid and nucleotide sequence 
of autoantibodies derived from human lupus present in immune complexes and renal 
eluates of subjects with active disease show features of diversification with a high rate of 
replacement or silent mutations and the clustering of mutations in the hypervariable region. 
This distinctive feature implies that a pure polyclonal activation cannot be the only 
mechanism responsible for autoantibody production. An antigen-driven process is more 
likely to play a role in their generation. It has been suggested that the antibodies may be 
stimulated by nucleic acid antigens or pathogens. B cells whose paratopes have 
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complementary determining regions (CDR) which are formed by amino acids that can 
promote DNA binding may be selectively stimulated by nucleic acid related structures (31).  
A number of studies support the role of free radicals in the initiation and progression of 
autoimmune response. Therefore, in chronic inflammatory diseases, peroxynitrite generated 
by phagocytic cells may cause damage to DNA and proteins, generating neoepitopes that 
lead to the production of antibodies cross-reacting with nDNA or histone proteins. 
Modification of native DNA or proteins by peroxynitrite might also lead to the generation of 
neoepitopes on the molecule, and may be one of the factors for the induction of the immune 
responses as seen in an autoimmune disease like systemic lupus erythematosus (SLE) (58). 
The peroxynitrite modified human DNA was found to be highly immunogenic in rabbits 
inducing high titre immunogen specific antibodies (Figure 4). The data demonstrate that the 
antibodies, though cross-reactive with various nucleic acids and polynucleotides, 
preferentially bind peroxynitrite-modified epitopes on DNA (58). 
 
 
Fig. 4. Antigenicity of peroxynitrite modified human DNA. Direct binding ELISA of anti-
peroxynitrite-human DNA antisera (○) and pre-immune sera (●). The microtitre plates were 
coated with peroxynitrite modified-human DNA (2.5 μg/ml).  
DNA is a non-immunogenic entity, but any significant unrepaired alteration in its basic 
structure could render it “foreign,” leading to the activation of immune pathways. A change 
in the structure of DNA could either be due to radiation or interaction with different free 
radicals. NO and its derivatives are among the radicals known to interact with DNA and are 
primarily involved in deamination of DNA bases. Peroxynitrite, on the other hand, leads to 
more extensive damage than that caused by an equivalent dose of ·NO. Formation occurs 
both intracellularly inside macrophages and extracellularly, and causes DNA strand breaks 
and modification of guanine (66). The two main products identified from the reaction of 
deoxyguanosine with peroxynitrite are 8-oxodeoxyguanine and 8-nitroguanine. The former 
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has long been regarded as a reliable biomarker for monitoring DNA damage in studies with 
various oxidizing agents. The peroxynitrite-modified DNA has been shown to acquire 
immunogenicity and was suspected to be one of the causes for generation of autoantibodies 
in cancer and autoimmune disorders (12,67). The peroxynitrite modified DNA is a potent 
immunizing stimulus, inducing high-titer immunogen-specific antibodies in rabbits. 
Peroxynitrite modification might have generated potential neoepitopes against which 
antibodies are raised. The analysis of cross-reactivity indicates that anti-peroxynitrite-DNA 
IgG is immunogen-specific, showing various extents of cross-reactivity attributable to 
sharing of common antigenic determinants. The common antigenic determinants between 
peroxynitrite-DNA and nDNA could possibly be the sugar-phosphate backbone, since 
peroxynitrite attacks DNA and causes single strand breaks through sugar fragmentation. 
Induced antibodies also recognized synthetic polynucleotides, representing A/B 
conformations, with a preference for the B-form (12). Elevated levels of ·NO in systemic 
lupus erythematosus (SLE) patients suggest a role for ·NO in the pathogenesis of the 
disease. Murine models of SLE demonstrate abnormally high levels of ·NO compared 
with normal mice, whereas systemic blockade of ·NO production reduces disease activity. 
Elevated serum nitrate levels correlate with indices of disease activity and, along with 
serum titers of anti-(ds DNA) antibodies, serve as indicators of SLE (68-69). Auto-antibody 
production in SLE has been attributed to either selective stimulation of autoreactive B-
cells by self-antigens or antigens crossreactive with self. The persistence of anti-DNA 
antibodies in SLE patients, despite systems to suppress self-recognition, suggests that the 
response is driven by an antigen resembling nDNA. The DNA damage by peroxynitrite is 
far more lethal than that caused by ·NO alone, leading to the perturbations in nDNA that 
render it immunogenic. This modified DNA might therefore play a role in the induction 
of circulating anti-DNA autoantibodies in various autoimmune disorders including SLE 
(12,59) 
Histones are small, highly conserved cationic proteins which bind DNA. They are weak 
immunogen because of their conserved nature. Histones are major constituent of cells’ 
chromatin and remain confined to nucleus. However, after apoptosis they may appear in 
circulation as nucleosomes. Incidence of autoantibodies against histone H1, H2A, H2B, H3 
and H4 are 60%, 53%, 48%, 36% and 29.5% respectively in the sera of SLE patients (70). 
Histones also act as autoantigens in humorally-mediated paraneoplastic diseases (71). 
Furthermore, anti-histone antibodies have also been reported in polymyositis / 
dermatomyositis (72). 
As peroxynitrite reaction involves free radical intermediates, it may favor cross-linking and 
aggregation during nitration. The extent of cross-linking depends on type of reagent used, 
protein concentration, type of protein and solvent conditions including pH. The exact 
chemical nature of the cross-linking is disputed but linkage of side chains of tyrosine residue 
is the common answer. Formation of tyrosyl radical by peroxynitrite and its reaction with 
another tyrosyl radical (on same or different histone molecule) may generate O,O′-
dityrosine covalent cross-links. Peroxynitrite induces an array of modifications in H2A 
structure namely-tyrosine nitration, formation of protein carbonyl, dityrosine and cross-
linking. Such gross structural changes might favor polymerization of native epitopes of H2A 
histone into potent immunogenic neo-epitopes. The histone proteins are conserved proteins 
and act as weak immunogens. However, they show strong immunogenicity after acetylation 
and alterations in amino acid structure or sequence can generate neo-epitopes on self 
proteins causing and immune attack. The oxidative and nitrative action of peroxynitrite 
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confers additional immunogenicity on H2A histone and probably there is a direct 
correlation between nitration and immunogenicity. In another words, peroxynityrite-
modified H2A still has some old epitopes which are scattered among neo-epitopes. Hence, 
immunization with peroxynityrite-modified H2A may produce polyspecific antibodies 
which can recognize both old and neo-epitopes or altogether there are two types of 
antibodies, one recognizing nitrated neo-epitopes and other binding exclusively with old 
epitopes (73). 
The mechanism of autoantibody production in diseases such as SLE has not yet been clearly 
identified. If antigen selection is an important aspect of differentiation, the nature of the 
stimulating antigen also remains to be determined. The origin of antibodies remains 
obscure, although modified DNA appears to be a causative factor in RA and SLE. It is 
possible that the production of autoantibodies may be the result of free radical attack on 
DNA or histone proteins causing changes at the macromolecule level. It is therefore 
postulated that in chronic inflammatory diseases, free radicals generated by phagocytic cells 
may cause damage to DNA and proteins and antibodies to self-antigen are produced. Also, 
a defect in the control of apoptosis and delayed clearance of apoptotic debris provide 
sustained interaction between free radicals and macromolecules, generating neoepitopes 
which subsequently result in autoimmunity and generating polyspecific autoantibodies (73).  
Sera of animals immunized with native and peroxynitrite-modified histones were tested on 
polysorp wells coated with respective immunogens (Figure 5). Modification by 100 μm 
peroxynitrite conferred more high immunogenicity on H2A histone (73).  
 
 
Fig. 5. Antigenicity of peroxynitrite modified proteins. Direct binding ELISA of 
experimentally induced antibodies against peroxynitrite-modified H2A (□) and native 
histone H2A (■). 
Accumulation of a variety of post-translationally modified self-proteins during inflammation 
may lead to generation or unmasking of new antigenic epitopes that in turn activate B-and/or 
T-cells, thereby impairing or bypassing immunological tolerance. Peroxynitrite-modified H2A 
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Accumulation of a variety of post-translationally modified self-proteins during inflammation 
may lead to generation or unmasking of new antigenic epitopes that in turn activate B-and/or 
T-cells, thereby impairing or bypassing immunological tolerance. Peroxynitrite-modified H2A 
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histone could act as an autoantigen leading to generation of anti-H2A histone antibodies. It is 
envisaged that anti-histone antibodies seen in a sub-group of SLE patients might originate 
from immunological activity of peroxynitrite-modified histones due to their protection from 
digestion by normal proteolytic machinery (61). In the context of anti-histone antibodies in 
drug induced lupus erythematosus, it is quite possible that the drug itself might mimic 
reaction(s) pathway(s) leading to abnormal synthesis of peroxynitrite. The peroxynitrite may 
then modify the structure of histone making it immunogenic (76). 
Hence, alteration of DNA or proteins resulting from photomodification or peroxynitrite 
could lead to the development of antibodies or mutations to modified DNA. Therefore, the 
DNA-lysine photoadduct and modified photoadducts could have important implications in 
toxicology, carcinogenesis, and autoimmune phenomena. Hence, understanding the 
pathophysiology of peroxynitrite could lead to important therapeutic interventions against 
this increasingly important and physiologically relevant reactive nitrogen species.  
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1. Introduction 
Silicosis is known as environmental and occupational pulmonary fibrosis and the most typical 
form of pneumoconiosis results from long-term exposure (ten years or more) to relatively low 
concentrations of silica dust and usually appears ten to thirty years after the first exposure 
(Hoffman & Wanderer, 2010; Madl, 2008; Rimal, 2005). Patients with this type of silicosis, 
especially in the early stages, may not have obvious signs or symptoms of disease, but 
abnormalities may be detected by x-ray. Chronic cough and exertional dyspnea are common 
clinical findings. Radiographically, chronic simple silicosis reveals a profusion of small (less 
than 10 mm in diameter) opacities, typically rounded, and predominating in the upper lung 
zones. Patients with silicosis are particularly susceptible to tuberculosis infection—known as 
silicotuberculosis (Brown, 2009). It is thought that silica damages pulmonary macrophages, 
inhibiting their ability to kill mycobacteria. Pulmonary complications of silicosis also include 
chronic bronchitis and airflow limitation, non-tuberculous Mycobacterium infection, fungal 
lung infection, compensatory emphysema, and pneumothorax (Cohe & Velho, 2002; Rees & 
Murray, 2007). Lung cancer is also considered to be associated with silicosis and the 
International Agency for Research on Cancer (IARC) categorized crystalline silica as a 
causative of lung cancer (Cocco, 2007; IARC, 1997; Pelucchi, 2006). In addition, it is well known 
that silicosis patients (SILs) often experience complications due to autoimmune diseases 
(Shanklin & Smalley, 1998; Steenland & Goldsmith, 1995; Uber & McReynolds, 1982) such as 
rheumatoid arthritis (known as Caplan syndrome) (Caplan, 1959, 1962), systemic lupus 
erythematosus (SLE) (Bartsch, 1980; Yamazaki 2007), systemic scleroderma (SSc) (Barnadas, 
1986; Cowie, 1987 Haustein, 1990; Haustein & Anderegg, 1998; Sluis-Cremer, 1985) and anti-
neutrophil cytoplasmic autoantibody (ANCA)-related vasculitis/nephritis (Bartůnková, 2006; 
Mulloy, 2003; Tervaert, 1998). 
Silica-induced dysregulation of autoimmunity has been thought to be caused by the 
adjuvant effect of silica (Cooper, 2008; Davis, 2001, Parks, 1999). Although this represents 
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1. Introduction 
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especially in the early stages, may not have obvious signs or symptoms of disease, but 
abnormalities may be detected by x-ray. Chronic cough and exertional dyspnea are common 
clinical findings. Radiographically, chronic simple silicosis reveals a profusion of small (less 
than 10 mm in diameter) opacities, typically rounded, and predominating in the upper lung 
zones. Patients with silicosis are particularly susceptible to tuberculosis infection—known as 
silicotuberculosis (Brown, 2009). It is thought that silica damages pulmonary macrophages, 
inhibiting their ability to kill mycobacteria. Pulmonary complications of silicosis also include 
chronic bronchitis and airflow limitation, non-tuberculous Mycobacterium infection, fungal 
lung infection, compensatory emphysema, and pneumothorax (Cohe & Velho, 2002; Rees & 
Murray, 2007). Lung cancer is also considered to be associated with silicosis and the 
International Agency for Research on Cancer (IARC) categorized crystalline silica as a 
causative of lung cancer (Cocco, 2007; IARC, 1997; Pelucchi, 2006). In addition, it is well known 
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rheumatoid arthritis (known as Caplan syndrome) (Caplan, 1959, 1962), systemic lupus 
erythematosus (SLE) (Bartsch, 1980; Yamazaki 2007), systemic scleroderma (SSc) (Barnadas, 
1986; Cowie, 1987 Haustein, 1990; Haustein & Anderegg, 1998; Sluis-Cremer, 1985) and anti-
neutrophil cytoplasmic autoantibody (ANCA)-related vasculitis/nephritis (Bartůnková, 2006; 
Mulloy, 2003; Tervaert, 1998). 
Silica-induced dysregulation of autoimmunity has been thought to be caused by the 
adjuvant effect of silica (Cooper, 2008; Davis, 2001, Parks, 1999). Although this represents 
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one mechanism by which silica might be involved in the development of autoimmune 
diseases, silica can influence circulating immunocompeting cells and dysregulate the T 
responder (Tresp) survival and activation status, since several different autoimmune 
diseases may be associated with silica dust exposure as mentioned above. In addition, silica 
may affect the regulatory T cell (Treg, CD4+25+FoxP3+), since Treg has been considered the 
most important subpopulation of T cells for the control of Tresp activation by the 
recognition of foreign and/or auto-antigens (Baecher-Allan, 2004; Bluestone & Tang, 2005; 
Schwartz, 2005). If the function or number of Treg is reduced, continuous stimulation of 
Tresp is thought to be maintained. 
Furthermore, recent findings regarding the NOD-like receptor family, pryin domain 
containing 3 (NLRP3, Nalp3)-inflammasome, have contributed substantially to our 
understanding of the sequential cellular events occurring when silica is inhaled into the 
pulmonary region and alveolar macrophages try to treat silica particles as a foreign 
substance (Cassel, 2008; Dostert, 2008; Hormung, 2008). 
At first, initial recognition of silica occurs by cell membrane receptors such as the 
macrophage receptor with collagenous structure (MARCO), scavenger receptor (SR)-AI and 
SR-AII (Brown, 2007; Hamilton, 2006; Thakur, 2009). The next stage involves capture of silica 
by macrophages and entrapment within lysosomes and their activation of the nucleotide-
binding domain and leucine-rich repeat containing proteins, the NLRP3 inflammasome, to 
cleave pro-caspase 1 to an active form (Cassel, 2008; Dostert, 2008; Hormung, 2008). 
Thereafter, cleavage of pro-interleukin (IL)-1β occurs to an active form for release to form 
fibrotic nodules and production of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) in the macrophages yielded (37-40). As a consequence, the induction of 
cellular and tissue damages occur due to the production of ROS and RNS and the apoptosis 
of alveolar macrophages. Various cytokines/chemokines such as IL-1β，tumor necrosis 
factor (TNF)-α, macrophage inflammatory protein (MIP)-1/2, monocyte-chemoattractant 
protein-1 (MCP-1) and IL-8 are produced that cause chronic inflammation and proliferation 
of collagenic fibers (Barrett, 1999; Hamilton, 2008; Hubbard, 2001; Porter, 2002). Silica 
particles are released from alveolar macrophages and the similar cellular reactions described 
above by newly-recognizing nearby macrophages will be repeated. Finally, silica particles 
are transferred to regional lymph nodes. As these cellular and molecular reactions are 
continuously repeated, pulmonary fibrosis will gradually and progressively appear. 
Even though details of these initial biological sequential reactions are recognized, it is still 
unclear how silica causes dysregulation of autoimmunity. From this viewpoint, we have 
been investigating the following perspectives: 
1. Alteration of Fas and related molecules to affect long-term survival of lymphocytes. 
2. Chronic activation of Tresp exposed to silica particles. 
3. Alteration of Treg function and/or numbers exposed to silica particles. 
In this chapter, we describe and summarize our experimental findings regarding the above 
three viewpoints, and insights concerning silica-induced dysregulation of autoimmunity 
will be discussed. Investigation using patient materials such as serum and lymphocytes 
were approved by the Institutional Ethics Committee of Kawasaki Medical School, Kusaka 
Hospital or Hinase-Urakami Iin. The specimens were only obtained from patients who gave 
documented informed consent. All of the patients were Japanese brickyard workers in Bizen 
City (Okayama prefecture, Japan), and were monitored at either Kusaka Hospital or the 
Hinase-Urakami Clinic. The silica in materials handled by these workers (e.g., dirt, sand, 
mud, concrete), and thus presenting the potential risk of being inhaled by these individuals 
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in their work environment, was estimated to reach levels as high as 40–60% (by mass). The 
subjects were diagnosed with pneumoconiosis according to the ILO 2000 Guideline (ILO, 
2004). These patients displayed neither clinical symptoms related to autoimmune diseases 
(e.g., sclerotic skin, Raynaud’s phenomenon, facial erythema, or arthralgia) nor any cancers.  
2. Alteration of Fas/CD95 and its related molecules in SILs 
The discovery of Fas has led to a remarkable improvement in our understanding of 
apoptosis and its signal transduction (Matiba, 1997; Nagata, 1996; Nagata & Golstein, 1995). 
Abnormal regulation of apoptosis, particularly in relation to the Fas/Fas ligand (FasL) 
pathway, has been thought to play a role in the pathogenesis of autoimmune diseases 
(Eguchi, 2001; Rudin, 1996; Yonehara, 2002). Mutations of the fas gene and the fas ligand gene 
which lead to defects in apoptosis have been found in autoimmune strains of mice (lpr mice 
and gld mice, respectively) and human autoimmune lymphoproliferative syndrome (ALPS) 
in childhood (Nagata, 1998; Nagata & Suda, 1995, Mountz & Edwards, 1992; Steinberg, 
1994). Fas/CD95, which is mainly expressed on the cell membrane of lymphocytes, usually 
exists as membrane-type Fas and forms a Fas-trimer after binding with FasL (Matiba, 1997; 
Nagata, 1996; Nagata & Golstein, 1995). The signal-transducing death domain located in the 
intracellular domain of Fas then recruits Fas-associated protein with Death Domain (FADD) 
and pro-caspase 8 to form the active death-inducing signaling complex (DISC) (Curtin & 
Cotter, 2003; Yu & Shi, 2008). Thereafter, activated caspase-8 triggers a caspase-cascade 
involving the activation of CAD/CPAN/DFF40 by removing its inhibitor, ICAD/DFF45, 
DNA fragmentation, and finally apoptotic cell death (Sabol, 1998; Sakahira, 1998). 
The most typical alternatively spliced variant of the wild-type fas gene transcript is known 
as soluble Fas (sFas). Since this variant transcript lacks 63 bp of the transmembrane domain, 
its product (sFas) can be secreted from cells to suppress membrane Fas-mediated apoptosis 
by blocking the binding between membrane Fas and the FasL in the extracellular region 
(Matiba, 1997; Nagata, 1996; Nagata & Golstein, 1995). If there is a high level of sFas in the 
extracellular regions, lymphocytes in these regions may avoid apoptosis and survive longer. 
Actually, there have been several studies showing elevated serum levels of sFas in patients 
with autoimmune diseases (Cheng, 1994; Knipping, 1995; Tokano, 1996).  
The following findings were obtained from our series of analyses of specimens from SILs. 
The detection of autoantibody to Fas and caspase-8, as well as topoisomerase I and 
desmoglein (Takata-Tomokuni, 2005; A. Ueki, 2001a, 2002; H. Ueki, 2001). Anti-Fas 
autoantibody detected in SILs was functionally active and caused Fas-mediated apoptosis 
(takata-Tomokuni, 2005). The level of serum sFas was higher in SILs than healthy volunteers 
(HVs), although the level of serum soluble FasL did not differ between SILs and HVs 
(Tomokuni, 1997, 1999). The mean fluorescent intensity (MFI) of membrane Fas was lower 
with lymphocytes from SILs than those from HVs, although total numbers of Fas-positive 
lymphocytes (membrane Fas expression) did not differ between the two populations 
(Otsuki, 2005). The weaker membrane Fas expressers (among lymphocytes) were identified 
to be weaker fas message expressers (Otsuki, 2005). The gene expression levels of 
extracellular inhibitor competing membrane Fas-FasL binding such as sFas, decoy receptor 3 
(DCR3), and other alternatively spliced variants of the fas gene were higher in peripheral 
blood mononuclear cells (PBMC) from SILs than HVs (Otsuki, 2000a, 2000b). The 
intracellular apoptosis-inhibitory genes including i-flice, sentrin, survivine and icad showed a 
lower expression in PBMC from SILs than HDs (Guo, 2001; Otsuki, 2000c).  
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subjects were diagnosed with pneumoconiosis according to the ILO 2000 Guideline (ILO, 
2004). These patients displayed neither clinical symptoms related to autoimmune diseases 
(e.g., sclerotic skin, Raynaud’s phenomenon, facial erythema, or arthralgia) nor any cancers.  
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apoptosis and its signal transduction (Matiba, 1997; Nagata, 1996; Nagata & Golstein, 1995). 
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and pro-caspase 8 to form the active death-inducing signaling complex (DISC) (Curtin & 
Cotter, 2003; Yu & Shi, 2008). Thereafter, activated caspase-8 triggers a caspase-cascade 
involving the activation of CAD/CPAN/DFF40 by removing its inhibitor, ICAD/DFF45, 
DNA fragmentation, and finally apoptotic cell death (Sabol, 1998; Sakahira, 1998). 
The most typical alternatively spliced variant of the wild-type fas gene transcript is known 
as soluble Fas (sFas). Since this variant transcript lacks 63 bp of the transmembrane domain, 
its product (sFas) can be secreted from cells to suppress membrane Fas-mediated apoptosis 
by blocking the binding between membrane Fas and the FasL in the extracellular region 
(Matiba, 1997; Nagata, 1996; Nagata & Golstein, 1995). If there is a high level of sFas in the 
extracellular regions, lymphocytes in these regions may avoid apoptosis and survive longer. 
Actually, there have been several studies showing elevated serum levels of sFas in patients 
with autoimmune diseases (Cheng, 1994; Knipping, 1995; Tokano, 1996).  
The following findings were obtained from our series of analyses of specimens from SILs. 
The detection of autoantibody to Fas and caspase-8, as well as topoisomerase I and 
desmoglein (Takata-Tomokuni, 2005; A. Ueki, 2001a, 2002; H. Ueki, 2001). Anti-Fas 
autoantibody detected in SILs was functionally active and caused Fas-mediated apoptosis 
(takata-Tomokuni, 2005). The level of serum sFas was higher in SILs than healthy volunteers 
(HVs), although the level of serum soluble FasL did not differ between SILs and HVs 
(Tomokuni, 1997, 1999). The mean fluorescent intensity (MFI) of membrane Fas was lower 
with lymphocytes from SILs than those from HVs, although total numbers of Fas-positive 
lymphocytes (membrane Fas expression) did not differ between the two populations 
(Otsuki, 2005). The weaker membrane Fas expressers (among lymphocytes) were identified 
to be weaker fas message expressers (Otsuki, 2005). The gene expression levels of 
extracellular inhibitor competing membrane Fas-FasL binding such as sFas, decoy receptor 3 
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blood mononuclear cells (PBMC) from SILs than HVs (Otsuki, 2000a, 2000b). The 
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lower expression in PBMC from SILs than HDs (Guo, 2001; Otsuki, 2000c).  
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Although significant mutations of fas and fas ligand genes were not detected, these results 
indicated that two populations of lymphocytes may exist in the peripheral blood of SILs. As 
shown on the right side of Fig. 1, one population is a weaker membrane Fas expresser and 
these cells may have developed out of an excessive transcription of the alternatively spliced 
fas gene and other variant messages. Therefore, these cells may be resistant to the functional 
anti-fas autoantibody, secrete higher levels of sFas, DCR3 and spliced variants, and are 
resistant to Fas-mediated apoptosis (Murakami, 2007, Otsuki, 2005, 2007). As reported 
previously (Otsuki, 2005), patients with a weaker MFI of membrane Fas often have a higher 
titer of anti-nuclear antibodies (ANA), and self-recognizing clones in silicosis may be 
included in the fraction because these clones may survive longer and show resistance to 
apoptosis.  
The other population, shown on the left side of Fig. 1, represents stronger membrane Fas 
expressers that may be sensitive to Fas-mediated apoptosis including cell death caused by 
anti-Fas autoantibody, show a reduced expression of intracellular inhibitor genes of Fas-
mediated apoptosis, and undergo apoptosis. These cells may be recruited from bone 
marrow after reaching the final stage of cell death. This recruited fraction would not have 
encountered silica and would be sensitive to Fas-mediated apoptosis. As a result, cells in 
this fraction would be continuously undergoing renewal and then apoptosis (Murakami, 
2007, Otsuki, 2005, 2007). 
The overall findings support the supposition that the long-term surviving subpopulation of 
T cells may include self-recognizing clones. However, these results provide no evidence that 
the lymphocytes in SILs are activated continuously. Thus, an investigation that incorporates 
experimental and patient-oriented studies is required to observe the chronic activation of 
Tresp by silica. 
3. Chronic activation of Tresp by exposure to silica 
To investigate the hypothesis that silica chronically activates Tresp, we first examined the in 
vitro activation of Tresp by exposure to silica (Wu, 2005). Freshly isolated PBMCs from HVs 
were cultured with or without phytohaemagglutinin (PHA), Min-U-silica (25 or 50 µg/ml) 
or chrysotile A (an asbestos, 50 µg/ml) for ten days. The expression of CD69 was used as the 
marker for early activation of T cells. Results showed that only silica can upregulate CD69 
expression in T cells slowly and gradually in a dose-dependent manner in regard to cell 
surface expression (as shown in Fig. 2-A) and the message level (Wu, 2005). Although the 
data is not shown here, it was evident that PHA can stimulate T cells and that CD69 
expression was observed at day 1 as the peak and then gradually reduced until day 5 (Wu, 
2005). Additionally, chrysotile A was not able to induce CD69 expression (Wu, 2005). In this 
study, the necessity of the existence of phagocytosed cells in contact with lymphocytes was 
also found, and soluble factors secreted from phagocytosed cells contributed to 
approximately half of the induced CD69 expression in T cells (Wu, 2005). These results 
indicated the importance of the NLRP3 inflammasome in these experimental situations. 
Moreover, if Tresp in SILs encounter silica at the pulmonary circulation and also regional 
lymph nodes where silica is accumulated after it is handled by alveolar macrophages, they 
can be exposed to silica chronically and recurrently. In view of this consideration, the 
activation of Tresp in circulating peripheral blood Tresp and collateral evidence of Tresp 
activation were then investigated. 
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Fig. 1. Schematic model of the dysregulation of Fas and Fas-related molecules found in 
patients with silicosis. Two groups (temporarily designated T cell - i – and - ii -) may exist 
among lymphocytes from these patients: a population repeatedly undergoing apoptosis 
caused by silica and recruited from bone marrow, and another population surviving in the 
long term by avoiding apoptosis due to self-producing inhibitory molecules such as soluble 
Fas that may include self-recognizing clones. 
With the recent recognition of Treg, most of the peripheral CD4+25+ T cells, particularly the 
higher expresser of CD25, are considered as Treg (Baecher-Allan, 2004; Bluestone & Tang, 
2005; Schwartz, 2005). However, activated Tresp also express CD25 on their surface. 
Although Treg is defined in regard to the nuclear forkhead box P3 (FoxP3) gene as the 
master gene of Treg to manifest Treg function in order to inhibit the Tresp activation 
response against auto, foreign, cancerous and transplanted antigens (Baecher-Allan, 2004; 
Bluestone & Tang, 2005; Schwartz, 2005), observation of FoxP3 expression by flow 
cytometry requires the permeabilization of cell surface and nuclear membranes. This 
procedure is not suitable for subsequent biological examinations using sorted cells. Thus, in 
the following experiments, CD4+25+ cells were sorted to examine gene expression and the 
inhibitory function of the fraction.  
As the marker for activation, we again used CD69 as an early activation marker and 
programmed cell death-1 (PD-1) genes (Saresella, 2008; Wang, 2009). Peripheral blood 
CD4+25- and CD4+25+ cells derived from HVs or SILs were collected by flow cytometry 
and relative gene expressions of CD69 and PD-1 were analyzed by real-time RT-PCR in 
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Although significant mutations of fas and fas ligand genes were not detected, these results 
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The overall findings support the supposition that the long-term surviving subpopulation of 
T cells may include self-recognizing clones. However, these results provide no evidence that 
the lymphocytes in SILs are activated continuously. Thus, an investigation that incorporates 
experimental and patient-oriented studies is required to observe the chronic activation of 
Tresp by silica. 
3. Chronic activation of Tresp by exposure to silica 
To investigate the hypothesis that silica chronically activates Tresp, we first examined the in 
vitro activation of Tresp by exposure to silica (Wu, 2005). Freshly isolated PBMCs from HVs 
were cultured with or without phytohaemagglutinin (PHA), Min-U-silica (25 or 50 µg/ml) 
or chrysotile A (an asbestos, 50 µg/ml) for ten days. The expression of CD69 was used as the 
marker for early activation of T cells. Results showed that only silica can upregulate CD69 
expression in T cells slowly and gradually in a dose-dependent manner in regard to cell 
surface expression (as shown in Fig. 2-A) and the message level (Wu, 2005). Although the 
data is not shown here, it was evident that PHA can stimulate T cells and that CD69 
expression was observed at day 1 as the peak and then gradually reduced until day 5 (Wu, 
2005). Additionally, chrysotile A was not able to induce CD69 expression (Wu, 2005). In this 
study, the necessity of the existence of phagocytosed cells in contact with lymphocytes was 
also found, and soluble factors secreted from phagocytosed cells contributed to 
approximately half of the induced CD69 expression in T cells (Wu, 2005). These results 
indicated the importance of the NLRP3 inflammasome in these experimental situations. 
Moreover, if Tresp in SILs encounter silica at the pulmonary circulation and also regional 
lymph nodes where silica is accumulated after it is handled by alveolar macrophages, they 
can be exposed to silica chronically and recurrently. In view of this consideration, the 
activation of Tresp in circulating peripheral blood Tresp and collateral evidence of Tresp 
activation were then investigated. 
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Fig. 1. Schematic model of the dysregulation of Fas and Fas-related molecules found in 
patients with silicosis. Two groups (temporarily designated T cell - i – and - ii -) may exist 
among lymphocytes from these patients: a population repeatedly undergoing apoptosis 
caused by silica and recruited from bone marrow, and another population surviving in the 
long term by avoiding apoptosis due to self-producing inhibitory molecules such as soluble 
Fas that may include self-recognizing clones. 
With the recent recognition of Treg, most of the peripheral CD4+25+ T cells, particularly the 
higher expresser of CD25, are considered as Treg (Baecher-Allan, 2004; Bluestone & Tang, 
2005; Schwartz, 2005). However, activated Tresp also express CD25 on their surface. 
Although Treg is defined in regard to the nuclear forkhead box P3 (FoxP3) gene as the 
master gene of Treg to manifest Treg function in order to inhibit the Tresp activation 
response against auto, foreign, cancerous and transplanted antigens (Baecher-Allan, 2004; 
Bluestone & Tang, 2005; Schwartz, 2005), observation of FoxP3 expression by flow 
cytometry requires the permeabilization of cell surface and nuclear membranes. This 
procedure is not suitable for subsequent biological examinations using sorted cells. Thus, in 
the following experiments, CD4+25+ cells were sorted to examine gene expression and the 
inhibitory function of the fraction.  
As the marker for activation, we again used CD69 as an early activation marker and 
programmed cell death-1 (PD-1) genes (Saresella, 2008; Wang, 2009). Peripheral blood 
CD4+25- and CD4+25+ cells derived from HVs or SILs were collected by flow cytometry 
and relative gene expressions of CD69 and PD-1 were analyzed by real-time RT-PCR in 
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comparison to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression (Hayashi, 
2010). As shown in Fig. 2-B, the CD4+25- fraction from both HVs and SILs revealed a higher 
expression of CD69 than CD25+ cells. In addition, CD69 expression in the CD25- fraction of 
SILs was significantly higher than that of HVs. Furthermore, as shown in Fig. 2-C, the 
expression of PD-1 was higher in the CD25- and CD25+ fractions of SILs than HVs. These 
findings supported the view that Tresp in SILs were chronically and recurrently activated 
and possessed long-term survival. Since CD69 expression was limited in the early stage of T 
cell activation, it is significant that the CD25+ fraction from both populations showed lower 
expression. However, both the CD25- and CD25+ fractions showed a higher expression of  
 
 
Fig. 2. Various examinations to recognize the effects of silica exposure on responder T cells 
(Tresp). ＊：p<0.05, ＊＊<0.01 and ▲：0.05<p<0.1. [A] Peripheral blood mononuclear cells 
from healthy volunteers (HVs) were incubated with or without silica particles (25 or 50 
µg/ml) for ten days. CD69 expression in CD4+ cells was analyzed by flow cytometry. [B] 
and [C] Peripheral blood CD4+25- and CD4+25+ cell fractions derived from HVs and 
silicosis patients (SILs) were sorted by flow cytometry, extracted total RNAs from individual 
fractions, and synthesized cDNA. Real-time RT-PCR analyses were employed to compare 
the gene expression of CD69 and PD-1, respectively. [D] and [E] Serum levels of the ANA 
titer and soluble IL-2 receptor (sIL-2R), respectively, were measured by ELISA methods and 
compared among HVs, SILs and patients with systemic sclerosis (SSc). In addition, after a 
numbered disease status set to 1 for HVs, 2 for SILs and 3 for SSc, correlations between 
disease status number and titers of ANA or sIL-2R were analyzed. 
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PD-1 (Hayashi, 2010). This may suggest that silica can activate both Tresp and Treg, and that 
the CD25+ fraction in SILs may include chronically activated Tresp in which surface CD25 
expression occurred continuously due to recurrent stimulation by silica (Hayashi, 2010). 
To investigate another marker of Tresp activation, we measured the serum soluble IL-2 
receptor (sIL-2R) in SILs and compared results with those obtained from HVs and patients 
with SSc, since sIL-2R is known to arise in the serum of apparently healthy individuals who 
subclinically possess neoplastic (i.e., certain lymphoid malignancies such as T cell leukemia 
and early cell leukemia), autoimmune or inflammatory diseases (Carlson, 1992; Nelson & 
Willerford, 1998; Pizzolo, 1991; Rubin & Nelson, 1990; Zerler, 1991). The high-affinity IL-2R 
is a multichain receptor which possesses at least three IL-2 binding chains: IL-2Rα/CD25 (55 
kDa), IL-2Rβ/CD122 (75 kDa) and IL-2Rγ/CD132 (64 kDa). sIL-2R is the naturally occurring 
soluble form of IL-2Rα. For this analysis, the serum titer of anti-nuclear antigens (ANA) was 
measured in HVs, SILs and SSc using the Enzyme-Linked ImmunoSorbent Assay (ELISA)-
based MESACUP ANA TEST (MBL Co. Ltd., Nagoya, Japan), which includes several 
recombinant proteins such as RNP, SS-A/Ro, SS-B/La, Scl-70, Jo-1 and Ribosomal P in vitro 
transcribed U1 RA and CENP-B protein, and purified antigen (Sm, SS-A/Ro, Scl-70m 
Histone and DNA) (Hayashi, 2009). As shown in Fig. 2-D, the ANA titer in SSc was the 
highest among the three groups, and significantly higher than that of HVs or SILs, whereas 
the ANA titer in SILs was also significantly higher than that of HVs. In addition, if disease 
status was numbered and set to 1 for HV, 2 for SIL and 3 for SSc, a significant positive 
correlation was obtained between the serum titer of ANA and disease status. Even our 
patients did not manifest any clinical symptoms for autoimmune diseases, and SILs 
subclinically tended to present a dysregulation of autoimmunity. Following these findings, 
serum sIL-2R was also analyzed in a manner similar to that used for the serum ANA titer. 
As shown in Fig. 2-E, SSc patients showed significantly higher serum sIL-2R than HVs or 
SILs, and the level shown by SILs tended to be higher than that shown by HVs. In addition, 
a significant positive correlation was detected between serum sIL-2R and disease status. 
These results suggest that sIL-2R may be used to detect immunological alteration in SILs, 
and that Tresp in SILs is activated chronically to an unknown higher level of sIL-2R 
(Hayashi, 2009). 
4. Chronic activation of Treg by exposure to silica 
As we have investigated Tresp activation in SILs as described above, the next point of 
interest was the function and activation of Treg. It has been revealed that CD4+25+ Treg 
contribute to maintaining self-tolerance by down-regulating the immune response to self 
and non-self antigens in an antigen-non-specific manner, presumably at the T cell activation 
stage (Baecher-Allan, 2004; Bluestone & Tang, 2005; Schwartz, 2005). Elimination and/or 
reduction of CD4+25+ T cells relieves this general suppression, thereby enhancing immune 
responses to non-self Ags and eliciting autoimmune responses to certain self-antigens. 
Recent studies have shown that CD4+25+ Treg specifically express transcription factor 
Foxp3 (Baecher-Allan, 2004; Bluestone & Tang, 2005; Schwartz, 2005). Genetic anomalies in 
Foxp3 cause autoimmune and inflammatory diseases in rodents and humans by affecting 
the development and function of CD4+CD25+ Treg (Baecher-Allan, 2004; Bluestone & Tang, 
2005; Schwartz, 2005). Clinically, a deficiency in Treg function or decrease in the proportion 
of Treg has been shown to influence the pathogenesis of collagen or autoimmune diseases 
such as multiple sclerosis (O’Connor & Anderton, 2008), rheumatoid arthritis (Toh & 
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comparison to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression (Hayashi, 
2010). As shown in Fig. 2-B, the CD4+25- fraction from both HVs and SILs revealed a higher 
expression of CD69 than CD25+ cells. In addition, CD69 expression in the CD25- fraction of 
SILs was significantly higher than that of HVs. Furthermore, as shown in Fig. 2-C, the 
expression of PD-1 was higher in the CD25- and CD25+ fractions of SILs than HVs. These 
findings supported the view that Tresp in SILs were chronically and recurrently activated 
and possessed long-term survival. Since CD69 expression was limited in the early stage of T 
cell activation, it is significant that the CD25+ fraction from both populations showed lower 
expression. However, both the CD25- and CD25+ fractions showed a higher expression of  
 
 
Fig. 2. Various examinations to recognize the effects of silica exposure on responder T cells 
(Tresp). ＊：p<0.05, ＊＊<0.01 and ▲：0.05<p<0.1. [A] Peripheral blood mononuclear cells 
from healthy volunteers (HVs) were incubated with or without silica particles (25 or 50 
µg/ml) for ten days. CD69 expression in CD4+ cells was analyzed by flow cytometry. [B] 
and [C] Peripheral blood CD4+25- and CD4+25+ cell fractions derived from HVs and 
silicosis patients (SILs) were sorted by flow cytometry, extracted total RNAs from individual 
fractions, and synthesized cDNA. Real-time RT-PCR analyses were employed to compare 
the gene expression of CD69 and PD-1, respectively. [D] and [E] Serum levels of the ANA 
titer and soluble IL-2 receptor (sIL-2R), respectively, were measured by ELISA methods and 
compared among HVs, SILs and patients with systemic sclerosis (SSc). In addition, after a 
numbered disease status set to 1 for HVs, 2 for SILs and 3 for SSc, correlations between 
disease status number and titers of ANA or sIL-2R were analyzed. 
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PD-1 (Hayashi, 2010). This may suggest that silica can activate both Tresp and Treg, and that 
the CD25+ fraction in SILs may include chronically activated Tresp in which surface CD25 
expression occurred continuously due to recurrent stimulation by silica (Hayashi, 2010). 
To investigate another marker of Tresp activation, we measured the serum soluble IL-2 
receptor (sIL-2R) in SILs and compared results with those obtained from HVs and patients 
with SSc, since sIL-2R is known to arise in the serum of apparently healthy individuals who 
subclinically possess neoplastic (i.e., certain lymphoid malignancies such as T cell leukemia 
and early cell leukemia), autoimmune or inflammatory diseases (Carlson, 1992; Nelson & 
Willerford, 1998; Pizzolo, 1991; Rubin & Nelson, 1990; Zerler, 1991). The high-affinity IL-2R 
is a multichain receptor which possesses at least three IL-2 binding chains: IL-2Rα/CD25 (55 
kDa), IL-2Rβ/CD122 (75 kDa) and IL-2Rγ/CD132 (64 kDa). sIL-2R is the naturally occurring 
soluble form of IL-2Rα. For this analysis, the serum titer of anti-nuclear antigens (ANA) was 
measured in HVs, SILs and SSc using the Enzyme-Linked ImmunoSorbent Assay (ELISA)-
based MESACUP ANA TEST (MBL Co. Ltd., Nagoya, Japan), which includes several 
recombinant proteins such as RNP, SS-A/Ro, SS-B/La, Scl-70, Jo-1 and Ribosomal P in vitro 
transcribed U1 RA and CENP-B protein, and purified antigen (Sm, SS-A/Ro, Scl-70m 
Histone and DNA) (Hayashi, 2009). As shown in Fig. 2-D, the ANA titer in SSc was the 
highest among the three groups, and significantly higher than that of HVs or SILs, whereas 
the ANA titer in SILs was also significantly higher than that of HVs. In addition, if disease 
status was numbered and set to 1 for HV, 2 for SIL and 3 for SSc, a significant positive 
correlation was obtained between the serum titer of ANA and disease status. Even our 
patients did not manifest any clinical symptoms for autoimmune diseases, and SILs 
subclinically tended to present a dysregulation of autoimmunity. Following these findings, 
serum sIL-2R was also analyzed in a manner similar to that used for the serum ANA titer. 
As shown in Fig. 2-E, SSc patients showed significantly higher serum sIL-2R than HVs or 
SILs, and the level shown by SILs tended to be higher than that shown by HVs. In addition, 
a significant positive correlation was detected between serum sIL-2R and disease status. 
These results suggest that sIL-2R may be used to detect immunological alteration in SILs, 
and that Tresp in SILs is activated chronically to an unknown higher level of sIL-2R 
(Hayashi, 2009). 
4. Chronic activation of Treg by exposure to silica 
As we have investigated Tresp activation in SILs as described above, the next point of 
interest was the function and activation of Treg. It has been revealed that CD4+25+ Treg 
contribute to maintaining self-tolerance by down-regulating the immune response to self 
and non-self antigens in an antigen-non-specific manner, presumably at the T cell activation 
stage (Baecher-Allan, 2004; Bluestone & Tang, 2005; Schwartz, 2005). Elimination and/or 
reduction of CD4+25+ T cells relieves this general suppression, thereby enhancing immune 
responses to non-self Ags and eliciting autoimmune responses to certain self-antigens. 
Recent studies have shown that CD4+25+ Treg specifically express transcription factor 
Foxp3 (Baecher-Allan, 2004; Bluestone & Tang, 2005; Schwartz, 2005). Genetic anomalies in 
Foxp3 cause autoimmune and inflammatory diseases in rodents and humans by affecting 
the development and function of CD4+CD25+ Treg (Baecher-Allan, 2004; Bluestone & Tang, 
2005; Schwartz, 2005). Clinically, a deficiency in Treg function or decrease in the proportion 
of Treg has been shown to influence the pathogenesis of collagen or autoimmune diseases 
such as multiple sclerosis (O’Connor & Anderton, 2008), rheumatoid arthritis (Toh & 
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Miossec, 2007), systemic lupus erythematosus (Mudd, 2006), and pemphigus vulgaris 
(Yokoyama & Amagai, 2010). These findings at the cellular and molecular levels provide 
firm evidence that CD4+25+Foxp3+ Treg cells are an indispensable cellular constituent of 
the normal immune system, and that these cells play crucial roles in establishing and 
maintaining immunologic self-tolerance and immune homeostasis.  
As mentioned above, CD25 molecules are also expressed on non-Treg subsets such as 
antigen-activated responder/effector T cells. Therefore, Foxp3 has been utilized as a useful 
marker to identify CD25+ regulatory T cells from CD25+ activated Tresp, although several 
distinguishable markers such as CD127 and PD-1 have been utilized to distinguish Treg 
from activated CD4+CD25+ Tresp (Liu, 2006; Hartigan-O’Connor, 2007; Saresella, 2008; 
Wang, 2009). 
As described above, since the peripheral blood CD4+25+ fraction showed higher PD-1 
expression (Fig. 2-C) and several findings demonstrate the chronic and recurrent activation 
of Tresp in SILs, the peripheral CD4+25+ fraction in SILs may be contaminated by these 
activated Tresp expressing CD25 on the base of Treg (Hayashi, 2010).  
Thus, we first analyzed the function of the Treg fraction (actually, the peripheral CD4+25+ 
fraction sorted by flow cytometry in which Treg is mainly included and there is no 
availability of FoxP3-sorted cells for biological use as mentioned above) (Wu, 2006). As 
shown in Fig. 3-A, the inhibitory function of the CD4+25+ sorted fraction from SILs was 
lower than that of HVs when this fraction was added to the mixed lymphocyte culture 
(MLR) (Tresp was stimulated by irradiated allo-PBMCs) with the ratio 1:1/4 or 1:1/2, and 
tended to be lower when added with the ratio 1:1/8 or 1:1. There may be a reduced number 
of true Treg in the CD4+25+ fraction from SILs or an impaired function of true Treg (wu, 
2006). Taken together with the results of chronic and recurrent activation of Tresp in SILs 
(Hayashi, 2010; Wu, 2005), these findings support the possibility that the CD4+25+ fraction 
in SILs may include activated Tresp due to silica exposure. To examine this possibility, Treg-
specific gene expression such as FoxP3 and cytotoxic T-lymphocyte antigen 4 (CTLA-4) was 
analyzed in CD4+25- and CD4+25+ fractions derived from HVs and SILs. As shown in Fig. 
3-B and 3-C, the CD4+25+ fraction from SILs lost the dominant expression levels of both 
genes. These results suggested the CD4+25+ fraction in SILs was contaminated with 
chronically activated Tresp by exposure to silica (Hayashi, 2010; Wu, 2006). As expected and 
shown in Fig. 3-D, the percentage of the CD4+25+ fraction in peripheral lymphocytes was 
significantly smaller in HVs than SILs. Although the CD4+FoxP3+ fraction did not differ 
between HVs and SILs, the CD25+FoxP3- population was higher in SILs than HVs (Hayashi, 
2010; Wu, 2006). These analyses indicated that the CD4+25+ fractions in SILs were 
contaminated by chronically activated Tresp due to exposure to silica (Hayashi, 2010; Wu, 
2006). Although this may explain the results of reduced inhibitory function of the CD4+25+ 
fraction from SILs, there may be another possibility regarding the number of true Treg in 
SILs. Even the percentage of the CD4+FoxP3+ fraction did not differ between SILs and HVs, 
and a certain loss of Treg may occur, otherwise the reduced inhibitory function may not be 
fully explained. 
We again take an interest with the Fas/CD95 molecule. As Tresp upregulated its CD25 
expression due to chronic exposure to silica, Treg may have excess expression of Fas/CD95 
because it has been shown that Treg expresses Fas/CD95 and is more sensitive to Fas-
mediated apoptosis than Tresp (Fritzsching, 2005, 2006). To investigate this possibility, 
peripheral blood mononuclear cells from HVs and SILs were stained with CD4, CD25, 
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Fig. 3. Various examinations to recognize the effects of silica exposure on regulatory T cells 
(Treg). ＊：p<0.05, ＊＊<0.01 and ▲：0.05<p<0.1. [A] The CD4+25- and CD4+25+ fractions 
from healthy volunteers (HVs) and silicosis patients (SILs) were collected by flow cytometry. 
CD4+25- cells with or without various ratios of CD4+25+ cells, such as 1:0, 1:1/8, 1:1/4, 1:1/2 
and 1:1, were applied to a mixed lymphocyte reaction (MLR). Allogenic irradiated peripheral 
blood mononuclear cells were used as a stimulator. Graphs express suppressive properties of 
added CD4+25+ fractions. The degree to which the added CD4+25+ fraction reduced Cd4+25- 
DNA synthesis was measured by the 3H-thymidine incorporation assay. [B] and [C] Peripheral 
blood CD4+25- and CD4+25+ cell fractions derived from HVs and SILs were sorted by flow 
cytometry, extracted total RNAs from individual fractions, and synthesized cDNA. Real-time 
RT-PCR analyses were employed to compare the gene expression of FoxP3 and CTLA-4, 
respectively. [D] Peripheral blood CD4+25+ and CD4+FoxP2+ populations were compared 
between HVs and SILs. [E] and [F] Peripheral blood CD4+FoxP3+ cells derived from HVs and 
SILs were compared in regard to CD95/Fas expression by means of fluorescent intensity and 
positive cell percentage, respectively. 
CD95/Fas and FoxP3, and CD95/Fas expression (MFI) and positive cell frequency were 
analyzed in the CD4+FoxP3+ cell fraction. As shown in Fig. 3-E (MFI) and 3-F (positive cell 
frequency), Treg from SILs showed significantly higher expression levels of CD95/Fas than 
those from HVs. In addition, CD4+25+ cells from SILs were significantly more sensitive 
against Fas-mediated apoptosis inducing monoclonal antibody (CH-11) than those from 
HVs (data not shown), and proceeded faster to apoptosis as previously reported (Hayashi, 
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Miossec, 2007), systemic lupus erythematosus (Mudd, 2006), and pemphigus vulgaris 
(Yokoyama & Amagai, 2010). These findings at the cellular and molecular levels provide 
firm evidence that CD4+25+Foxp3+ Treg cells are an indispensable cellular constituent of 
the normal immune system, and that these cells play crucial roles in establishing and 
maintaining immunologic self-tolerance and immune homeostasis.  
As mentioned above, CD25 molecules are also expressed on non-Treg subsets such as 
antigen-activated responder/effector T cells. Therefore, Foxp3 has been utilized as a useful 
marker to identify CD25+ regulatory T cells from CD25+ activated Tresp, although several 
distinguishable markers such as CD127 and PD-1 have been utilized to distinguish Treg 
from activated CD4+CD25+ Tresp (Liu, 2006; Hartigan-O’Connor, 2007; Saresella, 2008; 
Wang, 2009). 
As described above, since the peripheral blood CD4+25+ fraction showed higher PD-1 
expression (Fig. 2-C) and several findings demonstrate the chronic and recurrent activation 
of Tresp in SILs, the peripheral CD4+25+ fraction in SILs may be contaminated by these 
activated Tresp expressing CD25 on the base of Treg (Hayashi, 2010).  
Thus, we first analyzed the function of the Treg fraction (actually, the peripheral CD4+25+ 
fraction sorted by flow cytometry in which Treg is mainly included and there is no 
availability of FoxP3-sorted cells for biological use as mentioned above) (Wu, 2006). As 
shown in Fig. 3-A, the inhibitory function of the CD4+25+ sorted fraction from SILs was 
lower than that of HVs when this fraction was added to the mixed lymphocyte culture 
(MLR) (Tresp was stimulated by irradiated allo-PBMCs) with the ratio 1:1/4 or 1:1/2, and 
tended to be lower when added with the ratio 1:1/8 or 1:1. There may be a reduced number 
of true Treg in the CD4+25+ fraction from SILs or an impaired function of true Treg (wu, 
2006). Taken together with the results of chronic and recurrent activation of Tresp in SILs 
(Hayashi, 2010; Wu, 2005), these findings support the possibility that the CD4+25+ fraction 
in SILs may include activated Tresp due to silica exposure. To examine this possibility, Treg-
specific gene expression such as FoxP3 and cytotoxic T-lymphocyte antigen 4 (CTLA-4) was 
analyzed in CD4+25- and CD4+25+ fractions derived from HVs and SILs. As shown in Fig. 
3-B and 3-C, the CD4+25+ fraction from SILs lost the dominant expression levels of both 
genes. These results suggested the CD4+25+ fraction in SILs was contaminated with 
chronically activated Tresp by exposure to silica (Hayashi, 2010; Wu, 2006). As expected and 
shown in Fig. 3-D, the percentage of the CD4+25+ fraction in peripheral lymphocytes was 
significantly smaller in HVs than SILs. Although the CD4+FoxP3+ fraction did not differ 
between HVs and SILs, the CD25+FoxP3- population was higher in SILs than HVs (Hayashi, 
2010; Wu, 2006). These analyses indicated that the CD4+25+ fractions in SILs were 
contaminated by chronically activated Tresp due to exposure to silica (Hayashi, 2010; Wu, 
2006). Although this may explain the results of reduced inhibitory function of the CD4+25+ 
fraction from SILs, there may be another possibility regarding the number of true Treg in 
SILs. Even the percentage of the CD4+FoxP3+ fraction did not differ between SILs and HVs, 
and a certain loss of Treg may occur, otherwise the reduced inhibitory function may not be 
fully explained. 
We again take an interest with the Fas/CD95 molecule. As Tresp upregulated its CD25 
expression due to chronic exposure to silica, Treg may have excess expression of Fas/CD95 
because it has been shown that Treg expresses Fas/CD95 and is more sensitive to Fas-
mediated apoptosis than Tresp (Fritzsching, 2005, 2006). To investigate this possibility, 
peripheral blood mononuclear cells from HVs and SILs were stained with CD4, CD25, 
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Fig. 3. Various examinations to recognize the effects of silica exposure on regulatory T cells 
(Treg). ＊：p<0.05, ＊＊<0.01 and ▲：0.05<p<0.1. [A] The CD4+25- and CD4+25+ fractions 
from healthy volunteers (HVs) and silicosis patients (SILs) were collected by flow cytometry. 
CD4+25- cells with or without various ratios of CD4+25+ cells, such as 1:0, 1:1/8, 1:1/4, 1:1/2 
and 1:1, were applied to a mixed lymphocyte reaction (MLR). Allogenic irradiated peripheral 
blood mononuclear cells were used as a stimulator. Graphs express suppressive properties of 
added CD4+25+ fractions. The degree to which the added CD4+25+ fraction reduced Cd4+25- 
DNA synthesis was measured by the 3H-thymidine incorporation assay. [B] and [C] Peripheral 
blood CD4+25- and CD4+25+ cell fractions derived from HVs and SILs were sorted by flow 
cytometry, extracted total RNAs from individual fractions, and synthesized cDNA. Real-time 
RT-PCR analyses were employed to compare the gene expression of FoxP3 and CTLA-4, 
respectively. [D] Peripheral blood CD4+25+ and CD4+FoxP2+ populations were compared 
between HVs and SILs. [E] and [F] Peripheral blood CD4+FoxP3+ cells derived from HVs and 
SILs were compared in regard to CD95/Fas expression by means of fluorescent intensity and 
positive cell percentage, respectively. 
CD95/Fas and FoxP3, and CD95/Fas expression (MFI) and positive cell frequency were 
analyzed in the CD4+FoxP3+ cell fraction. As shown in Fig. 3-E (MFI) and 3-F (positive cell 
frequency), Treg from SILs showed significantly higher expression levels of CD95/Fas than 
those from HVs. In addition, CD4+25+ cells from SILs were significantly more sensitive 
against Fas-mediated apoptosis inducing monoclonal antibody (CH-11) than those from 
HVs (data not shown), and proceeded faster to apoptosis as previously reported (Hayashi, 
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2010). All of these findings indicate that Treg may lose its true Treg ability due to chronic 
activation of Treg by recurrent exposure to silica mediated by excess expression of 
Fas/CD95 on the Treg cell surface. 
5. Silica-induced dysfunction of the Treg fraction in SILs 
Our results and those of our previous findings suggest that silica can reconstitute the 
peripheral CD4+CD25+ fraction to facilitate a decline in the number and function of Treg by 
the activation of both Tresp and Treg cells (Hayashi, 2010; Maeda, 2010), as outlined in Fig. 4. 
 
 
Fig. 4. Schematic representation of the immunological effects of silica exposure on alteration 
of autoimmunity. Silica chronically activates CD4+FoxP3 T cells (Treg), resulting in the 
induction of higher Fas expression. This up-regulated Fas marks Treg for Fas-mediated 
apoptosis. However, silica induces the change of CD4+FoxP3- T cells (Tresp) to 
CD4+25+FoxP3- activated Tresp. This population contaminates the peripheral CD4+25+ 
fraction in which Treg should be located. This imbalance between a decreased Treg and 
increased activated Tresp results in a dysfunction of the so-called CD4+25+ Treg fraction, 
which may trigger the occurrence of autoimmune diseases such as SSc. However, the roles 
and alterations of Th17 in silica-exposed patients are unknown and should be clarified 
through further research in order to obtain a better understanding of the immunological 
effects of silica on the human immune system. 
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Many issues remain to be resolved, such as delineating the complications of SSc in SILs 
(Barnadas, 1986; Cowie, 1987 Haustein, 1990; Haustein & Anderegg, 1998; Sluis-Cremer, 
1985), or those complications associated with malignant tumors such as mesothelioma and 
lung cancer in patients exposed to the mineral silicate asbestos (Greillier, 2008; Toyokuni, 
2009; Miura, 2008). Regarding the relationship between tumor immunity and Treg function, 
it may be that Treg enhances cell numbers or function to reduce tumor immunity 
(Chattopadhyay, 2005; Danese & Rutella, 2007; Kretschmer, 2006). If this is the case, future 
investigations will need to determine whether silica and asbestos possess opposite effects on 
Treg. Furthermore, specific parameters will need to be examined such as the degree of silica 
exposure, the progression of respiratory diseases (Otsuki, 1999), and identification of a 
possible individual factor such as the HLA type (A. Ueki, 2001b) that leads to the 
development of autoimmune complications in SILs. 
In addition, the recent discovery of T helper type 17 cells (Th17) has contributed to the 
recognition of the occurrence of autoimmunity (Afzali, 2007; Awasthi & Kuchroo, 2009; 
Harrington, 2006; Jin, 2008; Louten, 2009; Stockinger, 2007). Research on the biology of Th17 
cells suggests a critical role for Th17 in the development of inflammatory and autoimmune 
diseases. Furthermore, Th17 has been shown to interact with Treg cells (Afzali, 2007; 
Awasthi & Kuchroo, 2009; Harrington, 2006; Jin, 2008; Louten, 2009; Stockinger, 2007). TGF-
β not only regulates the generation of Foxp3+ Treg cells, but together with IL-6 initiates 
Th17 differentiation. A reciprocal relationship between Th17 and Treg development has 
been proposed, since the generation of Foxp3+ Treg cells and Th17 cells both require TGF-β 
signaling. If the frequencies of Th17 and Treg were regulated by each other, silica-induced 
early loss of Treg may have an inverse effect by increasing the Th17 population, and 
represents another way to induce dysregulation of autoimmunity in SILs. Although we have 
just begun to investigate the status of Th17 in SILs, this is another important and critical 
issue to be resolved for a better understanding of environmental disturbance of 
autoimmunity such as that involving silica-induced autoimmune diseases (Shanklin & 
Smalley, 1998; Steenland & Goldsmith, 1995; Uber & McReynolds, 1982). 
In the future, a comprehensive understanding of the immunological effects of silica may 
lead to the discovery of preventive and therapeutic molecular targets for autoimmune 
diseases, and will help to clarify the pathophysiological mechanisms involved in the 
development of dysregulation of autoimmunity. 
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A functional immune system is able to distinguish between foreign antigens expressed by 
pathogens and self-antigens expressed by the body. The absence of a pathological response 
to self-antigens (e.g. tolerance) is dependent on a number of events that occur both centrally 
and peripherally. Central tolerance is induced at sites of lymphocyte development such as 
thymus and bone marrow for T cell and B cell respectively. On the other hand, peripheral 
tolerance occurs at sites of antigen recognition and processing, and includes secondary 
lymphoid as well as non-lymphoid tissues. Failure of central and/or peripheral tolerance 
can lead to increased development and expansion of pathogenic effector T cells and 
subsequent initiation and progression of autoimmunity. 
Type 1 Diabetes (T1D) is an autoimmune disease due to a chronic inflammation in the 
pancreas that leads to the destruction of insulin-producing -cells. The -cells are selectively 
destroyed via both direct and indirect mechanisms by different immune cell types. Studies 
in animal models and humans have demonstrated that T cells play a major role in -cell 
death. However, other cell types are present in the pancreatic infiltrate and in the pancreatic 
lymph node, where the initial presentation of islet antigen by dendritic cells (DC) to islet 
antigen specific T cells occurs. Besides different DC subsets, B cells and natural killer (NK) 
cells also contribute, with different roles, to -cell destruction. This suggests a strong 
crosstalk between the immune cells that are involved in pathogenesis and those involved in 
immune regulation.  
Herein, we will describe the autoimmune processes that result in clinical manifestation of 
this disease and we will discuss the immunologic basis supporting possible new therapeutic 
interventions.  
2. The breakdown of self-tolerance in Type 1 Diabetes  
T1D is the most common autoimmune disorder in childhood but the disease may become 
manifest at any age, even in adults. In the past decade, the incidence of T1D has increased 
considerably among children under the age of 15 years in most developed countries and, if 
the present trend continues, the current incidence is predicted to double in European 
children younger than 5 years, by 2020 (Patterson et al., 2009).  
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Despite a plethora of data in rodent models of the disease, the etiology and pathogenesis of 
T1D in humans is largely unknown. The onset of the disease and clinical/diagnostic signs 
are preceded by a long non-clinical phase during which an aggressive autoimmune reaction 
is proposed to be taking place. Clinical T1D is the result of end-stage insulitis, and it has 
been estimated that at the time of diagnosis only 10–20% of the β-cells are still functioning. 
Studies in the non-obese diabetic (NOD) mouse, a mouse model that spontaneously 
develops autoimmune diabetes, have highlighted the critical role of adaptive immune 
responses in the pathogenesis of the disease. Initial -cell death occurs physiologically in 
NOD mice, at 2-3 weeks of age, during tissue remodeling and -cell metabolic changes or it 
could occur by injury mediated, for example, by viral infections (Turley et al., 2003). Such -
cell death leads to activation of DC, priming and expansion of specific -cell-autoreactive T 
cells, initially in the pancreatic draining lymph nodes and subsequently in the pancreas 
itself. Ultimately, this chronic process ends with enough -cell mass destruction to need 
insulin therapy. 
It is now well established that a specific genetic constitution is required to develop diabetes. 
The most important genes contributing to disease susceptibility in humans are located in the 
HLA class II locus on chromosome 6. Additionally ten other genes or genetic regions have 
been associated with T1D (Morel et al., 1988; Todd et al., 2007). Nevertheless a relatively 
small proportion, less than 10%, of individuals with HLA-conferred diabetes susceptibility 
progress to clinical disease. This implies that additional factors, very likely environmental, 
are needed to trigger and drive β-cell destruction in genetically predisposed individuals.  
Several models illustrate hypotheses on the outcome of the interplay between genetic and 
environmental factors. The linear -cell decline hypothesis originally postulated by Eisenbarth 
remains the most widely referenced benchmark model for T1D (Eisenbarth, 1986). According 
to this model, genetically susceptible individuals at some point in time encounter certain 
environmental agents that trigger islet autoimmunity leading to a linear decay in -cell mass, 
development of autoantibodies, hyperglycemia, and eventually complete loss of C-peptide. 
While this view provides an explanation for the sequence of events observed during the course 
of T1D, it does not integrate factors contributing to the variability along the time axis during 
the prediabetic phase. Some authors argue that disease progression in T1D is not a linear 
process, but rather proceeds at variable steps in patients (Chatenoud & Bluestone, 2007). As 
mentioned before, there is an effect of specific genetic polymorphisms on disease susceptibility 
but, on the other hand, predisposing DNA sequence variations may by themselves never lead 
to T1D, or require some degree of environmental insult (viral infection) to culminate in 
hyperglycemia. Today a more detailed version of the nonlinear model depicting T1D as a 
“relapsing-remitting” disease has been proposed (Bonifacio et al., 1999; von Herrath et al., 
2007; van Belle et al., 2011). Specifically, this model posits that a disequilibrium between 
autoreactive effector T cells and T regulatory cells could develop over time and eventually lead 
to a decline in -cell mass. Whereas the net balance shifts to islet autoimmunity, this effect is 
temporarily counteracted by the -cells’ proliferative response, perhaps resulting in a late 
transient phase of reduced insulin requirement called the “honeymoon phase”. In an attempt 
to fit the role of infectious agents into this temporal T1D model, Von Herrath and colleagues 
introduced the “fertile field” hypothesis (von Herrath et al., 2003). The fertile field is described 
as a time window that follows viral infection. It can vary depending on the type, anatomical 
location, and duration of the virus-induced inflammatory response. This fertile field would 
allow autoreactive T cells to expand and lead to full-blown autoimmunity and clinical T1D 
(Figure 1). 
 





Fig. 1. How T1D might arise. The gure represents the -cell mass or function (represented 
by the orange line) as well as the different immunological phases (columns with 
alphabetized tabs on top) that occur in the pancreas and peripherally. Once the orange line 
of -cell function falls into the red zone, the individual is clinically diagnosed with T1D. 
Initially, a concurrence of genetic susceptibility and an environmental trigger sets an 
individual up for developing diabetes by causing -cell death. In the pancreas, -cell 
upregulate IFN and subsequently MHC class I. This exposes -cell to attack by pathogenic 
antigen specific T cells. Consequently, the released -cell antigens are picked up by resident 
APC and transferred to the pancreas-draining lymph nodes. Meanwhile in the periphery, a 
proinammatory environment favors effector T cell responses over Treg function. -cell 
antigens presented in this proinammatory context and with CD4 help initiate conversion of 
B cells into plasma cells and the appearance of insulin autoantibodies . Also, autoreactive 
CD8 T cells are stimulated to proliferate and migrate into the pancreas. The stress induced 
by this second wave of -cell killing causes some -cell to stop insulin production. The 
killing also causes the release of new -cell antigens that are picked up by APCs, including 
migrated B cells, which get shuttled to the pancreatic lymph node. This engages new 
antigen-specific clones of CD4 and CD8 T cells and B cells in a process called epitope 
spreading. Surprisingly, the autoimmune inammation can also stimulate some -cell 
proliferation so that the -cell mass temporarily increases. The uctuation between 
destructive autoreactive responses and -cell proliferation may create a cyclical relapse-
remitting prole of -cell mass (orange line). Eventually, the autoreactive response wins 
though, and T1D is diagnosed when only 10 –30% of functional -cell remains. The 
remission after clinically diagnosed diabetes is termed the honeymoon phase, a temporary 
state of relative self-sufcient insulin production.  
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3. Humoral -cell autoimmunity 
Human and murine T1D studies have shown that the appearance of autoantibodies is the 
first detectable pre-clinical sign of emerging β-cell autoimmunity. There are four disease-
related autoantibodies that have been shown to predict clinical T1D (Knip et al., 2002). These 
include classical islet cell antibodies (ICA), insulin autoantibodies (IAA), and autoantibodies 
to the 65 kD isoform of glutamic acid decarboxylase (GADA) and the protein tyrosine 
phosphatase-related IA-2 molecule (IA–2A). Insulin is the first antigenic target detectable 
during the early progression of diabetes (Nakayama et al., 2005), although most 
autoantibodies are targeted against the β-cells themselves and other β-cell secreted proteins 
(Atkinson & Eisenbarth, 2001). Recently, ZnT8, a pancreatic β-cell specific zinc transporter, 
has been identified as a candidate autoantigen associated with T1D (Wenzlau et al., 2007). 
During the progression of T1D, a process of autoantigen epitope spreading occurs. Epitope 
spreading provides an explanation of how the immune system is capable of recognizing 
increasing numbers of autoantigens in correlation with increased T1D disease severity (von 
Herrath et al., 2007). Epitope spreading begins with the immune system recognizing and 
mounting an immune response against a single antigen, which is recognized via a single 
epitope. Over time, new antigens can be recognized, and previously recognized antigens can 
be differentially processed by antigen presenting cells to generate multiple epitopes for a 
single antigen (Morran et al., 2010). 
The number and titer of detectable autoantibodies, rather than the specificity of the 
autoantibody, is unequivocally related to the risk of progression to overt T1D both in family 
studies and also in surveys based on general population cohorts. In family studies positivity 
for three to four autoantibodies is associated with a risk of developing clinical T1D in the 
range of 60–100% over the next 5–10 years (Barinas-Mitchell et al., 2004; Pietropaolo et al., 
2005; Barker, 2006).  
Islet specific autoantibodies are, however, considered more diagnostic than causative in 
T1D. It is generally accepted that the destruction of the β-cells is mediated by cellular 
immune responses. This is supported by the following facts: (a) T cells are present in 
insulitis; (b) disease progression is delayed by immunosuppressive drugs directed 
specifically against T cells; and (c) circulating autoreactive T cells can be detected in patients 
at clinical presentation of T1D (Roep, 2003). 
4. Immune cell crosstalk in Type 1 Diabetes 
4.1 T and B lymphocytes  
Studies in NOD mice have shown that autoreactive T cells are released into the circulation 
because of faulty presentation of self-antigens by disease-susceptible MHC molecules that 
prevent negative selection in the thymus (Trucco, 1992; McDevitt, 2001). Central tolerance 
can be broken even in the presence of disease-resistant MHC molecules. Indeed, it has been 
demonstrated that disruption of thymic expression of a single tissue-specific gene self-
molecule, as insulin for diabetes, is sufficient to trigger autoimmunity toward the specific 
tissue  (Figure 2) (Fan et al., 2009). 
In pre-diabetic mice, insulin specific T cells are the predominant component of islet-
infiltrating T cells. Multiple CD4+ and CD8+ T cell clones, targeting different insulin 
epitopes, have been isolated (Wegmann et al., 1994) demonstrating that T1D development 
depends on both CD4+ and CD8+ T cells. Moreover, T1D can only be transferred to 
 
 




                                     A)                                                                        B) 
Fig. 2. Transgenic mice that do not express insulin in the thymus (ID-TEC) develop diabetes 
within 3 weeks. A) Normal islet development of transgenic mice at day 1 after birth; B) 4 
week after birth only a small number of -cells are still present in the islets. Pancreatic 
section stained using anti-insulin (green), and glucagon (red) antibodies (Fan et al., 2009). 
immunocompromised syngeneic recipients by a combination of splenic CD4+ and CD8+ T 
cells from donor NOD mice but not by either T cell subset alone (Phillips et al., 2009). 
There are several ways in which autoreactive T cells can mediate β-cell death. CD8+ T cells 
may kill pancreatic β-cells through MHC class I mediated cytotoxicity, and both CD4+ and 
CD8+ T cells produce cytokines, such as interferon-γ (IFNγ), that induce expression of the 
death receptor Fas (CD95) and chemokine production by β-cells. Activation of Fas by Fas 
ligand (FasL)-expressing activated T cells can initiate β-cell apoptosis. Chemokine 
production by β-cells results in further recruitment of mononuclear cells to the site, thereby 
enhancing inflammation (Eizirik et al., 2009). In addition, IFNγ can activate macrophages 
and induce increased pro-inflammatory cytokine production, including interleukin-1β (IL-
1β) and tumour necrosis factor (TNF). β-cells express high levels of IL-1 receptor and seem 
to be more sensitive to IL-1β-induced apoptosis than other endocrine cells in the islet. This 
crosstalk between T cells and macrophages undoubtedly exacerbates the immune-mediated 
stress on β-cells and contributes to their destruction. IFNγ, IL-1β and TNF also induce the 
expression of reactive oxygen species (ROS) including nitric oxide by β-cells, and ROS have 
the potential to mediate apoptosis. 
Although T cells have a pathological role in T1D onset, there is also evidence supporting a 
role for a subset of T cells, the T regulatory cells (Tregs), able to prevent -cell death.  
Tregs play an indispensable role in maintaining homeostatic balance within the immune 
system. Tregs are involved in mediating normal immune responses against pathogens and 
terminating such responses when they are no longer required, as well as in preventing 
autoimmunity. Phenotypically, most Tregs express the surface marker CD25, the high 
affinity interleukin 2 (IL-2) receptor ligand-binding  chain, and Foxp3, an intracellular 
transcription factor (Fontenot et al., 2003). Because of that they are identified as 
CD4+CD25+Foxp3+ cells. Both CD25 and Foxp3 coordinate Treg development and function. 
In the thymus, IL-2 is critical for the development of Tregs, while, in the periphery, it has 
been shown that interleukin 7 (IL-7) can complement potentially limiting amounts of IL-2 in 
promoting Treg survival and functional fitness (Di Caro et al., 2011).  
Many studies in the NOD mouse strain have demonstrated the role of CD4+CD25+Foxp3+ 
Tregs in the maintenance of self-tolerance. Indeed, depletion of CD25-expressing T cells 
results in a marked acceleration of T1D and foxp3-/- NOD mice display an increased 
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3. Humoral -cell autoimmunity 
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incidence and earlier onset of the disease compared to wild type mice (Brunkow et al., 2001). 
In humans, patients with IPEX syndrome, who have a mutation in the FOXP3 gene, develop 
endocrine autoimmune disease including T1D (Bennett et al., 2001). Tregs can control or 
limit the activation of CD4+ and CD8+ T cells at various stages such as differentiation and/or 
proliferation during priming in the draining lymph node, inhibition of IL-2 production or 
trafficking to the pancreas.  
T cells are clearly of pivotal importance for T1D development, but there are also data 
suggesting an involvement of B-lymphocytes in initiation and progression of the disease. 
Recently, it was demonstrated that B cell depletion in NOD mice, either through gene 
targeting or antibody treatment, impaired the development of T1D (Hu et al., 2007) . 
The investigation of the roles of B cells in autoimmune inflammatory diseases has focused 
mainly on the ability of B cells to secrete autoantibodies. More recently, B cells have been 
identified as important sources of pro- and anti-inflammatory cytokines, for example IL-6 
and IL-10. B cells can either provide a quantitatively or functionally dominant source of 
cytokines. Moreover, they can have a role as antigen-presenting cells that maintain islet 
antigen-specific T cell activity  (Hu et al., 2007; Pescovitz et al., 2009).  
4.2 Innate immune cells 
As islet antigen-specific T cells can differentiate into either pathogenic effector T cells or 
regulatory T cells, many studies have investigated the role of innate immune cells in T1D, as 
these cells usually determine a specific type of immune response. Innate cells producing 
pro- or anti-inflammatory cytokines define the milieu in which islet antigen specific T cells 
are activated and whether a deleterious or protective immune response occurs in the 
pancreas (Figure 3). 
Macrophages are one of the two major antigen-presenting cells in islet infiltrates of NOD 
mice. It has been shown that inhibition of the macrophage influx into the pancreas, by 
blocking adhesion-promoting receptors on those cells, inhibited the development of T1D 
(Hutchings et al., 1990). In vitro and in vivo studies in mice and rats showed that the 
deleterious effect of macrophages on β-cells can be mediated through the production of TNF 
and IL-1β (Arnush et al., 1998; Dahlen et al., 1998). Interestingly, pro-inflammatory 
macrophages can be detected in pancreatic islets before T cell infiltration, as well as in 
NOD/scid (severe combined immunodeficient) mice, which lack functional B and T cells. 
Macrophages have been shown to produce IL-12 (Alleva et al., 2000) and to promote 
efficient differentiation of diabetogenic CD8+ cytotoxic T lymphocytes (CTLs) leading to 
T1D onset (Jun et al., 1999). More recent data suggest that recruitment of macrophages to 
islets is mediated by the secretion of CC-chemokine ligand 1 (CCL1) and CCL2 by CD4+ T 
cells and pancreatic β-cells, respectively (Cantor & Haskins, 2007; Martin et al., 2008). 
Macrophages recruited to the pancreas produce IL-1β, TNF and ROS that can cause β-cell 
death, revealing an additional role for macrophages in the destructive phase of T1D. Finally, 
TNF and IL-1β-producing macrophages have been observed in pancreatic islet infiltrates 
from patients with recent-onset T1D (Ueno et al., 2007). Together, these studies support a 
pathogenic role for macrophages in both the initiation and destruction phases of T1D at least 
in the mouse. 
NK cells mediate early protection against viruses and are involved in the killing of infected 
cells and tumours. NK cells are both cytotoxic and producers of cytokines, particularly 
IFNγ. Thus, NK cells could contribute directly and indirectly to the destruction of β-cells.  
 
 





Fig. 3. Cellular and molecular mechanisms in the development or prevention of T1D. The 
initiation phase of T1D takes place in the pancreas, where DCs capture and process β-cell 
antigens. β-cell damage can occur by ‘natural’ apoptosis or after viral infections. Activated 
DCs prime pathogenic islet antigen-specific T cells after migration to the draining lymph 
nodes and macrophages promote this activation through IL-12 secretion. The activation of 
islet antigen-specific T cells can be inhibited by DCs through various mechanisms, such as 
expansion of Tregs through production of  IDO, IL-10 and TGFβ. In the pancreas, β-cells can 
be killed by diabetogenic T cells and NK cells through the release of interferon-γ (IFNγ), 
granzymes and perforin, as well as by macrophages through the production of TNF, IL-1β 
and nitric oxide (NO). β-cell damage can be inhibited by Treg cells that inhibit diabetogenic 
T cells and innate immune cells through IL-10 and TGF-β. Tolerogenic DCs stimulated by 
NK cells could also control diabetogenic T cells through IDO production. Lastly, β-cells can 
inhibit diabetogenic T cells by expressing PDL1. This complex crosstalk between innate and 
adaptive immune cells results in the development or the prevention of T1D. (Figure adapted 
from Lehuen et al., 2010). 
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NK cells have been detected in the pancreas of patients with T1D and in T1D mouse models 
(Dotta et al., 2007; Alba et al., 2008; Brauner et al., 2010). Moreover, several reports have 
described a correlation between the frequency and/or activation of NK cells with the 
destructiveness of the pancreatic infiltrate (Poirot et al., 2004; Feuerer et al., 2009). NK cells 
isolated from the pancreas of diabetic mice have a more activated phenotype, proliferate 
more and spontaneously produce higher levels of IFNγ, which promote the effector function 
of diabetogenic CD4+ T cell, and express CD107a on their cell surface, a marker of granule 
exocytosis, reflecting their cytotoxic function (Gur et al., 2010). Interestingly, NK cells were 
observed in the pancreas in NOD mice before T cell infiltration and in the pancreas of NOD–
Rag mice, which lack mature B and T cells, suggesting that they could have a sentinel role in 
the pancreas. 
Besides macrophages and NK cells, an important role in the pathogenesis of an autoimmune 
response is played by DCs. DCs are a heterogeneous population of antigen presenting cell 
that check tissue homeostasis, initiate T cell mediated immunity and control the 
maintenance of the immune tolerant state. It is known that patients with a congenital DC 
deficiency develop autoimmune diseases (Ohnmacht et al., 2009). This highlights their role 
in mediating peripheral tolerance. DCs, depending on their subset and function, can activate 
Tregs. It has been shown that they mediate peripheral tolerance by inducing T cell depletion 
or anergy and expansion of antigen specific Tregs (Ueno et al., 2007).  
Studies aimed at elucidating the role of DCs in T1D have outlined beneficial as well as 
detrimental roles of this cell type in the autoimmune process. In the NOD/BDC2.5 
transgenic mouse model, it was demonstrated that DCs prevent the inflammation process in 
the pancreas by producing indole 2,3-dioxygenase (IDO), a tryptophan catabolizing enzyme 
that arrests T cell proliferation (Saxena et al., 2007). However, in the same model, it was 
shown that IFN type 1 is more intimately involved in the initiation of the destructive 
autoimmunity and is correlated with the increased DC expression in the pancreatic lymph 
nodes (Li et al., 2008). Alternatively, these two opposite findings might point to a dual role 
of DC in the autoimmune process most probably depending on the stage of DC maturation 
and capacity to activate specific immunomodulatory cell types. 
5. Immunotherapy to induce immunotolerance 
Individuals with T1D develop hyperglycemia due to insufficient insulin production by -cells 
in the pancreas. To prevent the rise of blood glucose to pathological levels, T1D patients have 
to receive a life long treatment with recombinant insulin. Despite insulin supplementation, 
rapid excursion of glucose levels, in these patients, increases the risk for severe complications 
such as cardiovascular diseases, nephropathy and neuropathy. Insulin replacement therapy 
cannot match the precision of endogenous insulin secretion, for this reason new treatments 
that, ideally, can cure the disease or at least delay/prevent the onset are needed.  
The new emerging therapies for T1D, aimed at regulating the autoimmune response largely 
involve broad based immunoregulatory strategies, including the inhibition or deletion of 
lymphocytes subsets and/or the use of agents that induce or re-establish immune tolerance 
via activation of regulatory cells (Chatenoud, 2003; Luo et al., 2010).  
5.1 Immunosuppressive drugs 
Several randomized clinical trials (RCT), based on preclinical study in animal models, have 
been performed to test the effect of different immunosuppressive drugs on diabetes 
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patients. Cyclosporin A (CSA) was employed in the first trials showing effects of 
immunosuppressive therapies on T1D. Continuous CSA treatment initiated soon after 
diagnosis eliminated the need for exogenous insulin (Bougneres et al., 1990; Carel et al., 
1996). However, the lack of lasting effects and renal toxicity of the drug diminished 
enthusiasm for this approach. Indeed, in considering immunosuppressive therapies we have 
to remember that these drugs increase the risk of developing infections and malignancies 
and that some of them have been shown to inhibit -cell regeneration (Nir et al., 2007). 
Within the multitude of immunosuppressive drugs, we are now focusing our overview on 
those drugs that are of particular interest because of their low levels of side effects and/or 
because they are able to induce Tregs or tolerogenic DCs. 
5.1.1 Anti T-lymphocyte Globulin (ATG) 
ATG is a very potent immunosuppressive drug. It depletes almost the entire T cell 
population in treated patients and is primarily used as inductive treatment after solid organ 
transplantation or in acute rejection settings in transplant patients. Since ATG is a polyclonal 
non-human protein mixture, common side effects include fever and serum sickness 
including arthralgia, rashes and lymphadenopathy. Administration over a longer period 
increases the risk for immunoproliferative disorders, which is why only short-term 
treatments are considered. A pilot trial involving new-onset T1D patients has shown a 
reduction of insulin requirement (Eisenbarth et al., 1985). In a more recent study, ATG 
(Fresenius) retarded the loss of C-peptide in new-onset patients without the need for 
continuous drug administration (Saudek et al., 2004) but additional studies are being 
performed to confirm these findings. 
5.1.2 Anti-CD3 
One of the most potent treatments at reversing new-onset diabetes in NOD mice is therapy 
with anti-CD3 mAb (Chatenoud et al., 1994). Chatenoud et al. showed that an intravenous 
treatment with anti-CD3 mAb resulted in a long-lasting restoration of normoglycemia in 
80% of treated NOD mice. The treatment was given for only 5 days indicating that 
continuous administration might not be required to reach a beneficial effect through 
restoration of the immune balance in favor of endogens tolerance. These studies also 
showed that treatment was only effective if it was given shortly after the onset of 
hyperglycemia (Chatenoud, 2003). These results in NOD mice have led to trials in humans 
using humanized Fc-engineered monoclonal anti-CD3 antibodies. So far, two antibodies 
have been tested in diabetic patients, hOKT3 g1 Ala-Ala (Teplizumab) (Herold et al., 2005) 
and ChAglyCD3 (Otelixizumab) (Keymeulen et al., 2005), and both have shown positive 
results in patients with T1D in terms of C-peptide preservation and reduction of insulin 
requirements (Herold et al., 2002). Additionally, sustained C-peptide levels for 
approximately 2 years and in some cases up to 5 years were observed (Herold et al., 2005, 
Keymeulen et al., 2005). The side effects of anti-CD3 treatment were predominantly 
headaches, fever and arthralgia. Moreover gastrointestinal symptoms and most importantly 
transient EBV-viremia with symptoms of acute mononucleosis were observed. All patients 
however recovered spontaneously. The mechanism of action of this treatment has been 
extensively investigated. It can be demonstrated that anti-CD3 treatment modulates the T 
cell receptors in a way that renders T cells blind to antigens, induces T cell anergy, blocks 
the IL-2 signaling pathway, and induces apoptosis (Chatenoud  & Blustone, 2007). 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
184 
NK cells have been detected in the pancreas of patients with T1D and in T1D mouse models 
(Dotta et al., 2007; Alba et al., 2008; Brauner et al., 2010). Moreover, several reports have 
described a correlation between the frequency and/or activation of NK cells with the 
destructiveness of the pancreatic infiltrate (Poirot et al., 2004; Feuerer et al., 2009). NK cells 
isolated from the pancreas of diabetic mice have a more activated phenotype, proliferate 
more and spontaneously produce higher levels of IFNγ, which promote the effector function 
of diabetogenic CD4+ T cell, and express CD107a on their cell surface, a marker of granule 
exocytosis, reflecting their cytotoxic function (Gur et al., 2010). Interestingly, NK cells were 
observed in the pancreas in NOD mice before T cell infiltration and in the pancreas of NOD–
Rag mice, which lack mature B and T cells, suggesting that they could have a sentinel role in 
the pancreas. 
Besides macrophages and NK cells, an important role in the pathogenesis of an autoimmune 
response is played by DCs. DCs are a heterogeneous population of antigen presenting cell 
that check tissue homeostasis, initiate T cell mediated immunity and control the 
maintenance of the immune tolerant state. It is known that patients with a congenital DC 
deficiency develop autoimmune diseases (Ohnmacht et al., 2009). This highlights their role 
in mediating peripheral tolerance. DCs, depending on their subset and function, can activate 
Tregs. It has been shown that they mediate peripheral tolerance by inducing T cell depletion 
or anergy and expansion of antigen specific Tregs (Ueno et al., 2007).  
Studies aimed at elucidating the role of DCs in T1D have outlined beneficial as well as 
detrimental roles of this cell type in the autoimmune process. In the NOD/BDC2.5 
transgenic mouse model, it was demonstrated that DCs prevent the inflammation process in 
the pancreas by producing indole 2,3-dioxygenase (IDO), a tryptophan catabolizing enzyme 
that arrests T cell proliferation (Saxena et al., 2007). However, in the same model, it was 
shown that IFN type 1 is more intimately involved in the initiation of the destructive 
autoimmunity and is correlated with the increased DC expression in the pancreatic lymph 
nodes (Li et al., 2008). Alternatively, these two opposite findings might point to a dual role 
of DC in the autoimmune process most probably depending on the stage of DC maturation 
and capacity to activate specific immunomodulatory cell types. 
5. Immunotherapy to induce immunotolerance 
Individuals with T1D develop hyperglycemia due to insufficient insulin production by -cells 
in the pancreas. To prevent the rise of blood glucose to pathological levels, T1D patients have 
to receive a life long treatment with recombinant insulin. Despite insulin supplementation, 
rapid excursion of glucose levels, in these patients, increases the risk for severe complications 
such as cardiovascular diseases, nephropathy and neuropathy. Insulin replacement therapy 
cannot match the precision of endogenous insulin secretion, for this reason new treatments 
that, ideally, can cure the disease or at least delay/prevent the onset are needed.  
The new emerging therapies for T1D, aimed at regulating the autoimmune response largely 
involve broad based immunoregulatory strategies, including the inhibition or deletion of 
lymphocytes subsets and/or the use of agents that induce or re-establish immune tolerance 
via activation of regulatory cells (Chatenoud, 2003; Luo et al., 2010).  
5.1 Immunosuppressive drugs 
Several randomized clinical trials (RCT), based on preclinical study in animal models, have 
been performed to test the effect of different immunosuppressive drugs on diabetes 
 
Tolerance and Autoimmunity in Type 1 Diabetes 
 
185 
patients. Cyclosporin A (CSA) was employed in the first trials showing effects of 
immunosuppressive therapies on T1D. Continuous CSA treatment initiated soon after 
diagnosis eliminated the need for exogenous insulin (Bougneres et al., 1990; Carel et al., 
1996). However, the lack of lasting effects and renal toxicity of the drug diminished 
enthusiasm for this approach. Indeed, in considering immunosuppressive therapies we have 
to remember that these drugs increase the risk of developing infections and malignancies 
and that some of them have been shown to inhibit -cell regeneration (Nir et al., 2007). 
Within the multitude of immunosuppressive drugs, we are now focusing our overview on 
those drugs that are of particular interest because of their low levels of side effects and/or 
because they are able to induce Tregs or tolerogenic DCs. 
5.1.1 Anti T-lymphocyte Globulin (ATG) 
ATG is a very potent immunosuppressive drug. It depletes almost the entire T cell 
population in treated patients and is primarily used as inductive treatment after solid organ 
transplantation or in acute rejection settings in transplant patients. Since ATG is a polyclonal 
non-human protein mixture, common side effects include fever and serum sickness 
including arthralgia, rashes and lymphadenopathy. Administration over a longer period 
increases the risk for immunoproliferative disorders, which is why only short-term 
treatments are considered. A pilot trial involving new-onset T1D patients has shown a 
reduction of insulin requirement (Eisenbarth et al., 1985). In a more recent study, ATG 
(Fresenius) retarded the loss of C-peptide in new-onset patients without the need for 
continuous drug administration (Saudek et al., 2004) but additional studies are being 
performed to confirm these findings. 
5.1.2 Anti-CD3 
One of the most potent treatments at reversing new-onset diabetes in NOD mice is therapy 
with anti-CD3 mAb (Chatenoud et al., 1994). Chatenoud et al. showed that an intravenous 
treatment with anti-CD3 mAb resulted in a long-lasting restoration of normoglycemia in 
80% of treated NOD mice. The treatment was given for only 5 days indicating that 
continuous administration might not be required to reach a beneficial effect through 
restoration of the immune balance in favor of endogens tolerance. These studies also 
showed that treatment was only effective if it was given shortly after the onset of 
hyperglycemia (Chatenoud, 2003). These results in NOD mice have led to trials in humans 
using humanized Fc-engineered monoclonal anti-CD3 antibodies. So far, two antibodies 
have been tested in diabetic patients, hOKT3 g1 Ala-Ala (Teplizumab) (Herold et al., 2005) 
and ChAglyCD3 (Otelixizumab) (Keymeulen et al., 2005), and both have shown positive 
results in patients with T1D in terms of C-peptide preservation and reduction of insulin 
requirements (Herold et al., 2002). Additionally, sustained C-peptide levels for 
approximately 2 years and in some cases up to 5 years were observed (Herold et al., 2005, 
Keymeulen et al., 2005). The side effects of anti-CD3 treatment were predominantly 
headaches, fever and arthralgia. Moreover gastrointestinal symptoms and most importantly 
transient EBV-viremia with symptoms of acute mononucleosis were observed. All patients 
however recovered spontaneously. The mechanism of action of this treatment has been 
extensively investigated. It can be demonstrated that anti-CD3 treatment modulates the T 
cell receptors in a way that renders T cells blind to antigens, induces T cell anergy, blocks 
the IL-2 signaling pathway, and induces apoptosis (Chatenoud  & Blustone, 2007). 
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Interestingly, it has also been shown that Tregs are less susceptible to anti-CD3 induced 
apoptosis; at least when administered in low doses, thus leading to higher numbers of T 
regulatory cells under the generalized CD3+ T cell lymphopenia. Taken together, these data 
have made anti-CD3 antibody a possible candidate for future combination therapies. 
However, the anti CD3 based phase III clinical trial by Lilly didn’t meet the target of the trial 




B cells are implicated in the pathogenesis of diabetes. Hu et al., (2007) and Xiu et al., (2008) 
have shown that diabetes can be prevented in NOD mice by depleting B cells with anti-
CD20 mAb before and at the time of onset of hyperglycemia (9–12-week-old mice) and can 
even reverse disease in about 30% of animals treated at the first appearance of 
hyperglycemia. Interestingly, cotransfer of B cells from the successfully treated mice 
diminished the rate of adoptive transfer of disease via T cells, suggesting a possible role for 
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activation of ‘‘regulatory’’ B cells. Others have shown that IL-10-producing B cells can be 
induced in mice depleted of CD20+ B cells (Yanaba et al., 2008). 
In a recent phase II clinical trial, depletion of B cells using an anti-CD20 mAb (Rituximab), 
has shown modest (23%) but significant improvement in -cell function 3 months after 
diagnosis and overall at 1 year, in antibody-treated compared to placebo-treated subjects 
(Pescovitz et al., 2009). There were also significant improvements in clinical parameters 
including glycated hemoglobin A1c, C-peptide level and insulin use. Side effects that appear 
frequently are mostly related to the administration itself and decrease over the course of the 
therapy. However the patients eventually returned to hyperglycemia as B cells reappeared 
to a great extent (69%) by the end of the year and the C-peptide level started to decline.  
This study could ultimately prove that there is a role for B cells in disease pathogenesis, 
which is scientifically of great interest. However, B cell depletion in this setting does not 
appear to mediate a significant deceleration of disease progression. 
5.2 Anti-inflammatory treatments 
5.2.1 Cytokine and cytokine receptor-directed therapies 
Cytokine and cytokine receptor-directed therapies are also in development for treatment of 
T1D. Human insulitis shows a considerably greater infiltration of innate immune cells such 
as macrophages and NK compared to NOD insulitis (Itoh et al., 1993; Dotta et al., 2007). 
Moreover, innate mediators (TNF-, IL-1, and type 1 interferons) were among the first 
molecules shown to have direct cytotoxic effects on -cells and were postulated to be the 
direct cause of -cell killing (Rabinovitch et al., 1990). Possibly because of its innate role in 
activating adaptive immune responses, it was not surprising that IL-1 receptor-deficient 
NOD mice had reduced development of diabetes (Thomas et al., 2004). Treatment with the 
IL-1 receptor antagonist (Anakinra) was shown to improve glucose control in patients with 
T2D (Donath & Mandrup-Poulsen, 2008). Interestingly, the drug mechanism appeared to 
involve a beneficial effect on -cells, reflected by an increase in the insulin:proinsulin ratio. 
-cells may be a source of IL-1, particularly in response to glucose, suggesting a destructive 
cycle in which hyperglycemia induces expression of the inflammatory mediator resulting in 
immune activation and further -cell destruction. Initial preclinical data do not suggest that 
IL-1 blockade alone will prevent or reverse T1D, but this could be an important target of a 
combination strategy. 
TNF- is considered to play an active role in the pathogenesis of T1D. TNF- is directly 
cytotoxic to -cells, suggesting this cytokine as an additional possible target for immune 
therapy. In a small pilot trial in children and adolescents early after diagnosis (< 30 days on 
average), the use of a TNF antagonist (Etanercept) resulted in preservation of residual 
insulin secretion compared with placebo (Mastrandrea et al., 2009). C-peptide loss was 
reduced, as well as a decrease in insulin needs. However there are contrasting data about 
targeting the TNF- pathways. Indeed, it has been shown, in vitro, that selective CD8+ 
autoreactive Tcell death induction can be activated by TNF-, suggesting the use of a TNF 
agonist instead of a TNF antagonist (Ban et al., 2008). The discrepancy could be due to the 
timing of TNF- blockade/ TNF- administration. 
5.3 Antigen specific strategies 
Establishment of a simple strategy that results in the emergence of antigen-specific 
regulatory T cells and the induction of tolerance to autoantigens is a desirable goal. It would 
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Interestingly, it has also been shown that Tregs are less susceptible to anti-CD3 induced 
apoptosis; at least when administered in low doses, thus leading to higher numbers of T 
regulatory cells under the generalized CD3+ T cell lymphopenia. Taken together, these data 
have made anti-CD3 antibody a possible candidate for future combination therapies. 
However, the anti CD3 based phase III clinical trial by Lilly didn’t meet the target of the trial 
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activation of ‘‘regulatory’’ B cells. Others have shown that IL-10-producing B cells can be 
induced in mice depleted of CD20+ B cells (Yanaba et al., 2008). 
In a recent phase II clinical trial, depletion of B cells using an anti-CD20 mAb (Rituximab), 
has shown modest (23%) but significant improvement in -cell function 3 months after 
diagnosis and overall at 1 year, in antibody-treated compared to placebo-treated subjects 
(Pescovitz et al., 2009). There were also significant improvements in clinical parameters 
including glycated hemoglobin A1c, C-peptide level and insulin use. Side effects that appear 
frequently are mostly related to the administration itself and decrease over the course of the 
therapy. However the patients eventually returned to hyperglycemia as B cells reappeared 
to a great extent (69%) by the end of the year and the C-peptide level started to decline.  
This study could ultimately prove that there is a role for B cells in disease pathogenesis, 
which is scientifically of great interest. However, B cell depletion in this setting does not 
appear to mediate a significant deceleration of disease progression. 
5.2 Anti-inflammatory treatments 
5.2.1 Cytokine and cytokine receptor-directed therapies 
Cytokine and cytokine receptor-directed therapies are also in development for treatment of 
T1D. Human insulitis shows a considerably greater infiltration of innate immune cells such 
as macrophages and NK compared to NOD insulitis (Itoh et al., 1993; Dotta et al., 2007). 
Moreover, innate mediators (TNF-, IL-1, and type 1 interferons) were among the first 
molecules shown to have direct cytotoxic effects on -cells and were postulated to be the 
direct cause of -cell killing (Rabinovitch et al., 1990). Possibly because of its innate role in 
activating adaptive immune responses, it was not surprising that IL-1 receptor-deficient 
NOD mice had reduced development of diabetes (Thomas et al., 2004). Treatment with the 
IL-1 receptor antagonist (Anakinra) was shown to improve glucose control in patients with 
T2D (Donath & Mandrup-Poulsen, 2008). Interestingly, the drug mechanism appeared to 
involve a beneficial effect on -cells, reflected by an increase in the insulin:proinsulin ratio. 
-cells may be a source of IL-1, particularly in response to glucose, suggesting a destructive 
cycle in which hyperglycemia induces expression of the inflammatory mediator resulting in 
immune activation and further -cell destruction. Initial preclinical data do not suggest that 
IL-1 blockade alone will prevent or reverse T1D, but this could be an important target of a 
combination strategy. 
TNF- is considered to play an active role in the pathogenesis of T1D. TNF- is directly 
cytotoxic to -cells, suggesting this cytokine as an additional possible target for immune 
therapy. In a small pilot trial in children and adolescents early after diagnosis (< 30 days on 
average), the use of a TNF antagonist (Etanercept) resulted in preservation of residual 
insulin secretion compared with placebo (Mastrandrea et al., 2009). C-peptide loss was 
reduced, as well as a decrease in insulin needs. However there are contrasting data about 
targeting the TNF- pathways. Indeed, it has been shown, in vitro, that selective CD8+ 
autoreactive Tcell death induction can be activated by TNF-, suggesting the use of a TNF 
agonist instead of a TNF antagonist (Ban et al., 2008). The discrepancy could be due to the 
timing of TNF- blockade/ TNF- administration. 
5.3 Antigen specific strategies 
Establishment of a simple strategy that results in the emergence of antigen-specific 
regulatory T cells and the induction of tolerance to autoantigens is a desirable goal. It would 
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ultimately stop the autoimmune process without inducing some of the major side effects 
that have been observed, for example, in chemical and antibody-based immunosuppressive 
treatments. Moreover, individuals at risk could be treated prior to significant destruction of 
-cell mass and clinical onset of disease. However, the risk of boosting autoreactivity should 
never be underestimated. As outlined earlier, several autoantigens have been described in 
T1D; insulin and GAD65 are believed to be the major autoantigens that drive the 
autoreactivity. Consequently they have been studied most intensively in terms of inducing 
tolerance in humans. 
5.3.1 Insulin 
Several clinical trials target insulin because it is the initiating antigen in the NOD model and 
is also a major autoantigen in human T1D (Nakayama et al., 2005; Fan et al., 2009). There 
have been a number of human new-onset trials using insulin therapy. In the 
immunotherapy diabetes (IMDIAB) trial, a total of 82 patients with clinical T1D were 
randomized to receive oral insulin or placebo (Pozzilli et al., 2000). At a 1-year follow-up, 
there was no difference between the insulin-treated and the placebo-treated groups with 
respect to mean C-peptide secretion, requirement for insulin therapy, or IgG insulin 
antibodies. Furthermore, in patients younger than 15 years, a tendency for low C-peptide at 
9 and 12 months was observed in the oral insulin group, suggesting acceleration in the 
decline of -cell function. These results are consistent with those seen in murine models 
where oral insulin was shown not to reverse new-onset diabetes (Fousteri et al., 2007). 
Interestingly, if nasal insulin therapy is used in combination with anti-CD3 therapy, a 
significant benefit in reversing recent-onset diabetes is then achieved in two animal models 
of autoimmune diabetes (Bresson et al., 2006). Expansion of insulin-specific Treg cells 
producing IL-10, TGF-, and IL-4, and possibly their modulation of antigen-presenting cells 
in local draining lymph nodes, were proposed as likely mechanisms. These findings should 
provide the basis for using combinatorial therapies in future trials for humans with recent-
onset diabetes. 
A recent phase I study using a single intramuscular injection of human insulin B chain in 
incomplete Freund’s adjuvant in 12 subjects with recent-onset diabetes showed that this 
therapy led to the development of lasting (at a 2 year follow-up) insulin B chain-specific 
Tregs (Orban et al., 2009). This study provides the basis for testing this modality of insulin B 
chain therapy in a larger T1D trial to determine the effect on glycemic level. Another 
ongoing phase I–II clinical trial of subcutaneous BHT-3021, a plasmid encoding proinsulin, 
is testing the safety, dose, and preliminary efficacy of this therapeutic modality in recent-
onset T1D patients  
5.3.2 Glutamate decarboxylase 65 
Immune therapies using GAD65 have also been tested in both animal models and human 
T1D. Interestingly, the initial antigenic region is confined to a few epitopes near the C 
terminus of the GAD protein but later spreads intramolecularly to other GAD determinants, 
followed by further intermolecular spreading to other -cell antigens. Consequently, 
tolerance induction by intravenous or intrathymic injections of GAD in female NOD mice at 
3 weeks of age eliminates the anti-GAD T cell responses, as well as subsequent spreading of 
the cascade of T cell responses to other -cell antigens and the development of insulitis or 
clinical diabetes (Tisch et al., 1993). Intravenous injections of GAD during the later stages of 
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disease still effectively blocked disease progression in prediabetic mice and protected 
syngeneic islet graft survival in diabetic NOD mice (Tian et al., 1996). The identification of 
Tregs in GAD-treated mice suggests a major role in the induction of tolerance by treatment 
with this autoantigen, which raises the question of whether GAD is targeted early in T1D 
(Tisch et al., 1998). 
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ultimately stop the autoimmune process without inducing some of the major side effects 
that have been observed, for example, in chemical and antibody-based immunosuppressive 
treatments. Moreover, individuals at risk could be treated prior to significant destruction of 
-cell mass and clinical onset of disease. However, the risk of boosting autoreactivity should 
never be underestimated. As outlined earlier, several autoantigens have been described in 
T1D; insulin and GAD65 are believed to be the major autoantigens that drive the 
autoreactivity. Consequently they have been studied most intensively in terms of inducing 
tolerance in humans. 
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Several clinical trials target insulin because it is the initiating antigen in the NOD model and 
is also a major autoantigen in human T1D (Nakayama et al., 2005; Fan et al., 2009). There 
have been a number of human new-onset trials using insulin therapy. In the 
immunotherapy diabetes (IMDIAB) trial, a total of 82 patients with clinical T1D were 
randomized to receive oral insulin or placebo (Pozzilli et al., 2000). At a 1-year follow-up, 
there was no difference between the insulin-treated and the placebo-treated groups with 
respect to mean C-peptide secretion, requirement for insulin therapy, or IgG insulin 
antibodies. Furthermore, in patients younger than 15 years, a tendency for low C-peptide at 
9 and 12 months was observed in the oral insulin group, suggesting acceleration in the 
decline of -cell function. These results are consistent with those seen in murine models 
where oral insulin was shown not to reverse new-onset diabetes (Fousteri et al., 2007). 
Interestingly, if nasal insulin therapy is used in combination with anti-CD3 therapy, a 
significant benefit in reversing recent-onset diabetes is then achieved in two animal models 
of autoimmune diabetes (Bresson et al., 2006). Expansion of insulin-specific Treg cells 
producing IL-10, TGF-, and IL-4, and possibly their modulation of antigen-presenting cells 
in local draining lymph nodes, were proposed as likely mechanisms. These findings should 
provide the basis for using combinatorial therapies in future trials for humans with recent-
onset diabetes. 
A recent phase I study using a single intramuscular injection of human insulin B chain in 
incomplete Freund’s adjuvant in 12 subjects with recent-onset diabetes showed that this 
therapy led to the development of lasting (at a 2 year follow-up) insulin B chain-specific 
Tregs (Orban et al., 2009). This study provides the basis for testing this modality of insulin B 
chain therapy in a larger T1D trial to determine the effect on glycemic level. Another 
ongoing phase I–II clinical trial of subcutaneous BHT-3021, a plasmid encoding proinsulin, 
is testing the safety, dose, and preliminary efficacy of this therapeutic modality in recent-
onset T1D patients  
5.3.2 Glutamate decarboxylase 65 
Immune therapies using GAD65 have also been tested in both animal models and human 
T1D. Interestingly, the initial antigenic region is confined to a few epitopes near the C 
terminus of the GAD protein but later spreads intramolecularly to other GAD determinants, 
followed by further intermolecular spreading to other -cell antigens. Consequently, 
tolerance induction by intravenous or intrathymic injections of GAD in female NOD mice at 
3 weeks of age eliminates the anti-GAD T cell responses, as well as subsequent spreading of 
the cascade of T cell responses to other -cell antigens and the development of insulitis or 
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disease still effectively blocked disease progression in prediabetic mice and protected 
syngeneic islet graft survival in diabetic NOD mice (Tian et al., 1996). The identification of 
Tregs in GAD-treated mice suggests a major role in the induction of tolerance by treatment 
with this autoantigen, which raises the question of whether GAD is targeted early in T1D 
(Tisch et al., 1998). 
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Promising preclinical data in the NOD model prompted two clinical trials using alum-
formulated human recombinant GAD65. A phase II safety and dose-finding trial conducted 
in patients with latent autoimmune diabetes in adults (LADA) (Agardh et al., 2005) showed 
the approach to be safe, and administration of two subcutaneous doses led to an increase of 
fasting and stimulated C-peptide at 24 weeks compared to baseline, a benefit that was 
associated with an increase in CD4+CD25+ Treg cells. In a second trial, in recent-onset T1D 
children between 10 and 18 years of age, a slower decline of fasting and stimulated C-
peptide in the GAD-alum group was observed compared to the placebo (Ludvigsson et al., 
2008). More importantly, the protective effect of GAD-alum was preferentially seen in those 
who received treatment within 6 months of diagnosis, suggesting that the autoimmune 
process is more susceptible to GAD-based modulatory therapy if initiated at an earlier stage. 
5.3.3 Heat shock protein 
Early controversies existed as to whether heat shock proteins (hsp) were true autoantigens 
implicated in the pathogenesis of T1D (Atkinson & Eisenbarth, 2001). However, extensive 
preclinical studies using the hsp60 peptide p277 demonstrated efficacy of peptide 
vaccination in halting disease progression in NOD mice (Elias et al., 1991; Elias & Cohen, 
1995). p277 treatment appeared to promote Th2-type cell responses with upregulation of IL-
10 and IL-13 and downregulation of IFN- (Elias et al., 1997; Jin et al., 2008). p277 also has 
inhibitory effects on the innate immune system via signaling through TLR-2, leading to 
inhibition of inflammatory lymphocyte chemotaxis (Nussbaum et al., 2006). The equivalent 
of human hsp60 p277 is a 24 amino acid synthetic peptide derived from the C terminus of 
the human hsp60, termed DiaPep277. Several phase I and II clinical trials in human T1D 
patients have been completed in Europe, and phase III trials are underway. A phase II trial 
was conducted in patients with established T1D but with residual -cell function (Huurman 
et al., 2007) and used a range of doses of subcutaneously administered DiaPep277. Results 
showed a trend of dose-dependent preservation of stimulated C-peptide secretion. Three 
additional trials were conducted in new-onset T1D patients (Raz et al., 2001; Lazar et al., 
2007; Schloot et al., 2007). Two of these trials enrolled adult TID patients, whereas the third 
enrolled pediatric T1D patients. The adult trials showed significantly better preservation of 
insulin synthesis as measured by C-peptide production in the treated groups compared with 
placebo, but this effect was not seen in the pediatric trial. Similar results were observed in 
one other trial performed in pediatric patients (Schloot et al., 2007), although in children 
with less aggressive disease progression based on genetic background, there appeared to be 
a trend to better preserved C-peptide at the end of the study period. In summary, phase II 
trials with DiaPep277 have shown some promise in preserving residual -cell function, 
which appears to be less effective in patients with more aggressive disease. A phase III trial 
is underway with results expected in later 2011. 
6. Cell therapy in type 1 diabetes  
Cellular adoptive-transfer-based approaches have shown significant promise preclinically in 
the NOD model, both in prediabetic and postdiabetic stages. The idea is to compensate a 
presumed deficiency in tolerogenic cells or tolerogenic cell/molecular signaling pathways 
by transferring cell types with immunomodulatory capacity. Specifically, both ex vivo 
expanded Tregs or induced CD4+CD25+Foxp3+ Tregs  (iTreg) have been shown to control 
ongoing autoimmunity and either prevent progression to diabetes or protect syngeneic islet 
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grafts and/or allow -cell recovery, thus inducing diabetes remission in NOD mice (Tang & 
Bluestone, 2006; Weber et al., 2006; Luo et al., 2007; Godebu et al., 2008). It is unclear 
whether antigen specificity is critically important in this approach because both 
nonspecifically-expanded polyclonal or induced Tregs and islet antigen-specific Tregs  have 
shown efficacy in controlling the disease. Additionally, it also appears that Tregs of one 
antigen specificity may be sufficient in controlling ongoing autoimmunity that is probably 
caused by autoaggressive T cells of multiple islet antigen specificities (Tarbell et al., 2004; 
Luo et al., 2007). Clearly delineating these characteristics of Treg adoptive-transfer therapy 
will have significant impact on the design of future clinical trials using this modality. 
Another strategy for enhancing Treg numbers in vivo is by DC-based therapy. It has been 
shown that direct injection of either DC from pancreatic draining lymph nodes or -cell 
antigen-pulsed immature DC protects prediabetic NOD mice from developing overt 
diabetes, possibly through the in vivo induction of Treg cells (Clare-Salzler et al., 1992; Lo et 
al., 2006). However, direct ex vivo DC therapy carries the potential risk of their acquiring an 
activated phenotype upon adoptive transfer, leading to immune activation to some 
antigen(s) rather than tolerance. 
6.1 Diabetes-suppressive dendritic cells 
Methods to stably maintain DC in an immature state, defined by low levels of surface 
costimulatory proteins that include CD80, CD86 and CD40, by downregulating these 
proteins or blocking their interaction with their ligands, are at the forefront of tolerogenic 
biologicals like the CTLA4-Ig protein. These strategies result in tolerance to allografts and 
prevention of autoimmune disease. We have considered two strategies to maintain DCs in a 
stably-immature state. The first involves ex vivo treatment with short double-stranded 
decoys of the NF-kappaB transcription factor and the second involves ex vivo treatment of 
DCs with antisense oligonucleotides (AS-ODN DC) targeting the primary transcripts of 
CD40, CD80 and CD86 concurrently. Both DC products are able to prevent and to reverse 
new onset T1D (Ma et al., 2003; Machen et al., 2004; Trucco & Giannoukakis, 2007; 
Giannoukakis et al., 2008). These preclinical studies have led to a recently completed phase I 
trial using autologous ex vivo-engineered DC from established diabetic patients 
(clinicaltrials.gov identifier NCT00445913), conducted at the University of Pittsburgh 
Medical Center (UPMC), to determine safety as a primary end-point (Figure 4).  
Mechanistically, functionally immature DCs, with low to absent costimulatory molecule 
expression, mediate peripheral tolerance by inducing T cell anergy and the expansion of 
antigen specific Foxp3+ CD25+ CD4+ Treg (Ueno et al., 2007).  
In our approach, AS-ODN DCs promote Treg cell survival through IL-7 signaling in 
addition to impaired provision of CD40, CD80 and CD86 costimulation (Harnaha et al., 
2006). AS-ODN DCs, but not control DC, produce IL-7, in response to a secondary action of 
the antisense oligonucleotides on Toll Like Receptor (TLR) signaling. It is known that CpG 
oligonucleotides, like the AS-ODN we use to make tolerogenic DCs, can activate TLR 
signaling and confer an immunoregulatory phenotype to DCs (Roberts et al., 2005; Jarnicki 
et al., 2008) and are thus useful for treatment of autoimmune conditions (Ho et al., 2005). It 
is possible that the oligonucleotides act in a sequence-nonspecific manner when interacting 
with TLRs, TLR9 in particular, based on conformation and higher order multistrand 
structures (Guiducci et al., 2008; Kindrachuk et al., 2008). For example, certain multimer 
formations or conformations would induce non-MyD88 signaling pathways, whereas others 
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Promising preclinical data in the NOD model prompted two clinical trials using alum-
formulated human recombinant GAD65. A phase II safety and dose-finding trial conducted 
in patients with latent autoimmune diabetes in adults (LADA) (Agardh et al., 2005) showed 
the approach to be safe, and administration of two subcutaneous doses led to an increase of 
fasting and stimulated C-peptide at 24 weeks compared to baseline, a benefit that was 
associated with an increase in CD4+CD25+ Treg cells. In a second trial, in recent-onset T1D 
children between 10 and 18 years of age, a slower decline of fasting and stimulated C-
peptide in the GAD-alum group was observed compared to the placebo (Ludvigsson et al., 
2008). More importantly, the protective effect of GAD-alum was preferentially seen in those 
who received treatment within 6 months of diagnosis, suggesting that the autoimmune 
process is more susceptible to GAD-based modulatory therapy if initiated at an earlier stage. 
5.3.3 Heat shock protein 
Early controversies existed as to whether heat shock proteins (hsp) were true autoantigens 
implicated in the pathogenesis of T1D (Atkinson & Eisenbarth, 2001). However, extensive 
preclinical studies using the hsp60 peptide p277 demonstrated efficacy of peptide 
vaccination in halting disease progression in NOD mice (Elias et al., 1991; Elias & Cohen, 
1995). p277 treatment appeared to promote Th2-type cell responses with upregulation of IL-
10 and IL-13 and downregulation of IFN- (Elias et al., 1997; Jin et al., 2008). p277 also has 
inhibitory effects on the innate immune system via signaling through TLR-2, leading to 
inhibition of inflammatory lymphocyte chemotaxis (Nussbaum et al., 2006). The equivalent 
of human hsp60 p277 is a 24 amino acid synthetic peptide derived from the C terminus of 
the human hsp60, termed DiaPep277. Several phase I and II clinical trials in human T1D 
patients have been completed in Europe, and phase III trials are underway. A phase II trial 
was conducted in patients with established T1D but with residual -cell function (Huurman 
et al., 2007) and used a range of doses of subcutaneously administered DiaPep277. Results 
showed a trend of dose-dependent preservation of stimulated C-peptide secretion. Three 
additional trials were conducted in new-onset T1D patients (Raz et al., 2001; Lazar et al., 
2007; Schloot et al., 2007). Two of these trials enrolled adult TID patients, whereas the third 
enrolled pediatric T1D patients. The adult trials showed significantly better preservation of 
insulin synthesis as measured by C-peptide production in the treated groups compared with 
placebo, but this effect was not seen in the pediatric trial. Similar results were observed in 
one other trial performed in pediatric patients (Schloot et al., 2007), although in children 
with less aggressive disease progression based on genetic background, there appeared to be 
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grafts and/or allow -cell recovery, thus inducing diabetes remission in NOD mice (Tang & 
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Fig. 4. DC-based clinical trial for T1D. Schematic of the procedures involved in the phase I 
clinical trial recently completed at the University of Pittsburgh to prove the safety of the DC-
based vaccine. (Giannoukakis et al., 2008) 
would recruit MyD88. We propose a model where AS-ODN treatment results in a 
coordinate downregulation of CD40, CD80 and CD86 and induction of IL-7 production via 
non-MyD88 TLR signals. At this time it is unclear which of the DNA-sensing TLRs 
transduces the AS-ODN effects. TLR3, TLR7, TLR8 and TLR9 are all equally possible, 
although the effect of chloroquine on IL- 7 production would suggest an endosomal TLR 
with TLR9 being the most likely candidate (Figure 5) (Di Caro & Giannoukakis, unpublished 
data). Indeed, the data indicating that CpG oligonucleotide-triggered TLR9 signaling confers 
immunosuppressive capacity to DC that can treat autoimmunity in vivo strengthens our 
hypothesis (Ho PP et al., 2005).  
 














Fig. 5. AS-ODN treatment of DC in vitro activates TLRs signals leading to IL-7 production. 
A) Western blot analysis of protein extracts from DC treated with AS-ODN for CD40, CD80 
and CD86 over time, using the indicated antibodies, shows activation of NFkB after 1 hour 
and activation of p38 MAP kinase and TRAF6 after 3 hours. B) p38 MAP kinase 
phosphorylation in AS-ODN DC in the presence of chloroquine, a specific inhibitor of 
endosomal TLR signaling (e.g. TLR9), is decreased, as demonstrated by LUMINEX-based 
nuclear transcription factor analysis. C) inhibition of p38 phosphorylation, using the p38 
MAP Kinase inhibitor SB203580, shows a complete abrogation of IL-7 production for each of 
the 7 days of generation of the AS-ODN DC.  
Recently, we identified a novel CD127+ CD25+ Foxp3+ T cell subpopulation that expresses 
the IL-7 receptor (CD127) and has immunosuppressive activity (Figure 6). More 
interestingly, exposure of this novel T cell subpopulation to IL-7 in vitro results in the 
phenotypic maturation of CD127+ CD25+ Foxp3+ T cells to the classical CD25HIGH Foxp3+ 
Treg (Figure 7) (Di Caro et al., 2011).  
IL-7 production by the AS-ODN DC could serve to mature the CD127+ Foxp3+ cells into 
powerfully suppressive CD25HIGH Foxp3+ Tregs, and maintain their survival for a longer 
time period, especially when the IL-2 concentration in the lymphoid environment is 
expected to be limiting, given the competition among CD25+ Tregs and CD25+ effector T 
cells for this critical cytokine. Furthermore, the apparent biregulation of cell surface CD25 
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Fig. 6. CD127+ CD25+ Foxp3+ T cell are functionally suppressive in vitro. Highly enriched, 
flow sorted CD4+CD25+CD127+ splenic T cells, isolated form FoxP3 promoter-GFP 
transgenic mice, are suppressive when added to a co-culture of syngeneic T cells and 




Fig. 7. IL-7 promotes an increase in prevalence of CD127-CD25+Foxp3+ cells. Incubation of 
splenic CD4+GFP+ T cells from Foxp3 promoter-GFP transgenic mice with IL-7 overnight 
results in an increase in CD25+GFP+ T cells, whereas IL-7 downregulates the prevalence of 
CD127+ GFP+ cells (Di Caro et al., 2011). 
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and CD127 on Tregs in response to their respective ligand availability and signaling, in 
peripheral lymphoid organs, could have two functions; Treg maintenance and suppressive 
competency. IL-7 could best serve Tregs under homeostatic conditions in the periphery 
where IL-2 production would be low. This would maintain a pool of CD4+ CD25HIGH Tregs 
as some type of "memory" Treg population. In contrast, in an environment where IL- 2 
would be acutely produced at high levels (i.e. vigorous proliferation of autoreactive T-cells), 
Tregs would compete as well as the effector T cells for IL-2 and therefore, IL-7 might not be 
as relevant.  
Through these mechanisms and others yet unknown, tolerogenic DC could modulate and 
restore the balance of pro and anti-inflammatory components of the immune system. Our 
data and the work carried out by other groups highlights the relevance of using tolerogenic 
DC to treat autoimmune diabetes as well as other tissue specific autoimmune disorders.  
7. Conclusion 
T1D most likely results from a combination of genetic susceptibility and exposure to an 
environmental trigger. The main effector mechanism is clearly an autoimmune reaction, 
which is also evident at time of clinical diagnosis. A better knowledge of the causes that lead 
to T1D is critical for prevention as well as for developing new therapies. Early detection is 
also required to maximally preserve the remaining -cell mass, because the ability to secrete 
even small amounts of insulin can make disease control easier and help minimize the 
complications due to chronic inadequate glycemic control. 
Much of our current understanding of T1D comes from the NOD mouse model, this 
autoimmune diabetes model, so far, has been useful to discover and develop treatments 
even if some of them were not as successful in humans (e.g. the anti-CD3 therapy). 
Today the landscape of possible treatment has been changed by the prospect that T1D 
progression may be blocked by the active stimulation of tolerance induced by autoantigen-
specific Tregs or tolerogenic DCs. The ultimate goal of autoimmune therapy is to silence the 
immune attack against self without sacrificing the patient’s protective immune response to 
pathogens. This will most likely be achieved by a therapy that combines a nonspecific 
immune suppressant and the induction of Tregs/ tolerogenic DCs. Regardless of the 
tolerogenic method employed for therapy, we think that early intervention in T1D patients 
is critical to prevent ongoing islet destruction and to establish an ideal microenvironment to 
allow the recovery of a normal -cell mass from endogenous progenitor cells. The chances 
for disease prevention will be improved by the identification of biomarkers identifying 
patients at risk as early in the disease process as possible. 
Major efforts on several fronts are still required to fully realize the benefits of the 
technological and scientific advances in autoimmune diabetes research even if substantial 
improvements in the cure of T1D patients were indeed promoted.  
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1. Introduction 
Type 1 diabetes (T1D), also known as Insulin dependent diabetes mellitus (IDDM) is an 
incurable multi-factorial autoimmune disorder. The disease is characterized by the loss of 
insulin producing beta cells of the pancreas resulting in abnormal metabolism of glucose 
which may lead to ketoacidosis and several other complications like retinopathy, 
nephropathy and even cardio-vascular diseases and pre-mature deaths (Pociot & 
Mcdermott, 2002). World-wide disease affects 1 in 300-400 children (Todd, 1995). Population 
based data from South India shows the incidence of T1D for four year period to be 
10.5/100,000/ year (Ramachandran et al., 1996). Similar prevalence of type 1 diabetes has 
been observed in North India. A study from district of Karnal in North India reported the 
prevalence to be 10.20/100,000 population, with a higher prevalence in urban (26.6/100,000) 
as compared to rural areas (4.27/100,000) (Kalra et al. 2010). T1D develops as a result of 
complex interaction of many genetic and environmental factors leading to autoimmune 
destruction of the insulin producing pancreatic beta cells. While 20 genomic intervals have 
been implicated for the manifestation of the disease (Pociot & Mcdermott, 2002), role of an 
intricate network of the products of these genes cannot be ruled out. However, unravelling 
different factors involved and how they interact in integrated networks is like solving a jig-
saw puzzle which is the aim of our studies. Basic problem with T1D patients is that by the 
time they first report to the physician, most of their pancreatic beta cells are already 
destroyed which leaves the clinicain with no option but to give daily insulin injections. So, 
there is a need to identify the prediabetics before the onset of the disease and device ways to 
inhibit autoimmunity in them. Following sections will show the work done in our 
laboratory to understand the intricate networks in which the genes involved in immune 
responses interact and their implications.  
2. Role of Major Histocompatibility Complex (IDDM1) 
The Major Histocompatibility Complex (MHC) region on chromosome 6p21.31 has been 
shown to have major role in predisposition to get type 1 diabetes. It is also called  IDDM1. 
2.1 Genes and proteins of the Major Histocompatibility Complex (MHC) 
The human MHC, Human Leukocyte Antigen (HLA) system is the most polymorphic system 
of the human genome with more than 5000 alleles. The alleles of HLA loci are co-dominant i.e. 
both the alleles at a particular locus are equally expressed. The genes of HLA code for 
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glycoprotein molecules which are expressed on nucleated cells and are responsible for the 
recognition of non-self from self. The function of MHC molecules is to present exogenous and 
endogenous antigens in the form of peptides to the T cells for subsequent immune response to 
take place. The gene map of the MHC region of man on chromosome 6p21.3 shows that it 
spans about 4 megabases (3,838,986 bp to be precise). It is the most gene-dense region of the 
human genome with 224 genes of which 128 are known to be expressed. 40% of the expressed 
genes in this region have immune related functions (Horton et al., 2004). 
There are two types of MHC molecules : MHC Class-I and Class-II which differ from each 
other in their constituents as well as their functions.  
2.1.1 MHC class-I genes and proteins 
MHC class-I genes are expressed on all nucleated cells in the form of cell surface 
glycoproteins. Function of MHC class-I molecules is to present antigenic peptides to CD8+ 
cytotoxic T cells (CTLs). The classical class-I genes in humans are HLA-A, HLA-B and HLA-
C. All these genes are very polymorphic with 1519 alleles for HLA-A locus, 2069 alleles for 
B-locus and 1016 alleles for C-locus and these numbers are increasing with the discovery of 
new alleles everyday.  
The MHC class-I molecule is a hetero-dimer of a heavy alpha chain (about 40-45 KDa) and 
the light chain, beta 2 microglobulin (β2m) of 12 KDa (Bjorkman et al., 1987). While the genes 
for the heavy chains i.e. the alpha chains are encoded on chromosome 6, the gene for β2m is 
encoded on human chromosome 15. The alpha chain of the MHC class-I molecule has three 
domains alpha 1 (α1), alpha 2 (α2)and alpha 3 (α3). Alpha 1 (α1) and alpha 2  (α2) domains 
are the most polymorphic domains since they constitute the peptide binding groove of the 
MHC molecule. The genes encoding MHC class-I alpha chain  have 8 exons with  second 
and the third exons of the alpha chain gene being most polymorphic since they code for  the 
α1 and α2 domains. The peptides that are presented by the MHC molecules have allele 
specific motifs, which means that certain peptides can be presented by certain MHC 
molecules. The affinity of the peptide to bind to the peptide binding groove is  determined 
by the anchors present on the peptide binding groove where the peptides go and bind 
through hydrogen bonds. Specific motifs on the peptides determine which peptides would 
bind to which MHC molecule (Falk et al., 1991, Garrett et al., 1989). 
2.1.2 MHC class-II genes and proteins 
MHC class-II glycoproteins in humans are HLA-DR, -DP and –DQ. The MHC class-II 
molecule is a heterodimer of two polypeptide chains: an alpha (25-33 KDa)  and a beta chain 
(24-29KDa) (Brown et al., 1993, De Vries & Van Rood, 1985). Unlike MHC class-I, both alpha 
and beta chains of the class-II molecule are encoded on chromosome 6. DRB1 gene encodes 
DR beta chain while DRA1 encodes DR alpha chain with 966 DRB1 alleles and 3 DRA1 
alleles. Similarly DQB1 and DPB1 encode beta chains of DQ and DP molecules with 144 and 
145 alleles respectively and DQA1 and DPA1 encode the alpha chains of DQ and DP 
molecules with 35 and 28 alleles respectively (Robinson et al., 2009).  
While HLA class-I molecules are expressed on all nucleated cells, HLA class-II molecules are 
expressed on antigen presenting cells like macrophages, dendritic cells, B cells, thymic 
epithelium and activated T cells (Holling et al., 2004). The function of MHC class-II 
molecules is to present antigenic peptides to the CD4+ T helper cells (Th cells) which in turn 
initiate a cascade of immunological events resulting in activation of CD8+ cytotoxic T cells 
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(Horton et al., 2004). When a non-self antigen is presented to CD4+ T helper cells, they get 
activated and secrete certain cytokines like Interferon gamma and TNF-alpha in case of Th1 
cells and IL-4, IL-5 and/or IL-6 in case of Th2 cells. While the cytokines secreted by Th1 cells 
activate the cytotoxic T cells which have already seen the antigen in the context of HLA 
class-I, Th2 cytokines activate the B cells to become plasma cells which make the antibodies 
against antigen they have seen. Thus an immune response takes place which varies in 
strength depending on the host factors and the peptides being presented. 
There are about 50,000-100,000 MHC molecules on each cell. Most MHC molecules are 
occupied by self peptides and the T cells are tolerized against them during thymic education 
so that auto-immune responses do not take place, however, some times something goes 
awry and there is a break in the tolerance resulting in recognition of self as non-self by the 
immune system resulting in an auto-immune response. This could be due to low expression 
of some antigens in the thymus which may result in self-reactive T cells to reach the 
peripheral circulation. Or it could be due to escape of self-reactive T cells from clonal 
deletion during T cell development. 
2.2 MHC and Type 1 diabetes 
Despite so much polymorphism, significant increase of one or more alleles of HLA in a 
disease population as compared to healthy controls, suggests functional implications due to 
their role in antigen presentation. We observed a significant increase of DRB1*03:01 (p<10-6, 
Odds Ratio (OR) =11.0), DRB1*04:01 (p<0.01, OR=6.4) and DRB1*04:05 (p<0.03, OR=5) in the 
patients (Figure 1a) using high resolution typing method of polymerase chain reaction 
followed by hybridization with sequence specific oligonucleotide probes(PCR-SSOP) (Rani 





























































































































































Fig. 1. Distribution of HLA-DRB1 alleles significantly increased in Type 1 diabetes. a. 
DRB1*03:01, DRB1*04:01, DRB1*04:05 showing significant increase and DRB1*04:03, 
DRB1*04:04 and DRB1*07:01 showing significant reduction in T1D patients as compared to 
healthy controls. b. shows the homozygosity and heterozygosity of predisposing and 
protective alleles significantly increased or reduced in the T1D patients. Homozygous 
DRB1*03:01/03:01, heterozygous DRB1*03:01/04:05, DRB1*03:01/04:01 and DRB1*03:01/X 
were significantly increased and DRB1*04:03/X and DRB1*07:01 X were significantly 
reduced in the T1D patients as compared to controls. 
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Fig. 1. Distribution of HLA-DRB1 alleles significantly increased in Type 1 diabetes. a. 
DRB1*03:01, DRB1*04:01, DRB1*04:05 showing significant increase and DRB1*04:03, 
DRB1*04:04 and DRB1*07:01 showing significant reduction in T1D patients as compared to 
healthy controls. b. shows the homozygosity and heterozygosity of predisposing and 
protective alleles significantly increased or reduced in the T1D patients. Homozygous 
DRB1*03:01/03:01, heterozygous DRB1*03:01/04:05, DRB1*03:01/04:01 and DRB1*03:01/X 
were significantly increased and DRB1*04:03/X and DRB1*07:01 X were significantly 
reduced in the T1D patients as compared to controls. 
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Our results were in concordance with earlier studies in North Indians (Gupta et al., 1991, 
Kanga et al., 2004, Mehra et al., 2002, Sanjeevi et al., 1999, Witt et al., 2002). However, we 
also observed DRB1*07:01(p<7x10-6, OR= 0.16), DRB1*04:03 (p< 0.02, OR=0.25) and 
DRB1*04:04 (p< 0.05, OR= 0.2) to be significantly decreased in the patients as compared to 
controls. We did not find any significant reduction of HLA-DR2 haplotype DRB1*15:01-
DQB1*06:02 which has been shown to confer strong protection from T1D in most ethnic 
groups (Baisch et al., 1990, Pugliese et al., 1995), probably because this haplotype has been 
found with a low frequency of only 1.06% in North Indians (Rani et al., 1998). On the other 
hand, we observed a marginally reduced frequency of DRB1*15:06 in patients as compared 
to controls, which did not remain significant when p was corrected for the number of alleles 
tested for DRB1 locus (Rani et al., 2004).  
Figure 1b shows the homozygosity and heterozygosity of DRB1*03:01 and DRB1*04 alleles 
significantly increased in T1D. Homozygous DRB1*03:01 (p<10-7, OR=14.54), heterozygous 
DRB1*03:01/*04:05 (p<0.03, OR =10.9) and DRB1*03:01/*04:01 (p<0.01, OR = 13) were 
significantly increased in the patients as compared to controls who lacked this heterozygous 
combination. Heterozygous 03:01/X (i.e. any other allele) (p<0.04, OR = 1.89) was also 
significantly increased in the patients as compared to controls.  Heterozygous DRB1*04:03/X 
(p<0.04, OR = 0.22) and DRB1*07:01/X (p < 10-7, OR = 0.066) were significantly reduced in 
the T1D patients as compared to controls suggesting their protective role. Significant 
protection has been shown to be associated with DRB1*04:03 allele in a Belgian study of 
diabetes (Van Der Auwera et al., 1995).  DRB1*03:01, DRB1*04:01 and DRB1*04:05 have also 
been shown to be associated with T1D patients in Sardinians, black population from 
Zimbabwe, Lithuanians, Czecks, Lebanese, Brazilians and African Americans (Alves et al., 
2009, Cucca et al., 1995, Ei Wafai et al., , Fernandez-Vina et al., 1993, Garcia-Pacheco et al., 
1992, Skrodeniene et al., , Tait et al., 1995, Weber et al.).  
Cucca et al suggested that amino acid position 74 and 86 in DR beta chain are the key 
residues in the P4 and P1 pockets of the peptide binding groove of HLA-DR molecules 
(Cucca et al., 2001).  A combined presence of Asp, Glu and Val in positions 57 (P9), 74 (P4) 
and 86 (P1) in protective DRB1*04:03 has been shown to be different from high risk 
DRB1*04:05 which has Ser, Ala and Gly at these positions. However, in the North Indians 
we observed DRB1*03:01 to be at highest risk and this allele has Asp, Arg, and Val in the 
three positions (Figure 2). A less predisposing allele in North Indians, DRB1*04:01 has Asp, 
Ala, Gly and the protective DRB1*04:04 and DRB1*07:01 have Asp, Ala, Val and Val, Gln 
and Gly in the three positions respectively. Thus, Asp, Arg and Val in DRB1*03:01 is entirely 
different from Val, Gln, and Gly in DRB1*07:01 which seems to be important in our study 
since all the four DR4 alleles are present in less than 10% of the patients or control samples. 
In essence, these data suggest that it is probably not 74 and 86 alone, rather an integration 
of all the pockets of the peptide binding groove that determines which peptide of an auto-
antigen would bind to the MHC molecule and result in auto-aggression based on the thymic 
education. 
We also studied the alleles of DQB1 locus. DQB1*02:01 which is linked to DRB1*03:01 was 
significantly increased (p<1x10-8, OR=5.08) in patients (Figure 3a). However DQB1*03:02 
and DQB1*03:07, alleles linked with DRB1*04:01, DRB1*04:03, DRB1*04:04 and DRB1*04:05 
were not significantly increased in the patients because two of these alleles DRB1*04:01 and 
DRB1*04:05 were increased in the patients and the other two DR4 alleles DRB1*04:03 and 
DRB1*04:04 were significantly reduced in the patients. DQB1*03:01 (p<6x10-4, OR=0.27) and 
 
 




























































Fig. 2. Peptide binding groove of the predisposing and protective HLA-DRB1 alleles 
showing positions 57 (P9), 74 (P4) and 86 (P1) for predisposing DRB1*03:01, DRB1*04:01 
and DRB1*04:05 and protective DRB1*07:01, DRB1*04:04 and DRB1*04:03  alleles. 
DQB1*05:03 (6x10-4, OR=0.28) were significantly reduced in the patients. Homozygosity of 
DQB1*02:01 was significantly (p<1x10-5, OR=5.4) increased in the patients (Figure 3b). 
DQB1*03:02 which was not significantly increased in the patients, showed a significant 
increase in heterozygous combination with DQB1*0201 (p<2x10-5, OR=34.16). In fact none of 
the controls had DQB1*0201/*0302 heterozygous combination. In a Swedish study, 
DQA1*0301/DQB1*0302 and heterozygous combinations of DQA1*0301/DQB1*0302 and 
DQA1*0201/DQB1*0501 have been shown to confer the highest susceptibility (Sanjeevi et al., 
1995).  
Some critical residues within the peptide binding sites of HLA-DQ beta chain have been 
proposed to play a crucial role in conferring predisposition to and protection from the 
diseases (Nepom & Kwok, 1998, Sheehy, 1992, Todd et al., 1987). Several studies have 
suggested that aspartic acid at DQ residue 57 confers protection while DQB1 alleles with 
alanine at that position (DQB1*02:01 and DQB1*03:02) and DQA1 with arginine at position 
52 (R52) confer susceptibility (Badenhoop et al., 1995, Chauffert et al., 1995, Todd et al., 1987). 
However, an individual can be either homozygous or heterozygous for alleles carrying 
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Rani et al., Tissue Antigens : 64:145-155, 2004  
Fig. 3. Distribution of HLA-DQB1 alleles in T1D patients and controls. a shows DQB1*02:01 
was significantly increased and DQB1*03:01  and DQB1*05:03 were significantly reduced in 
T1D patients as compared to controls. b. Homozygous and heterozygous DQB1 alleles in 
T1D. Homozygous DQB1*02:01/*02:01 and heterozygous DQB1*02:01/*03:02  were 
significantly increased and DQB1*03:02/X  were significantly reduced in T1D patients as 
compared to controls (Rani et al., 2004). 
Asp57 in DQB1 or Arg52 in DQA1. Our in-depth investigation revealed that  when DR3 
homozygosity was considered along with codon 57 of DQB1 and codon 52 of DQA1, the 
only combination that was significantly increased in the patients group as compared to  
the controls was DRB1*03:01,03:01-DQB1*XX-DQA1*RR, suggesting that DRB1*03:01 
association is primary since the DQB1 and DQA1 alleles which are in linkage disequilibrium 
with DRB1*03:01 have non-Asp57 (DQB1*X) and Arg52 (DQA1*R), respectively(Rani et al., 
1999).  
3. Insulin linked polymorphic region in T1D (IDDM2)  
Insulin linked polymorphic region (IDDM2) consists of a highly polymorphic stretch of 14-
15 base pair repeats of DNA lying 365 bp upstream of the initiation of transcription of the 
insulin (INS) gene. IDDM2 has been shown to have a role in transcription of insulin in 
thymus. Several forms of IDDM2 have been reported based on the number of repeats (Bell et 
al., 1981, Kennedy et al., 1995). These INS-variable number of tandem repeats (VNTR) are 
divided into three different classes based on their sizes: class-I (26-63 repeats), Class II (about 
85 repeats) and class III (141-209 repeats) (Bell et al., 1982, Bennett et al., 1995, Rotwein et al., 
1986). T1D is associated with class I homozygosity (Bell et al., 1981, Bennett et al., 1995, 
Kennedy et al., 1995, Lucassen et al., 1993). We studied INS-VNTR Class-I and Class-III 
alleles based on typing for Insulin gene 1127 Pst I site (3’end) by PCR-RFLP as described by 
Pugliese et al (Pugliese et al., 1997) 
Table 1 shows the frequencies of Insulin VNTR in T1D patients and healthy controls. While 
the frequency of class-I VNTR was increased significantly in the patients, class-III VNTR was 
decreased in them as compared to the controls. However, when the genotypes were studied, 
class I homozygosity was considerably increased in the patients as compared to controls, 
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giving an Odds ratio of 7.8.  Class I, III heterozygosity was significantly reduced in the 
patients (Rani et al., 2004). 
 
INS-VNTR DIABETES CONTROLS p value OR 
 No. % No. %
Class I 108 98.2 85 89.47 0.008 6.35
Class III 64 58.2 87 91.57 2 X 10-8 0.13
Genotypes
Class I, I 46 41.8 8 8.42 2X10-8 7.8
Class I, III 62 56.4 77 81.05 10-5 0.301 
Class III, III 2 1.8 10 10.52 0.008 0.157 
Table 1. INS-VNTR allele frequencies and Genotype frequencies in T1D patients and 
controls.  
3.1 Simultaneous presence of predisposing HLA-DRB1 and INS-VNTR alleles  
MHC and VNTR are encoded on two different chromosomes. However, they may have 
integrated roles in manifestation of T1D due to the functional implications of these genes. 
So, we studied if simultaneous presence of the predisposing alleles of the two genes had any 
role to play in manifestation of T1D. 
Our investigation revealed that homozygous Class-I INS-VNTR along with homozygous or 
heterozygous DRB1*03:01 were significantly increased in the T1D patients (p<1x10-8) with a 
Relative Risk of 70.81 (Rani et al., 2004). In fact, none of the controls had homozygous Class-I 
INS-VNTR along with DRB1*03:01 in homozygous or heterozygous state. This combination 
gives a positive predictive value (PPV) of 100% with a specificity of 100% and sensitivity of 
32.63% since only 32.63% of the patients showed this combination. Since DRB1*03:01 
homozygosity is significantly increased in the patients, homozygous DRB1*03:01 and 
heterozygous DRB1*03:01 only with DRB1*04:01 and DRB1*04:05 along with heterozygous I, 
III-INS-VNTR may also be considered as predisposing since it gives a relative risk of 10.55 
(Rani et al., 2004).  
If we add all these predisposing combinations i.e. simultaneous presence of homozygous or 
heterozygous HLA-DRB1*03:01 along with homozygous (Class-I, I) or heterozygous (I, III)  
VNTR class-I and III,  50.53% of the patients as compared to only 1.4% of the controls had 
these combinations giving a relative risk of 48.67. This combination gives a PPV of 97.96% 
with a specificity of 98.6% and sensitivity of 50.5% since only 50.5% of the patients showed 
this combination. Thus, our results showed that: (1) homozygous or heterozygous 
DRB1*03:01 along with homozygous Class-I INS-VNTR and (2) homozygous DRB*03:01 and 
heterozygous DRB1*03:01 only with DRB1*04:01 or DRB1*04:05 with heterozygous Class-I/III 
INS-VNTR may be used to predict a pre-diabetic before the onset of the disease in North 
Indian high risk group (Rani et al., 2004). However, typing a larger cohort may be required 
to confirm such a major increase in risk.   
Pathogenesis of T1D is extremely complex. Significant association with HLA-DRB1*03:01 
and INS-VNTR Class-I may have functional implications. Increase in frequency of particular 
MHC allele suggests that these molecules may be preferentially presenting certain auto-
peptides to the T cells resulting in subsequent autoimmune responses. Studies on INS-
VNTR, however, have shown that class-III alleles are associated with 2 to 3 fold higher 
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Fig. 3. Distribution of HLA-DQB1 alleles in T1D patients and controls. a shows DQB1*02:01 
was significantly increased and DQB1*03:01  and DQB1*05:03 were significantly reduced in 
T1D patients as compared to controls. b. Homozygous and heterozygous DQB1 alleles in 
T1D. Homozygous DQB1*02:01/*02:01 and heterozygous DQB1*02:01/*03:02  were 
significantly increased and DQB1*03:02/X  were significantly reduced in T1D patients as 
compared to controls (Rani et al., 2004). 
Asp57 in DQB1 or Arg52 in DQA1. Our in-depth investigation revealed that  when DR3 
homozygosity was considered along with codon 57 of DQB1 and codon 52 of DQA1, the 
only combination that was significantly increased in the patients group as compared to  
the controls was DRB1*03:01,03:01-DQB1*XX-DQA1*RR, suggesting that DRB1*03:01 
association is primary since the DQB1 and DQA1 alleles which are in linkage disequilibrium 
with DRB1*03:01 have non-Asp57 (DQB1*X) and Arg52 (DQA1*R), respectively(Rani et al., 
1999).  
3. Insulin linked polymorphic region in T1D (IDDM2)  
Insulin linked polymorphic region (IDDM2) consists of a highly polymorphic stretch of 14-
15 base pair repeats of DNA lying 365 bp upstream of the initiation of transcription of the 
insulin (INS) gene. IDDM2 has been shown to have a role in transcription of insulin in 
thymus. Several forms of IDDM2 have been reported based on the number of repeats (Bell et 
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alleles based on typing for Insulin gene 1127 Pst I site (3’end) by PCR-RFLP as described by 
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giving an Odds ratio of 7.8.  Class I, III heterozygosity was significantly reduced in the 
patients (Rani et al., 2004). 
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Indian high risk group (Rani et al., 2004). However, typing a larger cohort may be required 
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and INS-VNTR Class-I may have functional implications. Increase in frequency of particular 
MHC allele suggests that these molecules may be preferentially presenting certain auto-
peptides to the T cells resulting in subsequent autoimmune responses. Studies on INS-
VNTR, however, have shown that class-III alleles are associated with 2 to 3 fold higher 
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mRNA levels of insulin than Class-I in thymii of fetuses, suggesting poor expression of 
thymic INS expression  resulting in poor thymic education for insulin in people with 
homozygous Class-I,I and class-I,III VNTRs resulting in break of tolerance in predisposed 
individuals. However, higher expression of insulin in the thymii of individuals with 
homozygous class-III, III may be able to facilitate immune tolerance induction, as a 
mechanism for dominant protective effect of Class-III alleles (Pugliese et al., 1997, Vafiadis et 
al., 1997).   
Our results are contrary to that of Veijola et al. (Veijola et al., 1995) on Finnish children who 
showed that both 5' and 3' INS loci showed an association with T1D in non-DR3/non-DR4 
patients (Veijola et al., 1995). However, in our studies only 9.47% of the non-DR3/DR4 
patients were homozygous for Class-I INS-VNTR as compared to 4.2% controls and this 
difference was not significant statistically. Julier et al. (Julier et al., 1991), on the other hand, 
had reported that the risk contributed by the INS region was increased in DR4-positive 
patients. Again, in our study only 6.32% of the patients as compared to 1.39% of controls 
had INS-VNTR class-I homozygosity with DRB1*04:01 and DRB1*04:05 alleles and this 
difference was not significant statistically. 
4. Cytokine genes 
Cytokines are the coordinators of the immune system that interact in integrated networks 
and functions of one cytokine may be modulated or substituted by another (Bidwell et al., 
1999). A cascade of cytokines are involved in pro-inflammatory auto-immune responses 
in T1D. Single nucleotide polymorphisms (SNPs) in different pro-inflammatory and anti-
inflammatory cytokine genes at certain defined regions have been shown to be associated 
with differential amount of their production (Asderakis et al., 2001, Awad et al., 1998, 
Bittar et al., 2006, Burzotta et al., 2001, Fishman et al., 1998, Louis et al., 1998, Pociot et al., 
1993). Pro-inflammatory cytokines and their integrated influences are known to regulate 
complex immune responses during autoimmune destruction of tissues (Rabinovitch, 
1994). Hence it is necessary that they are studied and analysed in context of each other 
and not in isolation from each other. We had reported for the first time the integration and 
interaction of TNF-  gene with other cytokine genes and HLA-DRB1 and B loci alleles 
(Kumar et al., 2007). 
We studied the cytokine gene polymorphism using XIIIth International Histocompatibility 
Workshop’s (IHWC, Heidelberg kit) and One lambda’s cytokine typing kits (Canoga Park, 
CA, USA) based on Polymerase Chain reaction (PCR) with sequence specific primers (PCR-
SSP). PCR-SSPs were done for IFN- (A+874T) (14), TNF- (G-308A) (15), IL-6 (G-174C) (9), IL-10 
(A-1082G, T-819C, C-592A) (16), and TGF1 (Tcdn10C, Gcdn25C) (11). T→C substitution in nucleotide 
29, codon 10 of the first exon of TGF1, changes the amino acid Leu → Pro. Similarly G→ C 
substitution in nucleotide 74, codon 25 of first exon of TGF1, changes the amino acid Arg 
→ Pro. However, since we are studying the SNPs in the two codons, we will refer to the 
SNPs in codons 10 and 25 hereafter. and not the resultant amino acids to avoid any 
confusion and to maintain consistency with the other SNPs.   
Our results showed that the high producing genotype of TNF--308GA and AA were 
significantly increased and low producing genotype GG was significantly reduced in T1D 
patients as compared to controls (p < 7 x10-6). None of the other cytokine genes showed any 
significant difference between the patients and controls.  
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4.1 Simultaneous presence of TNF- genotypes with IFN-, IL-6, IL-10 and TGF-1 
genotypes and haplotypes 
TNF-, IFN-, IL-10, IL-6 and TGF-1 genes are localized on different chromosomes. TNF- 
is encoded on chromosome 6p21.3, IFN- is encoded on 12q14, IL-10 is encoded on 1q31-q32, 
IL-6 is encoded on 7p21 and TGF-1 is encoded on 19q13.2. However, the products of these 
genes interact in integrated networks. Since only TNF- showed a significant association 
with T1D, we studied whether simultaneous presence of TNF- genotypes with different 
genotypes of the other cytokines in an individual could suggest an interaction between these 
cytokine genes. 
 



















IFN-γ Int +874 N=235 N=128   N=235 N=128   
AA (L) 41 (17.4) 9 (7.0) 0.003
@ 2.79 (1. 25-6.42) 46 (19.6) 44 (34.4) 0.001
@ 0.465 (0.28-0.77) 
TA+TT (H) 56 (23.8) 15 (11.07) 0.003
@ 2.39 (1.24-4.66) 92 (39.1) 60 (46. 9) 0.188 
0.729 (0.461-
1.15) 
IL-6 -174 N=235 N=127$   N=235 N=127$   
CC (L) 11 (4.7) 1 (0.78) 0.03# 4.3 (1. 21-14.56) 14 (5.95) 8 (6.29) 0.531 
0.919 (0.357-
2.53) 
GG+GC (H) 86 (36.6) 23 (18.1) 0.0001
@  2.61 (1.5-4.56) 
124 
(52.75) 95 (74.8) 0.000004
@ 0.76 (0.227-0.621)  
IL-10 
Haplotypes* N=235 N=128   N=235 N=128   




(32.76) 57 (44.5) 0.03
# 0. 607 (0. 38-0.96) 
High Secretor 52 (22.1) 8 (6. 25) 0.0001
@ 4.26  (1.9-10.1) 
61 
(25.95) 47 (36.7) 0.04
# 0.6 (0.37-0.98) 
TGF-β1 
Haplotypes* N=235 N=128   N=235 N=128   
Low secretor 8 (3.4) 1 (0.8) 0.11 3.17 (0.87-12.11) 7 (2.98) 3 (2.3) 0.506 
1.17 (0.443-
3.23) 
High Secretor 89 (37.8) 23 (18.0) 0.00004
@  2.8 (1.6- 4.86) 
131 
(55.7) 101 (78.9) 0.000006
@ 0. 336 (0.198-0.568) 
N=Total number of samples studied,   $Number of  control samples studied for IL-6 were 127, one 
sample could not be typed due to PCR failure. TNF-α GA/AA have been combined as high secretor 
genotypes. 
# Corrected p value (pc) not significant, @ Corrected p value (pc) significant,  
*IL-10 : halpotype combinations -1082/-819/-590 : GCC,GCC; GCC,ACC; GCC,ATA= high secretors; 
ACC,ACC; ACC,ATA = Low secretors.  
TGF- β1 halpotype combinations Cdn10/Cdn25 : TG,TG; TG,CG; TG,CC; CG,CG =High secretors, 
CG,CC, CC,CC = Low secretors. 
Table 2. Simultaneous presence of TNF- genotypes with IFN-γ, IL-6, IL-10 and TGF-β1 
genotypes and haplotypes (Kumar et al., 2007). 
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mRNA levels of insulin than Class-I in thymii of fetuses, suggesting poor expression of 
thymic INS expression  resulting in poor thymic education for insulin in people with 
homozygous Class-I,I and class-I,III VNTRs resulting in break of tolerance in predisposed 
individuals. However, higher expression of insulin in the thymii of individuals with 
homozygous class-III, III may be able to facilitate immune tolerance induction, as a 
mechanism for dominant protective effect of Class-III alleles (Pugliese et al., 1997, Vafiadis et 
al., 1997).   
Our results are contrary to that of Veijola et al. (Veijola et al., 1995) on Finnish children who 
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difference was not significant statistically. Julier et al. (Julier et al., 1991), on the other hand, 
had reported that the risk contributed by the INS region was increased in DR4-positive 
patients. Again, in our study only 6.32% of the patients as compared to 1.39% of controls 
had INS-VNTR class-I homozygosity with DRB1*04:01 and DRB1*04:05 alleles and this 
difference was not significant statistically. 
4. Cytokine genes 
Cytokines are the coordinators of the immune system that interact in integrated networks 
and functions of one cytokine may be modulated or substituted by another (Bidwell et al., 
1999). A cascade of cytokines are involved in pro-inflammatory auto-immune responses 
in T1D. Single nucleotide polymorphisms (SNPs) in different pro-inflammatory and anti-
inflammatory cytokine genes at certain defined regions have been shown to be associated 
with differential amount of their production (Asderakis et al., 2001, Awad et al., 1998, 
Bittar et al., 2006, Burzotta et al., 2001, Fishman et al., 1998, Louis et al., 1998, Pociot et al., 
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We studied the cytokine gene polymorphism using XIIIth International Histocompatibility 
Workshop’s (IHWC, Heidelberg kit) and One lambda’s cytokine typing kits (Canoga Park, 
CA, USA) based on Polymerase Chain reaction (PCR) with sequence specific primers (PCR-
SSP). PCR-SSPs were done for IFN- (A+874T) (14), TNF- (G-308A) (15), IL-6 (G-174C) (9), IL-10 
(A-1082G, T-819C, C-592A) (16), and TGF1 (Tcdn10C, Gcdn25C) (11). T→C substitution in nucleotide 
29, codon 10 of the first exon of TGF1, changes the amino acid Leu → Pro. Similarly G→ C 
substitution in nucleotide 74, codon 25 of first exon of TGF1, changes the amino acid Arg 
→ Pro. However, since we are studying the SNPs in the two codons, we will refer to the 
SNPs in codons 10 and 25 hereafter. and not the resultant amino acids to avoid any 
confusion and to maintain consistency with the other SNPs.   
Our results showed that the high producing genotype of TNF--308GA and AA were 
significantly increased and low producing genotype GG was significantly reduced in T1D 
patients as compared to controls (p < 7 x10-6). None of the other cytokine genes showed any 
significant difference between the patients and controls.  
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4.1 Simultaneous presence of TNF- genotypes with IFN-, IL-6, IL-10 and TGF-1 
genotypes and haplotypes 
TNF-, IFN-, IL-10, IL-6 and TGF-1 genes are localized on different chromosomes. TNF- 
is encoded on chromosome 6p21.3, IFN- is encoded on 12q14, IL-10 is encoded on 1q31-q32, 
IL-6 is encoded on 7p21 and TGF-1 is encoded on 19q13.2. However, the products of these 
genes interact in integrated networks. Since only TNF- showed a significant association 
with T1D, we studied whether simultaneous presence of TNF- genotypes with different 
genotypes of the other cytokines in an individual could suggest an interaction between these 
cytokine genes. 
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ACC,ACC; ACC,ATA = Low secretors.  
TGF- β1 halpotype combinations Cdn10/Cdn25 : TG,TG; TG,CG; TG,CC; CG,CG =High secretors, 
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Table 2 shows the simultaneous presence of high and low secreting genotypes of TNF-, 
along with IFN-, IL-6, IL-10 and TGF-1 genotypes and haplotypes. When IFN- was 
studied by itself, it did not show any significant difference between patients and controls. 
However, when studied in the context of TNF- -308G/A, both low and high secretor 
genotypes, IFN- (+874AA and TA+TT respectively) along with high secretor genotypes of 
TNF- -308 GA+AA were significantly increased in patients as compared to controls, 
suggesting its effect is rather neutral. However, low producer genotypes of TNF- -308GG 
along with low producer genotype of  IFN- +874 AA seems to be protective. Interestingly, 
66. 7% of the patients who had low producer genotype of TNF- -308GG had high producer 
genotype of  IFN- +874 TA+TT. Hence, in the absence of high secretor genotype of TNF-, 
IFN- may have a role in autoimmune destruction of pancreatic beta cells. IFN- acts 
singularly as well as synergistically with other inflammatory stimuli to induce NO 
production which can be cytotoxic and thus has been implicated in pathogenesis of certain 
autoimmune and inflammatory diseases (Mccartney-Francis et al., 1993).  
Similarly, promoter SNPs of IL-6 -174G/C did not show any significant difference between 
patients and controls, but when studied in the context of TNF- -308G/A, high producer 
genotypes, IL-6 -174 GG+GC (Fishman et al., 1998)  were increased in patients with TNF- -
308 GA+AA. Kristiansen and Mandrup-Poulsen (Kristiansen & Mandrup-Poulsen, 2005) 
have shown that IL-6 promotes islet inflammation but is unable to promote β-cell 
destruction for which other pro-inflammatory cytokines are needed. The other pro-






p OR (95% C.I.) 
 No* % No* %   
B*8-DRB1*03 69 32.85 3 3.3 10-8 14.35  (4.19 -37.93) 
B*8- Non DRB1*03 2 0.95 1 1.1 0.662 0.865  (0.498-1.5) 
B*50 – DRB1*03 41 19.5 3 3.3 6x10-5 7.11  (2.04-21.47) 
B*50 – Non-DRB1*03 6 2.86 4 4.4 0.355 0.639  (0.155-2.77) 
B*58 – DRB1*03 36 17.1 5 5.5 0.003 3.55  (1.27-10.72) 
B*58 – Non DRB1*03 3 1.4 8 8.8 0.003 0.165  (0.06-0.433) 
NonB8/B50/58-DRB1*03 35 16.7 6 6.6 0.01 2.83  (1.09-7.82) 
NonB8/B50/B58/non 
DRB1*03 38 18.1 59 64.8 10
-8 0.12  (0.06-0.216) 
* No. of patients /Controls with the haplotypes shown in the first column. 
Table 3. Comparison of HLA-B-DRB1 haplotypes showing significant association, between 
patients and controls (Kumar et al., 2007) 
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TNF- α in patients with GA and AA genotypes and IFN- in patients with TNF- GG 
genotype. High producer genotype IL-6 -174 GG+GC along with low producer genotype of 
TNF- -308GG seems to be protective.  
Different haplotypes of IL-10 based on SNPs in the promoter region have been shown to be 
associated with quantity of IL-10 production in-vitro (Asderakis et al., 2001, Stanilova et al., 
2006). The frequency of low producer haplotype of IL-10 ATA (haplotype with positions -
1082/-819/-590) has been shown to be increased in the adult onset patients in Japan, with no 
significant differences between T1D patients and controls (Ide et al., 2002). Reynier et al 
(Reynier et al., 2006) did not see any significant association  of IL-10-1082G/A with T1D in 
French population. However, they did observe a significant association of IL-10 -1082 
polymorphism to be associated with GAD and IA-2 antibody at clinical onset. In our study 
also, we did not observe any significant difference between TID patients and controls when 
IL-10 was studied by itself. However, simultaneous presence of high producer genotypes of 
TNF- -308 GA+AA and high producer haplotypes of IL-10 in the patients may have a role 
in recruitment of islet specific CD8+ T cells and thus may have a role in insulitis through 
ICAM-1 dependent pathway. In non-obese diabetic (NOD) mice (animal model for human 
Type 1 diabetes) pancreatic IL-10 has been shown to hyper-induce ICAM-1 expression on 
vascular endothelium. However, in the absence of ICAM-1, insulitis and diabetes could be 
prevented, thus providing evidence that IL-10 is sufficient to drive pathogenic autoimmune 
responses and accelerated diabetes via an ICAM-1 dependent pathway (Balasa et al., 2000). 
Presence of IL-10 during early stages of IDDM has also been shown to favor the generation 
of effector CD8+ T cells leading to accelerated diabetes in NOD mice (Balasa et al., 2000). 
Treatment of young mice with anti-TNF- and anti-IL-10  mAb has also been shown to 
prevent diabetes and insulitis (Lee et al., 1996, Yang et al., 1994). 
Similarly, when TGF-1 was studied by itself, no significant difference was observed between 
patients and controls. A significant increase of high producer haplotypes of TGF-1 with TNF-
 -308 GA+AA and a significant decrease of high producer haplotypes of TGF-1 with TNF- -
308GG in T1D patients as compared to controls was observed. These results show that 
different cytokines  work in concert with each other and may alter or modulate their functions 
depending on the milieu. TGF-1 has been shown to be an extremely potent chemotactic factor 
in-vitro which influences monocyte recruitment and accumulation via increased expression of 
α and β integrins (Wahl et al., 1993). It has been shown to rapidly and transiently up-regulate 
α-4 integrin dependent adhesion of leukocyte cell lines and peripheral blood lymphocytes 
(Bartolome et al., 2003). α-4 integrin, in turn, has been shown to play a prominent role in the 
spontaneous development of insulitis and diabetes in NOD mice (Yang et al., 1997). Increased 
levels of TGF-1 have been associated with destruction of pancreatic beta cells and 
pathogenesis of diabetic complications (Korpinen et al., 2001). Hence, in the presence of high 
secretors of TNF-, the high secretor genotypes of TGF-1 may have a role both in destruction 
of pancreatic beta cells as well as in migration of CD4+ and CD8+ T cells into the pancreas 
(Insulitis) through α-4 integrin, which act against pancreatic beta cells along with Nitric oxide 
mediated cytotoxicity. Under these circumstances, TGF-1 may not be able to arrest the pro-
inflammatory functions of TNF- and IFN-. 
So, our data provides circumstantial evidence justifying the presence of high secretor 
genotypes of TNF- -308GA and AA along with high secretor genotypes of IL-6, IL-10 and 
TGF-β1 and provide an immunogenetic basis for the autoimmune responses in T1D. The 
data suggest that the beta cell destruction in T1D may be mediated by both CD4+ T helper 
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cells and CD8+ cytotoxic T cells recruited through Integrins and ICAM-1 dependent 
pathways in the pancreas for which cytokine genes seem to play a pivotal role. 
4.2 TNF- α and HLA genes 
TNF- gene is very closely linked to the MHC. Deng et al (Deng et al., 1996) observed that 
the TNF- associations in Caucasians and Chinese of Taiwan, may be due to its being in 
linkage disequilibrium with DR3-DQB1*0201 haplotype. We too had observed DRB1*03:01, 
DRB1*04:01 and DRB1*04:05 to be associated with T1D in North Indians  (Rani et al., 2004). 
Hence, we wanted to study if the TNF- association was independent of these alleles or due 
to linkage disequilibrium (LD) between TNF- -308A and the predisposing DRB1 alleles. 
Interestingly,  the LD analysis showed that both TNF- -308A as well as TNF- -308G alleles 
are in LD with DRB1*03:01, the most predisposing HLA-DRB1 allele, suggesting that the 
effect of TNF- -308A is not because of its being in LD with HLA-DRB1*03:01, the 
predisposing MHC allele. 
Since TNF- locus is very closely linked to HLA-B locus, we also studied the alleles of B-
locus for a possibility of TNF- -308A allele being in LD with one of the B-locus alleles . 
Surprisingly we observed LD between TNF- -308G with B*08 and  TNF- -308A allele with 
HLA B*50:01 and B*58:01. All the three B-locus alleles B*08:01, B*50:01 and B*58:01 were in 
linkage disequilibrium with DRB1*03:01 (Table 3). Because of HLA-B*08 being in LD with 









B*8- TNF-α  -308A-DRB1*03  19 0.045 -0.013 
B*8- TNF-α -308G-DRB1*03  75 0.179 0.015 
B*50- TNF-α  -308A-DRB1*03  42 0.1 0.0329 
B*50- TNF-α -308G-DRB1*03  32 0.076 -0.0023 
B*58- TNF-α  -308A-DRB1*03  33 0.079 0.0141 
B*58- TNF-α  -308G-DRB1*03  28 0.067 -0.0032 
Table 4. Linkage disequilibrium analysis of HLA-B- TNF-α -DRB1 haplotypes prevalent in  
T1D patients from North India (Kumar et al., 2007). 
However, B*50:01-DRB1*03:01 and B*58:01-DRB1*03:01 haplotypes were in LD with TNF- -
308A allele. We observed 48.8 % of the patients had B*08/non-B*08/non-B*50:01/non-
B*58:01-TNF--308G-DRB1*03:01 haplotypes as compared to 34 % with B*50:01/ B*58:01- 
TNF- -308A-DRB1*03:01 haplotypes. With this in-depth analysis, it becomes clear that the 
effect of TNF- -308A allele is not because of its being in LD with DRB1*03:01, B*08:01, 
B*50:01 or B*58:01, but due its functional implications and its integrated effect with other 
cytokines. In conclusion,  while the MHC may be  involved in auto-antigen presentation, 
TNF- alpha  and other cytokines play an integrated role in destruction of the pancreatic beta 
cells though enrichment and recruitment of autoantigen specific CD4+ and CD8+ T cells 
which have immunogenetic bases (Figure 6). 
5. Vitamin D receptor 
Vitamin D Receptor (VDR) is a ligand dependent transcription factor that belongs to the 
super family of the Nuclear Hormone Receptors (Evans, 1988). The ligand for VDR is 
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Vitamin D3 i.e., 1,25-(OH)2D3 which mediates its biological actions through VDR. When 
1,25-(OH)2D3 binds to VDR, it induces conformational changes in VDR promoting its hetero-
dimerization with Retinoid X Receptor (RXR), followed by translocation of this complex into 
the nucleus. The RXR-VDR heterodimer in turn binds to the vitamin D3 responsive elements 
(VDRE) in promoter regions of vitamin D responsive genes (Boonstra et al., 2001). This 
results in the regulatory function of Vitamin D3. In the absence of classical responsive 
elements, 1,25-(OH)2D3 may controls the expression of some genes like cytokine genes by 
targeting inducible transcription factors like NFAT in IL-2 in a sequence specific manner 
(Takeuchi et al., 1998). 1,25-(OH)2D3 has been shown to have an important immuno-
modulatory role since it represses transcription of Th1 cytokines like  IL-2 (Alroy et al., 1995, 
Bhalla et al., 1984), IFN-γ (Cippitelli & Santoni, 1998) and IL-12 (D'ambrosio et al., 1998) and 
up regulates the production of Th2 cytokines IL-4 and TGF-β1 (Cantorna et al., 1998). It has 
been shown to enhance the development of TH2 cells via a direct effect on naive CD4+ cells 
(Boonstra et al., 2001). Besides, 1,25-(OH)2D3 has also been shown to modulate the 
expression of HLA class-II alleles on monocytes and human bone cells (Rigby et al., 1990, 
Skjodt et al., 1990)  
Studies have shown that administration of Vitamin D3 in NOD mice,  before the onset of 
Insulitis, can effectively prevent the disease progression. However, when administered after 
the establishment of insulitis, vitamin D3 was not as effective. Similarly, in  humans too, 
vitamin D supplementation in early childhood has been shown to reduce the incidence of T1D 
(Hypponen et al., 2001, Jones et al., 1998). Since 1,25-(OH)2D3 mediatesi its effect through  VDR, 
we studied the VDR gene polymorphisms and their interaction with the most predisposing 
MHC alleles to investigate their role, if any, in the pathophysiology of T1D.  
The VDR SNPs studied include the T>C SNP in exon2 initiation codon detected with FokI 
restriction enzyme (Gross et al., 1996), the A>G SNP detected with BsmI (Morrison et al., 
1992) and G>T SNP detected with ApaI (Faraco et al., 1989) located in Intron  8, and a silent 
C>T SNP (Durrin et al., 1999) detected with TaqI, located in Exon 9. These SNPS were 
studied using PCR amplification and restriction digestion by the aforesaid enzymes as 
described earlier (Faraco et al., 1989, Hustmyer et al., 1993). We also studied the interaction 
between VDR alleles and predisposing HLA alleles using LD based statistics (Zhao et al., 
2006) and subsequently sequenced the promoter region of the predisposing MHC allele to 
detect the VDRE sequence which has been shown to modulate the expression of the HLA 
alleles (Ramagopalan et al., 2009), suggesting the functional implications of the statistically 
significant interaction (Israni et al., 2009). We further provided documentary evidence that 
expression of HLA class-II molecules was being modulated by vitamin D3. 
5.1 VDR FokI,  BsmI, ApaI and TaqI genotypes and haplotypes in T1D patients 
While there were no significant differences in the genotypes of ApaI and TaqI in patients and 
controls. FokI ‘ff’ was significantly increased in the patient group as compared to controls 
and BsmI ‘bb’ was significantly decreased in the patient group. However, these differences 
did not remain significant after Boneferroni’s correction (Israni et al., 2009). 
Haplotype analysis was carried out for the four restriction sites studied in the VDR gene in 
patients and controls using SHEsis program (http://202.120.7.14/analysis/myAnalysis.php) 
(Shi & He, 2005). Additionally, Famhap (http://famhap.meb.uni-bonn.de ) was used to 
confim the frequencies of the haplotypes. Haplotype FBAt and fBAT were significantly 
increased in T1D patients and fBAt was significantly reduced in them as compared to controls.  
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cells and CD8+ cytotoxic T cells recruited through Integrins and ICAM-1 dependent 
pathways in the pancreas for which cytokine genes seem to play a pivotal role. 
4.2 TNF- α and HLA genes 
TNF- gene is very closely linked to the MHC. Deng et al (Deng et al., 1996) observed that 
the TNF- associations in Caucasians and Chinese of Taiwan, may be due to its being in 
linkage disequilibrium with DR3-DQB1*0201 haplotype. We too had observed DRB1*03:01, 
DRB1*04:01 and DRB1*04:05 to be associated with T1D in North Indians  (Rani et al., 2004). 
Hence, we wanted to study if the TNF- association was independent of these alleles or due 
to linkage disequilibrium (LD) between TNF- -308A and the predisposing DRB1 alleles. 
Interestingly,  the LD analysis showed that both TNF- -308A as well as TNF- -308G alleles 
are in LD with DRB1*03:01, the most predisposing HLA-DRB1 allele, suggesting that the 
effect of TNF- -308A is not because of its being in LD with HLA-DRB1*03:01, the 
predisposing MHC allele. 
Since TNF- locus is very closely linked to HLA-B locus, we also studied the alleles of B-
locus for a possibility of TNF- -308A allele being in LD with one of the B-locus alleles . 
Surprisingly we observed LD between TNF- -308G with B*08 and  TNF- -308A allele with 
HLA B*50:01 and B*58:01. All the three B-locus alleles B*08:01, B*50:01 and B*58:01 were in 
linkage disequilibrium with DRB1*03:01 (Table 3). Because of HLA-B*08 being in LD with 









B*8- TNF-α  -308A-DRB1*03  19 0.045 -0.013 
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Vitamin D3 i.e., 1,25-(OH)2D3 which mediates its biological actions through VDR. When 
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5.2 Gene to gene interaction of VDR haplotypes with predisposing HLA alleles 
Simulateneous presence of different VDR haplotypes along with the predisposing HLA 
alleles was studied in patients. Interestingly, simultaneous presence of haplotypes FBAT and 
FbaT along with the predisposing DRB1 alleles was significantly increased while the same 
haplotypes were protective when associated with non-predisposing alleles of DRB1. Similar 
results were obtained with other haplotypes like FBAt, fBAT and fbaT in association with the 
predisposing HLA-DRB1 alleles (Israni et al., 2009). 
To study the interaction between two unlinked loci i.e., VDR and the predisposing HLA-
DRB1 alleles, we used LD based statistics as described by Zhao et al (Zhao et al., 2006). The 
analysis revealed that F and T alleles in the exons 2 and 9 for FokI and TaqI restriction sites 
respectively showed significant interactions with predisposing HLA-DRB1 allele DRB1*03:01 




Fig. 4. HLA- DRB1*03:01 promoter sequence from 3 subjects suffering from T1D and 3 
normal healthy individuals homozygous for DRB1*03:01.  Important regulatory elements 
like S-box, X-box, Y-box, CCAAY-box, TATA-box and VDRE are highlighted. Star (*) in the 
last row shows homology and dots (.) shows nucleotide substitution in one or more samples 
at that particular site and dashes(-) represent gaps inserted to maximize the homology. 
(Israni et al., 2009).  
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5.3 Sequence analysis of HLA DRB1*0301 promoter region 
Amongst the predisposing HLA-DRB1 alleles, majority of the patients (85.9%) had 
DRB1*03:01. Thus, we sought to look for the  VDRE in the promoter region of the allele. The 
promoter regions of 3 T1D subjects and 3 healthy controls homozygous for HLA-DRB1*03:01 
were amplified and sequenced to determine the VDRE variants in the North Indian 
population. Sequences were aligned using ClustalW2, and the presence of a VDRE was 
confirmed in-silico using JASPAR_CORE version 3.0 database using default conditions 
(Sandelin et al., 2004). Figure 4 shows the HLA- DRB1*03:01 promoter sequences showing 
the localization of vitamin D response element (VDRE) in the promoter region of HLA-
DRB1*0301 from the 6 subjects.  
Interestingly, the alignment showed exactly the same sequence of VDRE in the promoter 
region of HLA-DRB1*03:01 which has been shown to influence the expression of HLA allele 
DRB1*15:01 by Ramagopalan et al (Ramagopalan et al., 2009) suggesting the bases for 
interaction of VDR with HLA-DRB1*03:01 
5.4 Altered expression of HLA-DRB1*03:01 by 1,25-(OH)2D3  (Calcitriol) 
5.4.1 Flow cytometry 
To study if vitamin D3 administartion would alter the expression of MHC class-II, we 
stimulated HLA-DRB1*03:01 homozygous B-lymphoblastoid cell (B-LCL) line VAVY 
(International Histocompatibility Workshop cell line Number IHW09023) with 100nM of 
calcitriol (Sigma) for 24 hours and stained with anti-HLA DR-PE antibody (BD Biosciences) 
and acquired on BD-LSR to study the expression of HLA-DR on stimulated and 
unstimulated B-LCL The data was analysed using WinMDI 2.9 software. The results showed 
significantly higher expression of HLA-DR in the B-LCL stimulated with calcitriol as 
compared to the unstimulated one (Figure 5A and B). 
5.4.2 Real time PCR 
We also studied the levels of transcripts for HLA-DRB1 in B-LCL VAVY after 24 hour 
stimulation with calcitriol and compared it to unstimulated B-LCL  using real time PCR. The 
data shows 1.89 fold increase in the HLA-DRB1 transcripts from B-LCL stimulated with 
calcitriol as compared to the unstimulated one. These results were confirmed on perpheral 
blood mononuclear cells (PBMCs) derived from a normal healthy control homozygous for 
HLA-DRB1*03:01. 
Our results showed enhanced expression of HLA-DR on the B-LCLs stimulated with 
calcitriol as compared to the unstimulated one confirming that indeed the interaction of 
VDR with HLA-DRB1*03:01 is occurring through the VDRE present in the promoter region 
of the gene. Based on the earlier studies and the present data one can speculate that in the 
absence of required amount of Vitamin D in early life in the predisposed individuals with 
HLA-DRB1*03:01, the expression of the allele may be impaired in the thymus (Ramagopalan 
et al., 2009) resulting in escape from thymic deletion of autoreactive T cells leading to T1D 
manifestations.  
6. Conclusions 
Our studies show that simultaneous presence of DRB1*03:01 along with homozygous INS-
VNTR class-I was significantly increased ( p < 10-8) in T1D patients, giving a relative risk of 
70.81 (Rani et al., 2004). INS-VNTR class-I has been shown to be associated with lower 
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Fig. 5. Flow cytometric analysis of HLA-DR expression.  A: Histogram of HLA-DR-PE 
staining of B-LCL-VAVY cells treated with and without 100nM calcitriol. The figure shows 
enhanced expression of HLA-DR in stimulated B-LCL as compared to unstimulated one.  B: 
VAVY cells show a significant  increase in surface HLA-DR expression as determined by the 
geometric mean flurescence intensity of  antibody staining (Israni et al., 2009). 
expression of Insulin in thymii of fetuses as compared to Class-III alleles (Pugliese et al., 
1997, Vafiadis et al., 1997) which may be responsible for poor thymic education for insulin 
resulting in autoimmunity against pancreatic beta cells. Our studies provide additional 
evidence based on the statistically significant interaction between the predisposing HLA 
allele and high producer alleles of VDR which may be detrimental for the manifestation of 
T1D in the absence of 1,25-(OH)2D3 in early childhood and/or in-utero and this interaction is 
mediated by VDRE present in the promoter region of DRB1*03:01(Israni et al., 2009). With 
poor thymic education for insulin and HLA-DRB1*03:01 protein, environmental factors like 
viral infections, vitamin D deficiency and some milk proteins may be involved in initiation 
of the autoimmune responses against the pancreatic beta cells. While HLA class-II molecules 
may be involved in auto-antigen presentation to T helper cells, higher producing genotypes 
of pro-inflammatory cytokines like IFN-gamma and TNF-alpha may be involved in enhancing 
the cell mediated immune responses through proliferation of CD4+ and CD8+ T cells, while 
higher producing genotypes of IL-10 and TGF-beta may have a role in recruitment of these 
autoreactive T cells in the pancreas through ICAM-1 and Integerin dependent pathways. 
Final destruction of pancreatic beta cells may occur through CD4+ and CD8+ T cells and 
nitric oxide production since IFN- may act singularly as well as synergistically with other 
inflammatory stimuli to induce NO production which can be cytotoxic and thus may have a 
role in pathogenesis of T1D (Figure 6). Future studies should focus on developing 
approaches to inhibit autoimmunity before the onset of the disease. 
 
































Fig. 6. Conclusions of our studies. Predisposing genetic factors like MHC, INS-VNTR and 
VDR may be involved in poor thymic education for insulin and HLA-DRB1*03:01 protein 
resulting in recognition of self proteins as non-self by T cells . These genetic factors along 
with environmental factors like viral infections, vitamin D deficiency and some milk 
proteins may be involved in initiation of the autoimmune responses against the pancreatic 
beta cells. While HLA class-II molecules may be involved in auto-antigen presentation to T 
helper cells, higher producing genotypes of pro-inflammatory cytokines like IFN-γ and TNF-
α may be involved in the cell mediated immune responses. Higher producing genotypes of 
IL-10 and TGF-beta,  may have a role in recruitment of the autoreactive CD4+ and CD8+ T 
cells in the pancreas through ICAM-1 and Integerin dependent pathways respectively. Final 
destruction of pancreatic beta cells may occur through CD4+ and CD8+ T cells and nitric 
oxide production since IFN- may act singularly as well as synergistically with other 
inflammatory stimuli to induce NO production which can be cytotoxic and thus may have a 
role in pathogenesis of T1D. 
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1. Introduction 
Human autoimmune thyroid disorders (AITD), Graves’ disease (GD) and Hashimoto’s 
thyroiditis, are characterized by reactivity to self-thyroid antigens. Graves’ disease is the 
archetype for organ-specific autoimmune disorders, very important to our understanding 
the mechanisms responsible for progression of autoimmunity. 
It has been known for years that hyperthyroidism in Graves’disease is induced by 
immunological reaction, in which TSH receptor antibodies bind to the receptors on the 
surface of thyrocytes, activate them and initiate thyroid hormone production independent of 
the hypothalamic-hypophyseal control. It is known nowadays that, probably for 
environmental or endogenous reasons, Graves’disease may develop in genetically 
predisposed individuals [Weetman, 2004].  
2. Antigen presentation 
A small number of antigen presenting cells (APCs) as CD1a+ presenting dendritic cells (DC) 
were observed in the thyroids without AITD, but their number was significantly higher in 
the thyroids from Graves’ disease patients [Ben-Skowronek et al., 2007, 2008]. There are 
indications that such DCs are able to proliferate, which indicates that not all of the thyroid 
DCs need to have recently immigrated with the blood stream [Quadbeck et al. 2002]. CD1a 
antigen has the structure of an α-chain connected with β-microglobulins and is characteristic 
for immature APCs [Brigl & Brenner, 2004]. Thyroidal DCs are often in close contact with 
thyrocytes; they are clearly in an immature state and often show monocyte marker 
characteristics. The presence of positive reaction to CD1a protein in the granules of the 
apical part of some thyrocytes suggested that the thyrocytes may probably be antigen 
presenting cells in the thyroid autoimmune reactivity [Ben-Skowronek et al., 2007,2008]. The 
investigations of transgenic mice by Kimura et al. [Kimura et al., 2004] indicated that 
expression of class II MHC molecules on epithelial thyroid cells is not required for the 
initiation of an autoimmune attack to the thyroid. The initiation, then, seems to be mainly 
mediated by the professional antigen presenting cells in the lymphoid tissue. The antigen 
can be presented to CD4+ cells by conventional antigen presenting cells, particularly 
dendritic cells and also by B-cells and activated T-cells, and less effectively by thyrocytes. 
The antigen presentation by thyroid epithelial cells sustains the autoimmune reaction. 
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1. Introduction 
Human autoimmune thyroid disorders (AITD), Graves’ disease (GD) and Hashimoto’s 
thyroiditis, are characterized by reactivity to self-thyroid antigens. Graves’ disease is the 
archetype for organ-specific autoimmune disorders, very important to our understanding 
the mechanisms responsible for progression of autoimmunity. 
It has been known for years that hyperthyroidism in Graves’disease is induced by 
immunological reaction, in which TSH receptor antibodies bind to the receptors on the 
surface of thyrocytes, activate them and initiate thyroid hormone production independent of 
the hypothalamic-hypophyseal control. It is known nowadays that, probably for 
environmental or endogenous reasons, Graves’disease may develop in genetically 
predisposed individuals [Weetman, 2004].  
2. Antigen presentation 
A small number of antigen presenting cells (APCs) as CD1a+ presenting dendritic cells (DC) 
were observed in the thyroids without AITD, but their number was significantly higher in 
the thyroids from Graves’ disease patients [Ben-Skowronek et al., 2007, 2008]. There are 
indications that such DCs are able to proliferate, which indicates that not all of the thyroid 
DCs need to have recently immigrated with the blood stream [Quadbeck et al. 2002]. CD1a 
antigen has the structure of an α-chain connected with β-microglobulins and is characteristic 
for immature APCs [Brigl & Brenner, 2004]. Thyroidal DCs are often in close contact with 
thyrocytes; they are clearly in an immature state and often show monocyte marker 
characteristics. The presence of positive reaction to CD1a protein in the granules of the 
apical part of some thyrocytes suggested that the thyrocytes may probably be antigen 
presenting cells in the thyroid autoimmune reactivity [Ben-Skowronek et al., 2007,2008]. The 
investigations of transgenic mice by Kimura et al. [Kimura et al., 2004] indicated that 
expression of class II MHC molecules on epithelial thyroid cells is not required for the 
initiation of an autoimmune attack to the thyroid. The initiation, then, seems to be mainly 
mediated by the professional antigen presenting cells in the lymphoid tissue. The antigen 
can be presented to CD4+ cells by conventional antigen presenting cells, particularly 
dendritic cells and also by B-cells and activated T-cells, and less effectively by thyrocytes. 
The antigen presentation by thyroid epithelial cells sustains the autoimmune reaction. 
 




Fig. 1. The thyrocytes are antigen presenting cells and show reaction with the CD1a 
monoclonal antibody. Magn. 400x 
While analyzing the process of antigen presentation in thyroids sampled from patients, the 
treatment process should be taken into account. Metimazole and carbimazole change the 
presentation of antigens by thyrocytes. Thionamides have been reported to influence the 
expression the antigens of the major histocompatibility complex class I, IL-1 (interleukin-1), 
IL-6 (interleukin- 6), prostaglandins E2 produced by thyrocytes [Zantut-Wittmann et al., 
2001]. The expression of major histocompatibility complex class II is unchanged by 
thionamides [Dedecjus et al. 2010].  
Numerous investigations indicate that adhesion molecules are engaged in the process of 
migration of lymphocytes to the thyroid and lymphocyte adhesion [Arao et al., 2000]. 
Adhesion molecule ICAM-1 (Inter-Cellular Adhesion Molecule 1) belonging to the 
superfamily IgG is a natural ligand of antigen located on lymphocytes LFA-1 (Lymphocytic 
function-associated antigen - 1). This antigen belongs to the integrin-β2 superfamily 
[Springer, 1990]. ICAM-1 is located on different cells: fibroblasts, endotheliocytes, and 
thymocytes. It was identified on thyrocytes as well [Weetman et al., 1989, Martin et al., 1990, 
Springer,1990].The expression of ICAM-1 is regulated by proinflammatory cytokines: 
interferon γ, interleukin 1β (IL 1β) and TNF-α ( Tumor Necrosis Factor -1) [Dustin et al., 
1986, Martin et al., 1990, Springer 1990, Bagnasco et al., 1991]. In Graves’ disease, the ICAM-
1/LFA-1 pathway plays a key role in migration and settlement of lymphocytes in the 
thyroid, and particularly in the process of adhesion of lymphocytes to thyrocytes [Arao et 
al.,2000]. In vitro experiments have shown that thyrocytes behave like antigen presenting 
cells and can induce lymphocyte migration [Estienne et al., 2002].  
Expression of HLA DR II and the immunoglobulin Fc receptor (FcγRIIB2) has been found on 
the basal and apical surfaces of thyrocytes [Botazzo et al., 1983, Wu et al., 1999]. The 
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presentation of the latter antigen is dependent on the low level of androgens, which is 
probably connected with higher prevalence of AITD in women [Estienne et al., 2002]. 
Presentation of antigens by thyrocytes without the costimulatory molecule B7 does not lead 
to activation of T-cells [Marelli-Berg et al., 1997]. The expression APC characteristic antigens 
are dependent on TSH [Todd et al., 1987, Estienne et al., 2004]. Thyrocytes may produce 
HLA I under the influence of cytokines of lymphocytes present in the thyroid. In this way, 
the autoimmunologic reaction is sustained [Catalfamo et al., 1999].  
3. The development of autoimmune reaction 
When immune tolerance to thyroid antigens is broken, the endothelial cells of regional 
postcapillary venules are activated, allowing extravasation of blood leukocytes. In Graves’ 
disease, the lymphatic tissue arranged in lymphoid follicles containing T- cells may be 
formed in the thyroid. T-cells form infiltrations and lymphatic follicles but do not damage 
thyrocytes [Kuby et al., 2007].  
Graves’ disease patients seem to have mixed Th1/Th2 profiles. The lymphocyte subsets 
produce signal interleukin: Th1 – IL2 and Th2- IL4.The immunological response proceeds 
via T-cell receptor (TCR) antigen recognition, followed by activation of the T- cell through a 
combined effect of antigen recognition and co-stimulatory signals, including interleukin -1 
(IL-1) action leading to T- cell IL 2 secretion and IL-2 receptor expression and, subsequently, 
to proliferation of the T- cell into an active clone. [Janeway et al., 2001 Janeway & Medzhitov 
2002] 
In Graves’ disease, the increased percentage of CD4+ T helper cells, in comparison to non-
AITD, leads to development of humoral autoimmune response. Antigens of self-thyrocytes 
are presented in such a way that they are recognized by self – T-helper CD4+ lymphocytes. 
T-helper cells CD4+ sporadic occurred in thyroids of children from the control group, 
seldom in the simple goiter and slightly more often in the nontoxic nodular goiter. The 
number of T-helper cells in Graves’ disease was the largest [Ben-Skowronek et al., 2007, 
2008]. 
The subset of CD4+cells includes the regulatory lymphocytes - Tregs, which play a 
fundamental role in modulation of immunological response through their inhibitive effect 
on autoreactive T-cells [Piccirillo & Shevach,2004, Piccirillo & Thornton, 2004, Shewach, 
2006]. The mechanism of this suppression is unknown, but many investigators consider it to 
be dependent on the contact between lymphocytes and independent of secretion of IL-10 
and TGFβ [Piccirillo et.al. 2002,2003]. In the remission phase during thyrotoxic treatment, 
the subsets of lymphocytes were not different from the control group and from children 
with the simple goiter and nontoxic goiter [Bossowski et al. 2003]. The cells were 
characterized by expression of CD25 (the α-chain of IL2) and intracellular expression of 
FoxP3 (Forkhead winged helix box3). Only the subset of CD4+cells with maximal expression 
of CD25 (CD4+CD25+high) is responsible for the suppressor – regulatory effect of these 
lymphocytes [Cao et al., 2003, Baecher-Allan et al., 2001, 2003, Bossowski 2010]. The 
CD4+CD25+ cells can occur natural or can be induced – they are generated in the lymphatic 
tissue from CD4+CD25+ cells by different stimulant agents: by immature dendritic cells, IL-
10, TGFβ, supply of vitamin D3 or dexamethasone, anti-lymphatic treatment or small doses 
of antigens. The Treg cells not need costimulation of CD28-B7 for their development or 
activity. They play a pivotal role in sustenance of immunologic tolerance [Piccirillo & 
Shewach, 2004, Piccirillo & Thornton, 2004]. TGF-β is assumed to be necessary for the 
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regulatory function of Treg cells; it also prevents activation of lymphocytes and 
autoimmune reactions [Bommireddy et al., 2008]. The quantity of lymphocytes in this subset 
is decreased in Graves’ disease [Deshun et al., 2009].   
An increase in T-helper lymphocytes, especially in Th1 lymphocytes, results in activation 
of B lymphocytes and their transformation into plasma cells which produce thyroid 
antibodies, predominantly TRAB (TSH receptor antibody), TSI ( TSH stimulated 
immunoglobulin), and also TPO Ab ( Antithyroperoxidase antibody) and TG Ab ( 
Antithyroglobulin antibody). 
T cells CD8+ are observed in the thyroid more often in Graves’ disease than in non-AITD; 
they have a regulatory T-cell function. Electron microscopy examinations did not 
demonstrate any damage to thyrocytes, but CD8+ lymphocytes frequently entered the 
thyroid follicles through the basal membrane [Ben-Skowronek et al., 2009].  
The T-suppressor-cytotoxic CD8+ cells were observed in thyroid follicles between 
thyrocytes, in mononuclear infiltrations and in lymphatic follicles in the mantle zone. In 
light microscopy, CD8+ T-cells and adherent normal thyrocytes were visible in high 
magnifications. Bossowski et al. have found a correlation between expression of 
costimulatory molecules CTLA-4 and CD28 on T-cells and the level of antibodies against the 
TSH receptor [Bossowski et al., 2005]. The investigations of Negrini et al. [Negrini et al., 
2006] indicate a possibility of presentation of GITR receptors on the surface T-cells CD8+ 
characteristic for Treg cells. Own observations have confirmed this character of CD8+ T-
cells, because they are located between thyrocytes and do not cause apoptosis. 
 
 
Fig. 2. The CD8+ T-cell between thyrocytes in thyroid follicle wall. The thyrocytes are active 
and present no signs of apoptosis or cell damage. Magn. 400x. 
In vitro investigations and observations of the thyroid tissue in electron microscopy indicate 
the possibility of formation of the so-called immunological synapse of a character of a tight 
junction between lymphocytes and thyrocytes with participation of adhesive proteins. This 
physical contact may result in establishment of an immunological synapse able to stimulate 
intra thyroid T lymphocyte proliferation and differentiation. 
 




Fig. 3. T cells among thyrocytes in the thyroid epithelium. The thyrocytes are active without 
destruction signs. N- nucleus, Mv – microvilli, BM – basal membrane, BV – blood vessel. 
Transmission Electron Microscopy Magn. 15 000x. 
Recent investigations have suggested that a crucial role in peripheral tolerance or 
autoreactive T- cells is played by T regulatory subsets (Tregs) divided into two populations: 
naturally occurring and inducible [Wieczorek et al., 2009]. Tregs so far identified as 
participating in the pathogenesis of Graves’ disease include naturally occurring 
CD4+,CD25+T cells , C8+CD122+T cells and natural killer cells [Bossowski et al., 2010]. 
Comparison of immunohistochemical localization of CD4+ T cells in ultrastructural 
investigations has shown that lymphocytes CD4+T were small cells with large nuclei and a 
small amount of cytoplasm in contact with thyrocytes and other lymphocytes [Ben-
Skowronek et al., 2009].  
 
 
Fig. 4. The immunological synapse between T-cells and thytrocytes in Graves’ disease. 
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Rifa’i et al. [Rifa’i et al., 2004] have described subsets of naturally occurring Tregs 
CD8+CD25+. It is possible that CD8+T cells in contact with thyrocytes play the role of Tregs 
in the pathogenesis of Graves’ disease. The investigations of Negrini et al. [ Negrini et al. 
2006] have characterized a subpopulation of CD8 T suppressor lymphocytes able to inhibit 
both cell proliferation and cytotoxicity; they have observed that glucocorticoid–induced 
TNF-like receptor (GITR) is expressed on such CD8 T suppressor cells. The papers of 
Nakano et al. [Nakano et al., 2006] and Nagayama [Nagayama et al., 2007] suggest a 
preventive role of Tregs in autoimmune reaction in the thyroid with AITD. 
Patients with Graves’ disease have an increased number of circulating B-cells but plasma 
cells predominate in the thyroid. The close contact with T-cells (probably Th2 cells) and 
plasma cells has been frequently observed only in Graves’ disease and sporadically in the 
non-AITD and suggested the regulation function of the T-cells stimulating plasma cells to 
produce autoantibodies [Ben-Skowronek et al., 2008].  
The plasma cells in Graves’ disease penetrate between thyreocytes; nevertheless, they 
caused no destruction of thyroid follicles and epithelial cells. Ultrastructural changes in 
plasma cells were observed in patients with Graves’ disease: a large, active nucleus with a 
nucleolus, a well-developed rough endoplasmic reticulum in which antibodies were 
 
 
Fig. 5. The plasma cell producing antibodies in contact with thyrocytes. RBC-red blood cell, 
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produced. The number of plasma cells in the thyroid was inversely proportional to time of 
treatment, which proved the immunomodulant activity of thyrostatic drugs [Ben-
Skowronek et al., 2009].  
In Graves’ disease, the immunological deposits observed in the basal membrane of the 
thyroid follicles lead to thickening of this membrane and probably to changes in 
polarization of cell membranes. The thyrocytes in this region are columnar, with signs of 
increased activity (big nuclei; active, enlarged mitochondria; a big number of granules in the 
apical pole; long microvilli). [ Ben-Skowronek et al., 2008,2009]. The antibody deposits do 
not damage thyrocytes but enhance their activity and metabolism by activation of the THS 
receptors, and lead to hyperthyroidism. 
 
 
Fig. 6. The late phase of development of antibodies deposits in the basal membrane of the 
thyrocytes. Transmission Electron Microscopy Magn. 20 00x 
Numerous reports have shown that Th-1 cell activating the antibody-dependent cellular 
cytotoxicity (ADCC) can be detected in Graves’ disease, although the response is usually 
weak and not present in many patients [Guo et al., 1997, Metcalfe et al., 1997]. ADCC of 
thyroid cells is induced by anti TPO antibody positive sera, but other unknown antibody-
antigen systems and methimazole therapy also contribute. Large granular lymphocytes – 
phenotypic NK cells - are rarely present in the lumen of the thyroid follicle. Here, 
degenerative changes in the thyrocytes were observed by electron microscopy [Ben-
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Antibodies may be produced against the TSH receptor (TSH receptor stimulating antibodies 
– TS Ab, TSH binding inhibiton immunoglobulins – TBII, TSH stimulation blocking 
antibodies – TSBAb), against thyroperoxidase (TPO Ab), against thyroglobulin (TG Ab), 
against megalin [Marino et al., 1999], against the iodine symporter, against thyroid’s DNA, 
against components of external eye muscles and fibroblasts, against parietal cells and 
against platelets [Weetmann, 2004].  
The stimulating antibodies (TSAb) react with the TSH receptor and initiate activity of adenyl 
cyclase and phospholipase A2of the receptor, thus stimulating production of thyroid 
hormones and growth and division of thyrocytes [Orgiazzi et al.,1976, DiCerbo et al., 1999, 
Ewans et al.,1999, Morshed et al., 2009]. The blocking antibodies act like weak agonists of 
the TSH receptor [Lenzner et al., 2003, Schwarz-Lauer et al., 2002]. 
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Hashimoto’s Thyroiditis – Interactions of 
Lymphocytes, Thyroid Cells and Fibroblasts 
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1. Introduction 
Autoimmune Hashimoto’s thyroiditis involves painless enlargement of the thyroid, which, 
in histopathological analysis, is characterised by diffuse lymphocytic infiltrations, fibrosis, 
and atrophic changes. It is a diffuse process, a combination of epithelial cell destruction, 
lymphocyte infiltrations, and fibrosis. The incidence of Hashimoto’s thyroiditis ranges 
between 0,3 and 1,5 per 1000 persons. It is diagnosed 15-20 times more frequently in females 
than in males. The forms of Hashimoto’s thyroiditis include: euthyroid goitre, and goitre in 
subclinical or clinical hypothyroidism, hypothyroidism without goitre, silent thyroiditis, 
postpartum thyroiditis, alternating hyperthyroidism and hypothyroidism [Weetman 
&McGregor 1994]. 
Hashimoto’s thyroiditis is often associated with type I diabetes, coeliac disease and other 
autoimmune diseases. It is one of the components of the autoimmune polyglandular 
syndrome.  
In histopathological investigations of Hashimoto’s thyroiditis, the follicular epithelial cells in 
the thyroid are large and often eosinophilic; they are the so-called Hurthle or Askenazy cells 
packed with mitochondria. Lymphocyte clusters present between the follicles form typical 
lymphoid follicles in some sites. Infiltrations contain numerous plasma cells. In Hashimoto’s 
thyroiditis, the immunological attack appears to be destructive, rather than stimulating, as 
in Graves’ disease. Two variants of Hashimoto's thyroiditis have been reported so far: 
atrophic – related to gene HLA-DR3 inheritance, and hypertrophic – involving goitre 
enlargement associated with HLA-DR5 [Weetman, 2004]. A study of autoimmune 
thyroiditis in monozygotic twins demonstrated environmental factors inducing 
development of the disease [Brix et al., 2000]: high iodine intake, selenium deficiency, 
smoking, infectious diseases, e.g. hepatitis C, and some drugs [Duntas, 2008]. Prolonged 
exposure to iodine leads to enhanced iodination of thyroglobulin, which increases its 
antigenicity and initiates autoimmune processes in genetically predisposed individuals. 
Selenium deficiency causes a decrease in the activity of selenoproteins, including 
glutathione peroxidise, which leads to an increase in the concentration of hydrogen 
peroxide and development of inflammatory processes.  
Classical histopathological descriptions of the thyroid in Hashimoto’s thyroiditis emphasise 
the fact that the changes include destruction of thyrocytes, lymphocytic infiltration, and 
fibrosis. 
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2. The course of the immune response in Hashimoto's thyroiditis 
2.1 Antigen presentation 
Stimulation of the immune system depends on maturity of dendritic cells. Immature 
dendritic cells are characterized by expression of small numbers of co-stimulatory molecules 
and proinflammatory cytokines; they may also cause anergy. Maturing dendritic cells 
display significantly higher expression of MHC class II and co-stimulatory molecules, but 
low levels of proinflammatory cytokines. Only mature dendritic cells can induce regulatory 
T cells [Jonuleit et al., 2001; Menges et al., 2002; Gad et al., 2003; Wakkach et al., 2005]. 
Antigen presenting cells are more frequently found in Hashimoto’s thyroiditis than in 
healthy thyroid glands or individuals with non-autoimmune thyroid diseases (simple goitre, 
non-toxic nodular goitre) [Ben-Skowronek et al., 2008, 2011]. No mature dendritic cells 
presenting MHC class II antigens have been found in thyroid preparations. The 
investigations conducted by Kimura et al. have indicated that MHC class II antigens may be 
expressed on thyrocytes in the autoimmune thyroid inflammation. Our own research has 
shown a positive reaction with the monoclonal antibody CD1a specific for dendritic cells in 
some thyrocytes. This is not sufficient to initiate the autoimmune response, but sufficient to 
sustain it [Kimura et al., 2004]. 
2.2 Development of immunological reaction in the thyroid gland  
Lymphatic follicles appear inside the thyroid gland in the course of Hashimoto’s thyroiditis. 
The study of Armengol et al. has demonstrated higher levels of lymphokines and their 
ligands responsible for lymphocyte migration, settlement, and formation of lymphoid 
follicles (lymphotoxin α, lymphotoxin β, CC chemokine ligand (CCL)), and CXC (CXCL 12, 
CXCL13) chemokine ligands). Moreover, in response to inflammatory cytokines, thyrocytes 
can produce CXCL12. Tissue stress caused by viral or bacterial inflammation is likely to lead 
to formation of lymphoid follicles in the thyroid [Armengol, et al., 2003]. Production of 
cytokine ligands for CXCL21, CXCL 22, and CXCL 13 by thyrocytes is correlated with the 
level of anti-thyroid antibodies, and thus, directly with the inflammatory response in the 
thyroid [Armengol  et al., 2003]. 
From the physiological point of view, lymphoid follicles are small structures in which 
processes of somatic hypermutation, maturation of immune affinity receptors, switching of 
antibody isotypes (e.g. from IgM to IgG), and receptor control take place. Autoreactive T 
cells arise de novo in the germinal centres; here operates the mechanism sustaining 
tolerance - apoptosis of autoreactive lymphocytes [Pulendrav et al., 1997, Janevay et al., 
2002]. In autoimmune diseases of the thyroid, muscles, and joints as well as in Sjögren's 
syndrome and autoimmune alveolitis, the ectopic lymphoid tissue is arranged in lymphoid 
follicles in non-lymphatic organs, which do not contain physiological, growing lymphoid 
tissue [Crawford et al.1983, Schroeder et al., 1996, Wallace et al.1996, Shione et al  1997, Stott 
et al 1998, Itoh et. al 2000, Sims et al,. 2001]. The function of this lymphoid tissue, sometimes 
defined as tertiary lymphoid tissue (primary tissues - thymus and bone marrow, secondary - 
lymphatic glands and organs), is unclear [Weetman et al. 1994, Ruddle et al. 1999, Armengol 
et al , 2001]. The structure of the ectopic lymphoid follicles in the thyroid is similar to that of 
typical lymphoid follicles in lymphoid organs: they consist of a germinal centre and a 
peripheral zone (mantle zone) containing lymphocytes B and T, and dendritic cells. An 
analysis of immunoglobulin gene rearrangement (RAG1 and RAG2) has confirmed the 
possibility of formation of high endothelial venules in lymphoid follicles and production of 
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cytokines responsible for lymphocyte migration and settlement, which would trigger an 
autoimmune reaction [Armengol et al., 2001]. TG Ab, TPO Ab and TRAK  anti-thyroid 
antibodies are produced in B cells in the lymphoid follicles [Armengol et al., 2001]. High 
levels of antibodies against thyroglobulin (TG Ab) and thyroperoxidase (TPO Ab) are 
detected in the serum of patients with Hashimoto’s thyroiditis. These antibodies are 
regarded to have cytotoxic activity. However, investigations of thyroids of foetuses from 
mothers with Hashimoto’s thyroiditis did not show the expected damage. Hypothyroidism 
was observed only in some children.    
T cells originating from mice immunized with TPO strongly react with sequence 540-559; 
immunisation of mice with this peptide results in development of hypothyroidism and 
thyroiditis. Peptide 540-559 is probably a key factor in the immune response against TPO 
[Kawakami et al. 1992]. Natural HLA-DR-associated peptides have also been identified; they 
are present in the colloid, and some of them derive from thyroglobulin [Ng et al., 2006]. A 
larger proportion of lymphocytes binding to thyroglobulin are present in the thyroid than in 
peripheral blood [Heuer et al., 1996]. Being the major stimulatory antigen, thyroglobulin is 
indispensable for T cell response [Sugihara et al., 1993]. The severity of autoimmune 
reactions following immunization with thyroglobulin has been observed in transgenic mice 
producing IL-12 [Kimura et al.,2005].  
Immune reactions involving T cells are controlled by certain T lymphocyte subpopulations: 
CD4 + Treg and natural killer lymphocytes are employed in the control of the magnitude 
and class of the immune response, while lymphocytes CD8 + are responsible for recognition 
for self- and non-self- antigens [Jang et al., 2006].  
A slightly larger number of CD4 + cells have been observed in Hashimoto’s thyroiditis than 
in non-autoimmune thyroid diseases; however, the number was statistically significantly 
lower than in Graves' disease [ Ben-Skowronek et al., 2007,2008]. The studies of McLachlan 
suggest that the reduction in the number of Treg cells (particularly CD25) induces 
lymphocyte infiltration in the thyroid accompanied by transient or permanent 
hypothyroidism [Mc Lachlan et al., 2007]. 
Animal studies have shown that depletion of CD4 + CD25 + Treg in mice increases 
susceptibility to thyroiditis by enhancement of the immune reaction against thyroglobulin 
and exacerbates the existing thyroiditis, whereas an increase in the number of CD4 + CD25 
+ T cells restores resistance to thyroiditis [Morris et al., 2006,2007, Nagayama ey al. 2007]. It 
appears that an insufficient percentage of CD4 + T cells in Hashimoto's disease is the cause 
of the destructive autoimmune reaction in the thyroid. 
Suppressor/cytotoxic lymphocytes CD8 + have been found among thyrocytes in thyroid 
follicles, in lymphatic infiltrations and in the lymphoid follicles of the mantle zone. 
Glycoprotein CD8 present on the surface of cytotoxic lymphocytes may bind to the class I 
MHC molecule, which leads to activation of T cells CD8+. This activation is also dependent 
on co-stimulatory proteins binding to antigen CD28 (the so-called two-signal model). Once 
activated, cytotoxic lymphocytes may secrete cytotoxins, and granzymes and granulysins.  
They perforate the cell membrane and form pores, which induces apoptosis of the target 
cell. Another pathway leading to apoptosis is activation of the Fas ligand [Iannacone et al., 
2005,2006, Subramanian et. al., 2005]. Hypothyroidism in patients with autoimmune 
thyroiditis is associated with apoptosis of alveolar epithelial cells induced by cytokines. 
Expression of Fas ligand on thyrocytes of patients with Hashimoto thyroiditis and a weak 
reaction for Bcl-2 have been detected, which suggests cytokine-induced apoptosis 
[Kawakami et al., 1996, Mitsiiades et al.,1998, Stassi et al., 2002]. TPO-specific T cells cause 
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destruction through cytotoxic mechanisms involving CD4+ and CD8 + cells or programmed 
Fas- TNF-alpha-induced  apoptosis [Stassi et al., 2002]. In Hashimoto's disease, damaged 
thyrocytes in contact with CD8 + T lymphocytes may be observed in the light microscope. 
The electron microscopy has shown contact sites of lymphocytes with thyrocytes located in 
the thyroid follicular epithelium. Polarization of endolysosomes near the site of contact has 
been detected in the lymphocytes which displayed the T-cell phenotype of and CD8 + 
location. Similar observations of cultured CD8 + and dendritic cells in experimental 
conditions were conducted by Gardella et al. [Gardella et al., 2001]. The studies of  Negrini 
et al. [Negrini et al.,2006] have indicated possible presence of the GITR (Glucocorticoid-
Induced TNF-Like Receptor) antigen on the surface of CD8 + T cells, which would render 
them as regulatory Treg cells. Therefore, it is believed that cytotoxic T cells, K (killer) 
lymphocytes, NK (natural killer) cells, and regulatory (Treg) or suppressor T cells may play 
an important role in autoimmune thyroid damage. Some studies indicate the ability of T 
cells to transfer thyroid autoimmune processes, both in animals with experimental 
autoimmune thyroiditis and patients who have undergone bone marrow transplantation 
[Kawakami et al.,, 1992, Ng et al., 2006, Drabko et. al., 2006].  
Active lymphocytes B CD79alfa+ and antibody-producing plasma cells were found in a 
small percentage of thyroids from healthy children (4,11%), in the colloid goitre (1,83%) and 
the nodular goitre (5,22%). The largest number of CD79 alpha+ lymphocytes was observed 
in thyroid specimens from patients with Hashimoto’s thyroiditis (average 31,65%) In 
lymphatic infiltrates, plasma cells constituted almost half of the cells (46,67%), and 
amounted to 17,23% in the thyroid parenchyma. Foci of damaged thyroid follicles and 
numerous fibroblasts and collagen bands have been observed at the plasma cell 
accumulation sites. The thyroid glands in children with Hashimoto’s thyroiditis displayed 
characteristics of lymphocyte activation, the so-called blastic transformation, consisting in 
an increase in the volume of the cell and, particularly, of the nucleus, appearance of nucleoli 
and an increase in the cytoplasm volume through enlargement of the rough endoplasmic 
reticulum, in which antibody production takes place [Ben-Skowronek et al., 2007].  
Thyrocytes in Hashimoto’s thyroiditis are cuboidal or flat. The thyroid cells exhibit damage. 
Cell nuclei are often folded; secretory vesicles are sporadically present in the apical pole 
(sometimes there are no vesicles); and swollen mitochondria are present in the basal pole. The 
swollen part of thyrocytes without microvilli or with single microvilli projects into the lumen 
of the follicle. The basal membrane is thickened. Plasma cells, lymphocytes and fibroblasts are 
visible among the thyroid follicles. At the lymphoid infiltration sites, the lymphoid cells 
separate the thyroid epithelium from the basal membrane of the capillary blood vessels. 
Lymphocytes are often in direct contact with plasma cells. Plasma cells filled with 
concentrically arranged layers of the rough endoplasmic reticulum adhere to the basal 
membrane of the thyroid follicle and the surrounding thyrocytes. The thick, electron dense 
basal membrane contains numerous collagen fibres. The adjacent cytoplasmic membrane does 
not exhibit characteristic folds. The fibrous basal membrane hinders blood flow in the capillary 
blood vessels and deformed erythrocytes can be seen in their lumen. The exchange of nutrients 
and oxygen between thyrocytes, the interstitium, and blood vessels is impeded [Fig. 1]. 
3. Apoptosis in autoimmune thyroid diseases 
Apoptosis is a physiological form of cell death resulting from the need of multicellular 
organisms to maintain balance between dividing and dying cells. Typical morphological 
 
 




Fig. 1. A markedly thickened basal membrane of the thyroid follicle containing collagen 
fibres impedes thyrocyte contact with the capillary vessel lumen.  In the basal membrane is 
present lymphocyte  (phenotype lymphocyte T). The thyrocytes exhibit signs of damage of 
thyroid follicular cells– swollen mitochondria, dilated cisterns of the rough endoplasmic 
reticulum, absence of secretory granules, and atrophy of microvilli. Transmission Electron 
Microscope  Magn. 10 000x. 
changes in cells that received the signal to begin the apoptotic process include folding of the 
cell membrane, condensation of cytoplasm and cellular organelles, disappearance of the 
mitochondrial membrane, shrinkage of the nucleus, and condensation of chromatin 
[Yamazaki  et al., 2000, Lorenz et al., 2005]. 
Apoptosis can be initiated by T cells through two pathways: 
 by perforins secreted by lymphocytes into the junctions between lymphocytes and 
target cells; they perforate the cell membrane and form pores thus inducing osmotic 
lysis of the cell; simultaneously, granzymes B activate the caspase cascade, which leads 
to cell apoptosis; 
 the Fas ligand and TNF-related apotosis induced ligand (TRAIL) secreted by 
lymphocytes stimulate the so-called death receptors on the cell surface causing 
activation of caspase cascade through caspase 8 and 10. 
Lymphocytic infiltration and antibodies secreted by plasma cells lead to destruction of 
thyrocytes, but actively stimulate the production of collagen by fibroblasts. As a result, large 
amounts of collagen accumulate in the follicular and vascular basal membranes. In the final 
stage of the process, thyrocytes are destroyed via apoptosis. Typical signs of cell apoptosis 
are visible: chromatin condensation in the nuclei of thyroid epithelial cells, condensation of 
the cytosol and swelling of the mitochondria [Fig.2]. 
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Fig. 2. The last phase of destruction of the thyroid in Hashimoto’s thyroiditis. The thyrocytes 
are damaged due to apoptotic processes. Plasma cells and lymphocytes predominate in the 
interstitium. The fibroblast migrates to this place and produces collagen fibres. Transmission 
Electron Microscope. magn. 5000x. 
Various phases of thyrocyte death were visible at the lymphocyte infiltration sites; apoptosis 
was caused by active plasma cells and lymphocytes of the large granular lymphocyte 
phenotype (LGL) [Fig.2] Ultrastructural investigations have revealed that the reaction 
between lymphocytes and plasma cells producing antibody results in thyrocyte damage, 
which, in turn, changes the permeability of cell membranes and intracellular membranes 
and leads to accumulation of water in the endoplasmic reticulum cisterns in the 
mitochondria and cytoplasm. Consequently, the cell is enlarged, microvilli disappear, and 
swollen mitochondria occupy the basal pole of thyroid cells causing cell staining with acidic 
dyes. At the same time, electron-dense substances (probably antibodies) are deposited in the 
follicular basal membrane. In response, large amounts of collagen are secreted around the 
damaged follicles. Communication between the lumen of capillary vessels and thyrocytes is 
impeded; hence, the transport of oxygen, nutrients, and substrates for production of thyroid 
hormones is inhibited. The thyrocyte metabolism is decelerated, and production of hormone 
and protein colloid is disrupted. Thyrocytes gradually die and exfoliate into the follicle 
lumen. Lymphocytes migrate to replace them and form lymphoid follicles. Fibroblast bands 
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The contact between lymphocytes and thyrocytes in Hashimoto's thyroiditis forms an 
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Such cell junctions occur mainly in the lymphoid nodes. Very tight junctions are visible 
between lymphoblasts and B cells, which are phenotypically similar to plasma cells. 
Immunological synapses have been found also between lymphocytes [Ben-Skowronek in 
press] 
In Hashimoto's disease, activation of apoptotic processes is also associated with activation of 
Th1 cells, which enhance the activity of caspase and apoptosis through production of IFN-γ. 
While reduction in the number of CD4 + cell subsets in the thyroid parenchyma has been 
reported both in our own study and in animal models of the disease [Sugihara et al., 1993], 
an increase in the number of active CD4 + IL-4 + was observed in the peripheral blood 
[Maziotti et al., 2003]. However, no correlation has been found between the number of CD4 
+ T cells in the thyroid and the antiperoxidase antibody levels in serum [Watanabe et al., 
2002, Pandit et al., 2003].  
Antibody-dependent cell-mediated cytotoxicity (ADCC) plays an important role in 
development of Hashimoto's thyroiditis, whereas complement-dependent cytotoxicity (CDC) 
exerts a lesser effect. The thyroid peroxidase antigen evokes the reaction [Czarnocka et al., 
1985, Estienne et al., 2002, Guo et al., 2005 Rebuffat et al., 2006, Ng et al., 2004, 2006]. TPO Ab 
has been detected in 90% of Hashimoto’s thyroiditis patients [Rappaport et al.,  2001]. Anti-
TPO antibodies are various isotypes of the IgG antibodies. Anti-peroxidase antibodies TPOAb 
can damage thyrocytes through the ADCC and CDC mechanisms. The cytotoxic ADCC 
mechanism depends on the interaction between the target cell, antibody and effector cell. 
Monocytes, which due to FcγRI receptors are effector cells activated by TPOAb, can affect T 
cells and lead to destruction of thyrocytes [Rebuffat et al.,2008]. FcγRIII are present on Natural 
Killer cells and FcγRII on monocytes and neutrophils. All FcγR fragments are involved in the 
ADCC reaction [Rebuffat  et al., 2008]. The investigations of Giancotti and Williams et al. 
suggest that integrins β2 may participate in cytotoxic reactions involving FcγR [Giancotti et al., 
1999, Williams et al., 1999]. The study of Rebufatt et al. [Rebuffat  et al., 2008], however, 
indicates involvement of two monocytic cell lines in this process. 
It has not been sufficiently documented yet whether specific IgG antibody subclasses take 
part in thyrocyte damage [Metcalfe 1997, Guo 1997]. Xie L-D et al. investigated the 
occurrence of anti-TPO IgG subclasses and found that IgG1 was present in 70.2%, IgG2 in 
35.1%, IgG3 in 19.6%, and IgG4 in 66.1% of patients; increased proportion of IgG2 
predisposes to thyroid damage and hypothyroidism [Xie et al., 2008].  
Metcalfe et al. found no correlation between the IgG subclasses and thyrocyte damage in 
vitro [Metcalfe et al.,  1997], whereas Guo et al. demonstrated that thyrocyte damage is 
associated with subclass IgG1 [Guo et al.,  1997]. Recent studies conducted by Rebuffat et al. 
[Rebuffat et al., 2010, Pappenwali et al., 2010] indicate that anti-TPO antibodies exhibit 
moderate activity in the ADCC process and can be used in the new methods of treatment of 
papillary thyroid cancer, the cells of which show expression of TPO.  
Thyrocyte damage continues and is potentialized by the CDC reaction [Rebuffat et al., 2008]. 
Complement component C4, hyperexpressed on the surface of thyrocytes in Hashimoto’s 
thyroiditis, participates in this reaction [Blanchin  et al., 2003]. The key antigen here is 
thyroid peroxidase. The TPO ectodomain consists of a long module similar to 
myeloperoxidase, followed by a module similar to the complement control protein (CCP) 
and a module similar to the epidermal growth factor (EGF). The CCP contains a fragment 
that activates the complement. Therefore, TPO can activate the complement cascade without 
the help of immunoglobulins. Tg Ab antibodies do not fix the complement [Weetmann et al., 
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2004] and probably are not directly involved in the CDC reaction, which is related to the fact 
that thyroglobulin is not expressed on the surface of thyrocytes. 
Reduction or loss of intercellular communication in the final phase of Hashimoto’s 
thyroiditis may lead to destruction of thyrocytes and hypothyroidism [Greek et al., 1996, 
Green et al., 1997, DiMatola  et al., 2000] 
 Fibrocytes and fibroblasts in autoimmune thyroid diseases  
Fibrocytes and fibroblasts are frequently disregarded in analyses of autoimmune reactions 
in the thyroid. Ultrastructural studies have revealed significant participation of fibroblasts in 
the pathogenetic processes in Hashimoto's disease. They enter the space between the basal 
membrane and thyrocytes and produce substantial amounts of collagen, thus leading to 
thickening of the basal membrane and impeded contact between the capillary vessel lumen 
and thyrocytes [Fig. 1,2].  
Influx and proliferation of lymphocytes in the thyroid as well as production of collagen is a 
response to inflammation processes and a stimulus for further thyrocyte damage through 
isolation thereof from oxygen and nutrients in the blood vessels. Progressive damage of 
thyrocytes leads to release of large amounts of autoantigen and triggers the inflammatory 
response. Own observations indicate a possible direct impact of plasma cells, lymphocytes 
and fibroblasts, since thyroids of Hashimoto’s thyroiditis patients exhibit close contact 
between the groups of lymphocytes, plasma cells and fibroblasts. 
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1. Introduction  
Vitiligo is an idiopathic disorder of pigmentation characterised by the presence of 
depigmented skin macules due to the chronic and progressive loss of melanocytes from the 
cutaneous epidermis. Large population surveys have shown a worldwide incidence of 1-2% 
(Boisseau-Garsaud et al., 2000; Howitz et al., 1977; Majumder et al. 1993; Mehta et al., 1973), 
although a prevalence of 8.8% has been reported in India (Sehgal & Srivastava, 2007). The 
disease occurs independently of age and race, and both sexes are equally affected (Behl et 
al., 2003; Cho et al., 2000; Handa & Dogra, 2003; Hann & Lee, 1996; LePoole & Boissy, 1997; 
Zaima & Koga, 2002). In approximately half of all cases, vitiligo appears before the age of 20 
years, and 70-80% of patients develop the disease by the age of 30 years (Behl et al., 2003; 
Herane, 2003). Frequently, patients with vitiligo also suffer from other autoimmune 
conditions (Alkhateeb et al., 2003; Laberge et al., 2005). 
Usually, vitiligo is viewed as a minor disease, but the impact on patients’ psychological 
well-being and social interactions is often underestimated (Kent & Al’ Abadie, 1996; 
Ongenae et al., 2006; Porter et al., 1986). The treatment of choice in vitiligo is dependent 
upon factors which include vitiligo type (non-segmental, segmental), patient age, and 
location and stability of depigmented lesions (Taieb & Picardo, 2010). However, despite the 
many available therapeutic modalities (Abu Tahir et al., 2010; Olsson, 2010), repigmentation 
in the majority of vitiligo patients is rarely complete or long-lasting, so a better 
understanding of the precise aetiology and pathogenesis of the disease is crucial to 
improving the efficacy of treatment regimens. 
Currently, the exact aetiology of vitiligo remains obscure, but many factors have been 
implicated in the development of the disease including infections (Grimes et al., 1996; Shegan, 
1971), stress (Al'Abadie et al., 1994a), neural abnormalities (Al'Abadie et al., 1994b), defective 
melanocyte adhesion (Gauthier et al., 2003), and genetic susceptibility (Spritz, 2010). The 
biochemical hypothesis argues that melanocyte destruction is due to the accumulation of toxic 
metabolites from melanogenesis, the break-down of free-radical defence and an excess of 
hydrogen peroxide (Dell’Anna & Picardo, 2006; Schallreuter et al., 1991; Schallreuter et al., 
2001; Schallreuter et al., 2005). In addition, many studies have indicated a role for both cellular 
(Ogg et al., 1998; Van den Boorn et al., 2009; Wankowicz-Kalinska et al., 2003) and humoral 
(Gilhar et al., 1995; Naughton et al., 1983a; Norris et al., 1988a) immunity in the pathogenesis of 
vitiligo. Ultimately, these different factors may act independently or together to yield the same 
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effect, namely the disappearance of melanocytes from the skin and this is proposed in the 
convergence theory (Le Poole et al., 1993a). For example, autoimmunity might arise as a 
secondary phenomenon following the self-destruction of pigment cells and this might then 
amplify the damage to melanocytes. In addition, different pathogenic mechanisms could 
account for the various clinical types of vitiligo:  the possible neural mechanisms are usually 
related to segmental vitiligo, whereas autoimmunity is most often associated with the non-
segmental (generalised) form (Taieb, 2000).  
2. Immunological factors in vitiligo aetiology and pathogenesis 
The evidence for the role of autoimmunity in the aetiology and pathogenesis of vitiligo will 
be discussed in the next sections. 
2.1 Immuno-genetic factors 
The majority of cases of vitiligo are sporadic without a family history of the disease. 
Nevertheless, 15-20% of patients report at least one affected first-degree relative (Alkhateeb 
et al., 2003), lending evidence for a genetic role in the aetiology of vitiligo. Furthermore, 
among Caucasians, the risk of vitiligo developing in a patient’s sibling is approximately 
6.1% (Alkhateeb et al., 2003), an increase of 16-fold compared to the general Caucasian 
population where the prevalence of the disease is 0.38% (Howitz et al., 1977). Similarly, an 
increased risk among first-degree relatives is found in Indian-Pakistanis at 6.1% (Alkhateeb 
et al., 2003), in American Hispanic-Latinos at 4.8% (Alkhateeb et al., 2003) and in Han 
Chinese at 2.6% (Sun et al., 2006). A simple Mendelian inheritance pattern is not displayed 
in these familial aggregations of vitiligo cases (Alkhateeb et al., 2003; Bhatia et al., 1992; 
Carnevale et al., 1980; Das et al., 1985; Hafez et al., 1983; Laberge et al., 2005; Majumder et 
al., 1988; Majumder et al., 1993; Mehta et al., 1973; Nath et al., 1994; Sun et al., 2006), 
suggesting that the disease is probably transmitted as a polygenic trait. Indeed, earlier 
disease onset in familial cases (Alkhateeb et al., 2003; Laberge et al., 2005) and reduced risk 
of vitiligo with increasing genetic distance from the patient (Alkhateeb et al. 2003) are 
indicative of a polygenic disorder. Formal genetic segregation analyses of vitiligo have also 
suggested that multiple loci contribute to vitiligo susceptibility (Majumder et al., 1993; Nath 
et al., 1994; Sun et al., 2006). Seldomly have large multi-generation families been reported 
where vitiligo segregates in an autosomal dominant pattern (Alkhateeb et al., 2005). Twin 
studies have also provided evidence of a genetic component to vitiligo aetiology. For vitiligo 
in monozygotic twins, the concordance is 23% (Alkhateeb et al. 2003), a disease risk that is 
60-fold greater than that in the general population (Howitz et al., 1977) and 4-fold higher 
than that for a patient’s sibling (Alkhateeb et al., 2003). 
The genetic epidemiological evidence has prompted the search for genes which predispose 
an individual to vitiligo. Investigations have included families with vitiligo as well as 
cohorts of patients without a familial history of the disease (Cantón et al., 2005; Fain et al., 
2003). In addition, different approaches have been employed to identify genes which confer 
susceptibility to vitiligo including candidate gene association studies (Blomhoff et al., 2005; 
Cantón et al., 2005), genome-wide linkage studies (Chen et al., 2005; Fain et al., 2003; Liang 
et al., 2007; Spritz et al., 2004), and genome-wide association studies (Birlea et al., 2010; Jin et 
al., 2010a; Quan et al., 2010). The majority of genes and genetic loci so far identified have a 
role in the function of the immune system (Spritz, 2010), and these are summarised in the 
following sections. 
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2.1.1 Human leukocyte antigen alleles of the major histocompatibility complex 
Initial case-control analyses demonstrated an association between predisposition to vitiligo 
and several different human leukocyte antigen (HLA) alleles of the major histocompatibility 
complex (MHC), and these are summarised in Table 1. Although these studies showed weak 
and variable associations, a significant association of HLA-DR4 and vitiligo was 
demonstrated in several populations (Dunston et al. 1990; Foley et al. 1983; Venneker et al. 
1992) and a subsequent meta-analysis of a series of case-control studies reported association 




Associated HLA Allele  Reference 
American (Caucasian) DR4 Foley et al., 1983 
American (African) DR4, DQw3  Dunston et al., 1990 
American and British 
(European-derived, 
Caucasian)  
DRB1A*04-DQB1*0301 Fain et al., 2006 
American and British 
(European-derived, 
Caucasian)  
Class I (specifically A*0201) and II 
antigens 
Jin et al., 2010a 
Chinese (Han) DQA1*0302, DQB1*0303, 
DQB1*0503 
Yang et al., 2005 
Chinese (Han) A25-Cw*0602-DQA1*0302 Xia et al., 2006 
Chinese (Han and 
Uygar) 
Class I and II antigens Quan et al., 2010 
Dutch DR4, DR6, Cw6 Venneker et al., 1993; 
Venneker et al., 1992 
Dutch DRB4*0101, DQB1*0303 Zamani et al., 2001 
German (Northern) A2 Schallreuter et al., 1993 
Hungarian DR1, DR3 Poloy et al., 1991 
Italian A30, B27, Cw6, DQw3 Finco et al., 1991 
Italian (Northern) A3 Lorini et al., 1992 
Italian (Northern) A30, Cw6, DQw3  Orecchia et al., 1992 
Japanese A31, Bw46, Cw4 Ando et al., 1993 
Kuwaiti  B21, Cw6 Al-Fouzan et al., 1995 
Moroccan (Jewish) B13 Metzker et al., 1980 
Omani Bw6, DR7  Venkataram et al., 1995 
Slovak A2, Dw7 Buc et al., 1996 
Turkish DRB1*03, DRB1*04, DRB1*07 Tastan et al., 2004 
Yemeni  Bw35  Metzker et al., 1980 
Table 1. Association of human leukocyte antigen (HLA) alleles with vitiligo susceptibility  
More recently, the use of better analytical and statistical methods has revealed associations 
of vitiligo with HLA-DRB1*04, HLA-DRB1*03 and HLA-DRB1*07 alleles in Turkish patients 
(Tastan et al., 2004), with HLA-DRB4*0101 and HLA-DQB1*0303 in Dutch patients (Zamani 
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Table 1. Association of human leukocyte antigen (HLA) alleles with vitiligo susceptibility  
More recently, the use of better analytical and statistical methods has revealed associations 
of vitiligo with HLA-DRB1*04, HLA-DRB1*03 and HLA-DRB1*07 alleles in Turkish patients 
(Tastan et al., 2004), with HLA-DRB4*0101 and HLA-DQB1*0303 in Dutch patients (Zamani 
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et al., 2001), and HLA-A25-Cw*0602-DQA1*0302, HLA-DQA1*0302, HLA-DQB1*0303 and 
HLA-DQB1*0503 in Han Chinese patients (Xia et al., 2006; Yang et al., 2005). Furthermore, a 
study of 76 Caucasian multiplex vitiligo families found the HLA-DRB1A*04-DQB1*0301 
haplotype to be associated with a higher risk of developing vitiligo and with an earlier onset 
of the disease (Fain et al., 2006). Finally, two genome-wide association studies undertaken 
on populations of vitiligo patients have reported that predisposition of vitiligo is associated 
with HLA class I and II antigens (Jin et al., 2010a; Quan et al., 2010). 
2.1.2 Immune-response genes and loci 
Variations in several immune-response genes, including CCR6, FOXP1, FOXP3, TSLP and 
XBP1, have a confirmed association with predisposition to vitiligo and these are summarised in 
Table 2 (Birlea et al., 2011; Cheong et al., 2009; Jin et al., 2010a; Jin et al., 2010b; Quan et al., 2010; 
Ren et al., 2009). Of particular note, the allelic variation R620W of the PTPN22 gene, which 
encodes lymphoid protein tyrosine phosphatase, a molecule involved in T cell signalling, has 
been shown to confer vitiligo susceptibility in several independent reports (Cantón et al., 2005; 
Jin et al., 2010a; Laberge et al., 2008a; Laberge et al., 2008b). In addition, allelic variants in the 
NLRP1 gene (previously NALP1 or SLEV1), which encodes a key regulator of the innate 
immune system, have been reproducibly associated with an increased risk of vitiligo in 
different populations (Jin et al., 2007a; Jin et al., 2007b; Nath et al., 2001; Spritz et al., 2004).  
The study of variations in the cytotoxic T lymphocyte antigen 4 (CTLA4) gene has yielded 
conflicting results with respect to vitiligo susceptibility (Birlea et al., 2011; Birlea et al., 2009; 
Blomhoff et al., 2005; Deeba et al., 2010; Itirli et al., 2005; Kemp et al., 1999; Laberge et al., 
2008a; Pehlivan et al., 2009). Presently, allelic differences in CTLA4 appear to be 
predominantly associated with vitiligo occurring together with other autoimmune diseases 
(Blomhoff et al., 2005), and it has been suggested, therefore, that the association of CTLA4 
with vitiligo is probably secondary to its primary association with disorders such as 
autoimmune thyroid disease (Spritz, 2010).  
2.2 Associated autoimmune disease 
Vitiligo is frequently associated with other autoimmune disorders, particularly autoimmune 
thyroid disease (Boelaert et al., 2010; Ochi & DeGroot, 1969), autoimmune polyendocrine 
syndromes (Ahonen et al., 1990; Neufeld et al., 1990), pernicious anaemia (Dawber, 1970), 
Addison’s disease (Zelissen et al., 1995), and alopecia areata (Ahmed et al., 2007). 
Furthermore, patients with vitiligo are more likely to suffer from autoimmune conditions 
than those in the general population (Birlea et al., 2008; Cunliffe et al., 1968; Liu et al., 2005; 
Turnbridge et al., 1977). In a survey of more than 2,600 unselected Caucasian vitiligo 
patients, elevated frequencies of autoimmune thyroid disease, Addison’s disease, systemic 
lupus erythematosus and pernicious anaemia were found, with approximately 30% of 
patients being affected with at least one additional autoimmune disorder (Alkhateeb et al., 
2003). Moreover, these same autoimmune diseases occurred at an increased frequency in the 
first-degree relatives of the patients studied (Alkhateeb et al., 2003). Similarly, in multiplex 
generalised vitiligo families, higher frequencies of psoriasis, rheumatoid arthritis and type 1 
diabetes mellitus were noted in addition to autoimmune thyroid disease, Addison’s disease, 
systemic lupus erythematosus and pernicious anaemia (Laberge et al., 2005). Such data 
indicate that individuals can be genetically predisposed to a specific group of autoimmune 
diseases that includes vitiligo, and are also evidence for an autoimmune aetiology for this 
depigmenting disorder. 
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Autoimmune susceptibility locus 2. Function 
undefined. Associated with autoimmune disease. 
Spritz et al., 2004 
CCR6 
 
Cytokine-chemokine receptor for CCL20. Recruits 
immune cells on binding of ligand. Associated 
with inflammatory bowel disease. 
Jin et al., 2010a; Jin et 




C1q and tumour necrosis factor-related protein- 6. 
Associated with rheumatoid arthritis and type 1 
diabetes mellitus. 
Jin et al., 2010a 
FOXP1 Forkhead box P1. Transcription factor which 
regulates development of immune cells.  
Jin et al., 2010a; Jin et 
al., 2010b 
FOXP3 Forkhead box P3. Transcription factor which 
regulates regulatory T cell development. Causes 
autoimmune IPEX syndrome. 
Birlea et al., 2011 
GZMB 
 
Granzyme B. Regulates cell-mediated immune 
responses. 
Jin et al., 2010a 
IL2RA 
 
Interleukin (IL)-2 receptor alpha chain. Receptor 
for cytokine IL2 which induces T and B cell 
proliferation. Associated with many autoimmune 
diseases. 
Jin et al., 2010a 
LPP 
 
LIM domain-containing preferred translocation 
partner in lipoma. Function unknown. Associated 
with celiac disease and rheumatoid arthritis. 




NACHT leucine-rich-repeat protein 1. Functions 
in the innate immune response. Associated with 
many autoimmune diseases. 
Jin et al., 2007a; Jin et 
al., 2007b; Nath et al., 




Lymphoid protein tyrosine phosphatase. 
Negatively regulates T cell activation. Associated 
with many autoimmune diseases. 
Cantón et al., 2005; 
Jin et al., 2010a; 
Laberge et al., 2008a; 
Laberge et al., 2008b 
TSLP Thymic stromal lymphopoietin. Cytokine which 
induces naïve CD4+ T cells to produce T helper 
cell 2 cytokines.  
Birlea et al., 2011; 
Cheong et al., 2009 
UBASH3A Ubiquitin-associated and SH3 domain-containing 
A gene. Regulates T cell receptor signalling. 
Associated with type 1 diabetes mellitus. 
Jin et al., 2010a 
XBP1 
 
X-box binding protein 1. Transcription factor 
which regulates MHC class II gene expression. 
Associated with inflammatory bowel disease. 
Birlea et al., 2011; Ren 
et al., 2009 
Table 2. Confirmed associations of immune-response gene variants with vitiligo 
susceptibility 
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2.3 Animal models  
The study of animal models has added credence to the theory that immune mechanisms 
play a part in the development of vitiligo. Several spontaneous animal models of vitiligo 
exist, although the exact relevance of such models to the equivalent human disorder remains 
to be established (Boissy & Lamoreux, 1988). The well-documented Smyth chickens express 
a genetically inherited form of vitiligo-like depigmentation resulting from the loss of 
melanocytes in feather and ocular tissues (Smyth, 1989). In this avian model, vitiligo begins 
with an inherent melanocyte defect that is followed by an autoimmune response involving 
both humoral and cellular reactions that eliminate abnormal pigment cells (Boissy et al., 
1984; Boyle et al., 1987; Lamont & Smyth, 1981; Pardue et al., 1988). An increase in T cells in 
the feather pulp and circulating inflammatory leukocytes has been shown in Smyth chickens 
prior to the onset, and during the development of, vitiligo (Erf & Smyth, 1996; Erf et al., 
1995). Antibodies to chicken melanocytes have also been detected in the sera of 100% of 
Smyth chicks but not in the sera of normally pigmented birds (Austin et al., 1992). These 
antibodies were found to be present both before and during the presentation of vitiligo 
(Searle et al., 1991), and the primary target antigen was identified as the melanogenic 
enzyme tyrosinase-related protein-1 (Austin & Boissy, 1995). In other animals with vitiligo 
including horses, cats and dogs, antibody reactivity occurs against a similar pattern of 
melanocyte antigens to that found in patients with the disease (Naughton et al., 1983b; 
Naughton et al., 1986a), suggesting that similar immunological responses occur in both 
animals and humans.  
2.4 Vitiligo melanocytes 
Several studies have shown abnormal expression of MHC class II antigen HLA-DR and 
increased expression of intercellular adhesion molecule-1 by perilesional melanocytes in 
vitiligo compared with melanocytes from normal skin (Al Badri et al., 1993a; Hedley et al., 
1998; Van den Wijngaard et al., 2000). Since these molecules have important roles in antigen 
presentation and in the activation of helper T cells, their expression by melanocytes could 
contribute to the anti-melanocyte cellular immune responses that are seen in vitiligo (Ogg et 
al., 1998; Van den Boorne et al., 2009). Both vitiligo and normal melanocytes are also capable 
of expressing MHC class I molecules (Hedley et al., 1998), which could allow interaction 
with destructive cytotoxic T cells. Furthermore, melanocytes have an antigen processing and 
presenting capability which can make them target cells for T cell-mediated cytotoxicity (Le 
Poole et al., 1993b). In perilesional vitiligo biopsies, melanocytes express macrophage 
markers CD68 and CD36 (Van den Wijngaard et al., 2000) and reduced levels of membrane 
regulators of complement activation, including decay acceleration factor and membrane 
cofactor protein (Van den Wijngaard et al., 2002), which suggests a vulnerability of these 
cells to attack by macrophages and the complement system, respectively.  
2.5 Vitiligo treatments 
Repigmentation in vitiligo patients receiving treatment with immunosuppressive agents 
indirectly supports the theory that immune-mediated processes are involved in vitiligo 
pathogenesis. Topically applied tacrolimus (FK506), a therapeutic agent which exerts a 
potent immunosuppressive effect on T cells by blocking the action of the cytokine gene-
activating cofactor calcineurin (Homey et al., 1998), has resulted in successful 
repigmentation responses in vitiligo patients (Boone et al., 2007; Hartmann et al., 2008). 
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Topical corticosteroids, which have anti-inflammatory and immunosuppressive actions, are 
considered to be an effective first-line treatment in children and adults with segmental or 
non-segmental vitiligo of recent onset (Abu Tahir et al., 2010; Gawkrodger et al., 2010), and, 
indeed, following treatment of vitiligo patients with systemic steroids, a reduction in anti-
melanocyte antibody levels and in antibody-mediated anti-melanocyte cytotoxicity has been 
demonstrated (Hann et al., 1993; Takei et al., 1984). 
Psoralen with ultraviolet radiation (PUVA) is used as a second-line therapy for vitiligo 
(Alomar, 2010; Gawkrodger et al., 2010). Following PUVA treatment, a reduction in the 
number of Langerhans cells and a decrease in the expression of vitiligo-associated 
melanocyte antigens, which could lead to a blocking of antibody-dependent cell-mediated 
cytotoxicity against melanocytes, have been noted in vitiligo patients (Kao & Yu, 1992; Viac 
et al., 1997). In addition, ultraviolet radiation can induce the expression of anti-inflammatory 
cytokines, modulate the expression of intercellular adhesion molecule-1, and induce 
apoptosis of skin-infiltrating T lymphocytes (Duthie et al., 1999; Krutmann & Morita, 1999).  
2.6 Humoral immune responses 
2.6.1 Melanocyte antibodies   
Antibodies to melanocytes occur at a significantly increased frequency in the sera of vitiligo 
patients compared with healthy individuals (Cui et al., 1992; Cui et al., 1995; Farrokhi et al., 
2005; Hann et al., 1996a; Hann et al., 1996b; Naughton et al., 1983a; Naughton et al., 1983b; 
Rocha et al., 2002). As well as circulating antibodies, antibody deposits have been noted in 
the basement membrane zones of depigmented areas in patients with vitiligo (Uda et al., 
1984). However, no B cells or antibody has yet been isolated from vitiligo lesions. 
Interestingly, correlations can also exist between the incidence and level of melanocyte 
antibodies and both the activity and extent of vitiligo (Aronson & Hashimoto, 1987; Harning 
et al., 1991; Kemp et al., 2011; Naughton et al., 1986b; Yu et al., 1993), indicating that 
melanocyte antibodies are  possible markers of disease progression. 
Predominantly, melanocyte antibodies have been characterised as IgG (Cui et al., 1992; Cui 
et al., 1995; Farrokhi et al., 2005; Hann et al., 1996a; Hann et al., 1996b; Naughton et al., 
1983a; Naughton et al., 1983b; Rocha et al., 2002; Uda et al., 1984) and as belonging to 
subclasses IgG1, IgG2 and IgG3 (Xie et al., 1991), although anti-melanocyte IgA antibodies 
have also been reported (Aronson & Hashimoto, 1987). Initial immunoprecipitation studies 
using melanoma cell extracts revealed that antibodies in vitiligo patients were most 
commonly directed against antigens with molecular weights of 35, 40-45, 75, 90 and 150 kDa 
(Cui et al., 1992). Several of the proteins (40-45, 75 and 150 kDa) appeared to be common 
tissue antigens, while others (35 and 90 kDa) were preferentially expressed on melanocytes 
(Cui et al., 1992). In immunoblotting studies with melanocyte extracts, antigens of 45, 65, 
and 110 kDa have been identified (Hann et al., 1996b; Park et al., 1996), while vitiligo-
associated antibodies have been demonstrated to recognise melanoma cell proteins of 68, 70, 
88, 90, 110 and 165 kDa (Hann et al., 1996a; Rocha et al., 2002). 
The identity of several vitiligo-associated antibody targets has been reported and these are 
summarised in Table 3. Included are the melanogenic enzymes tyrosinase (Baharav et al., 
1996; Kemp et al., 1997a; Song et al., 1994) and tyrosinase-related protein-2 (Kemp et al., 
1997b; Okamoto et al., 1998), and the melanosomal matrix protein gp100 (Pmel17) (Kemp et 
al., 1998a). The technique of peptide phage-display has identified the melanin-concentrating 
hormone receptor 1 (MCHR1) and tyrosine hydroxylase as targets of vitiligo patient 
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2.3 Animal models  
The study of animal models has added credence to the theory that immune mechanisms 
play a part in the development of vitiligo. Several spontaneous animal models of vitiligo 
exist, although the exact relevance of such models to the equivalent human disorder remains 
to be established (Boissy & Lamoreux, 1988). The well-documented Smyth chickens express 
a genetically inherited form of vitiligo-like depigmentation resulting from the loss of 
melanocytes in feather and ocular tissues (Smyth, 1989). In this avian model, vitiligo begins 
with an inherent melanocyte defect that is followed by an autoimmune response involving 
both humoral and cellular reactions that eliminate abnormal pigment cells (Boissy et al., 
1984; Boyle et al., 1987; Lamont & Smyth, 1981; Pardue et al., 1988). An increase in T cells in 
the feather pulp and circulating inflammatory leukocytes has been shown in Smyth chickens 
prior to the onset, and during the development of, vitiligo (Erf & Smyth, 1996; Erf et al., 
1995). Antibodies to chicken melanocytes have also been detected in the sera of 100% of 
Smyth chicks but not in the sera of normally pigmented birds (Austin et al., 1992). These 
antibodies were found to be present both before and during the presentation of vitiligo 
(Searle et al., 1991), and the primary target antigen was identified as the melanogenic 
enzyme tyrosinase-related protein-1 (Austin & Boissy, 1995). In other animals with vitiligo 
including horses, cats and dogs, antibody reactivity occurs against a similar pattern of 
melanocyte antigens to that found in patients with the disease (Naughton et al., 1983b; 
Naughton et al., 1986a), suggesting that similar immunological responses occur in both 
animals and humans.  
2.4 Vitiligo melanocytes 
Several studies have shown abnormal expression of MHC class II antigen HLA-DR and 
increased expression of intercellular adhesion molecule-1 by perilesional melanocytes in 
vitiligo compared with melanocytes from normal skin (Al Badri et al., 1993a; Hedley et al., 
1998; Van den Wijngaard et al., 2000). Since these molecules have important roles in antigen 
presentation and in the activation of helper T cells, their expression by melanocytes could 
contribute to the anti-melanocyte cellular immune responses that are seen in vitiligo (Ogg et 
al., 1998; Van den Boorne et al., 2009). Both vitiligo and normal melanocytes are also capable 
of expressing MHC class I molecules (Hedley et al., 1998), which could allow interaction 
with destructive cytotoxic T cells. Furthermore, melanocytes have an antigen processing and 
presenting capability which can make them target cells for T cell-mediated cytotoxicity (Le 
Poole et al., 1993b). In perilesional vitiligo biopsies, melanocytes express macrophage 
markers CD68 and CD36 (Van den Wijngaard et al., 2000) and reduced levels of membrane 
regulators of complement activation, including decay acceleration factor and membrane 
cofactor protein (Van den Wijngaard et al., 2002), which suggests a vulnerability of these 
cells to attack by macrophages and the complement system, respectively.  
2.5 Vitiligo treatments 
Repigmentation in vitiligo patients receiving treatment with immunosuppressive agents 
indirectly supports the theory that immune-mediated processes are involved in vitiligo 
pathogenesis. Topically applied tacrolimus (FK506), a therapeutic agent which exerts a 
potent immunosuppressive effect on T cells by blocking the action of the cytokine gene-
activating cofactor calcineurin (Homey et al., 1998), has resulted in successful 
repigmentation responses in vitiligo patients (Boone et al., 2007; Hartmann et al., 2008). 
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Topical corticosteroids, which have anti-inflammatory and immunosuppressive actions, are 
considered to be an effective first-line treatment in children and adults with segmental or 
non-segmental vitiligo of recent onset (Abu Tahir et al., 2010; Gawkrodger et al., 2010), and, 
indeed, following treatment of vitiligo patients with systemic steroids, a reduction in anti-
melanocyte antibody levels and in antibody-mediated anti-melanocyte cytotoxicity has been 
demonstrated (Hann et al., 1993; Takei et al., 1984). 
Psoralen with ultraviolet radiation (PUVA) is used as a second-line therapy for vitiligo 
(Alomar, 2010; Gawkrodger et al., 2010). Following PUVA treatment, a reduction in the 
number of Langerhans cells and a decrease in the expression of vitiligo-associated 
melanocyte antigens, which could lead to a blocking of antibody-dependent cell-mediated 
cytotoxicity against melanocytes, have been noted in vitiligo patients (Kao & Yu, 1992; Viac 
et al., 1997). In addition, ultraviolet radiation can induce the expression of anti-inflammatory 
cytokines, modulate the expression of intercellular adhesion molecule-1, and induce 
apoptosis of skin-infiltrating T lymphocytes (Duthie et al., 1999; Krutmann & Morita, 1999).  
2.6 Humoral immune responses 
2.6.1 Melanocyte antibodies   
Antibodies to melanocytes occur at a significantly increased frequency in the sera of vitiligo 
patients compared with healthy individuals (Cui et al., 1992; Cui et al., 1995; Farrokhi et al., 
2005; Hann et al., 1996a; Hann et al., 1996b; Naughton et al., 1983a; Naughton et al., 1983b; 
Rocha et al., 2002). As well as circulating antibodies, antibody deposits have been noted in 
the basement membrane zones of depigmented areas in patients with vitiligo (Uda et al., 
1984). However, no B cells or antibody has yet been isolated from vitiligo lesions. 
Interestingly, correlations can also exist between the incidence and level of melanocyte 
antibodies and both the activity and extent of vitiligo (Aronson & Hashimoto, 1987; Harning 
et al., 1991; Kemp et al., 2011; Naughton et al., 1986b; Yu et al., 1993), indicating that 
melanocyte antibodies are  possible markers of disease progression. 
Predominantly, melanocyte antibodies have been characterised as IgG (Cui et al., 1992; Cui 
et al., 1995; Farrokhi et al., 2005; Hann et al., 1996a; Hann et al., 1996b; Naughton et al., 
1983a; Naughton et al., 1983b; Rocha et al., 2002; Uda et al., 1984) and as belonging to 
subclasses IgG1, IgG2 and IgG3 (Xie et al., 1991), although anti-melanocyte IgA antibodies 
have also been reported (Aronson & Hashimoto, 1987). Initial immunoprecipitation studies 
using melanoma cell extracts revealed that antibodies in vitiligo patients were most 
commonly directed against antigens with molecular weights of 35, 40-45, 75, 90 and 150 kDa 
(Cui et al., 1992). Several of the proteins (40-45, 75 and 150 kDa) appeared to be common 
tissue antigens, while others (35 and 90 kDa) were preferentially expressed on melanocytes 
(Cui et al., 1992). In immunoblotting studies with melanocyte extracts, antigens of 45, 65, 
and 110 kDa have been identified (Hann et al., 1996b; Park et al., 1996), while vitiligo-
associated antibodies have been demonstrated to recognise melanoma cell proteins of 68, 70, 
88, 90, 110 and 165 kDa (Hann et al., 1996a; Rocha et al., 2002). 
The identity of several vitiligo-associated antibody targets has been reported and these are 
summarised in Table 3. Included are the melanogenic enzymes tyrosinase (Baharav et al., 
1996; Kemp et al., 1997a; Song et al., 1994) and tyrosinase-related protein-2 (Kemp et al., 
1997b; Okamoto et al., 1998), and the melanosomal matrix protein gp100 (Pmel17) (Kemp et 
al., 1998a). The technique of peptide phage-display has identified the melanin-concentrating 
hormone receptor 1 (MCHR1) and tyrosine hydroxylase as targets of vitiligo patient 
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antibodies (Kemp et al., 2002). Recent proteomic analysis has also revealed lamin A is a 
vitiligo-associated antigen (Li et al., 2010). 
 







Lamin A 24/84 (28.6) 2/64 (3.1) Li et al., 2010 
MCHR1 9/55 (16.4) 0/28 (0) Kemp et al., 2002  
MCHR1 12/84 (14.3) Not reported Li et al., 2010 
Pmel17 3/53 (5.9) 0/20 (0) Kemp et al., 1998a  
SOX10 3/93 (3.2) 0/65 (0) Hedstrand et al., 2001  
SOX9 1/93 (1.1) 0/65 (0) Hedstrand et al., 2001  
Tyrosinase 16/26 (61) 0/31 (0) Song et al., 1994  
Tyrosinase 7/18 (39) 0/12 (0) Baharav et al., 1996  
Tyrosinase 5/46 (10.9) 0/20 (0) Kemp et al., 1997a  
TRP-1 3/53 (5.9) 0/20 (0) Kemp et al., 1998b  
TRP-1 8/84 (9.5) Not reported Li et al., 2010 
TRP-2 3/53 (5.9) 0/20 (0) Kemp et al., 1997b  
TRP-2 10/15 (67) 0/21 (0) Okamoto et al., 1998  
TRP-2 20/30 (67) 1/35 (2) Okamoto et al., 1998  
Tyrosine hydroxylase 18/79 (23) 0/28 (0) Kemp et al., 2011 
Table 3. Defined antibody targets in patients with vitiligo 
2.6.2 Pathogenic mechanisms  
With respect to pathogenic effects, vitiligo-associated antibodies are able to destroy 
melanocytes and melanoma cells in vitro and in vivo by complement-mediated damage and 
antibody-dependent cellular cytotoxicity (Fishman et al., 1993; Gottumukkala et al., 2006; 
Norris et al., 1998a). Complement-mediated cytolysis of melanocytes by vitiligo patient 
antibodies appears to be cell selective and more common in individuals with active disease 
(Cui et al., 1993). Passive immunisation of nude mice grafted with human skin has also 
indicated that IgG from vitiligo patients can induce melanocyte destruction (Gilhar et al., 
1995). Furthermore, IgG melanocyte antibodies from individuals with vitiligo can induce 
HLA-DR and intercellular adhesion molecule-1 expression on and release of interleukin-8 
from melanocytes (Yi et al., 2000). Such changes that may enhance the antigen-presenting 
activity of melanocytes allowing antigen-specific immune effector cell attack resulting in 
melanocyte destruction.  
Antibodies against MCHR1 have been shown to block the function of the receptor in a 
heterologous cell line (Gottumukkala et al., 2006). Stimulation of MCHR1 in cultured 
melanocytes with melanin-concentrating hormone (MCH) can down regulate the actions of 
-melanocyte-stimulating hormone, including the production of melanin, suggesting that 
the MCH/MCHR1 signalling pathway has a role with the melanocortins in regulating 
melanocyte function (Hoogduijn et al., 2002). Any adverse effects of MCHR1 antibodies 
upon the functioning of the receptor in melanocytes could potentially disrupt normal 
melanocyte behaviour, a feature that could precede the clinical manifestation of vitiligo. 
However, this has not yet been reported and is still the object of study. More recent work 
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has found that 69% (9/13) of vitiligo patient sera tested induced melanocyte detachment in a 
reconstructed epidermis model, although this was unrelated to either the extent or the 
activity of the disease (Cario-Andre et al., 2007). Further studies are needed to confirm that 
this serum effect is antibody mediated and, if so, that the antibody activity is specific to 
vitiligo patient sera. 
2.6.3 Other antibodies 
Circulating organ-specific autoantibodies, particularly to the thyroid, adrenal glands, gastric 
parietal cells, and pancreatic islet cells are commonly detected in the sera of vitiligo patients 
(Brostoff, 1969; Betterle et al., 1976; Mandry et al., 1996; Zauli et al., 1986). Moreover, 
antinuclear antibody and IgM-rheumatoid factor have been detected at a significant 
frequency in vitiligo patients (Farrokhi et al., 2005). Anti-keratinocyte intracellular 
antibodies that correlate with disease extent and activity have also been detected in vitiligo 
patients (Yu et al., 1993).  
2.7 Cellular immune responses 
2.7.1 Cytokines 
An imbalance of cytokines, which can affect melanocyte activity and survival, has been 
shown in vitiligo lesional skin (Moretti et al., 2002). The level of granulocyte-macrophage 
colony-stimulating factor is reduced in patients with active vitiligo compared with healthy 
controls (Yu et al., 1997; Moretti et al., 2002). This cytokine has been found to act as a growth 
factor for melanocytes and a decrease in its production slows down the proliferation of 
surviving melanocytes in vitiligo lesions (Imokawa et al., 1996). Other melanogenic 
cytokines, including stem cell factor and endothelin-1, are also lowered in depigmented 
lesions (Moretti et al., 2002). 
Serum levels of soluble interleukin-2 receptor can be used to monitor in vivo immune 
activation, and its elevation has been correlated with T cell-mediated immune disease. 
Indeed, the level of the soluble interleukin-2 receptor level in vitiligo patients is significantly 
increased compared with that of controls, indicating that the activation of T cells is a 
component in the pathogenesis of vitiligo (Tu et al., 1999; Yeo et al., 1999). The production of 
interleukin-6 by mononuclear cells is also elevated in vitiligo patients (Yu et al., 1997). This 
cytokine can induce the expression of intercellular adhesion molecule-1 on melanocytes 
thereby facilitating leukocyte-melanocyte interactions and consequently cause 
immunological damage (Kirnbauer et al., 1992). Increased production of interleukin-8, 
which can attract neutrophils to vitiligo lesions amplifying destructive inflammatory 
reactions, has also been reported in the mononuclear cells of vitiligo patients (Yu et al., 
1997). Furthermore, the expression of tumour necrosis factor-alpha, an inflammatory 
mediator involved in the pathogenesis of autoimmune disease, is significantly elevated in 
vitiligo skin (Moretti et al., 2002). However, the exact roles in vitiligo pathogenesis of these 
inflammatory cytokines, which can also act as paracrine inhibitors of melanocyte 
proliferation and of melanogenesis, remain to be determined. 
2.7.2 Macrophages 
Macrophage infiltration has been demonstrated in vitiligo lesions, with increased numbers 
present in perilesional skin (Le Poole et al., 1996; Van den Wijngaard et al., 2000). It is 
possible that macrophages are involved in clearing melanocytes that have been induced to 
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antibodies (Kemp et al., 2002). Recent proteomic analysis has also revealed lamin A is a 
vitiligo-associated antigen (Li et al., 2010). 
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melanocytes and melanoma cells in vitro and in vivo by complement-mediated damage and 
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Norris et al., 1998a). Complement-mediated cytolysis of melanocytes by vitiligo patient 
antibodies appears to be cell selective and more common in individuals with active disease 
(Cui et al., 1993). Passive immunisation of nude mice grafted with human skin has also 
indicated that IgG from vitiligo patients can induce melanocyte destruction (Gilhar et al., 
1995). Furthermore, IgG melanocyte antibodies from individuals with vitiligo can induce 
HLA-DR and intercellular adhesion molecule-1 expression on and release of interleukin-8 
from melanocytes (Yi et al., 2000). Such changes that may enhance the antigen-presenting 
activity of melanocytes allowing antigen-specific immune effector cell attack resulting in 
melanocyte destruction.  
Antibodies against MCHR1 have been shown to block the function of the receptor in a 
heterologous cell line (Gottumukkala et al., 2006). Stimulation of MCHR1 in cultured 
melanocytes with melanin-concentrating hormone (MCH) can down regulate the actions of 
-melanocyte-stimulating hormone, including the production of melanin, suggesting that 
the MCH/MCHR1 signalling pathway has a role with the melanocortins in regulating 
melanocyte function (Hoogduijn et al., 2002). Any adverse effects of MCHR1 antibodies 
upon the functioning of the receptor in melanocytes could potentially disrupt normal 
melanocyte behaviour, a feature that could precede the clinical manifestation of vitiligo. 
However, this has not yet been reported and is still the object of study. More recent work 
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has found that 69% (9/13) of vitiligo patient sera tested induced melanocyte detachment in a 
reconstructed epidermis model, although this was unrelated to either the extent or the 
activity of the disease (Cario-Andre et al., 2007). Further studies are needed to confirm that 
this serum effect is antibody mediated and, if so, that the antibody activity is specific to 
vitiligo patient sera. 
2.6.3 Other antibodies 
Circulating organ-specific autoantibodies, particularly to the thyroid, adrenal glands, gastric 
parietal cells, and pancreatic islet cells are commonly detected in the sera of vitiligo patients 
(Brostoff, 1969; Betterle et al., 1976; Mandry et al., 1996; Zauli et al., 1986). Moreover, 
antinuclear antibody and IgM-rheumatoid factor have been detected at a significant 
frequency in vitiligo patients (Farrokhi et al., 2005). Anti-keratinocyte intracellular 
antibodies that correlate with disease extent and activity have also been detected in vitiligo 
patients (Yu et al., 1993).  
2.7 Cellular immune responses 
2.7.1 Cytokines 
An imbalance of cytokines, which can affect melanocyte activity and survival, has been 
shown in vitiligo lesional skin (Moretti et al., 2002). The level of granulocyte-macrophage 
colony-stimulating factor is reduced in patients with active vitiligo compared with healthy 
controls (Yu et al., 1997; Moretti et al., 2002). This cytokine has been found to act as a growth 
factor for melanocytes and a decrease in its production slows down the proliferation of 
surviving melanocytes in vitiligo lesions (Imokawa et al., 1996). Other melanogenic 
cytokines, including stem cell factor and endothelin-1, are also lowered in depigmented 
lesions (Moretti et al., 2002). 
Serum levels of soluble interleukin-2 receptor can be used to monitor in vivo immune 
activation, and its elevation has been correlated with T cell-mediated immune disease. 
Indeed, the level of the soluble interleukin-2 receptor level in vitiligo patients is significantly 
increased compared with that of controls, indicating that the activation of T cells is a 
component in the pathogenesis of vitiligo (Tu et al., 1999; Yeo et al., 1999). The production of 
interleukin-6 by mononuclear cells is also elevated in vitiligo patients (Yu et al., 1997). This 
cytokine can induce the expression of intercellular adhesion molecule-1 on melanocytes 
thereby facilitating leukocyte-melanocyte interactions and consequently cause 
immunological damage (Kirnbauer et al., 1992). Increased production of interleukin-8, 
which can attract neutrophils to vitiligo lesions amplifying destructive inflammatory 
reactions, has also been reported in the mononuclear cells of vitiligo patients (Yu et al., 
1997). Furthermore, the expression of tumour necrosis factor-alpha, an inflammatory 
mediator involved in the pathogenesis of autoimmune disease, is significantly elevated in 
vitiligo skin (Moretti et al., 2002). However, the exact roles in vitiligo pathogenesis of these 
inflammatory cytokines, which can also act as paracrine inhibitors of melanocyte 
proliferation and of melanogenesis, remain to be determined. 
2.7.2 Macrophages 
Macrophage infiltration has been demonstrated in vitiligo lesions, with increased numbers 
present in perilesional skin (Le Poole et al., 1996; Van den Wijngaard et al., 2000). It is 
possible that macrophages are involved in clearing melanocytes that have been induced to 
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apoptose by cytotoxic T lymphocytes. Additional evidence for the active involvement of 
macrophages in vitiligo pathogenesis is demonstrated by their expression of 
immunoglobulin receptors: in a mouse model, it has been shown that macrophages, 
expressing the common gamma chain of the activating Fc gamma receptors, can mediate 
vitiligo in the presence and absence of complement C3 fraction (Trcka et al., 2002) 
2.7.3 Dendritic cells  
The density of Langerhans cells in vitiliginous skin has been variously reported as normal, 
increased and decreased compared with pigmented skin from the same patients and from 
control subjects (Claudy & Rouchouse, 1984; Hatchcome et al., 1987; Riley, 1967; Searle et al., 
1991). The differences in the documented Langerhans cells densities may be due to the type 
of vitiligo, the sampling techniques used or the site of skin biopsies. An increase in the 
number of Langerhans cells could contribute to the immunological processes that damage 
melanocytes. However, although degenerative changes in Langerhans cells have been 
observed in vitiligo skin lesions, their role in vitiligo still remains unclear. More recently, 
dendritic cell-mediated destruction of melanocytes has been demonstrated in vivo and in 
vitro (Kroll et al., 2005). This process is related to the release of heat-shock protein 70 by 
stressed melanocytes, which induces an immune response against the cells from which it is 
produced, and to the increased expression of tumour-necrosis factor-related apoptosis 
inducing ligand receptors on stressed melanocytes making them more prone to killing by 
dendritic cells (Denman et al., 2008; Kroll et al., 2005). 
2.7.4 T cells 
Autoimmune disorders are often associated with an expansion of peripheral helper T cells. 
However, with respect to vitiligo, inconsistent data regarding abnormalities in circulating 
helper T cells have been reported. An increase in the number of activated helper T cells was 
detected in patients with stable vitiligo as well as in their first-degree relatives when 
compared with healthy individuals (Abdel-Naser et al., 1992; D’Amelio et al., 1990; Soubiran 
et al., 1985). In contrast, a decrease in the helper T cell population has also been observed in 
individuals with vitiligo (Grimes et al., 1986; Halder et al., 1986). No simple explanation 
exists for these differences but they could be attributable to the factors such as the 
population of patients under study, disease characteristics and received treatments.  
Circulating melanocyte-specific cytotoxic T lymphocytes that target melanocyte-specific 
antigens, including Melan-A (MART-1), gp100 (Pmel17) and tyrosinase, have been detected 
in vitiligo patients (Lang et al., 2001; Ogg et al., 1998; Palermo et al., 2001). They express high 
levels of the skin-homing receptor cutaneous lymphocyte-associated antigen and their 
frequency correlates with both the extent and activity of the disease (Lang et al., 2001). In 
addition, melanocyte-specific T cells have cytotoxic reactivity towards melanocytes (Ogg et 
al., 1998). Such findings are consistent with a role for skin-homing, autoreactive, 
melanocyte-specific T cells in causing the destruction of melanocytes in vitiligo. 
Histological studies of skin biopsies from vitiligo patients have demonstrated that 
infiltrating cytotoxic and helper T cells are most prominent at the periphery of vitiligo 
lesions (Al Badri et al., 1993b; Van den Wijngaard et al., 2000). Many of the inflammatory 
cells are activated, as indicated by the expression of the MHC class II antigen HLA-DR, and 
a significant number also exhibit high levels of the receptor cutaneous lymphocyte-
associated antigen, typical of skin-homing T cells (Al Badri et al., 1993b; Van den Wijngaard 
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et al., 2000). Local activation of cytotoxic T cells at the perilesional epidermal/dermal 
junction of vitiliginous skin is also suggested by the presence of granzyme B+ and perforin+ 
cells (Van den Wijngaard, et al., 2000). There is evidence for interleukin-2 receptor and 
interferon-gamma receptor expression by the lymphocytic infiltrate (Abdel-Naser et al., 
1994), and also for down-regulation of the helper T cell 2-dependent CDw60 molecule in the 
vitiliginous epidermis suggesting that infiltrating T cells may exhibit a helper T cell 1-type 
cytokine production pattern which is consistent with cell-mediated organ-specific 
autoimmunity (Le Poole et al., 2003). In addition, perilesional T cell clones exhibit a 
predominant type-1-like cytokine secretion profile (Wankowicz-Kalinska et al., 2003). More 
recently it has been demonstrated that T lymphocytes obtained from perilesional skin 
biopsies are enriched for cytotoxic T cells that recognise melanocyte antigens tyrosinase, 
gp100 and MelanA (Van den Boorn et al., 2009). Moreover, upon infiltration of autologous 
pigmented skin, isolated perilesional T lymphocytes efficiently kill melanocytes, providing 
direct evidence that cytotoxic T cells can cause the depigmentation seen in vitiligo (Van den 
Boorn et al., 2009). Additional to this, are findings that regulatory T cells occur at a reduced 
level in the skin of vitiligo patients (Klarquist et al., 2010). This may allow the unchecked 
destruction of melanocytes by cytotoxic T cells in vitiligo lesions (Klarquist et al., 2010).  
3. Conclusion 
Autoimmunity is one hypothesis forwarded to explain the development of vitiligo due to 
the evidence presented in this review. However, it is most likely that interacting 
mechanisms, of which immune responses are a part, are responsible for the clinical 
manifestations of the disease (Le Poole et al., 1993a). In addition, although the evidence for 
the role of immune-related genes in the aetiology of vitiligo is clear, the limited concordance 
in identical twins (Alkhateeb et al., 2003) indicates that other factors, probably 
environmental, are also involved in its development, making the disease  complex, 
polygenic, and multi-factorial. Notably, in vitro studies have provided a link and a temporal 
sequence connecting cellular oxidative stress (Dell’Anna & Picardo, 2006; Schallreuter et al., 
1991; Schallreuter et al., 2001; Schallreuter et al., 2005) and the immune response in vitiligo: 
stressed melanocytes were found to mediate dendritic cell-activation with the consequent 
dendritic cell effector functions playing a role in the destruction of melanocytes (Kroll et al., 
2005). This work suggests that intrinsic damage to melanocytes could be the initiating event 
in vitiligo development followed by a secondary immune response by cytotoxic T cells 
which exacerbates the destruction of melanocytes and progresses the disease (Hariharan et 
al., 2010; Le Poole & Luiten, 2008; Van den Boorn et al., 2011). Indeed, 50% of vitiligo 
patients experience a Koebner phenomenon, whereby depigmented lesions develop at a site 
previously exposed to a physical stress (Le Poole & Luiten, 2008). 
As indicated, it is most likely that immune responses in vitiligo are of a secondary nature 
following melanocyte damage. Indeed, several vitiligo-associated autoantigens such as 
tyrosinase and gp100 are located intracellularly, and it has been suggested that either the 
formation of neo-antigens due to haptenation, the exposure of cryptic epitopes or the 
modification of proteins during apoptosis could account for immune responses to these 
molecules (Namazi, 2007; Westerhof & d’Ischia, 2007). Following processing by mature 
Langerhans cells, antigenic peptides could be presented to T cells which have escaped clonal 
deletion or to naïve T lymphocytes which have not been tolerised against cryptic epitopes 
(Namazi, 2007; Westerhof & d’Ischia, 2007). Antibodies could then be produced following 
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apoptose by cytotoxic T lymphocytes. Additional evidence for the active involvement of 
macrophages in vitiligo pathogenesis is demonstrated by their expression of 
immunoglobulin receptors: in a mouse model, it has been shown that macrophages, 
expressing the common gamma chain of the activating Fc gamma receptors, can mediate 
vitiligo in the presence and absence of complement C3 fraction (Trcka et al., 2002) 
2.7.3 Dendritic cells  
The density of Langerhans cells in vitiliginous skin has been variously reported as normal, 
increased and decreased compared with pigmented skin from the same patients and from 
control subjects (Claudy & Rouchouse, 1984; Hatchcome et al., 1987; Riley, 1967; Searle et al., 
1991). The differences in the documented Langerhans cells densities may be due to the type 
of vitiligo, the sampling techniques used or the site of skin biopsies. An increase in the 
number of Langerhans cells could contribute to the immunological processes that damage 
melanocytes. However, although degenerative changes in Langerhans cells have been 
observed in vitiligo skin lesions, their role in vitiligo still remains unclear. More recently, 
dendritic cell-mediated destruction of melanocytes has been demonstrated in vivo and in 
vitro (Kroll et al., 2005). This process is related to the release of heat-shock protein 70 by 
stressed melanocytes, which induces an immune response against the cells from which it is 
produced, and to the increased expression of tumour-necrosis factor-related apoptosis 
inducing ligand receptors on stressed melanocytes making them more prone to killing by 
dendritic cells (Denman et al., 2008; Kroll et al., 2005). 
2.7.4 T cells 
Autoimmune disorders are often associated with an expansion of peripheral helper T cells. 
However, with respect to vitiligo, inconsistent data regarding abnormalities in circulating 
helper T cells have been reported. An increase in the number of activated helper T cells was 
detected in patients with stable vitiligo as well as in their first-degree relatives when 
compared with healthy individuals (Abdel-Naser et al., 1992; D’Amelio et al., 1990; Soubiran 
et al., 1985). In contrast, a decrease in the helper T cell population has also been observed in 
individuals with vitiligo (Grimes et al., 1986; Halder et al., 1986). No simple explanation 
exists for these differences but they could be attributable to the factors such as the 
population of patients under study, disease characteristics and received treatments.  
Circulating melanocyte-specific cytotoxic T lymphocytes that target melanocyte-specific 
antigens, including Melan-A (MART-1), gp100 (Pmel17) and tyrosinase, have been detected 
in vitiligo patients (Lang et al., 2001; Ogg et al., 1998; Palermo et al., 2001). They express high 
levels of the skin-homing receptor cutaneous lymphocyte-associated antigen and their 
frequency correlates with both the extent and activity of the disease (Lang et al., 2001). In 
addition, melanocyte-specific T cells have cytotoxic reactivity towards melanocytes (Ogg et 
al., 1998). Such findings are consistent with a role for skin-homing, autoreactive, 
melanocyte-specific T cells in causing the destruction of melanocytes in vitiligo. 
Histological studies of skin biopsies from vitiligo patients have demonstrated that 
infiltrating cytotoxic and helper T cells are most prominent at the periphery of vitiligo 
lesions (Al Badri et al., 1993b; Van den Wijngaard et al., 2000). Many of the inflammatory 
cells are activated, as indicated by the expression of the MHC class II antigen HLA-DR, and 
a significant number also exhibit high levels of the receptor cutaneous lymphocyte-
associated antigen, typical of skin-homing T cells (Al Badri et al., 1993b; Van den Wijngaard 
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et al., 2000). Local activation of cytotoxic T cells at the perilesional epidermal/dermal 
junction of vitiliginous skin is also suggested by the presence of granzyme B+ and perforin+ 
cells (Van den Wijngaard, et al., 2000). There is evidence for interleukin-2 receptor and 
interferon-gamma receptor expression by the lymphocytic infiltrate (Abdel-Naser et al., 
1994), and also for down-regulation of the helper T cell 2-dependent CDw60 molecule in the 
vitiliginous epidermis suggesting that infiltrating T cells may exhibit a helper T cell 1-type 
cytokine production pattern which is consistent with cell-mediated organ-specific 
autoimmunity (Le Poole et al., 2003). In addition, perilesional T cell clones exhibit a 
predominant type-1-like cytokine secretion profile (Wankowicz-Kalinska et al., 2003). More 
recently it has been demonstrated that T lymphocytes obtained from perilesional skin 
biopsies are enriched for cytotoxic T cells that recognise melanocyte antigens tyrosinase, 
gp100 and MelanA (Van den Boorn et al., 2009). Moreover, upon infiltration of autologous 
pigmented skin, isolated perilesional T lymphocytes efficiently kill melanocytes, providing 
direct evidence that cytotoxic T cells can cause the depigmentation seen in vitiligo (Van den 
Boorn et al., 2009). Additional to this, are findings that regulatory T cells occur at a reduced 
level in the skin of vitiligo patients (Klarquist et al., 2010). This may allow the unchecked 
destruction of melanocytes by cytotoxic T cells in vitiligo lesions (Klarquist et al., 2010).  
3. Conclusion 
Autoimmunity is one hypothesis forwarded to explain the development of vitiligo due to 
the evidence presented in this review. However, it is most likely that interacting 
mechanisms, of which immune responses are a part, are responsible for the clinical 
manifestations of the disease (Le Poole et al., 1993a). In addition, although the evidence for 
the role of immune-related genes in the aetiology of vitiligo is clear, the limited concordance 
in identical twins (Alkhateeb et al., 2003) indicates that other factors, probably 
environmental, are also involved in its development, making the disease  complex, 
polygenic, and multi-factorial. Notably, in vitro studies have provided a link and a temporal 
sequence connecting cellular oxidative stress (Dell’Anna & Picardo, 2006; Schallreuter et al., 
1991; Schallreuter et al., 2001; Schallreuter et al., 2005) and the immune response in vitiligo: 
stressed melanocytes were found to mediate dendritic cell-activation with the consequent 
dendritic cell effector functions playing a role in the destruction of melanocytes (Kroll et al., 
2005). This work suggests that intrinsic damage to melanocytes could be the initiating event 
in vitiligo development followed by a secondary immune response by cytotoxic T cells 
which exacerbates the destruction of melanocytes and progresses the disease (Hariharan et 
al., 2010; Le Poole & Luiten, 2008; Van den Boorn et al., 2011). Indeed, 50% of vitiligo 
patients experience a Koebner phenomenon, whereby depigmented lesions develop at a site 
previously exposed to a physical stress (Le Poole & Luiten, 2008). 
As indicated, it is most likely that immune responses in vitiligo are of a secondary nature 
following melanocyte damage. Indeed, several vitiligo-associated autoantigens such as 
tyrosinase and gp100 are located intracellularly, and it has been suggested that either the 
formation of neo-antigens due to haptenation, the exposure of cryptic epitopes or the 
modification of proteins during apoptosis could account for immune responses to these 
molecules (Namazi, 2007; Westerhof & d’Ischia, 2007). Following processing by mature 
Langerhans cells, antigenic peptides could be presented to T cells which have escaped clonal 
deletion or to naïve T lymphocytes which have not been tolerised against cryptic epitopes 
(Namazi, 2007; Westerhof & d’Ischia, 2007). Antibodies could then be produced following 
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the stimulation of B lymphocytes by activated helper T cells (Namazi, 2007), and activated 
cytotoxic T cells could directly attack melanocytes expressing antigenic peptides on their 
surface in the context MHC class I molecules (Hedley et al., 1998; Le Poole et al., 1993b). In 
the case of immune reactivities against common cellular antigens, the selective destruction 
of melanocytes in vitiligo might occur because they are intrinsically more sensitive to 
immune-mediated injury than other skin cells (Norris et al., 1988b). 
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1. Ιntroduction 
Over the last years, accelerated atherosclerosis with consequent increased prevalence of 
cardiovascular disease (CV) in autoimmune patients, especially rheumatoid arthritis (RA) 
and systemic lupus erythematosus (SLE) has been well established (Toloza, Uribe et al. 
2004). However, traditional risk factors associated with atherosclerosis including among 
others smoking, dyslipidemia, diabetes mellitus (DM), hypertension (HT) and increased 
body mass index (BMI), do not fully account for the high rates of subclinical atherosclerosis 
in these patients (Meune, Touze et al. 2009). Ιn the present review, traditional and disease 
related risk factors of CV disease in the setting of chronic autoimmune disorders with 
special focus in RA, SLE and Sjogren’s syndrome (SS) will be discussed. 
2. Epidemiology of CV disease in systemic autoimmune disorders 
RA 
RA, a chronic systemic inflammatory disease affecting 0.5–1% of the adult population is 
associated with a two fold increase of CV disease. In a recent study by Evans et al, in 636 RA 
patients, the incidence of acute coronary syndromes (ACS) including myocardial infarction, 
unstable angina, cardiac arrest or death due to ischemic heart disease was 3.5 per 100 
patient-years with the presence of carotid plaque, CV risk factors (particularly diabetes or 
hypertension), active polyarticular disease, high cumulative dose of glucocorticoids and 
male sex, being high risk contributors (Evans, Escalante et al. 2011). In patients with early 
RA, higher intima media thickness (IMT) scores- a surrogate marker of subclinical 
atherosclerosis-  have been detected compared to healthy controls (Sodergren, Karp et al. 
2010) (Georgiadis, Voulgari et al. 2008). Of interest, treatment with methotrexate and 
prednisolone led to significant reduction of IMT scores compared to baseline after one year 
of treatment. Several studies so far have demonstrated the independent relationship of 
elevated inflammatory markers (Myasoedova and Gabriel 2010), with the effects of the 
atherosclerotic process being reversed, after disease activity and chronic inflammation in RA 
patients are controlled (Bisoendial, Stroes et al. 2011). 
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SLE is a highly heterogeneous autoimmune disease, affecting women of childbearing age, 
with substantial mortality and morbidity.  The effect of SLE on atherosclerotic disease has 
been recognised since the 70s, when Urowitz et al displayed a bimodal mortality peak; the 
first was attributed to disease activity and infections and the second to CV disease (Urowitz, 
Bookman et al. 1976). The prevalence of ischemic heart disease in SLE patients is estimated 
between 8% and 16% (Badui, Garcia-Rubi et al. 1985; Gladman and Urowitz 1987; Petri, 
Perez-Gutthann et al. 1992; Borchers, Keen et al. 2004) conferring a 50fold risk (Manzi, 
Meilahn et al. 1997). In regard to subclinical coronary artery disease, the rates seem to be 
even higher, reaching the percentage of 28%-40% (Manzi, Selzer et al. 1999; Svenungsson, 
Jensen-Urstad et al. 2001; Asanuma, Oeser et al. 2003; Manger, Kusus et al. 2003; Roman, 
Shanker et al. 2003; Vlachoyiannopoulos, Kanellopoulos et al. 2003). Esdaile et al revealed 
that even after statistical correction for the effects of all classical CV risk factors, patients 
with SLE still had a 7.9-fold increase in the risk of stroke and a 10.1-fold increase in risk of 
non-fatal myocardial infarction (Esdaile, Abrahamowicz et al. 2001). Given that standard 
Framingham scores cannot fully account for the rate of ischemic events, lupus is now 
regarded as an independent risk factor for the development of CV comorbidity (Manzi, 
Meilahn et al. 1997; Manzi 2000).  
SS 
SS or autoimmune epithelitis a slowly progressive autoimmune disease is characterized by 
salivary and lacrimal gland dysfunction and shares many common clinical and serologic 
features  with other immune mediated autoimmune diseases especially SLE (Mavragani and 
Moutsopoulos 2010). SS has been recently associated with increased rates of subclinical CV 
disease in a limited number of studies.  Vaudo et al, revealed higher carotid and femoral 
IMT scores in 37 untreated white women with primary SS compared to age and sex matched 
healthy counterparts, in association with leukopenia and the presence of anti-SSA 
antibodies (Vaudo, Bocci et al. 2005). In a subsequent study by Satish et al, patients with 
long standing disease demonstrated abnormal ankle brachial index (ABI) values compared 
to controls (Rachapalli, Kiely et al. 2009). While endothelium dependent flow mediated 
vasodilation (FMD) –a marker of endothelial function- did not differ significantly between 
primary SS patients and controls as a whole, the subset of patients with articular 
involvement or parotid gland enlargement had lower values of FMV than controls and 
patients without such characteristics.  
On the other hand, nitrate mediated vasodilation (NMV) values -detecting smooth muscle 
relaxation independently of endothelial contribution- were lower in primary SS patients and 
particularly in those characterized by leukopenia, rheumatoid factor (RF), anti-SSB 
antibodies, and articular involvement. Of interest, NMV values, were directly correlated to 
the number of the circulating white blood cells and inversely correlated to vascular cell 
adhesion molecule 1 (VCAM-1) levels (Gerli, Vaudo et al. 2010).  
3. Traditional CV risk factors in autoimmune diseases 
3.1 Metabolic syndrome 
The metabolic syndrome (MetS) describes a constellation of major risk factors for CV disease 
including dyslipidemia, obesity, hypertension and insulin resistance. Several studies so far 
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have documented the increased frequency of MetS in patients with chronic rheumatic 
diseases compared to healthy control populations; the higher proinflammatory cytokine 
burden impairs insulin sensitivity and promotes the adverse lipoprotein profile seen in 
MetS (Pereira, de Carvalho et al. 2009; Santos and Fonseca 2009). 
RA 
The relationship between the BMI and overall CV mortality in patients with RA is well 
recognised (Kitas and Gabriel 2011). Quiet unexpectedly, compared to the general 
population, the risk of CV disease in RA patients is increased in younger females with low 
body mass index (<20kg/m2), most likely due to the excess of inflammatory cytokines 
(Gabriel 2010; Ozbalkan, Efe et al. 2010; Kitas and Gabriel 2011). In accord with the previous 
observation, obesity is linked to hypertension and dyslipidemia, but with lower RA disease 
activity and consequently less CV mortality (Summers, Metsios et al. 2010). In contrast, in 
the study of Kallinoglou et al, multivariate analysis revealed an association of obesity with 
CV disease in patients with RA mainly due to concomitant presence of risk factors such as 
HT, high-density lipoprotein (HDL), insulin resistance and Mets (Stavropoulos-Kalinoglou, 
Metsios et al. 2009).  On the other hand, a recent study has shown that in patients with 
established RA, both very low and very high BMI and BF associate independently with 
increased disease activity and physical dysfunction but not with the presence of erosions or 
joint surgery (Stavropoulos-Kalinoglou, Metsios et al. 2009). While the long-term use of 
glucocorticoids in RA may collectively contribute to the development of Mets syndrome and 
atherosclerosis, no association with long term low dose glucocorticoid has been detected in 
this population (Toms, Panoulas et al. 2008).  Furthermore, Ku et al showed that RA patients 
have high basal levels of insulin and increased insulin resistance and that the degree of 
severity correlates with inflammatory indices (Ku, Imboden et al. 2009). Finally, in a study 
of a group of 105 Vietnamese women with early RA, a higher prevalence of MetS compared 
with healthy controls was demonstrated with disease activity, high inflammatory indices, 
disability score and less use of DMARDs being independent predictors (Dao, Do et al. 2010). 
The link between obesity and inflammation has recently attracted particular attention. 
Adipocytokines –a newly identified cytokine subset- have been associated with adipose 
tissue and include among others leptin, adiponectin, resistin and visfatin. Leptin is essential 
for the regulation of appetite and body weight, as well as the modulation of immune 
responses (Rho, Chung et al. 2010). While resistin and visfatin are associated with 
inflammation, insulin resistance and subclinical atherosclerosis, adiponectin is mainly anti-
inflammatory, and inversely associated with obesity, insulin resistance, CRP and CV risk 
(Fagerer and Kullich 2010; Yoshino, Kusunoki et al. 2011). 
In patients with RA, higher levels of adipocytokines have been detected compared to control 
subjects. In a recent report, leptin and visfatin levels were associated with insulin resistance, 
but not with the presence of coronary calcification (Ozgen, Koca et al. 2010; Rho, Chung et al. 
2010).  As expected, in contrast to adiponectin, which was negatively associated with CRP,  
leptin and resistin levels were positively linked to CRP titers (Yoshino, Kusunoki et al. 2011). 
While anti-tumor necrosis factor alpha (anti-TNF) treatment in RA patients does not change 
the levels of circulating visfatin and leptin (Popa, Netea et al. 2009; Gonzalez-Gay, Vazquez-
Rodriguez et al. 2010), data on adiponectin is contradictory. In the largest so far study 
including 97 patients with RA, serum adiponectin was increased after 12 months of anti-
TNF treatment (Nishida, Okada et al. 2008), an observation also confirmed in smaller 
reports with the same follow-up period, implying a potential underlying mechanism for CV 
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While anti-tumor necrosis factor alpha (anti-TNF) treatment in RA patients does not change 
the levels of circulating visfatin and leptin (Popa, Netea et al. 2009; Gonzalez-Gay, Vazquez-
Rodriguez et al. 2010), data on adiponectin is contradictory. In the largest so far study 
including 97 patients with RA, serum adiponectin was increased after 12 months of anti-
TNF treatment (Nishida, Okada et al. 2008), an observation also confirmed in smaller 
reports with the same follow-up period, implying a potential underlying mechanism for CV 
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risk reduction by anti-TNF agents (Komai, Morita et al. 2007; Serelis, Kontogianni et al. 2008; 
Engvall, Tengstrand et al. 2010). In contrast, with the exception of the Japanese study by 
Komai et al who revealed increased adiponectin levels as soon as 2 and 6 weeks, no changes 
or reduction in adiponectin levels have been reported by studies with a follow-up period of 
6 months (Derdemezis, Filippatos et al. 2009; Popa, Netea et al. 2009).  
SLE 
In a large cohort of 250 patients with SLE and equal number of age-sex matched controls, 
increased waist-to-hip ratio and sedentary lifestyle in SLE patients was found (Bruce, 
Urowitz et al. 2003). The prevalence of obesity in SLE has been recently estimated in a cohort 
of 145 patients by two methods.  Using the most common body composition measure (Body 
mass index, BMI), almost 30% were obese; using a more sensitive measure (by Dual X-ray 
absorptometry (DXA), the percentage rose to 50% (Katz, Gregorich et al. 2011). A higher 
prevalence of Mets was found in young lupus patients below 40 years compared to age 
matched controls (15.8% vs 4.2%) (Sabio, Zamora-Pasadas et al. 2008); the corresponding 
figures in the study of Chung et al  were 32.4% versus 10.9% (using the WHO definition that 
requires direct determination of insulin resistance ) and  29.4% versus 19.8% (using the 
National Cholesterol Education Program Adult Treatment Panel III definition -NCEP) and 
found to correlate with higher C-Reactive protein (CRP) levels and  endothelial injury. In a 
subsequent study by Mok et al, the prevalence of Mets was 16.3% in lupus patients and 
correlated with coronary atherosclerosis (Mok, Poon et al. 2010).  In another report, the 
presence of Mets was associated with higher aortic pulse wave velocity (PWV) –as an 
indicator of arterial stiffness- and increased biomarkers of subclinical atherosclerosis such as 
CRP, IL-6, C3, uric acid, homocysteine, fibrinogen and D-dimer (Sabio, Vargas-Hitos et al. 
2009). Insulin resistance per se as defined by the WHO criteria was more prevalent in lupus 
patients compared to controls (44.1% versus 24.8%) (Chung, Avalos et al. 2007).   
Similarly to RA, increased levels of adiponectin have been reported in SLE patients (Sada, 
Yamasaki et al. 2006; Chung, Long et al. 2009; Vadacca, Margiotta et al. 2009) and found to 
be associated with carotid plaque formation, as a physiologic attempt to limit endothelial 
damage (Sada, Yamasaki et al. 2006; Vadacca, Margiotta et al. 2009; Clancy and Ginzler 2010; 
Reynolds, Buyon et al. 2010).  Opposite are the findings reported by Chung et al, where 
lower levels of adiponectin were associated with insulin resistance, BMI and CRP but not 
with coronary atherosclerosis (Chung, Long et al. 2009). In a murine lupus model, 
adiponectin has been recently shown to exert protective effects against lupus activity and 
concomitant atherosclerotic disease. The use of the peroxisome proliferator-activated 
receptor gamma (PPARgamma) agonist rosiglitazone reduces autoantibody production, 
renal disease, and atherosclerosis in mouse models of SLE possibly through adiponectin 
induction. At the same time, lupus mice that lack adiponectin develop more severe disease 
compared to adiponectin-sufficient lupus mice with the administration of exogenous 
adiponectin ameliorating disease (Aprahamian, Bonegio et al. 2009). Leptin levels were 
associated with insulin resistance, BMI and CRP but not with coronary or carotid 
atherosclerosis (Vadacca, Margiotta et al. 2009). Administration of leptin in lupus prone 
model led to increased pro-inflammatory HDL scores, atherosclerosis, and accelerated 
proteinuria, revealing its proatherogenic role (Hahn, Lourencco et al. 2010). 
SS 
In patients with SS, a higher prevalence of associated dyslipidemia, DM, and hyperuricemia 
compared to age and sex-matched controls has been observed. Hypercholesterolemia was 
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associated with a lower frequency of immunological markers such as anti-Ro/SSA, anti-
La/SSB antibodies, low C3, and C4 levels, while hypertriglyceridemia and DM were 
positively associated with the presence of extraglandular (renal, liver,vasculitic) 
involvement. A higher prevalence of DM was found in patients treated with corticosteroids 
(Ramos-Casals, Brito-Zeron et al. 2007).  
3.2 Hypertension (HT) 
RA 
The prevalence of HT among patients with RA varies between different studies (Panoulas, 
Metsios et al. 2008). In the largest so far population study by Han et al. prevalence of HT 
was significantly higher in RA (34% vs 23.4%). However, a recent metaanalysis assessing the 
effect of traditional risk factors in the pathogenesis of CV disease in RA patients 
demonstrated similar rates of hypertension in RA patients compared to healthy controls 
(Gabriel 2010; Boyer, Gourraud et al. 2011). 
HT has been found to be associated with subclinical atherosclerosis and CV morbidity in RA 
patients (Panoulas, Douglas et al. 2007). In a recent Greek cohort study of 325 RA patients, 
with late disease onset, inadequate early control of disease activity and leflunomide 
treatment,  hypertension was clearly demonstrated to be an important risk factor for CV 
disease (Serelis, Panagiotakos et al. 2011).  
HT and low grade inflammation have been previously linked in general population studies 
(Panoulas, Douglas et al. 2007; Kitas and Gabriel 2011). High CRP leads to vasoconstriction 
though reduction of endothelial nitric oxide production, increase in expression of 
endothelin-1 and upregulation of angiotensin type 1 receptor expression; furthermore, it 
induces platelet adherence, oxidation and thrombosis. Apart from systemic inflammation, 
physical inactivity due to articular involvement, genetic predisposition, various medications 
including NSAIDs, corticosteroids, leflunomide and cyclosporine might account for 
deregulated arterial pressure in patients with RA  (Stavropoulos-Kalinoglou, Metsios et al. 
2009; Kitas and Gabriel 2011). 
Genetic contribution in occurrence of HT in RA patients was evidenced by the association of 
previously associated polymorphisms with HT in healthy populations.  In RA patients, 
TGFB1 869T/C and endothelin gene polymorphisms have been shown to be linked with HT, 
with the latter found to be associated with raised endothelin-1 (ET-1) levels.  In contrast to 
previous studies in healthy subjects, no associations between IL-6-174G/C and HT 
(Panoulas, Douglas et al. 2009) was detected.  Furthermore, a cross-sectional study did not 
demonstrate significant associations between RA disease activity and hypertension 
(Panoulas, Metsios et al. 2008; Kitas and Gabriel 2011). 
SLE 
HT is a well recognised risk factor for CV disease development in SLE patients (Petri, Perez-
Gutthann et al. 1992) as evidenced by several studies reporting its contribution in plaque 
formation (IMT measurement, coronary angiography) and arterial stiffening (Sella, Sato et 
al. 2003; Selzer, Sutton-Tyrrell et al. 2004; Maksimowicz-McKinnon, Magder et al. 2006; 
Cypiene, Dadoniene et al. 2010; Gallelli, Burdick et al. 2010). Several studies so far have 
confirmed the increased prevalence of arterial HT in these patients, ranging from 33% to 
56% (de Leeuw, Freire et al. 2006; Bellomio, Spindler et al. 2009; Duarte, Couto et al. 2009; 
Boucelma, Haddoum et al. 2011; Sabio, Vargas-Hitos et al. 2011). In an effort to investigate 
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risk reduction by anti-TNF agents (Komai, Morita et al. 2007; Serelis, Kontogianni et al. 2008; 
Engvall, Tengstrand et al. 2010). In contrast, with the exception of the Japanese study by 
Komai et al who revealed increased adiponectin levels as soon as 2 and 6 weeks, no changes 
or reduction in adiponectin levels have been reported by studies with a follow-up period of 
6 months (Derdemezis, Filippatos et al. 2009; Popa, Netea et al. 2009).  
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of 145 patients by two methods.  Using the most common body composition measure (Body 
mass index, BMI), almost 30% were obese; using a more sensitive measure (by Dual X-ray 
absorptometry (DXA), the percentage rose to 50% (Katz, Gregorich et al. 2011). A higher 
prevalence of Mets was found in young lupus patients below 40 years compared to age 
matched controls (15.8% vs 4.2%) (Sabio, Zamora-Pasadas et al. 2008); the corresponding 
figures in the study of Chung et al  were 32.4% versus 10.9% (using the WHO definition that 
requires direct determination of insulin resistance ) and  29.4% versus 19.8% (using the 
National Cholesterol Education Program Adult Treatment Panel III definition -NCEP) and 
found to correlate with higher C-Reactive protein (CRP) levels and  endothelial injury. In a 
subsequent study by Mok et al, the prevalence of Mets was 16.3% in lupus patients and 
correlated with coronary atherosclerosis (Mok, Poon et al. 2010).  In another report, the 
presence of Mets was associated with higher aortic pulse wave velocity (PWV) –as an 
indicator of arterial stiffness- and increased biomarkers of subclinical atherosclerosis such as 
CRP, IL-6, C3, uric acid, homocysteine, fibrinogen and D-dimer (Sabio, Vargas-Hitos et al. 
2009). Insulin resistance per se as defined by the WHO criteria was more prevalent in lupus 
patients compared to controls (44.1% versus 24.8%) (Chung, Avalos et al. 2007).   
Similarly to RA, increased levels of adiponectin have been reported in SLE patients (Sada, 
Yamasaki et al. 2006; Chung, Long et al. 2009; Vadacca, Margiotta et al. 2009) and found to 
be associated with carotid plaque formation, as a physiologic attempt to limit endothelial 
damage (Sada, Yamasaki et al. 2006; Vadacca, Margiotta et al. 2009; Clancy and Ginzler 2010; 
Reynolds, Buyon et al. 2010).  Opposite are the findings reported by Chung et al, where 
lower levels of adiponectin were associated with insulin resistance, BMI and CRP but not 
with coronary atherosclerosis (Chung, Long et al. 2009). In a murine lupus model, 
adiponectin has been recently shown to exert protective effects against lupus activity and 
concomitant atherosclerotic disease. The use of the peroxisome proliferator-activated 
receptor gamma (PPARgamma) agonist rosiglitazone reduces autoantibody production, 
renal disease, and atherosclerosis in mouse models of SLE possibly through adiponectin 
induction. At the same time, lupus mice that lack adiponectin develop more severe disease 
compared to adiponectin-sufficient lupus mice with the administration of exogenous 
adiponectin ameliorating disease (Aprahamian, Bonegio et al. 2009). Leptin levels were 
associated with insulin resistance, BMI and CRP but not with coronary or carotid 
atherosclerosis (Vadacca, Margiotta et al. 2009). Administration of leptin in lupus prone 
model led to increased pro-inflammatory HDL scores, atherosclerosis, and accelerated 
proteinuria, revealing its proatherogenic role (Hahn, Lourencco et al. 2010). 
SS 
In patients with SS, a higher prevalence of associated dyslipidemia, DM, and hyperuricemia 
compared to age and sex-matched controls has been observed. Hypercholesterolemia was 
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associated with a lower frequency of immunological markers such as anti-Ro/SSA, anti-
La/SSB antibodies, low C3, and C4 levels, while hypertriglyceridemia and DM were 
positively associated with the presence of extraglandular (renal, liver,vasculitic) 
involvement. A higher prevalence of DM was found in patients treated with corticosteroids 
(Ramos-Casals, Brito-Zeron et al. 2007).  
3.2 Hypertension (HT) 
RA 
The prevalence of HT among patients with RA varies between different studies (Panoulas, 
Metsios et al. 2008). In the largest so far population study by Han et al. prevalence of HT 
was significantly higher in RA (34% vs 23.4%). However, a recent metaanalysis assessing the 
effect of traditional risk factors in the pathogenesis of CV disease in RA patients 
demonstrated similar rates of hypertension in RA patients compared to healthy controls 
(Gabriel 2010; Boyer, Gourraud et al. 2011). 
HT has been found to be associated with subclinical atherosclerosis and CV morbidity in RA 
patients (Panoulas, Douglas et al. 2007). In a recent Greek cohort study of 325 RA patients, 
with late disease onset, inadequate early control of disease activity and leflunomide 
treatment,  hypertension was clearly demonstrated to be an important risk factor for CV 
disease (Serelis, Panagiotakos et al. 2011).  
HT and low grade inflammation have been previously linked in general population studies 
(Panoulas, Douglas et al. 2007; Kitas and Gabriel 2011). High CRP leads to vasoconstriction 
though reduction of endothelial nitric oxide production, increase in expression of 
endothelin-1 and upregulation of angiotensin type 1 receptor expression; furthermore, it 
induces platelet adherence, oxidation and thrombosis. Apart from systemic inflammation, 
physical inactivity due to articular involvement, genetic predisposition, various medications 
including NSAIDs, corticosteroids, leflunomide and cyclosporine might account for 
deregulated arterial pressure in patients with RA  (Stavropoulos-Kalinoglou, Metsios et al. 
2009; Kitas and Gabriel 2011). 
Genetic contribution in occurrence of HT in RA patients was evidenced by the association of 
previously associated polymorphisms with HT in healthy populations.  In RA patients, 
TGFB1 869T/C and endothelin gene polymorphisms have been shown to be linked with HT, 
with the latter found to be associated with raised endothelin-1 (ET-1) levels.  In contrast to 
previous studies in healthy subjects, no associations between IL-6-174G/C and HT 
(Panoulas, Douglas et al. 2009) was detected.  Furthermore, a cross-sectional study did not 
demonstrate significant associations between RA disease activity and hypertension 
(Panoulas, Metsios et al. 2008; Kitas and Gabriel 2011). 
SLE 
HT is a well recognised risk factor for CV disease development in SLE patients (Petri, Perez-
Gutthann et al. 1992) as evidenced by several studies reporting its contribution in plaque 
formation (IMT measurement, coronary angiography) and arterial stiffening (Sella, Sato et 
al. 2003; Selzer, Sutton-Tyrrell et al. 2004; Maksimowicz-McKinnon, Magder et al. 2006; 
Cypiene, Dadoniene et al. 2010; Gallelli, Burdick et al. 2010). Several studies so far have 
confirmed the increased prevalence of arterial HT in these patients, ranging from 33% to 
56% (de Leeuw, Freire et al. 2006; Bellomio, Spindler et al. 2009; Duarte, Couto et al. 2009; 
Boucelma, Haddoum et al. 2011; Sabio, Vargas-Hitos et al. 2011). In an effort to investigate 
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the contributors of HT in a cohort of 112 lupus patients, Sabio et al, reported that renal 
disease, insulin levels and disease activity indices such as Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI) were independent predictors of HT in these subjects. Of 
interest, in the younger age group (<40y), hypertension was also associated with higher non 
obesity-related insulin levels, while in the older group (>40y), with age and obesity (Sabio, 
Vargas-Hitos et al. 2011). 
Arterial hypertension did not seem to influence subclinical atherosclerotic disease in 
patients with pSS (Vaudo, Bocci et al. 2005; Rachapalli, Kiely et al. 2009; Gerli, Vaudo et al. 
2010). 
3.3 Dyslipidemia 
Increased levels of total cholesterol (TC), low-density-lipoprotein (LDL) cholesterol and 
decreased level of HDL cholesterol are associated with increased risk for CV disease in the 
general population (Nurmohamed 2009). Cholesterol is transported in the blood by LDL 
which contains esterified cholesterol and triglycerides surrounded by phospholipids, free 
cholesterol and apolipoprotein B100 (ApoB100). Circulating LDL particles can accumulate in 
the intima, where ApoB100 binds to proteoglycans of the extracellular matrix, they are 
oxidised (Hansson and Hermansson 2011) (oxLDLs), become proinflammatory and lead to 
endothelial activation. Monocytes are stimulated by macrophage colony-stimulating factor 
produced by activated endothelial cells and differentiate into macrophages. Macrophages 
upregulate their scavenger receptors that can take up oxLDL (Hahn, Grossman et al. 2008). 
Cholesterol accumulation in macrophages transforms them into foam cells that are 
characteristic of the atherosclerotic lesion. Dendritic cells (DCs) may take up LDL for 
antigen presentation in regional lymph nodes. In the normal artery wall, DCs promote 
antigen tolerization; however, atherogenesis leads to a switch from tolerance to the 
activation of adaptive immunity (Hansson and Hermansson 2011). Monocytes attract 
lymphocytes that recognize antigens and contribute to inflammation by releasing cytokines. 
As plaque matures, proteases and other proinflammatory molecules are produced, with 
hypertrophy of smooth muscle, damage to endothelial cells, bulging of plaque into the 
lumen of the artery, and formation of a fibrous cap over the plaque (Hahn, Grossman et al. 
2008). 
RA  
Lipoprotein (α) (Lp(α)) is a cholesterol-rich modified form of LDL (Van Doornum, McColl et 
al. 2002) that is transformed in the liver by covalent attachment of ApoB to ApoA, a member 
of the plasminogen gene family (Tabas, Williams et al. 2007). Lp(α) has been identified as an 
independent risk factor for coronary heart disease and elevated levels have been 
demonstrated in RA patients with active disease (Van Doornum, McColl et al. 2002). Several 
studies suggest that Lp(α) is associated with early atherosclerosis in RA and possibly in 
other autoimmune disorders (Dursunoglu, Evrengul et al. 2005; Wang, Hu et al. 2008).  In 
recent studies,  complexes of β2-glycoprotein I with Lp(α) ((β2)-GPI-Lp(α)) are found in sera 
of active RA patients and associate with oxLDL, ox-Lpa and CRP levels (Zhang, Li et al. 
2011).  
On the other hand, low HDL levels have been previously associated with RA related 
atherosclerosis implying the potential link between HDL and autoimmunity. HDL possesses 
anti-inflammatory effects and inhibits the ability of antigen-presenting cells (APCs) to 
stimulate T cells (Yu, Wang et al. 2010). Given that inflammation has been shown to 
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suppress total and LDL cholesterol, active RA patients have lower total cholesterol, low LDL 
and depressed HDL resulting in a higher atherogenic index (total cholesterol/HDL-
cholesterol ratio) (Nurmohamed 2009; Kitas and Gabriel 2011), although such alterations 
have been also observed 3-5 year prior to RA incidence (Myasoedova, Crowson et al. 2010). 
In a study of early RA patients higher levels of TC, LDL , triglycerides and very low levels in 
HDL have been observed compared to healthy controls resulting again in  a significantly 
higher atherogenic ratio of TC/HDL as well as that of LDL/HDL (Georgiadis, Papavasiliou 
et al. 2006). Raised autoantibody titers against oxLDL and low lipoprotein-associated 
phospholipase A2 (Lp-PLA2) plasma activity have been  also suggested as potential 
contributors in the pathogenesis of accelerated atherosclerosis in patients with early RA 
(Lourida, Georgiadis et al. 2007). Of interest, recent findings have revealed the contribution 
of several  known RA susceptible genes such as TRAF1/C5, STAT4 and HLA-DRB1-SE in 
dyslipidemia observed in these patients (Toms, Panoulas et al. 2011). 
Systemic inflammation, drug therapy, lifestyle and genetic factors can result not only in 
changes of overall lipid levels, but also can modify lipids structure and function (Toms, 
Symmons et al. 2010). Paraoxonase 1 (PON1) is an antiatherogenic enzyme with the ability 
to destroy biologically active oxLDL (Hahn, Grossman et al. 2008) and to protect LDL 
against oxidation (Zhao 2009). PON1 activity in RA patients is inversely related to CRP 
levels, suggesting that inflammation modulates PON activity (Ku, Imboden et al. 2009). 
SLE  
The classical pattern of dyslipoproteinemia in SLE is characterized by elevated levels of 
very-low-density lipoprotein cholesterol (VLDL), triglycerides and LDL and low levels of 
HDL (Borba, Bonfa et al. 2000), although HDL qualitative abnormalities such as 
peroxidation have been also described, often in association with active disease. Peroxidised 
HDLs (piHDLs) are unable to reverse cholesterol transport which normally clears oxLDL 
from the subendothelial space promoting endothelial injury. piHDLs occur in a larger 
proportion of patients with SLE compared to RA and  are associated with carotid artery 
plaque formation, documented CV disease and  low physical activity (McMahon, Grossman 
et al. 2006; McMahon, Grossman et al. 2009; Volkmann, Grossman et al. 2010). 
Apart from HDL, LDL can be also modified in SLE; Frostergard et al disclosed higher levels 
of oxidized epitopes on LDL in lupus patients compared to controls, which were associated 
with arterial disease and renal manifestations (Frostegard, Svenungsson et al. 2005). 
In a recent study, circulating lipoprotein remnant particles and the intermediate density 
lipoprotein (IDL) fraction have been strongly associated with IMT values in lupus patients 
(Gonzalez, Ribalta et al. 2010). Furthermore, reduced levels of apoA-I -the major 
apolipoprotein component of HDL- have been found in SLE patients with IgG 
anticardiolipin antibodies (Delgado Alves, Kumar et al. 2003) while antibodies to apoA-I 
have been previously documented in 32.5% of patients with SLE and 22.9% of patients with 
primary antiphospholipid syndrome (Dinu, Merrill et al. 1998).  
Anti-HDL, anti-CRP anti-Apo A-I have been detected in SLE patients, with the latter found 
to be associated with persistent disease activity. In the subset of patients with lupus 
nephritis, anti-Apo A-I and anti-HDL levels correlated with serum anti-double-stranded 
DNA levels (O'Neill, Giles et al. 2010). Woo et al evaluated the effects of L-4F, 
(apolipoprotein A-1 mimetic peptide), alone or with pravastatin, in apoE-/-Fas-/-C57BL/6 
female mice that spontaneously develop immunoglobulin G (IgG) autoantibodies, 
glomerulonephritis, osteopenia, and atherosclerotic lesions. As expected, L-4F treatment, 
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the contributors of HT in a cohort of 112 lupus patients, Sabio et al, reported that renal 
disease, insulin levels and disease activity indices such as Systemic Lupus Erythematosus 
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interest, in the younger age group (<40y), hypertension was also associated with higher non 
obesity-related insulin levels, while in the older group (>40y), with age and obesity (Sabio, 
Vargas-Hitos et al. 2011). 
Arterial hypertension did not seem to influence subclinical atherosclerotic disease in 
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general population (Nurmohamed 2009). Cholesterol is transported in the blood by LDL 
which contains esterified cholesterol and triglycerides surrounded by phospholipids, free 
cholesterol and apolipoprotein B100 (ApoB100). Circulating LDL particles can accumulate in 
the intima, where ApoB100 binds to proteoglycans of the extracellular matrix, they are 
oxidised (Hansson and Hermansson 2011) (oxLDLs), become proinflammatory and lead to 
endothelial activation. Monocytes are stimulated by macrophage colony-stimulating factor 
produced by activated endothelial cells and differentiate into macrophages. Macrophages 
upregulate their scavenger receptors that can take up oxLDL (Hahn, Grossman et al. 2008). 
Cholesterol accumulation in macrophages transforms them into foam cells that are 
characteristic of the atherosclerotic lesion. Dendritic cells (DCs) may take up LDL for 
antigen presentation in regional lymph nodes. In the normal artery wall, DCs promote 
antigen tolerization; however, atherogenesis leads to a switch from tolerance to the 
activation of adaptive immunity (Hansson and Hermansson 2011). Monocytes attract 
lymphocytes that recognize antigens and contribute to inflammation by releasing cytokines. 
As plaque matures, proteases and other proinflammatory molecules are produced, with 
hypertrophy of smooth muscle, damage to endothelial cells, bulging of plaque into the 
lumen of the artery, and formation of a fibrous cap over the plaque (Hahn, Grossman et al. 
2008). 
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Lipoprotein (α) (Lp(α)) is a cholesterol-rich modified form of LDL (Van Doornum, McColl et 
al. 2002) that is transformed in the liver by covalent attachment of ApoB to ApoA, a member 
of the plasminogen gene family (Tabas, Williams et al. 2007). Lp(α) has been identified as an 
independent risk factor for coronary heart disease and elevated levels have been 
demonstrated in RA patients with active disease (Van Doornum, McColl et al. 2002). Several 
studies suggest that Lp(α) is associated with early atherosclerosis in RA and possibly in 
other autoimmune disorders (Dursunoglu, Evrengul et al. 2005; Wang, Hu et al. 2008).  In 
recent studies,  complexes of β2-glycoprotein I with Lp(α) ((β2)-GPI-Lp(α)) are found in sera 
of active RA patients and associate with oxLDL, ox-Lpa and CRP levels (Zhang, Li et al. 
2011).  
On the other hand, low HDL levels have been previously associated with RA related 
atherosclerosis implying the potential link between HDL and autoimmunity. HDL possesses 
anti-inflammatory effects and inhibits the ability of antigen-presenting cells (APCs) to 
stimulate T cells (Yu, Wang et al. 2010). Given that inflammation has been shown to 
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suppress total and LDL cholesterol, active RA patients have lower total cholesterol, low LDL 
and depressed HDL resulting in a higher atherogenic index (total cholesterol/HDL-
cholesterol ratio) (Nurmohamed 2009; Kitas and Gabriel 2011), although such alterations 
have been also observed 3-5 year prior to RA incidence (Myasoedova, Crowson et al. 2010). 
In a study of early RA patients higher levels of TC, LDL , triglycerides and very low levels in 
HDL have been observed compared to healthy controls resulting again in  a significantly 
higher atherogenic ratio of TC/HDL as well as that of LDL/HDL (Georgiadis, Papavasiliou 
et al. 2006). Raised autoantibody titers against oxLDL and low lipoprotein-associated 
phospholipase A2 (Lp-PLA2) plasma activity have been  also suggested as potential 
contributors in the pathogenesis of accelerated atherosclerosis in patients with early RA 
(Lourida, Georgiadis et al. 2007). Of interest, recent findings have revealed the contribution 
of several  known RA susceptible genes such as TRAF1/C5, STAT4 and HLA-DRB1-SE in 
dyslipidemia observed in these patients (Toms, Panoulas et al. 2011). 
Systemic inflammation, drug therapy, lifestyle and genetic factors can result not only in 
changes of overall lipid levels, but also can modify lipids structure and function (Toms, 
Symmons et al. 2010). Paraoxonase 1 (PON1) is an antiatherogenic enzyme with the ability 
to destroy biologically active oxLDL (Hahn, Grossman et al. 2008) and to protect LDL 
against oxidation (Zhao 2009). PON1 activity in RA patients is inversely related to CRP 
levels, suggesting that inflammation modulates PON activity (Ku, Imboden et al. 2009). 
SLE  
The classical pattern of dyslipoproteinemia in SLE is characterized by elevated levels of 
very-low-density lipoprotein cholesterol (VLDL), triglycerides and LDL and low levels of 
HDL (Borba, Bonfa et al. 2000), although HDL qualitative abnormalities such as 
peroxidation have been also described, often in association with active disease. Peroxidised 
HDLs (piHDLs) are unable to reverse cholesterol transport which normally clears oxLDL 
from the subendothelial space promoting endothelial injury. piHDLs occur in a larger 
proportion of patients with SLE compared to RA and  are associated with carotid artery 
plaque formation, documented CV disease and  low physical activity (McMahon, Grossman 
et al. 2006; McMahon, Grossman et al. 2009; Volkmann, Grossman et al. 2010). 
Apart from HDL, LDL can be also modified in SLE; Frostergard et al disclosed higher levels 
of oxidized epitopes on LDL in lupus patients compared to controls, which were associated 
with arterial disease and renal manifestations (Frostegard, Svenungsson et al. 2005). 
In a recent study, circulating lipoprotein remnant particles and the intermediate density 
lipoprotein (IDL) fraction have been strongly associated with IMT values in lupus patients 
(Gonzalez, Ribalta et al. 2010). Furthermore, reduced levels of apoA-I -the major 
apolipoprotein component of HDL- have been found in SLE patients with IgG 
anticardiolipin antibodies (Delgado Alves, Kumar et al. 2003) while antibodies to apoA-I 
have been previously documented in 32.5% of patients with SLE and 22.9% of patients with 
primary antiphospholipid syndrome (Dinu, Merrill et al. 1998).  
Anti-HDL, anti-CRP anti-Apo A-I have been detected in SLE patients, with the latter found 
to be associated with persistent disease activity. In the subset of patients with lupus 
nephritis, anti-Apo A-I and anti-HDL levels correlated with serum anti-double-stranded 
DNA levels (O'Neill, Giles et al. 2010). Woo et al evaluated the effects of L-4F, 
(apolipoprotein A-1 mimetic peptide), alone or with pravastatin, in apoE-/-Fas-/-C57BL/6 
female mice that spontaneously develop immunoglobulin G (IgG) autoantibodies, 
glomerulonephritis, osteopenia, and atherosclerotic lesions. As expected, L-4F treatment, 
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significantly reduced IgG anti-dsDNA and IgG anti-oxPLs (anti-oxidised phospholipids), 
proteinuria, glomerulonephritis, and osteopenia in a murine lupus model of accelerated 
atherosclerosis (Woo, Lin et al. 2010). 
SS  
Low HDL cholesterol levels was a constant finding among SS patients in several studies 
(Vaudo, Bocci et al. 2005; Lodde, Sankar et al. 2006; Gerli, Vaudo et al. 2010). Of interest, 
HDL along with total cholesterol were found to be associated with immunoglobulin G 
levels. In particular, the presence of anti-SSA and anti-SSB antibodies have been linked to 
lower total cholesterol and reduced HDL cholesterol levels, respectively  (Lodde, Sankar et 
al. 2006). Subsequently, Cruz et al, showed a trend to dyslipidemia defined as total 
cholesterol >200mg/dL, HDL cholesterol<40mg/dL, LDL cholesterol>130mg/dL or 
triglycerides > 150mg/dL in patients with pSS compared to controls (Cruz, Fialho et al. 
2010). 
3.4 Smoking  
RA 
Smoking is an important risk factor for the development of both RA and CVD.  Smoking is 
associated with severe RA with more erosive disease and extra-articular involvement, as 
smokers are more likely to have positive RF and anti-CCP antibodies. It is not yet clear if 
smoking confers the same relative risk for CVD development in RA patients compared to 
the general population (Ozbalkan, Efe et al. 2010). Cigarette smoking is associated with 
reduced BMI and body fat (BF) in patients with RA, with heavy smoking particularly linked 
to lower muscle mass while smoking cessation appears to associate with increased BMI, BF, 
and waist circumference in these patients (Stavropoulos-Kalinoglou, Metsios et al. 2008).  In 
a recent metaanalysis by Gabriel, the prevalence of smoking, but not of the other traditional 
CV risk factors appears to be increased in RA compared to non-RA patients, at the time of 
RA incidence (Gabriel 2010).  
SLE 
Cigarette smoking along with HT have been identified as the main predictors of extracranial 
carotid artery atherosclerosis, in an early study including 240 SLE patients (Homer, Ingall et al. 
1991). While in the studies conducted by Asanuma and Roman, no association between 
smoking and carotid or coronary atherosclerosis  was detected (Asanuma, Oeser et al. 2003; 
Roman, Shanker et al. 2003), in a subsequent multiethnic US cohort of 546 SLE patients, the 
role of smoking in the development of vascular events (cardiovascular, cerebrovascular and 
peripheral) has been suggested (Toloza, Uribe et al. 2004). Similarly, Selzer et al, compared risk 
factors for subclinical vascular disease in different vascular beds (carotid and aorta) in SLE 
female patients. Smoking was identified as a factor correlating with carotid plaque severity, 
together with older age, systolic hypertension and lower albumin levels. In regard to aortic 
stiffness, risk factors included older age and higher systolic blood pressure but not smoking 
(Selzer, Sutton-Tyrrell et al. 2004). Finally, a race-smoking interaction was also identified, as 
amongst black women with SLE, those with a history of smoking have higher IMT values than 
non smokers. This effect did not apply to white patients (Scalzi, Bhatt et al. 2009). 
Smoking did not seem to influence subclinical atherosclerotic disease in patients with pSS 
(Vaudo, Bocci et al. 2005; Gerli, Vaudo et al. 2010). 
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3.5 Hyperomocysteinemia  
Hyperhomocysteinemia is a recognised risk factor for arterial and venous disease in the 
general population. Homocysteine increases oxidative stress on the endothelium and causes 
modification of LDL, inhibition of nitric oxide synthesis, proliferation of smooth muscle 
cells, intimal hyperplasia, increased protease activity, activation of proinflammatory 
mediators and thrombosis (Durga, Verhoef et al. 2004). Hyperhomocysteinemia can 
originate either from a genetic polymorphism and/or a variety of factors including folic acid 
or vitamin B12 deficiency, corticosteroid or methotrexate treatment, and renal dysfunction. 
Hyperhomocysteinemia has been reported in 20%-42% of patients with RA and is related to 
treatment with antifolate agents and greater disease activity.  Genetic investigations 
identified the C677T polymorphism in the gene coding for the MTHFR enzyme as a new 
candidate genetic risk factor for CV disease in the general population. The 677TT genotype 
is associated with higher plasma homocysteine levels than in heterozygotes or in 
individuals with wild-type C alleles (Palomino-Morales, Gonzalez-Juanatey et al. 2010). The 
increased levels of homocysteine caused by methotrexate therapy occur more often to 
patients heterozygous for the C677T mutation. Normal homocysteine levels are restored by 
folic acid supplementation (El Bouchti, Sordet et al. 2008). 
RA  
In a recent Spanish study of RA patients, the MTHFR A1298C rather the C677T was 
associated with increased risk of atherosclerosis, demonstrating that patients homozygous 
for the MTHFR 1298CC genotype had increased risk of CV events at 5 and 10 years follow 
up and more severe endothelial dysfunction (lower values of FMD %), when compared with 
those homozygous for the wild MTHFR 1298AA genotype (Palomino-Morales, Gonzalez-
Juanatey et al. 2010). Interestingly an ongoing study from our group indicate that Greek RA 
patients with carotid or femoral plaque formation have a higher prevalence of MTHFR AC 
and CC genotypes compared with those without. The so far available results show that 
MTHFR 1298 A>C gene polymorphism confers an increased risk for plaque formation 
(Mavragani 2011).    
SLE  
Attention has been drawn over the past few years to the role of homocysteine concentration 
in the development of subclinical atherosclerosis in SLE patients. In a prospective study, 
Petri identified elevated homocysteine levels as a risk factor for the later development of CV 
disease in SLE patients (Petri 2000). 
In the Toronto Risk Factor Study for coronary heart disease, SLE patients had homocysteine 
values>15μmoles/liter in a larger proportion compared to controls (11.6% versus 0.8%) 
despite having higher folate blood levels (Bruce, Urowitz et al. 2003). SLE patients with 
hyperhomocysteinemia have a threefold increase in odds ratio of thrombotic event (Refai, 
Al-Salem et al. 2002). 
Several studies linked hyperhomocysteinemia to subclinical atherosclerosis (Svenungsson, 
Jensen-Urstad et al. 2001; Von Feldt, Scalzi et al. 2006; Von Feldt 2008). Roman et al 
prospectively studied a cohort of SLE patients with matched controls and determined 
carotid IMT scores as well as the presence of plaque. Over a period of approximately 3 years 
of follow-up, 28% of the patients had progressive atherosclerosis, defined as a higher plaque 
score (new plaque or more extensive plaque).  Determinants of atherosclerotic progression 
after multivariate analysis were patient age at diagnosis, disease duration, and baseline 
homocysteine concentration. Lupus patients with stable plaque and progressive plaque 
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were different only in baseline homocysteine concentration (Roman, Crow et al. 2007). A 
recent study by Perna et al implied a relationship of both asymmetric dimethylarginine and 
homocysteine to arterial stiffness, but not to the presence or extent of carotid atherosclerosis 
(Perna, Roman et al. 2010). In the Rho et al study, homocysteine levels in SLE patients were 
linked to macrophage activation, reflected by increased serum neopterin concentrations. 
Neopterin (marker of monocyte and macrophage activation associated with atherosclerosis 
and CV risk in the general population) was associated with atherogenic mediators of 
inflammation and homocysteine in SLE, but not with coronary atherosclerosis (Rho, Solus et 
al. 2011). 
SS  
No data to date regarding the role of homocysteine in the pathogenesis of CV disease in the 
setting of Sjogren’s syndrome is available. 
4. Disease related contributors of atherosclerosis in systemic autoimmune 
diseases 
SLE 
A number of studies evaluated specific disease parameters and their effect on atherosclerotic 
disease in SLE patients. Disease duration appears to be an important factor in CVD 
development. An inverse relationship between SLE activity and plaque size was reported by 
Manzi et al and longer disease duration was independently associated with carotid plaque 
(Manzi, Selzer et al. 1999) and coronary calcium scores (Von Feldt, Scalzi et al. 2006). In a 
cross-sectional  and in a longitudinal study, Roman et al. found that longer disease duration 
and higher  Systemic Lupus International Collaborative Clinics (SLICC) damage index were 
independent predictors of carotid plaque formation(Roman, et al. 2003; Roman, et al. 2007). 
In another report,  SLE specific variables were associated with aortic stiffness and included 
older age, hypertension, higher C3 levels, lower white blood cell count, higher insulin levels, 
and renal disease (Selzer, Sutton-Tyrrell et al. 2004). 
Rua-Figueroa et al who assessed the changes in carotid IMT and the associated risk factors 
in patients with lupus in a two year period, identified basal measurement IMT, age at 
diagnosis, homocysteine, C3 and C5a as risk factors for IMT progression (Rua-Figueroa, 
Arencibia-Mireles et al. 2010). In accord with the previous findings, Haque et al compared 
SLE patients with verified clinical CV disease (myocardial infarction or angina pectoris) to 
patients without clinical CV disease. Male sex, older age, increased SLICC damage index, 
prior use of corticosteroids and azathioprine and more exposure to all classic CV risk factors 
were positively correlated with clinical CV disease (Haque, Gordon et al. 2010). In our SLE 
cohort, IMT and the presence of plaque were both statistically significant associated with 
age, hypertension, triglyceridelevels and SLICC damage index score and only plaque with 
the levels of C3 and C4 (Giannelou 2011). 
The role of SLE activity in the formation of non calcified coronary plaque (NCP) was 
investigated by Kiani et al.; unlike coronary calcium, which is not associated with SLE 
activity measures or with active serologies, NCP is more common in patients with active 
disease (Kiani, Vogel-Claussen et al. 2010). Additionally, the presence of lymphopenia and 
higher levels of serum creatinine and CRP seem to be disease related risk factors in the 
progression of carotid IMT in juvenile-onset SLE as demonstrated by  Huang et al (Huang, 
Chung et al. 2009). 
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Although under normal conditions vascular damage is expected to be coupled by 
acceleration in repair of the endothelium, SLE patients have decreased numbers of 
circulating EPCs and aberrant function of cells involved in the vascular repair. In particular, 
lupus EPCs/CACs (myeloid circulating angiogenic cells) have decreased capacity to 
differentiate into mature ECs and synthesize decreased amounts of the molecules vascular 
endothelial growth factor and hepatic growth factor (Rajagopalan, Somers et al. 2004; 
Denny, Thacker et al. 2007; Lee, Li et al. 2007; Moonen, de Leeuw et al. 2007; Westerweel, 
Luijten et al. 2007). IFNα -a central mediator in lupus pathogenesis- has been recently 
suggested as a major player of impaired vasculogenesis and atherogenic risk in lupus 
patients through transcriptional repression of proangiogenic IL-1 pathways, enhancement of 
foam cell formation, and platelet activation (Lood, Amisten et al. 2010; Thacker, Berthier et 
al. 2010; Li, Fu et al. 2011).   
Autoantibodies including antiOxLDL, AECAs (anti-endothelial cell antibodies) and 
antibodies against heat shock proteins and phospholipids (APLs) have been linked to lupus 
related CV disease. In regard to the role of the latter in the pathogenesis of CV disease in the 
setting of lupus, current evidence is rather conflicting. While in a multiethnic US cohort of 
patients with SLE, APLs were identified as an independent predictor of CV, cerebrovascular 
or peripheral vascular events (Toloza, Uribe et al. 2004), such an association has not been 
detected in three distinct large SLE cohorts (Manzi, Meilahn et al. 1997; Roman, Shanker et 
al. 2003; McMahon, Grossman et al. 2009). On the other hand, the presence of positive lupus 
anticoagulant or anti-β2glycoprotein-I antibodies have been also linked to development of 
myocardial infarction (Petri 2004). In lupus patients without previous CV history, the 
occurrence of a first ever CVE (defined as ischemic heart, cerebrovascular peripheral 
vascular disease or death due to CV disease) was dependent on the presence of positive 
APLs, markers of endothelial activation/damage advanced age and absence of 
thrombocytopenia  (Gustafsson, Gunnarsson et al. 2009). Proposed mechanisms of APL 
related CV risk include inhibition of binding of annexin A5 (a protein shown to inhibit to 
plaque rupture) to the endothelium or reduction of the activity of the atheroprotective 
enzyme PON1 (Cederholm, Svenungsson et al. 2005) (Delgado Alves, Ames et al. 2002). 
The role of anti-OxLDLs has not been yet clarified. In the general population, it is indicated 
that some aOxLDLs are decreased in the early stage of atherosclerosis development in non 
autoimmune disease but raised at later stages and in more advanced disease (Lopes-Virella, 
Virella et al. 1999; Wu, de Faire et al. 1999; Hulthe, Wiklund et al. 2001; Karvonen, 
Paivansalo et al. 2003). Anti-OxLDL antibodies have been detected in up to 80% of SLE 
patients with aPS (Vaarala, Alfthan et al. 1993), but no association with thrombosis has been 
identified (Aho, Vaarala et al. 1996). 
In another report by Svenungsson et al  anti-OxLDL antibodies were more common in SLE 
patients with a history of CV disease than in SLE controls or normal subjects (Svenungsson, 
Jensen-Urstad et al. 2001); titers of anti-OxLDL have been also found to be correlated with 
anti-double-stranded DNA antibody titres, complement activation and disease activity 
scores in patients with SLE (Gomez-Zumaquero, Tinahones et al. 2004). Of interest, 
increased atherosclerotic disease has been attributed to the presence of complexes of 
oxidized low-density liprotein/beta2 glycoprotein 1 (oxLDL/beta2GPI) and anti-complex 
IgG as well as IgM often in association with renal involvement and history of previous 
thromboembolic episodes (Bassi, Zampieri et al. 2009). 
Finally, autoantibodies to endothelial cell (AECAs) and heat shock proteins have been 
proposed as potential mediators of atherosclerotic risk in lupus patients. (George, Harats et 
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al. 1999; Mandal, Foteinos et al. 2005).AECAs are associated with lupus disease activity and 
vasculitis and can act directly on endothelial cells by promoting their activation (Margutti, 
Matarrese et al. 2008).  
RA 
Over the last decade, the inflammatory and immunologic mechanisms in the initiation and 
progression of atherosclerosis (Van Doornum, McColl et al. 2002) have become the focus of 
particular research interest. Pro-inflammatory cytokines such as TNF-α and IL-6 are released 
into the systemic circulation and have multiple effects on distant organs including the 
endothelium and the formation of the atherosclerotic plaque through upregulation of 
adhesion molecules such as vascular cellular adhesion molecule (VCAM), inhibiting of 
endothelial nitric oxide (eNOS) production and induction of formation of oxidized LDL (de 
Groot, Posthumus et al. 2010).  Blockade of TNF-α in RA reduces cytokine levels, leucocyte 
trafficking and platelet levels which may all promote atherosclerotic complications (Full, 
Ruisanchez et al. 2009). A recently identified new player in atherosclerosis pathogenesis is 
the macrophage migration inhibitory factor (MIF) which induces the pro-inflammatory 
mediators TNF-α, IL-1, IL-6 and metalloproteinases (MMPs), activates T cells and promotes 
angiogenesis. In mice with advanced atherosclerosis, MIF blockade led to plaque regression 
and reduced monocyte and T-cell content in the plaques (de Groot, Posthumus et al. 2010). 
The increased arterial stiffness found in RA patients is significantly correlated with disease 
duration and inflammatory markers such as CRP and IL-6 (Tabas, Williams et al. 2007). As 
the atherosclerotic plaque matures, the apoptosis of cells in the plaque leads to extracellular 
lipid accumulation and cellular debris formation. Under the influence of macrophage 
proteinases, the fibrous cap of the plaques weakens, ruptures and secondary thrombosis 
may occur (de Groot, Posthumus et al. 2010). 
In RA patients, genetic regulation of inflammation seems to be implicated in pathogenesis of 
accelerated atherosclerosis. Carriers of the allele IL-6-174 -found to be associated with higher 
IL-6 levels- demonstrated increased prevalence of CV disease (Panoulas, Douglas et al. 
2009). In another study by Gabriel et al, inflammatory indicators such as high erythrocyte 
sedimentation rate (ESR), swelling of small and large joints, rheumatoid nodules, vasculitis 
and rheumatoid lung disease were all statistically significantly associated with an increased 
of CV death after adjusting for the above mentioned traditional CV risk factors (Gabriel 
2010).  Moreover, in patients with RA, the disease activity scale (DAS) was inversely 
correlated with the number of circulating EPCs, which are hematopoietic stem cells 
involved in vascular repair, suggesting an additional mechanism of atherogenesis in these 
patients (Pakozdi, Besenyei et al. 2009; Szekanecz and Koch 2010). Similarly, in patients with 
lupus, increased levels of circulating apoptotic ECs were correlated with lupus disease 
activity and endothelial dysfunction. 
Serum concentration of autoantibodies in RA, specifically anti-modified  citrullinated 
vimentin (anti-MCV) and anti-cyclic citrullinated peptide (anti-CCP) were found to be 
positively correlated with disease activity  including hsCRP, IL-6, homeostasis model 
assessment for insulin resistance (HOMA-IR) index, serum levels of rheumatoid factors and 
IMT score. While anti-MCV and anti-CCP3 are equally sensitive in diagnosing early RA, the 
former appears to be very useful for monitoring associated subclinical atherosclerosis in 
early RA (El-Barbary, Kassem et al. 2011). 
 




Associations between signs of subclinical atherosclerosis with the presence of leukopenia, 
specific autoantibodies (RF, anti-SSA, anti-SSB), articular involvement and parotid gland 
enlargement, may suggest that immune dysregulation could contribute to the increased risk 
for atherosclerosis in pSS patients. In our SS cohort, subclinical atherosclerosis –detected by 
IMT determination- was associated with higher levels of salivary gland infiltration, reduced 
salivary flow as well as with the presence of SS specific autoantibodies (unpublished 
results)(Gravani et al,  2011), implying that SS related poor dental hygiene along with 
immune hyperactivity could contribute to the higher risk for atherosclerotic disease (Mattila, 
Nieminen et al. 1989)  
Finally, circulating CD4+, CD28- cells –previously associated with atherosclerotic risk- did 
not differ between pSS patients and controls. However, pSS patients demonstrated  higher 
levels of AECAs, (IgG and IgM), and sTM (soluble thrombomodulin), but lower levels of 
anti-Hsp60 (IgG and IgM) compared to their healthy counterparts, whereas anti-Hsp65 and 
anti-oxLDL antibody levels were similar in both groups (Vaudo, Bocci et al. 2005) (Gerli, 
Vaudo et al. 2010). 
5. Conclusion  
The increased prevalence of CV disease is well established in autoimmune diseases even 
after correction of the traditional risk factors. Several associations with disease related 
clinical or serological features, immunologic profile and proinflammatory cytokines are 
reported. Further investigation is needed to determine a yet unidentified, possibly disease 
specific mechanism in autoimmune patients. 
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1. Introduction 
Chronic periaortitis is an idiopathic disease whose hallmark is the presence of a fibro-
inflammatory tissue arising from the adventitia of the abdominal aorta and the common 
iliac arteries and extending into the surrounding retroperitoneum and frequently encasing 
neighboring structures such as the ureters and the inferior vena cava (Mitchinson, 1984; 
Parums, 1990). It should be regarded as a generalized disease with three different 
pathophysiological entities, specifically idiopathic retroperitoneal fibrosis, inflammatory 
abdominal aortic aneurysms, and perianeurysmal retroperitoneal fibrosis (Vaglio et al., 
2003; Jois et al., 2004).  
Idiopathic retroperitoneal fibrosis is characterized by periaortic fibroinflammatory tissue, 
which often causes obstruction of the ureters and other adjacent abdominal structures by 
extending into the retroperitoneum (Mitchinson, 1970; Gilkeson & Allen, 1996). A dilated 
aorta is usually not present in idiopathic retroperitoneal fibrosis. Its initial signs and 
symptoms are often nonspecific, such as malaise, anorexia, weight loss, fever, and flank, 
back, or abdominal pain. Inflammatory abdominal aortic aneurysms characteristically 
develop the mass around a dilated aorta, but usually do not cause obstructions (Crawford et 
al., 1985; Pennell et al., 1985). It usually presents with typical symptoms and signs 
characterized by the triad of abdominal or back pain, a pulsatile and sometimes tender 
abdominal mass, and an elevated erythrocyte sedimentation rate. Perianeurysmal 
retroperitoneal fibrosis, which represents a link between these two diagnoses, involves an 
abdominal aortic aneurysms surrounded by fibroinflammatory tissue that encases other 
abdominal organs (Serra et al, 1980).  
These definitions may be a little confusing, and it would probably be more appropriate to 
distinguish aneurysmal from nonaneurysmal forms of chronic periaortitis; idiopathic 
retroperitoneal fibrosis may be referred as non-aneurysmal chronic periaortitis, where as 
inflammatory abdominal aortic aneurysms and perianeurysmal retroperitoneal fibrosis as 
aneurysmal chronic periaortitis (Vaglio et al., 2006). 
It is important to diagnose chronic periaortitis early in its course in order to attempt to 
prevent the severe secondary complication of renal failure due to ureteric obstruction and 
the potentially fatal consequence of aortic rupture (Jois et al., 2004). Although most studies 
have considered these entities separately, these conditions have common clinical and 
histopathologic findings, and thus probably represent different manifestations of the same 
disease. 
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It is important to diagnose chronic periaortitis early in its course in order to attempt to 
prevent the severe secondary complication of renal failure due to ureteric obstruction and 
the potentially fatal consequence of aortic rupture (Jois et al., 2004). Although most studies 
have considered these entities separately, these conditions have common clinical and 
histopathologic findings, and thus probably represent different manifestations of the same 
disease. 
 




The prevalence of chronic periaortitis is not well known; the only available epidemiological 
data concern idiopathic retroperitoneal fibrosis and inflammatory abdominal aortic 
aneurysms. Reports from Duke University and the Mayo Clinic estimate that the incidence 
of idiopathic retroperitoneal fibrosis is less than 1 per 10,000 patients (Gilkeson & Allen 
1996). A recent study conducted in Finland on idiopathic retroperitoneal fibrosis has 
demonstrated that its incidence and prevalence are 1/1,000,000 person-year and 1.38 
cases/100,000 inhabitants (Uibu et al., 2004). On the other hand, data regarding the 
incidence of the aneurysmal forms of chronic periaortitis in the whole population are 
lacking, however they represent about 4% to 10% of all abdominal aortic aneurysms 
(Rasmussen et al, 1997; von Fritschen et al., 1999; Yusuf et al., 2007). 
Chronic periaortitis frequently develops in middle-aged adults with a mean age of 
approximately 60 years, but it may also occur in children (Miller et al. 2003; Uibu et al., 2004; 
Vaglio et al., 2006). Men are affected two to three times as often as women and that is even 
more pronounced in the inflammatory abdominal aortic aneurysms (Gilkeson & Allen 1996; 
Uibu et al., 2004; Vaglio et al., 2006). 
There is no evidence of a clear ethnic predisposition or familial clustering, and the disease 
has been reported in twins and siblings only in anecdotal cases (Duffy et al., 1984; Doolin et 
al. 1987). A few studies have addressed the question whether genetic factors may contribute 
to the development of chronic periaortitis. Recent studies have suggested that 
immunogenetic factors may be involved in the pathogenesis of the disease (Rasmussen et 
al., 1997; Martorana et al., 2006).  
A case-control study evaluated the prevalence of HLA alleles in patients with inflammatory 
abdominal aortic aneurysms compared with healthy subjects found that in the inflammatory 
abdominal aortic aneurysms a genetic risk determinant mapping at the HLA-DRB1 locus 
(Rasmussen et al., 1997). Additionally, they identified HLA-DRB1*15 and B1*0404 as 
predisposing alleles.  
Another recent case-control study on patients with chronic periaortitis and healthy controls 
in order to investigate the role of HLA in the susceptibility to chronic periaortitis revealed 
that the frequency of the HLA-DRB1*03 allele was markedly higher in patients with chronic 
periaortitis than in the controls (Martorana et al., 2006). The HLA-DRB1*03 allele is a well-
known marker of autoimmunity, since it is associated with a number of autoimmune 
diseases, which include systemic lupus erythematosus and autoimmune thyroid disease 
(Davidson and Diamond, 2001). Also, the HLA-B*08 allele was significantly associated with 
chronic periaortitis and it is itself linked to a wide range of immune-mediated diseases. 
Furthermore, the comparison of the clinical and laboratory characteristics of HLA-DRB1*03-
positive and HLA-DRB1*03-negative patients showed that the HLA-DRB1*03-positive 
patients with chronic periaortitis have higher acute-phase reactant levels at the time of 
diagnosis (Martorana et al., 2006). These results could imply that the HLA system not only 
confers susceptibility to the development of the disease but also plays a role in the 
modulation of the inflammatory response. 
More recently, CC chemokine receptor 5 (CCR5) gene delta 32 polymorphism has been 
mapped in 100 patients with chronic periaortitis (Boiardi L et al., 2011). The distribution of 
the CCR5 gene delta 32 genotype differed between patients with chronic periaortitis and 
controls (P = 0.01). The CCR5 gene delta 32 allele was more frequent in patients with chronic 
periaortitis [P = 0.02, odds ratio (OR) 2.8 (95% CI 1.2, 6.4)]. Furthermore, CCR5 gene delta 32 
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allele occurred more frequently in patients with inflammatory abdominal aortic aneurysms 
than in patients with idiopathic retroperitoneal fibrosis [P = 0.001, OR 6.4 (95% CI 2.1, 19.1)]. 
The CCR5 gene delta 32 allele frequency was higher in inflammatory abdominal aortic 
aneurysms patients without established atherosclerotic disease compared with controls [66.7 
vs 5.6%, P = 0.00001, OR 34.0 (95% CI 7.4, 156.3)].  
The CC chemokine receptor 5 is expressed on many immune cells, particularly Th1 cells, 
and acts by binding to different chemokines, including RANTES, MIP-1 and MIP-1. The 
CCR5 gene delta 32 polymorphism creates a truncated, nonfunctional receptor and probably 
shifts the immune response toward a Th2 pattern. Interestingly, the association between the 
CCR5 gene delta 32 polymorphism and aneurysmal chronic periaortitis is even stronger in 
patients without overt atherosclerotic disease, which suggests that immune mechanisms 
independent of atherosclerosis play a role in the pathogenesis of chronic periaortitis (Vaglio 
et al., 2011). 
Additionally, environmental and occupational agents have been shown to contribute to 
susceptibility to chronic periaortitis. In a recent study, it has been demonstrated that 
asbestos exposure is associated with a markedly increased risk of developing the chronic 
periaortitis, and smoking is also a significant risk factor (Uibu et al., 2004; Hellmann et al., 
2007). Although smoking is an established risk factor for classical atherosclerotic abdominal 
aortic aneurysms, its frequency is even higher in patients with inflammatory abdominal 
aortic aneurysms (Nitecki et al., 1996; Hellmann et al., 2007). 
3. Pathology 
Chronic periaortitis affects the aortic wall and the surrounding retroperitoneum. The 
classical macroscopic appearance of chronic periaortitis is grossly a whitish and hard 
periaortic mass which extends between the origin of the renal arteries and the bifurcation of 
the common iliac vessels and often distorting medially the ureters but histologically there is 
a continuum of lesions ranging from acute changes to chronic damage (Mitchinson, 1970). 
In the early stages of chronic periaortitis, or in patients with a prominent acute-phase 
reaction, the tissue is highly inflammatory, with numerous lymphocytes, plasma cells, 
macrophages and scattered eosinophils and loose deposits of collagen matrix in thick, 
irregular bands (Mitchinson, 1970; Corradi et al., 2007). In late disease, these aspects evolve, 
either spontaneously or after glucocorticoid therapy, into a relatively acellular fibrous tissue. 
Perivascular involvement of the thoracic aorta is not uncommon, while rarely atypical 
localizations such as peri-duodenal, peri-pancreatic and pelvic sites have also been found 
(Hughes & Buckley, 1993; Corradi et al., 2007).  
Microscopic examination shows signs of active mononuclear cell inflammation in a 
framework of fibrous tissue and fibroblasts (Serra et al, 1980; Gilkeson & Allen, 1996). The 
background of chronic periaortitis consists of varying degrees of fibrosis, characterized by a 
mild-to-moderate and mitotically inactive fibroblasts and myofibroblasts, which are 
immuno-histochemically positive for vimentin and, in the more cellular areas, for -smooth 
muscle actin (Vaglio et al., 2006). The fibrous component is particularly abundant in the late 
stages when the tissue becomes relatively avascular and acellular; its distribution is usually 
diffuse, but sometimes perivascular and perineural.  
The inflammatory infiltrate includes mononuclear cells such as T and B lymphocytes, 
macrophages and plasma cells, although scattered eosinophils can also be found 
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allele occurred more frequently in patients with inflammatory abdominal aortic aneurysms 
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(Mitchinson, 1970). The majority of lymphocytes, macrophages and most vascular 
endothelial cells are HLA-DR-positive. The Ki67 and BerH2 staining is found in B cells and 
T-helper cells, indicating that these cells were proliferating and activated (Meier et al., 2007).  
Two main inflammatory patterns are usually seen, perivascular and diffuse. The 
perivascular aggregates consist mainly of B lymphocytes and a smaller component of 
plasma cells, macrophages, and T lymphocytes, most of which are CD4+ (Corradi et al., 
2007). Sometimes, these follicular aggregates show a germinal center architecture. The 
sclerotic component consists of thick fascicles of type-I collagen, irregularly distributed 
along the lesion; a pathological hallmark is the presence of a regular circumferential fibrous 
bundle surrounding blood vessels and nerves. On the other hand, the diffuse infiltrate has 
an equal percentage of T cells and B cells. Scattered eosinophils are common, whereas 
neutrophils are rare (Mitchinson, 1970; Vaglio et al., 2003). In cases of severe inflammation, 
there may be focal infiltration of the small and medium-sized retroperitoneal vessels, with 
frank vasculitis and fibrinoid necrosis. 
The aortic wall also shows particular changes, such as atherosclerotic degeneration of the 
intima, medial thinning, and marked adventitial inflammation and fibrosis. The composition 
of the inflammatory infiltrate in the aortic wall is similar to the retroperitoneal one, with 
diffuse and perivascular patterns. The adventitial inflammatory infiltrate is often organized in 
lymphoid follicles (Sakata et al., 2008), which are examples of ectopic lymphoneogenesis and 
expression of a highly structured inflammatory or immune-mediated response. Adventitial 
vasa vasorum in aortas of chronic periaortitis show inflammatory infiltration up to frank 
necrotizing vasculitis, endarteritis obliterans, or obliterative phlebitis (Vaglio et al., 2003; 
Sakata et al., 2008). These aortic wall changes are found in all chronic periaortitis disease 
entities, regardless of the presence of aneurysmal dilatation.  
It is interesting to note that autopsy studies have documented the presence of adventitial 
inflammation in aortic sections lacking periaortic fibrosis, which may suggest that aortitis 
could precede the development of adventitial and periadventitial fibrosis (Mitchinson, 
1970). Another autopsy studies have shown that moderate adventitial inflammation and 
fibrosis may not be limited to the abdominal aorta, but may also involve its thoracic aorta 
(Mitchinson, 1972). 
Molecular analysis of aortic biopsies in patients with chronic periaortitis shows gene 
transcripts consistent with lymphocyte activation, such as IFN-, IL-1, IL-2 and IL-4, in 
keeping with the concept that chronic periaortitis is an active inflammatory aortic disease 
(Ramshaw et al., 1994). 
4. Pathogenesis 
Chronic periaortitis is idiopathic in nature, and its pathogenesis remains a matter of debate. 
Initially, it was postulated to represent a local inflammatory reaction to antigens such as 
ceroid and oxidised low-density lipoproteins (LDL), which can be found in the 
atherosclerotic plaques of the abdominal aorta (Parums et al., 1986; Parums et al., 1990; 
Ramshaw & Parums, 1994). Since an intact media constitutes an immunoprivileged site, the 
capacity of lipids deposited in the intima and media to elicit an inflammatory reaction in the 
adventitia may depend on the thinning or breach of the media itself, with consequent transit 
of the lipids. These can be processed by adventitial macrophages and presented to B and T 
cells, thus eliciting a local inflammatory reaction which eventually leads to adventitial and 
peri-aortic inflammation and fibrosis.  
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Morphologic and experimental findings showed that adventitial inflammation also seems to 
be more marked where the media is thinner (Mitchinson, 1972; Mitchinson 1984; Parums et al., 
1990). IgG has been detected in close apposition to extracellular ceroid, and serum antibodies 
to oxidized LDL and ceroid were more common in patients with chronic periaortitis than in 
healthy individuals (Parums et al., 1986; Parums et al., 1990). Furthermore, a wide spectrum of 
adhesion molecules and gene products for cytokines, such as interleukin-1, interleukin-2, 
interleukin-4, and interferon-, have been detected in the aortic adventitia, thus strengthening 
the hypothesis that chronic periaortitis is associated with active adventitial chronic 
inflammation (Ramshaw & Parums, 1994; Ramshaw et al., 1994). 
According to this hypothesis, advanced atherosclerosis is a sine qua non for the development 
of chronic periaortitis, which may be an exaggerated local immune response to plaque 
antigens. The notion that chronic periaortitis is secondary to atherosclerosis is challenged by 
several findings. There was no substantial difference in the incidence of advanced 
atherosclerosis between patients with chronic periaortitis and healthy controls (Uibu et al., 
2004; Breems et al., 2000). Also, chronic periaortitis may affect patients without 
atherosclerosis, and it has been reported in pediatric patients (Miller et al., 2003). A recent 
study showed no significant differences in anti-ox-LDL antibody levels between patients 
with chronic periaortitis and controls (van Bommel et al., 2011). 
Furthermore, a number of findings support the hypothesis that chronic periaortitis may be a 
manifestation of systemic disease rather than the result of a local reaction. These include its 
constitutional symptoms, the high acute-phase reactant levels, autoantibody positivity, and 
the frequent association with other autoimmune diseases (Gilkeson & Allen, 1996; Demko et 
al., 1997; Vaglio et al., 2003; Marcolongo et al., 2004). Additionally, the association with 
HLA-DRB1, a marker of autoimmune diseases, is an additional clue to its autoimmune 
origin (Martorana et al., 2006). 
Chronic periaortitis also has histologic similarities to large vessel vasculitis such as giant cell 
arteritis and Takayasu’s arteritis; prominent adventitial inflammation and the involvement 
of the vasa vasorum (Ramshaw et al., 1994; Vanoli et al., 2005; Vaglio et al., 2006; Salvarani 
et al., 2008), and sometimes extends beyond the abdominal aorta (Mitchinson 1972; Cid et 
al., 1998; Jois et al., 2004). In addition, in some patients with chronic periaortitis the disease 
involves not only the abdominal aorta and the iliac vessels, but also other vascular 
territories such as the thoracic aorta. This finding was already observed long time ago by 
autopsy studies (Mitchinson, 1972). Recently, in a study using 18F-fluorodeoxyglucose 
positron emission tomography, it have also shown that in some patients with chronic 
periaortitis the high 18F-fluorodeoxyglucose uptake in the abdominal aorta and in the 
common iliac arteries coexists with a pathologic uptake in the thoracic aorta and its main 
branches, which confirms the idea that chronic periaortitis is a systemic disease in some 
cases (Salvarani et al., 2005). 
These findings strengthen the idea that chronic periaortitis may originate as a primary 
arteritis involving the aorta. The perivascular- and sometimes transmural-involvement of 
vasa vasorum may represent the initial event of the disease. Its centrifugal extension could 
induce a fibro-inflammatory periaortic reaction, whereas its centripetal spreading could 
promote atherosclerosis, medial thinning and aneurysm formation (Vaglio & Buzio, 2005; 
Vaglio et al., 2006).  
Structural alterations of the aortic wall seen in chronic periaortitis result in part from 
degradation of the macromolecules, such as collagen and elastin. These changes are 
associated with excessive production of matrix metalloproteinases (MMPs), which are 
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(Mitchinson, 1970). The majority of lymphocytes, macrophages and most vascular 
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transcripts consistent with lymphocyte activation, such as IFN-, IL-1, IL-2 and IL-4, in 
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ceroid and oxidised low-density lipoproteins (LDL), which can be found in the 
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associated with excessive production of matrix metalloproteinases (MMPs), which are 
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assumed to orchestrate the widespread matrix destruction (Freestone et al., 1995). The 
inflammatory infiltrate is thought to play an etiologic role in aneurysm formation by direct 
local production of matrix-degrading enzymes and production of cytokines that induce 
resident mesenchymal cell production of MMPs (Newman et al., 1994). Recent findings 
suggest that both the local mesenchymal cell expression and the macrophage expression of 
MMPs are required for aneurysm formation (Longo et al., 2002).  
Both fibrillar collagen and elastin are highly organized in the lamellar structure of the aortic 
media. One potential mechanism for the complementary role of MMP-2 and MMP-9 is that 
MMP-2 primarily acts as a collagenase-initiating cleavage of the triple helix into one- and 
three-quarter lengths. The single  chains could then be degraded by MMP-9, releasing the 
coiled elastin and causing it to become fattened and attenuated. Rupture and expansion 
rates of abdominal aortic aneurysms have been linked to MMP-2 and MMP-9 levels in tissue 
and plasma (Petersen et al., 2000). Such observations appear consistent with the increased 
medial atrophy observed within inflammatory abdominal aortic aneurysms, because 
activated MMPs may weaken the media by causing destruction of elastic and collagen fibers 
and smooth muscle cells. 
As in many other immune-mediated diseases, environmental and infectious agents probably 
contribute to the pathogenesis of chronic periaortitis. As mentioned above, asbestos 
exposure and smoking are established risk factors (Uibu et al., 2004). It has been 
hypothesized that inflammation within the aortic wall may be a response to infection. Both 
herpes and cytomegalovirus have been described as potential agents (Tanaka et al., 1994). 
Recent interest has been focused on Chlamydia pneumoniae, which was found to be more 
prevalent in aneurysmal than in normal aortic tissue (Tang et al., 2005). 
5. Clinical features 
The clinical presentation of chronic periaortitis is insidious and vague. Lumbar, abdominal 
or flank pain is present in about 80% of the patients. It has been described as insidious, 
persistent and dull, poorly localized, unmodified by movement or rest. If the ureters are 
involved, the pain may be acute and colic-like (Baker et al., 1987; Vaglio et al., 2003; van 
Bommel et al., 2009). During the initial phases, patients may find relief using non-steroidal 
anti-inflammatory drugs, but the beneficial effect of these agents is transient (Gilkeson & 
Allen, 1996; Vaglio et al., 2006). 
In addition to pain, the commonest clinical manifestations are systemic symptoms, most 
likely related to the inflammatory nature of the disease: about 40 to 80% of patients 
complain of fatigue, anorexia, weight loss and low-grade fever (Baker et al., 1987; Kardar et 
al., 2002; Vaglio et al., 2003; Scheel et al., 2009). Ureteral obstruction is the most frequent 
complication of idiopathic retroperitoneal fibrosis. It involves both ureters in a high 
percentage of cases (50–80%) and may occur simultaneously (Kardar et al., 2002; van 
Bommel et al., 2007). Ureteric obstruction is commonly due to edema or inflammation rather 
than fibrosis. This observation is supported by the fact that the obstruction can improve 
rapidly with corticosteroid therapy (Baker et al., 1987; Nitecki et al., 1996).  
In cases of advanced bilateral ureteral obstruction, oliguria and symptoms secondary to 
uremic syndrome occur (Baker et al., 1987; Sterpetti et al., 1989; Jois et al., 2004). Varicocele 
and hydrocele, sometimes associated with testicular pain, are not uncommon, and also 
probably develop because of compression of the gonadal vessels (Baker et al., 1988; Vaglio et 
al., 2003). Constipation and claudication are less common. Lower limb edema and deep 
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venous thrombosis may occur, probably as a result of inferior vena cava and iliac vein 
involvement.  
Physical examination usually reveals abdominal tenderness and sometimes a palpable, 
pulsatile and tender abdominal mass. A periumbilical bruit may be heard in patients with 
inflammatory abdominal aortic aneurysms (Crawford et al., 1985; Nitecki et al., 1996). The 
combination of abdominal pain, a pulsatile mass with overlying bruit, constitutional 
symptoms, and high levels of acute-phase reactants usually distinguish inflammatory 
abdominal aortic aneurysms from noninflammatory abdominal aortic aneurysms. 
Laboratory examinations are useful, but not diagnostic for chronic periaortitis. Acute phase 
reactants such as the erythrocyte sedimentation rate and C-reactive protein are elevated in 
more than 80% of patients with active disease, in keeping with the presence of a systemic 
inflammation and are often used to monitor the clinical course of the disease (Kardar et al., 
2002; Marcolongo et al., 2004; Vaglio et al., 2006). The erythrocyte sedimentation rate and C-
reactive protein dramatically decrease or even normalize after a few weeks of therapy (van 
Bommel et al., 2007), whereas their sensitivity in heralding relapses is uncertain (Vaglio et 
al., 2005). A recent retrospective study investigated whether the erythrocyte sedimentation 
rate and C-reactive protein levels might predict response to glucocorticoid therapy, but 
found that baseline erythrocyte sedimentation rate and C-reactive protein did not 
discriminate between chronic periaortitis patients who experienced disease regression and 
those who showed mass stabilization or progression (Magrey et al., 2009). 
Renal dysfunction is related to the severity of ureteral involvement, but only 18-21% of 
patients actually experiences end-stage renal failure (Baker et al., 1987; Nitecki et al., 1996). 
Normochromic, normocytic anemia is often present as a result of systemic chronic 
inflammation. Leukocytosis, eosinophilia, and polyclonal hypergammaglobulinemia may be 
disclosed in some patients (Gilkeson & Allen, 1996). If polyclonal hypergammaglobulinemia 
is present, it is worthwhile assessing serum immunoglobulin levels and, if available, IgG 
subclasses; IgG4 is high in chronic periaortitis patients with features of IgG4-related 
systemic disease (Vaglio et al, 2011; J.R. Stone, 2011). 
Immunologic and autoimmune tests should always be assessed in patients with chronic 
periaortitis. Antinuclear antibodies have been reported in up to 60% of patients, whereas 
anti-dsDNA and antiextractable nuclear antigen antibodies are rare (Vaglio et al., 2003). 
Rheumatoid factor is not uncommon. The presence of these autoantibodies, although non-
organ-specific and often positive at low titers, may be a clue to an autoimmune origin of 
chronic periaortitis. Alternatively, they may be the earliest manifestation of a smoldering 
disorder that will clinically emerge late in the course of chronic periaortitis.  
On the other hand, certain autoantibodies actually indicate the presence of an associated 
autoimmune disease. When autoimmune thyroiditis coexists, antithyroglobulin and 
antithyroid microsome antibodies are positive (Vaglio et al., 2003). P-antineutrophil and C-
antineutrophil cytoplasmic antibodies have been detected in a few cases of chronic 
periaortitis associated with small vessel vasculitis, such as Wegener granulomatosis and 
microscopic polyangiitis (Kaipiainen-Seppanen et al., 1996; Aslangul et al., 2003). 
6. Evidence of systemic autoimmunity in chronic periaortitis 
Although it has been considered a localized inflammatory disease secondary to 
atherosclerosis, several genetic, clinical, laboratory and pathologic findings suggest that 
chronic periaortitis is a systemic autoimmune disease, perhaps involving a vasculitic process 
of small and medium vessels (Table 1). 
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assumed to orchestrate the widespread matrix destruction (Freestone et al., 1995). The 
inflammatory infiltrate is thought to play an etiologic role in aneurysm formation by direct 
local production of matrix-degrading enzymes and production of cytokines that induce 
resident mesenchymal cell production of MMPs (Newman et al., 1994). Recent findings 
suggest that both the local mesenchymal cell expression and the macrophage expression of 
MMPs are required for aneurysm formation (Longo et al., 2002).  
Both fibrillar collagen and elastin are highly organized in the lamellar structure of the aortic 
media. One potential mechanism for the complementary role of MMP-2 and MMP-9 is that 
MMP-2 primarily acts as a collagenase-initiating cleavage of the triple helix into one- and 
three-quarter lengths. The single  chains could then be degraded by MMP-9, releasing the 
coiled elastin and causing it to become fattened and attenuated. Rupture and expansion 
rates of abdominal aortic aneurysms have been linked to MMP-2 and MMP-9 levels in tissue 
and plasma (Petersen et al., 2000). Such observations appear consistent with the increased 
medial atrophy observed within inflammatory abdominal aortic aneurysms, because 
activated MMPs may weaken the media by causing destruction of elastic and collagen fibers 
and smooth muscle cells. 
As in many other immune-mediated diseases, environmental and infectious agents probably 
contribute to the pathogenesis of chronic periaortitis. As mentioned above, asbestos 
exposure and smoking are established risk factors (Uibu et al., 2004). It has been 
hypothesized that inflammation within the aortic wall may be a response to infection. Both 
herpes and cytomegalovirus have been described as potential agents (Tanaka et al., 1994). 
Recent interest has been focused on Chlamydia pneumoniae, which was found to be more 
prevalent in aneurysmal than in normal aortic tissue (Tang et al., 2005). 
5. Clinical features 
The clinical presentation of chronic periaortitis is insidious and vague. Lumbar, abdominal 
or flank pain is present in about 80% of the patients. It has been described as insidious, 
persistent and dull, poorly localized, unmodified by movement or rest. If the ureters are 
involved, the pain may be acute and colic-like (Baker et al., 1987; Vaglio et al., 2003; van 
Bommel et al., 2009). During the initial phases, patients may find relief using non-steroidal 
anti-inflammatory drugs, but the beneficial effect of these agents is transient (Gilkeson & 
Allen, 1996; Vaglio et al., 2006). 
In addition to pain, the commonest clinical manifestations are systemic symptoms, most 
likely related to the inflammatory nature of the disease: about 40 to 80% of patients 
complain of fatigue, anorexia, weight loss and low-grade fever (Baker et al., 1987; Kardar et 
al., 2002; Vaglio et al., 2003; Scheel et al., 2009). Ureteral obstruction is the most frequent 
complication of idiopathic retroperitoneal fibrosis. It involves both ureters in a high 
percentage of cases (50–80%) and may occur simultaneously (Kardar et al., 2002; van 
Bommel et al., 2007). Ureteric obstruction is commonly due to edema or inflammation rather 
than fibrosis. This observation is supported by the fact that the obstruction can improve 
rapidly with corticosteroid therapy (Baker et al., 1987; Nitecki et al., 1996).  
In cases of advanced bilateral ureteral obstruction, oliguria and symptoms secondary to 
uremic syndrome occur (Baker et al., 1987; Sterpetti et al., 1989; Jois et al., 2004). Varicocele 
and hydrocele, sometimes associated with testicular pain, are not uncommon, and also 
probably develop because of compression of the gonadal vessels (Baker et al., 1988; Vaglio et 
al., 2003). Constipation and claudication are less common. Lower limb edema and deep 
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venous thrombosis may occur, probably as a result of inferior vena cava and iliac vein 
involvement.  
Physical examination usually reveals abdominal tenderness and sometimes a palpable, 
pulsatile and tender abdominal mass. A periumbilical bruit may be heard in patients with 
inflammatory abdominal aortic aneurysms (Crawford et al., 1985; Nitecki et al., 1996). The 
combination of abdominal pain, a pulsatile mass with overlying bruit, constitutional 
symptoms, and high levels of acute-phase reactants usually distinguish inflammatory 
abdominal aortic aneurysms from noninflammatory abdominal aortic aneurysms. 
Laboratory examinations are useful, but not diagnostic for chronic periaortitis. Acute phase 
reactants such as the erythrocyte sedimentation rate and C-reactive protein are elevated in 
more than 80% of patients with active disease, in keeping with the presence of a systemic 
inflammation and are often used to monitor the clinical course of the disease (Kardar et al., 
2002; Marcolongo et al., 2004; Vaglio et al., 2006). The erythrocyte sedimentation rate and C-
reactive protein dramatically decrease or even normalize after a few weeks of therapy (van 
Bommel et al., 2007), whereas their sensitivity in heralding relapses is uncertain (Vaglio et 
al., 2005). A recent retrospective study investigated whether the erythrocyte sedimentation 
rate and C-reactive protein levels might predict response to glucocorticoid therapy, but 
found that baseline erythrocyte sedimentation rate and C-reactive protein did not 
discriminate between chronic periaortitis patients who experienced disease regression and 
those who showed mass stabilization or progression (Magrey et al., 2009). 
Renal dysfunction is related to the severity of ureteral involvement, but only 18-21% of 
patients actually experiences end-stage renal failure (Baker et al., 1987; Nitecki et al., 1996). 
Normochromic, normocytic anemia is often present as a result of systemic chronic 
inflammation. Leukocytosis, eosinophilia, and polyclonal hypergammaglobulinemia may be 
disclosed in some patients (Gilkeson & Allen, 1996). If polyclonal hypergammaglobulinemia 
is present, it is worthwhile assessing serum immunoglobulin levels and, if available, IgG 
subclasses; IgG4 is high in chronic periaortitis patients with features of IgG4-related 
systemic disease (Vaglio et al, 2011; J.R. Stone, 2011). 
Immunologic and autoimmune tests should always be assessed in patients with chronic 
periaortitis. Antinuclear antibodies have been reported in up to 60% of patients, whereas 
anti-dsDNA and antiextractable nuclear antigen antibodies are rare (Vaglio et al., 2003). 
Rheumatoid factor is not uncommon. The presence of these autoantibodies, although non-
organ-specific and often positive at low titers, may be a clue to an autoimmune origin of 
chronic periaortitis. Alternatively, they may be the earliest manifestation of a smoldering 
disorder that will clinically emerge late in the course of chronic periaortitis.  
On the other hand, certain autoantibodies actually indicate the presence of an associated 
autoimmune disease. When autoimmune thyroiditis coexists, antithyroglobulin and 
antithyroid microsome antibodies are positive (Vaglio et al., 2003). P-antineutrophil and C-
antineutrophil cytoplasmic antibodies have been detected in a few cases of chronic 
periaortitis associated with small vessel vasculitis, such as Wegener granulomatosis and 
microscopic polyangiitis (Kaipiainen-Seppanen et al., 1996; Aslangul et al., 2003). 
6. Evidence of systemic autoimmunity in chronic periaortitis 
Although it has been considered a localized inflammatory disease secondary to 
atherosclerosis, several genetic, clinical, laboratory and pathologic findings suggest that 
chronic periaortitis is a systemic autoimmune disease, perhaps involving a vasculitic process 
of small and medium vessels (Table 1). 
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Autoimmune Component Example 
Genetics Association with HLA-DRB1*03, DRB1*0404, DRB1*15 and 
HLA-B*08 
Association with CC chemokine receptor 5 (CCR5) gene delta 
32 polymorphism 
Autoantibodies Antinuclear antibody 
Anti-thyroid microsome and anti-thyroglobulin antibody 
Anti-neutrophil cytoplasmic antibody 
Rheumatoid factor 




Rapidly progressive glomerulonephritis 
Systemic vasculitis 
Rheumatoid arthritis 
Juvenile rheumatoid arthritis 
Ankylosing spondylitis 
Systemic lupus erythematosus 
Antiphospholipid syndrome 
IgG4-related systemic disease 
Histologic finding Small vessel vasculitis of retroperitoneal vessels and aortic vasa 
vasorum 
Ectopic lymphoid follicles with germinal centers in periaortic 
retroperitoneum and aortic adventitia 
Clinical manifestations Constitutional symptoms, such as fever, fatigue, weight loss, 
anorexia and sleep disturbances 
Systemic involvement of large arteries 
Laboratory findings High erythrocyte sedimentation rate  
High C-reactive protein 
Anemia 
Treatment response Rapid response to corticosteroids 
Prognosis Chronic-relapsing course 
Table 1. Summary of systemic autoimmune components implicated in chronic periaortitis 
6.1 Genetics 
Genetic association study revealed that patients with chronic periaortitis were associated 
with certain genetic markers, which is involved in the immune response and commonly 
associated with autoimmune or inflammatory disease. The HLA system plays a role in 
conferring susceptibility to chronic periaortitis (Rasmussen et al., 1997; Martorana et al., 
2006). The bias in expression of specific HLA alleles are defining features of autoimmune 
disease.  
The HLA-DRB1*03, DRB1*0404, DRB1*15 and HLA-B*08 alleles was significantly higher in 
patients with chronic periaortitis. These alleles are a well-known marker of autoimmunity, 
since it is associated with a number of autoimmune diseases such as systemic lupus 
erythematosus, rheumatoid arthritis, giant cell arteritis, autoimmune thyroiditis, type 1 
diabetes mellitus and myasthenia gravis.  
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The CC chemokine receptor 5 (CCR5) gene delta 32 polymorphism is associated with 
aneurysmal chronic periaortitis, which creates a truncated, nonfunctional receptor and 
probably shifts the immune response toward a Th2 pattern (Boiardi L et al., 2011). 
6.2 Autoantibodies 
Several autoantibodies are positive in varying proportions of patients, which may be a clue 
to an autoimmune origin of chronic periaortitis. Antinuclear antibodies are positive in up to 
50–60% of the cases, although their titer is often low (Vaglio et al., 2003). Anti-thyroid 
microsome and anti-thyroglobulin antibodies may be positive in 25–30% (Martorana et al., 
2006). Other autoantibodies, such as antineutrophil cytoplasmic antibodies, rheumatoid 
factor, and anti-smooth muscle may also be positive.  
6.3 Association with autoimmune disease 
Chronic periaortitis are frequently associated with autoimmune diseases involving other 
organs or structures. Two recent studies have showed a higher incidence of systemic 
autoimmune diseases. A case-control study comparing inflammatory abdominal aortic 
aneurysms and noninflammatory abdominal aortic aneurysms showed a higher incidence of 
systemic autoimmune diseases in the former group (Haug et al., 2003). In another study of 
16 consecutive patients with chronic periaortitis, three had antineutrophil cytoplasmic 
antibody-positive rapid progressive renal disease, three had autoimmune thyroiditis, and 
one had rheumatoid arthritis (Vaglio et al., 2003). 
Another frequently reported association is systemic vasculitides, which in most cases 
involve small and medium-sized vessel vasculitis, such as Wegener granulomatosis and 
polyarteritis nodosa (Akman et al., 1983; Hautekeete et al., 1990; De Roux-Serratrice et al., 
2002) or unclassifiable systemic vasculitis (Hellstrom & Perez-Stable, 1966; Littlejohn & 
Keystone, 1981). Antineutrophil cytoplasmic antibody-associated vasculitic syndromes are 
more and more often reported.  
Chronic periaortitis may frequently be associated with fibroinflammatory disorders 
affecting other organs, IgG4-related systemic disease, which have an autoimmune origin 
(Matsumoto et al., 2008; Ito et al., 2008; Kasashima et al., 2008; Sakata et al., 2008). Other 
rheumatic diseases reported in patients with chronic periaortitis include ankylosing 
spondylitis, juvenile rheumatoid arthritis, systemic lupus erythematosus and 
antiphospholipid syndrome (Leblanc et al., 2002; Tsai et al., 1996; Okada et al., 1999; Kim et 
al., 2010).  
6.4 Histologic findings 
Two peculiar histopathological findings may be interpreted as manifestations of 
autoimmunity. Firstly, about half of patients with chronic periaortitis had adventitial 
inflammation with vasa vasoritis in the small retroperitoneal vessels and the aortic vasa 
vasorum with mononuclear cell infiltration and sometimes fibrinoid necrosis (Mitchinson, 
1970; Vaglio et al., 2003; Lindell et al., 1987). Secondly, the inflammatory infiltrate may be 
organized in lymphoid structures such as lymphoid follicles with germinal centers in both 
periaortic retroperitoneum and aortic adventitia (Ramshaw & Parums, 1994). Ectopic 
lymphoid microstructures with germinal centers have been found in autoimmune disorders, 
such as the synovium in rheumatoid arthritis (Weyand et al., 2001).  
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since it is associated with a number of autoimmune diseases such as systemic lupus 
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The CC chemokine receptor 5 (CCR5) gene delta 32 polymorphism is associated with 
aneurysmal chronic periaortitis, which creates a truncated, nonfunctional receptor and 
probably shifts the immune response toward a Th2 pattern (Boiardi L et al., 2011). 
6.2 Autoantibodies 
Several autoantibodies are positive in varying proportions of patients, which may be a clue 
to an autoimmune origin of chronic periaortitis. Antinuclear antibodies are positive in up to 
50–60% of the cases, although their titer is often low (Vaglio et al., 2003). Anti-thyroid 
microsome and anti-thyroglobulin antibodies may be positive in 25–30% (Martorana et al., 
2006). Other autoantibodies, such as antineutrophil cytoplasmic antibodies, rheumatoid 
factor, and anti-smooth muscle may also be positive.  
6.3 Association with autoimmune disease 
Chronic periaortitis are frequently associated with autoimmune diseases involving other 
organs or structures. Two recent studies have showed a higher incidence of systemic 
autoimmune diseases. A case-control study comparing inflammatory abdominal aortic 
aneurysms and noninflammatory abdominal aortic aneurysms showed a higher incidence of 
systemic autoimmune diseases in the former group (Haug et al., 2003). In another study of 
16 consecutive patients with chronic periaortitis, three had antineutrophil cytoplasmic 
antibody-positive rapid progressive renal disease, three had autoimmune thyroiditis, and 
one had rheumatoid arthritis (Vaglio et al., 2003). 
Another frequently reported association is systemic vasculitides, which in most cases 
involve small and medium-sized vessel vasculitis, such as Wegener granulomatosis and 
polyarteritis nodosa (Akman et al., 1983; Hautekeete et al., 1990; De Roux-Serratrice et al., 
2002) or unclassifiable systemic vasculitis (Hellstrom & Perez-Stable, 1966; Littlejohn & 
Keystone, 1981). Antineutrophil cytoplasmic antibody-associated vasculitic syndromes are 
more and more often reported.  
Chronic periaortitis may frequently be associated with fibroinflammatory disorders 
affecting other organs, IgG4-related systemic disease, which have an autoimmune origin 
(Matsumoto et al., 2008; Ito et al., 2008; Kasashima et al., 2008; Sakata et al., 2008). Other 
rheumatic diseases reported in patients with chronic periaortitis include ankylosing 
spondylitis, juvenile rheumatoid arthritis, systemic lupus erythematosus and 
antiphospholipid syndrome (Leblanc et al., 2002; Tsai et al., 1996; Okada et al., 1999; Kim et 
al., 2010).  
6.4 Histologic findings 
Two peculiar histopathological findings may be interpreted as manifestations of 
autoimmunity. Firstly, about half of patients with chronic periaortitis had adventitial 
inflammation with vasa vasoritis in the small retroperitoneal vessels and the aortic vasa 
vasorum with mononuclear cell infiltration and sometimes fibrinoid necrosis (Mitchinson, 
1970; Vaglio et al., 2003; Lindell et al., 1987). Secondly, the inflammatory infiltrate may be 
organized in lymphoid structures such as lymphoid follicles with germinal centers in both 
periaortic retroperitoneum and aortic adventitia (Ramshaw & Parums, 1994). Ectopic 
lymphoid microstructures with germinal centers have been found in autoimmune disorders, 
such as the synovium in rheumatoid arthritis (Weyand et al., 2001).  
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6.5 Clinical manifestations 
Most patients with chronic periaortitis often complain of constitutional symptoms, such as 
fever, fatigue, weight loss, anorexia and sleep disturbances, which probably reflect the 
systemic inflammatory status (Baker et al., 1987; Vaglio et al., 2003). At least in a subgroup 
of patients, chronic periaortitis is a vasculitis affecting large vessels (Vaglio et al., 2011). 
6.6 Laboratory findings  
Chronic periaortitis usually present with high concentrations of acute-phase reactants such 
as erythrocyte sedimentation rate and C-reactive protein, varying degrees of anemia and, in 
a high percentage of cases, azotemia , which reflect the systemic inflammation (Kardar et al., 
2002; Vaglio et al., 2006). The erythrocyte sedimentation rate and C-reactive protein can also 
be used to monitor the disease course (van Bommel et al., 2007). 
6.7 Treatment response 
The clinical manifestations of chronic periaortitis promptly subside after the initiation of 
glucocorticoids therapy, which again is well in agreement with their inflammatory nature. 
In most patients, they induce remission of the clinical symptoms, normalization of the acute-
phase reactant levels, reduction in size of the retroperitoneal mass and also resolution of the 
obstructive complications (Kardar et al., 2002; Marcolongo et al., 2004; van Bommel et al., 
2007; Magrey et al., 2009). 
However, glucocorticoids have various significant side effects, which sometimes limit their 
prolonged use. The combination of glucocorticoids and immunosuppressants such as 
azathioprine, cyclophosphamide and methotrexate has recently been reported to yield 
favorable results in patients with chronic periaortitis (Marcolongo et al., 2004; Warnatz et al., 
2005). 
6.8 Prognosis 
As is the case in many inflammatory and autoimmune diseases, chronic periaortitis also has 
a chronic-relapsing course. The frequency of relapses may depend on the treatment 
approach, as they occur in 10% to 50% of patients treated with surgery alone and in about 
10% when combined immunosuppressive and surgical therapies are used (Baker et al., 
1988). 
7. IgG4-related systemic disease 
In recent years, numerous studies have reported chronic periaortitis in association with 
IgG4-related systemic disease, a group of autoimmune and fibrosing conditions 
characterized by high serum levels of IgG4 and tissue infiltration by IgG4-bearing plasma 
cells (Vaglio et al, 2011; J.R. Stone, 2011). These conditions share common histopathologic 
characteristics, such as diffuse lymphoplasmacytic infiltration, irregular fibrosis, 
eosinophilic infiltration, and obliterative phlebitis (Neild et al., 2006; Deshpande et al., 2006; 
Masaki et al., 2009).  
7.1 Idiopathic peritoneal fibrosis with IgG4-related systemic disease 
It has become clear that in a subset of patients with idiopathic retroperitoneal fibrosis, the 
disorder is in fact occurring in the setting of IgG4-related systemic disease. For 10 years, 
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there were several reports that autoimmune pancreatitis could be associated with 
inflammatory masses within the retroperitoneum, and it was later recognized that both 
conditions were a manifestation of IgG4-related systemic disease (J.R. Stone, 2011).  
In those reports revealed that the retroperitoneal involvement is typically not entirely 
diffuse, but present primarily as inflammatory masses that often primarily involve the 
abdominal aorta, the kidneys or the ureters (Hamano et al., 2002; Miyajima et al., 2006; 
Tanabe et al., 2006). The inflammatory masses are composed of lymphoplasmacytic 
inflammation and fibrosis with a substantial number of the plasma cells expressing IgG4. 
The nearly all patients revealed an aortic adventitial involvement, even in the absence of 
aortic aneurysm formation. 
In a recent study of retroperitoneal biopsies of patients with idiopathic retroperitoneal 
fibrosis, 10 of 17 cases were felt to be due to IgG-related systemic disease (Zen et al., 2009). 
In these 10 patients, the fraction of plasma cells staining for IgG4 ranged from 35 to 76% 
compared with 0 to 10% for the other seven patients. Furthermore, for the patients with 
IgG4-related disease, the mean serum IgG4 concentration was 695 mg/dl (range 154–2330 
mg/dl) compared with 30 mg/dl (range 10–53 mg/dl) for the other seven patients.  
7.2 Inflammatory abdominal aortic aneurysms with IgG4-related systemic disease 
There are several reports which have indicated that a subset of inflammatory abdominal 
aortic aneurysms cases is in fact a result of IgG4-related systemic disease (Sakata et al., 2008; 
Kasashima et al., 2008; Qian et al., 2009). A recent study comparing 11 cases of inflammatory 
abdominal aortic aneurysms to 12 cases of atherosclerotic abdominal aortic aneurysms and 
demonstrated that the aneurysms defined as inflammatory contained more IgG4+ plasma 
cells than those defined as atherosclerotic. However, in that study there was no clear 
delineation as to which inflammatory aneurysms actually represented involvement by IgG4-
related systemic disease. In addition, the fraction of plasma cells expressing IgG4 was not 
reported for either aneurysms group, making it unclear if the enhanced number of IgG4+ 
plasma cells was simply a manifestation of more plasma cells in general being present in the 
aneurysms labeled as inflammatory. 
There have been several cases reported of inflammatory abdominal aortic aneurysms, which 
were attributed to IgG4-related systemic disease, and which included pathologic evaluation 
of the aorta (Kasashima et al., 2008; Ito et al., 2008; Qian et al., 2009). Pathologically, most 
cases of IgG-4 related inflammatory abdominal aortic aneurysms showed the predominant 
involvement in adventitia with high fraction of IgG4+ infiltrating plasma cells and high 
serum IgG levels (J.R. Stone, 2011). 
Kasashima et al. reported that four of 10 cases (40%) of inflammatory abdominal aortic 
aneurysm were due to IgG4-related systemic disease with prominent IgG4+ plasma cell 
infiltration and high-IgG4 serum levels, whereas the remaining six had a mild (IgG4+ and 
total) plasma cell infiltration. Inflammation was more evident and tissue eosinophilia 
predominated in the IgG4-related inflammatory abdominal aortic aneurysms, whereas some 
degree of neutrophilic infiltration and only rare eosinophils were found in the non-IgG4-
related inflammatory abdominal aortic aneurysms. Because inflammatory aneurysms may 
represent 2–15% of all abdominal aortic aneurysms, this would suggest 1–6% of all 
abdominal aortic aneurysms could be due to IgG4-related inflammatory abdominal aortic 
aneurysms (J.R. Stone, 2011). 
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there were several reports that autoimmune pancreatitis could be associated with 
inflammatory masses within the retroperitoneum, and it was later recognized that both 
conditions were a manifestation of IgG4-related systemic disease (J.R. Stone, 2011).  
In those reports revealed that the retroperitoneal involvement is typically not entirely 
diffuse, but present primarily as inflammatory masses that often primarily involve the 
abdominal aorta, the kidneys or the ureters (Hamano et al., 2002; Miyajima et al., 2006; 
Tanabe et al., 2006). The inflammatory masses are composed of lymphoplasmacytic 
inflammation and fibrosis with a substantial number of the plasma cells expressing IgG4. 
The nearly all patients revealed an aortic adventitial involvement, even in the absence of 
aortic aneurysm formation. 
In a recent study of retroperitoneal biopsies of patients with idiopathic retroperitoneal 
fibrosis, 10 of 17 cases were felt to be due to IgG-related systemic disease (Zen et al., 2009). 
In these 10 patients, the fraction of plasma cells staining for IgG4 ranged from 35 to 76% 
compared with 0 to 10% for the other seven patients. Furthermore, for the patients with 
IgG4-related disease, the mean serum IgG4 concentration was 695 mg/dl (range 154–2330 
mg/dl) compared with 30 mg/dl (range 10–53 mg/dl) for the other seven patients.  
7.2 Inflammatory abdominal aortic aneurysms with IgG4-related systemic disease 
There are several reports which have indicated that a subset of inflammatory abdominal 
aortic aneurysms cases is in fact a result of IgG4-related systemic disease (Sakata et al., 2008; 
Kasashima et al., 2008; Qian et al., 2009). A recent study comparing 11 cases of inflammatory 
abdominal aortic aneurysms to 12 cases of atherosclerotic abdominal aortic aneurysms and 
demonstrated that the aneurysms defined as inflammatory contained more IgG4+ plasma 
cells than those defined as atherosclerotic. However, in that study there was no clear 
delineation as to which inflammatory aneurysms actually represented involvement by IgG4-
related systemic disease. In addition, the fraction of plasma cells expressing IgG4 was not 
reported for either aneurysms group, making it unclear if the enhanced number of IgG4+ 
plasma cells was simply a manifestation of more plasma cells in general being present in the 
aneurysms labeled as inflammatory. 
There have been several cases reported of inflammatory abdominal aortic aneurysms, which 
were attributed to IgG4-related systemic disease, and which included pathologic evaluation 
of the aorta (Kasashima et al., 2008; Ito et al., 2008; Qian et al., 2009). Pathologically, most 
cases of IgG-4 related inflammatory abdominal aortic aneurysms showed the predominant 
involvement in adventitia with high fraction of IgG4+ infiltrating plasma cells and high 
serum IgG levels (J.R. Stone, 2011). 
Kasashima et al. reported that four of 10 cases (40%) of inflammatory abdominal aortic 
aneurysm were due to IgG4-related systemic disease with prominent IgG4+ plasma cell 
infiltration and high-IgG4 serum levels, whereas the remaining six had a mild (IgG4+ and 
total) plasma cell infiltration. Inflammation was more evident and tissue eosinophilia 
predominated in the IgG4-related inflammatory abdominal aortic aneurysms, whereas some 
degree of neutrophilic infiltration and only rare eosinophils were found in the non-IgG4-
related inflammatory abdominal aortic aneurysms. Because inflammatory aneurysms may 
represent 2–15% of all abdominal aortic aneurysms, this would suggest 1–6% of all 
abdominal aortic aneurysms could be due to IgG4-related inflammatory abdominal aortic 
aneurysms (J.R. Stone, 2011). 
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7.3 Thoracic aortitis with IgG4-related systemic disease 
Until now, the six cases of thoracic aortitis due to IgG4-related systemic disease reported, 
which derived from surgical resections (Khosroshahi et al., 2009; J.H. Stone et al., 2009; 
Ishida et al., 2009; J.H. Stone et al., 2010; Kasashima et al., 2010). All six patients were men in 
an old age (65–74 years). The arch was the most commonly involved in five cases, with two 
cases having involvement of the ascending aorta, and only one case having involvement of 
the descending aorta. Five of the six patients presented with an aneurysm.  
According to histologic assessment, all displayed a prominent lymphoplasmacytic infiltrate, 
with a high percentage of the plasma cells staining for IgG4 (74–89%). In addition, at least 
five patients showed an obstructive phlebitis within the adventitia. In three cases, there was 
a marked predominance for the adventitia compared with the media and intima (J.R. Stone, 
2011). Serum IgG4 level was found to be markedly elevated in 2 patients who tested it and 
both of these patients had documented extra-aortic involvement. 
Assessment of all thoracic aortitis cases surgically resected in a 5-year at one institute 
revealed that IgG4-related systemic disease was responsible for three of four cases of 
lymphoplasmacytic aortitis and 9% of all cases of thoracic aortitis (J.H. Stone et al., 2010). 
According to that study, IgG4-related aortitis was present in 0.5% of all thoracic aorta 
resections. In a subsequent study from Japan, assessment of 125 thoracic aorta resections 
revealed two cases of IgG4-related aortitis, indicating 1.6% of all resected thoracic aortas 
contained IgG4-related aortitis (Khosroshahi et al., 2010).  
Although much remains to be clarified with regard to the pathogenesis of chronic 
periaortitis, it is conceivable that IgG4 may represent a link between chronic periaortitis and 
systemic fibro-inflammatory conditions. The analysis of IgG4-related cases may provide 
additional clues supporting the possible systemic large-vessel involvement in chronic 
periaortitis (Vaglio et al., 2011). 
8. Conclusion 
Chronic periaortitis is a chronic disease characterized by a retroperitoneal 
fibroinflammatory reaction surrounding the abdominal aorta, which may or may not be 
dilated. Although it has been considered a localized inflammatory response to advanced 
atherosclerosis, there is increasing evidence supporting the hypothesis of an underlying 
systemic autoimmune disease with vasculitic process involving small and medium vessels. 
Further studies are warranted in order to elucidate the potential triggers of the disease, the 
pathways leading to the aortic-periaortic inflammation and to the disproportionate 
fibrogenic reaction. 
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1. Introduction 
The formation of blood vessels is essential for preparing a closed circulatory system in the 
body, and for supply of oxygen and nutrients to all tissues and organs. One of the key 
mechanisms behind many autoimmune diseases is abnormal blood vessel structure and 
function. This dysfunction is reflected in some of the serious manifestations of rheumatoid 
arthritis (RA), type 1 diabetes mellitus (T1DM) and systemic sclerosis (SSc) that are currently 
difficult to treat, such as loss of fingers due to reduced blood flow, kidney failure due to 
renal hypertensive crisis and heart failure due to pulmonary arterial hypertension. The cells 
that line blood vessels (endothelial cells) not only confine blood to the vessels but actively 
participate in the recruitment of circulating cell subsets to sites of inflammation and vascular 
permeability for the exchange of solutes and gases. Collectively, endothelial cells play many 
roles in the development and maintenance of blood vessels. Blood vessel development 
occurs primarily via one of two mechanisms, angiogenesis (the generation of blood vessels 
from pre-existing vasculature) and vasculogenesis (the recruitment of endothelial progenitor 
cells from the bone marrow to sites of vascularisation). In recent decades, extensive studies 
have revealed that a variety of factors and their receptors regulate angiogenesis in 
vertebrates, including vascular endothelial growth factor (VEGF)-VEGFRs, angiopoietin-Tie, 
Ephrins-EphRs and Delta-Notch (reviewed by  Karamysheva (Karamysheva, 2008)). Indeed, 
targeting these molecules has resulted in significant advances in the treatment of cancer and 
cardiovascular disease. However, the burden of diseases that involve vascular dysfunction 
is immense and continues to rise with drug resistance, intolerance and ineffectiveness being 
significant contributors. Less is known about the mechanisms underpinning vasculogenesis 
and despite an explosion of research in this area over the past decade we are yet to fully 
exploit these cells for therapeutic benefit (Sen et al., 2011, Sieveking and Ng, 2009). This 
chapter discusses whether the endothelial progenitor cells (EPCs) from patients with 
autoimmune diseases, such as RA, T1DM and SSc, behave differently from normal EPCs 
and whether there are factors in the serum of these patients that may be responsible for this 
abnormal behaviour. The altered behaviour of EPCs in patients with autoimmune disease is 
poorly understood, based on limited studies to date. This chapter addresses whether EPCs 
would be a prime target for therapeutic intervention in the serious complications of 
autoimmune disease. 
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1. Introduction 
The formation of blood vessels is essential for preparing a closed circulatory system in the 
body, and for supply of oxygen and nutrients to all tissues and organs. One of the key 
mechanisms behind many autoimmune diseases is abnormal blood vessel structure and 
function. This dysfunction is reflected in some of the serious manifestations of rheumatoid 
arthritis (RA), type 1 diabetes mellitus (T1DM) and systemic sclerosis (SSc) that are currently 
difficult to treat, such as loss of fingers due to reduced blood flow, kidney failure due to 
renal hypertensive crisis and heart failure due to pulmonary arterial hypertension. The cells 
that line blood vessels (endothelial cells) not only confine blood to the vessels but actively 
participate in the recruitment of circulating cell subsets to sites of inflammation and vascular 
permeability for the exchange of solutes and gases. Collectively, endothelial cells play many 
roles in the development and maintenance of blood vessels. Blood vessel development 
occurs primarily via one of two mechanisms, angiogenesis (the generation of blood vessels 
from pre-existing vasculature) and vasculogenesis (the recruitment of endothelial progenitor 
cells from the bone marrow to sites of vascularisation). In recent decades, extensive studies 
have revealed that a variety of factors and their receptors regulate angiogenesis in 
vertebrates, including vascular endothelial growth factor (VEGF)-VEGFRs, angiopoietin-Tie, 
Ephrins-EphRs and Delta-Notch (reviewed by  Karamysheva (Karamysheva, 2008)). Indeed, 
targeting these molecules has resulted in significant advances in the treatment of cancer and 
cardiovascular disease. However, the burden of diseases that involve vascular dysfunction 
is immense and continues to rise with drug resistance, intolerance and ineffectiveness being 
significant contributors. Less is known about the mechanisms underpinning vasculogenesis 
and despite an explosion of research in this area over the past decade we are yet to fully 
exploit these cells for therapeutic benefit (Sen et al., 2011, Sieveking and Ng, 2009). This 
chapter discusses whether the endothelial progenitor cells (EPCs) from patients with 
autoimmune diseases, such as RA, T1DM and SSc, behave differently from normal EPCs 
and whether there are factors in the serum of these patients that may be responsible for this 
abnormal behaviour. The altered behaviour of EPCs in patients with autoimmune disease is 
poorly understood, based on limited studies to date. This chapter addresses whether EPCs 
would be a prime target for therapeutic intervention in the serious complications of 
autoimmune disease. 
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2. Vascular dysfunction in autoimmune disease 
2.1 Rheumatoid arthritis 
RA is a chronic and debilitating autoimmune disease that affects the joints. The disease is 
characterised by inflammation of the synovial tissue, which lines the joints and tendons. In 
healthy tissue, the synovium is made up of synovial cells, a network of capillaries and 
lymphatic vessels, and a well-organized matrix containing proteoglycan aggregates. 
Between the cartilage and synovium is the synovial fluid, which nourishes and lubricates 
the joint. In RA, cells of lympho-haematopoietic origin, e.g. T-helper cells, B cells and 
macrophages, infiltrate the synovium. The synovium also becomes thickened, from a layer 
of 1–2 cells to approximately 6–8 cells, and becomes locally invasive at the interface with the 
cartilage and the bone or tendon. The volume of the synovial fluid eventually increases in 
volume as a result of oedema, which causes swelling of the joints and pain. 
Several lines of evidence indicate that RA is associated with aberrant and severe 
vasculogenesis (i.e. the de novo formation of blood vessels) within the inflamed joints 
(Paleolog, 2009, Grisar et al., 2007, Grisar et al., 2005, Herbrig et al., 2006, Hirohata et al., 
2004, Jodon de Villeroche et al., 2010, Ruger et al., 2004, Silverman et al., 2007). One of the 
first observations of vasculogenesis in RA was the discovery that the synovial fluids from 
patients with RA contained a low molecular weight vasculogenesis factor apparently 
identical to that derived from tumours (Brown et al., 1980). Subsequent studies revealed that 
synovial fluid from patients with RA stimulated proliferation of human endothelial cells 
(Kumar et al., 1985) and the formation of tubular networks (Semble et al., 1985). A study of 
synovial tissue histology from patients with RA revealed that there is a significant 
correlation between the number of synovial blood vessels and vessel proliferation, 
mononuclear cell infiltration, fibrosis and clinical measurements of joint tenderness (Rooney 
et al., 1988). Capillaries are distributed more deeply in the synovium from patients with RA 
(Stevens et al., 1991). The different stages of rheumatoid arthritis are shown in Figure 1 
(upper panel). Although perivascular mononuclear cell infiltration and increased thickness 
of the synovial lining layer are observed in tissue from both inflamed and non-inflamed 
joints of RA patients, vascular proliferation is seen only in tissues from inflamed joints 
(FitzGerald et al., 1991). In addition, endothelial cells lining blood vessels within RA 
synovium have been shown to express cell cycle-associated antigens such as proliferating 
cell nuclear antigen and Ki67, and integrin alpha 5 beta 3, which is associated with 
vascular proliferation (Ceponis et al., 1998). Hypoxia, which can activate vasculogenesis 
factors and cause further invasion of the synovium, is another common event that occurs 
within the synovial joints in RA (FitzGerald et al., 1991, Muz et al., 2009). Taken together, 
these studies indicate that vascular dysfunction in synovial tissue is a likely therapeutic 
target in RA.  
2.2 Type 1 diabetes mellitus 
T1DM is a life-long autoimmune disease characterised by hyperglycaemia. Hyperglycaemia 
in T1DM occurs when the number of insulin-producing ß-cells in the pancreatic Islets of 
Langerhans drops below the number required to control glycaemia. Hyperglycaemia leads 
to macrovascular complications, such as coronary artery disease, peripheral arterial disease, 
and stroke, and microvascular complications, such as diabetic nephropathy, neuropathy, 
and retinopathy. Onset is early in life and patients exhibit increased risks of renal failure, 
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blindness, amputation, stroke and heart attack (Shapiro et al., 2006). Best available practice 
with insulin therapy is not a cure as it does not protect the remaining islets from 
inflammatory attack or the patient from long-term complications.  
Insulin-producing ß-cells, which comprise 60-80% of islet mass, are crucial for the 
maintenance of normal blood sugar. Pancreatic islets are highly metabolically active and 
densely vascularised with specialized endothelium – they receive 10% of pancreatic blood 
flow despite comprising only 1% of tissue mass. Pancreatic islets come under a myriad of 
cellular assaults during isolation including ischemia, enzymatic damage and physical stress. 
Dysfunction of the endothelium plays a critical role in the development of vascular 
complications in T1DM (Stehouwer et al., 1997, Flyvbjerg, 2000). Clinical trials have shown 
that hyperglycaemia leads to changes in the proliferation of endothelial cells, barrier 
function and the adhesion of other circulating cells to endothelial cells (Schalkwijk and 
Stehouwer, 2005). This vascular dysfunction may be mediated by several distinct 
mechanisms and different stages of diabetic retinopathy are shown in Figure 1 (middle 
panel). Hyperglycaemia results in an increase in intracellular glucose, which leads to an 
increase in the conversion of glucose to sorbitol via the polyol pathway. This increase in 
sorbitol can cause osmotic stress, tissue hypoxia and oxidative stress (Williamson et al., 
1993, Schalkwijk and Stehouwer, 2005). Hyperglycaemia also results in activation of protein 
kinase C, which can cause dysregulation of vascular permeability and blood flow, basement 
membrane thickening and impaired fibrinolysis (Williamson et al., 1993, Chen et al., 2000). 
In addition, hyperglycaemia causes increased glucosamine-6-phosphate and consequently 
increased transcription of cytokines such as transforming growth factor beta, which can 
regulate the proliferation and apoptosis of endothelial cells (Nerlich et al., 1998, Ziyadeh, 
2004). Greater insight into the mechanisms underlying endothelial dysfunction may lead to 
important treatment strategies which can reduce the morbidity and mortality rate caused by 
endothelial dysfunction in patients with T1DM.  
2.3 Systemic sclerosis 
SSc is a heterogeneous disease in which vascular dysfunction, extensive fibrosis and 
autoimmunity are the hallmark characteristics. The aetiology of SSc is unknown as there are 
many unresolved questions as to both cause and initiating factors (Geyer and Muller-
Ladner, 2011). Multiple genetic and environmental factors, combined with other specific 
factors (e.g. alterations to the immune system, vasculature and extracellular matrix) are the 
most likely causes of this insidious disorder. The pathophysiology of SSc is diverse and 
includes abnormal immunologic processes such as cytokine and chemokine dysregulation, 
abnormal T cell signalling, B cell dysfunction, endothelial injury, aberrant wound healing 
due to dysregulation of matrix homeostasis, abnormalities in the fibrinolytic system, 
polymorphisms in critical molecules of the immune system and matrix homeostasis, and 
microchimerism due to foetal/maternal placental exchange of HLA compatible cells 
(Gabrielli et al., 2009).  
Vascular dysfunction is an early event in SSc (Kahaleh, 2008) and the different stages of SSc 
are shown in Figure 1 (lower panel). The preferred site of early lesions in SSc is the 
perivascular space. Progressive wall thickening and perivascular infiltrates are features of 
the vascular lesions in this compartment, indicating the involvement of vascular smooth-
muscle cells and pericytes. Endothelial cells are the only type of mesodermal cell that  
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In rheumatoid arthritis (upper panel), circulating endothelial progenitor cells (EPCs) and vasculogenesis 
are causally linked to the influx of pro-inflammatory leukocytes and increased capillary beds contribute to 
thickening of the synovial lining and joint pain. In diabetic patients with proliferative retinopathy (middle 
panel), infiltrating EPCs contribute to the dense vascularisation in the eye and reduced vascular stability 
associated with blindness. Vascular injury is one of the early events in the pathogenesis of systemic 
sclerosis (lower panel) and is characterized by endothelial-cell damage and apoptosis, the proliferation of 
fibroblasts, production of collagen and infiltration of circulating leukocytes. Despite the increased number 
of circulating EPCs in these patients, the endothelial layer of the vasculature remains denuded and is 
ultimately obliterated. 
Fig. 1. Vascular dysfunction in autoimmune disease. 
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undergo apoptosis in early SSc, whereas vascular smooth-muscle cells and pericytes 
proliferate vigorously. This vascular damage, which eventually occurs in almost all organs 
(Harrison et al., 1993), presents as large gaps between endothelial cells, loss of integrity of 
the endothelial lining, and the formation of vacuoles in the endothelial cell cytoplasm. In 
addition, several basal lamina-like layers build up, mononuclear immune cells infiltrate the 
vessel walls, obliterative microvascular lesions occur, and the capillaries rarefy (Prescott et 
al., 1992, Fleming et al., 2008). In the later stages of SSc, relatively few small blood vessels 
remain. Serum levels of VEGF are high in SSc despite the progressive loss of blood vessels 
(Distler et al., 2004, Davies et al., 2006), possibly as a result of an adaptive response to 
hypoxia (Fleming et al., 2008, Kuwana et al., 2004, Cipriani et al., 2007). The molecular 
mechanisms underlying this defect in vasculogenesis are unknown and both vasculogenic 
(Davies et al., 2006, Distler et al., 2004) and anti-vasculogenic (Fleming et al., 2008, Hebbar et 
al., 2000, Scheja et al., 2000) factors have been detected in early SSc. Inflammatory cytokines, 
such as tumour necrosis factor (TNF), can stimulate or inhibit angiogenesis depending on 
the duration of the stimulus (Sainson et al., 2008). Collectively, these data indicate that 
vascular dysfunction is a common event in SSc and an important therapeutic target.  
3. Endothelial progenitor cells 
EPCs were first discovered in peripheral blood by Asahara and colleagues in 1997 (Asahara 
et al., 1997). This discovery revealed that vasculogenesis occurs after post-natal 
development. Vascular insult or disease causes the upregulation of cytokines such as VEGF, 
stromal cell-derived factor-1 (SDF-1) matrix metalloproteinase 9 (MMP9), hypoxia inducible 
factor 1α (HIF-1α) and erythropoietin (EPO) at the site of injury and this stimulates the 
release of EPCs from the stem cell niche in the bone marrow into the circulation (Aicher et 
al., 2005). EPCs then follow the cytokine gradient to the site of vascular trauma where 
they contribute to vasculogenesis either by (1) paracrine assistance (via production of 
VEGF and endothelial nitric oxide synthase (eNOS)) (2) integration or (3) new vessel 
formation (Figure 2). 
There are currently two distinct ways in which EPCs are identified, i.e. (1) they are directly 
identified in the peripheral blood by the surface antigen expression of any combination of 
CD133, CD34 and VEGR2 or (2) they are isolated from either peripheral blood (Asahara et 
al., 1997), umbilical cord blood (Asahara et al., 1997, Shi et al., 1998) or bone marrow (Shi et 
al., 1998) and cultured ex vivo. The complication associated with using the cell surface 
markers CD133, CD34 and VEGFR2 to identify EPCs is that these markers are not 
exclusively expressed on EPCs and can be found on many other cell types including the 
closely related haematopoietic progenitors and mature endothelial cells as well as 
fibroblasts, epithelial cells and cancer stem cells (Hirschi et al., 2008, Kumar and Caplice, 
2010). Further evidence of a need to standardise the isolation technique, culture conditions 
and phenotyping strategy is exemplified by Case et al., who suggest that it is not possible to 
culture EPCs from a CD133+ CD34+ VEGFR2+-sorted population (Case et al., 2007).  
Currently, the term ‘EPC’ is used to describe two populations of cells cultured in vitro, both 
of which show vascular potential, but differ in both phenotype and function. The first EPC 
population to be characterised in vitro were the early-outgrowth EPCs, or colony forming 
unit-endothelial cells (CFU-ECs). Early-outgrowth EPCs form colonies after 3-5 days in 
culture on fibronectin-coated wells, consist of multiple thin, flat cells emanating from a 
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Recruitment of endothelial cells from pre-existing vessel walls or circulating endothelial progenitor cells 
(EPCs) play a critical role in blood vessel development and repair during disease states. Mobilised 
bone-marrow derived EPCs with high proliferative capacity may have the potential to home to a site for 
vascularisation and act in a paracrine or autocrine way to promote vessel wall development. 
Abbreviations: SDF-1, stromal derived factor -1; MMP9, matrix metalloproteinase 9; VEGF, vascular 
endothelial growth factor; HIF-1α, hypoxia inducible factor 1α; EPO, erythropoietin; eNOS, endothelial 
nitric oxide. 
Fig. 2. Model of postnatal angiogenesis and vasculogenesis.  
central cluster of round cells and express CD133, VEGFR2 and CD34 (Hur et al., 2004). 
Early-outgrowth EPCs secrete pro-angiogenic factors (Hur et al., 2004, Rehman et al., 2003, 
Yoon et al., 2005), but are not able to form tubes when seeded alone in Matrigel (Rehman et 
al., 2003, Timmermans et al., 2007, Yoder et al., 2007, Yoon et al., 2005). When transplanted 
into mice, they are able to increase capillary density in a model of limb ischemia (Hur et al., 
2004, Yoon et al., 2005), suggesting that they contribute to tube formation through paracrine 
mechanisms. Early-outgrowth EPCs express the pan-leukocyte marker CD45 and the 
myeloid marker CD14 and have been shown to be of monocyte origin (Medina et al., 2010) 
and are thus not considered true endothelial cell progeny. 
The second EPC population to be characterised are the late-outgrowth EPCs, which as also 
referred to as outgrowth endothelial cells (OECs) and endothelial colony forming cells 
(ECFCs). Late-outgrowth EPCs can be isolated from bone marrow, cord blood and 
peripheral blood and form colonies with distinct cobblestone morphology, similar to that of 
endothelial cells within 2-4 weeks when cultured on either collagen or gelatin (Lin et al., 
2000, Shi et al., 1998). Late-outgrowth EPCs have 10 times the proliferative capacity of 
mature ECs, they express mature endothelial cell markers including von Willebrand factor 
(vWF), CD31 and VEGFR2, but not the progenitor marker CD133 and they are able to form 
tubes in Matrigel (Bompais et al., 2004, Ingram et al., 2004, Lin et al., 2000, Rehman et al., 
2003, Timmermans et al., 2007, Yoder et al., 2007, Yoon et al., 2005). Late-outgrowth EPCs 
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have been shown to increase neovascularisation in a mouse limb ischemic model (Hur et al., 
2004, Yoon et al., 2005) and are haemangioblastic in origin (Medina et al., 2010) and are thus 
considered to be true endothelial cell progeny. 
Whilst the monocytic early-outgrowth EPCs and the haemangioblastic late-outgrowth EPCs 
are distinct EPC populations, the combined therapeutic potential of these two EPC 
populations is greater than either of the EPC populations when delivered individually in a 
mouse model of limb ischemia (Yoon et al., 2005), suggesting that these EPC populations 
may function synergistically during vasculogenesis.  
4. Endothelial progenitor cells in autoimmune disease 
4.1 Endothelial progenitor cells in rheumatoid arthritis 
The association between EPC numbers and RA has brought about conflicting results (Table 1). 
Some studies have reported a lower circulating EPC number in RA patients compared with 
controls (Grisar et al., 2005, Herbrig et al., 2006), whilst others report higher numbers (Jodon de 
Villeroche et al., 2010) and a few report no differences (Egan et al., 2008, Kuwana et al., 2004). 
A schematic of a potential role for EPCs in RA is depicted in Figure 1 (upper panel). 
In the studies that reported lower circulating EPC numbers in patients with active RA 
compared to healthy controls (Grisar et al., 2005, Herbrig et al., 2006), the circulating EPCs 
were identified through the expression of CD133, CD34 and VEGFR2 and the formation of 
early-outgrowth EPC colonies. It is highly likely that these studies were not specifically 
identifying a pure EPC population, but rather a mixed population consisting of both early-
outgrowth EPCs, late-outgrowth EPCs and haematopoietic progenitors, as the biomarkers 
used to identify EPCs are not specific for any one cell type. 
In contrast, Jodan de Villeroche et al used a method to exclusively identify haemangioblastic 
late-outgrowth EPCs distinct from monocytic early-outgrowth EPCs (Jodon de Villeroche et 
al., 2010). Jodan de Villeroche et al exclusively monitored the number of late-outgrowth 
EPCs by detecting Lin-/7-aminoactinomycin (7-AAD)-/CD34+/CD133+/VEGFR2+ cells 
from CD14 depleted peripheral blood. This detection panel eliminated apoptotic cells (using 
7-AAD) and early-outgrowth EPCs (through CD14 depletion). Using these methods this 
study revealed that RA patients with active RA had significantly higher levels of circulating 
late-outgrowth EPCs compared with controls. To complement these findings, this study also 
investigated the formation of late-outgrowth EPC colonies and found that RA patients had a 
higher number of late-outgrowth colonies compared to controls. This study was the first to 
implement a method that made a distinction between the two EPC populations.  
4.2 Endothelial progenitor cells in type 1 diabetes mellitus 
A decrease in EPC number and function has been associated with T1DM and has been 
reported by several groups (Table 2). However before comparisons can be made between 
studies, it is important to consider the methods used to quantify EPC numbers in these 
studies. Circulating EPC numbers were quantified either by surface antigen expression on 
peripheral blood mononuclear cells (PBMNCs) (Brunner et al., 2009, Sibal et al., 2009), 
through the culture of early-outgrowth EPC colonies (Asnaghi et al., 2006) or through the 
uptake of acetylated LDL and binding of UEA-l to cultured PBMNCs (Loomans et al., 2004). 
To the best of our knowledge, there are currently no reports on the correlation between 
T1DM and the growth of late-outgrowth EPCs.  
 




Recruitment of endothelial cells from pre-existing vessel walls or circulating endothelial progenitor cells 
(EPCs) play a critical role in blood vessel development and repair during disease states. Mobilised 
bone-marrow derived EPCs with high proliferative capacity may have the potential to home to a site for 
vascularisation and act in a paracrine or autocrine way to promote vessel wall development. 
Abbreviations: SDF-1, stromal derived factor -1; MMP9, matrix metalloproteinase 9; VEGF, vascular 
endothelial growth factor; HIF-1α, hypoxia inducible factor 1α; EPO, erythropoietin; eNOS, endothelial 
nitric oxide. 
Fig. 2. Model of postnatal angiogenesis and vasculogenesis.  
central cluster of round cells and express CD133, VEGFR2 and CD34 (Hur et al., 2004). 
Early-outgrowth EPCs secrete pro-angiogenic factors (Hur et al., 2004, Rehman et al., 2003, 
Yoon et al., 2005), but are not able to form tubes when seeded alone in Matrigel (Rehman et 
al., 2003, Timmermans et al., 2007, Yoder et al., 2007, Yoon et al., 2005). When transplanted 
into mice, they are able to increase capillary density in a model of limb ischemia (Hur et al., 
2004, Yoon et al., 2005), suggesting that they contribute to tube formation through paracrine 
mechanisms. Early-outgrowth EPCs express the pan-leukocyte marker CD45 and the 
myeloid marker CD14 and have been shown to be of monocyte origin (Medina et al., 2010) 
and are thus not considered true endothelial cell progeny. 
The second EPC population to be characterised are the late-outgrowth EPCs, which as also 
referred to as outgrowth endothelial cells (OECs) and endothelial colony forming cells 
(ECFCs). Late-outgrowth EPCs can be isolated from bone marrow, cord blood and 
peripheral blood and form colonies with distinct cobblestone morphology, similar to that of 
endothelial cells within 2-4 weeks when cultured on either collagen or gelatin (Lin et al., 
2000, Shi et al., 1998). Late-outgrowth EPCs have 10 times the proliferative capacity of 
mature ECs, they express mature endothelial cell markers including von Willebrand factor 
(vWF), CD31 and VEGFR2, but not the progenitor marker CD133 and they are able to form 
tubes in Matrigel (Bompais et al., 2004, Ingram et al., 2004, Lin et al., 2000, Rehman et al., 
2003, Timmermans et al., 2007, Yoder et al., 2007, Yoon et al., 2005). Late-outgrowth EPCs 
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have been shown to increase neovascularisation in a mouse limb ischemic model (Hur et al., 
2004, Yoon et al., 2005) and are haemangioblastic in origin (Medina et al., 2010) and are thus 
considered to be true endothelial cell progeny. 
Whilst the monocytic early-outgrowth EPCs and the haemangioblastic late-outgrowth EPCs 
are distinct EPC populations, the combined therapeutic potential of these two EPC 
populations is greater than either of the EPC populations when delivered individually in a 
mouse model of limb ischemia (Yoon et al., 2005), suggesting that these EPC populations 
may function synergistically during vasculogenesis.  
4. Endothelial progenitor cells in autoimmune disease 
4.1 Endothelial progenitor cells in rheumatoid arthritis 
The association between EPC numbers and RA has brought about conflicting results (Table 1). 
Some studies have reported a lower circulating EPC number in RA patients compared with 
controls (Grisar et al., 2005, Herbrig et al., 2006), whilst others report higher numbers (Jodon de 
Villeroche et al., 2010) and a few report no differences (Egan et al., 2008, Kuwana et al., 2004). 
A schematic of a potential role for EPCs in RA is depicted in Figure 1 (upper panel). 
In the studies that reported lower circulating EPC numbers in patients with active RA 
compared to healthy controls (Grisar et al., 2005, Herbrig et al., 2006), the circulating EPCs 
were identified through the expression of CD133, CD34 and VEGFR2 and the formation of 
early-outgrowth EPC colonies. It is highly likely that these studies were not specifically 
identifying a pure EPC population, but rather a mixed population consisting of both early-
outgrowth EPCs, late-outgrowth EPCs and haematopoietic progenitors, as the biomarkers 
used to identify EPCs are not specific for any one cell type. 
In contrast, Jodan de Villeroche et al used a method to exclusively identify haemangioblastic 
late-outgrowth EPCs distinct from monocytic early-outgrowth EPCs (Jodon de Villeroche et 
al., 2010). Jodan de Villeroche et al exclusively monitored the number of late-outgrowth 
EPCs by detecting Lin-/7-aminoactinomycin (7-AAD)-/CD34+/CD133+/VEGFR2+ cells 
from CD14 depleted peripheral blood. This detection panel eliminated apoptotic cells (using 
7-AAD) and early-outgrowth EPCs (through CD14 depletion). Using these methods this 
study revealed that RA patients with active RA had significantly higher levels of circulating 
late-outgrowth EPCs compared with controls. To complement these findings, this study also 
investigated the formation of late-outgrowth EPC colonies and found that RA patients had a 
higher number of late-outgrowth colonies compared to controls. This study was the first to 
implement a method that made a distinction between the two EPC populations.  
4.2 Endothelial progenitor cells in type 1 diabetes mellitus 
A decrease in EPC number and function has been associated with T1DM and has been 
reported by several groups (Table 2). However before comparisons can be made between 
studies, it is important to consider the methods used to quantify EPC numbers in these 
studies. Circulating EPC numbers were quantified either by surface antigen expression on 
peripheral blood mononuclear cells (PBMNCs) (Brunner et al., 2009, Sibal et al., 2009), 
through the culture of early-outgrowth EPC colonies (Asnaghi et al., 2006) or through the 
uptake of acetylated LDL and binding of UEA-l to cultured PBMNCs (Loomans et al., 2004). 
To the best of our knowledge, there are currently no reports on the correlation between 
T1DM and the growth of late-outgrowth EPCs.  
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Reference Method of EPC identification Comments 
Grisar et al., 
2005 
Expression of CD133/CD34/VEGFR2 
from PBMNC using flow cytometry. 
EPCs were lower in active RA 
patients compared to healthy 
controls when assessing surface 
antigen expression. 
  
In vitro culture of PBMNCs and 
detection of early-outgrowth EPCs 
colonies. 
Reduced number of early-
outgrowth EPC colonies in 
active RA patients compared to 
healthy controls. 
Grisar et al., 
2007 
Expression of CD133/CD34/VEGFR2 
from PBMNC using flow cytometry. 
TNF may be partly responsible 
for the reduction of circulating 
EPCs seen in RA patients.  
      




PBMNCs using flow cytometry. 
No difference in the number of 
EPCs in RA patients and healthy 
controls when assessing surface 
antigen expression. 
  
In vitro culture of PBMNCs and 
detection of early-outgrowth EPCs 
colonies. 
Reduced number of early-
outgrowth EPCs in active RA 
patients compared to healthy 
controls. 
    
Early-outgrowth EPC colony 





Surface antigen profile Lin-/7AAD-
/CD34+/CD133+/VEGFR2+ from CD14-
depleted PBMNCs using flow cytometry.
RA patients had higher numbers 
of circulating EPCs than healthy 
controls. 
  In vitro culture PBMNCs and detection of late-outgrowth colonies. 
Circulating EPCs correlated 
with disease activity. 
Herbrig et al., 
2006 
In vitro culture of PMNCs and 
assessment of Ac-LDL uptake, UEA-1 
lectin binding and the surface antigen 
profile VE-
cadherin+/CD31+/VEGFR2+/CD146-. 
EPCs from RA patients showed 
reduced migratory activity in 
response to VEGF. 
Abbreviations: RA, rheumatoid arthritis; PBMNCs, peripheral blood mononuclear cells; EPCs, 
endothelial progenitor cells; Ac-LDL, acetylated-low density lipoprotein; UEA-1 lectin, Ulex Europaeus 
Lectin; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor. 
Table 1. Studies that have reported aberrant EPC numbers in patients with RA. 
EPC dysfunction has been seen in patients with T1DM, as shown by Loomans et al. when 
conditioned media from EPCs isolated from T1DM patients impaired in vitro tube 
formation of HUVEC (Loomans et al., 2004). An inverse relationship between the number of 
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EPCs and HbA1C in patients has also been identified (Loomans et al., 2004). Moreover, there 
appears to be an association between the progression of diabetic retinopathy and the level of 
circulating EPCs. In patients with T1DM and proliferative retinopathy a marked increase in 
circulating EPCs has been reported (Asnaghi et al., 2006, Brunner et al., 2009). Conversely, 
circulating EPC numbers have been identified as being lower in patients with T1DM and 
non-proliferative retinopathy (Brunner et al., 2009). These studies highlight how atypical 
EPC numbers and function are associated with T1DM pathology and a schematic of a 
potential role for EPCs in diabetic retinopathy is depicted in Figure 1 (middle panel). 
 
Reference Method of EPC identification Comments 
Loomans et al., 
2004 
In vitro culture of PMNCs and 
assessment of Ac-LDL uptake, UEA-1 
lectin binding and CD31 expression. 
T1DM patients had lower EPC 
levels compared to healthy 
controls. 
Sibal et al., 2009 
Expression of 
CD133/CD34/VEGFR2/VE-cadherin 
from PBMNC using flow cytometry. 
EPC counts were lower in 
patients with T1DM compared 
to healthy controls. 
Asnaghi et al., 
2006 Immunostaining with CD133 and CD31
Patients with T1DM and 
retinopathy had higher EPC 
levels than healthy controls and 
patients with T1DM and no 
retinopathy. 
  
In vitro culture of PBMNCs and 
detection of early-outgrowth EPCs 
colonies. 
Patients with T1DM and no 
retinopathy had lower EPC 
levels than healthy controls and 
patients with T1DM and 
retinopathy. 
Brunner et al., 
2008 
CPC surface antigen profile 
CD133+/CD34+ 
Patients with T1DM and 
proliferative retinopathy had 
increased levels of mature EPCs. 
  EPCs surface antigen profile CD133+/CD34+/VEGFR2+ 
 
Patients with T1DM and 
nonproliferative retinopathy 
had decreased levels of EPCs. 
  Mature surface antigen profile CD133+/CD34+/VEGFR2+/CD31+   
  Nonmature surface antigen profile CD133+/CD34+/VEGFR2+/CD31-   
Abbreviations: T1DM, type 1 diabetes mellitus; PBMNCs, peripheral blood mononuclear cells; EPCs, 
endothelial progenitor cells; CPC, circulating progenitor cells; Ac-LDL, acetylated-low density 
lipoprotein; UEA-1 lectin, Ulex Europaeus Lectin 
Table 2. Studies that have reported aberrant EPC numbers in patients with T1DM. 
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Reference Method of EPC identification Comments 
Grisar et al., 
2005 
Expression of CD133/CD34/VEGFR2 
from PBMNC using flow cytometry. 
EPCs were lower in active RA 
patients compared to healthy 
controls when assessing surface 
antigen expression. 
  
In vitro culture of PBMNCs and 
detection of early-outgrowth EPCs 
colonies. 
Reduced number of early-
outgrowth EPC colonies in 
active RA patients compared to 
healthy controls. 
Grisar et al., 
2007 
Expression of CD133/CD34/VEGFR2 
from PBMNC using flow cytometry. 
TNF may be partly responsible 
for the reduction of circulating 
EPCs seen in RA patients.  
      




PBMNCs using flow cytometry. 
No difference in the number of 
EPCs in RA patients and healthy 
controls when assessing surface 
antigen expression. 
  
In vitro culture of PBMNCs and 
detection of early-outgrowth EPCs 
colonies. 
Reduced number of early-
outgrowth EPCs in active RA 
patients compared to healthy 
controls. 
    
Early-outgrowth EPC colony 





Surface antigen profile Lin-/7AAD-
/CD34+/CD133+/VEGFR2+ from CD14-
depleted PBMNCs using flow cytometry.
RA patients had higher numbers 
of circulating EPCs than healthy 
controls. 
  In vitro culture PBMNCs and detection of late-outgrowth colonies. 
Circulating EPCs correlated 
with disease activity. 
Herbrig et al., 
2006 
In vitro culture of PMNCs and 
assessment of Ac-LDL uptake, UEA-1 
lectin binding and the surface antigen 
profile VE-
cadherin+/CD31+/VEGFR2+/CD146-. 
EPCs from RA patients showed 
reduced migratory activity in 
response to VEGF. 
Abbreviations: RA, rheumatoid arthritis; PBMNCs, peripheral blood mononuclear cells; EPCs, 
endothelial progenitor cells; Ac-LDL, acetylated-low density lipoprotein; UEA-1 lectin, Ulex Europaeus 
Lectin; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor. 
Table 1. Studies that have reported aberrant EPC numbers in patients with RA. 
EPC dysfunction has been seen in patients with T1DM, as shown by Loomans et al. when 
conditioned media from EPCs isolated from T1DM patients impaired in vitro tube 
formation of HUVEC (Loomans et al., 2004). An inverse relationship between the number of 
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EPCs and HbA1C in patients has also been identified (Loomans et al., 2004). Moreover, there 
appears to be an association between the progression of diabetic retinopathy and the level of 
circulating EPCs. In patients with T1DM and proliferative retinopathy a marked increase in 
circulating EPCs has been reported (Asnaghi et al., 2006, Brunner et al., 2009). Conversely, 
circulating EPC numbers have been identified as being lower in patients with T1DM and 
non-proliferative retinopathy (Brunner et al., 2009). These studies highlight how atypical 
EPC numbers and function are associated with T1DM pathology and a schematic of a 
potential role for EPCs in diabetic retinopathy is depicted in Figure 1 (middle panel). 
 
Reference Method of EPC identification Comments 
Loomans et al., 
2004 
In vitro culture of PMNCs and 
assessment of Ac-LDL uptake, UEA-1 
lectin binding and CD31 expression. 
T1DM patients had lower EPC 
levels compared to healthy 
controls. 
Sibal et al., 2009 
Expression of 
CD133/CD34/VEGFR2/VE-cadherin 
from PBMNC using flow cytometry. 
EPC counts were lower in 
patients with T1DM compared 
to healthy controls. 
Asnaghi et al., 
2006 Immunostaining with CD133 and CD31
Patients with T1DM and 
retinopathy had higher EPC 
levels than healthy controls and 
patients with T1DM and no 
retinopathy. 
  
In vitro culture of PBMNCs and 
detection of early-outgrowth EPCs 
colonies. 
Patients with T1DM and no 
retinopathy had lower EPC 
levels than healthy controls and 
patients with T1DM and 
retinopathy. 
Brunner et al., 
2008 
CPC surface antigen profile 
CD133+/CD34+ 
Patients with T1DM and 
proliferative retinopathy had 
increased levels of mature EPCs. 
  EPCs surface antigen profile CD133+/CD34+/VEGFR2+ 
 
Patients with T1DM and 
nonproliferative retinopathy 
had decreased levels of EPCs. 
  Mature surface antigen profile CD133+/CD34+/VEGFR2+/CD31+   
  Nonmature surface antigen profile CD133+/CD34+/VEGFR2+/CD31-   
Abbreviations: T1DM, type 1 diabetes mellitus; PBMNCs, peripheral blood mononuclear cells; EPCs, 
endothelial progenitor cells; CPC, circulating progenitor cells; Ac-LDL, acetylated-low density 
lipoprotein; UEA-1 lectin, Ulex Europaeus Lectin 
Table 2. Studies that have reported aberrant EPC numbers in patients with T1DM. 
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4.3 Endothelial progenitor cells in systemic sclerosis 
Aberrant EPC numbers within the circulation of patients with SSc has been described 
extensively (Table 3). The majority of these studies used flow cytometry to assess EPC 
numbers using various combinations of the markers CD133, CD34 and VEGFR2. As 
mentioned previously, the use of these markers does not unambiguously identify circulating 
EPCs as they are expressed by other progenitor cells and mature endothelial cells. Avouac et 
al describe the most stringent method of EPC identification, which involved culturing the 
PBMNCs from both SSc patients and healthy controls and assessing late-outgrowth EPC 
colony formation. This study showed that the number of late-outgrowth EPC colonies 
correlated with the number of circulating EPCs detected using the surface antigen profile 
Lin-/7AAD-/CD34+/CD133+/VEGFR2+ (Avouac et al., 2008).  
 
Reference Method of EPC identification Comments 
Allanore 
et al., 2007 
Expression of CD133/CD34 from 
PBMNC using flow cytometry. 
SSc patients had higher numbers of EPCs than 
osteoarthritis patients, but lower than RA 
patients. 
Yamaguchi 
et al., 2010 
In vitro culture of PBMNCs depleted for 
platelets.  
The number of early-outgrowth EPCs was 
higher in SSc patients compared to RA patients 




using flow cytometry and CD31/CD144 
by immunohistochemistry. 
Early-outgrowth EPCs derived from SSc 
patients showed greater vascular potential in 
vitro and in vivo than early-outgrowth EPCs 
derived from healthy controls. 
Kuwana 
et al., 2004 
Expression of CD133/CD34/VEGR2 
from CD34-enriched PBMNC using flow 
cytometry. 
EPCs were lower in SSc patients compared to 
RA patients and healthy controls. 
    
Levels of angiogenic factors within the 
circulation were higher in SSc patients than in 
health controls. 
Kuwana 
et al., 2006 
Expression of CD133/CD34/VEGR2 
from CD34-enriched PBMNC using flow 
cytometry. 
Atorvastatin treatment resulted in an increase 
in circulating EPCs from baseline, however 
levels did not reach those of healthy controls. 
Del Papa 
et al., 2004 
Surface antigen profile CD133+/CD34+ 
from PBMNC using flow cytometry. 
High levels of EPCs in patients with SSc and 
counts were higher in early stages of disease. 
Del Papa 
et al., 2006 
Surface antigen profile CD133+/CD45- 
from PBMNC and BM using flow 
cytometry. 
Circulating EPCs were higher in patients with 
early stage disease, but not in those with late 
stage disease. 
    BM EPCs were reduced and functionally impaired. 
Avouac 
et al., 2008 
Surface antigen profile Lin-/7AAD-
/CD34+/CD133+/VEGFR2+ from 
PBMNCs detected using flow cytometry.
Circulating EPC levels were higher in SSc 
patients than in healthy controls. 
  In vitro culture of PBMNCs and detection of late-outgrowth colonies. 
Positive correlation between the number of 
late-outgrowth EPC colonies and the level of 
circulating EPCs detected by flow cytometry in 
patients with SSc. 
Abbreviations: SSc, systemic sclerosis; PBMNCs, peripheral blood mononuclear cells; EPCs, endothelial 
progenitor cells; BM, bone marrow. 
Table 3. Studies that have reported aberrant EPC numbers in patients with SSc. 
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It has been well documented that circulating EPC numbers are elevated in patients with SSc 
(Allanore et al., 2007, Avouac et al., 2008, Del Papa et al., 2004, Del Papa et al., 2006, 
Yamaguchi et al., 2010).  However, two studies by Kuwana and colleagues have reported 
reduced EPC numbers in SSc patients (Kuwana et al., 2006, Kuwana et al., 2004).  Del Papa 
et al showed that in early stage SSc (3-5 years) there appears to be an increase in circulating 
EPCs and post 5 years, there appears to be either a normal or decreased number of 
circulating EPCs (Del Papa et al., 2006). A schematic of a potential role for EPCs in SSc is 
depicted in Figure 1 (lower panel). There is also evidence to suggest that the vascular 
function of EPCs from SSc patients is actually higher than that of healthy controls as early-
outgrowth EPCs from SSc patients are able to promote tube formation of HUVEC in vitro as 
well as enhance tumour growth and blood vessel formation in vivo (Yamaguchi et al., 2010).  
5. Therapeutic intervention targeting EPCs in autoimmune diseases 
There have been rapid advances in the field of therapeutic angiogenesis since the original 
description of bone marrow derived EPCs in 1997 (Asahara et al., 1997). Most of these 
bench-to-bed-side studies have been done in models of atherosclerosis and acute ischemic 
events such as myocardial infarction (MI) and critical limb ischemia. The first pre-clinical 
studies in these diseases were executed (within four years of their initial discovery) in a MI 
model in mice (Kocher et al., 2001) and demonstrated improvement in angiogenesis and 
cardiac function. This was followed by a series of publications showing the effectiveness of 
EPCs in preventing the extent of damage (Orlic et al., 2001) after MI as well as effectiveness 
in the large vessel occlusive damage (Griese et al., 2003) and prevention of atherosclerosis in 
a highly prone mouse model (Rausher et al, 2003). However, the exact mechanism of action 
of these interventions, in particular whether the benefit was due to neo-angiogenesis 
modulated by EPCs or due to paracrine mechanisms that improved the survival of resident 
endothelial cells, is not entirely clear.  
There was a rapid transition of these studies to humans as autologous marrow 
transplantation became a relatively safe and well established procedure in haematological 
malignancies and non-invasive methods to mobilise bone marrow progenitors became well 
established. In 2002, there were two studies published reporting the benefit of locally 
injecting ex-vivo expanded autologous bone marrow derived mononuclear cells in MI 
critical lower limb ischemia (Strauer et al., 2002, Tateishi-Yuyama et al., 2002). Furthermore, 
there have been multiple randomised controlled trials looking at the effectiveness of bone 
marrow derived cell therapies, which have been reviewed in a recent meta-analysis (Martin-
Rendon et al., 2008).  
The therapeutic use of EPCs in inflammatory diseases is more complicated as they have 
been implicated in pathogenesis of the inflammatory process as well as being an important 
cause of long term morbidity. There have been no studies of direct intervention with EPCs 
in autoimmune diseases. This is mainly due to their differential effects on the 
immunopathogenesis of these diseases. Attempts to understand this field are further 
bedevilled by observations of patients with systemic lupus erythematosus (SLE) who exhibit 
a significant decrease in circulating EPCs as well as a striking increase in premature 
atherosclerosis of unclear aetiology (de Leeuw et al., 2005, Westerweel et al., 2007) 
demonstrating no significant difference in EPC number between SLE patients without and 
with advanced coronary artery calcification (Baker et al., 2011). As detailed above, the 
inflammatory milieu in autoimmune diseases is characterized by neo-angiogenesis and as 
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4.3 Endothelial progenitor cells in systemic sclerosis 
Aberrant EPC numbers within the circulation of patients with SSc has been described 
extensively (Table 3). The majority of these studies used flow cytometry to assess EPC 
numbers using various combinations of the markers CD133, CD34 and VEGFR2. As 
mentioned previously, the use of these markers does not unambiguously identify circulating 
EPCs as they are expressed by other progenitor cells and mature endothelial cells. Avouac et 
al describe the most stringent method of EPC identification, which involved culturing the 
PBMNCs from both SSc patients and healthy controls and assessing late-outgrowth EPC 
colony formation. This study showed that the number of late-outgrowth EPC colonies 
correlated with the number of circulating EPCs detected using the surface antigen profile 
Lin-/7AAD-/CD34+/CD133+/VEGFR2+ (Avouac et al., 2008).  
 
Reference Method of EPC identification Comments 
Allanore 
et al., 2007 
Expression of CD133/CD34 from 
PBMNC using flow cytometry. 
SSc patients had higher numbers of EPCs than 
osteoarthritis patients, but lower than RA 
patients. 
Yamaguchi 
et al., 2010 
In vitro culture of PBMNCs depleted for 
platelets.  
The number of early-outgrowth EPCs was 
higher in SSc patients compared to RA patients 




using flow cytometry and CD31/CD144 
by immunohistochemistry. 
Early-outgrowth EPCs derived from SSc 
patients showed greater vascular potential in 
vitro and in vivo than early-outgrowth EPCs 
derived from healthy controls. 
Kuwana 
et al., 2004 
Expression of CD133/CD34/VEGR2 
from CD34-enriched PBMNC using flow 
cytometry. 
EPCs were lower in SSc patients compared to 
RA patients and healthy controls. 
    
Levels of angiogenic factors within the 
circulation were higher in SSc patients than in 
health controls. 
Kuwana 
et al., 2006 
Expression of CD133/CD34/VEGR2 
from CD34-enriched PBMNC using flow 
cytometry. 
Atorvastatin treatment resulted in an increase 
in circulating EPCs from baseline, however 
levels did not reach those of healthy controls. 
Del Papa 
et al., 2004 
Surface antigen profile CD133+/CD34+ 
from PBMNC using flow cytometry. 
High levels of EPCs in patients with SSc and 
counts were higher in early stages of disease. 
Del Papa 
et al., 2006 
Surface antigen profile CD133+/CD45- 
from PBMNC and BM using flow 
cytometry. 
Circulating EPCs were higher in patients with 
early stage disease, but not in those with late 
stage disease. 
    BM EPCs were reduced and functionally impaired. 
Avouac 
et al., 2008 
Surface antigen profile Lin-/7AAD-
/CD34+/CD133+/VEGFR2+ from 
PBMNCs detected using flow cytometry.
Circulating EPC levels were higher in SSc 
patients than in healthy controls. 
  In vitro culture of PBMNCs and detection of late-outgrowth colonies. 
Positive correlation between the number of 
late-outgrowth EPC colonies and the level of 
circulating EPCs detected by flow cytometry in 
patients with SSc. 
Abbreviations: SSc, systemic sclerosis; PBMNCs, peripheral blood mononuclear cells; EPCs, endothelial 
progenitor cells; BM, bone marrow. 
Table 3. Studies that have reported aberrant EPC numbers in patients with SSc. 
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It has been well documented that circulating EPC numbers are elevated in patients with SSc 
(Allanore et al., 2007, Avouac et al., 2008, Del Papa et al., 2004, Del Papa et al., 2006, 
Yamaguchi et al., 2010).  However, two studies by Kuwana and colleagues have reported 
reduced EPC numbers in SSc patients (Kuwana et al., 2006, Kuwana et al., 2004).  Del Papa 
et al showed that in early stage SSc (3-5 years) there appears to be an increase in circulating 
EPCs and post 5 years, there appears to be either a normal or decreased number of 
circulating EPCs (Del Papa et al., 2006). A schematic of a potential role for EPCs in SSc is 
depicted in Figure 1 (lower panel). There is also evidence to suggest that the vascular 
function of EPCs from SSc patients is actually higher than that of healthy controls as early-
outgrowth EPCs from SSc patients are able to promote tube formation of HUVEC in vitro as 
well as enhance tumour growth and blood vessel formation in vivo (Yamaguchi et al., 2010).  
5. Therapeutic intervention targeting EPCs in autoimmune diseases 
There have been rapid advances in the field of therapeutic angiogenesis since the original 
description of bone marrow derived EPCs in 1997 (Asahara et al., 1997). Most of these 
bench-to-bed-side studies have been done in models of atherosclerosis and acute ischemic 
events such as myocardial infarction (MI) and critical limb ischemia. The first pre-clinical 
studies in these diseases were executed (within four years of their initial discovery) in a MI 
model in mice (Kocher et al., 2001) and demonstrated improvement in angiogenesis and 
cardiac function. This was followed by a series of publications showing the effectiveness of 
EPCs in preventing the extent of damage (Orlic et al., 2001) after MI as well as effectiveness 
in the large vessel occlusive damage (Griese et al., 2003) and prevention of atherosclerosis in 
a highly prone mouse model (Rausher et al, 2003). However, the exact mechanism of action 
of these interventions, in particular whether the benefit was due to neo-angiogenesis 
modulated by EPCs or due to paracrine mechanisms that improved the survival of resident 
endothelial cells, is not entirely clear.  
There was a rapid transition of these studies to humans as autologous marrow 
transplantation became a relatively safe and well established procedure in haematological 
malignancies and non-invasive methods to mobilise bone marrow progenitors became well 
established. In 2002, there were two studies published reporting the benefit of locally 
injecting ex-vivo expanded autologous bone marrow derived mononuclear cells in MI 
critical lower limb ischemia (Strauer et al., 2002, Tateishi-Yuyama et al., 2002). Furthermore, 
there have been multiple randomised controlled trials looking at the effectiveness of bone 
marrow derived cell therapies, which have been reviewed in a recent meta-analysis (Martin-
Rendon et al., 2008).  
The therapeutic use of EPCs in inflammatory diseases is more complicated as they have 
been implicated in pathogenesis of the inflammatory process as well as being an important 
cause of long term morbidity. There have been no studies of direct intervention with EPCs 
in autoimmune diseases. This is mainly due to their differential effects on the 
immunopathogenesis of these diseases. Attempts to understand this field are further 
bedevilled by observations of patients with systemic lupus erythematosus (SLE) who exhibit 
a significant decrease in circulating EPCs as well as a striking increase in premature 
atherosclerosis of unclear aetiology (de Leeuw et al., 2005, Westerweel et al., 2007) 
demonstrating no significant difference in EPC number between SLE patients without and 
with advanced coronary artery calcification (Baker et al., 2011). As detailed above, the 
inflammatory milieu in autoimmune diseases is characterized by neo-angiogenesis and as 
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such it would seem that increased EPCs might contribute to inflammation. On the other 
hand, the most common cause of long term morbidity and mortality in these diseases is 
attributed to atherosclerosis and its complications where EPCs might have beneficial effect. 
There have been numerous studies looking at the effect of various disease modifying 
therapies in patients with autoimmune diseases on the circulating EPCs (both monocytic 
and haemangioblastic) reviewed in a recent article (Westerweel and Verhaar, 2009). These 
studies show an increase in the levels of circulating haemangioblastic EPCs after various 
immunosuppressive therapies including anti-TNF drugs, corticosteroids and 
hydroxychloroquine in these patients. However, the association of these changes with long 
term clinically useful outcome, such as incidence of atherosclerosis and coronary artery 
disease, has not been demonstrated. This finding is intriguing as it is well known from long 
term clinical studies that corticosteroids are known to promote atherosclerosis and anti-TNF 
medications reduce long term morbidity and mortality due to this complication (Kaplan, 
2010). Moreover, methotrexate, a commonly used disease modifying agent in various 
autoimmune diseases is known to induce EPC apoptosis in vitro (Herbrig et al., 2006) but 
has beneficial effects in patients.  
There needs to be better understanding of the role of EPCs in the different stages of the 
disease, i.e. early active versus long standing, and its pathophysiological implications 
relating to long term outcome of patients to be able to design studies with intervention 
directed at EPCs. The knowledge of various paracrine mechanisms involved in the 
beneficial effects of EPCs in atherosclerosis models might help to dissect the pathways 
involved in neo-angiogenesis versus survival of resident endothelial cells. This knowledge 
can then be exploited to design intervention at various stages of autoimmune diseases.        
6. Conclusions 
Faced with an ever-increasing burden of autoimmune diseases such as RA, T1DM and SSc, 
modern medicine is confronted with the need to provide new therapies that not only mitigate 
the symptoms of these diseases but may also facilitate regeneration of organ function. Given 
their role in development and in maintaining and repairing injured vessels, stem and 
progenitor cells represent an exciting alternative for regenerative medicine. Since their first 
identification over a decade ago, the use of EPCs as a diagnostic tool or therapeutic was 
greeted with great enthusiasm. However, progress in their clinical application remains limited 
by identification and ex vivo expansion factors, and as a result, variable functional attributes. It 
can be seen from the aforementioned examples that the timing and methods used to detect 
EPCs can greatly affect the outcome of studies. The major issues associated with EPC 
identification within the circulation are (1) identifying the bone marrow progenitors from the 
circulating mature endothelial cells and (2) defining the distinction between haemangioblastic 
late-outgrowth EPCs and monocytic early-outgrowth EPCs. These matters are the focus of 
ongoing research, especially the search for a unique EPC marker. Nevertheless, EPCs are a 
robust biomarker of vascular dysfunction (based on their direct interaction and influence on 
endothelial function), and the unique ability to monitor their peripheral number or function as 
a marker of response to therapy. Notwithstanding the current knowledge regarding EPC cell 
signalling, activation and migration, the precise mechanisms of activation of these cells and 
their functional significance is not known. In the research setting, continued understanding of 
EPC function improves insight into vasculogenesis, and the pathology of vascular dysfunction 
in autoimmune disease.  
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1. Introduction 
Patients affected by autoimmune diseases have demonstrated an increased risk of 
developing lymphoid malignancies. Non-Hodgkin lymphomas (NHL) have consistently 
been associated with several autoimmune conditions, such as, by way of example, 
rheumatoid arthritis (RA), Sjögren syndrome (SS) and systemic lupus erythematosus (SLE). 
Similarly, even if based on fewer studies, an increased risk of malignant lymphomas has 
also been associated with celiac disease, dermatitis herpetiformis, Hashimoto’s thyroiditis, 
and autoimmune haemolytic anemia. An association between other autoimmune conditions, 
such as inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), psoriasis and 
systemic sclerosis, and a higher risk of lymphoproliferative disorders has not been 
consistently proven (Askling et al, 2005, von Roon et al, 2007, Boffetta et al, 2001, Gelfand et 
al, 2006, Chatterjee et al, 2005). The magnitude of these associations varies widely among 
different studies. Reported relative risk is about two-fold in RA, 9-18 fold in SS, 3-6 fold in 
SLE, celiac disease and Hashimoto thyroiditis, and 2-10 fold in dermatitis herpetiformis. 
Epidemiologic analysis by NHL subtype have shown that diffuse large B-cell lymphoma 
(DLBCL) is more frequently associated with RA and SS, while extranodal marginal zone 
lymphoma, in the respective target organs, is strongly associated with SS (Theander et al, 
2004) and Hashimoto’s thyroiditis. Celiac disease is associated with a 520-fold increased risk 
of enteropathy-associated T-cell lymphoma of the small intestine (EATL). Autoimmune 
conditions of the skin including psoriasis, pemphigus and discoid lupus erythematosus 
have an increased risk of T-cell cutaneous lymphoma (Anderson et al, 2009). Hodgkin 
lymphoma has also been associated with some autoimmune conditions, such as RA, SLE 
and sclerodermia. On the other hand, it is still unclear why other autoimmune conditions, 
such as type 1 mellitus diabetes, multiple sclerosis, and sarcoidosis do not present an 
increased risk of lymphoma development. The exact mechanism of lymphomagenesis in the 
contest of autoimmunity remains largely unexplained, but it may be related to chronic 
antigenic stimulation, chronic inflammatory response and deficiency in 
immunesurveillance, promoting a multistep process of genetic instability resulting in 
accumulation of genetic alterations. In addition, immunosuppressive medications (e.g., 
methotrexate) may concur to alter patient’s immune status. In this chapter, we review the 
mainstream of epidemiologic studies, discuss the pathways underlying autoimmunity and 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
338 
Tateishi-Yuyama, E., Matsubara, H., Murohara, T., Ikeda, U., Shintani, S., Masaki, H., 
Amano, K., Kishimoto, Y., Yoshimoto, K., Akashi, H., Shimada, K., Iwasaka, T. & 
Imaizumi, T. 2002. Therapeutic angiogenesis for patients with limb ischaemia by 
autologous transplantation of bone-marrow cells: a pilot study and a randomised 
controlled trial. Lancet, 360, 427-35. 
Timmermans, F., Van Hauwermeiren, F., De Smedt, M., Raedt, R., Plasschaert, F., De 
Buyzere, M. L., Gillebert, T. C., Plum, J. & Vandekerckhove, B. 2007. Endothelial 
outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic 
precursors. Arterioscler Thromb Vasc Biol, 27, 1572-9. 
Westerweel, P. E., Luijten, R. K., Hoefer, I. E., Koomans, H. A., Derksen, R. H. & Verhaar, M. 
C. 2007. Haematopoietic and endothelial progenitor cells are deficient in quiescent 
systemic lupus erythematosus. Ann Rheum Dis, 66, 865-70. 
Westerweel, P. E. & Verhaar, M. C. 2009. Endothelial progenitor cell dysfunction in 
rheumatic disease. Nat Rev Rheumatol, 5, 332-40. 
Williamson, J. R., Chang, K., Frangos, M., Hasan, K. S., Ido, Y., Kawamura, T., Nyengaard, J. 
R., Van Den Enden, M., Kilo, C. & Tilton, R. G. 1993. Hyperglycemic 
pseudohypoxia and diabetic complications. Diabetes, 42, 801-13. 
Yamaguchi, Y., Okazaki, Y., Seta, N., Satoh, T., Takahashi, K., Ikezawa, Z. & Kuwana, M. 
2010. Enhanced angiogenic potency of monocytic endothelial progenitor cells in 
patients with systemic sclerosis. Arthritis Res Ther, 12, R205. 
Yoder, M. C., Mead, L. E., Prater, D., Krier, T. R., Mroueh, K. N., Li, F., Krasich, R., Temm, C. 
J., Prchal, J. T. & Ingram, D. A. 2007. Redefining endothelial progenitor cells via 
clonal analysis and hematopoietic stem/progenitor cell principals. Blood, 109, 1801-
9. 
Yoon, C. H., Hur, J., Park, K. W., Kim, J. H., Lee, C. S., Oh, I. Y., Kim, T. Y., Cho, H. J., Kang, 
H. J., Chae, I. H., Yang, H. K., Oh, B. H., Park, Y. B. & Kim, H. S. 2005. Synergistic 
neovascularization by mixed transplantation of early endothelial progenitor cells 
and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix 
metalloproteinases. Circulation, 112, 1618-27. 
Ziyadeh, F. N. 2004. Mediators of diabetic renal disease: the case for tgf-Beta as the major 
mediator. J Am Soc Nephrol, 15 Suppl 1, S55-7. 
18 
Autoimmune Disorders and Lymphomas 
Dolcetti R.1, Ponzoni M.2,3, Mappa S.2,4 and Ferreri A.J.M.2 
1Cancer Bioimmunotherapy Unit, Dept of Oncology, 
National Cancer Institute CRO-IRCCS, 
2Unit of Lymphoid Malignancies, Dept of Onco-Hematology,  
3Pathology Unit, 4Internal Medicine Unit; San Raffaele Scientific Institute 
Italy 
1. Introduction 
Patients affected by autoimmune diseases have demonstrated an increased risk of 
developing lymphoid malignancies. Non-Hodgkin lymphomas (NHL) have consistently 
been associated with several autoimmune conditions, such as, by way of example, 
rheumatoid arthritis (RA), Sjögren syndrome (SS) and systemic lupus erythematosus (SLE). 
Similarly, even if based on fewer studies, an increased risk of malignant lymphomas has 
also been associated with celiac disease, dermatitis herpetiformis, Hashimoto’s thyroiditis, 
and autoimmune haemolytic anemia. An association between other autoimmune conditions, 
such as inflammatory bowel diseases (Crohn’s disease and ulcerative colitis), psoriasis and 
systemic sclerosis, and a higher risk of lymphoproliferative disorders has not been 
consistently proven (Askling et al, 2005, von Roon et al, 2007, Boffetta et al, 2001, Gelfand et 
al, 2006, Chatterjee et al, 2005). The magnitude of these associations varies widely among 
different studies. Reported relative risk is about two-fold in RA, 9-18 fold in SS, 3-6 fold in 
SLE, celiac disease and Hashimoto thyroiditis, and 2-10 fold in dermatitis herpetiformis. 
Epidemiologic analysis by NHL subtype have shown that diffuse large B-cell lymphoma 
(DLBCL) is more frequently associated with RA and SS, while extranodal marginal zone 
lymphoma, in the respective target organs, is strongly associated with SS (Theander et al, 
2004) and Hashimoto’s thyroiditis. Celiac disease is associated with a 520-fold increased risk 
of enteropathy-associated T-cell lymphoma of the small intestine (EATL). Autoimmune 
conditions of the skin including psoriasis, pemphigus and discoid lupus erythematosus 
have an increased risk of T-cell cutaneous lymphoma (Anderson et al, 2009). Hodgkin 
lymphoma has also been associated with some autoimmune conditions, such as RA, SLE 
and sclerodermia. On the other hand, it is still unclear why other autoimmune conditions, 
such as type 1 mellitus diabetes, multiple sclerosis, and sarcoidosis do not present an 
increased risk of lymphoma development. The exact mechanism of lymphomagenesis in the 
contest of autoimmunity remains largely unexplained, but it may be related to chronic 
antigenic stimulation, chronic inflammatory response and deficiency in 
immunesurveillance, promoting a multistep process of genetic instability resulting in 
accumulation of genetic alterations. In addition, immunosuppressive medications (e.g., 
methotrexate) may concur to alter patient’s immune status. In this chapter, we review the 
mainstream of epidemiologic studies, discuss the pathways underlying autoimmunity and 
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lymphomas as well as mechanisms of lymphomagenesis, and summarize the characteristics 
of the various autoimmune diseases that may be associated with lymphoma. Therapeutic 
options for these clinically intriguing conditions are also discussed. 
2. Epidemiologic studies  
The first report of an association between autoimmunity and lymphomas was made in 1966 
(Mellors, 1966). Notwithstanding the low incidence of autoimmune and lymphoproliferative 
disorders in the general population,  large patients groups and long observation periods are 
needed to establish an association between these two conditions. In the past, many 
population-based case-control and cohort studies were carried out to confirm the 
consistence of an association between these two diseases. Registry-based cohort studies, 
which are generally based on hospital discharge diagnosis records, are able to evaluate large 
cohort of patients affected by different autoimmune disorders following them for the 
occurrence of cancer, usually using cancer registries. This method allows studying large 
number of patients with autoimmune diseases although lymphoma occurrence is a rare 
event. Despite the adequate statistical power of these studies, they may over select patients 
with severe disease, missing patients who are treated only as outpatients. On the other 
hand, case-control studies of lymphoma patients allows the evaluation of large numbers of 
well-characterized cancer cases, providing for a wider range of information about 
lymphoma subtype and covariate exposure of interest, with the disadvantage of rarity of 
some autoimmune disorders, the low statistical power and control selection bias. Therefore, 
both study designs have limitations in evaluating the consistence of this peculiar 
association. Another important limitation of these studies is the potential bias due to reverse 
causality (i.e., undiagnosed lymphoma causing paraneoplastic inflammation misclassified as 
rheumatic disease). Many studies have reported in fact a major risk of lymphoma 
development during the first year after diagnosis of autoimmune disease or have excluded 
from analysis this time interval. A meta-analysis of all previous available cohort studies 
relating SLE, RA and SS to the risk of NHL development showed that NHL is more frequent 
in patients affected by autoimmune diseases than in the general population, especially for SS 
and SLE (Zintzaras et al, 2005). Importantly, a reason for the inconsistent associations 
between many autoimmune conditions and NHL overall risk may lie in the molecular, 
morphologic and etiologic heterogeneity of the different NHL subtypes. One of the largest 
epidemiologic study published has performed a pooled analysis of self-reported 
autoimmune conditions and NHL different subtypes, including 29.423 participants in 12 
case-control studies over Europe, North America and Australia (Ekstrom Smedby et al, 
2008). The study concluded that an increased risk of NHL is associated only with few 
autoimmune disorders and that these associations are stronger for some lymphoma 
subtypes than others. In fact, a 6.5-fold increased risk of NHL was associated with SS, which 
is lower than in previous reports including only cohorts of hospitalized patients that may 
present a more severe form of disease. It has been observed a 250-fold increased risk of 
parotid gland NHL and a 1.000-fold increased risk of marginal zone B-cell lymphoma of 
mucosa-associated lymphoid tissue (MALT)-type of the parotid gland and an association 
with DLBCL. SLE has been associated with a 2.7-fold increased risk of NHL, in particular, 
DLBCL and MALT lymphomas. Haemolytic anaemia has been associated with DLBCL. In 
patients with celiac disease, an increased overall risk for NHL was not observed; only 
associations with entheropathy-associated T-cell lymphoma of small intestine and anaplastic 
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large T-cell lymphoma have been detected. Regarding RA, an overall increased risk of NHL 
was not observed, but only a moderately increased risk in patients treated with 
corticosteroids or immunosuppressant. Finally, inflammatory bowel disorders, type I 
diabetes, sarcoidosis, pernicious anaemia, and multiple sclerosis were not associated with 
increased risk of NHL. Importantly, this analysis demonstrated a persistent risk of 
lymphoma development also after ten year of autoimmune disease duration, excluding the 
risk of autoimmune phenomena triggered by yet undiagnosed lymphomas. Another large 
population-based case-control study form the U.S. Surveillance Epidemiology and End 
Results-Medicare database has been conducted on 44.350 lymphoid malignancy cases (> 67 
years) and 122.531 population-based controls (Anderson et al, 2009). Association between 
specific lymphoid malignancy subtypes and various autoimmune conditions has been also 
investigated. Although the study was limited to subjects over age 65, the strongest 
association by NHL subtype was observed between DLBCL and RA and SS; T-cell 
lymphoma and haemolytic anaemia, psoriasis, discoid lupus erythematosus, and celiac  
 
Studies Disease NHL 95% CI HL 95% 
CI 
p 
Zintzaras, 2005 Reumatoid arthritis 3.9 (SIR) 2.5-5.9 - - - 
 Systemic lupus erythematosus 7.4 3.3-17 - - - 
 Primary Sjögren syndrome 18.8 9.5-37.3 - - - 
Engels, 2005 Reumatoid arthritis 1.3 (OR) 0.8-2.1 - - 0.24 
 Systemic lupus erythematosus 1.3 0.3-5.6 - - 0.72 
 Primary Sjögren syndrome 4.9 0.6-43 - - 0.11 
Landgren, 2006 Reumatoid arthritis - - 2.7 
(OR) 
1.9-4.0 - 
 Systemic lupus erythematosus - - 5.8 2.2-
15.1 
- 
 Systemic scleroderma - - 0.6 0.1-6.2 - 
 Hashimoto thyroiditis - - 2.0 0.3-14 - 
Ekstrom 
Smedby, 2008 




- - < 
0.1 
 Systemic lupus erythematosus 2.69 1.68-4.3 - - 0.39 
 Primary Sjögren syndrome 4.75 1.79-
12.6 
- - 0.93 
 Secondary Sjögren syndrome 9.57 2.9-31.6 - - - 
 Celiac disease 1.5 0.89-
2.54 
- - 0.72 
Anderson, 2009 Rheumatoid arthritis (OR) 1.2 1.1-1.3 1.5 
(OR) 
1.1-2.0 - 
 Systemic lupus erythematosus 1.5 1.2-1.9 3.5 1.9-6.7 - 
 Sjögren syndrome 1.9 1.5-2.3 1.6 0.6-4.4 - 
 Systemic scleroderma 1.4 0.9-2.2 2.5 0.6-10 - 
 Hashimoto thyroiditis 1.1 0.8-1.4 2.1 1.0-4.8 - 
 Celiac disease 1.5 0.9-2.5 - - - 
Table 1. Epidemiologic studies 
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lymphomas as well as mechanisms of lymphomagenesis, and summarize the characteristics 
of the various autoimmune diseases that may be associated with lymphoma. Therapeutic 
options for these clinically intriguing conditions are also discussed. 
2. Epidemiologic studies  
The first report of an association between autoimmunity and lymphomas was made in 1966 
(Mellors, 1966). Notwithstanding the low incidence of autoimmune and lymphoproliferative 
disorders in the general population,  large patients groups and long observation periods are 
needed to establish an association between these two conditions. In the past, many 
population-based case-control and cohort studies were carried out to confirm the 
consistence of an association between these two diseases. Registry-based cohort studies, 
which are generally based on hospital discharge diagnosis records, are able to evaluate large 
cohort of patients affected by different autoimmune disorders following them for the 
occurrence of cancer, usually using cancer registries. This method allows studying large 
number of patients with autoimmune diseases although lymphoma occurrence is a rare 
event. Despite the adequate statistical power of these studies, they may over select patients 
with severe disease, missing patients who are treated only as outpatients. On the other 
hand, case-control studies of lymphoma patients allows the evaluation of large numbers of 
well-characterized cancer cases, providing for a wider range of information about 
lymphoma subtype and covariate exposure of interest, with the disadvantage of rarity of 
some autoimmune disorders, the low statistical power and control selection bias. Therefore, 
both study designs have limitations in evaluating the consistence of this peculiar 
association. Another important limitation of these studies is the potential bias due to reverse 
causality (i.e., undiagnosed lymphoma causing paraneoplastic inflammation misclassified as 
rheumatic disease). Many studies have reported in fact a major risk of lymphoma 
development during the first year after diagnosis of autoimmune disease or have excluded 
from analysis this time interval. A meta-analysis of all previous available cohort studies 
relating SLE, RA and SS to the risk of NHL development showed that NHL is more frequent 
in patients affected by autoimmune diseases than in the general population, especially for SS 
and SLE (Zintzaras et al, 2005). Importantly, a reason for the inconsistent associations 
between many autoimmune conditions and NHL overall risk may lie in the molecular, 
morphologic and etiologic heterogeneity of the different NHL subtypes. One of the largest 
epidemiologic study published has performed a pooled analysis of self-reported 
autoimmune conditions and NHL different subtypes, including 29.423 participants in 12 
case-control studies over Europe, North America and Australia (Ekstrom Smedby et al, 
2008). The study concluded that an increased risk of NHL is associated only with few 
autoimmune disorders and that these associations are stronger for some lymphoma 
subtypes than others. In fact, a 6.5-fold increased risk of NHL was associated with SS, which 
is lower than in previous reports including only cohorts of hospitalized patients that may 
present a more severe form of disease. It has been observed a 250-fold increased risk of 
parotid gland NHL and a 1.000-fold increased risk of marginal zone B-cell lymphoma of 
mucosa-associated lymphoid tissue (MALT)-type of the parotid gland and an association 
with DLBCL. SLE has been associated with a 2.7-fold increased risk of NHL, in particular, 
DLBCL and MALT lymphomas. Haemolytic anaemia has been associated with DLBCL. In 
patients with celiac disease, an increased overall risk for NHL was not observed; only 
associations with entheropathy-associated T-cell lymphoma of small intestine and anaplastic 
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large T-cell lymphoma have been detected. Regarding RA, an overall increased risk of NHL 
was not observed, but only a moderately increased risk in patients treated with 
corticosteroids or immunosuppressant. Finally, inflammatory bowel disorders, type I 
diabetes, sarcoidosis, pernicious anaemia, and multiple sclerosis were not associated with 
increased risk of NHL. Importantly, this analysis demonstrated a persistent risk of 
lymphoma development also after ten year of autoimmune disease duration, excluding the 
risk of autoimmune phenomena triggered by yet undiagnosed lymphomas. Another large 
population-based case-control study form the U.S. Surveillance Epidemiology and End 
Results-Medicare database has been conducted on 44.350 lymphoid malignancy cases (> 67 
years) and 122.531 population-based controls (Anderson et al, 2009). Association between 
specific lymphoid malignancy subtypes and various autoimmune conditions has been also 
investigated. Although the study was limited to subjects over age 65, the strongest 
association by NHL subtype was observed between DLBCL and RA and SS; T-cell 
lymphoma and haemolytic anaemia, psoriasis, discoid lupus erythematosus, and celiac  
 
Studies Disease NHL 95% CI HL 95% 
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p 
Zintzaras, 2005 Reumatoid arthritis 3.9 (SIR) 2.5-5.9 - - - 
 Systemic lupus erythematosus 7.4 3.3-17 - - - 
 Primary Sjögren syndrome 18.8 9.5-37.3 - - - 
Engels, 2005 Reumatoid arthritis 1.3 (OR) 0.8-2.1 - - 0.24 
 Systemic lupus erythematosus 1.3 0.3-5.6 - - 0.72 
 Primary Sjögren syndrome 4.9 0.6-43 - - 0.11 
Landgren, 2006 Reumatoid arthritis - - 2.7 
(OR) 
1.9-4.0 - 
 Systemic lupus erythematosus - - 5.8 2.2-
15.1 
- 
 Systemic scleroderma - - 0.6 0.1-6.2 - 
 Hashimoto thyroiditis - - 2.0 0.3-14 - 
Ekstrom 
Smedby, 2008 




- - < 
0.1 
 Systemic lupus erythematosus 2.69 1.68-4.3 - - 0.39 
 Primary Sjögren syndrome 4.75 1.79-
12.6 
- - 0.93 
 Secondary Sjögren syndrome 9.57 2.9-31.6 - - - 
 Celiac disease 1.5 0.89-
2.54 
- - 0.72 
Anderson, 2009 Rheumatoid arthritis (OR) 1.2 1.1-1.3 1.5 
(OR) 
1.1-2.0 - 
 Systemic lupus erythematosus 1.5 1.2-1.9 3.5 1.9-6.7 - 
 Sjögren syndrome 1.9 1.5-2.3 1.6 0.6-4.4 - 
 Systemic scleroderma 1.4 0.9-2.2 2.5 0.6-10 - 
 Hashimoto thyroiditis 1.1 0.8-1.4 2.1 1.0-4.8 - 
 Celiac disease 1.5 0.9-2.5 - - - 
Table 1. Epidemiologic studies 
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disease; marginal zone lymphoma and SLE and haemolytic anaemia; Hodgkin lymphoma 
(HL) and SLE. Additional analysis excluding data for up to 5 years before the diagnosis of 
malignancy have been also performed to exclude reverse causality, i.e., lymphoma causing 
autoimmune disorder. Another population based case-control study disclosed a solid 
association between NHL and SS and a small increase in NHL risk associated with SLE 
(Engels et al, 2005). While most epidemiologic studies demonstrated a consistent association 
between autoimmunity and NHL, there are only limited data on the risk of developing HL 
in these settings. A population-based case-control study during a 40-year period analyzed 
the association between 32 autoimmune disorders and risk of developing HL (Landgren et 
al, 2006), reporting a statistically significant increased risk to develop HL in patients with 
personal history of RA, SLE, sarcoidosis, or ITP. In addition, personal or family history of 
sarcoidosis and ulcerative colitis was associated with significantly increased risk of HL. 
3. Pathogenesis 
The aetiology of NHL remains largely unexplained, but some well-established risk factors 
have been identified. Under normal conditions, B and T lymphocytes respond to antigenic 
stimulation in a regulated manner and proliferative responses are self-limited. Immune 
dysregulation, leading to a continue lymphocyte proliferation, is considered to play a major 
role in lymphomagenesis, as demonstrated by an increased risk of lymphoma development 
in states of immunosuppression (i.e. following organ transplant or hereditary and acquired 
immunodeficiency syndromes). In addition, the occurrence of specific subtypes of NHL in  
 
 
Fig. 1. Proposed pathogenetic factors of lymphomagenesis in the context of autoimmunity 
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the context of infectious conditions suggests a pathogenic role also for inflammation and 
chronic immune stimulation. Autoimmune diseases have been considered a possible 
predisposing factor for lymphoma development as they are characterized by impairment of 
immune responses leading to a loss of tolerance to self-antigens, a deregulated lymphocyte 
reactivity with production of autoantibodies against specific tissues and organs. It is 
conceivable that a sustained antigen-driven B proliferation may increase the risk of adverse 
genetic events that may finally result in the emergence of a neoplastic clone. 
3.1 Immune dysregulation 
In the development of lymphoma at primary sites, such as MALT lymphomas arising in the 
parotid gland during the course of SS or in the thyroid gland in the case of chronic 
thyroiditis, and as T-cell lymphoma in small intestine of patients with celiac disease, a 
critical role is played by local chronic antigen-driven stimulation leading to the genesis of 
organized lymphoid tissue, the so called “tertiary“ lymphoid tissue, characterized by organ-
specific T- or B-cell proliferation, polyclonality and, eventually, oligo-monoclonality. 
3.1.1 Tertiary lymphoid tissue 
Chronic inflammatory infiltrates resembling the secondary lymphoid organs have been 
previously described as “tertiary lymphoid organs” (Picker, 1992) and can be induced by the 
same mediators of lymphoid ontogenesis, such as tumor necrosis factor (TNF)-beta and 
other members of the TNF family (Kratz et al, 1996), through induction of transcription 
factors, adhesion molecules, lymphoid-tissue-homing chemokines, and other cytokines 
(Hjelmstrom, 2001). The transcription factor named nuclear factor kappa-B (NF-κB) is 
induced by TNF proteins and is involved in lymphoid tissue development through 
chemokines, adhesion molecules and members of the TNF family themselves. TNF proteins 
are also required for the normal expression of CXCL13 and CCL21, two homing chemokines 
crucial for lymphoid neogenesis (Ngo et al, 1999). CXCR13 is normally produced by stromal 
cells in lymphoid tissues and attracts naive B cells and activated and memory T cells in vitro 
(Legler et al, 1998). CCL21 is a ligand for the CCR7 receptor that directs the migration of naive 
T cells and dendritic cells. Expression of CXCL13 and CCL21 has been found in disease models 
of chronic inflammation characterized by lymphoid neogenesis (Hjelmstrom, 2001). Chronic 
autoimmune diseases are characterized by a chronic inflammatory infiltrate in the target 
organs, with mononuclear cells and lymphoid follicles. The thyroid gland in patients affected 
by Hashimoto’s thyroiditis is organized in a structure that resembles a lymph node, including 
germinal centres, plasma cells and high endothelial venules (Knecht et al, 1981, Kabel et al, 
1989). Also the thymus of patients affected by autoimmune myasthenia gravis is 
characterized by the presence of ectopic lymphoid follicles with germinal centres containing 
activated B lymphocytes and plasma cells that produce autoantibodies (Soderstrom et al, 
1970, Leprince et al, 1990). SS is characterized by the presence of antigen-driven proliferation 
of B cells and lymphoid follicles with clonally expanded lymphocytes (Freimark et al, 1989, 
Stott et al, 1998). Similarly, there is an evidence for lymphoid neogenesis in the chronic 
synovial inflammation of patients with RA (Watson et al, 1994, Randen et al, 1995); B cell 
diversification, somatic hypermutation and plasma cells development occur in the synovial 
germinal centres (Schroder et al, 1996, Kim et al, 1999) and the homing chemokine CXCL13 
seems to be present in the synovial follicles of patients with RA (Hjelmstrom, 2001). 
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disease; marginal zone lymphoma and SLE and haemolytic anaemia; Hodgkin lymphoma 
(HL) and SLE. Additional analysis excluding data for up to 5 years before the diagnosis of 
malignancy have been also performed to exclude reverse causality, i.e., lymphoma causing 
autoimmune disorder. Another population based case-control study disclosed a solid 
association between NHL and SS and a small increase in NHL risk associated with SLE 
(Engels et al, 2005). While most epidemiologic studies demonstrated a consistent association 
between autoimmunity and NHL, there are only limited data on the risk of developing HL 
in these settings. A population-based case-control study during a 40-year period analyzed 
the association between 32 autoimmune disorders and risk of developing HL (Landgren et 
al, 2006), reporting a statistically significant increased risk to develop HL in patients with 
personal history of RA, SLE, sarcoidosis, or ITP. In addition, personal or family history of 
sarcoidosis and ulcerative colitis was associated with significantly increased risk of HL. 
3. Pathogenesis 
The aetiology of NHL remains largely unexplained, but some well-established risk factors 
have been identified. Under normal conditions, B and T lymphocytes respond to antigenic 
stimulation in a regulated manner and proliferative responses are self-limited. Immune 
dysregulation, leading to a continue lymphocyte proliferation, is considered to play a major 
role in lymphomagenesis, as demonstrated by an increased risk of lymphoma development 
in states of immunosuppression (i.e. following organ transplant or hereditary and acquired 
immunodeficiency syndromes). In addition, the occurrence of specific subtypes of NHL in  
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the context of infectious conditions suggests a pathogenic role also for inflammation and 
chronic immune stimulation. Autoimmune diseases have been considered a possible 
predisposing factor for lymphoma development as they are characterized by impairment of 
immune responses leading to a loss of tolerance to self-antigens, a deregulated lymphocyte 
reactivity with production of autoantibodies against specific tissues and organs. It is 
conceivable that a sustained antigen-driven B proliferation may increase the risk of adverse 
genetic events that may finally result in the emergence of a neoplastic clone. 
3.1 Immune dysregulation 
In the development of lymphoma at primary sites, such as MALT lymphomas arising in the 
parotid gland during the course of SS or in the thyroid gland in the case of chronic 
thyroiditis, and as T-cell lymphoma in small intestine of patients with celiac disease, a 
critical role is played by local chronic antigen-driven stimulation leading to the genesis of 
organized lymphoid tissue, the so called “tertiary“ lymphoid tissue, characterized by organ-
specific T- or B-cell proliferation, polyclonality and, eventually, oligo-monoclonality. 
3.1.1 Tertiary lymphoid tissue 
Chronic inflammatory infiltrates resembling the secondary lymphoid organs have been 
previously described as “tertiary lymphoid organs” (Picker, 1992) and can be induced by the 
same mediators of lymphoid ontogenesis, such as tumor necrosis factor (TNF)-beta and 
other members of the TNF family (Kratz et al, 1996), through induction of transcription 
factors, adhesion molecules, lymphoid-tissue-homing chemokines, and other cytokines 
(Hjelmstrom, 2001). The transcription factor named nuclear factor kappa-B (NF-κB) is 
induced by TNF proteins and is involved in lymphoid tissue development through 
chemokines, adhesion molecules and members of the TNF family themselves. TNF proteins 
are also required for the normal expression of CXCL13 and CCL21, two homing chemokines 
crucial for lymphoid neogenesis (Ngo et al, 1999). CXCR13 is normally produced by stromal 
cells in lymphoid tissues and attracts naive B cells and activated and memory T cells in vitro 
(Legler et al, 1998). CCL21 is a ligand for the CCR7 receptor that directs the migration of naive 
T cells and dendritic cells. Expression of CXCL13 and CCL21 has been found in disease models 
of chronic inflammation characterized by lymphoid neogenesis (Hjelmstrom, 2001). Chronic 
autoimmune diseases are characterized by a chronic inflammatory infiltrate in the target 
organs, with mononuclear cells and lymphoid follicles. The thyroid gland in patients affected 
by Hashimoto’s thyroiditis is organized in a structure that resembles a lymph node, including 
germinal centres, plasma cells and high endothelial venules (Knecht et al, 1981, Kabel et al, 
1989). Also the thymus of patients affected by autoimmune myasthenia gravis is 
characterized by the presence of ectopic lymphoid follicles with germinal centres containing 
activated B lymphocytes and plasma cells that produce autoantibodies (Soderstrom et al, 
1970, Leprince et al, 1990). SS is characterized by the presence of antigen-driven proliferation 
of B cells and lymphoid follicles with clonally expanded lymphocytes (Freimark et al, 1989, 
Stott et al, 1998). Similarly, there is an evidence for lymphoid neogenesis in the chronic 
synovial inflammation of patients with RA (Watson et al, 1994, Randen et al, 1995); B cell 
diversification, somatic hypermutation and plasma cells development occur in the synovial 
germinal centres (Schroder et al, 1996, Kim et al, 1999) and the homing chemokine CXCL13 
seems to be present in the synovial follicles of patients with RA (Hjelmstrom, 2001). 
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Expansion of B self-reactive lymphocytes is normally limited by several checkpoint 
mechanisms able to prevent the development of both autoimmunity and lymphoma. Both 
such diseases may be the result of a multistep process which ends up with the elimination of 
such aforementioned checkpoints. This multistep process regards both inherited and 
somatic mutations of genes involved in these pathways. For example, germinal and somatic 
mutations of Fas are associated with both autoimmune diseases and lymphoproliferative 
disorders, probably by inhibition of apoptosis. Somatic mutations occur physiologically in 
lymphocytes, during the course of somatic hypermutation of immunoglobulin genes in the 
germinal centre of lymphoid follicles of lymph nodes and spleen. VDJ recombination, 
isotype switching and somatic hypermutation, requiring double strand break and DNA 
rejoining, are susceptible to error and are known to activate oncogenes and inactivate tumour 
suppression mechanisms. Secondly, the epidemiological evidence of overlapping pathogenesis 
between autoimmunity and lymphoma may be explained by an enhanced lymphocyte 
proliferation resulting in increased rates of somatic mutations (Goodnow, 2007). Acquisition of 
distinct chromosomal translocations among reactive B cells, such as the t(11;18) in the course of 
Helicobacter pylori-positive chronic gastritis, is known to promote lymphomagenesis. 
Conversely, a similar risk was not found in other settings characterized by chronic immune 
responses, such as allergic diseases (Soderberg et al, 2006) or inflammatory bowel disease 
(Smedby et al, 2006).  
3.1.2 Triad autoimmunity-lymphoproliferation-lymphoma in Sjögren’s Syndrome 
Among all autoimmune diseases, SS better reflects the mechanism of the triad 
autoimmunity-lymphoproliferation-lymphoma. The underlying chronic inflammation, in 
fact, promotes the formation of organized lymphoid tissue, with a crucial role played by 
TNF-beta, characterized by the presence of high endothelial venules, dendritic cells and 
follicular dendritic cells, antigen-driven clonal proliferation of B cells, and lymphoid follicles 
with clonally expanded lymphocytes (Stott et al, 1998, Harris, 1999). The SS-associated 
chronic lymphoproliferation varies from benign to MALT-type lesions, MALT lymphomas, 
and even aggressive lymphomas (Burke, 1999). In fact, chronic antigen-driven polyclonal B-
cell activation in SS seems to support selection and expansion of auto-reactive B-cell clones 
through the processes of class switch recombination and somatic hypermutation (Stott et al, 
1998). Subsequent studies confirmed the selective accumulation of a B cell population 
characterized by a high rate of mutations in productively rearranged VL chain genes (Jacobi 
et al, 2002, Gellrich et al, 1999). The genetic instability associated with DNA hypermutation 
can favour the escape of malignant B cell clones with the consequent development of an 
overt B-cell lymphoma (Royer et al, 1997). The processes of class switch recombination and 
somatic hypermutation seem to critically depend on the enzyme activation-induced cytidine 
deaminase (AID). It has been shown (Bombardieri et al, 2007) that AID deaminase is 
expressed within follicular dendritic cell networks of the salivary gland of patients with SS, 
in a comparable way to that of secondary lymphoid organs, supporting the hypothesis that 
ectopic lymphoid tissue recapitulates the molecular setting necessary for local autoantibody 
production and B-cell expansion. The evolution of a non-malignant B-cell clone present in 
the parotid gland of a single patient with SS followed at multiple time points over a 7-year 
period to overt B-cell lymphoma has been documented (Gasparotto et al, 2003). In this case, 
lymphoma evolution occurred in a different site (lung) from that of the primary localization 
of B-cell proliferation (parotid gland), providing evidence that the pulmonary neoplastic 
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clone derived from the salivary gland clone, possibly through the acquisition of oncogenic 
alterations in cell regulatory genes able to confer a more aggressive phenotype.  
3.1.3 BAFF deregulation and apoptotic resistance 
Whether local antigen-driven stimulation and chronic inflammatory processes are important 
for the development of distant (typically nodal) NHL such as DLBCL is not yet known. 
Disease severity and inflammatory load are important determinants of NHL development in 
SS and RA (Theander et al, 2006, Baecklund et al, 2006a), with an increased risk of occurrence 
of DLBCL in these autoimmune disorders (Smedby et al, 2008), including factors related to 
cytokine profile, T cell subset balance and apoptotic resistance (Theander et al, 2006, Eguchi, 
2001). In RA and SLE, apoptotic resistance is increased and mediated by Bcl-2 expression, 
activation of NF-κB by inflammatory cytokines and growth factors, and abnormalities in the 
expression of B-cell activating factor (BAFF) (Eguchi, 2001, Mackay et al, 2005). BAFF is a 
critical regulator of B-cell homeostasis, and its excessive production causes multiple 
autoimmune symptoms in mice models and compromises apoptosis of autoreactive B cells. 
Deregulated BAFF expression has been described to lead to disease progression and 
perpetuation of humoral autoimmunity. Patients affected by systemic autoimmune diseases, 
such as SS, RA and SLE, have increased levels of BAFF in serum and synovial fluid with 
respect to healthy people. Moreover, serum levels of BAFF in SS correlate with the level of 
autoantibodies, and with rheumatoid factor in patients with RA. BAFF has been therefore 
proposed to play a major role in the development of SS and to contribute in the 
development of B-cell malignancies. In SS patients, the overexpression of BAFF can cause an 
excessive immunoglobulin production. In salivary glands of patients with SS, the reduced 
level of apoptosis among BAFF-expressing cells might lead to maintain signalling for tissue-
infiltrating B cells to proliferate and to become autoantibody-producing plasma cells, 
contributing to germinal centres formation and lymphoma development. Finally, mice 
carrying a BAFF transgene become highly susceptible to lymphoproliferation, autoimmunity 
and lymphoma development (Mackay et al, 1999). The possible pathogenetic role of BAFF in 
SS and lymphomagenesis has led to the development of agents neutralizing BAFF as a new 
therapeutic option for such patients (Szodoray & Jonsson, 2005). Belimumab, the fully human 
recombinant IgG monoclonal antibody to soluble B-lymphocyte stimulator human antibody 
(anti-Blys; LymphoStat-B) binds soluble BAFF and prevents interaction with its receptor 
(Baker et al, 2003). Encouraging results have been reported by  two large phase III randomized 
controlled trials of belimumab versus placebo in seropositive SLE patients with stable disease 
receiving standard of care treatment. The study showed that belimumab improved several 
markers of disease activity (in the central nervous system, vascular, musculoskeletal, 
immunologic and cutaneous) and promoted reduction of average steroid dose compared to 
placebo. Belimumab also determined significative changes in immunologic parameters, such 
as reduction of IgG and IgM and autoantibodies, increase in C3 and C4 levels, reduction of 
circulating CD20+ B cells (Thanou-Stavraki & Sawalha, 2011). In summary, a continuous 
antigen-driven stimulation in a microenvironment where normal regulatory mechanisms are 
absent may promote both autoimmunity and lymphoma development.  
3.2 Genetic factors 
Several studies explored the relationship between genetic factors and development of 
lymphoid malignancies in the different settings of autoimmunity. It has been suggested that 
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Expansion of B self-reactive lymphocytes is normally limited by several checkpoint 
mechanisms able to prevent the development of both autoimmunity and lymphoma. Both 
such diseases may be the result of a multistep process which ends up with the elimination of 
such aforementioned checkpoints. This multistep process regards both inherited and 
somatic mutations of genes involved in these pathways. For example, germinal and somatic 
mutations of Fas are associated with both autoimmune diseases and lymphoproliferative 
disorders, probably by inhibition of apoptosis. Somatic mutations occur physiologically in 
lymphocytes, during the course of somatic hypermutation of immunoglobulin genes in the 
germinal centre of lymphoid follicles of lymph nodes and spleen. VDJ recombination, 
isotype switching and somatic hypermutation, requiring double strand break and DNA 
rejoining, are susceptible to error and are known to activate oncogenes and inactivate tumour 
suppression mechanisms. Secondly, the epidemiological evidence of overlapping pathogenesis 
between autoimmunity and lymphoma may be explained by an enhanced lymphocyte 
proliferation resulting in increased rates of somatic mutations (Goodnow, 2007). Acquisition of 
distinct chromosomal translocations among reactive B cells, such as the t(11;18) in the course of 
Helicobacter pylori-positive chronic gastritis, is known to promote lymphomagenesis. 
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overt B-cell lymphoma (Royer et al, 1997). The processes of class switch recombination and 
somatic hypermutation seem to critically depend on the enzyme activation-induced cytidine 
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of B-cell proliferation (parotid gland), providing evidence that the pulmonary neoplastic 
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clone derived from the salivary gland clone, possibly through the acquisition of oncogenic 
alterations in cell regulatory genes able to confer a more aggressive phenotype.  
3.1.3 BAFF deregulation and apoptotic resistance 
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proposed to play a major role in the development of SS and to contribute in the 
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(anti-Blys; LymphoStat-B) binds soluble BAFF and prevents interaction with its receptor 
(Baker et al, 2003). Encouraging results have been reported by  two large phase III randomized 
controlled trials of belimumab versus placebo in seropositive SLE patients with stable disease 
receiving standard of care treatment. The study showed that belimumab improved several 
markers of disease activity (in the central nervous system, vascular, musculoskeletal, 
immunologic and cutaneous) and promoted reduction of average steroid dose compared to 
placebo. Belimumab also determined significative changes in immunologic parameters, such 
as reduction of IgG and IgM and autoantibodies, increase in C3 and C4 levels, reduction of 
circulating CD20+ B cells (Thanou-Stavraki & Sawalha, 2011). In summary, a continuous 
antigen-driven stimulation in a microenvironment where normal regulatory mechanisms are 
absent may promote both autoimmunity and lymphoma development.  
3.2 Genetic factors 
Several studies explored the relationship between genetic factors and development of 
lymphoid malignancies in the different settings of autoimmunity. It has been suggested that 
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some inherited mutations could be involved in pathogenesis of both diseases. For example, 
inherited mutations of the TNFSRF6 gene, which encodes the transmembrane protein Fas 
(CD59), a major mediator of lymphocyte apoptosis, lead to a genetic defect in apoptosis 
responsible of a familial syndrome called “autoimmune lymphoproliferative syndrome of 
childhood” (ALPS or Canale-Smith syndrome) characterized by chronic, non-malignant 
diffuse lymphadenopathy and hepatosplenomegaly together with hypergammaglobulinemia, 
autoantibodies and/or overt autoimmune diseases. These patients are at high risk of 
developing lymphomas, almost exclusively of the B-cell immunophenotype (HL, follicular, 
Burkitt and T-cell rich B-cell lymphoma) (Jackson & Puck, 1999) with an incidence of 13% (6 
out 46) among cases studied at the US National Institute of Health, with intervals from the 
onset of ALPS of 6-48 years (Mackay & Rose, 2001). However, previous population-based 
case control studies have failed to demonstrate that a family history of autoimmune disease 
is a risk factor for lymphoma development. A multicenter US study on 759 patients 
observed that a family history of dermatomyositis was associated with NHL, but not family 
history of 14 other autoimmune diseases (Engels et al, 2005). A statistically significant 
increase in risk of HL among patients with a family history of sarcoidosis or ulcerative 
colitis has been reported, but no association with a family history of other autoimmune 
conditions has been demonstrated (Landgren et al, 2006). Finally, an association between the 
risk of lymphoma development and a family history of a wide range of autoimmune 
diseases has not been detected in a population-based case-control study on 24,728 NHL 
patients (Mellemkjaer et al, 2008). Likewise, an increased risk of lymphoma occurrence 
among the first-degree relatives of RA patients has not been proven (Ekstrom et al, 2003). 
Therefore, studies evaluating whether genetic factors play a major role in lymphoma 
development have failed to prove  a consistent association in the context of most 
autoimmune diseases and available data about inherited mutations are still inconsistent. 
3.3 Therapeutic agents 
The role played by autoimmune disease therapy in the subsequent lymphoma development 
was extensively analyzed, although with inconclusive results. This seems to be due to a 
selection bias related to the fact that patients requiring therapy usually show a more 
aggressive disease. Thus, the comparison between treated and untreated patients may result 
in a falsely increased treatment-associated risk. Disease modifying anti-rheumatic drugs 
(DMARDs) such as methotrexate and azathioprine have been suggested to increase the 
relative risk of malignant lymphoma (Baecklund et al, 2006b, Bernatsky et al, 2008, Askling et 
al, 2009, Wolfe & Michaud, 2007). However, several large population-based studies failed to 
demonstrate an increased risk linked to methotrexate per se (Baecklund et al, 2006b, Mariette et 
al, 2002, Wolfe & Michaud, 2004). Corticosteroids, a mainstream of treatment of inflammatory 
diseases, have never been consistently associated with lymphoma development (Baecklund et 
al, 2006b). Studies about the relationship between nonsteroidal anti-inflammatory drugs 
(NSAID) and lymphoma are also inconsistent (Baecklund et al, 2006b, Sorensen et al, 2003). The 
only exception is constituted by 8 cases of hepatosplenic  T-cell lymphoma diagnosed among 
young patients treated with infliximab or adalimumab for inflammatory bowel disease. All 
patients were receiving concomitant immunosuppressive therapy with azathioprine or 
prednisone and it was not possible to ascertain if anti-TNF medication had an exclusive role in 
the pathogenesis of these lymphomas (Mackey et al, 2007). Conversely, although it has not 
been definitively demonstrated, postponing therapy could contribute to lymphoma 
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development; this could be due to a chronic worsening of the inflammatory 
microenvironment promoted by uncontrolled disease. In a population-based case-control 
study (Smedby et al, 2006), an increased risk of lymphoma occurrence was detected in 
patients with RA treated with NSAIDs, corticosteroids and other immunosuppressants but 
it was not confirmed in untreated patients. This may be related to the fact that the first 
cohort of patients had a more severe disease with higher levels of chronic inflammation that 
contributed to lymphoma development.  
3.3.1 NSAIDs and steroids 
Regular use of aspirin and NSAIDs has been hypothesized to be associated with reduced 
risk of development of colorectal cancer (RR= 0.5-0.8), and possibly of other cancers as 
stomach, breast, lung, pancreas, and ovary. Decreased cancer risk may be related to 
inhibition of prostaglandin synthesis, enhancement of cellular immune response or 
induction of apoptosis. RA patients, who frequently use long-lasting high doses of both 
aspirin and other NSAIDs, have a decreased risk of colorectal cancer and possibly female 
breast cancer (Beauparlant et al, 1999). Some prospective cohort and case-control studies 
analyzed the association between aspirin and non-aspirin NSAID use and risk of NHL with 
contradictory results. An inverse association was documented in a population-based case-
control study (OR=0.72; 95% CI= 0.56-0.91) (Holly et al, 1999) and a near significant 
association between regular use of aspirin and moderate decrease of NHL has also been 
reported in another hospital-based case-control study in men (OR= 0.82; 95% CI= 0.65-1.04), 
while women who used acetaminophen regularly experienced a 71% elevation in the risk of 
B-cell NHL (OR= 1.71; 95% CI 1.18-2.50) (Baker et al, 2005). A potential protective effect of 
analgesic use on NHL risk in women but not in men has also been reported (Beiderbeck et 
al, 2003). Conversely, a positive association between use of aspirin or acetaminophen and 
NHL has been observed among women, but not among men (RR=1.96; 95% CI=0.56-3.08) in 
a population-based study (Bernstein & Ross, 1992) and a suggestive positive association has 
also been reported in a prospective study cohort (RR=1.40; 95% CI= 0.99-1.97). This 
association was lost when aspirin was evaluated alone (Cerhan et al, 2003). Finally, no 
association between aspirin and other analgesics and lymphoma or leukaemia was observed 
in two other hospital-based case-control studies (Rosenberg et al, 1995, Cartwright et al, 
1988) and in a large study cohort (Sorensen et al, 2003). Although the exact reason of this 
gender discrepancies is unclear, a different response to pharmacologic agents could be 
referred to women’s lower body weight and high percentage of body fat or to endocrine 
milieu (Meibohm et al, 2002). In fact, clearance of both aspirin and acetaminophen positively 
correlates with body size and is faster in man rather than women (Miners et al, 1986) and 
some metabolizing enzymes are induced by hormones. Treatment with corticosteroids is 
one of the mainstreams of the management of systemic inflammatory diseases, because of 
their strong and fast anti-inflammatory effects. A linkage between corticosteroids and 
lymphoma risk was suspected in some studies (Bernstein & Ross, 1992, Kato et al, 2002, 
Zhang et al, 2004), whereas this association was excluded by others (Engels et al, 2005, 
Smedby et al, 2006, Beiderbeck et al, 2003, Chang et al, 2005). For example, a markedly 
reduced risk of lymphoma associated with steroid treatment has been observed in RA 
patients, also after adjustment for disease severity (Baecklund et al, 2006a). Also a case-
control study of 378 patients with RA-associated lymphoma demonstrated that treatment 
with oral steroids was associated with a 30% reduced risk of lymphoma (OR=0.69; 95% 
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some inherited mutations could be involved in pathogenesis of both diseases. For example, 
inherited mutations of the TNFSRF6 gene, which encodes the transmembrane protein Fas 
(CD59), a major mediator of lymphocyte apoptosis, lead to a genetic defect in apoptosis 
responsible of a familial syndrome called “autoimmune lymphoproliferative syndrome of 
childhood” (ALPS or Canale-Smith syndrome) characterized by chronic, non-malignant 
diffuse lymphadenopathy and hepatosplenomegaly together with hypergammaglobulinemia, 
autoantibodies and/or overt autoimmune diseases. These patients are at high risk of 
developing lymphomas, almost exclusively of the B-cell immunophenotype (HL, follicular, 
Burkitt and T-cell rich B-cell lymphoma) (Jackson & Puck, 1999) with an incidence of 13% (6 
out 46) among cases studied at the US National Institute of Health, with intervals from the 
onset of ALPS of 6-48 years (Mackay & Rose, 2001). However, previous population-based 
case control studies have failed to demonstrate that a family history of autoimmune disease 
is a risk factor for lymphoma development. A multicenter US study on 759 patients 
observed that a family history of dermatomyositis was associated with NHL, but not family 
history of 14 other autoimmune diseases (Engels et al, 2005). A statistically significant 
increase in risk of HL among patients with a family history of sarcoidosis or ulcerative 
colitis has been reported, but no association with a family history of other autoimmune 
conditions has been demonstrated (Landgren et al, 2006). Finally, an association between the 
risk of lymphoma development and a family history of a wide range of autoimmune 
diseases has not been detected in a population-based case-control study on 24,728 NHL 
patients (Mellemkjaer et al, 2008). Likewise, an increased risk of lymphoma occurrence 
among the first-degree relatives of RA patients has not been proven (Ekstrom et al, 2003). 
Therefore, studies evaluating whether genetic factors play a major role in lymphoma 
development have failed to prove  a consistent association in the context of most 
autoimmune diseases and available data about inherited mutations are still inconsistent. 
3.3 Therapeutic agents 
The role played by autoimmune disease therapy in the subsequent lymphoma development 
was extensively analyzed, although with inconclusive results. This seems to be due to a 
selection bias related to the fact that patients requiring therapy usually show a more 
aggressive disease. Thus, the comparison between treated and untreated patients may result 
in a falsely increased treatment-associated risk. Disease modifying anti-rheumatic drugs 
(DMARDs) such as methotrexate and azathioprine have been suggested to increase the 
relative risk of malignant lymphoma (Baecklund et al, 2006b, Bernatsky et al, 2008, Askling et 
al, 2009, Wolfe & Michaud, 2007). However, several large population-based studies failed to 
demonstrate an increased risk linked to methotrexate per se (Baecklund et al, 2006b, Mariette et 
al, 2002, Wolfe & Michaud, 2004). Corticosteroids, a mainstream of treatment of inflammatory 
diseases, have never been consistently associated with lymphoma development (Baecklund et 
al, 2006b). Studies about the relationship between nonsteroidal anti-inflammatory drugs 
(NSAID) and lymphoma are also inconsistent (Baecklund et al, 2006b, Sorensen et al, 2003). The 
only exception is constituted by 8 cases of hepatosplenic  T-cell lymphoma diagnosed among 
young patients treated with infliximab or adalimumab for inflammatory bowel disease. All 
patients were receiving concomitant immunosuppressive therapy with azathioprine or 
prednisone and it was not possible to ascertain if anti-TNF medication had an exclusive role in 
the pathogenesis of these lymphomas (Mackey et al, 2007). Conversely, although it has not 
been definitively demonstrated, postponing therapy could contribute to lymphoma 
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development; this could be due to a chronic worsening of the inflammatory 
microenvironment promoted by uncontrolled disease. In a population-based case-control 
study (Smedby et al, 2006), an increased risk of lymphoma occurrence was detected in 
patients with RA treated with NSAIDs, corticosteroids and other immunosuppressants but 
it was not confirmed in untreated patients. This may be related to the fact that the first 
cohort of patients had a more severe disease with higher levels of chronic inflammation that 
contributed to lymphoma development.  
3.3.1 NSAIDs and steroids 
Regular use of aspirin and NSAIDs has been hypothesized to be associated with reduced 
risk of development of colorectal cancer (RR= 0.5-0.8), and possibly of other cancers as 
stomach, breast, lung, pancreas, and ovary. Decreased cancer risk may be related to 
inhibition of prostaglandin synthesis, enhancement of cellular immune response or 
induction of apoptosis. RA patients, who frequently use long-lasting high doses of both 
aspirin and other NSAIDs, have a decreased risk of colorectal cancer and possibly female 
breast cancer (Beauparlant et al, 1999). Some prospective cohort and case-control studies 
analyzed the association between aspirin and non-aspirin NSAID use and risk of NHL with 
contradictory results. An inverse association was documented in a population-based case-
control study (OR=0.72; 95% CI= 0.56-0.91) (Holly et al, 1999) and a near significant 
association between regular use of aspirin and moderate decrease of NHL has also been 
reported in another hospital-based case-control study in men (OR= 0.82; 95% CI= 0.65-1.04), 
while women who used acetaminophen regularly experienced a 71% elevation in the risk of 
B-cell NHL (OR= 1.71; 95% CI 1.18-2.50) (Baker et al, 2005). A potential protective effect of 
analgesic use on NHL risk in women but not in men has also been reported (Beiderbeck et 
al, 2003). Conversely, a positive association between use of aspirin or acetaminophen and 
NHL has been observed among women, but not among men (RR=1.96; 95% CI=0.56-3.08) in 
a population-based study (Bernstein & Ross, 1992) and a suggestive positive association has 
also been reported in a prospective study cohort (RR=1.40; 95% CI= 0.99-1.97). This 
association was lost when aspirin was evaluated alone (Cerhan et al, 2003). Finally, no 
association between aspirin and other analgesics and lymphoma or leukaemia was observed 
in two other hospital-based case-control studies (Rosenberg et al, 1995, Cartwright et al, 
1988) and in a large study cohort (Sorensen et al, 2003). Although the exact reason of this 
gender discrepancies is unclear, a different response to pharmacologic agents could be 
referred to women’s lower body weight and high percentage of body fat or to endocrine 
milieu (Meibohm et al, 2002). In fact, clearance of both aspirin and acetaminophen positively 
correlates with body size and is faster in man rather than women (Miners et al, 1986) and 
some metabolizing enzymes are induced by hormones. Treatment with corticosteroids is 
one of the mainstreams of the management of systemic inflammatory diseases, because of 
their strong and fast anti-inflammatory effects. A linkage between corticosteroids and 
lymphoma risk was suspected in some studies (Bernstein & Ross, 1992, Kato et al, 2002, 
Zhang et al, 2004), whereas this association was excluded by others (Engels et al, 2005, 
Smedby et al, 2006, Beiderbeck et al, 2003, Chang et al, 2005). For example, a markedly 
reduced risk of lymphoma associated with steroid treatment has been observed in RA 
patients, also after adjustment for disease severity (Baecklund et al, 2006a). Also a case-
control study of 378 patients with RA-associated lymphoma demonstrated that treatment 
with oral steroids was associated with a 30% reduced risk of lymphoma (OR=0.69; 95% 
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CI=0.51-0.94); this feature remained also after adjustment for DMARDs treatment, disease 
activity and use of intra-articular steroids. Moreover, treatment up to 2 years showed no 
protective effect, while a treatment of more than 2 years was associated with a markedly 
reduced risk. Analysis by lymphoma subtype showed the strongest association between oral 
steroids and DLBCL (Hellgren et al, 2010b). The reduced lymphoma risk associated with 
steroid therapy might be explained by a reduced inflammatory activity induced by these 
drugs. Conversely, a meta-analysis of case-control and cohort studies reported between 1992 
and 2006 failed to prove an increased risk of lymphoma development over the last decades 
during which there has been an increased use of immunomodulatory drugs such as 
corticosteroids and NSAID, disproving thus any possible link between therapy and cancer 
(Bernatsky et al, 2007).  
3.3.2 Anti-TNF agents 
The use of biologic drugs as antagonists of TNF has been extensively evaluated for safety 
profile both in randomized (Bongartz et al, 2006, Leombruno et al, 2009) and observational 
studies (Wolfe & Michaud, 2007, Setoguchi et al, 2006, Askling et al, 2005). TNF plays an 
important role in tumour growth control and host defence, and biologic therapy targeting 
TNF determines an important immunomodulation, raising thus the concern of a possible 
increased risk of malignancies in patients treated with anti-TNF antibodies. Regarding 
short-term cancer risk, meta-analysis of clinical trials suggested an increased risk of cancer 
development (Bongartz et al, 2006, Leombruno et al, 2009, Bongartz et al, 2009), but 
observational studies did not confirm these results. Randomized controlled trials provide 
balanced groups for analysis and a well-selected study population but, on the other hand, 
considering that the time interval from the onset of cancer until its clinical manifestation is 
counted in years and not in months, any long-term effect of therapy cannot be correctly 
estimated using data from clinical trials. In addition, the overall number of cancers in these 
trials is modest, particularly in the control arm. In a review of data from the MedWatch 
post-market adverse event surveillance system of FDA, 26 cases of spontaneous 
lymphoproliferative disorders following treatment with etanercept or infliximab have been 
reported, with an estimated incidence of 19.9 per 10.000 person-year for etanercept and 6.6 
per 100.000 person-year for infliximab (Brown et al, 2002). These concerns were confirmed 
also by a meta-analysis of cancer risk in patients affected by RA treated with infliximab or 
adalimumab in randomized controlled trials, excluding patients treated with etanercept 
(Bongartz et al, 2006), which reported a pooled odds ratio for malignancy in the TNF treated 
vs. untreated patients of 3.3 (95% CI 1.2-9.1) in a dose-dependent manner. However, 
included trials were heterogeneous in terms of disease activity, disease duration and 
previous or concomitant DMARD treatment and usually lasted between 3 months and 1 
year, a relatively short interval for estimating cancer incidence. A subsequent update of this 
meta-analysis with additional data reported an odds ratio of 2.02 (Costenbader et al, 2006). 
Conversely, these results were not confirmed by another meta-analysis assessing 18 
randomized controlled trials for a total of 8.808 RA patients (Leombruno et al, 2009). 
Observational studies provide a major number of patients and longer follow-up, but they 
have also some limitations.  The first one is the non-random assignment to treatment, 
patients with more severe arthritis being more likely treated, and so that outcome could be 
related to severity of disease rather than treatment. Other limitations may be due to less 
selected study subjects and introduced bias such as age, sex, smoking history, disease 
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activity and baseline use of corticosteroids. Another bias could be introduced by physician’s 
decision not to prescribe anti-TNF treatment to a patient with a history of malignancies. 
Finally, last reason for the divergence between data from trials and from observational 
studies is the control chosen in the latter. In fact, patients newly starting therapy with anti-
TNF should be compared with patients newly starting therapy with other agents for the 
same disease (Ray, 2003). In Sweden, patients treated with anti-TNF drugs were included in 
a regional register since the introduction of etanercept and infliximab in 1999 (Geborek et al, 
2002). A study comparing 757 patients treated with etanercept or infliximab from 1999 to 
2002 with 800 patients who received conventional therapy showed no increased risk in solid 
tumors in anti-TNF treated patients, but, interestingly, five cases of lymphoma were 
identified among these patients (1.603 person-year), and, compared with conventional-
therapy cohort, the relative risk of lymphoma in patients treated with anti-TNF agents was 
4.9 (95% CI 0.9-26.2) (Geborek et al, 2005). Lymphoma incidence from follow–up of 18.572 
American RA patients compared with general population allowed to detect 29 cases of 
lymphoma, with an overall relative risk for lymphoma of 1.9 in patients with RA not treated 
with TNF antagonists and tripled (2.9) in patients receiving treatment with TNF antagonists; 
2.6 in those receiving infliximab with or without etanercept; and 3.8 in those receiving 
etanercept with or without infliximab (Wolfe & Michaud, 2004). The increased risk in the 
TNF antagonist treated group might be due to the fact that patients with the highest risk of 
lymphoma received TNF antagonists. Consequently, the authors were unable to conclude 
whether the increased standardized rate ratios were related to RA or truly associated with 
the drugs. Additionally, this study was not adjusted for patient characteristics other than 
age and sex. Analysis of cancer risk in TNF antagonists users using a Swedish registry of 
anti-TNF treated patients and community-based RA patients detected five cases of 
lymphoma per 1.603 person-year in the treated group and two cases per 3.948 person-year 
in the comparison group (Franklin et al, 2005). The adjusted hazard ratio for lymphoma was 
4.9 in anti-TNF treated group, suggesting a large increase in risk. Again, RA severity in 
patients never treated with anti-TNF agents may be minor. The comparison between a 
cohort of 4.160 RA patients treated with anti-TNF agents with 53.067 patients with untreated 
RA, showed that patients with RA are at increased risk of lymphomas in line with previous 
estimations, and using these expected RA rates as reference, that patients treated with TNF 
antagonists were not at any additional increased lymphoma risk compared with untreated 
patients (Askling et al, 2005). A cohort study using patients with RA treated with 
methotrexate (MTX) as a control group did not show any significant increase in the risk of 
cancer in biologic DMARDS users. This particular control group has been chosen because of 
similar disease severity between patients treated with these two strategies, and investigators 
have concluded that it is unlikely that RA patients who have received biologic agents have a 
greater risk of lymphoproliferative disorders compared with those treated with MTX 
(Setoguchi et al, 2006). A single observational study has reported relative risk for cancer 
occurrence per single anti-TNF agent (infliximab, etanercept, adalimumab), finding a 
positive association between biologic therapy and skin cancers, but not with other 
malignancies, with a median time of exposure of 3.0 years, for any of the three agents 
separately. However, patients were not followed-up from the start of anti-TNF therapy and 
so any assessment of risk per time since treatment start was not carried out (Wolfe & 
Michaud, 2007). Finally, the largest population-based study with the longest observation 
period investigating cancer risks associated with anti-TNF therapy in RA patients has failed 
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CI=0.51-0.94); this feature remained also after adjustment for DMARDs treatment, disease 
activity and use of intra-articular steroids. Moreover, treatment up to 2 years showed no 
protective effect, while a treatment of more than 2 years was associated with a markedly 
reduced risk. Analysis by lymphoma subtype showed the strongest association between oral 
steroids and DLBCL (Hellgren et al, 2010b). The reduced lymphoma risk associated with 
steroid therapy might be explained by a reduced inflammatory activity induced by these 
drugs. Conversely, a meta-analysis of case-control and cohort studies reported between 1992 
and 2006 failed to prove an increased risk of lymphoma development over the last decades 
during which there has been an increased use of immunomodulatory drugs such as 
corticosteroids and NSAID, disproving thus any possible link between therapy and cancer 
(Bernatsky et al, 2007).  
3.3.2 Anti-TNF agents 
The use of biologic drugs as antagonists of TNF has been extensively evaluated for safety 
profile both in randomized (Bongartz et al, 2006, Leombruno et al, 2009) and observational 
studies (Wolfe & Michaud, 2007, Setoguchi et al, 2006, Askling et al, 2005). TNF plays an 
important role in tumour growth control and host defence, and biologic therapy targeting 
TNF determines an important immunomodulation, raising thus the concern of a possible 
increased risk of malignancies in patients treated with anti-TNF antibodies. Regarding 
short-term cancer risk, meta-analysis of clinical trials suggested an increased risk of cancer 
development (Bongartz et al, 2006, Leombruno et al, 2009, Bongartz et al, 2009), but 
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activity and baseline use of corticosteroids. Another bias could be introduced by physician’s 
decision not to prescribe anti-TNF treatment to a patient with a history of malignancies. 
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to prove an overall increase of risk during the first 6 years after treatment start and during 
follow-up time. In fact patients treated with anti-TNF drugs had the same cancer risk of 
naïve patients and of those starting MTX or DMARDs combination therapy. Incidence or 
relative risk of cancer does not increase with time nor with duration of active therapy 
(Askling et al, 2009). 
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(HR) 0.51-2.37 - - - - - - 
Wolfe, 2007 1.7 




(OR) 0.52-3.06 - - - - - - 
Table 2. Lymphoma risk and anti-TNF agents 
3.3.3 Methotrexate 
Methotrexate (MTX) is a widely used DMARD in the context of autoimmune diseases. RA 
patients treated with MTX may develop a lymphoproliferative disorder (LPD) resembling 
lymphomas occurring in immunosuppressed patients (Ellman et al, 1991, Kingsmore et al, 
1992, Liote et al, 1995). LPD develops in RA patients at a frequency 2.0-5-fold higher than in 
general population. MTX-LPD is classified along with other iatrogenic immunodeficiency-
related LPDs by WHO classification (Swerdlow et al, 2008) and, among these, DLBCL 
accounts for about 50% of cases, with frequent extranodal involvement and HL for 10-20% 
of cases. MTX-LPD and non-MTX-LPD seem to share similar clinical findings in RA 
patients, such as sex, age, primary site, stage and outcome (5-year OS: 59% vs. 53%) 
(Hoshida et al, 2007). Conversely, other papers did not confirm increased incidence of 
lymphoma in MTX-treated RA patients, even after long-term follow-up (Moder et al, 1995, 
Bologna et al, 1997, Kremer, 1997, Weinblatt et al, 1998). In a prospective series of 18.572 RA 
patients, treatment with MTX alone has not been associated with an increased standardized 
incidence ratio for lymphoma with respect to untreated patients (1.7 vs 1.0) (Wolfe & 
Michaud, 2004). These results confirmed those reported in a 3-year national prospective 
study on French RA patients treated with MTX. Investigators have found no increase in 
lymphoma risk among treated patients compared with French general population. However, 
in the latter study, authors did not even find an increased lymphoma risk in RA patients 
overall compared to general population (Mariette et al, 2002). There are some case reports of 
lymphoma regression after MTX discontinuation in patients treated for autoimmune diseases 
(Liote et al, 1995, Kamel et al, 1993, Salloum et al, 1996). Complete remission occurred generally 
within 4 weeks after discontinuation of MTX and appeared to persist over a median follow-up 
of 15 months (4-60). On the other hand, partial remission occurred in a time interval longer 
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than four weeks, often about 2-3 months later (Rizzi et al, 2009). Regression of LPD after MTX 
discontinuation can be considered an evidence of the carcinogenic potential of MTX. This drug 
in fact is capable to directly induce reactivation of Epstein-Barr virus (EBV) infection with 
release of virions (Feng et al, 2004). An immunodeficient state provides the conditions for the 
development of lymphoma possibly through the activation of the oncogenic EBV. The EBV 
positive rate among patients affected by autoimmune disease and lymphoma is about 30% 
(Hoshida et al, 2007, Kamel et al, 1993). Moreover, patients affected by RA have an elevated 
number of EBV-infected circulating B lymphocytes and a major T-cell defect in EBV-specific 
suppression (Tosato et al, 1984). Taken together, the oncogenic role of EBV, the impaired 
immune response of RA patients to EBV and the additional immunosuppressive effect of MTX 
may account for EBV-positive lymphoma development in a small number of RA patients 
treated with MTX (Baecklund et al, 1998). The monoclonal antibody rituximab is currently 
used for the treatment of LPD after allogeneic transplantation. There are still few reports 
about its use for MTX-LPDs and more studies are warranted to elucidate its potential 
therapeutic role in this context. 
4. Autoimmune entities 
 
 Most frequent subtype Risk factors 
Rheumatoid arthritis Diffuse large B- cell 
lymphoma 
High inflammatory activity 
Male gender 
Sjögren syndrome MALT lymphoma Low serum immunoglobulins levels 
High serum β2 microglobulin level 
Disappearance of a positive 
rheumatoid factor 
Hypocomplementemia 
Low CD4 levels 




Diffuse large B- cell 
lymphoma 
Autoimmune haemolytic anaemia  
Leukopenia 
Chronic thrombocytopenia 
Salivary gland swellings 
Pulmonary infiltrates and/or 
recurrent pneumonia 
Hashimoto’s thyroiditis MALT lymphoma and 
diffuse large B-cell 
lymphoma 
- 
Systemic sclerosis B-cell lymphomas - 
Celiac disease Entheropathy-type T-
cell lymphoma 
Inadequate gluten-free diet 
Dermatitis herpetiformis Entheropathy-type T-
cell lymphoma 
Inadequate gluten-free diet 
Table 3. Most frequent histologic subtypes associated with singular autoimmune entities 
and known risk factors 
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4.1 Rheumatoid arthritis 
RA is a multisystem chronic autoimmune disorder affecting joint and almost any organ 
system, with inflammatory nodules formation, interstitial lung disease and leukocytoclastic 
vasculitis (Turesson & Matteson, 2004). Several studies have demonstrated that patients 
with RA have a 2-fold increased risk of developing lymphoma (Ekstrom et al, 2003, Franklin 
et al, 2006) and a link between disease severity and lymphoma risk exist (Smedby et al, 2006, 
Baecklund et al, 2006a). A nested case-control study performed to determine factors 
predisposing to lymphoma development in RA patients demonstrated that a high 
inflammatory activity is the greater risk factor with a an odds ratio of 25.8 compared with 
low inflammatory activity (Baecklund et al, 1998). Furthermore, a study on Felty syndrome, 
a complication of severe RA, reported a 13-fold relative risk for lymphoma compared with 
that of general population (Gridley et al, 1994). Men affected by RA display a higher 
standardized incidence ratio for the development of NHL and HL than female (Gridley et al, 
1993). Finally, a personal history of lymphoma in the years preceding diagnosis of 
autoimmune disease is not more common in patients affected by RA than expected in 
general population, while the increased risk of lymphoma development occurs in the first 10 
years from RA diagnosis. This proves that shared susceptibility or common risk factors are 
not the major explanation for this increased risk, but it indicates a critical link between the 
RA disease or its therapy and the subsequent lymphoma development (Hellgren et al, 
2010a). Interestingly, the reported relative risk rates remained relatively constant over time 
despite therapeutic changes occurred in RA.  
4.1.1 Pathogenesis  
The increased risk of lymphoma development in RA patients may arise from the interaction 
of multiple factors: activation of autoimmune B lymphocytes, chronic inflammation, poor 
EBV control and immunosuppressive therapy (Balandraud et al, 2005). It has been 
hypothesized that a constant immune stimulation of B cells by auto-antigens may result in 
both synovitis and lymphocyte activation, finally leading to malignant transformation 
(Symmons, 1985). Evidence of a B-cell activation is derived from the finding of increased 
levels of B cell activating factors in RA patients, such as BLy and APRIL, which are 
produced in the synovial lesions and can drive B cell expansion (Mackay et al, 2005, Seyler et 
al, 2005). Moreover, several studies have also reported oligoclonal B cell expansion both in 
the synovium and in the peripheral blood of RA patients (Berek & Kim, 1997). Whether the 
increased risk is entirely a consequence of the disease and/or of its treatment is not yet fully 
ascertained. Patients with RA may lack immunocompetence, being more susceptible to 
lymphoma development, or immunosuppressive treatment may concur to weaken the 
patient’s immune response. Therefore, lymphoma in RA could be due to a too strong or 
insufficient immunosuppressive therapy (Weyand et al, 2006). A matched case-control study 
on 378 consecutive Swedish RA patients in whom lymphoma occurred between 1964 and 
1995 and 378 healthy controls showed that 48% of lymphoma cases were DLBCLs, and, 
within those, EBV infection was detected in 12% of lymphomas. Approximately half of the 
patients had received corticosteroids; 44% had received intra-articular injection of steroids; 
over 70% of patients had been treated with DMARDs, most frequently antimalarial agents; a 
few patients had received azathioprine (6%) or MTX (6%) and none had received anti-TNF 
therapy. An increased lymphoma risk was found only in the azathioprine-treated group, 
while oral steroids proved to reduce this risk (OR 0.6), especially the intra-articular steroid 
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treatment (OR 0.2). Patients affected both by RA and lymphoma had received similar 
treatment than those without lymphoma (Baecklund et al, 2006a). In a Japanese cohort of RA 
patients not treated with immunosuppressive drugs, DLBCL was again the most frequently 
detected histotype and EBV was present in 30% of cases. Four cases were HL, all of them 
EBV positive (Hoshida et al, 2004). The increased risk of NHL development could be 
referred to the impaired capacity of RA patients to control infection of EBV (Balandraud et 
al, 2005). EBV is an oncogenic herpes virus involved in the pathogenesis of several 
lymphomas in the context of states of immunodeficiency (Young & Rickinson, 2004, 
Ambinder, 2003). EBV is not usually found in DLBCL of immunocompetent patients 
(Ambinder, 2003). EBV-related lymphomagenesis is characteristic in the setting of organ or 
bone marrow transplantation and congenital or acquired immunodeficiency disorders 
(Loren et al, 2003). Patients affected by RA have an impaired immune response to EBV. High 
serum titre of anti-EBV specific antibodies have been detected in some RA patients 
(Alspaugh et al, 1981), EBV-specific CD8+ T cells have been found in synovial fluid (Tan et 
al, 2000) and EBV DNA was isolated from the joints of RA patients (Edinger et al, 1999). An 
impaired control of the outgrowth of EBV infected cells in vitro was also observed (Tosato et 
al, 1981). This hypothesis is also supported by studies of EBV load in RA patients. In fact an 
increase in shedding of EBV in saliva and in the proportion of EBV-infected circulating B 
cells in RA patients has been shown (Tosato et al, 1984, Yao et al, 1986). The mean EBV load 
in peripheral blood of RA patients is more than 8-fold greater than in normal healthy 
control, similarly to what occurs in transplant recipients (Balandraud et al, 2003). 
Nonetheless, the overall incidence of EBV positivity in NHL reported in previous cohorts is 
24% (Baecklund et al, 2006a, Mariette et al, 2002), too low to entirely justify the increased 
incidence of lymphomas among these patients. 
4.1.2 Lymphoma subtypes 
DLBCL is the most common lymphoma subtype in RA patients, with a prevalence of 48%-
67% among all NHL (Mariette et al, 2002, Baecklund et al, 2003), a slightly higher incidence 
with respect to the general population of western countries, where DLCBL represents the 
30-40% of all NHL. DLBCLs can be further subdivided into germinal centre-like (GC) and 
activated B cell-like subtypes by gene expression profiling, characterized by a different 
cellular origin and a different prognosis. The majority of RA patients develops a DLBCL of 
non GC subtype, particular those with a severe and longstanding disease. These lymphomas 
are characterized by advanced stage at diagnosis, rapid progression and a worse prognosis 
(5-year OS: 16% vs. 33% for the GC subtypes). In those patients presenting a severe disease 
and a continuous immune stimulation, the proliferative drive might determine an increased 
risk of genetic aberrations, particularly in the peripheral activated B cells, the expansion of 
an uncontrolled peripheral B cell clone and therefore the development of a non-GC DLBCL. 
Otherwise, alternative pathways are also probably involved in lymphomagenesis, since only 
a minor proportion of DLBCL are of GC subtype (30%) and other lymphoma subtypes have 
also been reported in RA patients (Baecklund et al, 2006a). The human germinal-centre 
associated lymphoma protein (HGAL) is a marker of GC B cell derivation, expressed in the 
cytoplasm of GC lymphocytes and in lymphomas of GC derivation (Lossos et al, 2003, 
Natkunam et al, 2005), which inhibits cell migration in normal GC cells and lymphoma cells 
(Lu et al, 2007). HGAL immunoreactivity has been found in 38 (34%) of 111 RA-DLBCLs 
(Baecklund et al, 2006b), a lower proportion than that reported in DLBCL in general (68%) 
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(Natkunam et al, 2005), but not surprising giving the fact that the majority of RA-DLBCLs 
are of the non-GC type. HGAL expression has been associated with a limited-stage disease 
and better survival. The expression of HGAL as a GC marker may thus been associated with 
a better clinical course in RA-DLBCLs.  
4.2 Sjögren Syndrome 
SS is a chronic systemic autoimmune disease clinically characterized by dry mouth 
(xerostomia) and dry eyes (keratoconjunctivite sicca) (Kassan & Moutsopoulos, 2004). It is 
distinguished by a lymphoproliferative sialadenitis (LESA) with lymphocyte infiltration of 
salivary ducts, ductal epithelial cell proliferation and apoptosis (Daniels, 1984). This 
disorder can occur either alone, known as primary SS, or in the context of other systemic 
autoimmune disorders, such as RA, systemic sclerosis, SLE, which is known as secondary 
SS. Compared with the general population, an increased risk of developing NHL during the 
course of such disease was reported (Kassan et al, 1978, Ioannidis et al, 2002). Patients 
affected by SS, in fact, have an increased relative risk of 28 fold to develop extranodal MALT 
lymphoma (MZL) of the salivary gland and a 11-fold increased risk of developing a DLBCL 
arising de novo or by transformation of a previous indolent lymphoma (Smedby et al, 2006). 
Relative risk to develop a lymphoma is 8.7 for patients with primary SS form and 4.5 for 
patients with a secondary SS (Kauppi et al, 1997). NHL is the major complication during the 
course of the disease, with a prevalence of 4.3% (Voulgarelis et al, 1999). The high risk of 
lymphoma development suggests that it originates locally as a consequence of chronic 
lymphocyte activation due to the autoimmune setting.  
4.2.1 Pathogenesis 
Lymphocytes have a central role in the pathogenesis of both SS and lymphoma, but whether 
T or B lymphocytes play the leading role is controversial. From one side, biopsies of salivary 
and lachrymal glands are characterized by a mixed infiltrate of predominant CD4 and CD8 
T cells, showing restriction of TCR usage (Adamson et al, 1983). On the other side, primary 
SS is characterized by increased monoclonal Ig and by the development of lymphomas of B-
cell type. A B-cell mediated autoimmune response occurs in the salivary glands. A wide 
variety of nuclear auto-antigens are immune targets in SS patients. Anti-nuclear antibody as 
anti-SSA/Ro and anti-SSB/La are detectable in 70-85% of patients (Jonsson et al, 2003). The 
cause of B-cell hyperactivity in primary SS is not known. Exocrine glands of SS patients 
show an accumulation of B cells clustering in benign polyclonal aggregates (Brandtzaeg & 
Johansen, 2005), harbouring mutated IgVH genes and therefore being GC, marginal zone or 
memory B cells. Successively, an evolution from benign to malignant B lymphoproliferation 
has been described in the course of primary SS, but not of secondary (Anderson & Talal, 
1972). Initial benign polyclonal clusters of B-cells enlarge to organize lymphoid follicle-like 
structures with germinal centres (GCs), in which plasma cells differentiate. The role of local 
antigens is crucial for the development of these extralymphoid GCs (Youinou et al, 2010). 
The evolution from a benign B-cell aggregate to a malignant lymphoma may be therefore 
the consequence of the autoimmune response through the selection and expansion of a 
monoclonal B-cell clone (Friedman et al, 1991). Mutations of p53 are also involved in 
lymphoma development in these patients (Tapinos et al, 1999). Approximately 20% of SS 
patients exhibits monoclonal Igs in the serum and urine and mixed monoclonal 
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cryoglobulinemia (MMC) with an IgMk monoclonal rheumatoid factor (RF) component 
(Youinou et al, 1988, Tzioufas et al, 1986). Monoclonality therefore correlates with the 
transition from the autoimmune state to NHL. Various studies on clonality have 
demonstrated that SS patients with the same and persistent monoclonal B-cell expansion in 
follow-up biopsies are at higher risk of lymphoma developing. MALT lymphoma cells are 
found only in glands for years and a subsequent spread outside the salivary may involve the 
lymph nodes and other extranodal organs (Royer et al, 1997). 
4.2.2 Clinical characteristics 
The development of a malignant lymphoproliferation occurs only in a subset of SS patients 
and is characterized by the emergence of clinical and serologic parameters in the initial 
phases of disease, the monitoring of which is important for early detection of malignancy 
and timely therapeutic intervention (Tzioufas et al, 1986, Moutsopoulos et al, 1983). Usually, 
median age at lymphoma diagnosis is 58 years, and the median time from SS diagnosis is 7.5 
years (Voulgarelis et al, 1999). MZL is the most common histologic subtype, but also 
follicular lymphoma, lymphoplasmacytoid lymphoma and DLBCL have been reported 
(Kassan et al, 1978, Valesini et al, 1997, Mariette, 1999). MZL in SS patients is generally 
localized at diagnosis (stage I and II) and is characterized by a small tumour burden, good 
performance status and normal lactate dehydrogenase serum levels. The salivary glands are 
the most commonly involved organs, with parotid gland enlargement being the main 
presenting symptom, but near 20% of these lymphomas involve other extra-nodal sites, such 
as stomach, nasopharynx, skin, liver, kidney, and lung, justifying indeed the importance of a 
complete staging at diagnosis. Bone marrow involvement is rare (10% of cases) and B 
symptoms are uncommon. Other clinical manifestations are skin vasculitis, peripheral nerve 
and renal involvement, anemia, lymphopenia, monoclonal immunoglobulins and mixed 
monoclonal cryoglobulinemia (MMC) (Voulgarelis et al, 1999). Indolent lymphomas arisen 
in SS patients experience high-grade transformation, mostly in DLBCLs, in about 10% of 
cases. This evolution is characterized by nodal and extra-nodal dissemination and a 
unfavourable prognosis, with a median overall survival shorter than two years (Voulgarelis 
et al, 1999). It has been proven by immunohistochemical and genotypic studies that such 
DLBCLs arise from the same clone as indolent lymphomas, as a consequence of genetic 
alterations such as p53 allelic loss or mutation, hypermethylation of p15 and p16 genes, 
deletion of p16 gene (Du et al, 1996, Neumeister et al, 1997). 
4.2.3 Risk factors 
Some risk factors for lymphoma development have been identified in SS patients. 
Lymphoma risk seems to increase with disease severity, expressed by decreased levels of 
serum immunoglobulins, high serum β2-microglobulin levels  and disappearance of a 
previous positive rheumatoid factor (FR) (Anderson & Talal, 1972, Anaya et al, 1996); 
parotid gland enlargement, splenomegaly, lymphadenopathy (Kassan et al, 1978); low C4 
levels and palpable purpura (Ioannidis et al, 2002, Skopouli et al, 2000); MMC (Tzioufas et al, 
1996). A higher relative risk of developing lymphoproliferative disorders in patients with an 
early onset of disease has been suggested, with a significant and independent association 
between lymphoma development and low C4 levels (Ramos-Casals et al, 2005). An adverse 
prognostic value of low levels of C3 (Theander et al, 2004), vasculitis, severe involvement in 
parotid scintigraphy, hypocomplementaemia and/or cryoglobulins at diagnosis (Brito-
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(Natkunam et al, 2005), but not surprising giving the fact that the majority of RA-DLBCLs 
are of the non-GC type. HGAL expression has been associated with a limited-stage disease 
and better survival. The expression of HGAL as a GC marker may thus been associated with 
a better clinical course in RA-DLBCLs.  
4.2 Sjögren Syndrome 
SS is a chronic systemic autoimmune disease clinically characterized by dry mouth 
(xerostomia) and dry eyes (keratoconjunctivite sicca) (Kassan & Moutsopoulos, 2004). It is 
distinguished by a lymphoproliferative sialadenitis (LESA) with lymphocyte infiltration of 
salivary ducts, ductal epithelial cell proliferation and apoptosis (Daniels, 1984). This 
disorder can occur either alone, known as primary SS, or in the context of other systemic 
autoimmune disorders, such as RA, systemic sclerosis, SLE, which is known as secondary 
SS. Compared with the general population, an increased risk of developing NHL during the 
course of such disease was reported (Kassan et al, 1978, Ioannidis et al, 2002). Patients 
affected by SS, in fact, have an increased relative risk of 28 fold to develop extranodal MALT 
lymphoma (MZL) of the salivary gland and a 11-fold increased risk of developing a DLBCL 
arising de novo or by transformation of a previous indolent lymphoma (Smedby et al, 2006). 
Relative risk to develop a lymphoma is 8.7 for patients with primary SS form and 4.5 for 
patients with a secondary SS (Kauppi et al, 1997). NHL is the major complication during the 
course of the disease, with a prevalence of 4.3% (Voulgarelis et al, 1999). The high risk of 
lymphoma development suggests that it originates locally as a consequence of chronic 
lymphocyte activation due to the autoimmune setting.  
4.2.1 Pathogenesis 
Lymphocytes have a central role in the pathogenesis of both SS and lymphoma, but whether 
T or B lymphocytes play the leading role is controversial. From one side, biopsies of salivary 
and lachrymal glands are characterized by a mixed infiltrate of predominant CD4 and CD8 
T cells, showing restriction of TCR usage (Adamson et al, 1983). On the other side, primary 
SS is characterized by increased monoclonal Ig and by the development of lymphomas of B-
cell type. A B-cell mediated autoimmune response occurs in the salivary glands. A wide 
variety of nuclear auto-antigens are immune targets in SS patients. Anti-nuclear antibody as 
anti-SSA/Ro and anti-SSB/La are detectable in 70-85% of patients (Jonsson et al, 2003). The 
cause of B-cell hyperactivity in primary SS is not known. Exocrine glands of SS patients 
show an accumulation of B cells clustering in benign polyclonal aggregates (Brandtzaeg & 
Johansen, 2005), harbouring mutated IgVH genes and therefore being GC, marginal zone or 
memory B cells. Successively, an evolution from benign to malignant B lymphoproliferation 
has been described in the course of primary SS, but not of secondary (Anderson & Talal, 
1972). Initial benign polyclonal clusters of B-cells enlarge to organize lymphoid follicle-like 
structures with germinal centres (GCs), in which plasma cells differentiate. The role of local 
antigens is crucial for the development of these extralymphoid GCs (Youinou et al, 2010). 
The evolution from a benign B-cell aggregate to a malignant lymphoma may be therefore 
the consequence of the autoimmune response through the selection and expansion of a 
monoclonal B-cell clone (Friedman et al, 1991). Mutations of p53 are also involved in 
lymphoma development in these patients (Tapinos et al, 1999). Approximately 20% of SS 
patients exhibits monoclonal Igs in the serum and urine and mixed monoclonal 
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cryoglobulinemia (MMC) with an IgMk monoclonal rheumatoid factor (RF) component 
(Youinou et al, 1988, Tzioufas et al, 1986). Monoclonality therefore correlates with the 
transition from the autoimmune state to NHL. Various studies on clonality have 
demonstrated that SS patients with the same and persistent monoclonal B-cell expansion in 
follow-up biopsies are at higher risk of lymphoma developing. MALT lymphoma cells are 
found only in glands for years and a subsequent spread outside the salivary may involve the 
lymph nodes and other extranodal organs (Royer et al, 1997). 
4.2.2 Clinical characteristics 
The development of a malignant lymphoproliferation occurs only in a subset of SS patients 
and is characterized by the emergence of clinical and serologic parameters in the initial 
phases of disease, the monitoring of which is important for early detection of malignancy 
and timely therapeutic intervention (Tzioufas et al, 1986, Moutsopoulos et al, 1983). Usually, 
median age at lymphoma diagnosis is 58 years, and the median time from SS diagnosis is 7.5 
years (Voulgarelis et al, 1999). MZL is the most common histologic subtype, but also 
follicular lymphoma, lymphoplasmacytoid lymphoma and DLBCL have been reported 
(Kassan et al, 1978, Valesini et al, 1997, Mariette, 1999). MZL in SS patients is generally 
localized at diagnosis (stage I and II) and is characterized by a small tumour burden, good 
performance status and normal lactate dehydrogenase serum levels. The salivary glands are 
the most commonly involved organs, with parotid gland enlargement being the main 
presenting symptom, but near 20% of these lymphomas involve other extra-nodal sites, such 
as stomach, nasopharynx, skin, liver, kidney, and lung, justifying indeed the importance of a 
complete staging at diagnosis. Bone marrow involvement is rare (10% of cases) and B 
symptoms are uncommon. Other clinical manifestations are skin vasculitis, peripheral nerve 
and renal involvement, anemia, lymphopenia, monoclonal immunoglobulins and mixed 
monoclonal cryoglobulinemia (MMC) (Voulgarelis et al, 1999). Indolent lymphomas arisen 
in SS patients experience high-grade transformation, mostly in DLBCLs, in about 10% of 
cases. This evolution is characterized by nodal and extra-nodal dissemination and a 
unfavourable prognosis, with a median overall survival shorter than two years (Voulgarelis 
et al, 1999). It has been proven by immunohistochemical and genotypic studies that such 
DLBCLs arise from the same clone as indolent lymphomas, as a consequence of genetic 
alterations such as p53 allelic loss or mutation, hypermethylation of p15 and p16 genes, 
deletion of p16 gene (Du et al, 1996, Neumeister et al, 1997). 
4.2.3 Risk factors 
Some risk factors for lymphoma development have been identified in SS patients. 
Lymphoma risk seems to increase with disease severity, expressed by decreased levels of 
serum immunoglobulins, high serum β2-microglobulin levels  and disappearance of a 
previous positive rheumatoid factor (FR) (Anderson & Talal, 1972, Anaya et al, 1996); 
parotid gland enlargement, splenomegaly, lymphadenopathy (Kassan et al, 1978); low C4 
levels and palpable purpura (Ioannidis et al, 2002, Skopouli et al, 2000); MMC (Tzioufas et al, 
1996). A higher relative risk of developing lymphoproliferative disorders in patients with an 
early onset of disease has been suggested, with a significant and independent association 
between lymphoma development and low C4 levels (Ramos-Casals et al, 2005). An adverse 
prognostic value of low levels of C3 (Theander et al, 2004), vasculitis, severe involvement in 
parotid scintigraphy, hypocomplementaemia and/or cryoglobulins at diagnosis (Brito-
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Zeron et al, 2007) have been proposed in patients with primary SS. Patients with such risk 
factors should be closely monitored.  
4.2.4 Lymphoma treatment 
Many patients with localized MALT lymphoma may be managed with a “wait and watch” 
policy, with a median overall survival of 6.4 years (Voulgarelis et al, 1999). In a retrospective 
study (Ambrosetti et al, 2004), no difference in outcome between patients treated with 
surgery, radiotherapy or chemotherapy and those who were not treated has been reported. 
Single-agent chemotherapy is indicated (alkylating agents; purine analogues; monoclonal 
antibody rituximab) for multiple extra-nodal disease. The purine analogue cladribine has 
been associated with a 75% complete remission rate in patients with SS-associated MALT 
lymphoma (Voulgarelis et al, 2002); while the efficacy of the anti-CD20 monoclonal antibody 
rituximab is controversial (Pijpe et al, 2005, Quartuccio et al, 2009). Combined chemotherapy 
(CHOP-like regimens) should be reserved to patients with high tumour burden or 
aggressive lymphoma. R-CHOP regimen has been associated with complete remission 
(duration 10-23 months) in four patients with SS-aggressive NHL. Importantly, certain signs 
and symptoms of MC type II (purpura, peripheral neuropathy and arthralgias) significantly 
improved with treatment, the levels of circulating cryoglobulins and RF decreased, and C4 
levels returned to normal (Voulgarelis et al, 2006). 
4.3 Systemic Lupus Erythematosus 
SLE is a systemic autoimmune disease characterized by variable severity and a multisystem 
involvement, including cardiovascular, musculoskeletal, excretory, respiratory, and 
neurological involvement. Prognosis of SLE patients has considerably improved during the 
last decades, with an increase in 5-year survival from <50% before 1955 to >90% 
nowadays (Moss et al, 2002), due to the use of novel therapeutic options. Nevertheless, the 
incidence of late complications seems to be increased and mortality due to malignancies 
remains higher than that of general population (Nossent et al, 2007). This could be 
referred to the common pathogenic pathways in lupus and cancer. Lupus and various 
malignancies share some risk factors, such as genetic predisposition, viral infections 
(EBV), hormones (insulin-like growth factor, prolactin, oestrogen, and growth hormone) 
(Bernatsky et al, 2002, Poole et al, 2009). Another shared characteristic is represented by 
antiphospholipid antibodies, frequently present in both diseases and recently associated 
with cancer development (Tincani et al, 2010). SLE has been associated with a 2.7 - 4.1 fold 
increased risk of NHL development (Ekstrom Smedby et al, 2008, Abu-Shakra et al, 1993, 
Ekstrom et al, 2003), and some studies have also suggested a link between SLE and HL 
(Landgren et al, 2006, Bernatsky et al, 2007). A multi-site international cohort study 
calculated a standardized incidence ratio (SIR) for all hematologic malignancies of 2.75 
and for NHL of 3.64 (Bernatsky et al, 2005b). As far as HL, same authors observed a SIR of 
2.4 in another large multi-site international cohort (Bernatsky et al, 2007). The pooled 
analysis combining these data with those of other large cohort studies provided a SIR 
estimate for HL in SLE of 3.16. Generally, aggressive lymphomas, such as DLBCL are 
more common in SLE patients (Smedby et al, 2006, Simon et al, 2007, Bernatsky et al, 2005a, 
Lofstrom et al, 2007). In general population, DLBCL accounts for 30% of all lymphomas, 
but in SLE patients this percentage is between 38% and 64% (Smedby et al, 2006, 
Bernatsky et al, 2005a, King & Costenbader, 2007). No subtyping into germinal-centre like 
or activated B-cell like subtype has been reported. 
 




Concerning genetic predisposition, a possible reason for the increased risk of NHL in SLE is 
that distinct major histocompatibility complex (MHC)-haplotypes may predispose to both 
disorders (Okada et al, 1991). The role of immunosuppressive therapy is controversial; it 
may impair immune defence resulting in an increased risk of lymphomagenesis. However, 
SLE patients who have never been treated with immunosuppressive agents have the highest 
rate of NHL incidence during the first year from diagnosis, suggesting that the increased 
risk is not related to cumulative doses of therapy (Kiss et al, 2010). A nested case-cohort 
study performed to assess the HR for cancer within a multi-site international SLE cohort 
after exposure to immunosuppressive drugs (anti-malarial drugs, systemic glucocorticoids, 
NSAIDs, aspirin) showed an adjusted HR for overall cancer risk of 0.82. This risk seems to 
be higher when only haematological malignancies are considered (Bernatsky et al, 2008). In 
addition to extrinsic risk factors, there are also defects in the immune system contributing to 
the development of both SLE and lymphomas, as the abnormal B-cell activation due to the 
chronic and persistent antigen-stimulation, cell-cycle deregulation and impaired apoptosis, 
which leads to uncontrolled cell proliferation, an exaggerated humoral autoimmune 
response and the increased risk of oncogene translocation (Illes et al, 2009). The impaired 
immune response in SLE is thus characterized by the accumulation of activated self-reactive 
B and T cells (Xu & Wiernik, 2001). Many studies have underlined the role of impaired 
apoptosis in this process. For example, the MRL/lpr mouse, a murine SLE model, has 
defects in the Fas gene, leading to defects in apoptosis and subsequent development of SLE 
(Watanabe-Fukunaga et al, 1992). Mice with mutations of PTEN, a tumor suppressor gene, 
which impairs the Fas-mediated elimination of activated lymphocytes, develop SLE 
characterized by ANA antibodies, glomerulonephritis and lymphadenopathies (Di 
Cristofano et al, 1999). Also bcl-2, a proto-oncogene involved in the majority of B NHL, is 
highly expressed in SLE (Aringer et al, 1994), causing prolonged survival of auto-reactive B 
cells and thus favouring malignant transformation (Xu & Wiernik, 2001). The persistent 
clonal expansion of benign hyperactive B and T cells retained in lymph node of SLE patients 
in response to self-antigens exposes these cells to DNA damage, ultimately leading to 
neoplastic transformation (Xu & Wiernik, 2001). Increased serum levels of type-I Interferons 
(IFNs a/b) is also associated with active SLE disease (Theofilopoulos et al, 2005). The IFNs 
are cytokines that inhibit cell proliferation and modulate cell survival (Banchereau & 
Pascual, 2006), and also inhibit apoptosis induced by signalling through B-cell receptor (Su 
& David, 1999). The p202a murine protein is a member of the interferon-inducible p200-
protein family (Choubey & Kotzin, 2002). Increased levels of the p202 protein in splenic B 
cells of B6.Nba2 SLE susceptible mice determine defects of apoptosis and accumulation of B 
cells in the spleen (Xin et al, 2006) probably by inhibiting p53-mediated transcriptional 
activation of genes that encode pro-apoptotic proteins as well as transcriptional repression 
of genes that encode anti-apoptotic proteins. It is therefore possible that increased levels of 
p202 in B cells also contribute to enhance the risk of developing B-cell malignancies 
(Veeranki & Choubey, 2010). The murine p202 protein does not have any human 
homologue, but the human IFI16 protein, a member of the p200-protein family, is 
functionally similar. An increased expression of IFI16 protein in normal human cells 
determines cellular growth arrest and up to 29% of SLE patients present high auto-
antibodies titres to the IFI16 protein (Choubey et al, 2008). IFI16 protein binds p53, so basal 
and IFN-induced increased levels of IFI16 in SLE patients may inhibit the p53 mediated 
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Zeron et al, 2007) have been proposed in patients with primary SS. Patients with such risk 
factors should be closely monitored.  
4.2.4 Lymphoma treatment 
Many patients with localized MALT lymphoma may be managed with a “wait and watch” 
policy, with a median overall survival of 6.4 years (Voulgarelis et al, 1999). In a retrospective 
study (Ambrosetti et al, 2004), no difference in outcome between patients treated with 
surgery, radiotherapy or chemotherapy and those who were not treated has been reported. 
Single-agent chemotherapy is indicated (alkylating agents; purine analogues; monoclonal 
antibody rituximab) for multiple extra-nodal disease. The purine analogue cladribine has 
been associated with a 75% complete remission rate in patients with SS-associated MALT 
lymphoma (Voulgarelis et al, 2002); while the efficacy of the anti-CD20 monoclonal antibody 
rituximab is controversial (Pijpe et al, 2005, Quartuccio et al, 2009). Combined chemotherapy 
(CHOP-like regimens) should be reserved to patients with high tumour burden or 
aggressive lymphoma. R-CHOP regimen has been associated with complete remission 
(duration 10-23 months) in four patients with SS-aggressive NHL. Importantly, certain signs 
and symptoms of MC type II (purpura, peripheral neuropathy and arthralgias) significantly 
improved with treatment, the levels of circulating cryoglobulins and RF decreased, and C4 
levels returned to normal (Voulgarelis et al, 2006). 
4.3 Systemic Lupus Erythematosus 
SLE is a systemic autoimmune disease characterized by variable severity and a multisystem 
involvement, including cardiovascular, musculoskeletal, excretory, respiratory, and 
neurological involvement. Prognosis of SLE patients has considerably improved during the 
last decades, with an increase in 5-year survival from <50% before 1955 to >90% 
nowadays (Moss et al, 2002), due to the use of novel therapeutic options. Nevertheless, the 
incidence of late complications seems to be increased and mortality due to malignancies 
remains higher than that of general population (Nossent et al, 2007). This could be 
referred to the common pathogenic pathways in lupus and cancer. Lupus and various 
malignancies share some risk factors, such as genetic predisposition, viral infections 
(EBV), hormones (insulin-like growth factor, prolactin, oestrogen, and growth hormone) 
(Bernatsky et al, 2002, Poole et al, 2009). Another shared characteristic is represented by 
antiphospholipid antibodies, frequently present in both diseases and recently associated 
with cancer development (Tincani et al, 2010). SLE has been associated with a 2.7 - 4.1 fold 
increased risk of NHL development (Ekstrom Smedby et al, 2008, Abu-Shakra et al, 1993, 
Ekstrom et al, 2003), and some studies have also suggested a link between SLE and HL 
(Landgren et al, 2006, Bernatsky et al, 2007). A multi-site international cohort study 
calculated a standardized incidence ratio (SIR) for all hematologic malignancies of 2.75 
and for NHL of 3.64 (Bernatsky et al, 2005b). As far as HL, same authors observed a SIR of 
2.4 in another large multi-site international cohort (Bernatsky et al, 2007). The pooled 
analysis combining these data with those of other large cohort studies provided a SIR 
estimate for HL in SLE of 3.16. Generally, aggressive lymphomas, such as DLBCL are 
more common in SLE patients (Smedby et al, 2006, Simon et al, 2007, Bernatsky et al, 2005a, 
Lofstrom et al, 2007). In general population, DLBCL accounts for 30% of all lymphomas, 
but in SLE patients this percentage is between 38% and 64% (Smedby et al, 2006, 
Bernatsky et al, 2005a, King & Costenbader, 2007). No subtyping into germinal-centre like 
or activated B-cell like subtype has been reported. 
 




Concerning genetic predisposition, a possible reason for the increased risk of NHL in SLE is 
that distinct major histocompatibility complex (MHC)-haplotypes may predispose to both 
disorders (Okada et al, 1991). The role of immunosuppressive therapy is controversial; it 
may impair immune defence resulting in an increased risk of lymphomagenesis. However, 
SLE patients who have never been treated with immunosuppressive agents have the highest 
rate of NHL incidence during the first year from diagnosis, suggesting that the increased 
risk is not related to cumulative doses of therapy (Kiss et al, 2010). A nested case-cohort 
study performed to assess the HR for cancer within a multi-site international SLE cohort 
after exposure to immunosuppressive drugs (anti-malarial drugs, systemic glucocorticoids, 
NSAIDs, aspirin) showed an adjusted HR for overall cancer risk of 0.82. This risk seems to 
be higher when only haematological malignancies are considered (Bernatsky et al, 2008). In 
addition to extrinsic risk factors, there are also defects in the immune system contributing to 
the development of both SLE and lymphomas, as the abnormal B-cell activation due to the 
chronic and persistent antigen-stimulation, cell-cycle deregulation and impaired apoptosis, 
which leads to uncontrolled cell proliferation, an exaggerated humoral autoimmune 
response and the increased risk of oncogene translocation (Illes et al, 2009). The impaired 
immune response in SLE is thus characterized by the accumulation of activated self-reactive 
B and T cells (Xu & Wiernik, 2001). Many studies have underlined the role of impaired 
apoptosis in this process. For example, the MRL/lpr mouse, a murine SLE model, has 
defects in the Fas gene, leading to defects in apoptosis and subsequent development of SLE 
(Watanabe-Fukunaga et al, 1992). Mice with mutations of PTEN, a tumor suppressor gene, 
which impairs the Fas-mediated elimination of activated lymphocytes, develop SLE 
characterized by ANA antibodies, glomerulonephritis and lymphadenopathies (Di 
Cristofano et al, 1999). Also bcl-2, a proto-oncogene involved in the majority of B NHL, is 
highly expressed in SLE (Aringer et al, 1994), causing prolonged survival of auto-reactive B 
cells and thus favouring malignant transformation (Xu & Wiernik, 2001). The persistent 
clonal expansion of benign hyperactive B and T cells retained in lymph node of SLE patients 
in response to self-antigens exposes these cells to DNA damage, ultimately leading to 
neoplastic transformation (Xu & Wiernik, 2001). Increased serum levels of type-I Interferons 
(IFNs a/b) is also associated with active SLE disease (Theofilopoulos et al, 2005). The IFNs 
are cytokines that inhibit cell proliferation and modulate cell survival (Banchereau & 
Pascual, 2006), and also inhibit apoptosis induced by signalling through B-cell receptor (Su 
& David, 1999). The p202a murine protein is a member of the interferon-inducible p200-
protein family (Choubey & Kotzin, 2002). Increased levels of the p202 protein in splenic B 
cells of B6.Nba2 SLE susceptible mice determine defects of apoptosis and accumulation of B 
cells in the spleen (Xin et al, 2006) probably by inhibiting p53-mediated transcriptional 
activation of genes that encode pro-apoptotic proteins as well as transcriptional repression 
of genes that encode anti-apoptotic proteins. It is therefore possible that increased levels of 
p202 in B cells also contribute to enhance the risk of developing B-cell malignancies 
(Veeranki & Choubey, 2010). The murine p202 protein does not have any human 
homologue, but the human IFI16 protein, a member of the p200-protein family, is 
functionally similar. An increased expression of IFI16 protein in normal human cells 
determines cellular growth arrest and up to 29% of SLE patients present high auto-
antibodies titres to the IFI16 protein (Choubey et al, 2008). IFI16 protein binds p53, so basal 
and IFN-induced increased levels of IFI16 in SLE patients may inhibit the p53 mediated 
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transcription of target genes (Choubey et al, 2008). Finally, SLE patients have high plasma 
levels of BAFF (Do & Chen-Kiang, 2002), which activates NF-kB (Laabi & Strasser, 2000). 
Mice overexpressing BAFF develop a SLE-like disease and exhibit B-cell activation (Mackay 
et al, 1999). Also the increased level of IFI16 protein in B cells is capable to activate the NF-kB 
transcription factor, which persistent activation has been related to the development of B 
cell malignancies (Vallabhapurapu & Karin, 2009). In addition, NF-kB induces IL-6 
expression (Choubey & Panchanathan, 2008). Overall, these results suggest that the triad 
IFI16/NF-kB/IL-6 could be involved in the development of B-cell malignancies in SLE 
patients. Recently, it was also shown that antiribosomal-P-protein (anti-P) antibodies, 
present in nearly 15-20% of patients with SLE active disease, cross react with phospholipids 
(Caponi et al, 2007), enhancing the production of TNF-alfa and IL-6 by monocytes (Toubi & 
Shoenfeld, 2007), which increases proliferation of normal and clonal B cells. The role of EBV 
in the pathogenesis of lymphoma in SLE patients has not been fully investigated. An 
increased prevalence of EBV infection in young patients with SLE has been reported (James 
et al, 1997) and there are some observations that, in some cases, EBV may be a trigger of 
lymphomagenesis in SLE (Verdolini et al, 2002). In contrast, in a retrospective study 
analyzing lymphoma development in a large cohort of SLE patients, EBV positivity was 
found only in 17% of cases (King & Costenbader, 2007). Whether EBV infection causes SLE 
and/or lymphoma independently has not yet been ascertained.  
4.3.2 Clinical characteristics 
The emerge of NHL in a SLE patient is clinically difficult to recognize in the current practice, 
due to the fact that many lymphoma characteristics are already part of the autoimmune disease 
(lymphadenopathy, fever, weight loss, hepato-splenomegaly, cytopenias, autoantibodies), 
raising the possibility that SLE might be a paraneoplastic syndrome appearing in the context of 
the lymphoid malignancy. Some clinical SLE characteristics as haematological manifestations 
(autoimmune haemolytic anaemia, leukopenia, hyperglobulinemia, chronic thrombocytopenia) 
(King & Costenbader, 2007), sicca symptoms/salivary gland swellings, pulmonary infiltrates, 
and/or recurrent pneumonia (Lofstrom et al, 2007) have been associated with increased risk of 
developing lymphoma. The common involvement of mucosal membranes, salivary glands and 
lung parenchyma in patients developing a lymphoma could be due to the fact that, in an 
immune-deficient patient, an impaired barrier for exogenous agents, as viruses, favour 
recurrent infections, which may be involved in lymphomagenesis. Median age at lymphoma 
diagnosis is 50 years, with a median time interval from SLE diagnosis of 17.8 years (King & 
Costenbader, 2007). Diffuse large B cell lymphoma is the most common subtype (King & 
Costenbader, 2007). After diagnosis of NHL a 5-year survival probability of 47%-50% has 
been estimated (Bernatsky et al, 2005b, Lofstrom et al, 2007), and mortality in patients with 
both diseases is usually due to progressive B-cell malignancy (Xu & Wiernik, 2001). 
4.4 Hashimoto’s thyroiditis 
Hashimoto’s thyroiditis (HT) is an autoimmune chronic inflammatory disease of the 
thyroid, histologically characterized by a severe and progressive lymphocytic infiltration 
causing destruction of the glandular parenchyma and consequent goitre development and 
hypothyroidism. It commonly affects middle-aged women (Aozasa, 1990). The activation of 
CD4+ T lymphocytes specific for thyroid antigens is considered the trigger of the 
autoimmune process in HT (Weetman & McGregor, 1994, Dayan & Daniels, 1996). Auto-
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antibodies produced in HT are specific for thyreoglobulin, thyroperoxidase and the thyroid 
stimulating hormone receptor (TSH-R). The first two antibodies are not detected in all 
patients. Antibodies against TSH-R block the activation of this receptor, causing the 
functional impairment of the thyroid. On the other side, activated CD4+ T cells recruit 
cytotoxic CD8+ T cells and B cells into the thyroid causing the direct killing of thyroid cells. 
Patients affected by HT are at increased risk of developing primary thyroid lymphoma 
(PTL) with a relative risk of 67 fold for marginal zone B-cell lymphoma of MALT-type 
(Holm et al, 1985). Lymphoma typically occurs 20-30 years after the diagnosis of thyroiditis 
(Pedersen & Pedersen, 1996). HT is not only associated with thyroidal MALT lymphoma, 
but also with other extranodal lymphomas. In a retrospective study on 80 patients affected 
by MALT lymphoma, 13 (16%) had a concomitant diagnosis of HT; four of these patients 
had thyroidal lymphoma and nine had extra-thyroidal lymphomas (gastric, orbital, small 
intestinal, and salivary gland lymphomas) (Troch et al, 2008). PTL represents 5% of all 
thyroid malignancies (Staunton & Greening, 1973) and MALT lymphoma represent 25% of 
all PTLs (Thieblemont et al, 2002, Derringer et al, 2000). About 50% of patients diagnosed 
with PTL have a clinical history of HT (Niitsu et al, 2007, Rossi, 2009), even if only 0.5% of 
patients with HT develop PTL.  
4.4.1 Pathogenesis 
It has been hypothesized that the chronic antigenic stimulation caused by the autoimmune 
and inflammatory process in HT leads to the proliferation of newly formed lymphoid tissue 
and ultimately to malignant transformation. The thyroid gland does not contain native 
lymphoid tissue (Holm et al, 1985, Isaacson, 1997). The lymphoid tissue present in HT 
thyroid gland share many features with MALT (Hyjek & Isaacson, 1988). The presence of 
clonal B-cell populations has been demonstrated in HT thyroid specimens also in patients 
without evidence of lymphoma development (Saxena et al, 2004). The clonal IgH gene 
rearrangements carried by thyroid lymphomas may already be evident in the oligoclonal 
rearrangements characterizing HT, and a fraction of thyroid lymphomas use the same IgH 
utilized by anti-thyroid auto-antibodies (Rossi, 2009, Moshynska & Saxena, 2008). IGVH 
genes are extensively targeted by aberrant somatic hypermutation in thyroid DLBCL, MALT 
and follicular lymphoma, and also in 2 of 14 (14.3%) patients affected by HT, suggesting that 
these genetic alterations represent an early step in the process of B-cell lymphomagenesis. 
This aberrant activity of somatic hypermutation may introduce activating mutations and 
may cause genetic instability, favouring chromosomal translocation (Takakuwa et al, 2009).  
4.4.2 Clinical characteristics 
Patients developing a PTL clinically present a rapid growth of a thyroid mass, associated 
with hoarseness, stridor or, less commonly, with dysphagia or dyspnoea. The presence of B 
symptoms is uncommon in indolent subtypes (Ansell et al, 1999). Up to 90% of patients 
usually presents with early stage I or II lymphoma (Graff-Baker et al, 2010). The most 
common histologic subtypes are B cell-type, in particular MALT lymphomas and DLBCL. 
The other histological subtypes are exceptional (Thieblemont et al, 2002). MALT lymphoma 
is an indolent lymphoma, with a 5-year disease-free survival of over 95% (Graff-Baker et al, 
2010) and the disease tends to remain localized for a long time. Conversely, aggressive 
DLBCL usually arise from a pre-existing MALT lymphoma and a component of residual 
MALT lymphoma can be still found (Niitsu et al, 2007). DLBCL has a dismal prognosis 
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transcription of target genes (Choubey et al, 2008). Finally, SLE patients have high plasma 
levels of BAFF (Do & Chen-Kiang, 2002), which activates NF-kB (Laabi & Strasser, 2000). 
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et al, 1999). Also the increased level of IFI16 protein in B cells is capable to activate the NF-kB 
transcription factor, which persistent activation has been related to the development of B 
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increased prevalence of EBV infection in young patients with SLE has been reported (James 
et al, 1997) and there are some observations that, in some cases, EBV may be a trigger of 
lymphomagenesis in SLE (Verdolini et al, 2002). In contrast, in a retrospective study 
analyzing lymphoma development in a large cohort of SLE patients, EBV positivity was 
found only in 17% of cases (King & Costenbader, 2007). Whether EBV infection causes SLE 
and/or lymphoma independently has not yet been ascertained.  
4.3.2 Clinical characteristics 
The emerge of NHL in a SLE patient is clinically difficult to recognize in the current practice, 
due to the fact that many lymphoma characteristics are already part of the autoimmune disease 
(lymphadenopathy, fever, weight loss, hepato-splenomegaly, cytopenias, autoantibodies), 
raising the possibility that SLE might be a paraneoplastic syndrome appearing in the context of 
the lymphoid malignancy. Some clinical SLE characteristics as haematological manifestations 
(autoimmune haemolytic anaemia, leukopenia, hyperglobulinemia, chronic thrombocytopenia) 
(King & Costenbader, 2007), sicca symptoms/salivary gland swellings, pulmonary infiltrates, 
and/or recurrent pneumonia (Lofstrom et al, 2007) have been associated with increased risk of 
developing lymphoma. The common involvement of mucosal membranes, salivary glands and 
lung parenchyma in patients developing a lymphoma could be due to the fact that, in an 
immune-deficient patient, an impaired barrier for exogenous agents, as viruses, favour 
recurrent infections, which may be involved in lymphomagenesis. Median age at lymphoma 
diagnosis is 50 years, with a median time interval from SLE diagnosis of 17.8 years (King & 
Costenbader, 2007). Diffuse large B cell lymphoma is the most common subtype (King & 
Costenbader, 2007). After diagnosis of NHL a 5-year survival probability of 47%-50% has 
been estimated (Bernatsky et al, 2005b, Lofstrom et al, 2007), and mortality in patients with 
both diseases is usually due to progressive B-cell malignancy (Xu & Wiernik, 2001). 
4.4 Hashimoto’s thyroiditis 
Hashimoto’s thyroiditis (HT) is an autoimmune chronic inflammatory disease of the 
thyroid, histologically characterized by a severe and progressive lymphocytic infiltration 
causing destruction of the glandular parenchyma and consequent goitre development and 
hypothyroidism. It commonly affects middle-aged women (Aozasa, 1990). The activation of 
CD4+ T lymphocytes specific for thyroid antigens is considered the trigger of the 
autoimmune process in HT (Weetman & McGregor, 1994, Dayan & Daniels, 1996). Auto-
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antibodies produced in HT are specific for thyreoglobulin, thyroperoxidase and the thyroid 
stimulating hormone receptor (TSH-R). The first two antibodies are not detected in all 
patients. Antibodies against TSH-R block the activation of this receptor, causing the 
functional impairment of the thyroid. On the other side, activated CD4+ T cells recruit 
cytotoxic CD8+ T cells and B cells into the thyroid causing the direct killing of thyroid cells. 
Patients affected by HT are at increased risk of developing primary thyroid lymphoma 
(PTL) with a relative risk of 67 fold for marginal zone B-cell lymphoma of MALT-type 
(Holm et al, 1985). Lymphoma typically occurs 20-30 years after the diagnosis of thyroiditis 
(Pedersen & Pedersen, 1996). HT is not only associated with thyroidal MALT lymphoma, 
but also with other extranodal lymphomas. In a retrospective study on 80 patients affected 
by MALT lymphoma, 13 (16%) had a concomitant diagnosis of HT; four of these patients 
had thyroidal lymphoma and nine had extra-thyroidal lymphomas (gastric, orbital, small 
intestinal, and salivary gland lymphomas) (Troch et al, 2008). PTL represents 5% of all 
thyroid malignancies (Staunton & Greening, 1973) and MALT lymphoma represent 25% of 
all PTLs (Thieblemont et al, 2002, Derringer et al, 2000). About 50% of patients diagnosed 
with PTL have a clinical history of HT (Niitsu et al, 2007, Rossi, 2009), even if only 0.5% of 
patients with HT develop PTL.  
4.4.1 Pathogenesis 
It has been hypothesized that the chronic antigenic stimulation caused by the autoimmune 
and inflammatory process in HT leads to the proliferation of newly formed lymphoid tissue 
and ultimately to malignant transformation. The thyroid gland does not contain native 
lymphoid tissue (Holm et al, 1985, Isaacson, 1997). The lymphoid tissue present in HT 
thyroid gland share many features with MALT (Hyjek & Isaacson, 1988). The presence of 
clonal B-cell populations has been demonstrated in HT thyroid specimens also in patients 
without evidence of lymphoma development (Saxena et al, 2004). The clonal IgH gene 
rearrangements carried by thyroid lymphomas may already be evident in the oligoclonal 
rearrangements characterizing HT, and a fraction of thyroid lymphomas use the same IgH 
utilized by anti-thyroid auto-antibodies (Rossi, 2009, Moshynska & Saxena, 2008). IGVH 
genes are extensively targeted by aberrant somatic hypermutation in thyroid DLBCL, MALT 
and follicular lymphoma, and also in 2 of 14 (14.3%) patients affected by HT, suggesting that 
these genetic alterations represent an early step in the process of B-cell lymphomagenesis. 
This aberrant activity of somatic hypermutation may introduce activating mutations and 
may cause genetic instability, favouring chromosomal translocation (Takakuwa et al, 2009).  
4.4.2 Clinical characteristics 
Patients developing a PTL clinically present a rapid growth of a thyroid mass, associated 
with hoarseness, stridor or, less commonly, with dysphagia or dyspnoea. The presence of B 
symptoms is uncommon in indolent subtypes (Ansell et al, 1999). Up to 90% of patients 
usually presents with early stage I or II lymphoma (Graff-Baker et al, 2010). The most 
common histologic subtypes are B cell-type, in particular MALT lymphomas and DLBCL. 
The other histological subtypes are exceptional (Thieblemont et al, 2002). MALT lymphoma 
is an indolent lymphoma, with a 5-year disease-free survival of over 95% (Graff-Baker et al, 
2010) and the disease tends to remain localized for a long time. Conversely, aggressive 
DLBCL usually arise from a pre-existing MALT lymphoma and a component of residual 
MALT lymphoma can be still found (Niitsu et al, 2007). DLBCL has a dismal prognosis 
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despite polychemotherapic regimens, with a 5 year probability of survival of 44% 
(Thieblemont et al, 2002). Only rare cases of HL of the thyroid have been reported in the 
literature, but any association with underlying thyroiditis cannot be ascertained because of 
the small number of cases (Wang et al, 2005). Older age at diagnosis is associated with 
decreased disease-free survival (Graff-Baker et al, 2010). Tissue biopsies should be 
considered the gold standard for histological diagnosis (Thieblemont et al, 2002).  
4.4.3 Therapy 
Local treatment, such as surgical excision and radiotherapy, could represent a valid 
treatment strategy for patients with stage I or II MALT lymphoma of the thyroid gland 
(Tsang et al, 2003). Complete surgical resection improves prognosis over incomplete 
resection, with a 5-year OS of 100% (Thieblemont et al, 2002), although most authors 
currently believe that total thyroidectomy is unnecessary, exposing patients to the risks of 
surgery (recurrent laryngeal nerve damage and hypoparathyroidism) without conferring 
any survival advantage (Tupchong et al, 1986, Ruggiero et al, 2005, Klyachkin et al, 1998). 
Involved field radiotherapy is associated with a 5-year OS of 90% (Laing et al, 1994). 
Nonetheless, patients with thyroid malignant lymphoma treated with radiotherapy seem to 
have a higher incidence of hypothyroidism than those treated with chemotherapy (Tamura 
et al, 1981). Localized treatment plays a minor role in DLBCL, which requires aggressive 
anthracycline-based chemotherapy regimens (CHOP or CHOP-like), associated with 
rituximab, a monoclonal antibody directed against B-cell specific antigen CD20, and 
followed by involved-field radiotherapy. Chemotherapy alone may be considered in 
selected patients younger than 60 years and with no adverse prognostic factors (Reyes et al, 
2005). Rituximab is effective for autoimmune thyroid diseases such as Grave’s disease (El 
Fassi et al, 2007a, El Fassi et al, 2007b). The use of rituximab monotherapy in three cases of 
HT-related thyroid MALT lymphoma has also been reported. Rituximab monotherapy 
determined a significant decrease of anti-thyroid autoantibody levels, but it is still unknown 
whether thyroid dysfunction can be restored, and its use remains still controversial in HT 
(Kahara et al, 2011). 
4.5 Systemic sclerosis 
Systemic sclerosis (SSc) is a multisystem inflammatory disease with autoimmune features. It 
is characterized by vascular abnormalities and fibrosis of the skin and internal organs. Some 
retrospective studies have reported an increased risk of malignancies in SSc patients (Abu-
Shakra et al, 1993, Rosenthal et al, 1993, Derk et al, 2006), but data on the link between SSc 
and lymphoproliferative disorders are still controversial. This association was first proposed 
in 1953 (ZATUCHNI et al, 1953) and successively several epidemiological studies have been 
performed to explore this risk (Chatterjee et al, 2005, Hill et al, 2003, Duncan & Winkelmann, 
1979). A number of sporadic case reports have underlined the association between SSc and 
NHL, particularly with aggressive B-cell subtypes (Arnaud et al, 2006, Derk et al, 2004, 
Haviv et al, 1997) and some authors observed an increased risk of NHL among SSc patients, 
primarily within the first year after the onset of disease, but not beyond 4 years of follow up 
(Landgren et al, 2006, Mellemkjaer et al, 2008, Rosenthal et al, 1993).  Conversely, other 
studies failed to demonstrate a consistent association between SSc and lymphomas 
(Chatterjee et al, 2005, Rosenthal et al, 1995, Roumm & Medsger, 1985). In some cases, 
systemic sclerosis could even represent a paraneoplastic syndrome (Vettori et al, 2010). In a 
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population-based cohort study from south-west England to determine if patients with 
scleroderma have an increased risk of malignancy compared with general population, the 
highest risk among patients affected by scleroderma was found for haematological 
malignancies, especially for NHL (RR=25.8) (Siau et al, 2010). Another retrospective analysis 
of 218 Hungarian patients with SSc followed during a period of 12 years showed lymphoma 
development in three of them (1.38%), all of B cell phenotype, within 2 years after the onset 
of SSc. The incidence of lymphoma in this cohort was 38.3 cases per 100.000 patients per 
year (Szekanecz et al, 2008). Considering 24 studies analyzed in a review, characteristics 
associated to NHL development are old age, female sex, diffuse cutaneous subset and early 
disease. B-cell lymphoma represents the most frequent histotype and the interval between 
diagnosis of SSc and lymphoma onset is usually short (Vettori et al, 2010). Some sporadic 
cases have also reported an association with HL (Rosenthal et al, 1993, Duggal et al, 2002, 
Kedar et al, 1979, Hall et al, 1978).  
4.5.1 Pathogenesis 
The pathophysiological relationship between scleroderma and malignancy remains poorly 
understood. There might be multiple pathways leading to cancer in general, and 
lymphoproliferative disorders in particular. B cells have many pathogenic roles in SSc (Sato 
et al, 2004). SSc patients are indeed characterized by alterations of the B-cell homeostasis, 
such as expansion of naïve cells, decreased number of circulating but activated memory cells 
and defective natural killer cells activity (Sato et al, 2004, Horikawa et al, 2005). Therefore, 
altered B cell functions may be responsible of the higher incidence of B NHL. Also TGF-β, a 
cytokine involved in the regulation of connective tissue proteins, which is highly expressed 
in SSc tissues, might play an important role since dysregulated signalling of the TGF-β is 
capable to induce tumorigenesis (Grady, 2005). Moreover, the malignant transformation 
might be a consequence of chronic tissue damage. Finally, EBV-encoded small RNAs have 
been detected in the majority of DLBCLs associated with systemic rheumatic diseases, 
including SSc (Kojima et al, 2006). In conclusion, a clear relationship between SSc and NHL 
has not yet been ascertained and further studies with higher number of patients are required 
to clarify the coexistence of these two entities. 
4.6 Celiac disease 
Celiac disease (CD) is a chronic autoimmune enteropathy affecting small-intestine, triggered 
by gluten proteins from wheat, barley and rye. The small-intestinal mucosal injury caused 
by the autoimmune response determines malabsorption which results in gastrointestinal 
symptoms (diarrhoea, weight loss, abdominal pain, anorexia, lactose intolerance, abdominal 
distension and irritability) and/or non-gastrointestinal features (iron-deficiency anaemia, 
dermatitis herpetiformis, chronic fatigue, joint pain/inflammation, migraines, depression, 
attention-deficit disorder, epilepsy, osteoporosis/osteopenia, infertility and/or recurrent 
fetal loss, vitamin deficiencies, short stature, failure to thrive, delayed puberty, dental 
defects and autoimmune disorders). The diagnosis of CD is based on histologic 
characteristics of small-bowel biopsy and on clinical and histological remission after a strict 
gluten-free diet. The presence of circulating CD-associated antibodies, such as IgA against 
the endomysium of connective tissue and against tissue transglutaminase, at time of 
diagnosis and their normalization after a gluten-free diet support the diagnosis of CD. Most 
CD patients display specific pairs of allelic variants in two HLA genes, HLA-DQA1 and 
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despite polychemotherapic regimens, with a 5 year probability of survival of 44% 
(Thieblemont et al, 2002). Only rare cases of HL of the thyroid have been reported in the 
literature, but any association with underlying thyroiditis cannot be ascertained because of 
the small number of cases (Wang et al, 2005). Older age at diagnosis is associated with 
decreased disease-free survival (Graff-Baker et al, 2010). Tissue biopsies should be 
considered the gold standard for histological diagnosis (Thieblemont et al, 2002).  
4.4.3 Therapy 
Local treatment, such as surgical excision and radiotherapy, could represent a valid 
treatment strategy for patients with stage I or II MALT lymphoma of the thyroid gland 
(Tsang et al, 2003). Complete surgical resection improves prognosis over incomplete 
resection, with a 5-year OS of 100% (Thieblemont et al, 2002), although most authors 
currently believe that total thyroidectomy is unnecessary, exposing patients to the risks of 
surgery (recurrent laryngeal nerve damage and hypoparathyroidism) without conferring 
any survival advantage (Tupchong et al, 1986, Ruggiero et al, 2005, Klyachkin et al, 1998). 
Involved field radiotherapy is associated with a 5-year OS of 90% (Laing et al, 1994). 
Nonetheless, patients with thyroid malignant lymphoma treated with radiotherapy seem to 
have a higher incidence of hypothyroidism than those treated with chemotherapy (Tamura 
et al, 1981). Localized treatment plays a minor role in DLBCL, which requires aggressive 
anthracycline-based chemotherapy regimens (CHOP or CHOP-like), associated with 
rituximab, a monoclonal antibody directed against B-cell specific antigen CD20, and 
followed by involved-field radiotherapy. Chemotherapy alone may be considered in 
selected patients younger than 60 years and with no adverse prognostic factors (Reyes et al, 
2005). Rituximab is effective for autoimmune thyroid diseases such as Grave’s disease (El 
Fassi et al, 2007a, El Fassi et al, 2007b). The use of rituximab monotherapy in three cases of 
HT-related thyroid MALT lymphoma has also been reported. Rituximab monotherapy 
determined a significant decrease of anti-thyroid autoantibody levels, but it is still unknown 
whether thyroid dysfunction can be restored, and its use remains still controversial in HT 
(Kahara et al, 2011). 
4.5 Systemic sclerosis 
Systemic sclerosis (SSc) is a multisystem inflammatory disease with autoimmune features. It 
is characterized by vascular abnormalities and fibrosis of the skin and internal organs. Some 
retrospective studies have reported an increased risk of malignancies in SSc patients (Abu-
Shakra et al, 1993, Rosenthal et al, 1993, Derk et al, 2006), but data on the link between SSc 
and lymphoproliferative disorders are still controversial. This association was first proposed 
in 1953 (ZATUCHNI et al, 1953) and successively several epidemiological studies have been 
performed to explore this risk (Chatterjee et al, 2005, Hill et al, 2003, Duncan & Winkelmann, 
1979). A number of sporadic case reports have underlined the association between SSc and 
NHL, particularly with aggressive B-cell subtypes (Arnaud et al, 2006, Derk et al, 2004, 
Haviv et al, 1997) and some authors observed an increased risk of NHL among SSc patients, 
primarily within the first year after the onset of disease, but not beyond 4 years of follow up 
(Landgren et al, 2006, Mellemkjaer et al, 2008, Rosenthal et al, 1993).  Conversely, other 
studies failed to demonstrate a consistent association between SSc and lymphomas 
(Chatterjee et al, 2005, Rosenthal et al, 1995, Roumm & Medsger, 1985). In some cases, 
systemic sclerosis could even represent a paraneoplastic syndrome (Vettori et al, 2010). In a 
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population-based cohort study from south-west England to determine if patients with 
scleroderma have an increased risk of malignancy compared with general population, the 
highest risk among patients affected by scleroderma was found for haematological 
malignancies, especially for NHL (RR=25.8) (Siau et al, 2010). Another retrospective analysis 
of 218 Hungarian patients with SSc followed during a period of 12 years showed lymphoma 
development in three of them (1.38%), all of B cell phenotype, within 2 years after the onset 
of SSc. The incidence of lymphoma in this cohort was 38.3 cases per 100.000 patients per 
year (Szekanecz et al, 2008). Considering 24 studies analyzed in a review, characteristics 
associated to NHL development are old age, female sex, diffuse cutaneous subset and early 
disease. B-cell lymphoma represents the most frequent histotype and the interval between 
diagnosis of SSc and lymphoma onset is usually short (Vettori et al, 2010). Some sporadic 
cases have also reported an association with HL (Rosenthal et al, 1993, Duggal et al, 2002, 
Kedar et al, 1979, Hall et al, 1978).  
4.5.1 Pathogenesis 
The pathophysiological relationship between scleroderma and malignancy remains poorly 
understood. There might be multiple pathways leading to cancer in general, and 
lymphoproliferative disorders in particular. B cells have many pathogenic roles in SSc (Sato 
et al, 2004). SSc patients are indeed characterized by alterations of the B-cell homeostasis, 
such as expansion of naïve cells, decreased number of circulating but activated memory cells 
and defective natural killer cells activity (Sato et al, 2004, Horikawa et al, 2005). Therefore, 
altered B cell functions may be responsible of the higher incidence of B NHL. Also TGF-β, a 
cytokine involved in the regulation of connective tissue proteins, which is highly expressed 
in SSc tissues, might play an important role since dysregulated signalling of the TGF-β is 
capable to induce tumorigenesis (Grady, 2005). Moreover, the malignant transformation 
might be a consequence of chronic tissue damage. Finally, EBV-encoded small RNAs have 
been detected in the majority of DLBCLs associated with systemic rheumatic diseases, 
including SSc (Kojima et al, 2006). In conclusion, a clear relationship between SSc and NHL 
has not yet been ascertained and further studies with higher number of patients are required 
to clarify the coexistence of these two entities. 
4.6 Celiac disease 
Celiac disease (CD) is a chronic autoimmune enteropathy affecting small-intestine, triggered 
by gluten proteins from wheat, barley and rye. The small-intestinal mucosal injury caused 
by the autoimmune response determines malabsorption which results in gastrointestinal 
symptoms (diarrhoea, weight loss, abdominal pain, anorexia, lactose intolerance, abdominal 
distension and irritability) and/or non-gastrointestinal features (iron-deficiency anaemia, 
dermatitis herpetiformis, chronic fatigue, joint pain/inflammation, migraines, depression, 
attention-deficit disorder, epilepsy, osteoporosis/osteopenia, infertility and/or recurrent 
fetal loss, vitamin deficiencies, short stature, failure to thrive, delayed puberty, dental 
defects and autoimmune disorders). The diagnosis of CD is based on histologic 
characteristics of small-bowel biopsy and on clinical and histological remission after a strict 
gluten-free diet. The presence of circulating CD-associated antibodies, such as IgA against 
the endomysium of connective tissue and against tissue transglutaminase, at time of 
diagnosis and their normalization after a gluten-free diet support the diagnosis of CD. Most 
CD patients display specific pairs of allelic variants in two HLA genes, HLA-DQA1 and 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
362 
HLA-DQB1. Adhering to a strict gluten-free diet usually results in healing of the damaged 
small-intestinal mucosa and improvement of intestinal absorption. A gluten-free diet is 
sufficient to treat the majority of patients. Two–5% of patients with adult-onset CD, 
especially those diagnosed above the age of 50, does not respond to a gluten-free diet (Tack 
et al, 2010a). Refractory celiac disease (RCD) is defined when clinical and histological 
symptoms recur after a good response to a gluten-free diet or persist after more than 12 
months of strict diet. Patients affected by CD are at increased risk of lymphoma 
development, not only primary gastrointestinal, but at any site. The occurrence of an EATL 
is the main cause of death in RCD patient. About 50-60% of patients with RCD type II 
develop an EATL within 5 years (Al-Toma et al, 2007, Di Sabatino & Corazza, 2009, Daum et 
al, 2003). Despite the strong association between CD and EATL, the majority of lymphomas 
associated with CD are of different histologies, such as DLBCL and peripheral T cell 
lymphomas (Catassi et al, 2002, Mearin et al, 2006, Smedby et al, 2005, Halfdanarson et al, 
2010). 
4.6.1 Epidemiology 
Earlier estimates of risk of NHL in CD amply varies, from no increased risk (Collin et al, 
1994) to a 42-fold (Holmes et al, 1989) or a 69-fold increased risk of NHL (Corrao et al, 2001). 
A significant increased risk of NHL among CD patients has been reported, with a SIR of 2.2 
(95% CI 1.3-3.6) for B-cell NHL and 3.6 (95% CI 2.3-5.2) for lymphomas of non-intestinal 
origin (Smedby et al, 2005), most common subtype being DLBCL. The RR for T cell NHL was 
50-fold increased. Patients with B-cell lymphomas have been demonstrated to have a better 
prognosis that those with T cell NHL (Halfdanarson et al, 2010). To investigate the frequency 
of CD among patients with NHL a prospective, multi-centre case-control study was 
conducted in 10 European countries between 1998 and 2002, showing that patients with CD 
have a significantly increased risk of developing NHL (OR=2.6 95%CI=1.4-4.9) in 
comparison with the general population. Importantly, the increased frequency of CD in 
NHL occurred in those celiac patients diagnosed clinically before screening and not in 
undiagnosed CD (Mearin et al, 2006). Another large nationwide population-based study 
assessed and compared risk of developing a lymphoproliferative disease among three 
different classes of subjects: patients affected by CD, patients with small bowel intestinal 
inflammation and patients with latent CD. It was showed an increased risk of 
lymphoproliferative malignancy (HR=2.82 95% CI 2.36-3.37) associated with the presence of 
a biopsy-proven CD, even after 5 years of follow up, but not with latent CD. The increased 
risk regarded NHL of the T cell and the B cell type as well as HL (Elfstrom et al, 2011). The 
risk of developing a lymphoma in CD patients is related to the age of diagnosis of CD. As a 
matter of fact, mean age at diagnosis of patients who develops a cancer is higher than that of 
patients who did not (Silano et al, 2007). This could be due to the diagnostic delay causing a 
prolonged period of dietary exposure to gluten (Holmes et al, 1989, Corrao et al, 2001). The 
risk of developing a malignancy in patients with CD who adhere to a gluten-free diet for 
five consecutive years or more is not increased compared with that of general population 
(Holmes et al, 1989, Lewis et al, 1996, Silano et al, 2008). 
4.6.2 EATL  
EATL is an intestinal tumour of intraepithelial T lymphocytes, usually presenting as a 
neoplasm composed of large lymphoid cells and often associated with necrosis and an 
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inflammatory background, including large number of histiocytes and eosinophils. The 
adjacent intestinal mucosa frequently shows enteropathy with villous atrophy, crypt 
hyperplasia, increased lamina propria lymphocytes and plasma cells and intraepithelial 
lymphocytosis (Chott et al, 1998). In 10-20% of cases, lymphoma is composed of 
monomorphic medium-sized cells with no inflammatory background and rare necrosis 
(type II EATL) and may occur sporadically, not associated with CD. EATL more often 
occurs in the jejunum or ileum as one or more ulcerating mucosal lesions that invade the 
wall of intestine and frequently cause perforation. The time interval between diagnosis of 
CD and development of lymphoma varies from 2 months to more than 5 years (Ilyas et al, 
1995). HLA genotyping shows that patients with EATL have the CD-associated DQA1*0501, 
DQB1*0201 phenotype, and additional HLA-DR/DQ alleles may increase the risk of 
lymphoma (Wright, 1995).  
4.6.2.1 Pathogenesis 
RCD patients can be classified as RCD type I and type II. Type-II RCD patients have >20% 
phenotypically aberrant intraepithelial lymphocytes (IEL), expressing cytoplasmatic CD3, 
but lacking surface expression of CD3, CD4 and CD8, while type-I RCD patients have 
normal IEL (Cellier et al, 2000, Patey-Mariaud De Serre et al, 2000). IEL with aberrant 
phenotype also show monoclonal T-cell receptor (TCR)-gamma rearrangement (Bagdi et al, 
1999), suggesting that these cells constitute a neoplastic population. Moreover, in those 
patients with type II RCD who subsequently develop EATL, the IEL share the same 
monoclonal TCR-gamma as the subsequent T-cell lymphoma (Cellier et al, 2000, Cellier et al, 
1998, Daum et al, 2005, Ashton-Key et al, 1997) and carry gain of chromosome 1q in common 
with 16% of EATL (Verkarre et al, 2003). Therefore, type II RCD may be considered an 
example of cryptic intraepithelial T-cell lymphoma (Daum et al, 2001). CD30+ IEL in RCD II 
seem to indicate a worse prognosis, including risk of developing lymphoma (Farstad et al, 
2002). Also interleukin 15 (IL15) might play a role in lymphomagenesis. Uncontrolled 
overexpression of IL15 by enterocytes in patients with type-II RCD promotes and maintain 
activation of IEL, favouring the emergence of T-cell clonal proliferations and the subsequent 
transformation into EATL (Mention et al, 2003).  
4.6.2.2 Clinical characteristics and prognosis 
EATL often present at older age (mean > 60 years) and in patients with a reduced 
performance status. In most cases disease is disseminated at diagnosis. Patients generally 
present with abdominal pain, often associated with jejunal perforation, weight loss, 
diarrhoea or bowel obstruction. Since obstruction and perforation are frequent, many cases 
are diagnosed at laparotomy. EATL is characterized by multifocal presentation in 10-25% of 
cases. Neurologic symptoms are reported in approximately 6% of adults with CD, of which 
cerebellar ataxia is the most frequent one. EATL is an aggressive malignancy that, if 
untreated, leads to death due to multifocal intestinal perforation caused by refractory 
malignant ulcers. The prognosis of EATL is very poor compared with that of intestinal B cell 
lymphomas (Domizio et al, 1993). It shows low chemosensitivity, rapid tumour growth and 
a tendency to dissemination with about 80% of patients experiencing relapse, even after 5 
years of follow up, and a 1- and 5-year survival rates of 31-39% and 8-20% respectively (Al-
Toma et al, 2007, Daum et al, 2003). Overall, the dismal prognosis of these patients reflects in 
part late diagnosis and in part the poor performance status due to the compromised 
immunological and nutritional status (Gale et al, 2000). Stage is the main prognostic factor, 
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HLA-DQB1. Adhering to a strict gluten-free diet usually results in healing of the damaged 
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patients who did not (Silano et al, 2007). This could be due to the diagnostic delay causing a 
prolonged period of dietary exposure to gluten (Holmes et al, 1989, Corrao et al, 2001). The 
risk of developing a malignancy in patients with CD who adhere to a gluten-free diet for 
five consecutive years or more is not increased compared with that of general population 
(Holmes et al, 1989, Lewis et al, 1996, Silano et al, 2008). 
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EATL is an intestinal tumour of intraepithelial T lymphocytes, usually presenting as a 
neoplasm composed of large lymphoid cells and often associated with necrosis and an 
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(type II EATL) and may occur sporadically, not associated with CD. EATL more often 
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wall of intestine and frequently cause perforation. The time interval between diagnosis of 
CD and development of lymphoma varies from 2 months to more than 5 years (Ilyas et al, 
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DQB1*0201 phenotype, and additional HLA-DR/DQ alleles may increase the risk of 
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but lacking surface expression of CD3, CD4 and CD8, while type-I RCD patients have 
normal IEL (Cellier et al, 2000, Patey-Mariaud De Serre et al, 2000). IEL with aberrant 
phenotype also show monoclonal T-cell receptor (TCR)-gamma rearrangement (Bagdi et al, 
1999), suggesting that these cells constitute a neoplastic population. Moreover, in those 
patients with type II RCD who subsequently develop EATL, the IEL share the same 
monoclonal TCR-gamma as the subsequent T-cell lymphoma (Cellier et al, 2000, Cellier et al, 
1998, Daum et al, 2005, Ashton-Key et al, 1997) and carry gain of chromosome 1q in common 
with 16% of EATL (Verkarre et al, 2003). Therefore, type II RCD may be considered an 
example of cryptic intraepithelial T-cell lymphoma (Daum et al, 2001). CD30+ IEL in RCD II 
seem to indicate a worse prognosis, including risk of developing lymphoma (Farstad et al, 
2002). Also interleukin 15 (IL15) might play a role in lymphomagenesis. Uncontrolled 
overexpression of IL15 by enterocytes in patients with type-II RCD promotes and maintain 
activation of IEL, favouring the emergence of T-cell clonal proliferations and the subsequent 
transformation into EATL (Mention et al, 2003).  
4.6.2.2 Clinical characteristics and prognosis 
EATL often present at older age (mean > 60 years) and in patients with a reduced 
performance status. In most cases disease is disseminated at diagnosis. Patients generally 
present with abdominal pain, often associated with jejunal perforation, weight loss, 
diarrhoea or bowel obstruction. Since obstruction and perforation are frequent, many cases 
are diagnosed at laparotomy. EATL is characterized by multifocal presentation in 10-25% of 
cases. Neurologic symptoms are reported in approximately 6% of adults with CD, of which 
cerebellar ataxia is the most frequent one. EATL is an aggressive malignancy that, if 
untreated, leads to death due to multifocal intestinal perforation caused by refractory 
malignant ulcers. The prognosis of EATL is very poor compared with that of intestinal B cell 
lymphomas (Domizio et al, 1993). It shows low chemosensitivity, rapid tumour growth and 
a tendency to dissemination with about 80% of patients experiencing relapse, even after 5 
years of follow up, and a 1- and 5-year survival rates of 31-39% and 8-20% respectively (Al-
Toma et al, 2007, Daum et al, 2003). Overall, the dismal prognosis of these patients reflects in 
part late diagnosis and in part the poor performance status due to the compromised 
immunological and nutritional status (Gale et al, 2000). Stage is the main prognostic factor, 
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with a 5-year cause-specific survival higher than 60% for patients with limited disease and 
25% for those with advanced stage (d'Amore et al, 1994, Chott et al, 1992). 
4.6.2.3 Therapy 
A standard treatment for patients with EATL has not been established, and reported results 
are overall unsatisfactory. Most patients with EATL are managed with a surgical approach 
as the primary strategy. Even if surgery is not a curative approach, debulking and resection 
of masses at high risk of perforation following chemotherapy or occlusion are frequently 
indicated in these patients. Involved-field radiotherapy 35 Gy was indicated in some 
patients with bulky disease or incomplete resection (Novakovic et al, 2006), but it is used 
almost exclusively with palliative purposes. Combined treatment modality with debulking 
surgery followed by systemic anthracycline-containing polichemotherapy, with or without 
consolidation radiotherapy, showed an ORR of 58%, a 5-year FFS of 3% and a 5-year OS of 
20-25% (Domizio et al, 1993, Gale et al, 2000, d'Amore et al, 1994, Morton et al, 1993). Many 
patients are unable to complete the chemotherapy program and do not receive radiotherapy 
due to rapid disease progression, poor nutritional and performance status, associated with 
local and systemic complications (Daum et al, 2003, Gale et al, 2000). Given the dismal 
prognosis of patients treated with conventional chemotherapy, some authors assessed 
feasibility and activity of high-dose chemotherapy supported by autologous stem cell 
transplantation as upfront treatment of EATL, with conflicting results. Most of these studies 
are based on small retrospective series of patients with disomogeneous characteristics, and 
utilizing different conditioning regimens (Al-Toma et al, 2007, Bishton & Haynes, 2007). 
High-dose chemotherapy with IVE/MTX (ifosfamide, vincristine, etoposide, methotrexate) 
followed by ASCT has been associated with significantly better outcome in comparison with 
historical controls treated with conventional anthracycline-based chemotherapy. In fact, 
patients treated with IVE/MTX-ASCT had an improved remission rate (69% vs. 42%); lower 
death rates and higher 5-year PFS and OS (52% vs. 22% and 60% vs. 22%, respectively) 
(Sieniawski et al, 2010). Interestingly, chemotherapy supported by ASCT may also prevent 
EATL development in patients with RCD (Meijer et al, 2004). In fact, in a retrospective series 
of 18 patients with RCD type II, 13 patients successfully underwent conditioning with 
fludarabine and melphalan supported by ASCT, with a significant reduction of the aberrant 
T-cells in duodenal biopsies associated with improvement in clinical well-being and 
normalization of hematologic and biochemical markers. After a follow up > 2 years EATL 
developed only in one transplanted patients, with a 4-year survival rate of 66% (Tack et al, 
2010b). Alemtuzumab, a humanized anti-CD52 monoclonal antibody has been rarely used 
in EATL. The combination of gemcitabine and alemtuzumab has been successfully used in 
an elderly patients with poor performance status and extra-intestinal dissemination of EATL 
both at diagnosis and relapse (Soldini et al, 2008). Another patient with EATL was treated 
with alemtuzumab-CHOP combination at diagnosis in a prospective phase II trial on T-cell 
lymphomas achieving a short-lasting complete remission (Gallamini et al, 2007). Moreover, 
alemtuzumab was successfully used in the treatment of a patient with RCD at high risk of 
developing EATL, obtaining a total recovery of duodenal biopsy (Vivas et al, 2006). Patients 
with refractory or relapsed EATL and without formal contraindications should be therefore 
managed with high-dose chemotherapy supported by ASCT. Two patients in CR were 
treated with allogeneic SCT with reduced intensity conditioning regimen, with a HLA 
identical sibling donor. Both patients relapsed within few months after transplantation (van 
de Water et al, 2010). 
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4.7 Dermatitis herpetiformis 
Dermatitis herpetiformis (DH) is a gluten-sensitive skin disease characterized by an itchy, 
blistering rash which diagnosis is based on the presence of granular IgA deposits in the 
epidermal-dermal junction observed by direct immunofluorescence. About 75-80% of 
patients have an associated gluten-sensitive enteropathy with villous atrophy identical to 
that found in CD, even if gastrointestinal symptoms are rare, and the remaining show 
increased amount of  receptor bearing T lymphocytes in the jejunal mucosa (Savilahti et al, 
1992, Reunala, 1998). Both enteropathy and cutaneous rash recover with a gluten-free diet 
and relapse when diet is withdrawn (Fry et al, 1973, Reunala et al, 1977), suggesting that DH 
might be a cutaneous manifestation of CD. Moreover, almost all patients affected by DH 
carry the HLA alleles DQA1*0501 and DQB1*0201 typical of CD (Fronek et al, 1991). Since 
1970, it is thought that patients with DH but without clinical sign of CD have an increased 
risk of developing cancer (Gjone & Nordoy, 1970), and some cases of patients with DH and 
lymphoma were reported (Jenkins et al, 1983, Reunala et al, 1982). The first large population-
based cohort study assessing lymphoma risk in DH included 976 patients affected by DH 
without concomitant CD diagnosed from 1964 to 1983 in Sweden (Sigurgeirsson et al, 1994). 
The RR of developing cancer resulted 1.4 (95% CI= 1.1-1.7) in male patients and 1.2 (95% CI= 
0.8-1.7) in female patients. This increased risk lost significance if lymphomas were excluded 
from analysis. In fact, analyzing cancer by subtype, it was found only a significant 
association with NHL (RR 5.4 95% CI= 2.2-11.1 in male patients and 4.5 95% CI=0.9-13.2 in 
female patients). The median time between the first admission to hospital and diagnosis of 
lymphoma was 4 years and the median age at diagnosis was 64 years. Most lymphomas 
were localized outside the gastrointestinal tract and were of the B cell phenotype. Only one 
case was classified as EATL. DH indeed is not only associated with EATL, but also with B-
cell lymphomas, which may occur both within and outside the gastrointestinal tract as nodal 
or extranodal disease (Hervonen et al, 2005, Viljamaa et al, 2006). One possible reason for this 
discrepancy may be the less severe small bowel damage in DH with respect to that in CD. 
Occurrence of malignancy was assessed in another DH-patient cohort mainly treated with 
dapsone and gluten-free diet compared with patients affected by CD and general 
population (Collin et al, 1996). This study cohort included 305 consecutive Finnish patients 
diagnosed with DH from 1970 to 1992 and 383 patients diagnosed with CD. The only 
significantly increased SIR was that for NHL among patients with DH (10.3; 95% CI 2.8-
26.3), while the overall incidence of other malignancies was not increased. Of four patients 
who developed NHL, three were adhering to a gluten-free diet, but two for less than five 
years, which is probably a too short period to exhibit a protective effect against malignancy 
(Holmes et al, 1989). Extension of the follow up period for a further 12 years confirmed that 
patients who have adhered to a strict gluten-free diet for more than 5 years have no 
increased risk of developing lymphoma compared to the general population (Lewis et al, 
1996), supporting the protective role of a gluten-free diet against lymphoma development in 
DH (Hervonen et al, 2005). Moreover, three patients had abnormal small bowel villous 
architecture, while one patient had normal mucosa, implying that a normal small bowel 
mucosa in DH does not protect from lymphoma. Another retrospective cohort study has 
reported a 2-fold increased risk for malignant lymphoma (SIR=1.9; 95% CI 0.8-3.9) (Askling 
et al, 2002). Importantly, NHL occurrence seems to be reduced in DH patients whose 
diagnosis was made over the recent years (Viljamaa et al, 2006) maybe due to a less 
adherence of patients to a gluten-free diet in the past, not considered as essential as 
nowadays in DH. First-degree relatives of patients with DH or CD have an higher risk of 
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with a 5-year cause-specific survival higher than 60% for patients with limited disease and 
25% for those with advanced stage (d'Amore et al, 1994, Chott et al, 1992). 
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A standard treatment for patients with EATL has not been established, and reported results 
are overall unsatisfactory. Most patients with EATL are managed with a surgical approach 
as the primary strategy. Even if surgery is not a curative approach, debulking and resection 
of masses at high risk of perforation following chemotherapy or occlusion are frequently 
indicated in these patients. Involved-field radiotherapy 35 Gy was indicated in some 
patients with bulky disease or incomplete resection (Novakovic et al, 2006), but it is used 
almost exclusively with palliative purposes. Combined treatment modality with debulking 
surgery followed by systemic anthracycline-containing polichemotherapy, with or without 
consolidation radiotherapy, showed an ORR of 58%, a 5-year FFS of 3% and a 5-year OS of 
20-25% (Domizio et al, 1993, Gale et al, 2000, d'Amore et al, 1994, Morton et al, 1993). Many 
patients are unable to complete the chemotherapy program and do not receive radiotherapy 
due to rapid disease progression, poor nutritional and performance status, associated with 
local and systemic complications (Daum et al, 2003, Gale et al, 2000). Given the dismal 
prognosis of patients treated with conventional chemotherapy, some authors assessed 
feasibility and activity of high-dose chemotherapy supported by autologous stem cell 
transplantation as upfront treatment of EATL, with conflicting results. Most of these studies 
are based on small retrospective series of patients with disomogeneous characteristics, and 
utilizing different conditioning regimens (Al-Toma et al, 2007, Bishton & Haynes, 2007). 
High-dose chemotherapy with IVE/MTX (ifosfamide, vincristine, etoposide, methotrexate) 
followed by ASCT has been associated with significantly better outcome in comparison with 
historical controls treated with conventional anthracycline-based chemotherapy. In fact, 
patients treated with IVE/MTX-ASCT had an improved remission rate (69% vs. 42%); lower 
death rates and higher 5-year PFS and OS (52% vs. 22% and 60% vs. 22%, respectively) 
(Sieniawski et al, 2010). Interestingly, chemotherapy supported by ASCT may also prevent 
EATL development in patients with RCD (Meijer et al, 2004). In fact, in a retrospective series 
of 18 patients with RCD type II, 13 patients successfully underwent conditioning with 
fludarabine and melphalan supported by ASCT, with a significant reduction of the aberrant 
T-cells in duodenal biopsies associated with improvement in clinical well-being and 
normalization of hematologic and biochemical markers. After a follow up > 2 years EATL 
developed only in one transplanted patients, with a 4-year survival rate of 66% (Tack et al, 
2010b). Alemtuzumab, a humanized anti-CD52 monoclonal antibody has been rarely used 
in EATL. The combination of gemcitabine and alemtuzumab has been successfully used in 
an elderly patients with poor performance status and extra-intestinal dissemination of EATL 
both at diagnosis and relapse (Soldini et al, 2008). Another patient with EATL was treated 
with alemtuzumab-CHOP combination at diagnosis in a prospective phase II trial on T-cell 
lymphomas achieving a short-lasting complete remission (Gallamini et al, 2007). Moreover, 
alemtuzumab was successfully used in the treatment of a patient with RCD at high risk of 
developing EATL, obtaining a total recovery of duodenal biopsy (Vivas et al, 2006). Patients 
with refractory or relapsed EATL and without formal contraindications should be therefore 
managed with high-dose chemotherapy supported by ASCT. Two patients in CR were 
treated with allogeneic SCT with reduced intensity conditioning regimen, with a HLA 
identical sibling donor. Both patients relapsed within few months after transplantation (van 
de Water et al, 2010). 
 
Autoimmune Disorders and Lymphomas 
 
365 
4.7 Dermatitis herpetiformis 
Dermatitis herpetiformis (DH) is a gluten-sensitive skin disease characterized by an itchy, 
blistering rash which diagnosis is based on the presence of granular IgA deposits in the 
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that found in CD, even if gastrointestinal symptoms are rare, and the remaining show 
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might be a cutaneous manifestation of CD. Moreover, almost all patients affected by DH 
carry the HLA alleles DQA1*0501 and DQB1*0201 typical of CD (Fronek et al, 1991). Since 
1970, it is thought that patients with DH but without clinical sign of CD have an increased 
risk of developing cancer (Gjone & Nordoy, 1970), and some cases of patients with DH and 
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association with NHL (RR 5.4 95% CI= 2.2-11.1 in male patients and 4.5 95% CI=0.9-13.2 in 
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diagnosed with DH from 1970 to 1992 and 383 patients diagnosed with CD. The only 
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26.3), while the overall incidence of other malignancies was not increased. Of four patients 
who developed NHL, three were adhering to a gluten-free diet, but two for less than five 
years, which is probably a too short period to exhibit a protective effect against malignancy 
(Holmes et al, 1989). Extension of the follow up period for a further 12 years confirmed that 
patients who have adhered to a strict gluten-free diet for more than 5 years have no 
increased risk of developing lymphoma compared to the general population (Lewis et al, 
1996), supporting the protective role of a gluten-free diet against lymphoma development in 
DH (Hervonen et al, 2005). Moreover, three patients had abnormal small bowel villous 
architecture, while one patient had normal mucosa, implying that a normal small bowel 
mucosa in DH does not protect from lymphoma. Another retrospective cohort study has 
reported a 2-fold increased risk for malignant lymphoma (SIR=1.9; 95% CI 0.8-3.9) (Askling 
et al, 2002). Importantly, NHL occurrence seems to be reduced in DH patients whose 
diagnosis was made over the recent years (Viljamaa et al, 2006) maybe due to a less 
adherence of patients to a gluten-free diet in the past, not considered as essential as 
nowadays in DH. First-degree relatives of patients with DH or CD have an higher risk of 
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developing a gluten-sensitive enteropathy (Hervonen et al, 2002). This is not true for 
lymphoma risk, as demonstrated in a large series of patients with DH and their first-degree 
relatives, where three lymphoma cases (0.2%) were diagnosed among 1.825 first-degree 
relatives, compared with the prevalence in the general population of 0.1%. The 
aetiopathology of lymphoma development in patients with DH is unknown, but several 
mechanisms may be involved, such as the polyclonal stimulation of B or T lymphocytes by 
gluten in the gastrointestinal tract, leading to the transformation in a malignant clone. 
5. Conclusions 
The relationship existing between autoimmunity and cancer continues to fascinate clinicians 
and physicians. Many pathogenic and therapeutic overlaps have been demonstrated so far 
in these two intriguing and closely interrelated fields but several challenges remain open to 
future development. The exact pathogenic mechanism connecting both diseases remain still 
poorly understood and additional studies will explore genetic, biologic and inflammatory 
mechanisms underlying lymphoma development. Further epidemiologic studies are needed 
to ascertain which host factors may predispose in the setting of an autoimmune disease to 
develop a malignancy in general, and a lymphoproliferative disorder in particular, in order 
to define more accurately the pre-treatment risk. Finally, more surveillance studies will 
clarify if novel immunomodulatory treatments increase or decrease lymphoma risk. A more 
clear elucidation of these critical issues will lead to the development of novel therapeutic 
options able to improve the prevention and/or treatment of lymphomas in the setting of 
autoimmunity. 
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developing a gluten-sensitive enteropathy (Hervonen et al, 2002). This is not true for 
lymphoma risk, as demonstrated in a large series of patients with DH and their first-degree 
relatives, where three lymphoma cases (0.2%) were diagnosed among 1.825 first-degree 
relatives, compared with the prevalence in the general population of 0.1%. The 
aetiopathology of lymphoma development in patients with DH is unknown, but several 
mechanisms may be involved, such as the polyclonal stimulation of B or T lymphocytes by 
gluten in the gastrointestinal tract, leading to the transformation in a malignant clone. 
5. Conclusions 
The relationship existing between autoimmunity and cancer continues to fascinate clinicians 
and physicians. Many pathogenic and therapeutic overlaps have been demonstrated so far 
in these two intriguing and closely interrelated fields but several challenges remain open to 
future development. The exact pathogenic mechanism connecting both diseases remain still 
poorly understood and additional studies will explore genetic, biologic and inflammatory 
mechanisms underlying lymphoma development. Further epidemiologic studies are needed 
to ascertain which host factors may predispose in the setting of an autoimmune disease to 
develop a malignancy in general, and a lymphoproliferative disorder in particular, in order 
to define more accurately the pre-treatment risk. Finally, more surveillance studies will 
clarify if novel immunomodulatory treatments increase or decrease lymphoma risk. A more 
clear elucidation of these critical issues will lead to the development of novel therapeutic 
options able to improve the prevention and/or treatment of lymphomas in the setting of 
autoimmunity. 
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affects both young and elderly people. The increasing incidence of tumour discovery is a 
consequence of improving diagnosis techniques and sensitization acts, thus facilitating a 
precocious identification and consequently an immediate therapeutic approach 
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wide variations in incidence and severity (Silink, 2002). Autoimmune diseases arise from an 
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the body and they are due to the breakdown of immune tolerance to specific self-antigens. 
Cancers and autoimmunity are often coincident—more coincident than is generally 
appreciated; thereby it has been raised more interest the relationship and the possible 
temporal consequence between autoimmune disease and cancer onset. Particularly, since a 
high level of autoimmunity is unhealthy, a low level of autoimmunity may actually be 
beneficial, thereby autoimmune reactions may be considered as a defence processes played 
by the host against tumour, or  it may be possible that the anti-tumour immune response 
may result in elicitation of auto-antibodies against various auto-antigens, including self 
antigens expressed in tumour cells. 
Some autoimmune diseases, such as Sjögren's syndrome, rheumatoid arthritis and systemic 
lupus erythematosus have been associated with the development of lymphoproliferative 
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The mechanism behind disease etiology remains unknown for most autoimmune diseases. 
This situation is distinct from cancer where our understanding of how genetic mutations 
lead to disease, is increasing. These advancements in cancer biology may have provided a 
very important piece to the autoimmunity puzzle. However, the relationship between 
cancer and autoimmunity is not well known. Despite minimal supporting evidence, the 
standard model for explaining this coincidence is that autoimmunity leads to cancer due to 
the rapid cell division associated with the regeneration of damaged tissues at the site of 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
386 
subchondral bone: Proposal for a two-compartment model of immune-mediated 
disease with implications for immunotherapeutic strategies. Clinical Immunology 
and Immunopathology, 73, 27-37.  
Weetman, A.P. & McGregor, A.M. (1994) Autoimmune thyroid disease: Further 
developments in our understanding. Endocrine Reviews, 15, 788-830.  
Weinblatt, M.E., Maier, A.L., Fraser, P.A. & Coblyn, J.S. (1998) Longterm prospective study 
of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy. 
The Journal of Rheumatology, 25, 238-242.  
Weyand, C.M., Goronzy, J.J. & Kurtin, P.J. (2006) Lymphoma in rheumatoid arthritis: An 
immune system set up for failure. Arthritis and Rheumatism, 54, 685-689.  
Wolfe, F. & Michaud, K. (2007) The effect of methotrexate and anti-tumor necrosis factor 
therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 
89,710 person-years of observation. Arthritis and Rheumatism, 56, 1433-1439.  
Wolfe, F. & Michaud, K. (2004) Lymphoma in rheumatoid arthritis: The effect of 
methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis and 
Rheumatism, 50, 1740-1751.  
Wright, D.H. (1995) The major complications of coeliac disease. Bailliere's Clinical 
Gastroenterology, 9, 351-369.  
Xin, H., D'Souza, S., Jorgensen, T.N., Vaughan, A.T., Lengyel, P., Kotzin, B.L. & Choubey, D. 
(2006) Increased expression of Ifi202, an IFN-activatable gene, in B6.Nba2 lupus 
susceptible mice inhibits p53-mediated apoptosis. Journal of Immunology (Baltimore, 
Md.: 1950), 176, 5863-5870.  
Xu, Y. & Wiernik, P.H. (2001) Systemic lupus erythematosus and B-cell hematologic 
neoplasm. Lupus, 10, 841-850.  
Yao, Q.Y., Rickinson, A.B., Gaston, J.S. & Epstein, M.A. (1986) Disturbance of the epstein-
barr virus-host balance in rheumatoid arthritis patients: A quantitative study. 
Clinical and Experimental Immunology, 64, 302-310.  
Youinou, P., Devauchelle-Pensec, V. & Pers, J.O. (2010) Significance of B cells and B cell 
clonality in sjogren's syndrome. Arthritis and Rheumatism, 62, 2605-2610.  
Youinou, P., Papadopoulos, N.M., Katsikis, P., Pennec, Y.L., Jouquan, J., Lelong, A. & 
Moutsopoulos, H.M. (1988) Monoclonal immunoglobulins in the serum of patients 
with primary sjogren's syndrome. Clinical and Experimental Rheumatology, 6, 247-252.  
Young, L.S. & Rickinson, A.B. (2004) Epstein-barr virus: 40 years on. Nature Reviews.Cancer, 
4, 757-768.  
Zatuchni, J., Campbell, W.N. & Zarafonetis, C.J. (1953) Pulmonary fibrosis and terminal 
bronchiolar (alveolar-cell) carcinoma in scleroderma. Cancer, 6, 1147-1158.  
Zhang, Y., Holford, T.R., Leaderer, B., Zahm, S.H., Boyle, P., Morton, L.M., Zhang, B., Zou, 
K., Flynn, S., Tallini, G., Owens, P.H. & Zheng, T. (2004) Prior medical conditions 
and medication use and risk of non-hodgkin lymphoma in connecticut united 
states women. Cancer Causes & Control : CCC, 15, 419-428.  
Zintzaras, E., Voulgarelis, M. & Moutsopoulos, H.M. (2005) The risk of lymphoma 
development in autoimmune diseases: A meta-analysis. Archives of Internal 
Medicine, 165, 2337-2344.  
19 
A Possible Link Between 
Autoimmunity and Cancer 
Erika Cristaldi, Giulia Malaguarnera, 
Alessandra Rando and Mariano Malaguarnera 
University of Catania 
Italy 
1. Introduction 
The most important cause of mortality after cardiovascular diseases is due to cancer, that 
affects both young and elderly people. The increasing incidence of tumour discovery is a 
consequence of improving diagnosis techniques and sensitization acts, thus facilitating a 
precocious identification and consequently an immediate therapeutic approach 
(Malaguarnera et al., 2010). 
Autoimmune diseases represent one of the main growing health problem worldwide with 
wide variations in incidence and severity (Silink, 2002). Autoimmune diseases arise from an 
overactive immune response of the body against substances and tissues normally present in 
the body and they are due to the breakdown of immune tolerance to specific self-antigens. 
Cancers and autoimmunity are often coincident—more coincident than is generally 
appreciated; thereby it has been raised more interest the relationship and the possible 
temporal consequence between autoimmune disease and cancer onset. Particularly, since a 
high level of autoimmunity is unhealthy, a low level of autoimmunity may actually be 
beneficial, thereby autoimmune reactions may be considered as a defence processes played 
by the host against tumour, or  it may be possible that the anti-tumour immune response 
may result in elicitation of auto-antibodies against various auto-antigens, including self 
antigens expressed in tumour cells. 
Some autoimmune diseases, such as Sjögren's syndrome, rheumatoid arthritis and systemic 
lupus erythematosus have been associated with the development of lymphoproliferative 
malignancies (Kiss et al., 2010), and a pleyade of autoantibodies have been found in patients 
with solid tumours (Bei et al., 2009). In addition, patients with dermatomyositis have a 
greater risk of developing solid-organ malignancies than the general population. In these 
patients, cancer can precede, parallel or follow myositis diagnosis (Zampieri et al., 2010). 
The mechanism behind disease etiology remains unknown for most autoimmune diseases. 
This situation is distinct from cancer where our understanding of how genetic mutations 
lead to disease, is increasing. These advancements in cancer biology may have provided a 
very important piece to the autoimmunity puzzle. However, the relationship between 
cancer and autoimmunity is not well known. Despite minimal supporting evidence, the 
standard model for explaining this coincidence is that autoimmunity leads to cancer due to 
the rapid cell division associated with the regeneration of damaged tissues at the site of 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
388 
inflammation (Coussens & Werb, 2002). The relationship between autoimmunity and cancer 
was investigated, focusing on implication of immune system, apoptosis and new 
therapeutic agents for autoimmune diseases.  
2. Break tolerance mechanisms in autoimmune diseases 
The clinical signs and symptoms of different autoimmune diseases overlap, and individual 
patients often present with syndromes that combine features of more than one disease. 
Different autoimmune diseases share some genetic predisposing factors, including human 
leukocyte antigen (HLA) alleles (SLEGEN et al., 2008) or the T-cell regulatory gene CTLA-4 
(Ueda et al., 2003). Our current knowledge suggests that multiple mutation might be needed 
before a self-reactive clone bypasses sequential tolerance-checkpoints and gives rise to an 
autoimmune disease (Baechler et al., 2003). The development of autoantibodies reflects a 
loss of B- and T- cell tolerance, which might result from a combination of genetic 
predisposition, persistent inflammatory responses, abnormal handling of apoptotic material 
and immune complexes, abnormal presentation of self-antigens and other events. As a high 
level of autoimmunity is unhealthy, a low level of autoimmunity may actually be beneficial. 
First, low-level autoimmunity might aid in the recognition of neoplastic cells by CD8+ T 
cells, and thus reducing the incidence of cancer. Second, autoimmunity may have an 
important role, allowing a rapid immune response in the early stages of an infection when 
the availability of foreign antigens limits the response (i.e., when there are few pathogens 
present).   
Diseases such as rheumatoid arthritis and tireotoxicosis are associated with the loss of 
immunological tolerance, which is the ability of an individual to ignore self, while reacting 
to non-self. This breakage leads to the immune system mounting an effective and specific 
immune response against self determinants. The exact genesis of immunological tolerance is 
still unclear, but several theories have been proposed to explain its origin. Two hypotheses 
have gained widespread attention among immunologists: 
 Clonal Deletion theory, proposed by Burnet (1988), according to which self-reactive 
lymphoid cells are destroyed during their development. The extent to which the 
thymus can mediate tolerance to tissue-specific proteins and how organ specific 
tolerance is mediated remains an open question. While some tissue-specific proteins 
might reach the thymus through the circulation, this mechanism may be unnecessary 
due to expression within the thymus of the autoimmune regulator protein AIRE, which 
acts as a promiscuous ubiquitin ligase with the potential function of controlling 
transcription of a broad array of tissue-specific target genes in thymic epithelial cells 
(Nagamine et al., 1997). 
 Clonal Anergy theory, proposed by Nossal et al.  (1982), in which self-reactive T- or B-
cells become inactivated in the normal individual and cannot amplify the immune 
response. This process is based upon the requirement of two signals for T-cell 
activation. The first is provided by the recognition of MHC-complexes and the second is 
due to the interaction between CD28 on T cells and B7 on activated antigen presenting 
cell (APC), that are induced by pro-inflammatory factors, such as bacterial products, 
pro-inflammatory cytokines, and other signals. 
Previously, conditions such as cancer could not stimulate immune responses due to lack of co-
stimulatory signals. However, this notion was based on cancers at late or advanced stages of 
disease, when tumour-induced immunosuppression may be at its highest degree (e.g. through 
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production of the regulatory cytokines, transforming growth factor (TGF)-β and IL-10); in fact 
there is a considerable potential for newly transformed cells to evoke danger signals through 
the engagement of pro-inflammatory signaling pathways (Eisenlohr & Rothstein, 2006). 
3. Autoimmune diseases and cancer - pathogenetic aspects 
Positive associations have been reported between certain lymphomas and inflammation, 
autoimmune disease and infectious agents (Rosenquist, 2008). 
Normally, tolerance checkpoints silence self-reactive T and B cells by preventing 
uncontrolled stimulation through self-antigens exposure. Several observations suggest that 
lymphocyte clones having bypassed tolerance mechanisms may be involved both in 
autoimmunity and malignancy (Goodnow, 2007). There are epidemiological observations of 
autoimmunity and lymphoma occurring simultaneously in diseases like systemic lupus 
erythematosus, rheumatoid arthritis and Sjögren's syndrome regardless of the use of 
immunosuppressive therapy (Bernatsky et al., 2007). 
Infectious agents causing lymphomas can be classified according to several mechanisms. 
First, some viruses can directly transform lymphocytes as for Burkitt’s lymphomas that may 
occur following infection with HIV; as well as T-cell lymphomas may occur following 
chronic antigen challenge with wheat in celiac disease (Cellier et al., 2000). Second, some 
infections increase lymphoma risk through chronic immune stimulation (Engels, 2007), 
which is also present in autoimmune diseases. Since uncontrolled stimulation of antigen 
receptors and lymphocyte proliferation triggered by chronic infection (e.g. Helicobacter 
pylori) may result in mucosa-associated lymphoid- tissue B-cell lymphomas (Suarez et 
al.,2006), it may be supposed that chronic stimulation of autoreactive cells paired with 
somatic hypermutation and recombinase activator gene (RAG) activity directed at non-
antigen receptor loci may underlie lymphoma in systemic lupus erythematosus, rheumatoid 
arthritis and Sjögren's syndrome (Schuetz et al., 2010). 
Treatments for autoimmune and chronic inflammatory disorders could also affect the risk of 
lymphoproliferative malignancies. Another reason for the association could be shared 
environmental risk factors (Landgren et al., 2006), and in some autoimmune diseases genetic 
mutations are discovered, leading to lymphoproliferation (Turbyville & Rao, 2010). Somatic 
mutations in lymphocytes may additionally contribute to the pathogenesis of autoimmunity 
and lymphoid malignancies as observed in patients with autoimmune lymphoproliferative 
syndrome carrying a mutated FAS gene in a single hematopoietic stem cell that contributes 
to a small fraction of blood cells. These patients may present with autoimmune symptoms 
and lymphoma formation just like patients with inherited FAS mutations (Holzelova et al., 
2004). 
4. The role of adaptive immunity 
4.1 Treg cells 
Regulatory T (Treg) cells are currently considered as key players in the mechanisms of 
peripheral immune tolerance. They are classified in natural and inducible CD4+CD25+ 
FOXP3+ Treg cells. The transcription regulator FOXP3 (Forkhead box P3) appears to be 
required for the development, maintenance, and suppressor function of Treg cells (Hori et 
al., 2003), and the loss of FOXP3 in Treg cells - or its reduced expression - leads to the 
acquisition of effector T-cell properties including the production of non-Treg cell specific 
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and lymphoid malignancies as observed in patients with autoimmune lymphoproliferative 
syndrome carrying a mutated FAS gene in a single hematopoietic stem cell that contributes 
to a small fraction of blood cells. These patients may present with autoimmune symptoms 
and lymphoma formation just like patients with inherited FAS mutations (Holzelova et al., 
2004). 
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4.1 Treg cells 
Regulatory T (Treg) cells are currently considered as key players in the mechanisms of 
peripheral immune tolerance. They are classified in natural and inducible CD4+CD25+ 
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al., 2003), and the loss of FOXP3 in Treg cells - or its reduced expression - leads to the 
acquisition of effector T-cell properties including the production of non-Treg cell specific 
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cytokines (Wan & Flavell, 2007). Treg cells are engaged in the control of immune self-
tolerance, allograft rejection, allergy, and are also important for inhibiting the effector 
functions during infection and tumours development. In addition, the removal or a 
functional defect of Treg cells from normal rodents leads to the development of various 
autoimmune diseases (Weiner, 2001), because these cells actively suppress the activation 
and expansion of autoreactive immune cells. 
Sometimes the studies investigating the role of Treg cells in SLE, have given controversial 
results (Khun et al., 2009). Most studies have found a reduced or normal frequency of Treg 
cells in SLE (La Cava, 2008), although other studies may have shown increased number. It 
has been observed a decreased number of Treg cells, during active disease flares (Miyara et 
al., 2005) and active SLE pediatric patients, thereby showing a poor suppressive capacity 
and an inverse correlation between Treg cells and  disease activity as well as autoantibody 
levels (Lee et al., 2006). However, treatment with corticosteroids and/or 
immunosuppressive agents has been found to promote an increase in the number of Treg 
cells, particularly of peripheral Treg cells. Also, increased mRNA levels of CD25, FOXP3, 
and GITR have been found in B-cell depleted patients treated with rituximab at the time of B 
cell repopulation (Cepika et al., 2007).  
In the collagen-induced arthritis model of systemic joint inflammation, the adoptive transfer 
of Treg cells protects from disease, whereas a depletion of Treg cells accelerates it (Morgan 
et al., 2005). Furthermore, in patients with early rheumatoid arthritis (RA), a reduced 
number of peripheral Treg cells is observed (Lawson et al., 2006), although the synovial 
fluid can often contain increased numbers of Treg cells (Cao et al., 2003). 
Furthermore, increased frequency of Foxp3+ Treg cells has been documented in tumour 
tissues and peripheral blood of patients with several types of cancer consistent with a role in 
tumour escape from immunological control. And also, not only the quantitative aspect of 
Treg cells, but also their functions are different between tumour patients and healthy 
control. Treg cells are considered inhibitors of anti-tumour immunity and 
CD4+CD25+Foxp3+ regulatory T cells have been considered as a candidate for cancer 
immunotherapy for over a decade. Attempts to block or eliminate Treg cells have been 
made by the use of chemotherapy; these strategies, aimed at block Treg cells induction and 
migration, may be clinically useful, as suggested by experimental evidences in tumour 
models (Langier et al., 2010). 
Data concerning the role of CD4+CD25+ regulatory T cells in human cancer derived from a 
work, which showed that the presence of such Treg cells in advanced ovarian cancer 
correlated with reduced survival (Curiel et al., 2004). In addition,  TGF-β is a cytokine 
produced by Treg and Type 1 T regulatory cells, that is involved in the suppression of T cell 
proliferation and function (M.L. Chen et al., 2005). The experimental results supplied by 
other researchs indicate that TGF-β, secreted by ovarian carcinoma cells, owns vital function 
in the process of converting peripheral CD4+CD25– T cells into CD4+CD25+ regulatory T 
cells, likely providing a possible immunotherapeutic target for ovarian cancer (Zheng et al., 
2004).  
One of the new therapeutic approach to cancer is based on the adoptive transfer of tumour-
specific cytotoxic T cells and anti-CD25 antibodies. A combination of Treg cell-depletion, 
using anti-CD25 monoclonal antibodies, and cytotoxic T lymphocytes administration is a 
possible approach for treatment of cancers which enable further exploration in the clinical 
setting (Ohmura et al., 2008), though these future approaches suggest a possible 
development of autoimmune diseases, due to decreased Treg cells occurrence. 
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4.2 Dendritic cells 
Dendritic cells have been recognized as the most efficient antigen presenting cells that have 
the capacity to initiate naïve T-cell response in vitro and in vivo. During their differentiation 
and maturation pathways, DCs can efficiently capture, process and present antigens for T-
cell activation. The functional activities of DCs mainly depend on their state of activation 
and differentiation: iDC are involved in the maintenance of peripheral tolerance whereas 
mature DC can efficiently induce the development of effector T cells. Thereby, accumulated 
iDCs, which are educated at the tumour site, act as functional inhibitors of a tumour-specific 
immune response in cancer, immature pDCs are activated by Toll-like receptors, which lead 
to B- and T-cell immune responses in autoimmune disease (Lang et al., 2005). The 
immunological tolerance is produced by tumour-derived soluble factors (TDSFs) and 
immature dendritic cells (iDCs), which inhibit DC and T-cell activation, and exclusively 
inhibit the DNA–IgG immune complex, inducing pro-inflammatory responses needed for an 
immune response. Immunological ignorance is produced by reduced levels of tumour 
antigens. Dendritic cells not only initiate T-cell responses, but are also involved in silencing 
T-cell immune response. DC can play a central role in the development of T-cell tolerance, 
and its maintenance in the periphery is critical for the prevention of autoimmunity. 
4.3 T helper 17 cells (Th17) 
T helper 17 cells constitute a third subset of T helper cells that are important in the 
development of autoimmune diseases and in the immune response against infections.  
These cells are characterized as preferential producers of IL-17A, IL-17F, IL-21, IL-22 and IL-
26 in humans. The IL-17 production is required to differentiate Th17 cells, from IFN-γ 
producing Th1 cells, or IL-4 producing Th2 cells. IL-17 (A and F) induces production of a 
broad range of pro-inflammatory cytokines and chemokines, including IL-6, colony-
stimulating factors, chemokines (CCL2, CCL7, CXCL1, and CCL20), human β-defensin-2 
and matrix metalloproteinases (MMP-3 and MMP-13), by a variety of cells (Weaver et al., 
2007). Conversely, inhibition of IL-17 signaling leads to impaired host defence against 
bacterial infection (Ye et al., 2001) and resistance to autoimmune diseases (Yang et al., 2008). 
IL-17 regulates host defence against infectious organisms through promoting granulopoiesis 
and neutrophil trafficking (Linden et al., 2005).  
Although FOXP3+ Treg cells are critical for control of autoimmunity and inflammation 
(Sakaguchi, 2004), Th17 cells have been implicated in mediating inflammation and 
autoimmune diseases (Weaver et al., 2007). It has been shown that the balance between Treg 
and Th17 cells is a key factor which regulates T-helper cell function relating to the Th1  Th2 
shift in autoimmune disease and graft versus host disease (GVHD) (Afzali et al., 2007). In 
fact, elevated levels of IL-17 have been associated with inflammatory diseases in humans, 
including rheumatoid arthritis, scleritis, uveitis, asthma, systemic lupus erythematosus, and 
allograft rejection (Kolls & Linden, 2004). 
However, there are limited information on the balance between Treg and Th17 cells in 
cancer patients and on the active role played by Th 17 in anti-tumour immunity (Kryczek et 
al., 2009). The function of IL-17 in tumour immunity is a controversial subject. The effects of 
IL-17 on tumour development are directly influenced by the existence of an adaptive 
immune system. In the presence of lymphocytes, IL-17 promotes tumour rejection, whereas 
in the absence of those, IL-17 favours tumour growth and angiogenesis (Martin-Orozco & 
Chen Dong, 2009a). By using IL-17-deficient mice in a model of lung melanoma, it has been 
provided direct evidence for a protective role of IL-17 in anti tumour responses (Martin-
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tumour escape from immunological control. And also, not only the quantitative aspect of 
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CD4+CD25+Foxp3+ regulatory T cells have been considered as a candidate for cancer 
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development of autoimmune diseases, due to decreased Treg cells occurrence. 
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4.2 Dendritic cells 
Dendritic cells have been recognized as the most efficient antigen presenting cells that have 
the capacity to initiate naïve T-cell response in vitro and in vivo. During their differentiation 
and maturation pathways, DCs can efficiently capture, process and present antigens for T-
cell activation. The functional activities of DCs mainly depend on their state of activation 
and differentiation: iDC are involved in the maintenance of peripheral tolerance whereas 
mature DC can efficiently induce the development of effector T cells. Thereby, accumulated 
iDCs, which are educated at the tumour site, act as functional inhibitors of a tumour-specific 
immune response in cancer, immature pDCs are activated by Toll-like receptors, which lead 
to B- and T-cell immune responses in autoimmune disease (Lang et al., 2005). The 
immunological tolerance is produced by tumour-derived soluble factors (TDSFs) and 
immature dendritic cells (iDCs), which inhibit DC and T-cell activation, and exclusively 
inhibit the DNA–IgG immune complex, inducing pro-inflammatory responses needed for an 
immune response. Immunological ignorance is produced by reduced levels of tumour 
antigens. Dendritic cells not only initiate T-cell responses, but are also involved in silencing 
T-cell immune response. DC can play a central role in the development of T-cell tolerance, 
and its maintenance in the periphery is critical for the prevention of autoimmunity. 
4.3 T helper 17 cells (Th17) 
T helper 17 cells constitute a third subset of T helper cells that are important in the 
development of autoimmune diseases and in the immune response against infections.  
These cells are characterized as preferential producers of IL-17A, IL-17F, IL-21, IL-22 and IL-
26 in humans. The IL-17 production is required to differentiate Th17 cells, from IFN-γ 
producing Th1 cells, or IL-4 producing Th2 cells. IL-17 (A and F) induces production of a 
broad range of pro-inflammatory cytokines and chemokines, including IL-6, colony-
stimulating factors, chemokines (CCL2, CCL7, CXCL1, and CCL20), human β-defensin-2 
and matrix metalloproteinases (MMP-3 and MMP-13), by a variety of cells (Weaver et al., 
2007). Conversely, inhibition of IL-17 signaling leads to impaired host defence against 
bacterial infection (Ye et al., 2001) and resistance to autoimmune diseases (Yang et al., 2008). 
IL-17 regulates host defence against infectious organisms through promoting granulopoiesis 
and neutrophil trafficking (Linden et al., 2005).  
Although FOXP3+ Treg cells are critical for control of autoimmunity and inflammation 
(Sakaguchi, 2004), Th17 cells have been implicated in mediating inflammation and 
autoimmune diseases (Weaver et al., 2007). It has been shown that the balance between Treg 
and Th17 cells is a key factor which regulates T-helper cell function relating to the Th1  Th2 
shift in autoimmune disease and graft versus host disease (GVHD) (Afzali et al., 2007). In 
fact, elevated levels of IL-17 have been associated with inflammatory diseases in humans, 
including rheumatoid arthritis, scleritis, uveitis, asthma, systemic lupus erythematosus, and 
allograft rejection (Kolls & Linden, 2004). 
However, there are limited information on the balance between Treg and Th17 cells in 
cancer patients and on the active role played by Th 17 in anti-tumour immunity (Kryczek et 
al., 2009). The function of IL-17 in tumour immunity is a controversial subject. The effects of 
IL-17 on tumour development are directly influenced by the existence of an adaptive 
immune system. In the presence of lymphocytes, IL-17 promotes tumour rejection, whereas 
in the absence of those, IL-17 favours tumour growth and angiogenesis (Martin-Orozco & 
Chen Dong, 2009a). By using IL-17-deficient mice in a model of lung melanoma, it has been 
provided direct evidence for a protective role of IL-17 in anti tumour responses (Martin-
 
Autoimmune Disorders – Pathogenetic Aspects 
 
392 
Orozco et al., 2009b). It has also found that Th17 cells provided better protection to tumours 
than Th1 cells, and this difference was largely due to their unique ability to promote CD8+ T 
cell priming. In Th17- but not Th1-treated tumour-bearing mice, it has been observed 
increased numbers of CD8+ T cells in the lung, suggesting that Th17 cells may promote the 
activation or recruitment of tumour antigen-specific CD8+ T cells (Martin-Orozco et al., 2009 
b). There are data supporting the existence of IL17-producing effector CD8+ T cells (Tc17) 
which are also induced by IL23  and may play a role in cancer development as well as in 
autoimmunity (Ciric et al., 2009). Thereby, the protective role of Th 17 cells, inhibiting 
tumour growth, may influence the onset of autoimmune diseases. 
5. Apoptosis mechanism 
Apoptosis is an active, genetically controlled process of cell death required to ensure that 
the rate of cell division were balanced by the rate of cell death in multicellular organisms. 
The control of apoptosis is critical for the homeostasis of the immune system as it happens 
during infections, where antigen specific lymphocytes need to rapidly proliferate. After 
clearance of the infectious microbe lymphocytes need to die in order to prevent 
dysregulated proliferation with the consequence of leukemia or lymphoma (Lorenz et al., 
2000). Importantly, as explained below, during apoptotic breakdown many nuclear 
constituents are post-translation modified, possibly altering antigenicity. Therefore it is not 
surprising that failure to achieve programmed cell death and to clear apoptotic cell 
fragments may be discussed as a key pathogenetic factor leading to autoimmunity. This 
could be explained by a failure to kill an autoreactive cell or by inducing autoantibodies 
against apoptotically modified cellular constituents. If the preload is excessive, as in massive 
cell death (e.g. upon infection), regulatory clearance mechanisms cannot effectively remove 
apoptotic residuals and thereby allowing the persistence of antigens for stimulation of the 
immune system. During apoptosis, the cellular contents of the nucleus, cytosol and 
membrane are brought together in close proximity, a mechanism that could lead to epitope 
spreading (Vidalino et al., 2009). Altered structures of intracellular proteins produced 
during cleavage events in apoptosis could also be a source of immunogenic antigens. 
Altered apoptosis mechanism is associated with the pathogenesis of a wide array of 
diseases: cancer, neurodegeneration, autoimmunity, heart disease and others. 
5.1 Phases of apoptotic death 
Apoptotic cell death can be divided into a "triggering phase" (e.g., ligation of "dedicated 
death receptor" such as Fas, or withdrawal of growth/survival factors), a "signaling phase" 
(e.g., protein kinase cascades that include MAPK family, JNK and p38), an "execution phase" 
(e.g., activation of caspases and nucleases), and a "burial phase" (e.g. phagocytosis of dying 
cells by neighboring cells) (Utz & Anderson, 1998).  
5.1.1 Triggering phase 
Fas ligand (FasL) and tumor necrosis factor α (TNF-α) are the prototypical inducers of 
apoptosis. These ligands induce clustering of their respective receptors (Fas, TNFR-I or 
TNFR-II), which leads to recruitment of the early signal-transducing molecules. The 
Fas/FasL system is the most studied receptor mediated apoptotic pathway. Fas/Apo-
1/CD95 is a type I trans membrane protein with a cysteine-rich extracellular domain and is 
a member of the tumor necrosis factor receptor (TNFR) superfamily (Itoh & Nagata, 1993). A 
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variety of cell types express Fas, but differing between tissues for the expression levels. Its 
ligand, FasL, is a type II transmembrane protein that can also exist as a soluble factor in a 
stable trimer configuration (Mountz et al.,1994). On ligation of FasL, Fas trimerizes and 
recruits an adaptor protein known as Fas-associated protein with death domain (FADD, also 
called MORT-1) through its intracellular death domain (Chinnaiyan et al., 1995). The 
cytotoxic signal is further propagated as FADD recruits and interacts with another adapter 
protein as FADD-like interleukin-1β converting enzyme (FLICE), also known as caspase-8 
(Muzio et al., 1997). Formation of the Fas-FADD-FLICE/ caspase-8 complex, known as 
death-inducing signal complex (DISC), facilitates the autocleavage and activation of 
caspase- 8 (Kischkel et al., 1995). A protein known as inhibitor of FLICE (I-FLICE) and 
FLICE-inhibitory protein (FLIP) can prevent the formation of DISC required for further 
apoptotic signaling (Irmler et al., 1997). 
5.1.2 Signaling phase 
Apoptosis is a multistep process and protein kinases have been implicated both in the 
upstream induction phase of apoptosis and in the downstream execution stage, as the direct 
targets for caspases. The serine/threonine protein kinases that have been suggested to play 
a role in apoptosis are the mitogen- activated protein kinase (MAPK) family, specifically, 
p42/ 44 ERK, p38 MAPK and c-Jun N-terminal kinase (JNK), cyclic AMP-dependent protein 
kinase A (PKA), protein kinase B (PKB), or Akt and protein kinase C (PKC). The activation 
of JNK/SAPK and p38 MAP kinases is generally associated with the promotion of 
apoptosis, while p42/44 ERK activity inhibits apoptosis (Mc  Cubrey et al., 2000).  
5.1.3 Execution phase 
In mammalian cells, activation of caspases is achieved through at least two independent 
mechanisms which are initiated by distinct caspases, but results in activation of common 
executioner caspases. Once activated, caspase-8 can induce either directly or indirectly the 
activation of a number of distal caspases such as caspase-3, -6 and -7 (CD95 type I cells) 
(Muzio et al., 1997). Another pathway for caspase activation involves cytochrome c, which 
in mammalian cells is often released from the mitochondria into the cytosol during 
apoptosis (CD95 type II cells) (Scaffidi et al., 1999) (fig.1). 
5.2 The cell death regulator: Bcl-2 and TNF-R 
The B cell leukemia-2 (Bcl-2) was the first mammalian cell death regulator identified. Bcl-2 
and the tumor necrosis factor receptor (TNF-R) family contribute to the regulation of 
apoptosis with their corresponding ligands. The proto-oncogene Bcl-2 has been cloned from 
the t(14:18) chromosomal translocation breakpoint in human follicular centre B lymphoma 
(Korsmeyer, 1995) and its function was first discovered when it was over-expressed in 
cytokine-dependent haematopoietic cell lines. Upon removal of the growth factor, Bcl-2 
promoted survival of these cells in the quiescent state (Gerl & Vaux, 2005). An important 
discovery from the studies in lymphocytes was that Bcl-2 did not only promote survival of 
growth factor-deprived cells but could inhibit apoptosis triggered by a broad range of 
physiological or experimentally applied cytotoxic stimuli (Sentman et al., 1991). Bcl-2 family 
can be divided into two groups according to their function: those which are structurally 
most similar to Bcl-2 and inhibit apoptosis, on the other side there are the members of the 
Bcl-2 family that enhance cell death. The mitochondrial pathway, is triggered by 
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cell death (e.g. upon infection), regulatory clearance mechanisms cannot effectively remove 
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during cleavage events in apoptosis could also be a source of immunogenic antigens. 
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Apoptotic cell death can be divided into a "triggering phase" (e.g., ligation of "dedicated 
death receptor" such as Fas, or withdrawal of growth/survival factors), a "signaling phase" 
(e.g., protein kinase cascades that include MAPK family, JNK and p38), an "execution phase" 
(e.g., activation of caspases and nucleases), and a "burial phase" (e.g. phagocytosis of dying 
cells by neighboring cells) (Utz & Anderson, 1998).  
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Fas ligand (FasL) and tumor necrosis factor α (TNF-α) are the prototypical inducers of 
apoptosis. These ligands induce clustering of their respective receptors (Fas, TNFR-I or 
TNFR-II), which leads to recruitment of the early signal-transducing molecules. The 
Fas/FasL system is the most studied receptor mediated apoptotic pathway. Fas/Apo-
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variety of cell types express Fas, but differing between tissues for the expression levels. Its 
ligand, FasL, is a type II transmembrane protein that can also exist as a soluble factor in a 
stable trimer configuration (Mountz et al.,1994). On ligation of FasL, Fas trimerizes and 
recruits an adaptor protein known as Fas-associated protein with death domain (FADD, also 
called MORT-1) through its intracellular death domain (Chinnaiyan et al., 1995). The 
cytotoxic signal is further propagated as FADD recruits and interacts with another adapter 
protein as FADD-like interleukin-1β converting enzyme (FLICE), also known as caspase-8 
(Muzio et al., 1997). Formation of the Fas-FADD-FLICE/ caspase-8 complex, known as 
death-inducing signal complex (DISC), facilitates the autocleavage and activation of 
caspase- 8 (Kischkel et al., 1995). A protein known as inhibitor of FLICE (I-FLICE) and 
FLICE-inhibitory protein (FLIP) can prevent the formation of DISC required for further 
apoptotic signaling (Irmler et al., 1997). 
5.1.2 Signaling phase 
Apoptosis is a multistep process and protein kinases have been implicated both in the 
upstream induction phase of apoptosis and in the downstream execution stage, as the direct 
targets for caspases. The serine/threonine protein kinases that have been suggested to play 
a role in apoptosis are the mitogen- activated protein kinase (MAPK) family, specifically, 
p42/ 44 ERK, p38 MAPK and c-Jun N-terminal kinase (JNK), cyclic AMP-dependent protein 
kinase A (PKA), protein kinase B (PKB), or Akt and protein kinase C (PKC). The activation 
of JNK/SAPK and p38 MAP kinases is generally associated with the promotion of 
apoptosis, while p42/44 ERK activity inhibits apoptosis (Mc  Cubrey et al., 2000).  
5.1.3 Execution phase 
In mammalian cells, activation of caspases is achieved through at least two independent 
mechanisms which are initiated by distinct caspases, but results in activation of common 
executioner caspases. Once activated, caspase-8 can induce either directly or indirectly the 
activation of a number of distal caspases such as caspase-3, -6 and -7 (CD95 type I cells) 
(Muzio et al., 1997). Another pathway for caspase activation involves cytochrome c, which 
in mammalian cells is often released from the mitochondria into the cytosol during 
apoptosis (CD95 type II cells) (Scaffidi et al., 1999) (fig.1). 
5.2 The cell death regulator: Bcl-2 and TNF-R 
The B cell leukemia-2 (Bcl-2) was the first mammalian cell death regulator identified. Bcl-2 
and the tumor necrosis factor receptor (TNF-R) family contribute to the regulation of 
apoptosis with their corresponding ligands. The proto-oncogene Bcl-2 has been cloned from 
the t(14:18) chromosomal translocation breakpoint in human follicular centre B lymphoma 
(Korsmeyer, 1995) and its function was first discovered when it was over-expressed in 
cytokine-dependent haematopoietic cell lines. Upon removal of the growth factor, Bcl-2 
promoted survival of these cells in the quiescent state (Gerl & Vaux, 2005). An important 
discovery from the studies in lymphocytes was that Bcl-2 did not only promote survival of 
growth factor-deprived cells but could inhibit apoptosis triggered by a broad range of 
physiological or experimentally applied cytotoxic stimuli (Sentman et al., 1991). Bcl-2 family 
can be divided into two groups according to their function: those which are structurally 
most similar to Bcl-2 and inhibit apoptosis, on the other side there are the members of the 
Bcl-2 family that enhance cell death. The mitochondrial pathway, is triggered by 
 
 






































Fig. 1. ADEDs: Anti-apoptotic Death Effector Domain proteins; Akt: serine/threonine 
protein kinase ; Apaf-1: Apoptotic protease activating factors-1; BAD: Bcl-2-associated death 
promoter protein; Bax: Bcl-2–associated X protein; Bcl-2: B-cell lymphoma 2; Bcl-xl: B-cell 
lymphoma-extra large; CTL: Cytolytic T-cells; Cyto-c: Cytochrome-c; DED: Death Effector 
Domains; FADD: Fas-associated death domain; Flip: FLICE (Fadd-Like Interleukin-1β 
Converting Enzyme) inhibitory protein; HTRA2/Omi: mammalian homolog of the bacterial 
high temperature requirement protein (HTRA); IAPs: Inhibitor of apoptosis protein; IKK: 
IκB kinase  ; IκB: Inhibitor of κB ; NFkB: nuclear factor kappa-B; NK: Natural Killer; PI3K: 
phosphatidylinositol 3-kinase ; SMAC: Second Mitocondrial-derived Activator of Caspase ; 
TNFR: Tumor Necrosis Factor Receptors; TRAIL-Rs: TNF-related apoptosis inducing ligand-
Receptors. 
proapoptotic members of the Bcl-2 family. In response to environmental cues these proteins 
engage another set of proapoptotic Bcl-2 members, the Bax sub family residing on the 
mitochondrial outer membranes or in the cytosol. The interaction induces the latter to 
oligomerize and insert into the mitochondrial membrane (Eskes et al., 2000). Here the 
complex acts to trigger the sudden and complete release of cytochrome c and other proteins 
from all of the mitochondria in the cell. Bcl-2 block death by preventing the mitochondrial 
release of the intermembrane proteins, including cytochrome c (Moriishi et al., 1999). A 
protein with the dual name of Smac/DIABLO is released from the mitochondria along with 
cytochrome c during apoptosis, and this protein functions to promote caspase activation by 
associating with the Apaf- 1 apoptosome and inhibiting inhibitor of apoptosis proteins. 
Members of the tumour necrosis factor (TNF) receptor family and their corresponding 
ligands are critical regulators of apoptosis, and also control other cellular processes 
(Wallach, 1997). CD95 (also called Fas or APO-1) and p55 TNF-RI receptors, and a few other 
members of the family, contain a cytoplasmic region, called “death domain” (DD), which is 
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essential for inducing apoptosis (Tartaglia et al., 1993). Upon receptor activation, the death 
domain undergoes interaction with a death domain in the adaptor proteins FADD (Fas-
Associated protein with Death Domain)/Mort-1 or TRADD (Tumor necrosis factor receptor 
type 1-associated DEATH domain protein) (Hsu et al., 1996). FADD/MORT 1 binds directly 
to CD95 and indirectly to p55 TNF-R I via TRADD, and it is essential for cell death signaling 
from both receptors. This complex binds caspase-8, therefore inducing its self-processing 
(Boldin et al., 1996). The members of the TNF receptor family (death receptors) bearing 
death domain can also activate signaling pathways that promote survival, proliferation, and 
differentiation of cells. Signaling via TRADD is essential for TNF-induced activation of Jun 
kinase and its absence renders cells less susceptible to the pro-apoptotic activity of TNF (Yeh 
et al., 1997). Death domain RIP (receptor-interacting protein) kinase is required for TNF-
receptor transduced activation of NF-kB and its absence also sensitizes cells to TNF-induced 
apoptosis (Kelliher 1998). This indicates that Jun kinase and NF-kB elicit signals that protect 
cells against death receptor-induced apoptosis. Moreover, FADD/MORT1, which was 
originally thought to transducing only a death signal (Hsu et al., 1996), it is now known to 
be also essential for mitogen-induced proliferation of T lymphocytes (Zhang et al., 1998).  
5.3 The role of apoptosis in development, function and homeostasis of lymphocytes 
Apoptosis plays a critical role in the immune system, both during the development of B and 
T cells in primary lymphoid organs as well as during immune responses of mature 
lymphocytes (Strasser et al., 1995). Programmed cell death is thought to be responsible for 
the elimination of immature B and T cells that failed to receive a survival signal due to both 
the lack of growth factors, and either to the failure to productively rearrange antigen 
receptor genes, or failure of the T cell antigen receptor on thymocytes to bind to MHC 
molecules on stromal cells (lack of positive selection) (Lu & Osmond, 1997). The effector 
functions of activated lymphocytes (i.e. secretion of antibodies, production of cytokines or 
cytotoxicity) are potentially hazardous and it is therefore beneficial to delete these cells 
when an infection has been overcome (Strasser et al., 1995). The survival of T lymphoblasts 
is controlled by two distinct mechanisms, both availability of growth factors (e.g. IL-2) and 
exposure to death ligands (e.g. Fas ligand), which are produced by T cells themselves as a 
consequence of repeated TCR stimulation (Brunner et al., 1995). The lack of IL-2 triggers a 
death pathway that can be inhibited by Bcl-2, instead the pathway triggered by Fas ligand is 
insensitive to Bcl-2 and its homologues (Newton et al., 1998). The death pathway controlled 
by growth factors and Bcl-2 is thought to be responsible for removing T cells activated by 
foreign, non-persisting antigens, while death receptor-signaling is critical for removal of 
activated T cells specific to self-antigens or persistent foreign antigens (Van Parijs et al., 
1998).   
6. Apoptosis in autoimmune disease 
The association between autoimmunity and apoptotic cell death is under extensive 
investigation. The process of apoptosis defines a series of biochemical and morphologic 
events that contribute to the normal homeostasis and regulation of immune autoreactivity 
(Mevorach et al., 1998). During apoptosis, the cellular components as the nucleus, cytosol 
and, membrane are brought together in close proximity, a mechanism that could lead to 
epitopes spreading. Altered structures of intracellular proteins produced during cleavage 
events in apoptosis could also be a source of immunogenic antigens, as cleavage by 
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engage another set of proapoptotic Bcl-2 members, the Bax sub family residing on the 
mitochondrial outer membranes or in the cytosol. The interaction induces the latter to 
oligomerize and insert into the mitochondrial membrane (Eskes et al., 2000). Here the 
complex acts to trigger the sudden and complete release of cytochrome c and other proteins 
from all of the mitochondria in the cell. Bcl-2 block death by preventing the mitochondrial 
release of the intermembrane proteins, including cytochrome c (Moriishi et al., 1999). A 
protein with the dual name of Smac/DIABLO is released from the mitochondria along with 
cytochrome c during apoptosis, and this protein functions to promote caspase activation by 
associating with the Apaf- 1 apoptosome and inhibiting inhibitor of apoptosis proteins. 
Members of the tumour necrosis factor (TNF) receptor family and their corresponding 
ligands are critical regulators of apoptosis, and also control other cellular processes 
(Wallach, 1997). CD95 (also called Fas or APO-1) and p55 TNF-RI receptors, and a few other 
members of the family, contain a cytoplasmic region, called “death domain” (DD), which is 
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essential for inducing apoptosis (Tartaglia et al., 1993). Upon receptor activation, the death 
domain undergoes interaction with a death domain in the adaptor proteins FADD (Fas-
Associated protein with Death Domain)/Mort-1 or TRADD (Tumor necrosis factor receptor 
type 1-associated DEATH domain protein) (Hsu et al., 1996). FADD/MORT 1 binds directly 
to CD95 and indirectly to p55 TNF-R I via TRADD, and it is essential for cell death signaling 
from both receptors. This complex binds caspase-8, therefore inducing its self-processing 
(Boldin et al., 1996). The members of the TNF receptor family (death receptors) bearing 
death domain can also activate signaling pathways that promote survival, proliferation, and 
differentiation of cells. Signaling via TRADD is essential for TNF-induced activation of Jun 
kinase and its absence renders cells less susceptible to the pro-apoptotic activity of TNF (Yeh 
et al., 1997). Death domain RIP (receptor-interacting protein) kinase is required for TNF-
receptor transduced activation of NF-kB and its absence also sensitizes cells to TNF-induced 
apoptosis (Kelliher 1998). This indicates that Jun kinase and NF-kB elicit signals that protect 
cells against death receptor-induced apoptosis. Moreover, FADD/MORT1, which was 
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lymphocytes (Strasser et al., 1995). Programmed cell death is thought to be responsible for 
the elimination of immature B and T cells that failed to receive a survival signal due to both 
the lack of growth factors, and either to the failure to productively rearrange antigen 
receptor genes, or failure of the T cell antigen receptor on thymocytes to bind to MHC 
molecules on stromal cells (lack of positive selection) (Lu & Osmond, 1997). The effector 
functions of activated lymphocytes (i.e. secretion of antibodies, production of cytokines or 
cytotoxicity) are potentially hazardous and it is therefore beneficial to delete these cells 
when an infection has been overcome (Strasser et al., 1995). The survival of T lymphoblasts 
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exposure to death ligands (e.g. Fas ligand), which are produced by T cells themselves as a 
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death pathway that can be inhibited by Bcl-2, instead the pathway triggered by Fas ligand is 
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activated T cells specific to self-antigens or persistent foreign antigens (Van Parijs et al., 
1998).   
6. Apoptosis in autoimmune disease 
The association between autoimmunity and apoptotic cell death is under extensive 
investigation. The process of apoptosis defines a series of biochemical and morphologic 
events that contribute to the normal homeostasis and regulation of immune autoreactivity 
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granzyme B is a common phenomenon for the release of autoantigens. If cell death is 
excessive, regulatory clearance mechanisms may not effectively remove apoptotic debris, 
thereby leading to the persistence of antigens for immune system stimulation. Also, the 
resistance to clearance by defective proteins may lead to autoimmune phenomenon. 
Furthermore, the rapid clearance of apoptotic cells by macrophages is important to inhibit 
inflammation and autoimmune responses against intracellular antigens. Mice deficient in 
receptor tyrosine kinases, such as Tyro 3, Axl, and Mer, have defective clearance of 
apoptotic cells, lymphadenopathy, and features of autoimmunity (Scott et al., 2001). A 
common feature of autoimmune diseases such as systemic lupus erythematosus, systemic 
sclerosis, Sjogren's syndrome, and mixed connective tissue disease is the breakdown of 
tolerance to self antigens, which induces the production of antibodies reactive with multiple 
self proteins (Von Muhlen & Tan, 1995). Accumulating evidences show that modifications of 
autoantigens during apoptosis lead to the development of autoantibodies, thus bypassing 
normal mechanisms of tolerance (Amoura et al., 1999). Furthermore, direct evidence exists 
associating faulty apoptotic machinery with the development of autoimmune disease in 
experimental models and in human disease. Genetic evidences have shown that defects in 
individual cell-death genes can lead to autoimmune disease. In humans, direct evidence was 
found in deficient Fas patients, leading to the development of the autoimmune 
lymphoproliferative syndrome, manifested by lymphadenopathy, renal disease and 
hemolytic anemia. This syndrome parallels the autoimmune phenomena found in mrl/lpr 
mice that lack the Fas protein (Straus et al., 1999). In addition, expression of a bcl-2 
transgene in mouse B lymphocytes causes extended survival of B lineage cells, sustained 
humoral immune responses and consequently accumulation of non-transformed B cells and 
plasma cells and increased levels of serum Ig (O’Reilly et al.,1997). Auto-antibody-secreting 
plasma cells have been found in normal individuals, but they had no detrimental effect since 
they were relatively infrequent and short-lived. Expression of a bcl-2 transgene prolongs the 
survival of such cells and consequently auto-antibodies reach pathogenic levels.  
6.1 Apoptosis and systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is an autoimmune disease clinically characterized by a 
broad variety of symptoms, mostly affecting the joints. In Europe the incidence of this 
disease is about 1/10,000. Based on new therapeutic approaches, most of the patients will 
experience a remission and about 90% of SLE patients are still alive after a five year follow-
up (Pons-Estel, et al., 2010). The etiopathogenesis of SLE, although partially understood, is 
due to multifactorial process. Genetic predisposition in association with environmental 
factors, including infectious agents, drugs, occupational factors, and food may lead to 
profound alterations in immune system (Love,1994). These changes include the appearance 
of autoantibodies with different specificity, altered T cell function, as well as a defective 
phagocytosis and changes in oncogenes (Kalden et al., 1991). In the pathogenesis of systemic 
lupus erythematosus an important role is due to a dysregulated apoptosis, which may 
contribute to development of the disease, regulating the induction of nuclear antibodies 
frequently found in SLE. This hypothesis is partly based on experiments with an animal 
model used for SLE (i.e. MRL/lpr mice). Mutational inactivation of the genes encoding 
CD95 (lpr) or its ligand, Fas ligand (gld), cause lymphadenopathy and SLE-like autoimmune 
disease in mice (Adachi et al., 1995). Two spontaneous mutations found in the CD95 gene 
have been considered the cause of deficient expression of a membrane molecule Fas/Apo-1 
(CD95). Animals with a deficient expression of Fas/Apo 1 molecule showed an insufficient 
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elimination of lymphocytes, leading to the assumption that autoreactive lymphocytes could 
survive and consequently cause autoimmune phenomena (Watson et al., 1992). However, in  
all humans with SLE the Fas/Apo-1 dependent apoptosis pathway was unaffected (Mysler 
et al., 1994), and patients with a defect in the Fas/Apo-1 molecule develop a non malignant 
lymphoproliferation (Rieux-Laucat, 1995).  Although this,  it has been reported in patients 
with SLE increased numbers of apoptotic lymphocytes and macrophages (Emlen et al., 
1994). Likely, this could be the result of both a fail during the apoptosis phase and an 
increased triggering of apoptosis, thus delaying the end of programmed cell death process. 
A sustained apoptotic activity, due to continuous stimuli, is responsible of producing 
autoantigens, which may lead to the development of autoantibodies directed against 
macromolecular complex, thereby acting some pathologic effects. In summary, SLE is a 
complex disorder in which defects in apoptosis and impaired clearance are strong 
contributing factors for susceptibility, onset and severity of the disease. 
6.2 Apoptosis in rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory disease, characterized by chronic 
synovial inflammation and synovial cell proliferation, both responsible of  “pannus” 
production. Its development is related to mononuclear cell infiltration, neoangiogenesis, and 
abnormal proliferation of fibroblast-like synoviocytes  (FLS). The pathogenesis of the 
rheumatoid pannus, has been partly explained by a study on FLS biology (Pap et al., 2000). 
Two general mechanisms contribute to synovial hyperplasia: increased FLS proliferation 
and decreased synoviocyte apoptosis. However, apoptotis of synovial cells has been also 
identified in histologic sections, suggesting that the relative rate of apoptotic cells to 
proliferating cells is suppressed in proliferating tissues such as in the synovium of RA 
patients (Sekine et al., 1996). Several studies have examined the mechanisms that could 
contribute to the resistance against Fas-mediated apoptosis in RA, demonstrating that 
though Fas is normally expressed by the cells of the pannus both in vivo and in vitro, the 
persistence of synovial proliferation in RA patients may lead to bone damage and cartilage 
erosion (Kawakami et al., 1999). The function of the Fas/FasL system seems to be 
inadequate to eliminate the cells in the proliferating RA synovium suggesting a strong anti-
apoptotic effect in the RA joint.  
FLICE inhibitory protein (Flip) is highly expressed at sites of erosion, in the pannus, in the 
lining, and in the areas of the synovial tissue where apoptosis has not been observed 
(Perlman et al., 2001). This prospect was supported by the fact that, when synovial tissues 
were examined by immunohistochemistry, high levels of Flip were associated with low 
levels of apoptosis in early RA. In contrast, decreased Flip was detected later in the disease 
course, and this was related with increased apoptosis and decreased numbers of 
macrophages (Catrina et al., 2002). In addition, it has been supposed that the potential 
beneficial effects of TNF-α  antagonist therapy might be related to the reduction of Flip, 
which would permit Fas/FasL-mediated apoptosis and result in subsequent clinical 
improvement. 
In the antigen-induced arthritis model of RA, Bcl-2 was present at sites of early erosion and 
correlated with levels for erosion and inflammation, thus supporting the importance of this 
factor. Since either the presence of Bcl-2 or anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-
xL, A1 and myeloid-cell leukaemia sequence 1) at sites of early erosion in antigen-induced 
model of arthritis was greatly expressed on synovial fibroblasts, in the synovial lining and in 
the sublining region from RA patients, it has been largely examined the potential 
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mechanisms that may contribute to the augmented expression of Bcl-2 (Perlman et al., 2001). 
Activated  NF-kB, has been implicated in the regulation of gene transcription that 
contributes to cytokine generation, expression of cell surface adhesion epitopes, lymphocyte 
maturation, protection from TNF-α induced apoptosis, and antigen processing and 
presentation by MHC class I molecules. NF-kB is expressed in almost all cell types, and 
plays a significant role in regulating the production of inflammatory cytokines, such as 
TNF-α, IL-1 and IL-6, as well as anti-apoptotic molecules such as Flip (Pope & Perlman, 
2000). Different cytokines such as IL-lβ, platelet-derived growth factor (PDGF), basic 
fibroblast growth factor (bFGF), transforming growth factor β (TGF-β) and TNF-α are 
present in synovial tissues of RA patients, promoting the proliferation of human synovial 
cells. Fas antigen expression on synovial cells is inhibited by the addition of TGF-βl with up-
regulation of Bcl-2, Bcl-xL and XIAP. The expression of FLIP, is increased in bFGF-treated 
synovial cells. These results show that bFGF treatment augmented the expression of FLIP, 
resulting in resistance toward Fas-mediated apoptosis. The tumour suppressor gene p53 
regulates cell cycle, DNA repair, and inhibits angiogenesis. Although, early study reported 
an upregulation of p53 expression in RA joints (Firestein et al., 1996), a more recent 
interesting study about the role of several genes, involved in apoptosis mechanisms, 
reported that p53 gene was deeply reduced in peripheral blood mononuclear cells from 
patients with RA, SLE, insulin-dependent diabetes mellitus and multiple sclerosis compared 
with that in normal controls; thus suggesting, that the decreased expression of p53, might 
contribute to the development of autoimmune disease, possibly by failing to eliminate 
potentially pathogenetic cells (Maas et al., 2002). Its increase is due to DNA damage, thus 
permitting DNA repair through  cell cycle prolongation, or leading to apoptosis in more 
severe cases. Deletions, mutations or other mechanisms leading to its lost are often 
associated with tumour growth.  
Although Fas and FasL are greatly expressed on synovial lining macrophages, paucity of 
apoptosis within the joint might be the result of a variety of mechanisms. An improved 
understanding of the mechanisms regulating apoptosis will provide insights to aid with a 
more effective therapy patients with RA.  
6.3 Apoptosis and Sjögren’s syndrome  
Sjögren’s syndrome (SS) is a chronic autoimmune disorder, occurring primarily in women, 
affecting the salivary and lacrimal glands. The histopathological changes in the minor 
salivary gland biopsy are characterized by the infiltration of these glands by mononuclear 
cells with secondary destruction of the parenchymal tissue, resulting in oral and ocular 
dryness (Moutsopoulos et al., 1980). The pathogenesis of glandular damage in Sjögren’s 
syndrome is currently poorly understood; however, the predominance among the 
infiltrating mononuclear cells of activated CD4+ T cells suggests that cell-mediated 
immunity plays an important role in tissue destruction (Skopouli et al., 1991). In recent 
years, it has been reported that the expression of the apoptosis regulating-proteins in 
salivary glands of Sjögren’s syndrome patients suggests a role for apoptotic cell death in the 
pathogenesis of glandular damage (Patel & McHugh, 2000). The resistance of infiltrating 
mononuclear cells to apoptosis may result in longer survival that might also increase the 
production of pro-inflammatory cytokines and autoantibodies, or predispose to the late 
development of lymphoma in some Sjögren’s syndrome patients. T lymphocytes induce 
apoptotic cell death through either the release of proteases, such as perforin and granzymes, 
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or the interaction of FasL, expressed by activated CD4+ T cells, with Fas on target cells 
(Russell & Ley, 2002).  In murine models, defective signaling and blocked apoptosis caused 
by mutations in Fas or FasL resulted in autoimmune disease as well as lymphadenopathy 
(Skarstein et al., 1997).  Corresponding mutations were not found in genes encoding Fas and 
FasL in primary Sjögren’s syndrome patients (Bolstad et al., 2000). However, it has been 
suggested that increased levels of Fas induced apoptosis among epithelial cells explaining 
the damage of the glands. On the other hand, increased expression of intracellular anti-
apoptotic molecules could lead to dysregulation of apoptosis and the formation of large foci 
of infiltrating mononuclear cells. In the field of autoimmune disease, a common feature is 
the lack of specific serum markers of disease. Among the most widely used serological 
markers in confirming the diagnosis of Sjögren’s syndrome (SS), there are anti-SSB/La and 
SSA / Ro antibodies, with a prevalence between 70 and 80% . Although this prevalence is 
high, they are not specific for Sjögren’s syndrome, but also found patients with other 
autoimmune diseases: anti-SSA / Ro in 35% of patients with systemic lupus erythematosus 
and 85% of patients with congenital heart block (BCC), and anti-SSB / La in 15% of patients 
with systemic lupus erythematosus. SSA and SSB are two ribonucleoproteins, located 
mainly in the nucleus and in the cytoplasm. In patients with Sjögren’s syndrome it has been 
recently studied a new autoantibody that recognizes a structural protein, bound to actin, 
and that is part of the cytoplasmic skeleton: the α-fodrin (Ulbricht et al., 2003). The fodrin 
has a localization predominantly near the inner surface of the cell membrane and 
physiologically it participates in the process of cellular secretion. When antibodies directed 
against the α-fodrin are present, the cellular mechanism of secretion is impaired. Since the 
salivary glands are rich in α-fodrin, their secretory mechanism is inhibited, resulting in 
xerostomia and keratoconjunctivitis sicca. Therefore α-fodrin antibodies would more 
precocious than those commonly used in the diagnosis of SS (anti-Ro and anti-La), 
especially in the early stages of the disease. The cleaved α-fodrin fragment has been shown 
to be a marker of apoptosis (Janicke et al., 1998). Furthermore, a monospecific antibody 
recognizing the cleaved α-fodrin is available. In Sjögren’s syndrome, cleaved α-fodrin 
autoantigen is greatly expressed on ductal epithelium, on sporadic acinar cells and strongly 
associated with infiltrating mononuclear cells, however it is rarely detected in normal 
salivary glands. Further studies are required to verify the specific association of cleaved α-
fodrin with primary and secondary Sjögren's syndrome. Therefore based on results of 
studies of SS-like disease in mice, there may be 2 distinct phases in the pathogenesis of SS 
(Humphreys-Beher et al.,  1999). The first, a lymphocyte-independent step may be 
characterized by a genetically determined anomaly responsible for epithelial cell apoptosis, 
resulting in either the production of nucleosomes or the exposure on the cell membrane of 
autoantigens, such as α-fodrin, SS-A (Ro), and SS-B (La) ribonucleoproteins. In fact, 
apoptosis allows the translocation either of the ribonucleoproteins SS-A (Ro) and SS-B (La) 
or the cytoplasmic protein α-fodrin on epithelial cell membranes, where they may be 
exposed to antigen-presenting cells such as macrophages, and thus generate an autoimmune 
response (McArthur et al., 2002). After this phase, an elevated expression of 
proinflammatory cytokines and metalloproteases also may occur, with consequent 
degradation of epithelial basal membranes (Pérez et al.,  2000). The second phase is 
characterized by mononuclear cells (MNC) infiltration, lymphocyte mediated apoptosis 
through Fas/FasL interaction, perforin and granzyme B release and production of cytokines 
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or the interaction of FasL, expressed by activated CD4+ T cells, with Fas on target cells 
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(IFN-γ, TNF-α, and TGF-β1) leading to glandular damage and secretory flow injury (Perez 
et al., 2000). Improved understanding of the primary cellular events responsible for the 
glandular damage occurring in SS may allow the discovery of new therapeutic strategies 
able to interfere with the mediators of apoptosis and thus prevent epithelial cell death and 
consequent impairment of secretory function.  
7. Apoptosis and malignancies  
Altered function of apoptosis mechanism occurs frequently in cancers and has been 
implicated in many events relevant for the pathogenesis and progression of tumours, 
including cell accumulation caused by failure of programmed cell death (Reed, 1999). 
Thereby, it may be induce a permissive environment for genetic instability and oncogene 
activation, promote resistance to immune cell attack, and contribute to resist to the cytotoxic 
effects of chemotherapy and radiation, allowing tumour cell survival. In the same way, 
defects in DNA repair and chromosome segregation normally trigger cell suicide as a 
defence mechanism for eradicating genetically unstable cells. Apoptosis defects permit the 
survival of the genetically unstable cells, and thus provide opportunities of selection of 
progressively aggressive clones (Anthoney et al., 1996). In addition, apoptosis defects play a 
role in tumour resistance to hypoxia, growth factor deprivation, immune surveillance 
mechanisms, chemotherapy, and radiation (Medh & Thompson, 2000). Tumour 
immunosuppression that favours tumour progression and metastasis is the consequence of 
the activation of an immunosuppressive network, mediated by several tumour-derived 
soluble factors, such as interleukin- 10 (IL-10), transforming growth factor (TGF)- β and 
vascular endothelial growth factor (VEGF), and which involves the primary tumour site, 
secondary lymphoid organs and peripheral vessels (Zou, 2005).  There are different 
pathways leading to dysregulated immune responses in cancer and autoimmune disease, 
such as the impaired clearance of apoptotic cells, played by macrophages. Although the fact 
that tumour cells generate pro-inflammatory conditions, the immune cells induce an anti-
inflammatory environment , due to impaired clearance of apoptotic cells by macrophages 
during the turnover of tumour cells. The impaired clearance of apoptotic cells induces anti-
DNA antibodies to self-antigens that lead to a pseudo-autoimmune status, which, 
provoking a pro-inflammatory response, allows tumour progression (Kim et al., 2005). The 
increased concentration of autoantibodies and dendritic cells can induce the production of 
CD4+ CD25+ regulatory T cells (Tregs) that inhibit T-cell function, causing immunological 
tolerance (Ward et al., 2004). Thus, it is likely that cancer immunosuppression is produced 
by tumour-derived soluble factors, due to an anti-inflammatory response to immune cells 
triggered by a defective apoptotic cell clearance, and increased concentration of Treg cells.  
There are  significant differences in immunological dysregulation between cancer and 
autoimmune disease. In the first case, the impaired clearance of apoptotic cells causes 
accumulation of autoantibodies, which is attributed to the inhibition of T-cell function 
through increased Treg cells, which play a crucial role in immunological tolerance in cancer 
cells. In autoimmune diseases, defective apoptotic cell clearance causes accumulation of 
DNA–IgG immune complexes, which provokes an immune response through Toll-like 
receptor 9 (TLR9), leading to tissue injury. Unfortunately, the Treg cells are decreased and 
dysregulated, in this case (Lang et al., 2005). 
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7.1 Apoptosis and the genes that control it - effect on the malignant phenotype  
Elucidation of the genetic alterations of molecules with a central role in apoptosis pathway 
has provided new insights into tumour biology, revealing novel strategies for combating 
cancer. More weight has been placed on core apoptosis components such as, Bcl-2 family 
proteins, death receptor signaling, endogenous inhibitors of caspases, transcriptional control 
of apoptosis, apoptosis regulation by oncogenes and tumour suppressor genes. The proteins 
of Bcl-2 family play a key role in the normal regulation of apoptosis and aberrant expression 
of members of this family has been associated with several tumours. The anti-apoptotic 
members include Bcl-2 and Bcl-xl and the pro-apoptotic members include Bax, Bad, Bim, Bid 
(Chang et al., 2003). Experiments involving knockout mice have contributed to our 
understanding of the role of Bcl-2 family members in tumourigenesis. Bad-knockout mice 
develop B-cell lymphomas and are less able to hold-out with sub-lethal doses of γ-
irradiation (Ranger et al., 2003), while Bid-knockout mice develop myelomonocytic 
leukemia (Zinkel et al., 2005). Interesting results, involving tumours and Bcl-2, derive from 
studies undergone on human beings. Over-expression of Bcl-2 has been observed in both B-
cell lymphomas (where it was originally discovered) as well as in non-Hodgkin’s 
lymphomas. Furthermore, over-expression of Bcl-2 has been observed in solid tumours such 
as lung, renal, stomach, and brain cancer. Instead, lower levels of Bcl-2 have been observed 
in breast cancers. However, either over-expression of Bcl-2 in some subtypes of lymphoma 
or low levels in breast cancer correlate with poor prognosis (Gascoyne et al., 1997; Chang et 
al.,2003). It seems that the prognostic value of Bcl-2 expression differs between tumour  
types and in some cases there may be no correlation with disease progression. The 
importance of p53 in maintaining genome stability is exemplified by the finding that 
approximately half of all human tumours carry mutant p53. At present, there are > 10 
million people with tumours that contain inactivated p53, while a similar number have 
tumours in which the p53 pathway is in part blocked by inactivation of other signaling 
components (Brown et al., 2009). It is well confirmed that the p53 response is defective in 
most cancers, either by mutations or deletions in the p53 gene, or by alterations in the p53 
pathway caused by other oncogenic events. These observations have raised a wide range of 
clinical possibilities both for diagnosis and treatment, rendering p53 an ideal target for anti-
cancer drug design. p53 mutations, the first tumour suppressor gene linked to apoptosis, 
occur in the most of human tumours and are often associated with advanced tumour stage 
and poor patient prognosis. Studies using p53 knockout mice demonstrated  that 
endogenous p53 could play a part in apoptosis, in fact p53 has been required for radiation-
induced cell death in the thymus, but not cell death induced by glucocorticoids or other 
apoptotic stimuli (Lowe et al., 1993). p53 can exhibits different and global functions (e.g. 
promote apoptosis, cell-cycle arrest and senescence). Evidences indicate that p53 apoptotic 
activity is important in tumour suppression. Therefore, the occurrence of p53 mutations 
correlates with a decreased apoptosis in some transgenic mice (Attardi & Jacks, 1999) and in 
clonal progression of  tumour cells (Bardeesy et al., 1995). Furthermore alterations of several 
p53 effectors in apoptosis (e.g. Bax, apaf-1 and casp-9) can promote oncogenic 
transformation and tumour development in mouse model systems (Soengas et al., 1999). 
Activation of p53 is sufficient to directly or indirectly trigger apoptosis by inducing pro-
apoptotic Bcl-2 family members (Schuler et al., 2000).  In addition, alterations in genes 
encoding various modulators of NF-kB can occur in several types of B-cell malignancies, 
including non-Hodgkin lymphomas, B-chronic lymphocytic leukemia, and multiple 
myeloma (Rayet & Gelinas, 1999).  
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8. The role of TNF-α antagonist therapy in cancer onset 
As biologic therapy becomes more common in treating a spectrum of conditions, awareness 
of side-effects is becoming more important. Mouse models and in vitro experiences indicate 
that TNF-α plays an important role in tumour growth control. Thus, anti- TNF-α agents 
might influence the risk of malignancy.  
TNF-α is one of main regulator of chronic inflammation and contributes to tumour 
development, therefore suggesting  a role in the progression of solid tumours. However, 
therapy with TNF-blockers, such as infliximab or etanercept, in patients with advanced 
cancer was well tolerated, with no evidence of disease acceleration (E.R. Brown et al., 2008). 
Nevertheless, a systematic review and metanalysis of data from randomized controlled 
trials of monoclonal antibodies against TNF-α in patients with rheumatoid arthritis showed 
that there were 29 case of cancers in patients with infliximab group compared to 3 in the 
control group (Bongartz et al., 2006). In a study of 404 patients with Crohn’s disease and 404 
matched controls, there were 3 cases of breast cancer in the infliximab-exposed group 
compared to 1 case in the other group (Biancone et al., 2006). In the Swedish nationwide 
cancer registry, 4160 patients exposed to TNF-α antagonists (etanercept, infliximab, or 
adalimumab) were identified (Askling et al., 2005a). Although it has been reported 67 solid 
cancers, including 8 cases of breast cancer, it has not been found excess risk of solid cancer 
in this cohort.  
TNF-α generates a variety of cellular responses that may either promote or inhibit 
tumourigenesis. This variability may explain the discrepancies in study results. Some 
studies on experimental models suggest increased tumour progression with TNF-α 
blockade. Clinical trials, in contrast, suggest that TNF-α blockade may decrease the activity 
of solid cancers (kidney and breast). These discordant data generate uncertainty about the 
potential effects of TNF-α antagonists on the risk of human malignancies in general and on 
male breast cancer in particular (Williams, 2008). Infliximab is a chimeric mouse-human 
monoclonal antibody targeting TNF-α. Blocking the actions of tumour necrosis factor-alpha 
is highly effective in treating several inflammatory disorders. Although safety data have 
been encouraging, there are reports of immunosuppressive sequelae resulting from the use 
of the drug.  
The soluble dimeric form of p75 TNF receptor, etanercept, binds free TNF in the circulation 
and cell-bound TNF, thus acting as a competitive inhibitor, blocking TNF interaction with 
TNF receptors on cell surface (Tsimberidou & Giles, 2002). It inhibits binding of both TNF 
and lymphotoxin (LT)-a (also known as TNF-β) to cell surface TNF receptors, rendering 
TNF biologically inactive. It has been postulated that etanercept acts both as a cytokine 
carrier and TNF antagonist, and can modulate biological responses that are induced or 
regulated by TNF, such as expression of adhesion molecules responsible for leukocyte 
migration (Tsimberidou & Giles, 2002). Etanercept has shown activity and is currently 
indicated in patients with moderately to severely active rheumatoid arthritis; moderately to 
severely active polyarticular-course juvenile rheumatoid arthritis with inadequate response 
to disease-modifying antirheumatic drugs; or psoriatic arthritis (Lovell et al., 2000; Mease et 
al., 2000). In a pilot study, it was given Etanercept to 13 patients affected by cutaneous T-cell 
lymphoma (CTCL), because of the role played by TNF in tumour progression. An 
improvement was observed in patients with early disease, and a larger cohort of patients 
with early disease merits investigation, while it is unlikely that it will be effective in patients 
with advanced CTCL (Tsimberidou et al., 2004).  
 
A Possible Link Between Autoimmunity and Cancer 
 
403 
Adalimumab is a fully human recombinant IgG1 monoclonal antibody with specificity for 
human TNF-α. Bongartz et al. (2006) conducted a systematic review and meta-analysis that 
included 9 trials employing either infliximab or adalimumab in 3493 patients with RA 
versus 1512 patients taking placebo to further elucidate the carcinogenic potential of TNF-α 
blockers. The odds ratio for malignancy was found to be 3.3, and the incidence of cancer was 
associated with higher doses of the biologic. For patients treated with anti-TNF-α antibodies 
included in these trials, the number needed to harm was 154 within the 6- to 12-month 
follow-up period. But the study failed to give some adjustments. 
The relationship between lymphoma and TNF-α blockers has been documented in a few case 
reports focusing on psoriasis patients. One report reviewed relevant data in the MedWatch 
postmarketing adverse event surveillance system run by the Food and Drug Administration 
and discovered 26 cases of lymphoma following treatment with either etanercept (18 cases) or 
infliximab (8 cases) (S.L. Brown, 2002). Frequently, those receiving etanercept were reported to 
be taking MTX concurrently (5 of 18) or had a history of prior exposure to MTX (4 of 18), or a 
history of exposure to another immunosuppressive agent (4 of 18). Another noteworthy 
clinical feature of the lymphomas observed was the very short latent period of only few weeks 
between the initiation of anti-TNF therapy and the development of malignancy. 
In two instances (one etanercept, one infliximab), lymphoma regression was observed 
following discontinuation of the TNF-α -blocker in the absence of specific cytotoxic therapy 
directed toward the lymphoma. 
The association between lymphoma and biologic therapy was weakened by data reported 
by Askling et al. (2005b) who epidemiologically studied cohorts of RA patients with either 
long-standing disease, incident disease, or TNF-α -antagonist treated disease linked with the 
Swedish Cancer Registry. The lymphoma risk in those treated with TNF-blockers was no 
higher versus the other RA cohorts, given that the standardized incidence ratio (SIR) for RA 
patients on TNF blockers was 2.9 and not statistically significant after adjustment for sex, 
age, and disease duration from the SIR of 2.0 in control subjects with RA. 
A study reviewed 1440 patients having psoriasis treated with etanercept for more than 5 
years, without founding any increase of malignancies (Burge, 2003). However, a multitude 
of recent case reports have begun to strengthen the link between anti-TNF-α therapy and 
induction or rapid reactivation of latent malignancies. 
In the literature many case-reports were found about the cancer onset after anti-TNF-α 
therapy, such as anorectal carcinoma (Melichar et al., 2006) and non-Hodgkin Lymphoma 
(Bickston et al.,  1999) after infliximab therapy in Crohn’s disease, cutaneous and systemic T-
cell lymphoma after treatment with infliximab and also with etanercept (Adams et al., 2004). 
One reason for the safety concerns surrounding anti-TNF-α  therapy is the role of the 
members of the TNF family in normal immune system development and function (Bazzoni 
& Beutler, 1996). However, ‘‘knock-out’’ mutations of the TNF gene complex in mouse 
models of disease cause an increased susceptibility to certain infections, but not 
autoimmunity or malignancy (Erickson et al., 1994). In addition, it is noteworthy the absence 
of a clear immunosuppressive effects of TNF antagonism in preclinical and human studies. 
Thus, in contrast to the pleiotropic effects of TNF with the immune system, blockade of TNF 
with infliximab does not suppress global immune function in the manner of drugs such as 
azathioprine (Meenan et al., 1997). Therapy with infliximab has not been associated with 
decreases in absolute lymphocyte counts (Meenan et al., 1997), development of anergy 
(Feldmann et al., 1997), or emergence of opportunistic viral and fungal infections. Together, 
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these data suggest that blockade of TNF with a drug such as infliximab may lead to limited 
and selective rather than broad-spectrum immune suppression.  
Also for adalimumab therapy carried on patients affected by rheumatoid arthritis it was 
observed the incidence of cancer, especially the onset of melanoma in two patients, after two 
years from the start of therapy with adalimumab (Dewan et al., 2009). 
However, it is not easy to establish clearly the real risk associated with anti- TNF-α therapies 
because of various confounding factors including possible increased predisposition to 
cancer due to the underlying disorder and the concomitant or prior use of other potentially 
cancer-promoting therapies. 
9. Possible link between autoimmune diseases and cancer 
In many systemic autoimmune diseases, where disproportional humoral autoimmune 
responses are pivotal in the pathogenesis (e.g. systemic lupus erythematosus and Sjögren’s 
syndrome), exaggerated B-cell processes exist, resembling B-cell malignancies (Illes et al., 
2009). Both conditions are characterized by cell-cycle regulation abnormalities, which affect 
lymphocyte survival, proliferation and differentiation, as well. 
9.1 Systemic lupus erythematosus  
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, characterized by a 
wide array of symptoms and organ involvements, leading to varying disease courses and 
outcome. In patients with SLE, the incidence and risk of malignancy development is 
increased. The malignancies occurred frequently in SLE patients are Non-Hodgkin’s 
Lymphoma, Hodgkin’s Lymphoma, as well as solid tumours, as lung, cervical and breast 
cancer (Kiss et al., 2010). 
The frequent occurrence of malignancies can be associated with the common pathogenetic 
pathways for cancer and autoimmune disease development. This phenomenon is reinforced 
by the following notions: generally, in autoimmune diseases malignancies occur with high 
frequency; in neoplastic disorders, autoimmune diseases can develop, as part of the 
paraneoplastic syndrome; also, immunosuppressive treatment in autoimmune diseases 
increases the development of malignancies (Zintzaras et al., 2005).  
The long-term, in many instances aggressive immunosuppressive treatment in lupus is 
evidently related to the development of malignant transformations and manifest tumours. 
Besides these common extrinsic etiological factors, the intrinsic errors of the immune system 
contribute to the development of both disease entities (Bernatsky et al., 2002).  
9.1.1 Cancer before systemic lupus erythematosus 
Since the clinical appearance of Non-Hodgkin’s Lymphoma and systemic lupus 
erythematosus is similar, and it is sometimes difficult to distinguish the two disease entities 
in the initial phases, these raise the possibility that SLE might be a paraneoplastic syndrome 
and appears on the grounds of the lymphoid malignancy (Kiss et al., 2010). 
9.1.2 Cancer after systemic lupus erythematosus 
The pathogenic background behind the more frequent presence of NHL in SLE can be due 
to the chronic, persistent antigen-stimulus, chronic inflammation, uncontrolled B cell 
proliferation, defected apoptosis, and the increased risk of oncogene translocation. Common 
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environmental and genetic factors, linked with major histocompatibility complex (MHC)-
associated genes, further contribute to lymphomagenesis in lupus. Also, treatment with 
immunomodulating and immunosuppressive drugs, commonly used in SLE can contribute 
to the development of lymphomagenesis, either by directly causing mutagenesis, or by 
weakening the immune surveillance, which can lead to uncontrolled B cell proliferation 
(Kiss et al., 2010). 
In 9% of SLE patients may occur some inflammatory diseases, such as pneumonitis-fibrosis 
or bronchiolitis obliterans organizing pneumonia, that may lead to a chronic stimulation 
and extensive DNA damage which underlie lung cancer. 
Moreover, in female affected by SLE it has been reported a higher risk of breast cancer, 
without any family history or exogenous hormonal exposure (Ramsey-Goldman et al., 1998). 
Thereby, likely the pathological immune responses triggered by the autoimmune disease 
can lead to uncontrolled cell proliferation and decreased apoptosis, and breast cancer 
development, indeed (Kiss et al.,2010). 
9.1.3 Antiphospholipid antibodies 
Another link between lupus and malignant diseases can be served by antiphospholipid 
antibodies (aPL), frequently present in SLE and cancer as well. 
Patients with cancer are at higher risk of thromboembolic complications than healthy people 
for many reasons. It is known that an important thrombogenic mechanism is mediated by 
antiphospholipid antibodies (aPL). Although the evidence on their association, the 
relationship between aPL presence and cancer is contradictory. It is unclear whether aPL 
antibody positivity has a pathogenetic role in the development of thromboses or whether, in 
contrast, these antibodies are an epiphenomenon in cancer patients (Reinstein & Shoenfeld, 
2007). 
In the last years a higher prevalence of aPL antibodies was observed in patients with solid 
tumours compared to controls (Zuckerman et al., 1995) and in patients with haematological 
malignancies (Pusterla et al., 2004). The reasons of this increased antibody production are 
only partially clarified: their production may be induced by particular immunotherapy of 
cancer such as interferon α (Becker et al., 1994) or started by immune system response to 
new tumour antigens (Sawamura et al., 1994). 
In particular it is possible that autoantibodies to malignant cells arise secondary to changes 
in the cell membrane that induce exposure of certain antigens that are normally facing the 
intracellular compartment (Reinstein & Shoenfeld, 2007), then activating pathogenetic 
autoreactive human T cells (Yamaguchi et al., 2007). In this context, it has been reported that 
viable tumour cells (Fernandes et al., 2006) as well as tumour blood vessels (Ran et al., 2002) 
showed increased exposure of anionic phospholipids on the outer layer of their membranes, 
directly triggering coagulation cascade by providing a procoagulatory surface (Vogt et al., 
1997). Therefore, tumour microenvironment may be a source of anionic lipid surfaces that 
facilitate aPL antibodies production. It is also possible that tumoural cells directly synthetize 
antibodies as in the case of multiple myeloma or Waldenstrom's macroglobulinemia 
(Tincani et al., 2010). 
Moreover, an interesting study carried on aPL antibodies healthy carriers, reported that the 
major cause of morbidity and mortality was the occurrence of malignancies, in particular 
non-Hodgkin’s lymphoma seemed to affect  this group with an higher incidence than the 
general population (Finazzi, 1997). 
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9.2 Rheumatic arthritis 
The link between autoimmune phenomena, particularly rheumatic arthritis, and cancers has 
been suggested in several studies. It may be due to the generation of autoantibodies against 
self and non-self antigens, paraneoplastic syndromes or by chemotherapy. 
As the presence of autoantibodies has been identified in the sera of patients both with solid 
tumours and haematological malignancies, it may be considered as the consequence of the 
immune response against the tumour (Conrad, 2000). 
The natural autoantibodies (NAA), frequently occurring in high titres in the sera of patients 
with multiple myeloma, Waldenstrom’s macroglobulinemia, chronic lymphocytic 
leukaemia, and B cell lymphoma, are generated by CD5+ B cells. They are mainly IgM, 
which bind with low affinity self and non-self antigens, and they also have rheumatoid 
factor activity (Abu-Shakra et al., 2001). This autoantibody activity is the result of malignant 
transformation of B cells, that produce autoantibodies (Dighiero, 1998). 
9.2.1 Cancer after rheumatic arthritis 
An increased occurrence of malignancies in patients with established rheumatoid arthritis 
(RA) has been found by several studies (Bernatsky et al., 2006). In most cases, the higher rate 
of cancer is linked to the use of immunosuppressive therapy, and the tumour generally 
takes several years to develop.  
9.2.2 Cancer before rheumatic arthritis 
However, the early manifestation of an occult malignancy may be a rapid-onset arthritis 
mimicking rheumatoid arthritis. More often, the rheumatoid arthritis-like syndrome 
precedes the development of cancer by 6–12 months. (Racanelli et al., 2008) 
Rheumatoid arthritis-like syndromes have been associated with malignancies of the lung, 
colon, breast, ovary, stomach and oropharynx cancer and with haematopoietic malignancies. 
(Andrai et al., 2006) 
Patients with paraneoplastic rheumatic disease generally exhibit a form of asymmetric 
polyarthritis that may be confused with seronegative rheumatoid arthritis or 
spondyloarthropathy. 
The paraneoplastic disorders disappear after surgical removal or pharmacological treatment 
of the cancer, otherwise these treatments have any influence on rheumatic symptoms that 
are tumour-associated (Naschitz, 2001).  
9.3 Polymyositis and dermatomyositis 
The association between malignancy and autoimmune myositis, in particular polymyositis 
(PM) and dermatomyositis (DM), has been largely described (Briani et al., 2006). The 
diagnosis of tumour can precede, parallel or follow myositis diagnosis. Most commonly 
cancer is diagnosed after the onset of myositis, but in many cases the course of the 
myopathy paralleled the course of the tumour (Zampieri et al., 2010). The incidence of 
cancer in patients with an established autoimmune myopathies was estimated ranging from 
6% to 60% (Hill et al., 2001). In contrast, the incidence of myopathies as an early 
manifestation of an occult malignancies is undefined.  
9.3.1 Cancer before autoimmune myositis 
The malignancies more frequently associated with PM and DM are  ovarian, colorectal, 
breast, and lung cancer (Wakata et al., 2002). The so called “paraneoplastic” inflammatory 
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myopathies are autoimmune myositis, that develop in patients with primary cancer as the 
consequence of its presence. In the paraneoplastic syndromes the surgical removal or 
pharmacological treatment of cancer results in the disappearance of the clinical symptoms of 
the paraneoplastic disease (Raccanelli et al., 2008). Some myopathies can develop also in 
response to chemotherapeutic agents used to treat cancer (Chakravarty & Genovese, 2003). 
The paraneoplastic myositis show different clinical features and laboratory data, as well as a 
later onset and a lower or absent response to immunosuppressive drugs (Buchbinder et al., 
2001). 
9.3.2 Cancer after autoimmune myositis 
Patients with DM have a greater risk of developing malignancy than the general population, 
while PM patients seem to be associated to a lesser extent to an increased risk. Also the 
drugs used to treat autoimmune myositis can be responsible for cancer onset in these 
patients. These drugs are administered in order to modulate the response of immune system 
and therefore their use can induce an altered state of immune surveillance which can be 
responsible for the consequent development of tumour (Szekanecz et al., 2006). 
The pathogenetic molecular mechanisms underlying the association between cancer and 
myositis are still unknown, even though some hypotheses have been purposed (Eisenlohr & 
Rothstein, 2006). It is possible that an immune  response directed against cancer cells in both 
breast and lung adenocarcinoma, as well as hepatocellular carcinoma, cross-reacts with 
regenerating muscle cells (Casciola-Rosen et al., 2005). These regenerating muscle fibers and 
tumour cells expressing myositis specific autoantigens, may be responsible for the induction 
of autoimmune response in those patients with a predisposing genetic background to 
autoimmunity. Casciola-Rosen et al. (2005) have been demonstrated that some tumours (e.g. 
breast, lung adenocarcinoma, and hepatocellular carcinoma), but not the corresponding 
normal tissues, express high levels of myositis autoantigens. It has been also demonstrated 
that in affected muscles from myositis patients, regenerating myoblasts overexpress 
myositis specific autoantigens and notably the expression of these autoantigens by tumour 
cells as well as by regenerating myoblasts, indicates a possible antigenic similarity between 
the two cell populations (Casciola-Rosen et al., 2005). 
9.4 Sjögren’s syndrome 
The link between Sjögren's syndrome (SS) and non-Hodgkin's lymphoma (NHL) is one of 
the strongest among all the known associations between systemic autoimmune diseases and 
malignancies. The occurrence of NHL has been reported to be as much as 44-fold greater in 
Sjögren's syndrome than in the general population (Kovács et al., 2010). In the majority of 
patients, the histopathologic type of lymphoma is mucosa-associated lymphoid tissue 
(MALT) type B cell lymphoma, i.e. extranodal marginal zone B cell lymphoma, and in about 
30% of SS patients, other types of NHL can be observed. In SS, the predominant cellular 
components of the focal lymphocytic infiltration in the salivary glands are CD4+T 
lymphocytes. The evolution of a malignant proliferation of B-lymphocytes from this 
inflammatory infiltration is due to a complex process. The ultimate step in this process is the 
transition from benign B cell proliferation to malignant expansion. The uncontrolled 
expansion of B-lymphocytes is a result of various genetic alterations, typically translocations 
involving immunoglobulin gene loci and proto-oncogenes or other genes involved in cell-
cycle regulation (Kovács et al., 2010). 
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myopathies are autoimmune myositis, that develop in patients with primary cancer as the 
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the paraneoplastic disease (Raccanelli et al., 2008). Some myopathies can develop also in 
response to chemotherapeutic agents used to treat cancer (Chakravarty & Genovese, 2003). 
The paraneoplastic myositis show different clinical features and laboratory data, as well as a 
later onset and a lower or absent response to immunosuppressive drugs (Buchbinder et al., 
2001). 
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Patients with DM have a greater risk of developing malignancy than the general population, 
while PM patients seem to be associated to a lesser extent to an increased risk. Also the 
drugs used to treat autoimmune myositis can be responsible for cancer onset in these 
patients. These drugs are administered in order to modulate the response of immune system 
and therefore their use can induce an altered state of immune surveillance which can be 
responsible for the consequent development of tumour (Szekanecz et al., 2006). 
The pathogenetic molecular mechanisms underlying the association between cancer and 
myositis are still unknown, even though some hypotheses have been purposed (Eisenlohr & 
Rothstein, 2006). It is possible that an immune  response directed against cancer cells in both 
breast and lung adenocarcinoma, as well as hepatocellular carcinoma, cross-reacts with 
regenerating muscle cells (Casciola-Rosen et al., 2005). These regenerating muscle fibers and 
tumour cells expressing myositis specific autoantigens, may be responsible for the induction 
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autoimmunity. Casciola-Rosen et al. (2005) have been demonstrated that some tumours (e.g. 
breast, lung adenocarcinoma, and hepatocellular carcinoma), but not the corresponding 
normal tissues, express high levels of myositis autoantigens. It has been also demonstrated 
that in affected muscles from myositis patients, regenerating myoblasts overexpress 
myositis specific autoantigens and notably the expression of these autoantigens by tumour 
cells as well as by regenerating myoblasts, indicates a possible antigenic similarity between 
the two cell populations (Casciola-Rosen et al., 2005). 
9.4 Sjögren’s syndrome 
The link between Sjögren's syndrome (SS) and non-Hodgkin's lymphoma (NHL) is one of 
the strongest among all the known associations between systemic autoimmune diseases and 
malignancies. The occurrence of NHL has been reported to be as much as 44-fold greater in 
Sjögren's syndrome than in the general population (Kovács et al., 2010). In the majority of 
patients, the histopathologic type of lymphoma is mucosa-associated lymphoid tissue 
(MALT) type B cell lymphoma, i.e. extranodal marginal zone B cell lymphoma, and in about 
30% of SS patients, other types of NHL can be observed. In SS, the predominant cellular 
components of the focal lymphocytic infiltration in the salivary glands are CD4+T 
lymphocytes. The evolution of a malignant proliferation of B-lymphocytes from this 
inflammatory infiltration is due to a complex process. The ultimate step in this process is the 
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10. Conclusion  
The relationship between autoimmunity and cancer has been investigated, focusing on 
implication of immune system, apoptosis and new therapeutic agents for autoimmune 
diseases. Autoimmune diseases, characterized by chronic inflammatory state, with 
continuous antigenic stimulation, may contribute to haematological malignancies and solid 
tumours development. However , the role of new therapeutic agents, as biologic drugs  used 
more frequently in autoimmune diseases treatment, is controversial and need further 
studies in depth, since they may be involved in cancer onset, as well. The autoimmune 
diseases, as rheumatoid disorders, systemic lupus erythematosus or myositis may occur 
before or concomitant with a tumour, as paraneoplastic syndromes, which regress after 
cancer removal.  
Apoptosis is a critical regulator of cellular and humoral immune responses, appearing to 
play a critical role in the deletion of lymphocytes after an inflammatory state, as well as in 
the control of tumour cell survival, leading to unchecked tumour growing, if the genes of 
apoptosis show some mutations. Therefore, understanding normal apoptosis mechanisms is 
critical for developing a better know-how from which to undertake strategies for improving 
autoimmune diseases and cancer therapy. 
In addition, it is an interesting task the different immune responses against autoantigen 
occurring during autoimmunity and cancer, which are involved in alterations of 
immunological tolerance and maintenance of immunological tolerance, respectively. Thus it 
is easy to understand that immunological tolerance in cancer and autoimmune disease has 
opposite effects in the patient: in cancer patients it stimulates the growth of the cancer, but 
in patients with autoimmune disease immunological tolerance may stop the attack by 
autoantibodies and thereby benefit the patient. In fact, cancer cells are able to employ a 
pseudo-autoimmune status (cancer associated autoimmune disease) and induce 
immunological tolerance by producing autoantibodies to tumour antigens derived from 
impaired clearance of apoptotic cells, resulting in an increase of regulatory T cells, thus 
increasing tolerance toward tumour cells. 
However, further investigations are needed to better define new therapeutic strategies 
controlling inflammatory components, responsible of both autoimmunity and cancer 
progression. 
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1. Introduction 
In humans, female’s humoral and cellular immunity are actually stronger than men 
(Nalbandian & Kovats, 2005) and present a higher antibody serum titration than men 
(Giron-Gonzalez et al., 2000) which could logically and possibly explain their gender 
predisposition and susceptibility to autoimmunity. Holding an autoimmune disease and 
becoming pregnant is a serious matter for a woman and knowledge of the course of the 
condition during pregnancy is essential. Relational variations exist between types of 
autoimmuny during pregnancy and consequently proper advices from physicians are 
provided accordingly. In Systemic lupus erythematosus, all advices provided to the patients 
are meant to dissuade women from getting pregnant while being in a relapse stage of the 
disease and better wait for the end of the flare pathological course.  As for Rheumatoid 
arthritis and multiple sclerosis, no real dangers are encountered while being pregnant and 
while the disease symptoms are expressed it still does not present life threatening risks to 
the gestation. In Myasthenia gravis, during gestation the risks are variable and retrospective 
studies show increase complications. 
Logically, the baby carrying semi-allogenic antigens should prompt an autoimmune 
reaction from the mother. However a plethora of tolerance measures is put into action by 
both the mother and the foetus.  Pre implantation immunological events are in place to best 
prepare the nidation of the foetus into the mother endometrium. There is large paucity of 
published scientific research studies that have attempted to understand the entire 
pregnancy immune profile due to low power studies, limiting longitudinal samplings and 
narrow immune component analysis. However, a recent study has shown a Th1 toTh2 shift 
with increase interleukin 10 synthesis and a decrease responses to pro-inflammatory 
cytokines such as TNFα, Il-1β and Il-6 during pregnancy (Denney et al., 2011). 
Immunological adaptations occur early in gestation and are mediated by the uterine 
epithelium including the fallopian tube secretion of granulocyte macrophage colony 
stimulating factors (GM-CSF) (Rosendaal, 1975). In addition, the trophoblast that is derived 
from the fertilized egg secretes GM-CSF to prepare best for the next step of implantation 
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and formation of the placenta (Burgess et al., 1977). Post implantation, the placenta is 
formed to accommodate, protect and feed with key nutrients the growing foetus. The 
placenta is formed of different layers with the basal plate or deciduas basalis, a structure in 
direct contact with the endometrium, the intermediate layer being the lacunar system and 
finally the chorionic plate made of two leaflets, the chorionic plate and the amniotic plate. 
Interestingly, the content of the decidua is composed of different key factors aiming at 
inducing tolerance and include cells such as maternal Natural killers and regulatory T-cells. 
Natural killer cells are secreting lots of cytokines with immunoregulation purposes and are 
non cytotoxic (Chantakru et al., 2002). As for the regulatory T-cells, data showed that human 
chorionic gonadotropin hormone is responsible for the attraction of such cells in the 
placenta (Schumacher et al., 2009). It has also been proved that Treg are key determinants in 
murine pregnancy (Zenclussen et al., 2005) with possibly the mediation of interleukin 10 
(Taylor et al., 2006 & Akdis et al., 2001). The relative proportion of immune cells found in 
the deciduas are as follows, 70% of natural killers (Moffet et al., 2004), 20% of macrophages 
(Lessin et al., 1988), around 2% of T lymphocytes (Lessin et al., 1988), 1% of dendritic cells 
(Gardner et al., 2003) and very minute B cell lymphocytes (Veenstra Van Nieuwenhoven et 
al., 2003).  In addition, regulatory proteins decreasing complement action are found in the 
decidua basalis more precisely on the syncyciotrophoblast T-cells along with cellular 
membranar Fas ligands and MHC molecules. MHC molecules consist of class III MHC 
molecules but lack of particular HLAI and HLA II molecules including HLA-A and -B as 
well as HLA-DP, -DQ and –DR is noticed (Landek-Salgado et al., 2010). Interestingly the 
placenta is maintaining a tied tolerance status mediated by each of its functional molecular 
and cellular components playing a major role in this process. Mostly, any activated T-cells 
that would reach this mother-foetus interface border would be bound to Fas ligand on their 
Fas receptor condemning them to enter apoptosis (Pongcharoen et al., 2004). This apoptotic 
process is mediated by Fas pathway through the activation of the death induce signaling 
complex that ultimately activates the caspase apoptotic cascade. More importantly, 
regulatory T-cells accumulating in the decidua during pregnancy, dampen any pro-
inflammatory that harm the foetus (Tilburgs et al., 2008).  
Along with this immunosuppressive function, an immune tolerance is strongly put in place. 
Transient gestational lowering reactivity is set to prevent potent T-cells from reacting 
against the semi-allogenic foetus and previously demonstrated in animal studies (Tafuri et 
al., 1995). Immuno tolerance features that directly play roles on pro-inflammatory immune 
cells are relying on particular cells called T regulatory cells or Tregs (Kuniyasu et al., 2000). 
Tregs can be Th4 lymphocytes or T8 lymphocytes and are mostly found to act as 
immunomodulators in regions of inflammation (Gavin et al., 2002). The action is mediated 
by contact inhibition of non Treg cells such include subsets of T 4 and T8 lymphocytic cells. 
Specific markers are differentiating these subsets from regulatory to non regulatory effective 
T-cells (Teff) and include CD25 markers (α chain of IL-2 receptor) with the so called CD4+ 
CD25+ and CD8+CD25+ cells. Additional markers are also found in Tregs such as FoxP3+ 
marker, a repressor activator of activated T-cells such as CD4+CD25+FoxP3+ Treg cells or 
Cd8+ CD25+ CDFoxP3+ Treg cells. Another Treg marker is CXCR3+ seen in CD8+ CXCR3+ 
Treg cells. The Treg mediation in tolerance restoration can be undertaken through different 
mechanisms. Tolerance could be undertaken by contact interaction such as Fas- Fas ligand 
interaction dictating an apoptotic faith to the Teff cells (Watanabe et al, 2002). The other way 
Tregs are promoting tolerance to Teff cells is to inhibit Teff cytokine synthesis and 
 
Mechanism of Autoimmunity in Pregnancy - The Good and the Bad 423 
subsequently their Teff cytolytic activation as well as diminishing their proliferation 
(Duthoit et al., 2005). Teff cells can be CD8+ or CD4+ cells with the latter being classified 
into two types, TH1 and TH2 both differing in action as pro-inflammatory and anti-
inflammatory actions respectively. Briefly, the Th1 activation pathway consists in interferon 
γ inducing activation of its cell surface receptor on T cells and subsequent intracellular 
cascade activation. Such cascade leads to the activation of the transcription factor T-bet 
which function is to bind DNA responsive elements of genes within the nucleus. The main 
responsive elements controlled and activated belong to the genes interferon γ and IL-12 
receptor β2 chain. Upon activation, further expression of these genes is undertaken and IL-
12 receptor becomes widely available at higher amounts in the cellular T-cell membranar 
surface and therefore can be prompted to activation due to the presence of local IL-12 
cytokine. IL-12 receptor actiavtion induces a second cascade that is Stat 4 dependent, with 
the ultimate goal to produce furthermore T-bet transcription factor. Relation between Tregs 
and pro-inflammatory TH1 and CD8+ T-cells demonstrate an interesting phenomenon that 
is build around the competition for Interleukin 2 binding. In sites of inflammation, binding 
of IL-2 by Tregs diminishes the availability of IL-2 to Teffs and therefore limiting their 
growth, function and even at early stage turning Teffs to be anergic towards antigens 
(Piccirillo et al., 2001). Briefly, T-cells are activated through the contact of antigen with T-cell 
receptor under the restriction of MHC class molecules. Such binding activates p56lck 
tyrosine kinase with subsequent downstream phosphorylation of proteins and activation of 
phospholipase C. Such phospholipase generates from phosphatidyl inositol diphosphate, 
two compounds; the diacyl glycerol and inositol tri-phosphate, IP3.  The endoplasmic 
reticulum IP3 receptor is therefore activated with release of calcium in the cytosol. Such 
Ca2++ induces a membranar activation of the cell membrane calcium release activated 
calcium channel named CRAC and subsequently increases highly the intracellular Ca2++ 
concentration. High levels of Ca2++ activate caclineurin, a phosphatase that 
dephosphorylates the transcriptional factor NFAT (nuclear factor of activated T-cells). Such 
dephosphorylated NFAT translocates into the nucleus to reach responsive elements of Il-2, 
AP1 and NFKB enabling their expression and future function. Beside the roles of Tregs as 
pro-apoptotic cytolytic Teff cells inducers and Teff cells expansion inhibitors, Tregs are 
capable to modulate the  inflammatory ‘soup’ and pattern observed in inflammation sites. 
Such action of Tregs is mediated by their synthesis and secretion of both TGFβ and 
interleukin 10. A higher content of Il-10 is maintained due to Teffs response to TGFβ action 
and secondly by Il-10 action on dictating Teffs to respond with higher affinity to TGFβ. In 
addition, the constant increase of progesterone in gestation, which is peaking at the third 
trimester, is responsible for the activation of particular subsets of T-cells called γδ T-cells. 
Upon binding to its receptor, progesterone activates γδ T-cells to secrete Il-10 and 
progesterone induced blocking factor (PIBF) that result in the inhibition of natural killer 
cells (Barakonyi et al., 1999). In addition, these cells synthesise TGFβ that enhances the 
mother’s T-cell tolerance for the foetus (Mincheva-Nilsson et al., 1992). 
2. Autoimmunity and pregnancy 
Women are more prevalent to autoimmunity and 3 to 5% will be affected by such disorders. 
During pregnancy, clinical course of several autoimmune disease are expressed with 
variable degrees. Some range from higher remission of signs and symptoms while others are 
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cells are relying on particular cells called T regulatory cells or Tregs (Kuniyasu et al., 2000). 
Tregs can be Th4 lymphocytes or T8 lymphocytes and are mostly found to act as 
immunomodulators in regions of inflammation (Gavin et al., 2002). The action is mediated 
by contact inhibition of non Treg cells such include subsets of T 4 and T8 lymphocytic cells. 
Specific markers are differentiating these subsets from regulatory to non regulatory effective 
T-cells (Teff) and include CD25 markers (α chain of IL-2 receptor) with the so called CD4+ 
CD25+ and CD8+CD25+ cells. Additional markers are also found in Tregs such as FoxP3+ 
marker, a repressor activator of activated T-cells such as CD4+CD25+FoxP3+ Treg cells or 
Cd8+ CD25+ CDFoxP3+ Treg cells. Another Treg marker is CXCR3+ seen in CD8+ CXCR3+ 
Treg cells. The Treg mediation in tolerance restoration can be undertaken through different 
mechanisms. Tolerance could be undertaken by contact interaction such as Fas- Fas ligand 
interaction dictating an apoptotic faith to the Teff cells (Watanabe et al, 2002). The other way 
Tregs are promoting tolerance to Teff cells is to inhibit Teff cytokine synthesis and 
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subsequently their Teff cytolytic activation as well as diminishing their proliferation 
(Duthoit et al., 2005). Teff cells can be CD8+ or CD4+ cells with the latter being classified 
into two types, TH1 and TH2 both differing in action as pro-inflammatory and anti-
inflammatory actions respectively. Briefly, the Th1 activation pathway consists in interferon 
γ inducing activation of its cell surface receptor on T cells and subsequent intracellular 
cascade activation. Such cascade leads to the activation of the transcription factor T-bet 
which function is to bind DNA responsive elements of genes within the nucleus. The main 
responsive elements controlled and activated belong to the genes interferon γ and IL-12 
receptor β2 chain. Upon activation, further expression of these genes is undertaken and IL-
12 receptor becomes widely available at higher amounts in the cellular T-cell membranar 
surface and therefore can be prompted to activation due to the presence of local IL-12 
cytokine. IL-12 receptor actiavtion induces a second cascade that is Stat 4 dependent, with 
the ultimate goal to produce furthermore T-bet transcription factor. Relation between Tregs 
and pro-inflammatory TH1 and CD8+ T-cells demonstrate an interesting phenomenon that 
is build around the competition for Interleukin 2 binding. In sites of inflammation, binding 
of IL-2 by Tregs diminishes the availability of IL-2 to Teffs and therefore limiting their 
growth, function and even at early stage turning Teffs to be anergic towards antigens 
(Piccirillo et al., 2001). Briefly, T-cells are activated through the contact of antigen with T-cell 
receptor under the restriction of MHC class molecules. Such binding activates p56lck 
tyrosine kinase with subsequent downstream phosphorylation of proteins and activation of 
phospholipase C. Such phospholipase generates from phosphatidyl inositol diphosphate, 
two compounds; the diacyl glycerol and inositol tri-phosphate, IP3.  The endoplasmic 
reticulum IP3 receptor is therefore activated with release of calcium in the cytosol. Such 
Ca2++ induces a membranar activation of the cell membrane calcium release activated 
calcium channel named CRAC and subsequently increases highly the intracellular Ca2++ 
concentration. High levels of Ca2++ activate caclineurin, a phosphatase that 
dephosphorylates the transcriptional factor NFAT (nuclear factor of activated T-cells). Such 
dephosphorylated NFAT translocates into the nucleus to reach responsive elements of Il-2, 
AP1 and NFKB enabling their expression and future function. Beside the roles of Tregs as 
pro-apoptotic cytolytic Teff cells inducers and Teff cells expansion inhibitors, Tregs are 
capable to modulate the  inflammatory ‘soup’ and pattern observed in inflammation sites. 
Such action of Tregs is mediated by their synthesis and secretion of both TGFβ and 
interleukin 10. A higher content of Il-10 is maintained due to Teffs response to TGFβ action 
and secondly by Il-10 action on dictating Teffs to respond with higher affinity to TGFβ. In 
addition, the constant increase of progesterone in gestation, which is peaking at the third 
trimester, is responsible for the activation of particular subsets of T-cells called γδ T-cells. 
Upon binding to its receptor, progesterone activates γδ T-cells to secrete Il-10 and 
progesterone induced blocking factor (PIBF) that result in the inhibition of natural killer 
cells (Barakonyi et al., 1999). In addition, these cells synthesise TGFβ that enhances the 
mother’s T-cell tolerance for the foetus (Mincheva-Nilsson et al., 1992). 
2. Autoimmunity and pregnancy 
Women are more prevalent to autoimmunity and 3 to 5% will be affected by such disorders. 
During pregnancy, clinical course of several autoimmune disease are expressed with 
variable degrees. Some range from higher remission of signs and symptoms while others are 
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being increased in exacerbations. These influences observed in Pregnancy denote a complex 
interaction between the pathophysiological course of the disease and the physiological 
adaptations during pregnancy.  Presence of a wide spectrum of auto-antibodies correlates 
with the parturient pathophysiological course. In some autoimmune diseases, the risk of 
transient neonatal illness could be observed and can range from low risk as in myasthenia 
gravis to relatively higher as in Lupus. Self tolerance mechanisms at the cellular and genetic 
levels are modulated during pregnancy by these autoimmune diseases. Such modulation 
might reside at different levels and include, allelic variation with the HLA loci and 
expression, physiological adaptations during pregnancy  (hormones) and alteration towards 
the host immunity or the foetal antigens (paternal HLAs), cytokine profile during 
pregnancy, HLA from foetus (HLA-G), structural interface integrity between foetus and 
mother, status of  intrinsic and extrinsic controls preventing-autoimmunity. 
We aim in this review at discussing the immunological events that surround pregnancy and 
autoimmunity especially by focusing on Systemic lupus erythematosus, Rheumatoid 
arthritis, Myasthenia gravis and Multiple sclerosis. 
2.1 Systemic Lupus Erythematosus 
2.1.1 Pathophysiology of SLE 
Systemic lupus erythematosus (SLE) is an autoimmune disease mainly affecting the 
connective tissue that consequently demonstrating a plethora of systemic effects mostly 
observed in individuals of African-Asian origin. A staggering 9:1 ratio females to males is 
noted with a peak age of onset in young woman between 25 and 35 years of age. More than 
98% of SLE patients are positive for the antinuclear auto-antibody (ANA), a marker of the 
disease. Other auto-antibodies are used to better refine the diagnosis of SLE and include anti 
cytoplasmic and anti DNA antibodies. The pathology shows a diverse range of symptoms 
affecting several organs ranging from common cutaneous lesions, serous membrane 
alteration and intermittent joints debilitations. More precisely, facial malar rashes, 
arthralagia, polyathritis, pleurisy, pericarditis are experienced along with other symptoms 
like Raynand’s phenomenon and fever. The etiology of this complex disease is unknown but 
several hypotheses have been raised.  Cellular release of antigens from apoptotic and 
necrotic cells is raised that will trigger macrophage phagocytosis and subsequent antigen 
presentation, under MHC class II, of such autoantigens to both T and B-cells. Intracellular 
and extracellular signaling are thought to be dysregulated such as the so called  interferon 
signature, a cytokine profile under scrutiny as links with IRF5 has been shown to be 
associated with SLE (Graham et al., 2006). CD19 positive B-cells are of high attention in 
research as several auto-antibodies are pathogenic in the disease such as the anti nuclear 
antibodies (Madaio et al., 2003). 
The genetics of SLE has pinpointed several chromosomal loci with interestingly the 1q23-24 
region also called the pentraxin locus, a region harboring some key candidates including the 
CRP4 allele gene and the PDCD1 gene. A single nucleotide polymorphism in the PDCD1 
gene was found to disrupt an intronic enhancer that prevents the gene from further 
activation with subsequent apoptotic process alterations. Other hypotheses have been 
investigated such as the possible occupational exposure or environmental effects but with 
no direct significant links to the disease. An interesting phenomenon though is well 
documented with the attention on precipitating factors. Such precipitating factors seen in 
SLE are the intake of oral estrogen contraceptives and hormonal replacement therapies 
(HRT) (Sanchez-Guerrero et al., 1997). Several studies including a nurse health study for 
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oral contraceptive use have shown an increase of 1.9 time SLE manifestations compared to 
non users (Sanchez-Guerrero et al., 1995) and similar effect have been demonstrated with 
HRT (Cooper et al., 2002). In addition a lot of evidence is showing that the SLE 
manifestations are correlated with ovarian cycle alterations (Shabanova et al., 2008). A clear 
link is seen between hormonal changes and SLE therefore higher vigilance is sought for SLE 
women willing to become pregnant.  
2.1.2 Modulation effects of pregnancy in SLE mothers 
Pregnancy presents as a life experience where mother’s hormonal levels are evolutionally 
and physiologically adapting to host the baby. Careful monitoring is undertaken as different 
gestational outcome scenarios are observed, with some being unpredictable, due to 
recurrence of flares and possible life threatening issues affecting both the mother and the 
child. Such dangers ranges from intra-uterine growth retardations in 30% of cases (Meyer 
Oliver, 2003), preterm birth with 25-30% of cases to miscarriages and foetal death. Co-
morbidity is most likely to be observed in SLE patients with increase manifestation of the 
disease in the third trimester of gestation. Lots of evidence show detrimental effects to the 
kidney such as lupus nephritis, and atheroslcerotic pathophysiological establishments 
(Roman et al., 2003 and Asanuma et al., 2003) all to which can be further aggravated with 
other common pregnancy experienced problems like seen with preeclampsia occurrence. 
Death of the mother can be observed with common SLE risks due to high elevations of 
pulmonary hypertension. In 37% of SLE pregnant patients, mild increased of pulmonary 
arterial hypertension can be seen (Johnson et al., 2004).  Such monitoring requires the use of 
several tests, serum antibodies, choice of specific medication, compliance with 
hydroxychloroquine, as well as the monitoring of SLE disease activity index (SLEDAI) 
measuring the flaring panel observed in SLE patients. Interestingly, SLE patients would 
have positive benefits and gains to start their gestation in period of remission before 
conception. An otherwise preconception with active disease otherwise shows increased 
flares with particularly renal disease associated problems (Moroni et al., 2002). In addition, 
lower birth weigths and high number of caesarian deliveries are encountered in proliferative 
nephritis cohorts. Foetal loss in SLE is a major problem with several studies attempting to 
link this fatal outcome to molecular triggering factors. The Hughes syndrome is a 
phospholipid induced pregnancy syndrome commonly named the antiphospholipid 
syndrome. Such syndrome is part of the coagulopathy diseases and SLE pregnant women 
are commonly tested for the presence of lupus anticoagulant factor, an anti phospholipid 
factor named anti-cardiolipin. This immunoglobulin G anti-cardiolipin antibody targets the 
apoprotein H or beta 2 glycoprotein 1. Such antibody prevents the glycoprotein from 
undertaking its possible known function as an inhibitor of the intrinsic coagulation cascade, 
an inhibition required and mediated by the release of complement molecules, C3 and C5 
from the liver. As a consequence, SLE mothers with increase anti-ApoH denote a 
procoagulant pattern with detrimental foetal loss as an outcome. Interestingly, with 
treatment regimens of aspirin and heparin intakes, levels of live birth rates from SLE 
pregnant patients is now around 80% (Clark et al., 2007 and Girardi et al., 2004). Several 
markers for the disease have been found to better classify and understand the pathological 
course. 
Efforts of the research community have helped in the discovery of a series of serum markers 
for SLE such as adipokine, a cell to cell signaling protein secreted by the adipose tissue (De 
Sanctis et al., 2009), CD40L or CD154 found in T-cell surface (De Sanctis et al., 2009 b) and 
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being increased in exacerbations. These influences observed in Pregnancy denote a complex 
interaction between the pathophysiological course of the disease and the physiological 
adaptations during pregnancy.  Presence of a wide spectrum of auto-antibodies correlates 
with the parturient pathophysiological course. In some autoimmune diseases, the risk of 
transient neonatal illness could be observed and can range from low risk as in myasthenia 
gravis to relatively higher as in Lupus. Self tolerance mechanisms at the cellular and genetic 
levels are modulated during pregnancy by these autoimmune diseases. Such modulation 
might reside at different levels and include, allelic variation with the HLA loci and 
expression, physiological adaptations during pregnancy  (hormones) and alteration towards 
the host immunity or the foetal antigens (paternal HLAs), cytokine profile during 
pregnancy, HLA from foetus (HLA-G), structural interface integrity between foetus and 
mother, status of  intrinsic and extrinsic controls preventing-autoimmunity. 
We aim in this review at discussing the immunological events that surround pregnancy and 
autoimmunity especially by focusing on Systemic lupus erythematosus, Rheumatoid 
arthritis, Myasthenia gravis and Multiple sclerosis. 
2.1 Systemic Lupus Erythematosus 
2.1.1 Pathophysiology of SLE 
Systemic lupus erythematosus (SLE) is an autoimmune disease mainly affecting the 
connective tissue that consequently demonstrating a plethora of systemic effects mostly 
observed in individuals of African-Asian origin. A staggering 9:1 ratio females to males is 
noted with a peak age of onset in young woman between 25 and 35 years of age. More than 
98% of SLE patients are positive for the antinuclear auto-antibody (ANA), a marker of the 
disease. Other auto-antibodies are used to better refine the diagnosis of SLE and include anti 
cytoplasmic and anti DNA antibodies. The pathology shows a diverse range of symptoms 
affecting several organs ranging from common cutaneous lesions, serous membrane 
alteration and intermittent joints debilitations. More precisely, facial malar rashes, 
arthralagia, polyathritis, pleurisy, pericarditis are experienced along with other symptoms 
like Raynand’s phenomenon and fever. The etiology of this complex disease is unknown but 
several hypotheses have been raised.  Cellular release of antigens from apoptotic and 
necrotic cells is raised that will trigger macrophage phagocytosis and subsequent antigen 
presentation, under MHC class II, of such autoantigens to both T and B-cells. Intracellular 
and extracellular signaling are thought to be dysregulated such as the so called  interferon 
signature, a cytokine profile under scrutiny as links with IRF5 has been shown to be 
associated with SLE (Graham et al., 2006). CD19 positive B-cells are of high attention in 
research as several auto-antibodies are pathogenic in the disease such as the anti nuclear 
antibodies (Madaio et al., 2003). 
The genetics of SLE has pinpointed several chromosomal loci with interestingly the 1q23-24 
region also called the pentraxin locus, a region harboring some key candidates including the 
CRP4 allele gene and the PDCD1 gene. A single nucleotide polymorphism in the PDCD1 
gene was found to disrupt an intronic enhancer that prevents the gene from further 
activation with subsequent apoptotic process alterations. Other hypotheses have been 
investigated such as the possible occupational exposure or environmental effects but with 
no direct significant links to the disease. An interesting phenomenon though is well 
documented with the attention on precipitating factors. Such precipitating factors seen in 
SLE are the intake of oral estrogen contraceptives and hormonal replacement therapies 
(HRT) (Sanchez-Guerrero et al., 1997). Several studies including a nurse health study for 
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oral contraceptive use have shown an increase of 1.9 time SLE manifestations compared to 
non users (Sanchez-Guerrero et al., 1995) and similar effect have been demonstrated with 
HRT (Cooper et al., 2002). In addition a lot of evidence is showing that the SLE 
manifestations are correlated with ovarian cycle alterations (Shabanova et al., 2008). A clear 
link is seen between hormonal changes and SLE therefore higher vigilance is sought for SLE 
women willing to become pregnant.  
2.1.2 Modulation effects of pregnancy in SLE mothers 
Pregnancy presents as a life experience where mother’s hormonal levels are evolutionally 
and physiologically adapting to host the baby. Careful monitoring is undertaken as different 
gestational outcome scenarios are observed, with some being unpredictable, due to 
recurrence of flares and possible life threatening issues affecting both the mother and the 
child. Such dangers ranges from intra-uterine growth retardations in 30% of cases (Meyer 
Oliver, 2003), preterm birth with 25-30% of cases to miscarriages and foetal death. Co-
morbidity is most likely to be observed in SLE patients with increase manifestation of the 
disease in the third trimester of gestation. Lots of evidence show detrimental effects to the 
kidney such as lupus nephritis, and atheroslcerotic pathophysiological establishments 
(Roman et al., 2003 and Asanuma et al., 2003) all to which can be further aggravated with 
other common pregnancy experienced problems like seen with preeclampsia occurrence. 
Death of the mother can be observed with common SLE risks due to high elevations of 
pulmonary hypertension. In 37% of SLE pregnant patients, mild increased of pulmonary 
arterial hypertension can be seen (Johnson et al., 2004).  Such monitoring requires the use of 
several tests, serum antibodies, choice of specific medication, compliance with 
hydroxychloroquine, as well as the monitoring of SLE disease activity index (SLEDAI) 
measuring the flaring panel observed in SLE patients. Interestingly, SLE patients would 
have positive benefits and gains to start their gestation in period of remission before 
conception. An otherwise preconception with active disease otherwise shows increased 
flares with particularly renal disease associated problems (Moroni et al., 2002). In addition, 
lower birth weigths and high number of caesarian deliveries are encountered in proliferative 
nephritis cohorts. Foetal loss in SLE is a major problem with several studies attempting to 
link this fatal outcome to molecular triggering factors. The Hughes syndrome is a 
phospholipid induced pregnancy syndrome commonly named the antiphospholipid 
syndrome. Such syndrome is part of the coagulopathy diseases and SLE pregnant women 
are commonly tested for the presence of lupus anticoagulant factor, an anti phospholipid 
factor named anti-cardiolipin. This immunoglobulin G anti-cardiolipin antibody targets the 
apoprotein H or beta 2 glycoprotein 1. Such antibody prevents the glycoprotein from 
undertaking its possible known function as an inhibitor of the intrinsic coagulation cascade, 
an inhibition required and mediated by the release of complement molecules, C3 and C5 
from the liver. As a consequence, SLE mothers with increase anti-ApoH denote a 
procoagulant pattern with detrimental foetal loss as an outcome. Interestingly, with 
treatment regimens of aspirin and heparin intakes, levels of live birth rates from SLE 
pregnant patients is now around 80% (Clark et al., 2007 and Girardi et al., 2004). Several 
markers for the disease have been found to better classify and understand the pathological 
course. 
Efforts of the research community have helped in the discovery of a series of serum markers 
for SLE such as adipokine, a cell to cell signaling protein secreted by the adipose tissue (De 
Sanctis et al., 2009), CD40L or CD154 found in T-cell surface (De Sanctis et al., 2009 b) and 
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the poly-reactive immunoglobulin M from B-cells (Zhang et al., 2009). All these markers 
denote an intense cell to cell communication and intense modulatory involvement of the 
immune system. Both arms of the immunity system are involved in SLE and particular 
attentions are drawn to further unravel the pathophysiological mechanism in SLE patient’s 
immunity. SLE immune dysregulation involves a role to T-cell activation (Fernandez et al., 
2009), B-cell signaling (Liu et al., 2009 and Peng, 2009) along with altered chemokine 
patterns (Youinou et al., 2009 and Wittmann et al., 2009) with IL-6 playing a role in 
polyarthritis and joint damage (Fonseca et al., 2009) and as mentioned previously an 
interferon signature (Finke et al., 2009).  
The complex cascade of T-cell activation from the T-cell receptor (TCR) the consequently 
increase in intracellular content of Ca2++ and NFAT mediated IL-2 Transcriptional 
activation is an important immune component in SLE. In SLE, such pathway of activation is 
altered and seems to be associated with the calcium processing. ER calcium content not 
being an issue, a lot of attention was given to CRAC and studies have shown altered 
efficiency in this Ca2+ channel. Evidence has also shown that in SLE patients a Ca+ 
alteration was observed and linked to an upstream mitochondrial dysregulation. Evidence 
of high membrane hyperpolarisation (MHP) of the inner membrane of the mitochondrial 
has been pinpointed in SLE T-cells with subsequent ATP decreasing synthesis and failure to 
regenerate glutathione reduced forms, a anti oxidant molecule.   Such dysregulation seems 
to be as well the cause of the unbalance fate observed in SLE T-cells deaths. Instead of 
progressing to a program cell death, with the common FAS pathway and death inducing 
signaling complex cascade, SLE T-cells instead enter necrosis. As both ATP and reduced 
glutathione pools are low, apoptosis is prevented and as such unbalance of quality cell 
death tends to develop into two main consequences. First, necrosis is favored and induces 
inflammation whereas apoptotic bodies do not. Secondly, in SLE, such overall dysregulation 
of calcium (katsiari et al., 2002), ATP formation (Perl et al., 2004) and low antioxidant 
capacity profile (Wang et al., 2010) is in favor to auto-reactive T-cells. 
A strong correlation has been found between CXCL10 and SLE disease (Kong et al., 2009). 
CXCL10 is the interferon inducible factor, chemokine (C-X-C motif) ligand 10 also known as 
IP10 that acts on the receptor CXCR3. Interestingly, the gene coding for such receptor is the 
unique chemokine receptor found in chromosome X. This is in clear contrast to all other 
chemokine receptor genes, suggesting unique functions for CXCR3 and the ligand CXCL10 
in possibly the role in SLE immunity. In sites of inflammation, a subset of B-cells with high 
expression of the marker CD19, a co-receptor of the B-cell receptor and known to be 
implicated in auto-immuniy, shows elevated CXCR3 levels (Nicholas et al., 2007). More 
challenges are met during pregnancy where placental tissues and the new born semi-
allogenic foetal cells are brought together along with SLE (Doria et al., 2008).  High 
consequences were recently tabulated in pregnant women with SLE with approximately 
25% of women presenting with disease exacerbations (Lockshin et al., 1989).  
2.2 Myasthenia and pregnancy 
2.2.1 Pathophysiology of myasthenia gravis 
Besides T-cells, breakdown of self tolerance in autoimmune diseases can be associated with 
humoral B-cell mediated immunity producing pathological auto-antibodies contributing to 
tissue damage as seen in myasthenia gravis (MG). MG is an autoimmune disease affecting 
predominantly women with clinical muscle fatigability with patients suffering from degrees 
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of weakness at various body systems.  Under approximately 40 years of age, women are 
prevalent but after 50 years of age, incidence is then lesser in women than men. (Grob et al., 
2008).  The disease is categorised into two clinical presentations with on one hand, the 
ocular MG affecting of the levator and extra ocular palpebrae skeletal muscles with common 
diplopia and ptosis and in the other hand, generalised MG affecting other skeletal muscles. 
Interestingly, the disease can occur as relapsing remitting and the onset of symptomatology 
is varying from acute to subacute. Auto-antibodies target different antigens including the 
acetylcholine receptor (AchR) and, in most intense disease presentation, target the muscle 
specific muscle protein named MuSK (Padua et al., 2006). AchR and MusK seropositivity 
lead to neuromuscular dysfunctions. In the case of anti AChR, the antibodies trigger 
neutralisation of AChR function (Drachman et al., 1982), as well as antibody dependent 
complement activation with membrane attack complex formation (Engel et al., 1987) and 
finally antibody cross link with the ACHR  leading to the destruction of AChR. The early 
onset MG is also associated with the possible occurrence of other autoimmune insults most 
commonly against the thyroid (Christensen, 1995). In early onset MG, the thymus gland is 
enlarged and patients present with multiple auto-antibodies. However, late onset MG is not 
associated with enlarged thymus. Association of HLA markers with individual type of MG 
onset has been undertaken and data showed that the early onset MG is associated with 
HLA-B8 and DR3 (Compston et al., 1980) whereas late onset MG is associated with HLA B7 
and DR2 (Maggi et al., 1991). Immunologically the thymus is a primary lymphoid organ 
with a highly responsible function to maturate T-cells. T-cells that were produced in the 
bone marrow enter the thymus to become thymocytes to undergo a subsequent series of 
selection. The whole thymus is built to this process with a well vascularised content, clusters 
of different types of cells including antigen presenting cells such as macrophages, dendritic 
cells and parenchymal epithelial cells. When maturation of thymocytes is terminated, an 
efferent drainage successfully drains these cells into mediastinal lymph nodes. This selection 
is aiming at positively selecting immature T-cells which T-cell receptor would recognise 
MHC molecules. In the other hand, the negative selection aims at discarding the T-cells that 
would react to autoantigens presented by APCs. A failure in undertaking the removal of 
autoimmune T-cells is thought to be the problem occurring in MG disease. Certain T-cells, 
Th4 or CD4 + were investigated for their possible cell mediated autoimmune 
dysregulations. Interestingly though, both patients and free of disease normal individuals 
do have autoimmune T-cells targeting AChR (Schluep et al., 1987).  Using experimental 
autoimmune myasthenia gravis (EAMG) animal models with Th1 deficient cells, 
researchers have shown actually that such animals have susceptibility to autoimmunity 
(Balasa et al., 1997). In this latter study, the focus was to distinguish between wild type and 
EAMG interferon gamma knockout mice. Result showed that EAMG knockout mice had no 
weakness to their muscles and were resistance to MG. However, the level of proliferation of 
AChR primed lymph nodes was still proliferating as normally observed in wild type mice.   
As interferon gamma is the primary pro-inflammatory stimulator of TH1 cells with 
downstream activation of the T-bet transcription factor inducing further interferon gamma 
transcription, MG autoimmunity induced solely with Th1 cannot be explaining the entire 
course of the disease. Even other types of autoimmunity such as in multiple sclerosis 
experimental allergic encephalomyelitis animals, observation of both interferon gamma 
deficient mice and T-bet knockout mice did not protect these autoimmunity disorders 
(Ferber et al., 1996). In Balasa et al. study, lymphogenic changes using mice with intact 
thymus were investigated but researchers focus is also turned into directly thymectomized 
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the poly-reactive immunoglobulin M from B-cells (Zhang et al., 2009). All these markers 
denote an intense cell to cell communication and intense modulatory involvement of the 
immune system. Both arms of the immunity system are involved in SLE and particular 
attentions are drawn to further unravel the pathophysiological mechanism in SLE patient’s 
immunity. SLE immune dysregulation involves a role to T-cell activation (Fernandez et al., 
2009), B-cell signaling (Liu et al., 2009 and Peng, 2009) along with altered chemokine 
patterns (Youinou et al., 2009 and Wittmann et al., 2009) with IL-6 playing a role in 
polyarthritis and joint damage (Fonseca et al., 2009) and as mentioned previously an 
interferon signature (Finke et al., 2009).  
The complex cascade of T-cell activation from the T-cell receptor (TCR) the consequently 
increase in intracellular content of Ca2++ and NFAT mediated IL-2 Transcriptional 
activation is an important immune component in SLE. In SLE, such pathway of activation is 
altered and seems to be associated with the calcium processing. ER calcium content not 
being an issue, a lot of attention was given to CRAC and studies have shown altered 
efficiency in this Ca2+ channel. Evidence has also shown that in SLE patients a Ca+ 
alteration was observed and linked to an upstream mitochondrial dysregulation. Evidence 
of high membrane hyperpolarisation (MHP) of the inner membrane of the mitochondrial 
has been pinpointed in SLE T-cells with subsequent ATP decreasing synthesis and failure to 
regenerate glutathione reduced forms, a anti oxidant molecule.   Such dysregulation seems 
to be as well the cause of the unbalance fate observed in SLE T-cells deaths. Instead of 
progressing to a program cell death, with the common FAS pathway and death inducing 
signaling complex cascade, SLE T-cells instead enter necrosis. As both ATP and reduced 
glutathione pools are low, apoptosis is prevented and as such unbalance of quality cell 
death tends to develop into two main consequences. First, necrosis is favored and induces 
inflammation whereas apoptotic bodies do not. Secondly, in SLE, such overall dysregulation 
of calcium (katsiari et al., 2002), ATP formation (Perl et al., 2004) and low antioxidant 
capacity profile (Wang et al., 2010) is in favor to auto-reactive T-cells. 
A strong correlation has been found between CXCL10 and SLE disease (Kong et al., 2009). 
CXCL10 is the interferon inducible factor, chemokine (C-X-C motif) ligand 10 also known as 
IP10 that acts on the receptor CXCR3. Interestingly, the gene coding for such receptor is the 
unique chemokine receptor found in chromosome X. This is in clear contrast to all other 
chemokine receptor genes, suggesting unique functions for CXCR3 and the ligand CXCL10 
in possibly the role in SLE immunity. In sites of inflammation, a subset of B-cells with high 
expression of the marker CD19, a co-receptor of the B-cell receptor and known to be 
implicated in auto-immuniy, shows elevated CXCR3 levels (Nicholas et al., 2007). More 
challenges are met during pregnancy where placental tissues and the new born semi-
allogenic foetal cells are brought together along with SLE (Doria et al., 2008).  High 
consequences were recently tabulated in pregnant women with SLE with approximately 
25% of women presenting with disease exacerbations (Lockshin et al., 1989).  
2.2 Myasthenia and pregnancy 
2.2.1 Pathophysiology of myasthenia gravis 
Besides T-cells, breakdown of self tolerance in autoimmune diseases can be associated with 
humoral B-cell mediated immunity producing pathological auto-antibodies contributing to 
tissue damage as seen in myasthenia gravis (MG). MG is an autoimmune disease affecting 
predominantly women with clinical muscle fatigability with patients suffering from degrees 
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of weakness at various body systems.  Under approximately 40 years of age, women are 
prevalent but after 50 years of age, incidence is then lesser in women than men. (Grob et al., 
2008).  The disease is categorised into two clinical presentations with on one hand, the 
ocular MG affecting of the levator and extra ocular palpebrae skeletal muscles with common 
diplopia and ptosis and in the other hand, generalised MG affecting other skeletal muscles. 
Interestingly, the disease can occur as relapsing remitting and the onset of symptomatology 
is varying from acute to subacute. Auto-antibodies target different antigens including the 
acetylcholine receptor (AchR) and, in most intense disease presentation, target the muscle 
specific muscle protein named MuSK (Padua et al., 2006). AchR and MusK seropositivity 
lead to neuromuscular dysfunctions. In the case of anti AChR, the antibodies trigger 
neutralisation of AChR function (Drachman et al., 1982), as well as antibody dependent 
complement activation with membrane attack complex formation (Engel et al., 1987) and 
finally antibody cross link with the ACHR  leading to the destruction of AChR. The early 
onset MG is also associated with the possible occurrence of other autoimmune insults most 
commonly against the thyroid (Christensen, 1995). In early onset MG, the thymus gland is 
enlarged and patients present with multiple auto-antibodies. However, late onset MG is not 
associated with enlarged thymus. Association of HLA markers with individual type of MG 
onset has been undertaken and data showed that the early onset MG is associated with 
HLA-B8 and DR3 (Compston et al., 1980) whereas late onset MG is associated with HLA B7 
and DR2 (Maggi et al., 1991). Immunologically the thymus is a primary lymphoid organ 
with a highly responsible function to maturate T-cells. T-cells that were produced in the 
bone marrow enter the thymus to become thymocytes to undergo a subsequent series of 
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cells and parenchymal epithelial cells. When maturation of thymocytes is terminated, an 
efferent drainage successfully drains these cells into mediastinal lymph nodes. This selection 
is aiming at positively selecting immature T-cells which T-cell receptor would recognise 
MHC molecules. In the other hand, the negative selection aims at discarding the T-cells that 
would react to autoantigens presented by APCs. A failure in undertaking the removal of 
autoimmune T-cells is thought to be the problem occurring in MG disease. Certain T-cells, 
Th4 or CD4 + were investigated for their possible cell mediated autoimmune 
dysregulations. Interestingly though, both patients and free of disease normal individuals 
do have autoimmune T-cells targeting AChR (Schluep et al., 1987).  Using experimental 
autoimmune myasthenia gravis (EAMG) animal models with Th1 deficient cells, 
researchers have shown actually that such animals have susceptibility to autoimmunity 
(Balasa et al., 1997). In this latter study, the focus was to distinguish between wild type and 
EAMG interferon gamma knockout mice. Result showed that EAMG knockout mice had no 
weakness to their muscles and were resistance to MG. However, the level of proliferation of 
AChR primed lymph nodes was still proliferating as normally observed in wild type mice.   
As interferon gamma is the primary pro-inflammatory stimulator of TH1 cells with 
downstream activation of the T-bet transcription factor inducing further interferon gamma 
transcription, MG autoimmunity induced solely with Th1 cannot be explaining the entire 
course of the disease. Even other types of autoimmunity such as in multiple sclerosis 
experimental allergic encephalomyelitis animals, observation of both interferon gamma 
deficient mice and T-bet knockout mice did not protect these autoimmunity disorders 
(Ferber et al., 1996). In Balasa et al. study, lymphogenic changes using mice with intact 
thymus were investigated but researchers focus is also turned into directly thymectomized 
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animals. The thymic tissue is also harboring regulatory T-cells CD4+ CD25+ cells or Tregs 
that are anergic to antigen presentation (Crispin et al., 2003). These cells act as suppressors 
of effective autoimmune T-cells as demonstrated in Tregs deficient animal studies showing 
increase signs of autoimmunity disorders (Sakaguchi et al., 1995). Particular markers on the 
surface of Tregs are responsible for the immunological self tolerance function of Treg and 
include CD80, CD28, CD40 and CTLA4 with the later being a strong negative regulator of T-
cell activity. Other subsets of cells called CD4+ CD25+ CD103+ are showing furthermore 
potentials in self tolerance and suppressive functional features in comparison to CD4+ 
CD25+ T-cells.  
2.2.2 Modulation effects of pregnancy in Myasthenia gravis mothers 
T-cells detain estrogen receptors on their membrane and studies have shown a high 
correlation between estrogens and disease detrimental activity. Interestingly, estrogens 
induce an expansion of specific Th1 effector cells with subsequent MG autoimmunity and 
increase of anti AChR antibodies (Delpy et al., 2005).  In normal pregnancy, Tregs mediate 
immune tolerance (Guerin et al., 2009) and data previous data show that in early pregnancy 
estrogens do act on these CD4+ CD25+ T-cells to mediate indeed immunosuppression and 
higher immune tolerance. Such effect is relayed by progesterone during the rest of the 
gestation (Mao et al., 2010). Such positive effect might resign in the difference between 
CD4+ CD25+ and CD4+ CD25- T-cells. Differential gene expression of these two subsets 
showed higher expression levels of CTLA4, galactin, CD103, TNFRSF18, TNFRSF4 and the 
glucocorticoid induced TNF receptor called GITR (McHugh et al., 2002) in CD4+ CD25+ 
cells. Interestingly, inhibition of GITR abrogates regulatory T-cell activity precipitating 
autoimmunity. In addition, GITR can be activated by progesterone receptor (Nelson et al., 
1999 and Kanamaru et al., 2004) and possibly progesterone acts on Treg cells by 
upregulating GITR among other effects. Interestingly, in studies experimenting EAMG 
animals, the treatment of analogs of myasthenogenic peptides notably demonstrated a 
decrease in lymph node proliferation as well as a decrease of INFγ involving the action of 
CD8+ Tregs (Ben-David et al., 2007).  
Newborn can develop neonatal MG and is observed in around 10 % of mother holding the 
burden of the disease (Beekman etal., 1997). This acquisition is mediated by the passage 
from the mother to the foetus of immunoglobulin G anti acetylcholine receptors. In large 
majority, babies do not pursue the course of neonatal MG and few weeks following their 
birth, neonatal MG naturally undergo full resolution. 
2.3 Rheumatoid arthritis and pregnancy 
2.3.1 Pathophysiology of rheumatoid arthritis  
Rheumatoid arthritis is a severe chronic inflammatory disease of relatively high prevalence 
that primarily affects the joints via a systemic autoimmune reaction. While its aetiology 
remains unknown, many cell populations contribute to the inflammatory response in the 
synovium, leading to joint erosions, joint deformation and loss of function.    Histological 
features often include proliferation of synovial cells, plasma and lymphoid cell infiltration, 
neovascularisation, macrophage accumulation and typical palisading structure of the cell 
lining hyperblasting synovial membranes. One particular hallmark used in diagnosis of RA 
is the rheumatoid factor (RF) and the particular association with HLA-DR4. Common 
cytokine abnormalities in RA include an increase in tumor necrosis factor alpha (TNFα) and 
interleukin-1β (IL-1β) with subsequent induction of metalloproteinases (MMPs) degrading 
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the synovial matrix (Dayer et al., 2001).  Gene expression studies sampling synovial tissue 
have highlighted the heterogeneous nature of the disease and suggest the existence and 
contribution of multiple pathogenic pathways (van der Pouw Kraan et al. 2003).  As tissue 
biopsies are invasive, alternative and clinically more practical studies of gene expression 
changes in peripheral blood mononuclear cells (PBMC) from patients with RA have been 
reported (Olsen et al., 2004 & Edwards et al., 2007), with a recent study highlighting that 10 
differentially regulated transcripts in RA patient PBMC mapped to chromosome region 
6p21.3, the major histocompatibility (MHC) locus III (Edwards et al., 2007). In addition to 
the cellular involvement, Rheumatoid arthritis is an auto-antibody disorder that will 
ultimately affect the joints. Antibodies like IgM and IgA are known to target the Fc 
fragments of IgG but in addition targeted citrullinated antigens are found in RA patients but 
are not exclusive to these patients.  The autoimmune attack mainly is associated with 
elevated amounts of Tumor necrosis factor (Feldmann et al., 1996) and elevation of specific 
joint cells (found in both cartilage and synovium). The synovium contains macrophage like 
synovial cells and fibroblast like synovial cells. In RA, the joint macrophage like cells are 
known to secrete a large panel of pro-inflammatory cytokines whereas the fibroblast like 
cells are showing invasive the cartilage (Muller-Ladner et al., 1996) and are responsible, at 
some extent, to joint destruction with osteoclastic activity (Tolboom et al., 2005). 
Interestingly, inhibiting and preventing osteoclast induce destruction of the joints is not 
associated cessation of the overall localised pro-inflammatory profile (Cohen et al., 2008). 
Common therapeutic agents used in treating RA include disease-modifying anti-rheumatic 
drugs (DMARDs), such as methotrexate, non steroidal anti-inflammatory drugs (NSAIDs), 
corticosteroids and Tumor Necrosis Factor (TNF) inhibitors which inhibit the pro-
inflammatory activity of TNF, identified as a key mediator in the inflammatory response. 
Despite the improvement of joint function in 60-80% of patients with TNF inhibitors and 
methotrexate combination therapy, a remaining 20-40% of patients do not respond to this 
treatment (Baton et al., 2000 & Keystone et al., 2004 & Maini et al., 2004). 
2.3.2 Modulation effects of pregnancy in Rheumatoid Arthritis mothers 
In pregnancy, RA signs are improved in more than 76% of cases (Pope et al., 1983) but 
beneficial signs disappear postpartum for approximately 6 to 8 months post delivery. These 
gestational ameliorations seem to be independent of cortisol rises in pregnancy and 
independent to administration of different exogenous estrogen levels (Van den Brink et al., 
1992). Of note, twenty five percent of RA pregnant women have continuing active arthritis. 
Interestingly two reports reported that pregnancy decreases by two fold in RA when 
compared to nulliparous RA women (Spector et al., 1990 & Hazes et al., 1990). During 
pregnancy, important tolerance occurs in RA. Auto-reactive B cells in RA are somewhat 
down-regulated since serum levels of alloantibodies remain the same while improvement in 
the severity is observed (Elenkov et al., 1997). Autoantibodies such as ANA have been 
reported to decrease in RA pregnancy (Ostensen et al., 1983) as well as the rheumatoic 
factor, RF (Pope et al., 1983). Interstingly, the disparity between the foetus and the mother 
seems to be positive for the pregnancy course in RA (Nelson et al, 1993). The impact of the 
disease on pregnancy and outcomes of RA to gestation seem to show no adverse effects with 
RA women falling pregnant and giving birth with no life threatening consequences. 
However, postpartum flares are high and possibly aggravated due to high correlated levels 
of prolactin postpartum (Zrour et al., 2010). The influence of pregnancy on RA disease is still 
unknown and no explannations to date are given for the reasons for observing either 
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animals. The thymic tissue is also harboring regulatory T-cells CD4+ CD25+ cells or Tregs 
that are anergic to antigen presentation (Crispin et al., 2003). These cells act as suppressors 
of effective autoimmune T-cells as demonstrated in Tregs deficient animal studies showing 
increase signs of autoimmunity disorders (Sakaguchi et al., 1995). Particular markers on the 
surface of Tregs are responsible for the immunological self tolerance function of Treg and 
include CD80, CD28, CD40 and CTLA4 with the later being a strong negative regulator of T-
cell activity. Other subsets of cells called CD4+ CD25+ CD103+ are showing furthermore 
potentials in self tolerance and suppressive functional features in comparison to CD4+ 
CD25+ T-cells.  
2.2.2 Modulation effects of pregnancy in Myasthenia gravis mothers 
T-cells detain estrogen receptors on their membrane and studies have shown a high 
correlation between estrogens and disease detrimental activity. Interestingly, estrogens 
induce an expansion of specific Th1 effector cells with subsequent MG autoimmunity and 
increase of anti AChR antibodies (Delpy et al., 2005).  In normal pregnancy, Tregs mediate 
immune tolerance (Guerin et al., 2009) and data previous data show that in early pregnancy 
estrogens do act on these CD4+ CD25+ T-cells to mediate indeed immunosuppression and 
higher immune tolerance. Such effect is relayed by progesterone during the rest of the 
gestation (Mao et al., 2010). Such positive effect might resign in the difference between 
CD4+ CD25+ and CD4+ CD25- T-cells. Differential gene expression of these two subsets 
showed higher expression levels of CTLA4, galactin, CD103, TNFRSF18, TNFRSF4 and the 
glucocorticoid induced TNF receptor called GITR (McHugh et al., 2002) in CD4+ CD25+ 
cells. Interestingly, inhibition of GITR abrogates regulatory T-cell activity precipitating 
autoimmunity. In addition, GITR can be activated by progesterone receptor (Nelson et al., 
1999 and Kanamaru et al., 2004) and possibly progesterone acts on Treg cells by 
upregulating GITR among other effects. Interestingly, in studies experimenting EAMG 
animals, the treatment of analogs of myasthenogenic peptides notably demonstrated a 
decrease in lymph node proliferation as well as a decrease of INFγ involving the action of 
CD8+ Tregs (Ben-David et al., 2007).  
Newborn can develop neonatal MG and is observed in around 10 % of mother holding the 
burden of the disease (Beekman etal., 1997). This acquisition is mediated by the passage 
from the mother to the foetus of immunoglobulin G anti acetylcholine receptors. In large 
majority, babies do not pursue the course of neonatal MG and few weeks following their 
birth, neonatal MG naturally undergo full resolution. 
2.3 Rheumatoid arthritis and pregnancy 
2.3.1 Pathophysiology of rheumatoid arthritis  
Rheumatoid arthritis is a severe chronic inflammatory disease of relatively high prevalence 
that primarily affects the joints via a systemic autoimmune reaction. While its aetiology 
remains unknown, many cell populations contribute to the inflammatory response in the 
synovium, leading to joint erosions, joint deformation and loss of function.    Histological 
features often include proliferation of synovial cells, plasma and lymphoid cell infiltration, 
neovascularisation, macrophage accumulation and typical palisading structure of the cell 
lining hyperblasting synovial membranes. One particular hallmark used in diagnosis of RA 
is the rheumatoid factor (RF) and the particular association with HLA-DR4. Common 
cytokine abnormalities in RA include an increase in tumor necrosis factor alpha (TNFα) and 
interleukin-1β (IL-1β) with subsequent induction of metalloproteinases (MMPs) degrading 
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the synovial matrix (Dayer et al., 2001).  Gene expression studies sampling synovial tissue 
have highlighted the heterogeneous nature of the disease and suggest the existence and 
contribution of multiple pathogenic pathways (van der Pouw Kraan et al. 2003).  As tissue 
biopsies are invasive, alternative and clinically more practical studies of gene expression 
changes in peripheral blood mononuclear cells (PBMC) from patients with RA have been 
reported (Olsen et al., 2004 & Edwards et al., 2007), with a recent study highlighting that 10 
differentially regulated transcripts in RA patient PBMC mapped to chromosome region 
6p21.3, the major histocompatibility (MHC) locus III (Edwards et al., 2007). In addition to 
the cellular involvement, Rheumatoid arthritis is an auto-antibody disorder that will 
ultimately affect the joints. Antibodies like IgM and IgA are known to target the Fc 
fragments of IgG but in addition targeted citrullinated antigens are found in RA patients but 
are not exclusive to these patients.  The autoimmune attack mainly is associated with 
elevated amounts of Tumor necrosis factor (Feldmann et al., 1996) and elevation of specific 
joint cells (found in both cartilage and synovium). The synovium contains macrophage like 
synovial cells and fibroblast like synovial cells. In RA, the joint macrophage like cells are 
known to secrete a large panel of pro-inflammatory cytokines whereas the fibroblast like 
cells are showing invasive the cartilage (Muller-Ladner et al., 1996) and are responsible, at 
some extent, to joint destruction with osteoclastic activity (Tolboom et al., 2005). 
Interestingly, inhibiting and preventing osteoclast induce destruction of the joints is not 
associated cessation of the overall localised pro-inflammatory profile (Cohen et al., 2008). 
Common therapeutic agents used in treating RA include disease-modifying anti-rheumatic 
drugs (DMARDs), such as methotrexate, non steroidal anti-inflammatory drugs (NSAIDs), 
corticosteroids and Tumor Necrosis Factor (TNF) inhibitors which inhibit the pro-
inflammatory activity of TNF, identified as a key mediator in the inflammatory response. 
Despite the improvement of joint function in 60-80% of patients with TNF inhibitors and 
methotrexate combination therapy, a remaining 20-40% of patients do not respond to this 
treatment (Baton et al., 2000 & Keystone et al., 2004 & Maini et al., 2004). 
2.3.2 Modulation effects of pregnancy in Rheumatoid Arthritis mothers 
In pregnancy, RA signs are improved in more than 76% of cases (Pope et al., 1983) but 
beneficial signs disappear postpartum for approximately 6 to 8 months post delivery. These 
gestational ameliorations seem to be independent of cortisol rises in pregnancy and 
independent to administration of different exogenous estrogen levels (Van den Brink et al., 
1992). Of note, twenty five percent of RA pregnant women have continuing active arthritis. 
Interestingly two reports reported that pregnancy decreases by two fold in RA when 
compared to nulliparous RA women (Spector et al., 1990 & Hazes et al., 1990). During 
pregnancy, important tolerance occurs in RA. Auto-reactive B cells in RA are somewhat 
down-regulated since serum levels of alloantibodies remain the same while improvement in 
the severity is observed (Elenkov et al., 1997). Autoantibodies such as ANA have been 
reported to decrease in RA pregnancy (Ostensen et al., 1983) as well as the rheumatoic 
factor, RF (Pope et al., 1983). Interstingly, the disparity between the foetus and the mother 
seems to be positive for the pregnancy course in RA (Nelson et al, 1993). The impact of the 
disease on pregnancy and outcomes of RA to gestation seem to show no adverse effects with 
RA women falling pregnant and giving birth with no life threatening consequences. 
However, postpartum flares are high and possibly aggravated due to high correlated levels 
of prolactin postpartum (Zrour et al., 2010). The influence of pregnancy on RA disease is still 
unknown and no explannations to date are given for the reasons for observing either 
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remission or none of  RA during pregnancy. As for the remissions, attention is dedicated to 
the maternofetal HLA incompatibility but investigations is generating contrasting reports 
(Brennan et al., 2000). As for what is possibly occuring in RA and pregancy, a hormonal 
conditioning mediated by estradiol and progesterone contribute to a  shift from TH1 to Th2 
immune profile (Ekerfelt et al., 1997) and suppression of both autoreactive T cells and NK 
cells (Otensen & Villiger, 2002). 
2.4 Multiple Sclerosis and pregnancy 
2.4.1 Pathophysiology of Multiple Sclerosis 
MS is a neurological debilitating disorder that affects particularly Caucasians in their second 
to fourth decades of their life (Weinshenker BG, 1998). MS was characterised for the first 
time, by Dr Jean Martin Charcot in 1868 from the hospital “Salpêtrière”, in Paris who 
reported the presence of multiple plaques in the central nervous system (CNS) of a deceased 
patient. Despite the progress of research in the last 150 years the aetiology of MS remains 
still unknown.  
The disorder is well documented for its neuroinflammatory course and symptoms. The 
disease has particular hallmarks and is more prevalent in women, and symptoms appear 
typically between 20 and 40 years of age (Weinshenker BG, 1998). Females account for 
approximately 60% of MS cases (Weinshenker BG et al., 1994). There are several forms of 
MS, characterised by the degree of symptomatic debilitation over time: Benign MS (B-MS), 
Relapsing Remitting MS (RR-MS), Secondary Progressive (SP-MS), Progressive-Relapsing 
MS (PR-MS), Primary Progressive MS (PP-MS). MS plaques appear as lesions in the normal 
white matter (NWM) and occasionally in the gray matter (Peterson et al., 2001). Lesions are 
restricted to the CNS and are not present in the peripheral nervous system (PNS). Plaques 
are classified into three main types: acute (A), chronic active (CA) and chronic silent (CS) MS 
lesions. Acute MS lesions are not well-demarcated (oedematous) and are filled with 
macrophages commonly containing myelin debris. Additionally, these lesions contain 
hypertrophic astrocytes but no fibrous astrogliosis with an abundance of demyelinated 
axons. This plaque-type is characterised by the presence of perivascular lymphocytic 
infiltration and damaged of the blood brain barrier (BBB) (Gay et al., 1991).  Chronic active 
MS lesions, are the second type and do contain a well-demarcated margin. In this case the 
centre of the plaque is lacking in lymphocyte activity. Instead macrophages reside in a 
margin which contains the debris of myelin degeneration. These macrophages are microglia 
in origin. The centre of a CA plaque is astrogliotic, with a generally absence of myelin. 
However, in this case the centre of CA lesions is characterised by signs of remyelination.  
In contrast to both CA and A lesions, CS MS lesions have a highly demarcated margin with 
a fibrous centre with no inflammatory component. Remyelination can occur in the centre 
and within the margin. These plaques appear circular and differ from other forms of 
demyelination (eg. Balo’s syndrome). Balo’s syndrome, is characterised by alternate rings of 
degeneration and regeneration (or intact myelin)(Moore et al., 1985). MS also has an 
autoimmune component, characterised by infiltration in the CNS of activated T-cells that are 
auto-reactive to myelin white matter proteins. MS is also more prevalent at higher latitudes 
of the globe (Hernan et al., 1999), suggesting a strong environmental influence; while 
disease susceptibility has a strong genetic link, as evidenced by numerous twin studies 
(Mumford et al., 1994). Symptoms include limb weakness, sensory loss, visual alterations 
and bladder dysfunction, and the appearance of lesions or plaques that are disseminated in 
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time and space. Multiple sclerosis is an autoimmune disease of the central nervous system, 
characterized by zones of demyelination and inflammatory plaques.   
The genetic of MS has been extensively researched and a major focus in comparison to other 
autoimmune diseases. Studies appreciating the concordance of twins have shown a six time 
increase in risk in monozygoting than among dizogotic twins (Sadovnick et al, 1993).  
2.4.1.1 The Major Histocompatibility Complex (MHC) and Multiple Sclerosis 
The MHC Locus on Chromosome 6p has been linked to the pathogenenesis of MS with the 
fundamental basis of this association being established as a strong association with HLA-
DRB1*15 of the class II gene HLA-DRB1(Fogdell et al., 1995). In addition to the problem in 
exploring possible etiological reasons behind MS, epistatic interaction across alleles are 
taking place that even  are mors of a risky as seen with HLA-DRB1*08, on interaction with 
HLA-DRB1*15. A number of genes have been implicated in MS pathophysiology and were 
discovered throughout both immunological and genetic studies. One of the most consistent 
findings has been an association of specific major histocompatibility class II haplotypes in 
MS (Kellar-Wood et al., 1995). The MHC region in 6p21.3, includes MHC I, II and III. As all 
evidences are supporting an autoimmune basis for MS, the MHC locus is the focus of a lot of 
research attention as the genes in this locus are involved in antigen presentation. Class I and 
class II are involved in antigen presentation to CD8 and CD4 lymphocytes respectively. 
Class I has a region containing HLA loci (HLA A, B, C, E, F, G) known to be altered in 
normal pregnancy especially at the placental border between the foetus and the mother. 
Association between MS and molecules on the chromosome 6p21 is variable to the type of 
population studied. Northern European populations affected with MS do show an 
association with Class II DR15 and DQ6 phenotypes in (Hillert, 1994).  In the other hand, 
Asians with MS are associated with DPB1 (Ito et al., 1998).  
The MHC Class II locus is composed of genes coding for proteins LMP2 (proteasome 
subunit, beta type, 9) and LMP7 (proteasome subunit, beta type, 7), two protein being 
integrative of the proteasome complex. Normally, viral proteins or cellular proteins are 
turned into small peptides by the proteasome. These fragmented petides are then entering 
the reticulum endoplasmic (RE) binding with new synthesised MHC class I molecules. Both 
molecules are then deposited to the surface cell where the peptide is then presented to 
vigilant immune cells. The translocation into the RE is facilitated by the transporter 1, ATP-
binding cassette (TAP) 1 and 2 which are coded by genes in the MHC Class II region. 
Studies attempted to demonstrate a probable association between TAP1 and TAP2 locus 
polymorphisms but data showed no association with MS (Vandevyver et al., 1994). 
However, the same study revealed though a differential level of gene expression of these 
two genes between affected and non-affected tissues. Interestingly, a lot of attention was 
brought into a region 100kb telomeric to HLA F. This locus harbors the myelin 
oligodendrocyte glycoprotein (MOG), another potential candidate gene in multiple sclerosis 
as it plays an important role in myelin sheath maintenance and immunogenicity. 
Experiments using antisera raised against MOG would activate a downstream signaling 
pathway resulting in the degradation of microtubules and disruption of myelin basic 
protein (MBP) (Johns et al., 1999). This pathway is also triggered by antibodies of a marker 
of myelin-producing cells, the galactolipid galactocerebroside, that was illustrated in glioma 
cells (Joshi et al., 1992), with possibly engaging a second messenger (most likely Inositol 
Phosphate 3) activating a voltage Ca2+
 
channel (Joshi et al., 1998) that ultimately results into 
in an increase of intracellular calcium and microtubule disruption.  
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remission or none of  RA during pregnancy. As for the remissions, attention is dedicated to 
the maternofetal HLA incompatibility but investigations is generating contrasting reports 
(Brennan et al., 2000). As for what is possibly occuring in RA and pregancy, a hormonal 
conditioning mediated by estradiol and progesterone contribute to a  shift from TH1 to Th2 
immune profile (Ekerfelt et al., 1997) and suppression of both autoreactive T cells and NK 
cells (Otensen & Villiger, 2002). 
2.4 Multiple Sclerosis and pregnancy 
2.4.1 Pathophysiology of Multiple Sclerosis 
MS is a neurological debilitating disorder that affects particularly Caucasians in their second 
to fourth decades of their life (Weinshenker BG, 1998). MS was characterised for the first 
time, by Dr Jean Martin Charcot in 1868 from the hospital “Salpêtrière”, in Paris who 
reported the presence of multiple plaques in the central nervous system (CNS) of a deceased 
patient. Despite the progress of research in the last 150 years the aetiology of MS remains 
still unknown.  
The disorder is well documented for its neuroinflammatory course and symptoms. The 
disease has particular hallmarks and is more prevalent in women, and symptoms appear 
typically between 20 and 40 years of age (Weinshenker BG, 1998). Females account for 
approximately 60% of MS cases (Weinshenker BG et al., 1994). There are several forms of 
MS, characterised by the degree of symptomatic debilitation over time: Benign MS (B-MS), 
Relapsing Remitting MS (RR-MS), Secondary Progressive (SP-MS), Progressive-Relapsing 
MS (PR-MS), Primary Progressive MS (PP-MS). MS plaques appear as lesions in the normal 
white matter (NWM) and occasionally in the gray matter (Peterson et al., 2001). Lesions are 
restricted to the CNS and are not present in the peripheral nervous system (PNS). Plaques 
are classified into three main types: acute (A), chronic active (CA) and chronic silent (CS) MS 
lesions. Acute MS lesions are not well-demarcated (oedematous) and are filled with 
macrophages commonly containing myelin debris. Additionally, these lesions contain 
hypertrophic astrocytes but no fibrous astrogliosis with an abundance of demyelinated 
axons. This plaque-type is characterised by the presence of perivascular lymphocytic 
infiltration and damaged of the blood brain barrier (BBB) (Gay et al., 1991).  Chronic active 
MS lesions, are the second type and do contain a well-demarcated margin. In this case the 
centre of the plaque is lacking in lymphocyte activity. Instead macrophages reside in a 
margin which contains the debris of myelin degeneration. These macrophages are microglia 
in origin. The centre of a CA plaque is astrogliotic, with a generally absence of myelin. 
However, in this case the centre of CA lesions is characterised by signs of remyelination.  
In contrast to both CA and A lesions, CS MS lesions have a highly demarcated margin with 
a fibrous centre with no inflammatory component. Remyelination can occur in the centre 
and within the margin. These plaques appear circular and differ from other forms of 
demyelination (eg. Balo’s syndrome). Balo’s syndrome, is characterised by alternate rings of 
degeneration and regeneration (or intact myelin)(Moore et al., 1985). MS also has an 
autoimmune component, characterised by infiltration in the CNS of activated T-cells that are 
auto-reactive to myelin white matter proteins. MS is also more prevalent at higher latitudes 
of the globe (Hernan et al., 1999), suggesting a strong environmental influence; while 
disease susceptibility has a strong genetic link, as evidenced by numerous twin studies 
(Mumford et al., 1994). Symptoms include limb weakness, sensory loss, visual alterations 
and bladder dysfunction, and the appearance of lesions or plaques that are disseminated in 
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time and space. Multiple sclerosis is an autoimmune disease of the central nervous system, 
characterized by zones of demyelination and inflammatory plaques.   
The genetic of MS has been extensively researched and a major focus in comparison to other 
autoimmune diseases. Studies appreciating the concordance of twins have shown a six time 
increase in risk in monozygoting than among dizogotic twins (Sadovnick et al, 1993).  
2.4.1.1 The Major Histocompatibility Complex (MHC) and Multiple Sclerosis 
The MHC Locus on Chromosome 6p has been linked to the pathogenenesis of MS with the 
fundamental basis of this association being established as a strong association with HLA-
DRB1*15 of the class II gene HLA-DRB1(Fogdell et al., 1995). In addition to the problem in 
exploring possible etiological reasons behind MS, epistatic interaction across alleles are 
taking place that even  are mors of a risky as seen with HLA-DRB1*08, on interaction with 
HLA-DRB1*15. A number of genes have been implicated in MS pathophysiology and were 
discovered throughout both immunological and genetic studies. One of the most consistent 
findings has been an association of specific major histocompatibility class II haplotypes in 
MS (Kellar-Wood et al., 1995). The MHC region in 6p21.3, includes MHC I, II and III. As all 
evidences are supporting an autoimmune basis for MS, the MHC locus is the focus of a lot of 
research attention as the genes in this locus are involved in antigen presentation. Class I and 
class II are involved in antigen presentation to CD8 and CD4 lymphocytes respectively. 
Class I has a region containing HLA loci (HLA A, B, C, E, F, G) known to be altered in 
normal pregnancy especially at the placental border between the foetus and the mother. 
Association between MS and molecules on the chromosome 6p21 is variable to the type of 
population studied. Northern European populations affected with MS do show an 
association with Class II DR15 and DQ6 phenotypes in (Hillert, 1994).  In the other hand, 
Asians with MS are associated with DPB1 (Ito et al., 1998).  
The MHC Class II locus is composed of genes coding for proteins LMP2 (proteasome 
subunit, beta type, 9) and LMP7 (proteasome subunit, beta type, 7), two protein being 
integrative of the proteasome complex. Normally, viral proteins or cellular proteins are 
turned into small peptides by the proteasome. These fragmented petides are then entering 
the reticulum endoplasmic (RE) binding with new synthesised MHC class I molecules. Both 
molecules are then deposited to the surface cell where the peptide is then presented to 
vigilant immune cells. The translocation into the RE is facilitated by the transporter 1, ATP-
binding cassette (TAP) 1 and 2 which are coded by genes in the MHC Class II region. 
Studies attempted to demonstrate a probable association between TAP1 and TAP2 locus 
polymorphisms but data showed no association with MS (Vandevyver et al., 1994). 
However, the same study revealed though a differential level of gene expression of these 
two genes between affected and non-affected tissues. Interestingly, a lot of attention was 
brought into a region 100kb telomeric to HLA F. This locus harbors the myelin 
oligodendrocyte glycoprotein (MOG), another potential candidate gene in multiple sclerosis 
as it plays an important role in myelin sheath maintenance and immunogenicity. 
Experiments using antisera raised against MOG would activate a downstream signaling 
pathway resulting in the degradation of microtubules and disruption of myelin basic 
protein (MBP) (Johns et al., 1999). This pathway is also triggered by antibodies of a marker 
of myelin-producing cells, the galactolipid galactocerebroside, that was illustrated in glioma 
cells (Joshi et al., 1992), with possibly engaging a second messenger (most likely Inositol 
Phosphate 3) activating a voltage Ca2+
 
channel (Joshi et al., 1998) that ultimately results into 
in an increase of intracellular calcium and microtubule disruption.  
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In the Class III MHC region, candidate genes possibly implicated in MS pathology include 
the steroid enzyme 21-hydroxylase gene (CYP21A2) and heat shock proteins (HSP): HSP70-1 
and HSP70-2. In addition, MHC class III region contains genes coding for complement 
molecules of the immune system and interestingly the tumour necrosis factor genes (TNFα 
and TNFβ). In Multiple sclerosis, TNFα has been shown to be toxic to oligodendrocytes and 
myelin (Wingerchuk et al., 1997). In MS plaques, TNFβ is present and is at the origin of 
tissue repair (De Groot et al., 1999). Some studies have investigated TNFα polymorphisms 
(Wingerchuk et al., 1997) however no association was found with MS except in HLA-DR2+ 
MS patients compared with HLA-DR2- individuals (Oturai et al., 1999). Studies 
investigating Caucasians of European descent have shown that class II HLA alleles are more 
strongly associated with the HLA-DR2 haplotype in MS (Haines et al., 1998).  
Noteworthy a predominant immunological hallmark of multiple sclerosis is the important 
clonal expansion of class I MHC T8 lymphocytes observed in MS (Gay et al., 1997).   
2.4.1.2 Immunological mechanism involved in MS 
The immune system response is comprised of two immune systems: humoral and cellular. 
In the case of MS, both systems apply resulting in CNS inflammation coupled with 
degeneration in myelin sheath. A plethora of cells may be involved in this disorder 
including microglial cells (macrophages of the CNS), B and T lymphocytes, natural killer 
cells and peripheral macrophages (Li et al., 1993). Their activities are coupled with the 
secretion of activating signals such as cytokines and interleukines that upon production 
affect surrounding cells. It has been reported that auto-reactive T-cells exist in the peripheral 
blood from both MS affected and healthy individuals (Lindert et al., 1999). In order to reach 
the CNS, the immune cells have to cross through the BBB but only activated T-cells can 
penetrate this fence. However, it has been reported that in MS the BBB undergoes a 
breakdown resulting in facilitated passage of immune cells (McDonald et al., 1992). The 
activation of T-cells is supposed to be due to a misguided immune response secondary to 
cross recognition of epitopes shared between a microbial pathogen and a putative antigen in 
the CNS (Wucherpfennig et al., 1995). These CNS-antigen specific T-cells transmigrate 
through the endothelial BBB by secreting and expressing adhesion molecules such as 
selectins and integrins (Monteyne et al., 1997). The T-cells occupy the CNS in regions where 
further events take place. Furthermore, once they have occupied the CNS, the T-cells 
stimulate the entry of further immune cells such as peripheral macrophages. Passage of 
macrophages in the CNS is facilitated by the T-cell induced BBB disruption due to secretion 
of activated matrix metalloproteases (MMPs). In the cerebrospinal fluid of MS patients, a 
high gelatinase (MMP9) concentration has been found (Rosenberg et al., 1996). Gelatinase B 
breaks down the BBB and its inhibition, by serine protease inhibitors, shows a protective 
effect on the MS animal model, EAE Lewis rats (Brosnan et al., 1980). In the parenchymal of 
the CNS, T-cells are reactivated with the myelin antigen proximity and secrete a vast group 
of pro-inflammatory agents such as interferon gamma (INFγ), tumour necrosing factor alpha 
and beta (TNFα and TNFβ), interleukin 2 (IL-2) (Olsson et al., 1995). IL-2 is an autocrine 
interleukin triggering a T-cell auto-activation loop process. On both astrocytes and microglial 
cells, those inflammatory mediators trigger an up-regulation of MHC class II molecules. The 
increase of MHC class II molecules at the surface of these cells improves the amount of antigen 
presenting cells. Moreover, microglia as well as T lymphocytes are developing a proliferating 
process in response of INFγ action (Martino et al., 1995 & Grau et al., 1997). Interestingly, T-bet 
knockout mice show resistance to autoimmunity (Bettelli et al., 2004). 
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Activated astrocytes trigger an up-regulation of adhesion molecules at the surface of the 
BBB (Weiss et al., 1998). Chemo-attractants are produced such as the monocyte chemo-
attractant protein 1 (MCP-1) (Van Der Voon et al., 1999) that chemically orientate peripheral 
phagocytes towards the BBB. The BBB endothelium is thus facilitated for further influx of 
inflammatory cells such as macrophages. Even macrophages disrupt the BBB with the 
secretion of neurotoxins (Brosnan et al., 1981). Secondly, activated astrocytes are able to 
excrete more pro-inflammatory molecules that turn the local CNS microglia (CNS resident 
macrophages) into ameboid microglia, a more active macrophage state. The activated 
astrocytes excrete factors such as GM-CSF (granulocyte monocyte-colony stimulating factor) 
whose role is to induce the proliferation of the ameboid cells.  
The local microglia plays an important role in local antigen presentation in the CNS of EAE 
animals (Bauer et al., 1994) allowing an immune response. The microglia is expressing B7 
(Dangond et al., 1997) and vascular cell adhesion molecule (VCAM-1). These two molecules 
bind CD28 and the very late antigen 4 (VLA4) respectively, on the surface of T-cells (Chabot 
et al., 1997) and these molecular interactions affect T-cell activation. Complement receptors 
(CR1 and CR2) are also found and are molecules that allow the binding of complement 
coated targets to phagocytosis. Complement activation constitutes the major component 
mechanism of humoral immunity. Contact with complement permits a better activation of 
the microglia but also the release of TNFα and interleukins (IL-1 and IL-6) (Rajan et al., 
1996). Microglia express receptors for Fc fragments of immunoglobulins (Ulvestad et al., 
1994) and completes an association action with B-lymphocytes. Those B-lymphocytes, fewer 
in numbers, can pass the damaged BBB and produce antibodies against myelin proteins 
(Gerritse et al., 1994). The antibodies are observed, after a lumbo-puncture, in CSF from MS 
patients appearing as oligoclonal bands in agarose gel electrophoresis. T-cell infiltration in 
the CNS not only induces microglial activation but also triggers the recruitment of high 
numbers of macrophages (Hulkower et al., 1993).  
Besides inflammation, demyelination is the second most characteristic feature of MS 
pathology. Both microglia and macrophages are capable of ingesting myelin in EAE animals 
(Rinner et al., 1995). However, oligodendrocytes do not express MHC calls II molecules so 
CD4+T-cells cannot have a direct effect. Studies have shown that both complement and 
immunoglobulins are detected on oligodendrocytes and microglia in MS brain but none of 
the studies have ever shown the complement system alone (Fabry et al., 1994). 
Oligodendrocytes are damaged via antibody cell mediated cytotoxicity (ADCC) triggered by 
microglia, macrophages with the help of T4+, B-cells and complements molecules (Ozawa et 
al., 1994). The macrophages act as APCs via the major histocompatibility molecule class II. 
Their activities are indicators of ongoing demyelination activity (Li et al., 1993). 
Furthermore, the interaction of B-cells with T4 cells (CD40-CD40L) turns the B-lymphocytes 
into APCs, which in consequence increase the myelinotoxic activity. Antibodies to CD 40 
ligand (CD 40L) can prevent the MS like disease in EAE animals (Boon et al., 2001). MBP-
specific CD8+ T-cells are detected in MS plaques and have been shown to be cytotoxic in 
vitro on HLA-A2 not HLA-A3 transfected oligodendrocyte cell lines in the presence of MBP 
peptide 110-118 (Jurewicz et al., 1998).  
2.4.2 Modulation effects of pregnancy in Multiple Sclerosis mothers 
A first and remarkable large prospective study was undertaken to monitor MS and 
pregnancy relation and finally counseling MS pregnant women for their venture into 
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pregnancy relation and finally counseling MS pregnant women for their venture into 
 
Autoimmune Disorders – Pathogenetic Aspects 434 
pregnancy (Confavreux et al, 1998). MS disease does not affect the outcome of pregnancy 
and interestingly from the first to the successive trimesters of gestation, a decrease in 
exacerbation rates is observed with at the third trimester a decrease of 87.5% of relapse 
rates (Confavreux et al., 1998). This gestational decrease in symptomatology is directly 
observed with a decrease of MS MRI abnormalities in the CNS in MS pregnant women 
(Van Walderveen et al., 1994). Most interestingly MS patients entering pregnancy even 
show a reduced MS progressive course and severity in comparison to controls 
(Runmarker et al., 1995 & Verdru et al., 1994). No differences in rates of caesarians are 
seen in MS (Mueller et al., 2002). A lot of attention is driven towards obvious gestational 
steroids such as estrogens and progesterone. Previous studies have shown the 
autoimmune protection of estrogens which action decrease TNF-α secretion from 
microglial cells (Dimayuga et al., 2005) and the neurosteroid enhancement effects of 
progesterone on myelin formation (Jung-Testas et al., 1999). Progesterone has been shown 
to act on myelination in the peripheral nervous system with marked remyelination 
following cryo-lesions in mouse sciatic nerves (Koenig et al., 2000). Progesterone acts on 
its receptor, progesterone receptor (PGR), a receptor localized in Chromosome 11q12, a 
locus with denotes slight association in MS susceptibility in Australia (Ban et al, 2003). In 
animals, progesterone shows remarkable actions as a neuro-protector agent (Singh et al., 
2008). Activation of the PR by progesterone exerts immunosuppressive roles by directly 
inhibiting a subunit of NF-κB, a well known intermediate of the pro-inflammatory 
molecule TNF alpha action (Kalkhoven et al., 1996). In addition, it has been demonstrated 
that progesterone exerts a protective role on damage brain tissues (Cutler et al., 2007) 
especially in Traumatic Brain Injuries (TBI) (VanLandingham et al., 2007). 
A very interesting study has been undertaken to assess the immunogenic activity occurring 
in MS pregnancy (Saraste et al., 2007). Natural killer cells and B and T-cells populations with 
both CD4+ and CD8 + T-cells were all assessed during pregnancy in MS with staggering 
results showing a decrease from first to third trimester of nearly 40% of NK count in blood 
of MS patients to then increase by 53% by three months postpartum. In healthy pregnant 
women a same trend of decrease in NK population is observed (Saraste et al., 2007). This 
fluctuation of such important innate immunity cellular component is obviously strongly 
altered by pregnancy and accomplished seen in MS women. Steroids such as progesterone 
were investigated to establish their roles on NK cells and it has been shown that 
progesterone induces apoptosis of mature peripheral blood natural killers CD16+ CD56 dim 
(Arruvito et al., 2008). In Saraste et al. study, an important hallmark demonstrated though a 
grand difference in CD4+/CD8+ ratios in MS pregnant women versus healthy pregnant 
women. In From the first to third trimester, MS pregnant women have a CD4+/CD8+ ratio 
of  1.9 that increase to 2.7 in the third trimester whereas  healthy pregnant women showed 
an inverse trend from 2.4 to 1.6. Authors attempted to give an explanation by seeing such 
trend as either an increase in T regulatory T-cells or the act that T-cells were prevented from 
reaching the CNS in pregnancy. 
In contrary to gestational time, post partum MS condition is associated with an increase of 
relapse rate (Bernardi et al., 1991) to resume back to baseline values approximately three 
months post partum (Roullet et al.,1993). Breast feeding is not affecting the postpartum 
relapse rate frequency and could be encouraged by the physician except if particular drug 
treatments are in use (Nelson et al., 1988). 
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3. Conclusion 
The following review was aimed at understanding the interactive relation of the 
physiological gestational adaptations in coexistence with particular autoimmune diseases. 
Discussion focused on four diseases that include SLE, MS, MG and RA. Such relation is of 
no doubt a very complicating process that progressively starts to unravel.  Thanks to the 
overall international research on both the pathogenic mechanism of autoimmunity and 
enhancement of gestational immunity understanding, new hypothesises and more 
importantly more insights are found.  A powerful physiological protective process occurs in 
pregnancy, a process strong enough to demonstrate decrease symptomatology in MS, RA 
and MG pregnancies. In the other hand, SLE pregnancies do not follow such trend and even 
is showing further aggravation. Mothers are facing a double challenge by undertaking all 
physiological adaptations of their pregnancy and going through these autoimmune 
diseases. Steroid hormones play an important role and attempt to orchestrate the foeto-
maternal immunological cross communication. In addition regulatory T cells are the direct 
biological ‘diplomats’ that taking act on immune-modulating this complex biological 
enigma. 
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1. Introduction 
To ensure a fruitful and healthy pregnancy, every maternal organ system needs to adapt to 
the novel physiological needs raised by the developing fetus. The maternal immune system 
is no exception. Since the conceptus is half of foreign origins, presenting paternal antigens, it 
is considered a semi-allograft to maternal immunity. Therefore, an immune tolerance must 
develop to avoid immunological rejection of the fetus. In the normal course of pregnancy, 
the mother extends her ‘definition of self’ for 40 weeks on the foreign antigens of the fetus, 
and the conceptus is accepted by the mother’s immune system. The impairment of this 
tolerance and the development of an abnormal immune response directed at the fetus play a 
major role in adverse pregnancy outcomes, including spontaneous abortion, preterm labour 
and preeclampsia. In recurrent abortion and preeclampsia, abnormal maternal immune 
reactions have an autoimmune character, and the disorders resemble many features 
typically seen in autoimmune diseases, or in association with autoimmune reactions. 
Although this does not mean that recurrent abortion or preeclampsia should be considered 
autoimmune conditions, it still suggests that abnormal autoimmune processes play an 
important role in their pathogenesis. In this regard, preeclampsia mimics autoimmune 
responses observed in both allograft rejection and graft-versus-host disease. 
Several aspects of the development of the pregnancy-specific immune tolerance have been 
described recently. Initially, the contact between maternal and fetal cells is taking place on a 
local level and is restricted to the decidua, but during the second trimester of pregnancy, it is 
extended to the entire body of the mother. Both the innate and adaptive arms of immunity 
are involved in these events. In this chapter we will focus on the role of T lymphocytes, the 
adaptive cellular elements of the immune system. We will discuss the characteristic 
alterations of T lymphocyte subsets in prevalence and functionality in healthy and 
pathologic development of the immune tolerance in human pregnancy. 
2. Th1 and Th2 cells 
T helper (Th) lymphocytes are traditionally classified into the Th1 and Th2 subsets based on 
their cytokine production pattern (Romagnani, 1991). The most important cytokines 
produced by Th1 cells are interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) and 
interferon-γ (IFN-γ). Considered to be the main effectors of phagocyte-induced host defense, 
these cells are highly protective against infections sustained by intracellular agents. On the 
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other hand, Th2 cells produce IL-4, which stimulates IgE and IgG1 antibody production, IL-
5, which promotes the growth and differentiation of eosinophils, and IL-10 and IL-13, which 
together with IL-4 inhibit macrophage functions. The Th2 subset is mainly responsible for 
phagocyte-independent host defense, for example against helminthic infections. 
For many years, it was hypothesized that normal pregnancy induces a shift from Th1 
immunity towards Th2 immunity. However, it has been demonstrated recently that the 
levels of particular Th1 cytokines are raised, instead of lowered in normal pregnancy 
compared with the non-pregnant state (Challis et al., 2009). Current findings indicate that 
gravidity is both a pro-inflammatory and an anti-inflammatory condition, depending upon 
the stage of gestation. Grossly, pregnancy has three distinct immunological phases. The 
events of implantation and the first trimester require a strong inflammatory response to 
ensure the adequate remodelling of the uterine epithelium and the removal of cellular 
debris following the implantation of the blastocyst. Therefore, healthy pregnancy cannot be 
regarded as merely a state of relative immunosuppression, as once thought. On the contrary, 
by means of various cytokines, successful implantation is dependent upon the active 
contribution of the maternal immune system to stimulate adequate invasion of the 
trophoblastic tissue into the maternal uterine wall. Thus, the first trimester of pregnancy is 
hallmarked by pro-inflammatory events. The second immunological phase of gravidity 
consists of the second and third trimesters. This is the period of fetal growth and 
development, when an anti-inflammatory state is established. Finally, delivery represents 
the third immunological phase of pregnancy, when pro-inflammatory events dominate 
again and promote uterinal contractions to deliver the fetus and the placenta (Mor & 
Cardenas, 2010). 
IFN-γ appears to be a key cytokine in the regulation of pregnancy related inflammatory 
events. Under pathologic conditions with insufficient immune tolerance such as in 
preeclampsia, IFN-γ production is significantly increased compared with healthy pregnancy 
(Piccinni, 2010). In mice, it was reported that IL-4, IL-5 and IL-10 are detectable at the 
fetomaternal interface during all periods of gestation, whereas the presence of IFN-γ is 
transient, being detectable only in the first period (Lin et al., 1993; Wegmann et al., 1993). 
Although decidual NK cells are able to produce IFN-γ (Ashkar et al., 1998), they do not have 
a central role in fetal allograft rejection, since they do not express receptors specific for 
antigens and thus are not sensitive for the presence of paternal alloantigens. The significance 
of local Th2-type cytokine production in the decidua has been observed in humans as well. 
Piccinni et al. measured cytokine production in decidual CD4 cells isolated from women 
with recurrent spontaneous abortions. Compared with women with a normal pregnancy, 
the decidual CD4 cells from women with abortion show a defect in IL-4 and IL-10 
production (Piccinni et al., 1998). 
The antigens of the developing fetus are present at two interfaces as pregnancy progresses. 
The first interface is found between the invasive extravillous cytotrophoblast and maternal 
immune cells in the decidua. This local, tissue interface is of importance for immune 
adaptation during implantation. The second interface is that between the 
syncytiotrophoblast and the immune cells in maternal blood. This systemic interface is 
established at about the 10th gestational week and becomes increasingly important in the 
second half of pregnancy (Sargent et al., 2006a). Two contrary requirements influence the 
extent of invasion by fetal extravillous cytotrophoblast cells in the maternal decidua: the 
anchorage of the placenta to ensure fetal nutrition and the protection of the uterine wall 
against over-invasion (von Rango, 2008). If, due to excessive immunological tolerance and 
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acceptance of trophoblast cells, the uterine wall is over-invaded, pathologic conditions, such 
as placenta accreta, increta or percreta might develop (Bulmer, 1992). If the adequate 
invasion of the uterinal spiral arterioles by extravillous cytotrophoblasts does not occur, this 
sets up the conditions for placental hypoxia and oxidative stress that eventually triggers a 
maternal systemic inflammatory response, leading to clinical manifestations of preeclampsia 
(von Rango, 2008). 
This disorder is characterized by hypertension, proteinuria, edema and endothelial 
dysfunction generally evolving in the third trimester of pregnancy; however, it may also 
occur earlier. Although preeclampsia is quite common (i.e. it affects about 5-8% of all 
pregnancies globally), its clear cause and the mechanisms leading to immune dysfunction 
remain to be elucidated. Preeclampsia is estimated to be responsible for about 70,000 
maternal deaths each year worldwide (Walker, 2000). HELLP syndrome (consisting of 
hemolysis, elevated liver enzymes, low platelet count) and eclampsia are other 
manifestations of the same disorder. Although these conditions are generally coupled with a 
number of other symptoms (including headaches, abdominal pain, nausea, vomiting, 
abnormal vision, dyspnoe, anxiety, mental confusion, seizures), these manifestations are not 
necessarily more serious than preeclampsia. Besides a maternal systemic inflammatory 
response, signs of systemic vasoconstriction may also be observed in the mother in these 
pregnancy-associated disorders (Baumwell & Karumanchi, 2007). 
In preeclampsia, the anti-inflammatory state during the second and third trimesters 
develops insufficiently (Saito et al., 2007). An excessive maternal systemic inflammation is 
considered to be a dominant component in the pathogenesis of this pregnancy-specific 
disorder, since its important feature is the absence of Th2 skewness and thus the 
predominance of pro-inflammatory cytokines. Saito et al. reported on their observations 
regarding higher prevalence of IFN-γ and lower prevalence of IL-4-producing CD4 
lymphocytes among peripheral blood mononuclear cells (PBMCs) of preeclamptic women 
compared with healthy pregnant women. Furthermore, the percentage of Th1 and Th2 cells 
and the Th1/Th2 ratio correlated with IFN-γ and IL-4 secretion levels (Saito et al., 1999a). In 
another study, this group observed increased production of IL-2, IFN-γ and TNF-α by 
PBMCs in preeclampsia and, interestingly, a positive correlation between mean blood 
pressure and Th1 cytokines (Saito et al., 1999b). The shift to a predominant Th1-type 
immunity in preeclampsia is reinforced by other experiments on intracellular cytokine 
measurements in T and NK cells, as well as by the assessment of cytokine secretion levels of 
PBMCs isolated from preeclamptic patients. (Azizieh et al., 2005; Darmochwal-Kolarz et al., 
2002; Rein et al., 2002). 
3. The influence of galectin-1 on the Th1/Th2 cell ratio 
Previous studies demonstrated that soluble factors may also play a role in the development 
of the Th2 shift characteristic for healthy pregnancy. Such a factor is galectin-1, also 
produced by peripheral lymphocytes. Galectin-1, a 14 kDa protein, is a β-galactoside-
binding mammalian lectin. Within the immune system, it is expressed by activated T, B and 
NK cells as well as macrophages (Blaser et al., 1998; Koopman et al., 2003; Rabinovich et al., 
1998; Zuniga et al., 2001). Galectin-1 exerts immunoregulatory effects through various 
mechanisms. By binding to the cell surface glycoproteins, it inhibits T cell proliferation and 
induces apoptosis of activated Th1, Th17 and CD8 cells (Blaser et al., 1998; Perillo et al., 
1995; Toscano et al., 2007). Galectin-1 has been demonstrated in vitro to inhibit T cell 
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acceptance of trophoblast cells, the uterine wall is over-invaded, pathologic conditions, such 
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adhesion to the extracellular matrix and to abrogate the secretion of proinflammatory 
cytokines (Rabinovich et al., 1999a). Furthermore, in vivo administration of galectin-1 in 
experimental models of autoimmunity skewed the balance toward a Th2-dominant cytokine 
profile (Rabinovich et al., 1999b; Toscano et al., 2006). Recent data show that galectin-1 
promotes fetomaternal tolerance, since treatment with recombinant galectin-1 prevented 
fetal loss in an abortion-prone mouse model. The protective effect of galectin-1 was 
abrogated in regulatory T cell (Treg) depleted mice (Blois et al., 2007). Garin et al. showed 
that Tregs selectively up-regulate galectin-1 expression (Garin et al., 2007). Experiments 
using galectin-1 homozygous null mutant mice showed a reduced regulatory activity in 
Tregs and the blockage of galectin-1 binding diminished the inhibitory effects of human and 
mouse Treg cells (Rabinovich et al., 1998). These findings suggest that Tregs expressing 
galectin-1 may also support the acceptance of the fetus by maternal immune cells. 
In a recent study, we measured circulating galectin-1 and anti-galectin-1 autoantibody 
levels, as well as intracellular galectin-1 expression of unstimulated peripheral blood T and 
NK cells in healthy pregnancy and preeclampsia (Molvarec et al., 2011). Our findings 
indicate that the majority of CD4+ and CD8+ T cells and NK cells express intracellular 
galectin-1 in healthy pregnant women, while only a small fraction of them do so in healthy 
non-pregnant women. In preeclampsia, the proportion of galectin-1-expressing peripheral T 
and NK cells was markedly decreased compared with healthy pregnancy. However, 
circulating levels of galectin-1 and anti-galectin-1 autoantibodies were not altered in 
preeclamptic patients as compared to healthy pregnant women, nor were related to the 
proportions of galectin-1-expressing peripheral blood lymphocytes in any of the study 
groups. 
While Th1 and Th17 cells are susceptible to galectin-1-induced cell death, Th2 cells are 
protected from galectin-1 due to the differential sialylation of their cell surface 
glycoproteins. Indeed, galectin-1-deficient mice were shown to develop greater Th1 and 
Th17 responses (Toscano et al., 2007). Therefore, it is tempting to speculate that decreased 
production of galectin-1 by circulating T and NK cells might contribute to the development 
of the pro-inflammatory Th1 and Th17 immune responses, which are characteristic features 
of preeclampsia (Saito et al., 1999b; Toldi et al., 2011a). 
4. Regulatory T cells 
The recent discovery of a distinct T helper lymphocyte subset, referred to as Th17 cells, led 
to the transformation of the Th1/Th2 paradigm of immunity into a four-component model. 
This novel viewpoint incorporates Th1, Th2, Th17 and regulatory T cells (Tregs) as elements 
of a complex and mutually interacting network in the establishment of pregnancy-specific 
immune tolerance. Indeed, besides the imbalance of Th1 and Th2 cells, alterations of the 
prevalence of Th17 and Treg cells have been suggested to be of importance in the 
pathogenesis of adverse pregnancy outcomes (Saito, 2010). 
Tregs are important regulators of tolerance induction. During pregnancy, a systemic 
expansion of Tregs specific for paternally derived cells can be observed already at very early 
stages, indicating that their function is to protect paternally derived cells from immune 
rejection (Mjösberg et al., 2007). The prevalence of Tregs expands in the periphery and these 
cells are also present at significant numbers at the fetomaternal interface, preferentially in 
the maternal decidua. Sasaki et al. were the first to describe an increase in the CD4+ CD25+ 
Treg cell prevalence in decidual tissue in early human pregnancy (Sasaki et al., 2004). This 
 
T Lymphocyte Characteristics and Immune Tolerance During Human Pregnancy 
 
451 
was supported by the works of Heikkinen et al. and Somerset et al. who observed an 
increase in the population of CD4+ CD25+ circulating Treg cells in early pregnancy and 
described a peak of this population during the second trimester and a subsequent gradual 
decrease to levels slightly higher than non-pregnant levels during the postpartum period 
(Heikkinen et al., 2004; Somerset et al., 2004). The tolerogenic impact of Tregs needs 
permanent antigen presentation without inflammatory co-stimulation. This explains the 
transient nature of the fetal tolerance and the fact that, especially during the first weeks of 
pregnancy, inflammatory infection of the mother may compromise pregnancy outcome. An 
expansion of Tregs in the decidua in healthy pregnant women accompanied by a low 
occurrence of Th17 cells was recently confirmed by Mjösberg et al. (Mjösberg et al., 2009). 
Furthermore, these authors propose that Tregs may be in charge of controlling the Th1 
activity found locally in healthy early pregnancy. 
Decreased Treg cell numbers during pregnancy are associated with immunological rejection 
of the fetus (Zenclussen, 2006). Sasaki et al. reported that spontaneous abortion cases are 
associated with lower systemic Treg levels when compared to normally developing 
pregnancies (Sasaki et al., 2004). A number of groups including ours demonstrated that the 
prevalence of peripheral Tregs is lower in preeclampsia compared with healthy pregnancy 
(Darmochwal-Kolarz et al., 2007; Sasaki et al., 2007; Steinborn et al., 2008; Toldi et al., 2008). 
Furthermore, Sasaki et al. reported that the prevalence of Tregs is lower not only in 
peripheral blood samples but also in deciduas of preeclamptic patients compared with 
healthy pregnant women (Sasaki et al., 2007). 
Tregs function in a delicate cellular network that includes inducer (myeloid and lymphoid 
dendritic cells) and target cells (CD4 and CD8 cells, NK cells and NKT cells) of Tregs (Fig. 1). 
Besides the peripheral prevalence of Tregs, we also characterized the prevalence of inducers 
and cellular targets of this T cell subset in preeclampsia and healthy pregnancy in the third 
trimester. We made efforts to find out whether the alteration of the number of Treg inducers 
is associated with the decreased number of Tregs. According to a previous study, the ratio 
of these cells is skewed toward the myeloid dendritic cells in the third trimester of 
preeclamptic pregnancy (Darmochwal-Kolarz et al., 2003). Theoretically, this may contribute 
to low Treg prevalence due to the lower Treg inducer capacity of myeloid dendritic cells 
than that of lymphoid dendritic cells (Ito et al., 2007). In our patients, however, the 
prevalence and ratio of myeloid and lymphoid dendritic cells did not differ, possibly 
indicating that dendritic cells are not responsible for low Treg numbers, at least in this stage 
of pregnancy. The lack of association may support the contribution of non-cellular factors, 
including pro-inflammatory cytokines such as TNF-α which has a direct inhibitory effect on 
suppressive Treg function in vitro (Valencia et al., 2006). TNF-α and other pro-inflammatory 
cytokine levels (such as IFN-γ, IL-6 and IL-12) are reportedly increased in PE (Rusterholz et 
al., 2007). Lower Treg numbers are not reflected in the proportion of NK, NK-T and 
activated CD4 and CD8 cells, at least at this stage of pregnancy. This does not exclude, 
however, that the function (such as the cytokine production pattern) of these cells is 
modified due to altered Treg numbers. 
Steinborn et al. further analyzed the prevalence of Tregs using various markers to identify 
this subset. Their analysis revealed two distinct Treg subsets that differed with regard to 
their FoxP3 and CD25 expression: CD4+ CD25+ FoxP3high+ and CD4+ CD25high+ FoxP3+ 
cells. When monitoring the two populations during healthy pregnancy and preeclampsia, 
they found a strong increase in the percentage of the CD4+ CD25+ FoxP3high+ Treg 
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(Based on Toldi et al., 2008.) 
Fig. 1. The cellular network of regulatory T cells (Tregs). Tregs are in connection with 
inducer and target cells through various mechanisms of activation and inhibition. 
population during the first and second trimesters, while in the third trimester, this Treg 
subset decreased gradually until term. The prevalence of CD4+ CD25+ FoxP3high+ Tregs 
correlated with suppressive capacity: Treg cells obtained from healthy pregnant women 
during the first and second trimester showed a two-fold higher suppressive activity than 
cells obtained in the third trimester or at term. The same correlation was true for patients 
affected by preeclampsia. The significantly diminished percentage of CD4+ CD25+ 
FoxP3high+ Tregs correlated with low suppressive capacity. In contrast to healthy 
pregnancy, the percentage of CD4+ CD25high+ FoxP3+ Treg cells was found to be increased 
in the circulation of preeclamptic women. In healthy pregnant women these cells expanded 
during the first trimester and reached maximum levels in the second trimester. Therefore, in 
preeclamptic women the population of CD4+ CD25high+ FoxP3+ Treg cells was particularly 
apparent, while the population of CD4+ CD25+ FoxP3high+ Tregs was significantly 
decreased. The authors proposed that CD4+ CD25+ FoxP3high+ and CD4+ CD25high+ 
FoxP3+ cell populations represent distinct Treg subsets, and that abnormalities in the 
balance of these subsets are associated with the presence of preeclampsia (Steinborn et al., 
2008). 
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5. The role of regulatory T cells in the process of tolerance induction 
Preeclampsia occurs more frequently in the first conception (Dekker & Sibai, 1998). 
However, preeclampsia appears to be a problem of primipaternity rather than 
primigravidity, since epidemiological data indicate that when the conception is with a new 
partner in multiparous mothers, the risk increases to the level seen in the first pregnancy 
(Robillard et al., 1993; Trupin et al., 1996). The symptoms of preeclampsia regress rapidly 
after delivery, suggesting that the exposure of the maternal immune system to the fetus and 
placenta, expressing paternal alloantigens, are of central importance in the pathogenesis. 
In donated spermatozoa, semen exposure does not occur and the fetus is a semi-allograft to 
the mother. The risk of preeclampsia in donated spermatozoa is very high (18.2%) (Salha et 
al., 1999), suggesting that semen exposure reduces the risk of preeclampsia. Soluble MHC 
class I antigens in the seminal fluid are taken up by vaginal and uterine epithelial cells, and 
these antigens might induce tolerance to cells expressing paternally derived MHC class I 
antigens. Indeed, semen triggers an influx of antigen-presenting cells into the female 
reproductive tract (Robertson et al., 2003). Usually, the fetus is a semi-allograft to the 
maternal host. The risk of preeclampsia is also increased in complete allograft-pregnant 
cases. In ovum donation, the antigens of the fetus are derived from the husband and the 
donor woman. Exposure to the husband’s semen is appropriately present. The risk of 
preeclampsia in ovum donation cases is high (16%), suggesting that the allografted fetus is a 
greater challenge for the maternal immune system, and is a risk factor for preeclampsia 
(Salha et al., 1999). In donated embryo transfer cases, the fetus is an allograft and semen 
exposure is not present. In this case, this risk of preeclampsia is even higher (33%), probably 
due to an additive effect of the allografted fetus and the absence of sperm exposure. 
Regulatory T cells, which induce tolerance to paternal antigens, may explain these 
epidemiological findings. Darmochwal-Kolarz et al. demonstrated that the levels of CD4+ 
CD45RO+ and CD8+ CD25+ cells are increased in preeclampsia, suggesting the activation of 
CD4+ and CD8+ T lymphocytes. It seems possible that the activation of T lymphocytes is 
associated with the deficiency of Tregs (Darmochwal-Kolarz etal., 2007). Before the first 
pregnancy, Treg cell numbers may increase due to seminal priming. Koelman et al. reported 
that soluble MHC class I antigens are present in the seminal fluid. It is well known that 
continuous oral exposure to antigens induces tolerance, called ‘oral tolerance’. Similarly, a 
continuous vaginal exposure to paternal soluble MHC class I antigens may induce tolerance 
to these antigens (Koelman et al., 2000). Robertson et al. suggest that insemination activates 
the maternal immune system and leads to hypo-responsiveness in T cells reactive with 
paternal alloantigens in mice (Robertson et al., 2003). This idea is supported by the 
epidemiological finding that condom users have a high risk for preeclampsia (Klonoff-
Cohen et al., 1989). 
The prevalence of Tregs is low in the mother before pregnancy (Fig. 2). This minor 
population of T cells, which reacts to paternal antigens and induces tolerance to them, 
expands after conception. When a threshold of prevalence is reached, sufficient immune 
tolerance to paternal antigens is achieved to ensure a healthy development of pregnancy. If 
the prevalence of Tregs does not reach the threshold, the risk for the development of 
preeclampsia is high. Subsequently, Tregs increase to a maximum in the second trimester of 
pregnancy and gradually decrease in the third trimester (Somerset et al., 2004). This finding 
is related to the clinical observation that the symptoms of preeclampsia generally appear in 
the third trimester, after 24 weeks of gestation. After delivery, the prevalence of Tregs may 
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Fig. 1. The cellular network of regulatory T cells (Tregs). Tregs are in connection with 
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cells obtained in the third trimester or at term. The same correlation was true for patients 
affected by preeclampsia. The significantly diminished percentage of CD4+ CD25+ 
FoxP3high+ Tregs correlated with low suppressive capacity. In contrast to healthy 
pregnancy, the percentage of CD4+ CD25high+ FoxP3+ Treg cells was found to be increased 
in the circulation of preeclamptic women. In healthy pregnant women these cells expanded 
during the first trimester and reached maximum levels in the second trimester. Therefore, in 
preeclamptic women the population of CD4+ CD25high+ FoxP3+ Treg cells was particularly 
apparent, while the population of CD4+ CD25+ FoxP3high+ Tregs was significantly 
decreased. The authors proposed that CD4+ CD25+ FoxP3high+ and CD4+ CD25high+ 
FoxP3+ cell populations represent distinct Treg subsets, and that abnormalities in the 
balance of these subsets are associated with the presence of preeclampsia (Steinborn et al., 
2008). 
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is related to the clinical observation that the symptoms of preeclampsia generally appear in 
the third trimester, after 24 weeks of gestation. After delivery, the prevalence of Tregs may 
 
 




Fig. 2. Alterations of maternal regulatory T cell (Treg) numbers during pregnancy. The 
prevalence of Tregs is low before pregnancy. When a threshold of Treg prevalence is 
reached during healthy pregnancy (black curve), the symptoms of preeclampsia do not 
develop. This is aided by seminal priming. If the prevalence of Tregs does not reach the 
threshold, the risk of preeclampsia is high (green curve). After the conception of a second 
pregnancy with the same partner, the number of Tregs increases more rapidly compared 
with the first pregnancy, independently from the initial prevalence of Tregs during the first 
pregnancy. However, in a second pregnancy with a new partner, the risk for developing 
preeclampsia is similar to that in the first pregnancy (blue curve). An increasing interval (> 
10 years) between the second and third deliveries was associated with an increasing risk of 
preeclampsia, and a lower prevalence of Tregs. 
rapidly decrease and at the beginning of a second pregnancy, there may be only a low 
number of Tregs present. Seminal priming may keep the number of these cells to a certain 
level (Fig. 2). After the conception of a second pregnancy with the same partner, the number 
of Tregs increases more rapidly compared with the first pregnancy, independently from the 
initial prevalence of Tregs (and the presence or lack of preeclampsia) during the first 
pregnancy. However, in a second pregnancy with a new partner, Tregs which induce 
tolerance to the new partner’s antigens may be very rare. Therefore, the risk for developing 
preeclampsia is similar to that in the first pregnancy. 
Skjaerven et al. reported that preeclampsia occurred in 3.9% of first pregnancies, 1.7% of 
second pregnancies, and 1.8% of third pregnancies when mothers had the same partner. 
Furthermore, an increasing interval between the second and third deliveries was associated 
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with an increasing risk of preeclampsia. When more than 10 years had passed after the 
previous delivery, the frequency rose to 3.0%. They also showed that a paternal change was 
not associated with an increased risk of preeclampsia after adjustment for the interval 
between births (Skjaerven et al., 2002). These findings might be explained by the population 
of Tregs. Tregs may gradually decrease and reach very low levels when more than 10 years 
have passed after the last delivery. A low level of these tolerance-inducing T cells may be 
maintained by seminal priming. However, in a subsequent pregnancy, some pregnant 
women may not be able to achieve adequate tolerance, resulting in an increased risk of 
preeclampsia. 
6. Th17 cells 
CD4+ IL-17+ (Th17) cells, this recently identified subpopulation of CD4 lymphocytes, 
originate from a developmental lineage that is distinct from both Th1 and Th2 cells. Th17 
cells produce IL-17 and other pro-inflammatory cytokines. IL-17 has an important role in the 
development of autoimmune disorders and in the induction and maintenance of chronic 
inflammation (Basso et al., 2009). The effect of Th17 cells on the inflammatory balance is 
opposed by Tregs. Th17 cells and Tregs originate from the same developmental lineage, 
distinct from both Th1 and Th2 cells. An exclusive dichotomy was observed in their 
generation: either Th17 or Treg cells develop from the ancestor cells depending on whether 
they are activated in the presence of transforming growth factor-β (TGF-β) or TGF-β plus 
inflammatory cytokines (Basso et al., 2009). 
In addition to their distinct role in the regulation of the inflammatory status, Th1, Th2, Th17 
and Treg cells mutually influence one another through the production of different cytokines. 
For instance, an increase in the Th17/Treg cell ratio may contribute to a shift towards the 
Th1 direction because IL-17 induces the production of other pro-inflammatory cytokines, 
such as that of IFN-γ (Afzali et al., 2007), while the inhibitory effect of Tregs on Th1 cells is 
decreased at the same time. 
In a previous study, Santner-Nanan et al. found that, besides a higher prevalence of Tregs, 
the percentage of Th17 cells is significantly decreased in the third trimester of healthy 
pregnancy compared with non-pregnant controls and preeclamptic patients. Consequently, 
the Th17/Treg cell ratio was significantly decreased in healthy but not in preeclamptic 
pregnancies. Thus, preeclampsia is associated with the absence of normal systemic skewing 
away from IL-17 production towards FoxP3 expression. Additionally, preeclamptic women 
had significantly higher levels of soluble endoglin, an inhibitor of TGF-β receptor signaling, 
which may bias towards IL-17 production (Santner-Nanan et al., 2009). 
In accordance with the above data, we also found that simultaneously with higher than 
normal Th17 numbers, the prevalence of Tregs is lower in PE, resulting in an elevated 
Th17/Treg ratio compared with uncomplicated pregnancy. The altered ratio of Th17/Treg 
cells may contribute to the shift towards the Th1 direction in preeclampsia. However, we 
could not detect a correlation between the prevalence of Th17 and Th1 cells (using the cell 
surface marker, CXCR3 for the identification of the latter subset). Thus, the effect of Th17 
cells and IL-17 on the inflammatory status is more likely to be exerted in a direct manner 
rather than through the modulation of the Th1/Th2 balance in preeclampsia (Toldi et al., 
2011a). 
The alterations of Th17 cells have been observed in other pregnancy-related disorders as 
well, suggesting that the balance of Th17 cells and Tregs and not only that of Th1 and Th2 
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cells has crucial effects on the inflammatory status in human pregnancy. Ito et al. recently 
demonstrated the importance of IL-17-producing cells in the pathomechanism of preterm 
labour (Ito et al., 2010). Nakashima et al. found that the prevalence of decidual IL-17-
producing cells is significantly higher in inevitable abortion cases (but not in missed 
abortion) than in normal pregnancy, indicating that these cells might be involved in the 
induction of inflammation in the late stage of abortion, but not in the early stage 
(Nakashima et al., 2010). In another study, Wang et al. showed that the prevalence of Th17 
cells in the peripheral blood and decidua is increased in unexplained recurrent spontaneous 
abortion patients (Wang et al., 2010). They observed that the expression of a Th17-associated 
factor, RAR-related orphan receptor gamma (ROR-γ or RORc), is also higher in peripheral 
blood lymphocytes and decidua of these patients. In a recent study, Jianjun et al. found that 
the mRNA level of this factor in PBMCs and decidua is elevated in preeclamptic patients 
when compared with healthy pregnant women (Jianjun et al., 2010). Therefore, the increased 
expression of this transcription factor may partly be responsible for the increased prevalence 
of Th17 cells in peripheral blood of preeclamptic patients. 
7. IL-17-producing CD8 and NK cells 
Although IL-17 was first identified in CD4 cells, later on other immune cells, including CD8 
and NK cells, were also shown to produce this cytokine (Passos et al., 2010; Shin et al., 1999). 
Emerging evidence suggests that these IL-17-producing lymphocyte subsets, especially NK 
cells, largely contribute to the inflammatory status during pregnancy. Sargent et al. 
proposed that the innate rather than the adaptive immune system controls immune 
regulation during human pregnancy, and that NK cells are of central importance to this 
process (Sargent et al., 2006b; Sargent et al., 2007). The aberrant activation of NK cells both 
systematically and locally in the placenta may be of major interest in the malfunction of 
immune tolerance and the pathogenesis of pregnancy-associated disorders. 
In our previously unpublished investigation, we measured the peripheral prevalence of IL-
17-producing cells in the CD4, CD8 and NK subsets and that of the IL-17 producing CD4, 
CD8 and NK cells in the overall lymphocyte population. We took peripheral blood samples 
from 24 healthy non-pregnant and 23 healthy pregnant age-matched women (with a median 
of 32 and 33 years, respectively), in the third trimester of pregnancy (with a median of 31 
weeks of gestation). Non-pregnant women were in the early follicular phase of the 
menstrual cycle (between cycle days 3 and 5), and none of them received hormonal 
contraception. Informed consent was obtained from all participating subjects. We separated 
the mononuclear cells from the samples and performed cell surface marker and intracellular 
cytokine staining. Finally, samples were measured on a flow cytometer. 
The prevalence of Th17 cells was lower among healthy pregnant compared with healthy 
non-pregnant women (2.8 [2.4-3.1] % vs. 3.2 [2.9-3.5] %). The prevalence of CD8+ IL-17+ 
(Tc17) cells among CD8 lymphocytes was higher in healthy pregnant than in healthy non-
pregnant samples (4.8 [3.6-6.2] % vs. 2.4 [1.7-3.7] %). The frequency of CD56+ IL-17+ (IL-17-
producing NK) cells was lower in healthy pregnant than in healthy non-pregnant samples 
(1.0 [0.6-1.2] % vs. 1.6 [1.1-2.5] %). 
We further analyzed the frequency of IL-17-producing CD4, CD8 and NK lymphocytes. 
After the initial assessment of the Th17, Tc17 and IL-17-producing NK cell prevalence 
among CD4, CD8 and NK cells, respectively (Fig. 3, graphs a-c), we also determined the 
prevalence of these subsets among the overall lymphocyte population (Fig. 3, graphs d-f) 
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along with the frequency of CD4+ IL-17-, CD8+ IL-17- and CD56+ IL-17- cells among the 
overall lymphocyte population (Fig. 3, graphs g-i). 
Our findings revealed two different mechanisms explaining the differing alterations 
observed in the prevalence of Th17 and Tc17 cells in the study groups. The alteration of 
CD4+ IL-17+ cell prevalence in the overall lymphocyte subset (Fig. 3, graph d) followed that 
seen among CD4 cells (Fig. 3, graph a), as the frequency of CD4+ IL-17- cells was 
comparable in both study groups (Fig. 3, graph g). Therefore, the prevalence of Th17 (CD4+ 
IL-17+) cells show absolute alterations, since Th17 cell numbers are altered not only in the 
CD4 subset, but also in the overall lymphocyte population. In contrast, Tc17 cell frequencies 
do not show significant difference if assessed among the overall lymphocyte population 
(Fig. 3, graph e); only the prevalence of CD8+ IL-17- cells differs between the study groups 
 
 
Fig. 3. Box-plots representing the prevalence of IL-17+ cells among CD4, CD8 and NK 
(CD56+) cells (graphs a-c) and in the overall lymphocyte population (ly) (graphs d-f), as well 
as the prevalence of IL-17- cells in the overall lymphocyte population (ly) (graphs g-i) in 
healthy non-pregnant (HNP) and healthy pregnant (HP) women. Horizontal line: median, 
box: interquartile range, whisker: range. * p values less than 0.05 were regarded significant. 
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(Fig. 3, graph h) and the direction of IL-17- cell alteration is the opposite of that seen at Tc17 
cell prevalence in the CD8 subset (Fig. 3, graph b). Therefore, the prevalence of Tc17 cells 
does not show absolute alterations, only relative ones, as a consequence of different CD8+ 
IL-17- cell frequencies in the study groups. The alteration of IL-17-producing NK cell 
prevalences among parent populations showed similar tendencies to that observed in case 
of CD4 cells. 
Of note, existing data are not consistent concerning the alterations of CD4 and CD8 cell 
frequencies during pregnancy. Tallon et al. found that CD4 cell numbers decrease in the 
second and third trimesters, while CD8 cells decrease during the third trimester (Tallon et 
al., 1984). Another study demonstrated that peripheral blood CD8 cells decreased during the 
first trimester, while CD4 cells decreased in the third trimester, with both populations 
increasing to non-pregnant values four months postpartum (Watanabe et al., 1997). The 
investigations by Kühnert et al. found no significant changes in the percentage CD4 and 
CD8 lymphocytes, nor in the CD4/CD8 ratio at any stage of pregnancy or postpartum. 
Based on our results, the apparent increase in Tc17 cell prevalence in healthy pregnancy 
compared with non-pregnant controls appears to be the consequence of decreased CD8+ IL-
17- cell frequency in this group, resulting in a higher proportion of Tc17 cells in the CD8 
subset. Since Tc17 cells have been described to have a lower cytotoxic activity in comparison 
with CD8+ IL-17- cells (Huber et al., 2009), the decrease in the latter subset and a relative 
increase in Tc17 prevalence may be regarded as part of the immunosuppressive mechanisms 
characterizing healthy pregnancy. 
In preeclampsia, our results show that in addition to CD4 cells, the prevalence of CD8 and 
NK cells that express IL-17 is also higher compared with healthy pregnant women. IL-17 
production by these lymphocyte subsets might contribute to the development of a systemic 
pro-inflammatory environment in PE (Toldi et al., 2011a). 
8. Lymphocyte activation kinetics 
Previous studies demonstrated that not only the prevalence of T lymphocyte subsets, but also 
their functionality is altered during pregnancy. For instance, calcium handling of T cells differs 
in healthy pregnancy and in the non-pregnant state. Previous reports indicate a sustained 
increase of basal intracellular calcium level in lymphocytes of healthy pregnant and 
preeclamptic women compared with non-pregnant women, with the highest levels in 
preeclampsia (Hojo et al., 1999; Thway et al., 2004; von Dadelszen et al., 1999). The availability 
of cytoplasmic free calcium has an important role in controlling the level of lymphocyte 
activation. We hypothesized that the elements of calcium handling of activated T lymphocytes, 
including lymphocyte potassium channels, may be affected in healthy pregnancy and 
preeclampsia compared to the non-pregnant state. Voltage-gated Kv1.3 channels along with 
calcium-dependent IKCa1 channels play a key role in the regulation of intracellular calcium 
homeostasis as they counterbalance the increase of cytoplasmic free calcium content in the 
course of lymphocyte activation. These channels grant the efflux of potassium from the 
cytoplasm, thus maintaining an electrochemical potential gradient needed for further calcium 
entry. Specific inhibition of these channels results in a diminished calcium influx into 
lymphocytes and a lower level of lymphocyte activation (Panyi et al., 2006). Our group 
characterized the activation-elicited calcium influx in the Th1, Th2, CD4 and CD8 lymphocyte 
subsets in healthy pregnant, preeclamptic and non-pregnant women and tested its alteration 
upon the inhibition of Kv1.3 and IKCa1 potassium channels (Toldi et al., 2011b). 
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Until recently, primarily single-cell techniques were applied to study the process of 
lymphocyte activation, and no reliable high-throughput method was available to investigate 
lymphocyte activation kinetics in more than one lymphocyte subsets simultaneously. The 
use of single-cell techniques are limited by the fact that they are not suitable for the 
description of kinetic processes in a complex cellular milieu that contains different types of 
interacting immune cells. For this purpose, we developed a novel, flow cytometry-based 
approach that enabled us to monitor lymphocyte activation simultaneously in different 
lymphocyte subtypes. 
For our measurements, we collected peripheral blood samples from healthy pregnant, 
preeclamptic and non-pregnant women. PBMCs were separated by a standard density 
gradient centrifugation. PBMCs were then incubated with conjugated anti-human surface 
marker monoclonal antibodies (CD4, CD8, CXCR3 for Th1 cells, CCR4 for Th2 cells) to 
identify lymphocyte subsets and were loaded with calcium sensitive Fluo-3 and Fura Red 
dyes to monitor alterations of the cytoplasmic free calcium level. PBMCs were divided into 
three vials. One vial was treated with margatoxin (MGTX), a selective blocker of the Kv1.3 
channel. Another vial was treated with a triarylmethane compound (TRAM), a specific 
inhibitor of the IKCa1 channel. The third vial was used as control. Measurements were 
initiated directly after the addition of 20 µg of phytohemagglutinin (PHA) as an unspecific 
activating stimulus. Cell fluorescence data were measured and recorded for 10 minutes in a 
kinetic manner on flow cytometer. 
Data acquired from the measurements were evaluated by fitting a double-logistic function 
for each recording (Kaposi et al., 2008). This function is used to describe measurements that 
have an increasing and a decreasing intensity as time passes. The software also calculates 
parameter values describing each function, such as the Maximum value (Max), the Time to 
reach maximum value (tmax), and the Area Under the Curve (AUC). These parameters 
represent different characteristics of lymphocyte calcium influx kinetics. The Maximum 
value represents the peak value of the calcium influx curve upon lymphocyte activation, 
thus it reflects the maximal amount of cytoplasmic free calcium in the course of activation. 
The Time to reach maximum value describes how soon the peak value of the calcium influx 
curve is reached. The Area Under the Curve describes the full amount of cytoplasmic free 
calcium during the whole period of lymphocyte activation and thus the magnitude of the 
elicited calcium response in general. 
Our results indicate that calcium influx kinetics in activated T lymphocytes markedly differs 
in healthy pregnancy compared with the non-pregnant state: AUC values of the calcium 
response are lower in healthy pregnancy in the Th1, CD4 and CD8 lymphocyte subsets (Fig. 
4). Based on this observation, it is reasonable to assume that the physiological immune 
tolerance towards fetal antigens in pregnancy is partly attributed to a lower calcium 
response. This hypothesis is further supported by the particular role of the impaired 
function of Th1 and CD8 lymphocyte subsets in maternal immune tolerance. On contrary to 
Th1 cells, the activation induced calcium response of the Th2 subset is not decreased 
compared with the non-pregnant state. The decreased activation of the Th1 subset (reflected 
by low AUC values in our study) and the lack of decrease in Th2 cells may partly be 
responsible for the well established Th2 skewness in healthy pregnancy. 
Unlike in healthy pregnancy, we could not detect a difference in the AUC values of calcium 
influx kinetics of Th1 and CD8 cells in preeclampsia compared to non-pregnant women (Fig. 
4). The absence of calcium influx characteristics specific for healthy pregnancy suggests that 
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Fig. 4. Calcium influx kinetics of peripheral Th1 lymphocytes isolated from healthy non-
pregnant (HNP), healthy pregnant (HP) and preeclamptic (PE) women (without lymphocyte 
potassium channel inhibitor treatment). Calcium influx is lower in healthy pregnancy 
compared with the non-pregnant state and preeclampsia. 
this element may associate with the impaired maternal immune tolerance present in 
preeclampsia, since the calcium influx kinetics is comparable to that seen in non-pregnant 
samples. Indeed, the maintained activation properties of Th1 lymphocytes in preeclamptic 
patients may contribute to the lack of Th2 dominance associated with normal pregnancy. 
Similarly to the Th1 subset, CD8 cells in preeclampsia are also characterized by the lack of 
suppressed activation kinetics. Thus the decrease of cytotoxic activity observed in healthy 
pregnancy (Malinowski et al., 1994) is not present in preeclampsia. Interestingly, tmax values 
were decreased in Th2 and CD4 cells in preeclampsia compared with healthy pregnancy. 
This finding may indicate an increased reactivity of lymphocytes in preeclampsia, possibly 
reflecting an elevated responsiveness of T lymphocytes due to the ongoing maternal 
systemic inflammation. 
Since Kv1.3 and IKCa1 potassium channels significantly influence the calcium response 
elicited upon lymphocyte activation, we tested their expression and function in healthy 
pregnancy and preeclampsia. According to comparable fluorescence values of the samples 
stained with specific antibodies against Kv1.3 channels, their expression is not altered in any 
of the investigated T lymphocyte subsets. Therefore, the differences detected between 
calcium influx of non-pregnant, healthy pregnant and preeclamptic lymphocytes upon 
treatment with specific inhibitors of the potassium channels is probably due to the altered 
function, and not to the altered expression of these channels. 
Our results suggest that the overall lymphocyte population and particularly the CD4 subset 
are sensitive to MGTX and TRAM inhibition in each investigated study group, indicating 
that both Kv1.3 and IKCa1 channels play an important regulatory role in calcium influx. 
This is reflected by the decrease of the AUC and Max values compared with the respective 
samples where no inhibitors were applied. However, the sensitivity of calcium influx 
measured in other lymphocyte subsets shows clear variability. It is of particular interest that 
calcium influx of Th2 lymphocytes in healthy pregnancy was insensitive to potassium 
channel inhibition, while calcium influx decreased significantly in non-pregnant samples 
upon treatment with the specific channel blockers. Of note, Th2 lymphocytes in 
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preeclampsia presented with non-pregnant-like characteristics, and were also sensitive to 
MGTX and TRAM treatment. Since the regulatory function of Kv1.3 and IKCa1 channels on 
calcium influx appears to be limited in healthy pregnant samples (as the inhibition of these 
channels did not result in a decrease of the AUC and Max values), it is tempting to speculate 
that this may be an element contributing to the Th2 shift present in healthy pregnancy, but 
absent in preeclampsia. This hypothesis may be supported by reports suggesting that the 
shape of calcium influx influenced by potassium channel functions may determine the 
cytokine production profile of helper T lymphocytes (Dolmetsch et al., 1998; Fanger et al., 
2000). 
Interestingly, other differences were also observed between healthy pregnancy and 
preeclampsia. While calcium influx in CD8 and Th1 lymphocytes was resistant to potassium 
channel inhibition in preeclamptic samples, that of healthy pregnant lymphocytes was 
sensitive. Similarly to Th2 cells, while it is unclear whether the resistance of Th1 
lymphocytes to potassium channel inhibition is reflected in their function, the insensitivity 
of the Th1 subset to the inhibition of regulatory lymphocyte potassium channels in 
preeclampsia may be linked to the Th1 skewness. 
Our findings suggest that there is a characteristic pattern of calcium influx in T lymphocytes 
and its sensitivity to potassium channel inhibition in normal pregnancy that is missing in 
preeclampsia. This raises the notion that T lymphocyte calcium handling may have a role in 
the development of the pregnancy-specific immune tolerance. 
9. The association between preeclampsia and autoimmunity 
Considering the immunological alterations described in preeclampsia, one may notice 
characteristic similarities in the etiology shared with autoimmune disorders. As a result of 
the impaired immune tolerance, preeclampsia is distinguished by many features typically 
seen in autoimmune diseases, or in association with autoimmune reactions. This does not 
mean that preeclampsia should be considered an autoimmune condition. However, it does 
suggest that abnormal autoimmune processes play an important part in the pathogenesis of 
preeclampsia. An interpretation of preeclampsia can be found in analogies to organ rejection 
after allograft transplantation and in graft-versus-host disease (GVHD); like preeclampsia, 
these conditions are also characterized by a multitude of systemic symptoms. The 
similarities with acute organ rejection and GVHD are paralleled by the notion that if a 100% 
allograft can elicit autoimmune responses during organ transplantation, one should not be 
surprised that a 50:50 autograft-allograft can do the same thing. This recognition may lead to 
better clinical approaches to preeclampsia and thereby to better diagnosis and treatment 
(Gleicher, 2007). 
The clinical relationship between autoimmune diseases and pregnancy is unique. No other 
diseases are characterized by an exacerbation pattern that is particularly pronounced in the 
peripartum and postpartum periods (Gleicher et al., 1993). A recently recognized example is 
peripartum cardiomyopathy, with disease flares from late pregnancy up to approximately 
three months postpartum (Ansari et al., 2002). Preeclampsia is also characterized by a 
peripartal exacerbation pattern, with the majority of cases developing after 36 weeks of 
gestation. 
Besides the cellular abnormalities already discussed, autoantibody abnormalities have also 
been reported in association with preeclampsia. So far, a number of autoantibodies have 
been implicated in the pathogenesis (Branch et al., 1994; Milliez et al., 1990; Rappaport et al., 
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1990; Yamamoto et al., 1993). The most important one of them appears to be an agonistic 
autoantibody against the angiotensin II type 1 receptor (Wallukat et al., 1999). Moreover, as 
in classical autoimmune diseases, more severe preeclampsia appears to result in more 
autoantibody abnormalities (El-Roeiy et al., 1991). Evidence suggests that classical, 
nonorgan-specific autoantibodies, such as antiphospholipid antibodies, are characteristic of 
preeclampsia, and especially in its more severe clinical expression (El-Roeiy et al., 1991; 
Yamamoto et al., 1993). Dekker et al. therefore recommended active laboratory surveillance 
for patients at risk (Dekker et al., 1995). 
Both GVHD-related and classical autoimmune conditions often improve upon treatments 
that have been found successful also in preeclampsia and HELLP syndrome. Three 
examples are the treatment with corticosteroids, removal of autoantibody abnormalities via 
plasmapheresis, and the competitive binding of autoantibodies with intravenous 
immunoglobulin (Katz et al., 1990; Martin et al., 1990; Martin et al., 2006). 
Considering the significant degree of bidirectional cell traffic during pregnancy, one can 
speculate that, in analogy to GVHD, the autoimmune phenomena, seen in association with 
preeclampsia, may be immune responses by fetal lymphocytes to epitopes shared by mother 
and fetus. Alternatively, the autoimmune response in preeclampsia could be distinct from 
that in GVHD, and purely autoimmune in nature. This would then represent an immune 
response solely against maternal self-epitopes on fetal cells that have entered the maternal 
circulation. A number of observations indicate that the paternal genotype is of importance 
in that regard. For instance, the more similar the paternal histocompatibility complex is to 
that of the mother, the more likely a miscarriage will occur due to increased autoantigenity 
(Kishore et al., 1996). The fetus is not only an allograft but also an autograft. Since one half of 
the fetus is maternally derived in its antigenicity, the maternal immune system also faces an 
unprecedented autoimmune load. At no other period in life needs the maternal immune 
system to be prepared for autoimmune challenges of this extent. The immunological 
adjustment to pregnancy, therefore, does not only involve the development of tolerance to 
the paternal allogenic, but also to the maternal autoimmunogenic components of the fetus. 
Autoimmune phenomena are mostly seen in two periods of pregnancy: during early 
conception and the peripartum period. In early conception, abnormal immune activation 
may be coupled with pregnancy loss. Later stage presentation appears to be associated with 
preeclampsia. Indeed, women with early autoimmune activation, who (with treatment) do 
not miscarry, demonstrate a greatly increased risk for preeclampsia (Gleicher et al., 1993). 
This observation supports the idea of a common alloimmune or autoimmune etiology for 
both of these conditions. It has also been suggested that an analogy might exist not only 
between chronic graft rejection and preeclampsia, but also between acute graft rejection and 
recurrent abortion (Wilczyński, 2006). 
Accepting the concept that preeclampsia is characterized by autoimmune phenomena may 
have benefits for better diagnosis and treatment. For example, autoimmune phenomena 
usually go through pre- or subclinical stages before their clinical manifestation. Laboratory 
markers are often already detectable at those early stages (Davidson & Diamond, 2001). If 
the autoimmune phenomena of preeclampsia were to follow a similar pattern, earlier 
diagnosis and specific treatment might become possible. 
10. Conclusion 
T lymphocytes play a central role in the development of the maternal immune tolerance 
during pregnancy. Pathologic alterations of T cells in prevalence and functionality 
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contribute to the onset of pregnancy-related disorders, and might represent a possible future 
target for therapeutic intervention. 
It has been recognized for many years that the prevalence of distinct T cell subpopulations 
are subject to a characteristic adjustment during pregnancy in order to facilitate the specific 
needs raised by the developing fetus. The course of this adjustment may be insufficient in 
pregnancy-related disorders. Recently, it has been demonstrated that not only cell numbers, 
but also the functionality of cells needs to go through specific alterations to help the 
maternal immune system in acquisition of the pregnancy-specific tolerance. As an example, 
we have demonstrated that there is a characteristic pattern of calcium influx in T 
lymphocytes and its sensitivity to lymphocyte potassium channel inhibition in healthy 
pregnancy that is missing in preeclampsia, raising the notion that T lymphocyte calcium 
handling may have a role in the distinctive immune status of uncomplicated pregnancy. 
Further research needs to be carried out applying different methods to identify additional 
factors involved in these alterations. This approach might lead to better strategies for the 
prevention and treatment of adverse pregnancy outcomes, facilitating the development and 
maintenance of immune tolerance needed for healthy pregnancy. 
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1. Introduction 
The skeletal and immune systems are interconnected in normal (physiologic) and pathologic 
conditions. Both systems are intimately coupled, as osteoclastogenesis and hematopoiesis 
occur in the bone marrow. Osteoclasts, macrophages, and dendritic cells also share common 
precursors. Furthermore, the skeletal and immune systems share various cytokines, 
receptors, adaptor proteins, signaling molecules, and transcription factors, thereby allowing 
crosstalk to occur between the various cells and their respective signal transduction 
pathways involved in osteoclastogenesis and hematopoiesis.  
Hematopoietic stem cells are maintained in the bone marrow. Adjacent osteoblast 
precursors produce signals that control hematopoietic stem cell replication and 
differentiation. Hematopoietic stem cells may either maintain their pluripotency or 
differentiate into multipotential progenitor cells, which have the capacity to form common 
lymphoid progenitor or common myeloid precursor cells. Common lymphoid progenitor 
cells undergo additional differentiation to form T lymphocytes, B lymphocytes, or natural 
killer cells, whereas common myeloid precursor cells form all other myeloid lineages and 
preosteoclasts. Activated osteoclasts are formed from the fusion of preosteoclasts and 
multinucleated osteoclasts, the regulation of which is complex and affected by multiple 
factors. Multipotential stem cells differentiate into chondrocytes, adipocytes, and 
mesenchyme precursors; the latter undergo differentiation to form preosteoblasts and, 
eventually, mature matrix-producing osteoblasts. Osteoblasts may remain on the bone 
surface as lining cells or undergo terminal differentiation to form osteocytes, which become 
encased in the mineralized bone matrix [1]. The shared lineages and paracrine signaling 
between osteoclasts and hematopoietic cells highlight the potential for bone-targeted agents 
to influence the immune system.  
2. Transduction signaling pathways between skeletal and immune system  
The skeletal and immune systems share various signal transduction pathways, thereby 
allowing a complex interplay to occur between bone metabolism and immunology. 
Furthermore, immune system components, such as T cells, cytokines, and chemokines, can 
exert substantial effects on osteoclastogenesis. 
 22 
Osteoimmunology and Cancer 
- Clinical Implications 
Evangelos Terpos, Maria Gkotzamanidou, 
Dimitrios Christoulas and Meletios A. Dimopoulos 
Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, 
Greece 
1. Introduction 
The skeletal and immune systems are interconnected in normal (physiologic) and pathologic 
conditions. Both systems are intimately coupled, as osteoclastogenesis and hematopoiesis 
occur in the bone marrow. Osteoclasts, macrophages, and dendritic cells also share common 
precursors. Furthermore, the skeletal and immune systems share various cytokines, 
receptors, adaptor proteins, signaling molecules, and transcription factors, thereby allowing 
crosstalk to occur between the various cells and their respective signal transduction 
pathways involved in osteoclastogenesis and hematopoiesis.  
Hematopoietic stem cells are maintained in the bone marrow. Adjacent osteoblast 
precursors produce signals that control hematopoietic stem cell replication and 
differentiation. Hematopoietic stem cells may either maintain their pluripotency or 
differentiate into multipotential progenitor cells, which have the capacity to form common 
lymphoid progenitor or common myeloid precursor cells. Common lymphoid progenitor 
cells undergo additional differentiation to form T lymphocytes, B lymphocytes, or natural 
killer cells, whereas common myeloid precursor cells form all other myeloid lineages and 
preosteoclasts. Activated osteoclasts are formed from the fusion of preosteoclasts and 
multinucleated osteoclasts, the regulation of which is complex and affected by multiple 
factors. Multipotential stem cells differentiate into chondrocytes, adipocytes, and 
mesenchyme precursors; the latter undergo differentiation to form preosteoblasts and, 
eventually, mature matrix-producing osteoblasts. Osteoblasts may remain on the bone 
surface as lining cells or undergo terminal differentiation to form osteocytes, which become 
encased in the mineralized bone matrix [1]. The shared lineages and paracrine signaling 
between osteoclasts and hematopoietic cells highlight the potential for bone-targeted agents 
to influence the immune system.  
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2.1 Osteoclastogenesis and immune system 
Osteoclastogenesis is primarily regulated via interactions between c-FMS and macrophage 
colony-stimulating factor, receptor activator of nuclear factor (NF)-kappaB (RANK) and 
RANK ligand (RANKL), and immunoglobulin (Ig)-like receptors and their ligands [2]. The 
role of RANK signaling in osteoclastogenesis has also been reviewed elsewhere [2-16]. Other 
key regulatory pathways are described below. 
RANK/RANKL/osteoprotegerin signaling 
Receptor activator of NF-κΒ ligand is a member of the tumor necrosis factor (TNF) cytokine 
superfamily that is expressed by osteoblasts, monocytes, neutrophils, dendritic cells, B 
lymphocytes, and T lymphocytes [3]. Secretion of RANKL by osteoclastogenesis-supporting 
cells (osteoblasts and synovial fibroblasts) occurs in response to osteoclastogenic factors 
such as 1,25-dihydroxyvitamin D3, prostaglandin E2, and parathyroid hormone [2]. T cells 
express RANKL as a type-2 membrane-bound protein and also release it in soluble form, 
although the function of the soluble form remains unknown [16]. Inflammatory cytokines, 
such as interleukin (IL)-1, IL-6, and TNF-α, also potently induce RANKL expression on 
osteoblasts and synovial fibroblasts, thereby stimulating RANKL signaling [2].  
Receptor activator of NF-κB, the RANKL receptor, shares high homology with CD40, which is 
expressed on lymphocytes and, similar to RANKL, is reported to play a role in atherosclerosis 
and coronary artery disease [17-19]. Interaction of RANK with RANKL is inhibited by 
osteoprotegerin (OPG), a soluble competitor (decoy) receptor that binds to RANKL [12, 13]. 
Receptor activator of NF-κB lacks intrinsic enzymatic activity in its intracellular domain and 
transduces signals by recruiting adaptor molecules such as the TNF-receptor–associated factor 
(TRAF) family of proteins, especially TRAF6 [4, 5, 15]. By an unknown mechanism, RANKL 
binding to RANK induces trimerization of RANK and TRAF6, leading to activation of NF-κB 
and of mitogen-activated protein kinases such as Jun N-terminal kinase and p38 [6]. Activated 
RANK can also lead to stimulation of Ig-like receptor signaling. 
Nuclear factor of activated t cells cytoplasmic (NFATc)-1 pathway 
Expression of NFATc-1, the master regulator of osteoclast differentiation, depends on 
induction of the TRAF6–NF-κB and c-FOS pathways, in addition to activation of calcium 
signaling [20]. Nuclear factor of activated T cells cytoplasmic-1 is initially induced by 
TRAF6-activated NF-κB and NFATc-2. After translocation into the nucleus, NFATc-1 
autoregulates its own expression by binding to the NFAT-binding site of its promoter, 
enabling robust induction of NFATc-1 expression [21]. Activator protein 1 and continuous 
activation of calcium signaling by calcineurin are crucial for NFATc-1 autoamplification 
[20]. Nuclear factor of activated T cells cytoplasmic-1 cooperates with other transcription 
factors, such as AP1, PU.1, microphthalmia-associated transcription factor, and cyclic AMP 
responsive-element-binding protein, to regulate various osteoclast-specific genes, including 
tartrate-resistant acid phosphatase, cathepsin K, calcitonin receptor, osteoclast-associated 
receptor, and β3-integrin [2, 20, 22-24].  
2.2 Cytokines, chemokines and osteoclastogenesis 
Immune cells produce a variety of proinflammatory cytokines that contribute to bone 
damage [25]. Tumor necrosis factor-alpha and IL-1, -3, -6, -7, -11, -15, and -17 potentiate 
bone loss by inducing RANKL expression on osteoblasts or by increasing osteoclast 
differentiation and activation. In contrast, IL-4, -5, -10, -12, -13, and -18, and interferon (IFN)-
α, -β, and -γ, inhibit osteoclastogenesis by directly or indirectly blocking RANKL signaling 
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(Table 1). Interleukin-1 stimulates TRAF6 expression, thereby potentiating the RANKL-
RANK signaling cascade and inducing mature osteoclasts to perform bone-resorbing 
activity. Interferon gamma down-regulates TRAF6 expression via proteosomal degradation,  
 
Cytokine Main producer cells 






RANKL T-cells; Osteoblasts 
Osteoclast 













IL-6 Th2 cells; dendritic cells 
Mesenchymal cells; 
T cells Activation 









Mesenchymal cells Activation 














natural killer T 
cells 
Osteoclast 






















Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, 
interleukin; RANKL, receptor activator of nuclear factor-κB ligand; Th, T-helper;  
TNF, tumor necrosis factor. 
Table 1. Cytokines Involved in Osteoclastogenesis 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
474 
2.1 Osteoclastogenesis and immune system 
Osteoclastogenesis is primarily regulated via interactions between c-FMS and macrophage 
colony-stimulating factor, receptor activator of nuclear factor (NF)-kappaB (RANK) and 
RANK ligand (RANKL), and immunoglobulin (Ig)-like receptors and their ligands [2]. The 
role of RANK signaling in osteoclastogenesis has also been reviewed elsewhere [2-16]. Other 
key regulatory pathways are described below. 
RANK/RANKL/osteoprotegerin signaling 
Receptor activator of NF-κΒ ligand is a member of the tumor necrosis factor (TNF) cytokine 
superfamily that is expressed by osteoblasts, monocytes, neutrophils, dendritic cells, B 
lymphocytes, and T lymphocytes [3]. Secretion of RANKL by osteoclastogenesis-supporting 
cells (osteoblasts and synovial fibroblasts) occurs in response to osteoclastogenic factors 
such as 1,25-dihydroxyvitamin D3, prostaglandin E2, and parathyroid hormone [2]. T cells 
express RANKL as a type-2 membrane-bound protein and also release it in soluble form, 
although the function of the soluble form remains unknown [16]. Inflammatory cytokines, 
such as interleukin (IL)-1, IL-6, and TNF-α, also potently induce RANKL expression on 
osteoblasts and synovial fibroblasts, thereby stimulating RANKL signaling [2].  
Receptor activator of NF-κB, the RANKL receptor, shares high homology with CD40, which is 
expressed on lymphocytes and, similar to RANKL, is reported to play a role in atherosclerosis 
and coronary artery disease [17-19]. Interaction of RANK with RANKL is inhibited by 
osteoprotegerin (OPG), a soluble competitor (decoy) receptor that binds to RANKL [12, 13]. 
Receptor activator of NF-κB lacks intrinsic enzymatic activity in its intracellular domain and 
transduces signals by recruiting adaptor molecules such as the TNF-receptor–associated factor 
(TRAF) family of proteins, especially TRAF6 [4, 5, 15]. By an unknown mechanism, RANKL 
binding to RANK induces trimerization of RANK and TRAF6, leading to activation of NF-κB 
and of mitogen-activated protein kinases such as Jun N-terminal kinase and p38 [6]. Activated 
RANK can also lead to stimulation of Ig-like receptor signaling. 
Nuclear factor of activated t cells cytoplasmic (NFATc)-1 pathway 
Expression of NFATc-1, the master regulator of osteoclast differentiation, depends on 
induction of the TRAF6–NF-κB and c-FOS pathways, in addition to activation of calcium 
signaling [20]. Nuclear factor of activated T cells cytoplasmic-1 is initially induced by 
TRAF6-activated NF-κB and NFATc-2. After translocation into the nucleus, NFATc-1 
autoregulates its own expression by binding to the NFAT-binding site of its promoter, 
enabling robust induction of NFATc-1 expression [21]. Activator protein 1 and continuous 
activation of calcium signaling by calcineurin are crucial for NFATc-1 autoamplification 
[20]. Nuclear factor of activated T cells cytoplasmic-1 cooperates with other transcription 
factors, such as AP1, PU.1, microphthalmia-associated transcription factor, and cyclic AMP 
responsive-element-binding protein, to regulate various osteoclast-specific genes, including 
tartrate-resistant acid phosphatase, cathepsin K, calcitonin receptor, osteoclast-associated 
receptor, and β3-integrin [2, 20, 22-24].  
2.2 Cytokines, chemokines and osteoclastogenesis 
Immune cells produce a variety of proinflammatory cytokines that contribute to bone 
damage [25]. Tumor necrosis factor-alpha and IL-1, -3, -6, -7, -11, -15, and -17 potentiate 
bone loss by inducing RANKL expression on osteoblasts or by increasing osteoclast 
differentiation and activation. In contrast, IL-4, -5, -10, -12, -13, and -18, and interferon (IFN)-
α, -β, and -γ, inhibit osteoclastogenesis by directly or indirectly blocking RANKL signaling 
 
Osteoimmunology and Cancer - Clinical Implications 
 
475 
(Table 1). Interleukin-1 stimulates TRAF6 expression, thereby potentiating the RANKL-
RANK signaling cascade and inducing mature osteoclasts to perform bone-resorbing 
activity. Interferon gamma down-regulates TRAF6 expression via proteosomal degradation,  
 
Cytokine Main producer cells 






RANKL T-cells; Osteoblasts 
Osteoclast 













IL-6 Th2 cells; dendritic cells 
Mesenchymal cells; 
T cells Activation 









Mesenchymal cells Activation 














natural killer T 
cells 
Osteoclast 






















Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, 
interleukin; RANKL, receptor activator of nuclear factor-κB ligand; Th, T-helper;  
TNF, tumor necrosis factor. 
Table 1. Cytokines Involved in Osteoclastogenesis 
 
Autoimmune Disorders – Pathogenetic Aspects 
 
476 
resulting in termination of osteoclast formation [26, 27]. Receptor activator of NF-κB induces 
expression of IFN-β in osteoclast precursor cells, and IFN-β functions as a negative-feedback 
regulator of osteoclast differentiation by interfering with RANKL-induced c-FOS expression 
[28]. Tumor necrosis factor-alpha stimulates NF-κB activation primarily via interacting with 
TRAF2. Although TNF-α alone cannot induce osteoclastogenesis and TNF-α overexpression 
cannot rescue RANKL deficiency, TNF-α combined with transforming growth factor (TGF)-
β induces osteoclastogenesis even in the absence of RANK or TRAF6 [29-31]. These results 
suggest that TNF-α plays a pivotal role in the pathologic activation of osteoclasts associated 
with inflammation [2]. Osteoblast-mediated bone formation is also affected by various 
soluble cytokines such as TNF-α, IL-1, and IL-4 [32]. The molecular mechanisms involved in 
osteoblast regulation by the immune system and the pathologic significance of such 
regulation are less understood than in osteoclasts.  
2.3 T cells and osteoclastogenesis 
In general, activated T cells exert an inhibitory effect on osteoclastogenesis. The CD4+ T 
helper (Th) cells have traditionally been divided into 2 main subtypes—Th1 and Th2—based 
on their associated cytokine profiles. The Th1 cells mainly produce IFN-γ and IL-2, and 
mediate cellular immunity. In contrast, Th2 cells mainly produce IL-4, IL-5, and IL-10, and 
mediate humoral immunity. Although T cells express RANKL, most Th1 cytokines, as well 
as certain Th2 cytokines (eg, IL-4 and IL-10), exert an inhibitory effect on osteoclastogenesis. 
However, the Th-cell subset involved in producing IL-17 (Th17 cells) is considered to be the 
typical osteoclastogenic Th subset. The Th17 cells express RANKL at higher levels than Th1 
or Th2 cells and, as a result, may directly participate in osteoclastogenesis. In addition, Th17 
cells do not produce large amounts of IFN-γ, an inhibitor of osteoclastogenesis. 
Furthermore, Th17 cells activate local inflammation, triggering release of proinflammatory 
cytokines that potentiate RANKL expression on osteoclastogenesis-supporting cells and 
RANKL-RANK signal transduction in osteoclast precursor cells [33]. Interleukin-17, 
produced by Th17 cells, induces the synthesis of matrix-degrading enzymes, such as matrix 
metalloproteinases, that mediate bone and cartilage degradation [34]. The effects of Th17 
cells on osteoclastogenesis are balanced by regulatory T cells, which suppress osteoclast 
formation via a cytokine-dependent mechanism mediated by TGF-β, IFN-γ, IL-4, and IL-10 
[35-37]. Therefore, the effects of T cells on osteoclastogenesis depend on the balance between 
positive and negative factors expressed by these cells under pathologic conditions.  
3. Disruption of the skeletal and immune systems in cancer 
Tumorigenesis can disrupt the skeletal and immune systems. Tumor growth and metastasis 
necessitate evasion of the immune system, especially phosphoantigen-targeted gamma delta 
T cells (γδ T cells), which can detect and destroy cancer cells. Immune system components 
also play other key roles in tumor development and progression. For example, tumor-
associated macrophages (TAMs) are abundant in the bone microenvironment and influence 
multiple steps in tumor development, including growth, survival, invasion, and metastasis, 
as well as angiogenesis and lymphangiogenesis [38, 39]. During early metastasis of solid 
tumors, disseminated tumor cells (DTCs) survive in the bone marrow of patients with 
various tumor types. Cancers for which DTCs have been detected in patients who have not 
developed overt metastases include breast, colon, gastric, lung, and prostate cancers [40-46]. 
The hematopoietic niche in the bone marrow also provides a “harbor” for DTCs to survive 
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despite anticancer therapies. Whether this niche also harbors cancer cells against anticancer 
immune defenses is unknown. However, the shared signal transduction pathways among 
the bone remodeling and immune system machineries in this common microenvironment 
suggest that activation of this vicious cycle of tumor growth and osteolytic bone destruction 
could also lead to localized immunosuppression or recruitment of metastasis-supporting 
TAMs, an unfortunate juxtaposition of osteoimmunology effects. Later in the disease course, 
interactions between malignant cells and bone may result in a vicious cycle of bone 
destruction and cancer growth (the “seed and soil theory”) [47]. The effects of cancer on 
bone can result in skeletal-related events (SREs) that include pathologic fracture, spinal cord 
compression, hypercalcemia of malignancy, and the need for radiotherapy. Furthermore, 
some cancers such as myeloma can exert additional deleterious effects on bone metabolism 
via inducing osteolysis, systemic bone loss, and suppression of new bone formation 
throughout the skeleton [48, 49]. 
3.1 Osteoclastogenesis and cancer cell growth and metastases 
Osteoclast-mediated osteolysis results in release of growth factors in the bone 
microenvironment that facilitate cancer growth and metastases. Bone-derived cytokines 
provide a chemotactic stimulus for directed tumor cell migration [50]. Recent studies 
established that RANKL is a chemoattractant that increases migration and invasion of 
RANK-positive cancer cells (bone tropism) [51, 52]. In preclinical models, bone resorption 
by bone cell cultures stimulated proliferation of various tumor cell types, including breast 
cancer that possessed bone-metastasizing properties [53]. In animal models, cancer cells 
located immediately adjacent to bone surfaces had significantly greater proliferation rates 
compared with those distant from bone, suggesting a mitogenic effect within the bone 
microenvironment [54]. Furthermore, in an animal model wherein bone resorption was 
stimulated by tumor cells, the proliferation rate of metastatic cancer cells was increased in 
bone but not in other tissues [55].  
3.2 Cancer cell biology and bone resorption 
Cancer cells stimulate osteoclast-mediated osteolysis via several mechanisms. Cancer cells 
may express RANKL and RANK, up-regulate RANKL expression by other osteoimmune 
cell types, down-regulate OPG expression, and stimulate release of factors that activate 
RANKL-RANK signaling in osteoclasts [56]. Expression of RANKL has been detected in 
prostate cancer cells [57] and multiple myeloma (MM) cells [58, 59], and RANKL expression 
by MM cells correlated with the propensity to cause bone destruction [58]. Although breast 
cancer cells do not typically express RANKL [60, 61], they can up-regulate RANKL 
expression by osteoblasts [60, 61] and bone marrow stromal cells [61, 62]. Prostate cancer 
cells can up-regulate RANKL expression in osteoblasts [63], and MM cells up-regulate 
RANKL expression in bone marrow stromal cells [64], endothelial cells [65], and T cells [66]. 
Several studies also reported expression of functional RANK by breast cancer, prostate, and 
melanoma cell lines [51, 52]. Breast cancer cells and MM cells down-regulate OPG 
production by osteoblasts and bone marrow stromal cells [60, 64]. Multiple myeloma cells 
express the heparin sulfate proteoglycan, syndecan, on their surface, which sequesters and 
degrades heparin-binding proteins including OPG [67]. Notably, the RANKL-OPG balance 
is disturbed in severe osteolytic pathologies in favor of RANKL, with large quantities of 
OPG being released within the tumor microenvironment to counterbalance high RANKL 
concentrations [64, 68].  
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Clodronate [70] Multiple myeloma 350 Yes Yes No NE 
Clodronate [72] Multiple myeloma 536 Yes Yes No +/–
a 
Clodronate [74] Breast cancer 173 Yes Yes No No 
Clodronate [75] Prostate cancer 819 NR NR No Yes 
Pamidronate [76] Multiple myeloma 392 Yes Yes Yes +/–
b 






1,648 Yes Yes Yes Yes 
Zoledronic acid 




and other solid 
tumors 






122 Yes Yes Yes NE 
Denosumab [82] Breast cancer 2,046 Yes NE Yes NE 
Abbreviations: NE, not evaluated; NR, not reported; SREs, skeletal-related events. 
aIn a post hoc analysis, patients without vertebral fracture at study entry survived significantly longer 
on clodronate therapy (median survival was 23 months longer compared with patients receiving 
placebo). 
bSurvival of patients with more advanced disease was significantly increased in the pamidronate group 
(median survival of 21 vs 14 months, P = .041). 
Table 2. Efficacy of Bone-Targeted Agents in Patients With Bone Metastases 
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4. Bone-targeted therapies and immune system in cancer 
4.1 Early generation bisphosphonates 
In general, early generation bisphosphonates do not appear to activate the immune system 
against cancer cells. However, clodronate combined with IL-2 stimulated proliferation of γδ 
T cells in the absence of other cellular components in peripheral blood mononuclear cell 
(PBMC) cultures (wherein nitrogen-containing bisphosphonates have been tested), and 
clodronate-treated γδ T cells exhibited higher cytotoxic activity against neuroblastoma cells 
compared with untreated control cells [69]. There are currently no data on whether these 
effects can result in meaningful anticancer activities in in vivo models. Clodronate has 
shown efficacy in preventing SREs in patients with bone metastases from MM [70-73] and 
breast cancer [74], and was recently reported to significantly prolong survival in men with 
bone metastases from prostate cancer [75] (Table 2) [70, 72, 74-82]. Results from trials in the 
adjuvant breast cancer setting were inconsistent, and provided some evidence to suggest 
that clodronate can delay not only metastasis to bone but also to visceral sites. 
4.2 Nitrogen-containing bisphosphonates 
Nitrogen-containing bisphosphonates, such as zoledronic acid (ZOL) and pamidronate, 
cause immune system activation against cancer cells via activating γδ T cells [83, 84]. By 
blocking G-protein signaling, these agents prevent differentiation of monocytes into 
osteoclasts, inhibit osteoclast recruitment and maturation, induce osteoclast apoptosis, and 
inhibit adhesion of osteoclasts to bone [85].  
Pamidronate therapy is associated with SRE reductions in patients with bone metastases 
from MM [76]. Although there was no overall difference in survival between pamidronate- 
and placebo-treated patients, pamidronate prolonged survival among patients who had 
received more than 1 previous antimyeloma regimen (14 vs 21 months; P = .041; N = 392) 
[86]. Although evidence is limited, pamidronate has demonstrated effects on the immune 
system that may result in anticancer activity. Treatment with pamidronate induced 
expansion of γδ T cells in PBMC cultures from healthy donors, and pamidronate-activated 
γδ T cells produced immunostimulatory cytokines and exhibited specific cytotoxicity 
against lymphoma and myeloma cell lines. Furthermore, pamidronate-treated bone marrow 
cultures from patients with MM exhibited reduced plasma cell survival compared with 
untreated cultures, especially in pamidronate-treated cultures, in which activation of bone 
marrow γδ T cells was evident (14 of 24 patients) [87].  
Administration of ibandronate to patients with advanced MM failed to reduce bone 
morbidity or prolong survival [77]. Ibandronate also produced a lesser reduction in markers 
of bone resorption and disease activity, including N-telopeptide of type I collagen (NTX), IL-
6, and β2-microglobulin, compared with pamidronate [88]. However, ibandronate has 
demonstrated efficacy in the reduction of skeletal complications in other tumor types such 
as breast cancer [89]. 
Numerous studies established that zoledronic acid (ZOL) exhibits consistent efficacy in 
delaying and preventing SREs in patients with malignant bone disease from MM [78, 90, 91] 
and various solid tumors including breast [79], lung [80, 92], and prostate cancers [81]. In a 
25-month randomized trial comparing ZOL with pamidronate in patients with bone lesions 
from MM or breast cancer (N = 1,648), a 15-minute infusion of 4 mg ZOL was at least as 
effective as a 2-hour infusion of 90 mg pamidronate at reducing the risk of SRE 
complications in the overall population [78]. Similarly, treating patients with lung cancer 
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system that may result in anticancer activity. Treatment with pamidronate induced 
expansion of γδ T cells in PBMC cultures from healthy donors, and pamidronate-activated 
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against lymphoma and myeloma cell lines. Furthermore, pamidronate-treated bone marrow 
cultures from patients with MM exhibited reduced plasma cell survival compared with 
untreated cultures, especially in pamidronate-treated cultures, in which activation of bone 
marrow γδ T cells was evident (14 of 24 patients) [87].  
Administration of ibandronate to patients with advanced MM failed to reduce bone 
morbidity or prolong survival [77]. Ibandronate also produced a lesser reduction in markers 
of bone resorption and disease activity, including N-telopeptide of type I collagen (NTX), IL-
6, and β2-microglobulin, compared with pamidronate [88]. However, ibandronate has 
demonstrated efficacy in the reduction of skeletal complications in other tumor types such 
as breast cancer [89]. 
Numerous studies established that zoledronic acid (ZOL) exhibits consistent efficacy in 
delaying and preventing SREs in patients with malignant bone disease from MM [78, 90, 91] 
and various solid tumors including breast [79], lung [80, 92], and prostate cancers [81]. In a 
25-month randomized trial comparing ZOL with pamidronate in patients with bone lesions 
from MM or breast cancer (N = 1,648), a 15-minute infusion of 4 mg ZOL was at least as 
effective as a 2-hour infusion of 90 mg pamidronate at reducing the risk of SRE 
complications in the overall population [78]. Similarly, treating patients with lung cancer 
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and other solid tumors with ZOL resulted in fewer patients developing SREs (ZOL 8 mg 
reduced to 4 mg = 36%, placebo = 46%; P = .023; N = 773) [80]. Administration of ZOL to 
men with hormone-refractory metastatic prostate cancer also reduced the proportion of 
patients with SREs (38% vs 49%; P = .028 vs placebo; N = 122) [81]. 
A recent study also demonstrated that ZOL may elicit anticancer effects associated with 
immune system stimulation. Zoledronic acid activated γδ T cells in vitro, and administration 
of ZOL to patients with prostate cancer resulted in the activation of γδ T cells in peripheral 
blood after the first infusion. Moreover, after the first ZOL infusion, serum prostate-specific 
antigen (PSA) levels were reduced in 3 of 11 evaluable patients, and PSA velocity was reduced 
in 5 of 10 evaluable patients [93]. These results suggest that ZOL-activated γδ T cells may be 
associated with the induction of an anticancer response in patients with prostate cancer. 
Numerous in vitro studies established that ZOL directly and indirectly inhibits multiple 
steps involved in the processes of cancer development and progression. In addition, ZOL 
stimulates cancer cell apoptosis and expansion of γδ T cells, which play an important role in 
immune surveillance against neoplasia [94]. Preclinical studies reported that ZOL elicits 
anticancer activity in various cancer types and exhibits synergy with cytotoxic agents [95-
100]. Four separate studies reported that ZOL reduced the persistence of DTCs in the bone 
marrow of patients with breast cancer [101-104]. In the clinical setting, adding ZOL to 
standard anticancer therapy improved clinical outcomes in early breast cancer. 
Administration of ZOL combined with adjuvant endocrine therapy to premenopausal 
women improved disease-free survival (hazard ratio [HR] = 0.64; P = .01) compared with 
endocrine therapy alone in the ABCSG-12 trial (N = 1,803) [105]. Similarly, ZOL plus 
neoadjuvant chemotherapy reduced residual invasive tumor size by 44% compared with 
chemotherapy in an exploratory subgroup from the AZURE trial (P = .006; n = 205) [106]. A 
multivariate analysis adjusted for potential prognostic factors in addition to neoadjuvant 
treatment group demonstrated that patients treated with ZOL plus neoadjuvant 
chemotherapy had a 2-fold greater complete pathologic response rate (breast and axilla) 
compared with patients treated with chemotherapy alone (odds ratio = 2.2; P = .1457). In the 
ZO-FAST (N = 1,065; median follow-up = 48 months; HR = 0.59; P = .0176) and Z-FAST (N = 
602; median follow-up = 61 months; P = .6283) studies in postmenopausal women receiving 
adjuvant letrozole, immediate addition of ZOL reduced disease recurrence [107, 108]. In 
contrast with ABCSG-12, which had disease-free survival as a primary endpoint, ZO-FAST 
and Z-FAST were not designed or powered to evaluate disease recurrence (primary 
endpoints were bone loss); however, these studies demonstrated that upfront 
administration of ZOL resulted in improved disease-free survival among women with 
breast cancer. Subset analyses of the phase III clinical studies revealed that ZOL significantly 
prolonged survival compared with placebo among patients with high baseline NTX levels. 
Benefits were independent of SRE prevention, and multiple anticancer mechanisms, some of 
which involved immune system activation, may have contributed [109, 110]. Additionally, 
ZOL elicited anticancer responses in patients with MM, bladder cancer, lung cancer, or 
advanced solid tumors [111-114]. The Medical Research Council (MRC) Myeloma IX trial 
demonstrated that, after median follow-up of 3.7 years, ZOL significantly improved overall 
survival (by 5.5 months; 16% reduction in risk of death; P = .0118) and progression-free 
survival (by 2 months; 12% reduction in risk of disease progression; P = .0179) versus 
clodronate in patients with newly diagnosed MM (N = 1,960 evaluable patients) [111]. The 
survival benefit associated with ZOL was maintained in analyses adjusting for the potential 
effects of SREs on survival (P = .0178 vs clodronate), again supporting anticancer 
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mechanisms for ZOL, which may involve positive effects on anticancer immune responses 
[111]. 
4.3 Anti-RANKL agents 
Denosumab is a fully human IgG2 monoclonal antibody that binds to RANKL with high 
affinity and specificity, thereby inhibiting osteoclastogenesis. The effects of denosumab on 
bone remodeling have been evaluated in patients with postmenopausal osteoporosis, 
rheumatoid arthritis, and various cancers [115-118]. Limited safety data from the advanced 
cancer setting have been released. However, results from phase III studies in bone-loss 
settings suggested that adverse immunologic effects might occur. The FREEDOM trial, a 
phase III clinical study of 7,868 healthy postmenopausal women with osteoporosis, 
demonstrated that denosumab reduced the risk of new vertebral fractures by 68% compared 
with placebo (P < .001) [117]. A number of recent studies also demonstrated that denosumab 
can prevent SREs among patients with bone metastases from breast cancer, prostate cancer, 
other solid tumors, or MM. Denosumab was superior to ZOL in delaying time to first on-
study SRE (HR = 0.82; P = .01 superiority), and time to first and subsequent on-study SREs 
(rate ratio = 0.77; P = .001) in 2,046 patients with advanced breast cancer [82], and in 
delaying time to first on-study SRE in patients with advanced castration-resistant prostate 
cancer (CRPC) (HR = 0.82; P = .008 superiority; N = 1,901) [119]. Median time to first on-
study SRE was 20.7 months for denosumab versus 17.1 months for ZOL [119]. However, a 
significantly greater proportion of denosumab-treated patients experienced increased PSA 
levels compared with ZOL-treated patients (3.8% vs 2.0%, respectively; P < .05) [119]. Based 
on these results, it is possible that RANKL inhibition may impair immunosurveillance. 
Denosumab was non-inferior to ZOL in delaying time to first SRE in 1,776 patients with 
other advanced solid tumors or MM (HR = 0.84; P = .0007) [115]. Denosumab demonstrated 
antitumor activity in a phase II trial in 37 patients with benign giant-cell tumor (GCT) of 
bone, a tumor type that overexpresses RANKL and is associated with increased osteoclastic 
activity [120]. Given the low metastatic potential of GCT, the results observed in this patient 
population may not translate to patients with malignancies wherein the pathophysiology is 
distinct from that of GCT. Anticancer activity of blocking RANKL has been recently 
described in mouse models. RANKL inhibition was acting directly on hormone-induced 
mammary epithelium at early stages in tumorigenesis, and the permissive contribution of 
progesterone to increased mammary cancer incidence was due to RANKL-dependent 
proliferative changes in the mammary epithelium [121]. Based on these data, we assume 
that denosumab may have an anticancer activity; however, this has not yet been 
demonstrated in the clinical setting. Signaling via the RANKL-RANK pathway is involved 
in B-cell and T-cell differentiation and in survival of dendritic cells. As a result, concerns 
have been raised regarding possible immunosuppression with RANKL inhibitors. Recent 
clinical studies suggest that increased infection risk may be associated with denosumab 
therapy. The incidence of skin infections requiring hospitalization (cellulitis: 0.3% vs < 0.1% 
for placebo; P = .002) and endocarditis (3 patients vs 0 for placebo) was increased among 
postmenopausal women with osteoporosis who received denosumab therapy (FREEDOM) 
[115, 117]. A meta-analysis of 10,329 patients with osteopenia or osteoporosis also reported 
an increased risk of serious infections (odds ratio = 4.54 for denosumab vs placebo; P = .03) 
[122]. Serious infections were reported in 2.3% of denosumab-treated patients with early 
stage breast cancer compared with 0.8% of placebo-treated patients (P = not reported [NR]; 
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N = 249; HALT-BC trial) [123]. Similarly, serious infections occurred at a higher incidence 
among denosumab-treated patients with androgen-dependent prostate cancer (5.9% vs 4.6% 
for placebo; P = NR; N = 1,468; HALT-PC trial) [124]. Urinary-tract infections also occurred 
more frequently among denosumab-treated patients with prostate cancer-related bone 
metastases (15% vs 6% for bisphosphonates; P = NR; N = 49) [125]. 
Denosumab is specific for human and certain nonhuman primate RANKL, and fails to 
inactivate rodent RANKL. Consequently, no carcinogenicity studies have been performed 
with denosumab because of the absence of an appropriate animal model. However, safety 
analyses from clinical trials of denosumab to prevent bone loss in patients receiving 
hormone-ablation therapy (HALT) for early stage breast or prostate cancer suggest that the 
potential for cancer progression may be increased with denosumab therapy. Among 1,456 
patients with androgen-dependent prostate cancer in HALT-PC, 8.2% (n = 60) of 
denosumab-treated patients and 5.5% (n = 40) of placebo-treated patients experienced 
metastatic events (P = NR) [115]. Similarly, metastatic events were reported in 7% (n = 9) of 
denosumab-treated patients compared with 4.2% (n = 5) of placebo-treated patients with 
breast cancer in HALT-BC (P = NR; N = 249) [115]. Indeed, given the significantly increased 
rates of PSA progression in patients with CRPC and the significantly reduced survival in 
patients with MM treated with denosumab versus ZOL in the phase III clinical trials 
program (HR = 2.26) [126], further investigations on the potential effects of RANKL 
inhibition on cancer immunosurveillance and response are warranted. 
5. Conclusions 
The skeletal and immune systems have a complex relationship under normal (physiologic) 
and pathologic conditions. The RANKL-RANK-OPG signal transduction pathway plays a 
key role in regulating osteoclastogenesis. However, the effects of RANKL signaling are not 
limited to the skeletal system; RANKL is also expressed in other regulatory systems 
including the immune, cardiovascular, endocrine, and nervous systems. Expression of 
RANKL in the immune system regulates antigen-specific T-cell and B-cell responses, as well 
as the ability of T cells to interact with dendritic cells. Furthermore, RANKL directly affects 
the survival of antigen-presenting dendritic cells, which help other cells in the immune 
system to recognize and destroy abnormal cells and foreign antigens. Because of the 
systemic nature of RANKL expression, RANKL inhibition to prevent bone destruction may 
result in unintended consequences outside of the bone, including immune suppression with 
resulting possible increases in risk of infection or new malignancies. The long-term safety 
profiles of agents targeting this pathway are not yet known.  
Currently available therapies designed to reduce pathologic osteolysis may also result in 
modulation of the immune system. Nitrogen-containing bisphosphonates such as ZOL exert 
beneficial effects on the immune system, resulting in activation of anticancer responses, as 
demonstrated in several clinical studies in various malignancies. Careful consideration 
should be paid to the shared pathways in bone immunology to maximize beneficial and 
minimize potentially negative effects in the clinical setting. 
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